{
  "questions": [
    {
      "body": "Describe RankMHC",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39555889"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 64,
          "text": "RankMHC: Learning to Rank Class-I Peptide-MHC Structural Models.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39555889"
        },
        {
          "offsetInBeginSection": 1314,
          "offsetInEndSection": 1771,
          "text": "We present RankMHC, an LTR-based pMHC binding mode identification predictor, which is specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions, as well as previous Machine Learning (ML)-based binding pose predictors. We further demonstrate that RankMHC can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39555889"
        }
      ],
      "id": "67d74cde18b1e36f2e00003c",
      "ideal_answer": [
        "RankMHC is an LTR-based pMHC binding mode identification predictor, which is specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions, as well as previous Machine Learning (ML)-based binding pose predictors.",
        "RankMHC is a computational tool used in the field of immunology to predict the binding affinity of peptides to major histocompatibility complex (MHC) molecules. It is often used in the context of mass spectrometry data to help identify potential epitopes for vaccine development or disease research. RankMHC uses algorithms to rank peptides based on their likelihood of binding to specific MHC alleles, aiding in the identification of peptides that may be relevant for immune responses.",
        "RankMHC is a Learning-to-Rank (LTR) predictor that identifies the most accurate peptide-MHC (pMHC) binding mode from an ensemble of conformations. It outperforms traditional peptide-ligand scoring functions and previous Machine Learning-based predictors by ranking poses based on their similarity to the native structure. Compatible with multiple pMHC structural modeling tools and protocols, RankMHC is a versatile tool for peptide antigen identification, particularly useful in developing therapies against bacterial, viral infections, and cancer. Its predictive capability enhances the accuracy of selecting the best peptide pose for immune response therapies.",
        "RankMHC is an LTR-based predictor specifically designed to identify and rank peptide-MHC (pMHC) binding modes with high accuracy. It focuses on predicting the most accurate ranking of pMHC conformations, aiding in understanding how peptides bind to MHC molecules. This tool is crucial for immunology research, as it supports the study of T cell recognition and immune responses, potentially advancing disease treatment by targeting pMHC complexes. RankMHC\u0027s effectiveness is highlighted by its prediction success rates, making it a valuable asset for future research and design in TCR/pMHC complex interactions.",
        "RankMHC is a Learning-to-Rank (LTR)-based predictor designed to identify the most accurate binding modes of peptide-MHC (pMHC) structural models. It surpasses traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors in bioinformatic analysis.",
        "RankMHC is a computational tool used for predicting and ranking peptide-MHC (Major Histocompatibility Complex) binding affinities. It is designed to help identify which peptides are most likely to bind to MHC molecules, which is a crucial step in understanding immune responses and developing vaccines or immunotherapies. RankMHC uses algorithms to analyze peptide sequences and predict their binding strength to specific MHC alleles, aiding researchers in prioritizing peptides for further experimental validation.",
        "RankMHC is a computational tool designed to predict peptide-MHC binding modes and rank potential binding peptides to MHC molecules. It uses a Learning-to-Rank approach to identify the most accurate peptide-MHC binding mode from structural models, outperforming traditional scoring functions and previous machine learning predictors. Additionally, RankMHC evaluates interaction energies using statistical pairwise contact potentials, effectively identifying peptides with high binding potential without relying solely on allele-specific binding motifs.",
        "RankMHC is a computational tool used to predict the binding affinity of peptides to major histocompatibility complex (MHC) molecules, aiding in the identification of potential T-cell epitopes for immunological research and vaccine development.",
        "RankMHC is a computational tool designed to predict the binding affinity of peptides to Major Histocompatibility Complex (MHC) molecules. This prediction is important for understanding immune responses, as MHC molecules present peptide fragments to T cells, which then recognize and respond to these antigens. RankMHC employs machine learning algorithms and extensive datasets of known peptide-MHC interactions to rank peptides based on their likelihood of binding to specific MHC alleles. This tool is valuable in immunology research, vaccine development, and cancer immunotherapy, where identifying potential epitopes is essential.",
        "RankMHC is an LTR-based predictor designed to identify and rank the most accurate binding modes of peptide-MHC (pMHC) conformations. It is versatile and can be used in conjunction with various pMHC structural modeling tools that employ different modeling protocols.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. It can be used with various pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is an LTR-based (learning to rank) model specifically designed to predict the most accurate binding mode for class-I peptide-MHC structural models. It ranks an ensemble of pMHC conformations to select the best binding pose and has been trained specifically for this task. The results show that it outperforms traditional peptide-ligand scoring functions and earlier machine learning-based predictors. Additionally, RankMHC is versatile and can be used with various pMHC structural modeling tools that utilize different protocols.",
        "RankMHC is a tool designed for predicting the binding affinity between peptides and MHC (Major Histocompatibility Complex) molecules. It leverages machine learning techniques to rank peptides based on their likelihood of binding to specific MHC alleles. This is crucial in understanding immune responses, as MHC molecules present peptide fragments on cell surfaces for T cell recognition. RankMHC assists researchers in identifying potential T cell epitopes, which are key targets for vaccine development and immunotherapy. By accurately predicting peptide-MHC interactions, RankMHC aids in narrowing down candidate peptides for experimental validation, thereby accelerating the process of identifying immunologically relevant targets.",
        "RankMHC is a Learning-to-Rank (LTR) based predictor specifically designed to accurately rank an ensemble of peptide-MHC (pMHC) conformations, outperforming traditional scoring functions and other machine learning-based binding pose predictors.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor, specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations.",
        "RankMHC is a Learning-to-Rank (LTR) based predictor designed to identify the most accurate peptide binding pose from an ensemble of peptide-Major Histocompatibility Complex (pMHC) conformations. It excels over traditional peptide-ligand scoring functions and previous ML-based predictors. Compatible with various pMHC structural modeling tools and protocols, RankMHC aims to enhance peptide antigen identification. This improvement is crucial for developing effective therapies against diseases like bacterial and viral infections, as well as cancer, by providing a more accurate pMHC structural analysis.",
        "RankMHC is a Learning-to-Rank (LTR)-based predictor designed for identifying binding modes of peptide-MHC (pMHC) complexes. It is specifically trained to accurately rank an ensemble of pMHC conformations, outperforming traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. RankMHC can be integrated with various pMHC structural modeling tools that utilize different protocols, enhancing its versatility in predicting the most representative peptide poses within the MHC-I cleft. Additionally, it calculates MHC-I/II binding affinities across the human leukocyte antigen landscape, contributing to the understanding of immune responses and aiding in drug and vaccine design.",
        "RankMHC is a computational tool used for predicting and ranking peptide-MHC (Major Histocompatibility Complex) binding affinities. It is designed to help identify potential epitopes for vaccine development and immunotherapy by evaluating how well different peptides bind to MHC molecules. RankMHC uses machine learning algorithms and large datasets of known peptide-MHC interactions to provide accurate predictions, aiding researchers in understanding immune responses and designing targeted treatments.",
        "RankMHC is a Learning-to-Rank (LTR) based predictor that aims to identify the most accurate binding mode or peptide pose from an ensemble of candidate peptide-MHC structural models. It is specifically trained to predict the ranking of peptide-MHC conformations such that the top-ranked pose is the one closest to the native structure. RankMHC outperforms classical protein-ligand scoring functions and previous machine learning-based binding pose predictors in identifying the binding mode of peptides to MHC class I receptors, which is crucial for developing therapies against diseases like cancer, viral and bacterial infections.",
        "RankMHC is a computational tool used in the field of immunology to predict the binding affinity of peptides to major histocompatibility complex (MHC) molecules. It is often used in the context of mass spectrometry data to help identify potential epitopes for vaccine development or disease research. RankMHC uses algorithms to rank peptides based on their likelihood of binding to specific MHC alleles, aiding in the identification of peptides that may elicit an immune response.",
        "RankMHC is a machine learning-based tool that aims to identify the most accurate binding mode (or pose) of a peptide to a major histocompatibility complex (MHC) class I receptor from an ensemble of candidate peptide-MHC structural models. It frames the binding mode identification problem as a learning-to-rank task and uses a ranking model specifically trained to predict the most representative ranking of the peptide-MHC conformations. RankMHC outperforms traditional scoring functions and previous machine learning methods for this task, and can be used with different structural modeling tools employing various modeling protocols.",
        "RankMHC is a method for predicting peptide-MHC binding using a combination of structural and sequence features. It uses a support vector machine (SVM) to predict the binding of peptides to MHC class I and II molecules. The method is trained on a dataset of 1,000 peptides and 100 MHC molecules, and is able to predict the binding of peptides to MHC molecules with an accuracy of 80-90%. The method is also able to predict the binding of peptides to MHC molecules with a high degree of specificity, with a false positive rate of less than 1%.",
        "RankMHC is a machine learning-based tool that aims to identify the correct binding mode (or pose) of a peptide to a Major Histocompatibility Complex (MHC) class I receptor from an ensemble of candidate peptide-MHC structural models. It frames the problem as a learning-to-rank task and uses a ranking model trained on structural features to predict the ranking of the candidate poses, with the top-ranked pose being predicted as the most accurate representation of the actual binding mode. RankMHC outperforms traditional scoring functions and previous machine learning methods for this task.",
        "RankMHC is a Learning-to-Rank based predictor designed to identify the most accurate peptide binding modes in peptide-MHC structural models, improving the accuracy of identifying peptide antigens for immune response therapies.",
        "RankMHC is a machine learning-based method that aims to identify the most accurate binding mode (or pose) of a peptide to a class-I major histocompatibility complex (MHC) receptor from an ensemble of candidate peptide-MHC structural models. It frames the problem as a learning-to-rank task, where it is trained to predict the ranking of the peptide-MHC conformations such that the top-ranked conformation is closest to the native binding structure. RankMHC outperforms traditional protein-ligand scoring functions and previous machine learning methods for this task. It can be used with different structural modeling tools that generate ensembles of peptide-MHC models.",
        "RankMHC is a Learning-to-Rank predictor that identifies the most accurate peptide-MHC binding mode from multiple conformations, outperforming traditional and previous ML-based methods. Compatible with various pMHC modeling tools, it enhances peptide antigen identification, crucial for developing effective therapies against bacterial and viral infections, and cancer, by providing more accurate pMHC structural analysis for improved immune response treatments.",
        "RankMHC is a Learning-to-Rank (LTR)-based predictor designed to identify the most accurate binding modes of peptide-MHC (pMHC) conformations. It surpasses traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors, as demonstrated by bioinformatic analysis.",
        "RankMHC is a Learning-to-Rank (LTR) predictor that identifies the most accurate ranking of an ensemble of peptide-MHC (pMHC) conformations, outperforming classical peptide-ligand scoring functions and previous Machine Learning-based binding pose predictors.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor that is specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. It is designed to identify the binding modes of peptide-MHC (pMHC) complexes, which are crucial for immune recognition and T-cell activation. According to recent studies, Class I Major Histocompatibility Complex (MHC) molecules play a central role in immunology by binding to intracellular peptides and displaying them at the cell surface for recognition by T-cells. RankMHC aims to predict the correct ranking of pMHC conformations, which is essential for understanding the interactions between T-cells and pMHC complexes, and has the potential to facilitate the design of novel therapeutic strategies targeting these complexes. By accurately predicting the binding modes of pMHC complexes, RankMHC can contribute to a better understanding of immune recognition and the development of new treatments for diseases.",
        "RankMHC is a machine learning approach based on learning to rank that is designed to predict the most accurate ranking among an ensemble of peptide-MHC structural conformations. It specifically targets Class-I peptide-MHC binding mode identification. By prioritizing the best structural models of peptide-MHC complexes, RankMHC outperforms traditional peptide-ligand scoring functions as well as previous machine learning-based binding pose predictors. It is versatile and can be integrated with various pMHC structural modeling tools that use diverse modeling protocols.",
        "RankMHC is a Learning-to-Rank based predictor designed to identify the most accurate peptide-MHC structural model from a set of candidate poses, outperforming traditional scoring functions and other ML predictors, and is compatible with various pMHC modeling tools.",
        "RankMHC is an LTR-based predictor designed to identify the most accurate ranking of peptide-MHC (pMHC) binding conformations. It is compatible with various pMHC structural modeling tools, making it versatile for different structural modeling protocols.",
        "RankMHC is an LTR-based predictor designed to identify pMHC binding modes. It is specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions and previous Machine Learning (ML)-based binding pose predictors. It can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is a Learning to Rank (LTR) predictor developed to identify peptide-MHC (pMHC) binding modes. It has been demonstrated to surpass traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors, as evidenced by structural modeling studies.",
        "RankMHC is a Learning-to-Rank based predictor designed to identify peptide binding modes in class-I MHC structural models, outperforming traditional scoring functions and previous machine learning-based predictors.",
        "RankMHC is a Learning-to-Rank (LTR) predictor for peptide-MHC binding mode identification. It is specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions, as well as previous Machine Learning (ML)-based binding pose predictors. It can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is a machine learning-based computational tool designed to predict and rank peptide-MHC (pMHC) binding conformations. Using a Learning to Rank (LTR) approach, it can accurately identify the most probable structural models of peptide-MHC interactions. The method outperforms traditional peptide-ligand scoring functions and previous machine learning predictors, and has the flexibility to work with multiple structural modeling protocols for peptide-MHC complexes.",
        "RankMHC is a Learning-to-Rank (LTR)-based peptide-MHC (pMHC) binding mode identification predictor. It is specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions, as well as previous Machine Learning (ML)-based binding pose predictors. It can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is a computational tool that utilizes machine learning to evaluate and rank structural models of class I peptide MHC complexes. Its primary goal is to determine which model best represents the interaction between peptides and MHC molecules, enhancing our understanding of immune responses. By assessing these models, RankMHC contributes to fields like vaccine development and drug target identification, aiding in the accurate prediction of antigen presentation and T cell recognition.",
        "RankMHC is a Learning-to-Rank (LTR) based predictor designed to identify the most accurate peptide binding pose in class-I Peptide-Major Histocompatibility Complex (pMHC) structural models. It ranks an ensemble of pMHC conformations, outperforming traditional scoring functions and previous Machine Learning-based predictors. Notably, RankMHC is versatile and compatible with various pMHC structural modeling tools and protocols, enhancing its utility in predicting optimal pMHC conformations. This capability can be leveraged to improve the identification of peptide antigens, potentially aiding in the development of therapies for diseases such as bacterial and viral infections, and cancer.",
        "RankMHC is a computational method designed to rank structural models of Class I Peptide MHC complexes. It employs machine learning techniques to evaluate and prioritize these models based on their accuracy and relevance. By focusing on factors such as binding affinity and structural stability, RankMHC aids researchers in identifying the most accurate models for studying peptide MHC interactions, which is crucial for advancements in immunology, including vaccine development and understanding immune responses to diseases like cancer and autoimmune disorders. This tool enhances our ability to predict how peptides bind to MHC molecules, contributing significantly to molecular level insights into the immune system.",
        "RankMHC is a learning-to-rank based predictor specifically designed to identify the most accurate ranking of an ensemble of peptide-MHC (pMHC) conformations. It is trained to predict the binding mode of class-I peptide-MHC structural models, outperforming traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. This tool can be utilized in conjunction with various pMHC structural modeling tools that employ different protocols, making it a versatile and effective solution for predicting pMHC binding modes. According to studies, RankMHC demonstrates superior performance, highlighting its potential as a valuable resource in the field of immunology and structural biology.",
        "RankMHC is a machine learning-based tool designed to predict the most accurate ranking of peptide-major histocompatibility complex (pMHC) conformations, outperforming traditional scoring functions and previous ML-based predictors. It can be integrated with various pMHC structural modeling tools regardless of their specific protocols.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor, specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions and previous Machine Learning-based binding pose predictors.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor, specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. It outperforms classical peptide-ligand scoring functions, as well as previous Machine Learning (ML)-based binding pose predictors. RankMHC can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is a machine learning-based predictor that ranks class-I peptide-MHC structural models for accurate binding mode identification.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor, which is specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. It outperforms classical peptide-ligand scoring functions, as well as previous Machine Learning (ML)-based binding pose predictors and can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is a Learning-to-Rank (LTR)-based predictor designed for identifying peptide-MHC (pMHC) binding modes. It is specifically trained to accurately rank an ensemble of pMHC conformations, outperforming traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. RankMHC can be integrated with various pMHC structural modeling tools that utilize different protocols, enhancing its versatility in predicting the most representative peptide poses within the MHC-I cleft. The approach optimizes peptide-MHC binding rankings through ranking-based learning objectives, ultimately aiding in the identification of potential therapeutic targets for immunotherapy.",
        "RankMHC is a Learning to Rank (LTR)-based predictor designed to identify the most accurate ranking of peptide-MHC (pMHC) structural models. It excels in predicting the optimal binding mode of pMHC complexes by outperforming traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. RankMHC\u0027s versatility lies in its compatibility with various pMHC structural modeling tools, regardless of their specific protocols, making it a robust and adaptable tool in the field of structural bioinformatics.",
        "RankMHC is a learning-to-rank (LTR) based predictor specifically developed for class-I peptide-MHC structural models. It selects the most accurate binding mode from an ensemble of peptide-MHC conformations by ranking them based on their likelihood of representing the true binding pose. In this context, learning-to-rank means the method is trained to prioritize the best models over others rather than merely scoring them. RankMHC outperforms traditional peptide-ligand scoring functions and earlier machine learning-based pose predictors and is designed to work with a variety of structural modeling tools and protocols, highlighting its versatility.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor. It is trained to predict the most accurate ranking of an ensemble of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions and previous ML-based binding pose predictors.",
        "RankMHC is a machine learning-based predictor that identifies the most accurate ranking of an ensemble of peptide-MHC (pMHC) conformations. It outperforms classical peptide-ligand scoring functions and previous ML-based binding pose predictors. RankMHC can be used with various pMHC structural modeling tools that employ different structural modeling protocols.",
        "RankMHC is a pMHC binding mode identification predictor based on Learning to Rank (LTR). It is trained to predict the most accurate ranking of an ensemble of peptide-MHC (pMHC) conformations. RankMHC outperforms classical peptide-ligand scoring functions and previous Machine Learning-based binding pose predictors. RankMHC can be used with various pMHC structural modeling tools that employ different structural modeling protocols.",
        "RankMHC is an LTR-based predictor designed for identifying the most accurate ranking of peptide-MHC (pMHC) binding conformations. It surpasses traditional peptide-ligand scoring functions and previous machine learning-based pose predictors in performance. Additionally, RankMHC can be integrated with various pMHC structural modeling tools that employ different protocols.",
        "RankMHC is a Learning-to-Rank (LTR)-based predictor designed for identifying the most accurate binding mode of peptide-MHC (pMHC) conformations. It addresses the challenge of selecting the peptide pose from an ensemble that closely resembles an unavailable native structure, which is often difficult using traditional protein-ligand scoring functions. RankMHC has been shown to outperform classical scoring methods and previous machine learning-based binding pose predictors. Additionally, it is compatible with various pMHC structural modeling tools that utilize different modeling protocols, enhancing its utility in peptide antigen identification workflows critical for immune response elicitation in therapies for infections and cancer.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor. It is specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions, as well as previous Machine Learning (ML)-based binding pose predictors. RankMHC can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is a machine learning-based predictor designed to identify and rank peptide-MHC (pMHC) binding conformations with high accuracy. It utilizes a learning-to-rank (LTR) approach and has been shown to outperform traditional peptide-ligand scoring methods and previous ML-based predictors. Additionally, RankMHC is compatible with various pMHC structural modeling tools and protocols.",
        "RankMHC is a learning-to-rank (LTR) based predictor specifically designed to identify the most accurate peptide-MHC (pMHC) binding mode from an ensemble of conformations. It outperforms traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. RankMHC can be used with various pMHC structural modeling tools that employ different protocols, making it a versatile tool for predicting pMHC binding modes.",
        "RankMHC is a learning-to-rank (LTR) based predictor designed for identifying binding modes of peptide-MHC (pMHC) complexes. It is specifically trained to accurately rank an ensemble of pMHC conformations, outperforming traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. RankMHC can be integrated with various pMHC structural modeling tools that utilize different protocols, enhancing its versatility in predicting peptide-MHC interactions. The method optimizes the rankings of peptide-MHC bindings through ranking-based learning objectives, facilitating the identification of potential MHC-I binding candidates from large proteomes and aiding in the discovery of therapeutically relevant neoantigens.",
        "RankMHC is a Learning-to-Rank (LTR)-based predictor for peptide-MHC (pMHC) binding mode identification. It is trained to predict the most accurate ranking of an ensemble of pMHC conformations. The binding of peptides to class-I Major Histocompability Complex (MHC) receptors and their subsequent recognition downstream by T-cell receptors are crucial processes for most multicellular organisms to be able to fight various diseases. RankMHC can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is a learning-to-rank (LTR) based predictor designed for identifying binding modes of peptide-MHC (pMHC) complexes. It is specifically trained to accurately rank an ensemble of pMHC conformations, outperforming traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. RankMHC can be integrated with various pMHC structural modeling tools that utilize different protocols, enhancing its versatility in predicting the most representative peptide poses within the MHC-I cleft. The approach optimizes rankings of peptide-MHC bindings through ranking-based learning objectives, providing a more reliable method for identifying potential therapeutic targets in immunotherapy.",
        "RankMHC is an LTR-based (Learning to Rank) predictor designed to identify the binding mode of peptide-MHC (pMHC) complexes. It is trained to predict the most accurate ranking of an ensemble of pMHC conformations and outperforms classical peptide-ligand scoring functions and previous ML-based binding pose predictors. RankMHC can be used with various pMHC structural modeling tools that employ different structural modeling protocols.",
        "RankMHC is a Learning-to-Rank (LTR) based predictor designed to identify the most accurate binding mode of peptide-Major Histocompatibility Complex (pMHC) structural models. It ranks an ensemble of pMHC conformations, outperforming traditional scoring functions and previous machine learning-based predictors. Compatible with various pMHC structural modeling tools using different protocols, RankMHC is a valuable tool in immunology and structural biology, particularly for identifying peptide antigens to develop therapies against bacterial and viral infections, and cancer. Its versatility and predictive accuracy make it a standout in the field.",
        "RankMHC is a learning-to-rank (LTR) based predictor designed for identifying binding modes of peptide-MHC (pMHC) complexes. It is specifically trained to accurately rank an ensemble of pMHC conformations, outperforming traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. RankMHC is versatile and can be integrated with various pMHC structural modeling tools that utilize different modeling protocols, enhancing its applicability in predicting the most representative peptide poses within the MHC-I cleft.",
        "RankMHC is a computational tool designed to rank Class-I peptide-MHC (Major Histocompatibility Complex) structural models. It uses machine learning techniques to evaluate and prioritize the binding affinity and structural compatibility of peptides with MHC molecules, which is crucial for understanding immune responses and developing immunotherapies.",
        "RankMHC is a Learning-to-Rank (LTR) based predictor that identifies the most accurate peptide binding pose in class-I Peptide-Major Histocompatibility Complex (pMHC) structural models. By ranking an ensemble of pMHC conformations, it outperforms traditional scoring functions and previous Machine Learning-based predictors. Versatile and compatible with various pMHC structural modeling tools, RankMHC enhances the identification of peptide antigens, facilitating the development of therapies against bacterial and viral infections, and cancer.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor, which is specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions, as well as previous Machine Learning (ML)-based binding pose predictors. We further demonstrate that RankMHC can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is a computational approach designed to evaluate and rank the structural models of Class I peptide MHC (Major Histocompatibility Complex) complexes. This method employs machine learning techniques to assess how effectively these complexes can present antigens for recognition by T cells, which is crucial for immune response modulation. By analyzing the 3D structures of peptide MHC interactions, RankMHC predicts their functional effectiveness, such as antigen presentation efficiency and stability. This tool is particularly valuable in immunology research for applications like vaccine development and understanding immune system dynamics.",
        "RankMHC is a pMHC binding mode identification predictor based on Learning to Rank (LTR). It is trained to predict the most accurate ranking of pMHC conformations. RankMHC outperforms classical peptide-ligand scoring functions and ML-based binding pose predictors and can be used with many pMHC structural modeling tools.",
        "RankMHC is a Learning to Rank (LTR)-based predictor designed to identify peptide-MHC (pMHC) binding modes. It is specifically trained to accurately rank ensembles of pMHC conformations, determining which structural models are most likely to represent the native binding mode. RankMHC demonstrates superior performance compared to traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. A key advantage of RankMHC is its versatility, as it can be integrated with various pMHC structural modeling tools that employ different protocols, making it a valuable tool for immunological research and potentially for applications in vaccine design and immunotherapy.",
        "RankMHC is a learning-to-rank (LTR) based predictor designed for identifying the binding modes of class-I peptide-MHC complexes. It specifically ranks an ensemble of pMHC conformations to predict the most accurate structural models. In studies, RankMHC has shown superior performance compared to traditional peptide-ligand scoring functions and other machine learning-based predictors, making it a more reliable tool for predicting pMHC binding modes.",
        "RankMHC is a machine learning-based predictor specifically designed to identify the most accurate peptide-MHC (pMHC) binding mode by ranking an ensemble of pMHC conformations. It outperforms traditional peptide-ligand scoring functions and previous machine learning-based binding pose predictors. RankMHC can be used with various pMHC structural modeling tools that employ different protocols, making it a versatile tool for predicting pMHC interactions.",
        "RankMHC is a machine learning-based predictor that can accurately rank an ensemble of peptide-MHC (pMHC) structural models to identify the most likely binding mode. It outperforms traditional peptide-ligand scoring functions and previous ML-based binding pose predictors. RankMHC can be used with various pMHC structural modeling tools that employ different modeling protocols.",
        "RankMHC is a Learning-to-Rank based tool designed to predict the most accurate peptide binding mode in class-I Peptide-Major Histocompatibility Complex (pMHC) structural models. It achieves this by ranking an ensemble of pMHC conformations, outperforming traditional scoring functions and previous Machine Learning-based predictors. Compatible with various pMHC structural modeling tools, RankMHC is invaluable for identifying peptide antigens, thereby supporting the development of targeted therapies against bacterial and viral infections, as well as cancer, with enhanced precision.",
        "RankMHC is a learning-to-rank (LTR) predictor designed to identify Class-I peptide-MHC binding modes by accurately ranking ensemble pMHC conformations. It outperforms traditional scoring functions and machine learning-based predictors and is versatile in compatibility with various pMHC structural modeling tools for predicting binding modes.",
        "RankMHC is a machine learning-based predictor that employs a learning-to-rank (LTR) strategy to identify and select the most accurate structural models of peptide–MHC class I binding modes. It does this by ranking an ensemble of pMHC conformations generated from various structural modeling tools, ensuring that the top-ranked model is the one most likely to reflect the correct binding mode. By outperforming traditional peptide–ligand scoring functions and earlier machine learning approaches, RankMHC demonstrates improved accuracy in identifying optimal pMHC structures. Its design allows it to be used alongside different pMHC modeling protocols, making it versatile and effective in the structural modeling of peptide–MHC interactions.",
        "RankMHC is a Learning to Rank-based tool that predicts the most accurate ranking of peptide-Major Histocompatibility Complex (pMHC) structural models, outperforming traditional scoring functions and previous ML-based predictors, with the versatility to work with various pMHC modeling tools and protocols.",
        "RankMHC is an LTR-based pMHC binding mode identification predictor specifically trained to predict the most accurate ranking of an ensemble of pMHC conformations. It outperforms classical peptide-ligand scoring functions and previous Machine Learning (ML)-based binding pose predictors. RankMHC can be used with many pMHC structural modeling tools that use different structural modeling protocols.",
        "RankMHC is an advanced LTR-based predictor designed to identify pMHC (peptide-MHC) binding modes by accurately ranking ensembles of pMHC conformations. It demonstrates superior performance compared to traditional scoring functions and other machine learning-based binding pose predictors, while offering compatibility with various pMHC structural modeling tools and protocols.",
        "RankMHC is an advanced predictor designed to accurately rank the conformations of peptide-major histocompatibility complex (pMHC) structures. It surpasses traditional scoring functions and previous machine learning-based predictors in identifying the most accurate pMHC binding modes, making it a valuable tool for enhancing various pMHC structural modeling protocols.",
        "RankMHC is a tool that uses Learning to Rank (LTR) to predict the most accurate ranking of an ensemble of peptide-MHC (pMHC) conformations, helping to identify the best pMHC binding mode. It outperforms classical peptide-ligand scoring functions and other ML-based binding pose predictors and can be used with various pMHC structural modeling tools."
      ]
    },
    {
      "body": "What proportion of colorectal cancer cases are not assignable to any of the consensus molecular subtype (CMS) groups?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26457759",
        "http://www.ncbi.nlm.nih.gov/pubmed/27325016",
        "http://www.ncbi.nlm.nih.gov/pubmed/30563495"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 884,
          "offsetInEndSection": 990,
          "text": "Samples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26457759"
        },
        {
          "offsetInBeginSection": 340,
          "offsetInEndSection": 990,
          "text": "We show marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features: CMS1 (microsatellite instability immune, 14%), hypermutated, microsatellite unstable and strong immune activation; CMS2 (canonical, 37%), epithelial, marked WNT and MYC signaling activation; CMS3 (metabolic, 13%), epithelial and evident metabolic dysregulation; and CMS4 (mesenchymal, 23%), prominent transforming growth factor-β activation, stromal invasion and angiogenesis. Samples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26457759"
        },
        {
          "offsetInBeginSection": 1604,
          "offsetInEndSection": 1782,
          "text": "A large percentage of unclassified samples according to the consensus molecular subtypes (CMS) classifier was found in the LB group (43%), whereas 76% HB tumors belonged to CMS2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30563495"
        },
        {
          "offsetInBeginSection": 1162,
          "offsetInEndSection": 1599,
          "text": "The recent Consensus Molecular Subtypes (CMS) Consortium analysing CRC expression profiling data from multiple studies described four CMS groups: almost all hypermutated MSI cancers fell into the first category CMS1 (MSI-immune, 14 %) with the remaining MSS cancers subcategorised into three groups of CMS2 (canonical, 37 %), CMS3 (metabolic, 13 %) and CMS4 (mesenchymal, 23 %), with a residual unclassified group (mixed features, 13 %).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325016"
        }
      ],
      "type": "factoid",
      "id": "65f7741fc4010b4d78000027",
      "ideal_answer": [
        "Samples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity.",
        "13% of colorectal cancer cases are not assignable to any of the consensus molecular subtype (CMS) groups.",
        "According to the consensus molecular subtype (CMS) classification of colorectal cancer, around 13% of cases are not clearly assignable to any of the four CMS groups (CMS1, CMS2, CMS3, CMS4). These cases are described as having \u0027mixed features\u0027 and may represent a transition phenotype or intratumoral heterogeneity.",
        "Colorectal cancer is classified into four consensus molecular subtypes (CMS) based on gene expression profiles: CMS1 (microsatellite instability immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal). However, a subset of colorectal cancer cases, approximately 10-20%, do not fit neatly into any of these CMS categories and are thus considered \"unclassified\" or \"mixed.\" These cases may exhibit characteristics of multiple subtypes or lack distinct features that align with the defined CMS groups.",
        "Approximately 8% to 13% of colorectal cancer cases may not be assignable to any of the Consensus Molecular Subtype (CMS) groups, with the range reflecting variability between study contexts and interpretations of \u0027mixed features\u0027.",
        "The proportion of colorectal cancer cases that are not assignable to any of the consensus molecular subtype (CMS) groups is approximately 13%.",
        "Colorectal cancer is classified into four consensus molecular subtypes (CMS) based on gene expression profiles: CMS1 (microsatellite instability immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal). However, a subset of colorectal cancer cases, approximately 10-20%, cannot be clearly assigned to any of these CMS groups. These unclassified cases may exhibit mixed features or lack distinct characteristics that align with the defined subtypes, highlighting the complexity and heterogeneity of colorectal cancer.",
        "According to the provided context, 13% of colorectal cancer cases are not assignable to any of the consensus molecular subtype (CMS) groups, as they fall into a residual unclassified group with mixed features.",
        "A total of 13% of colorectal cancer cases do not fit into any of the CMS groups.",
        "The proportion of colorectal cancer cases that cannot be assigned to any of the consensus molecular subtype (CMS) groups is estimated to be approximately 5-10%. This range reflects the fact that while most cases can be classified into one of the four CMS subtypes, a small fraction does not fit neatly into these categories due to unique molecular characteristics. For precise and updated figures, consulting recent studies or authoritative reviews on CMS classifications in colorectal cancer is recommended.",
        "Based on the provided abstracts, it is mentioned that samples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity and could not be classified into any of the four consensus molecular subtypes (CMS) groups. Therefore, the proportion of colorectal cancer cases that are not assignable to any of the CMS groups is 13%.",
        "According to the studies, around 13% of colorectal cancer cases could not be assigned to any of the four consensus molecular subtypes (CMS1-CMS4) and were classified as having \u0027mixed features\u0027. These cases possibly represent a transition phenotype or intratumoral heterogeneity.",
        "Colorectal cancer is classified into four consensus molecular subtypes (CMS) based on gene expression profiles, which are CMS1 (microsatellite instability immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal). However, a small proportion of colorectal cancer cases do not fit neatly into any of these categories. These unassignable cases, often referred to as \"mixed\" or \"unknown\" subtype, account for approximately 10-20% of colorectal cancer cases. This variability can be due to heterogeneity in tumor biology or limitations in the classification methodology.",
        "According to the consensus molecular subtypes (CMS) classification of colorectal cancer, around 13% of cases are not assignable to any of the four CMS groups (CMS1-4) and are considered to have mixed features, possibly representing a transition phenotype or intratumoral heterogeneity.",
        "The proportion of colorectal cancer cases that are not assignable to any of the consensus molecular subtype (CMS) groups is 13%.",
        "According to the studies, around 13% of colorectal cancer cases could not be clearly assigned to any of the four consensus molecular subtypes (CMS) and were considered to have mixed features, possibly representing a transition phenotype or intratumoral heterogeneity.",
        "Based on the context, it appears that the question is asking about the proportion of colorectal cancer cases that are not assignable to any of the consensus molecular subtype (CMS) groups. \n\nThe answer is not directly provided in the given text, but it can be inferred that a significant proportion of cases are unclassifiable or do not fit into the four consensus molecular subtypes (CMS 1-4). However, the exact proportion is not mentioned.\n\nFrom the text, it can be inferred that the CMS classification is one of the most robust classifications for colorectal cancer, and it captures tumor heterogeneity at the gene-expression level. However, it is also mentioned that attempts to stratify CRC using molecular features for prognostic and predictive purposes in clinical conditions had limited success.\n\nTherefore, the answer to the question would be that a significant proportion of colorectal cancer cases, possibly up to 20%, do not fit into the four consensus molecular subtypes (CMS 1-4), but the exact",
        "According to the consensus molecular subtype (CMS) classification of colorectal cancer, around 13% of cases are classified as having mixed features and cannot be definitively assigned to any of the four main CMS groups (CMS1, CMS2, CMS3, CMS4). These cases may represent transitional phenotypes or intratumoral heterogeneity.",
        "Approximately 8% to 13% of colorectal cancer cases cannot be assigned to any Consensus Molecular Subtype (CMS) group, due to variability in study contexts and interpretations of mixed features, as evidenced by specific study findings of 8% in a metastatic CRC pilot study and up to 13% in the CMS Consortium analysis.",
        "Approximately 13% of colorectal cancer (CRC) cases are not assignable to any of the consensus molecular subtype (CMS) groups. This statistic is derived from RNA sequencing and classification studies, which indicate that a subset of CRC cases remains unclassifiable using the established CMS classifier. Further bioinformatic analyses suggest that alternative methods, such as image-based consensus molecular subtype (imCMS) classification, may classify some of these previously unclassifiable cases, highlighting the limitations of traditional RNA expression profiling. Additionally, reviews of individual mouse models support the notion that some CRC cases may not fit into any CMS groups.",
        "According to the Consensus Molecular Subtypes (CMS) Consortium, a residual unclassified group (mixed features) accounts for approximately 13% of colorectal cancer cases, which are not assignable to any of the CMS groups.",
        "Approximately 13%",
        "Approximately 13% of colorectal cancer cases are not assignable to any of the consensus molecular subtype (CMS) groups, as they fall into a residual unclassified group with mixed features. This is based on the analysis by the CMS Consortium, which categorized most cases into four distinct CMS groups but left a small proportion unclassified.",
        "Based on the provided abstracts, the proportion of colorectal cancer cases not assignable to any of the consensus molecular subtype (CMS) groups varies. One study classified 18.2% of patients as unclassified. Another study found a large percentage of unclassified samples (43%) in a specific group (LB). Additionally, a higher proportion of Hispanic/Latino patients exhibited indeterminate CMS classifications, suggesting that subtype classification methods could benefit from enhanced patient diversity.",
        "Approximately 13% of colorectal cancer (CRC) cases are not assignable to any of the consensus molecular subtype (CMS) groups, as determined by RNA sequencing and the established CMS classifier. Additionally, alternative methods such as image-based consensus molecular subtype (imCMS) classification have been suggested to classify samples that were previously unclassifiable by traditional RNA expression profiling.",
        "According to the research context, approximately 13% of colorectal cancer samples exhibit mixed features that do not clearly fit into standard consensus molecular subtype (CMS) groups, potentially representing a transition phenotype or intratumoral heterogeneity.",
        "In colorectal cancer, approximately 13% of cases exhibit mixed features, which may indicate a transition phenotype or intratumoral heterogeneity. These cases are not assignable to any specific consensus molecular subtype (CMS) group.",
        "Approximately 13% of colorectal cancer cases, characterized by samples with mixed features, cannot be assigned to any of the four consensus molecular subtype (CMS) groups. This unassignability may be due to these cases representing a transition phenotype or exhibiting intratumoral heterogeneity.",
        "In colorectal cancer studies, approximately 13% of cases exhibit mixed features and cannot be assigned to any of the consensus molecular subtype (CMS) groups. This proportion may represent a transition phenotype or could be due to intratumoral heterogeneity within the tumor.",
        "According to recent studies, a notable proportion of colorectal cancer cases exhibit mixed features, which may indicate either a transition phenotype or intratumoral heterogeneity. Specifically, approximately 13% of samples display such mixed characteristics, suggesting that these cases do not fit neatly into any one of the consensus molecular subtype (CMS) groups. This finding implies that a significant percentage of colorectal cancer cases cannot be assigned to a specific CMS group, highlighting the complexity and diversity of this disease. As a result, these unassignable cases may require further investigation to better understand their underlying biology and develop effective treatment strategies.",
        "Approximately 13% of colorectal cancer cases exhibit mixed features and cannot be definitively assigned to any of the consensus molecular subtypes (CMS), potentially indicating a transition phenotype or intratumoral heterogeneity.",
        "In colorectal cancer cases, approximately 13% exhibit mixed features that prevent their assignment to any of the Consensus Molecular Subtype (CMS) groups. These instances are often attributed to a transition phenotype or intratumoral heterogeneity, where the tumor\\\u0027s genetic makeup varies significantly across different regions. This heterogeneity can make it challenging to classify such cases neatly into established subtypes, which are typically used for prognostic and therapeutic purposes.",
        "13%",
        "13% of samples with mixed features possibly represent a transition phenotype or intratumoral heterogeneity, and are not assignable to any of the consensus molecular subtype (CMS) groups.",
        "Approximately 13% of colorectal cancer cases exhibit mixed features that do not fit neatly into any of the consensus molecular subtype (CMS) groups. These mixed feature samples may represent a transitional phenotype or intratumoral heterogeneity, indicating a complex biological state that does not align with the more clearly defined CMS subtypes. This suggests that while the CMS classification system is comprehensive, it may not fully capture the heterogeneity present in all colorectal cancer cases.",
        "Approximately 13% of colorectal cancer cases exhibit mixed features that do not fit into any consensus molecular subtype (CMS) groups. These cases may represent a transition phenotype or intratumoral heterogeneity, indicating complexity in their molecular characteristics.",
        "13% of colorectal cancer cases are not assignable to any of the consensus molecular subtype (CMS) groups. These samples have mixed features. They possibly represent a transition phenotype or intratumoral heterogeneity.",
        "Approximately 13% of colorectal cancer cases exhibit mixed features that do not fit into any consensus molecular subtype (CMS) groups. These cases may represent a transition phenotype or intratumoral heterogeneity, indicating a more complex nature of the disease in these instances. The remaining 87% of cases are typically assignable to one of the CMS groups, which are classifications based on molecular characteristics such as gene expression profiles. This suggests that while most colorectal cancers can be categorized into specific subtypes, a notable minority cannot due to their complexity or mixed features.",
        "In colorectal cancer, approximately 13% of samples exhibit mixed features that do not fit neatly into any single consensus molecular subtype (CMS) group. These samples may represent a transition phenotype or reflect intratumoral heterogeneity, indicating the complexity and variability within tumor biology.",
        "Approximately 13% of colorectal cancer cases are not assignable to any of the consensus molecular subtype (CMS) groups, as they exhibit mixed features that may represent a transition phenotype or intratumoral heterogeneity.",
        "According to the provided abstract, approximately 13% of colorectal cancer cases are not assignable to any of the consensus molecular subtype (CMS) groups, as they exhibit mixed features, possibly representing a transition phenotype or intratumoral heterogeneity.",
        "Approximately 13% of colorectal cancer cases cannot be assigned to any Consensus Molecular Subtype (CMS) group, characterized by mixed features possibly representing a transition phenotype or intratumoral heterogeneity.",
        "In the context of colorectal cancer, a subset of cases, approximately 13%, exhibit mixed features that do not align with any of the established consensus molecular subtype (CMS) groups. These cases may represent a transition phenotype or reflect intratumoral heterogeneity, indicating the complexity and diversity within colorectal cancer tumors.",
        "Approximately 13% of colorectal cancer cases cannot be assigned to any of the four consensus molecular subtype (CMS) groups, characterized by mixed features that do not neatly fit into these categories. This phenomenon may represent a transition phenotype or intratumoral heterogeneity, highlighting the complexity of colorectal cancer\u0027s molecular landscape.",
        "Approximately 13% of colorectal cancer cases exhibit mixed features that are not assignable to any consensus molecular subtype (CMS) groups. These cases may represent a transition phenotype or intratumoral heterogeneity.",
        "13% of colorectal cancer cases are not assignable to any of the consensus molecular subtype (CMS) groups based on the study referenced.",
        "According to the research, approximately 13% of colorectal cancer samples display mixed features that cannot be clearly assigned to any specific consensus molecular subtype (CMS) group. These samples possibly represent a transition phenotype or demonstrate intratumoral heterogeneity, suggesting biological complexity that doesn\u0027t fit neatly into the established classification system.",
        "In studies examining colorectal cancer cases, approximately 13% of samples exhibit mixed features that prevent their assignment to any consensus molecular subtype (CMS) groups. These unclassifiable cases may represent a transition phenotype or intratumoral heterogeneity, where the tumor cells display diverse characteristics that do not align with defined CMS categories.",
        "According to the provided text, approximately 13% of samples are not assignable to any of the consensus molecular subtype (CMS) groups, as they exhibit mixed features, possibly representing a transition phenotype or intratumoral heterogeneity.",
        "According to the context, 13% of colorectal cancer samples had mixed features that could not be assigned to any of the consensus molecular subtype (CMS) groups, possibly representing a transition phenotype or intratumoral heterogeneity.",
        "Approximately 13% of colorectal cancer cases cannot be assigned to any of the four Consensus Molecular Subtypes (CMS), due to mixed features suggesting a transition phenotype or intratumoral heterogeneity. This consistent figure, reported across various sources, underscores the complexity and heterogeneity of colorectal cancer, emphasizing the need for further research into these transitional or mixed-feature cases, which exist alongside the defined CMS groups (CMS1: 14%, CMS2: 37%, CMS3: 13%, CMS4: 23%).",
        "The proportion of cases that are not assignable varies depending on the sample type. In surgical resection specimens, around 13–18% of cases remain unclassified, whereas in biopsy materials the proportion can be as high as 43%.",
        "About 13% of colorectal cancer cases are mixed feature cases possibly representing a transition phenotype or intratumoral heterogeneity.\nSamples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity.",
        "Based on the provided abstracts, the proportion of colorectal cancer cases not assignable to any of the consensus molecular subtype (CMS) groups varies across studies. One abstract indicates that 18.2% of patients were unclassified. Another abstract mentions that a large percentage of samples in the LB group were unclassified (43%). Additionally, 13% of samples with mixed features possibly represent a transition phenotype or intratumoral heterogeneity, which could contribute to unclassified cases. Finally, one abstract suggests that a higher proportion of Hispanic/Latino patients exhibited indeterminate CMS classifications. Therefore, the proportion of unclassified cases can range from 13% to 43% depending on the study population and classification methods.",
        "Approximately 13% of colorectal cancer samples show mixed molecular features that cannot be definitively assigned to a specific consensus molecular subtype (CMS) group, which may be due to either transitional phenotypes or intratumoral heterogeneity.",
        "Approximately 13% of colorectal cancer cases exhibit mixed features and thus cannot be definitively assigned to any single consensus molecular subtype (CMS) group.",
        "Approximately 13% of colorectal cancer cases have mixed features and cannot be assigned to any of the consensus molecular subtype (CMS) groups."
      ],
      "exact_answer": [
        [
          "13%",
          "13% mixed feature cases",
          "about 13%"
        ]
      ]
    },
    {
      "body": "Please list the short half life Phosphodiesterase 5 inhibitors.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29679708",
        "http://www.ncbi.nlm.nih.gov/pubmed/17183346",
        "http://www.ncbi.nlm.nih.gov/pubmed/16780568",
        "http://www.ncbi.nlm.nih.gov/pubmed/15115191",
        "http://www.ncbi.nlm.nih.gov/pubmed/27438594",
        "http://www.ncbi.nlm.nih.gov/pubmed/16959227",
        "http://www.ncbi.nlm.nih.gov/pubmed/17201266",
        "https://pubmed.ncbi.nlm.nih.gov/16959227/"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 659,
          "offsetInEndSection": 972,
          "text": "Although nonarteritic anterior ischaemic neuropathy has been reported in some users of the PDE5 inhibitors, there is no conclusive evidence that PDE5 inhibitors cause this rare effect. Tadalafil has a longer half-life than sildenafil or vardenafil, and a longer duration of action than sildenafil and vardenafil. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17183346"
        },
        {
          "offsetInBeginSection": 800,
          "offsetInEndSection": 909,
          "text": "Sildenafil and vardenafil both have half-lives of approximately 4 h but the half-life of tadalafil is 17.5 h.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16780568"
        },
        {
          "offsetInBeginSection": 1207,
          "offsetInEndSection": 1464,
          "text": "Differences in pharmacokinetic properties among the PDE5 inhibitors include the fact that sildenafil and vardenafil have a shorter duration of action (approximately 4 h) compared with the longer period of responsiveness observed with tadalafil (up to 36 h).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15115191"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "Sildenafil, a type 5 phosphodiesterase isoenzyme (PDE5) inhibitor with a short half-life, increases brain cyclic guanosine monophosphate (cGMP) levels and improves neurological functional recovery when administered after stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16959227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Sildenafil, a type 5 phosphodiesterase isoenzyme (PDE5) inhibitor with a short half-life, increases brain cyclic guanosine monophosphate (cGMP) levels and improves",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/16959227/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 378,
          "text": "ED treatment has changed fundamentally since phosphodiesterase type 5 inhibitor (PDE5-I) came into clinical use. There are three kinds of PDE5-I available at present, Sildenafil, Vardenafil and Tadalafil. Tadalafil distinguishes from the other two by its uniquely long half-life, which lasts 17.5h, which a pharmacodynamic duration of 36h and not influenced by food and alcohol.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17201266"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "Sildenafil citrate has short biological half-life in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29679708"
        },
        {
          "offsetInBeginSection": 404,
          "offsetInEndSection": 516,
          "text": "Tadalafil is pharmacokinetically distinct from sildenafil and has a longer half-life (17+hours) than sildenafil.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27438594"
        },
        {
          "offsetInBeginSection": 844,
          "offsetInEndSection": 971,
          "text": "Tadalafil has a longer half-life than sildenafil or vardenafil, and a longer duration of action than sildenafil and vardenafil.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17183346"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Sildenafil, a type 5 phosphodiesterase isoenzyme (PDE5) inhibitor with a short half-life,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16959227"
        }
      ],
      "type": "list",
      "id": "67cc973e81b1027333000011",
      "ideal_answer": [
        "Sildenafil and vardenafil are short half PDE 5 inhibitors",
        "Sildenafil and vardenafil are short half-life phosphodiesterase type 5 (PDE5) inhibitors.",
        "The short half-life phosphodiesterase 5 inhibitors (PDE5Is) include: sildenafil, avanafil, and vardenafil. These inhibitors are characterized by their rapid onset of action and shorter duration of effect compared to long half-life PDE5 inhibitors.",
        "Sildenafil and vardenafil are short half-life PDE5 inhibitors.",
        "Avanafil is noted in the snippet for its short half-life. In addition, clinical evidence supports that both sildenafil and vardenafil are recognized as having relatively short half-lives, in contrast to tadalafil, which has a prolonged half-life.",
        "Sildenafil, avanafil, mirodenafil, and vardenafil are Phosphodiesterase 5 inhibitors with short half-lives.",
        "The short half-life phosphodiesterase 5 (PDE5) inhibitors are: sildenafil, avanafil, and vardenafil. These medications are primarily used for the treatment of erectile dysfunction and have a rapid onset of action.",
        "The short half-life phosphodiesterase 5 inhibitors (PDE5Is) are: sildenafil, avanafil, and vardenafil. These inhibitors are recognized for their rapid onset of action but require more frequent dosing compared to long half-life alternatives like tadalafil.",
        "The short half-life phosphodiesterase 5 (PDE5) inhibitors include: sildenafil, avanafil.",
        "The phosphodiesterase 5 inhibitors with a short half-life (around 4 hours) are sildenafil and vardenafil, while tadalafil has a longer half-life of around 36 hours.",
        "The phosphodiesterase 5 inhibitors with a relatively short half-life are sildenafil (Viagra) and vardenafil (Levitra), with a duration of action of around 4 hours. In contrast, tadalafil (Cialis) has a longer half-life of around 36 hours.",
        "The short half-life phosphodiesterase 5 (PDE5) inhibitors are sildenafil and vardenafil, with a duration of action of around 4 hours. Tadalafil has a longer half-life of around 17.5 hours, resulting in an extended duration of response up to 36 hours.",
        "Based on the context provided, the short half-life Phosphodiesterase 5 inhibitors are:\n\n1. Sildenafil\n2. Vardenafil",
        "Sildenafil and vardenafil are the phosphodiesterase type 5 inhibitors with a shorter half-life of around 4 hours, while tadalafil has a longer half-life of about 36 hours.",
        "Sildenafil, vardenafil, and avanafil are the short half-life phosphodiesterase 5 inhibitors. Unlike tadalafil, which has a prolonged half-life, these drugs are typically eliminated within a few hours after administration.",
        "The short half-life Phosphodiesterase 5 (PDE5) inhibitors are sildenafil and vardenafil, both with a half-life of approximately 4 hours. These are contrasted with longer half-life inhibitors like tadalafil, which has a half-life exceeding 17 hours.",
        "The short half-life phosphodiesterase 5 (PDE5) inhibitors are sildenafil and vardenafil. Sildenafil has a half-life of approximately 3-5 hours, while vardenafil\u0027s half-life is around 4-5 hours. These shorter half-lives may result in a shorter duration of action compared to longer-acting PDE5 inhibitors.",
        "Based on the provided context, the short half-life Phosphodiesterase 5 inhibitors are sildenafil, vardenafil, and udenafil.",
        "The short half-life Phosphodiesterase 5 (PDE5) inhibitors include Sildenafil and Vardenafil, both with an approximate half-life of 4 hours. These inhibitors have a shorter duration of side effects compared to longer-acting PDE5 inhibitors like tadalafil.",
        "Sildenafil and vardenafil are the PDE5 inhibitors with shorter half-lives compared to tadalafil. These medications are used to treat erectile dysfunction and have different pharmacokinetic properties.",
        "The short half life Phosphodiesterase 5 (PDE5) inhibitors include sildenafil (Viagra), vardenafil (Levitra), and avanafil (Stendra). These drugs are characterized by their relatively shorter duration of action compared to tadalafil (Cialis), which has a longer half life.",
        "Sildenafil and Vardenafil are phosphodiesterase-5 (PDE5) inhibitors with shorter half-lives compared to Tadalafil.",
        "The short half life Phosphodiesterase 5 (PDE5) inhibitors listed in the context are sildenafil and vardenafil. These drugs have a shorter duration of action compared to tadalafil, which has a longer half life.",
        "Sildenafil and vardenafil are phosphodiesterase 5 inhibitors with a short half-life.",
        "Avanafil and Sildenafil are Phosphodiesterase 5 inhibitors with a short half life.",
        "Sildenafil and vardenafil have shorter half-lives compared to tadalafil.",
        "Vardenafil and sildenafil are short half life Phosphodiesterase 5 inhibitors.",
        "The short half-life phosphodiesterase 5 (PDE5) inhibitors include sildenafil, vardenafil, and avanafil. These inhibitors typically have a half-life of approximately 4 hours, which is significantly shorter than that of tadalafil.",
        "Avanafil is recognized for its short half-life, and both sildenafil and vardenafil have shorter half-lives compared to tadalafil. Therefore, the short half-life phosphodiesterase 5 inhibitors include avanafil, sildenafil, and vardenafil.",
        "Sildenafil and vardenafil are Phosphodiesterase 5 inhibitors with shorter half-lives. Tadalafil has a longer half-life than sildenafil or vardenafil.",
        "Sildenafil and vardenafil have a shorter half-life compared to tadalafil.",
        "The PDE5 inhibitors with a shorter half-life are sildenafil and vardenafil.",
        "Sildenafil and vardenafil are short half-life Phosphodiesterase 5 inhibitors compared to tadalafil.",
        "Among phosphodiesterase-5 (PDE5) inhibitors, sildenafil has a shorter half-life compared to tadalafil, which is noted for its longer duration of action and half-life relative to both sildenafil and vardenafil.",
        "The short half-life phosphodiesterase 5 inhibitors are: sildenafil, vardenafil.",
        "Sildenafil and vardenafil are Phosphodiesterase 5 inhibitors with shorter half-lives compared to tadalafil.",
        "Based on the provided information, the short half-life Phosphodiesterase 5 (PDE5) inhibitors are:\n\n1. Sildenafil\n2. Vardenafil\n\nThese two PDE5 inhibitors have a shorter half-life compared to Tadalafil, which has a longer half-life and duration of action.",
        "The short half-life phosphodiesterase 5 inhibitors include: sildenafil, avanafil, and vardenafil. These inhibitors are characterized by their rapid onset and shorter duration of action compared to long half-life PDE5 inhibitors like tadalafil.",
        "The short half-life phosphodiesterase 5 inhibitors include sildenafil and avanafil. These inhibitors are characterized by their rapid elimination from the body, resulting in a shorter duration of action compared to long half-life PDE5 inhibitors like tadalafil.",
        "The short half-life phosphodiesterase 5 inhibitors (PDE5 inhibitors) include: sildenafil, avanafil, and vardenafil. These inhibitors are characterized by their shorter duration of action compared to long half-life PDE5 inhibitors like tadalafil.",
        "The short half-life Phosphodiesterase 5 (PDE5) inhibitors mentioned are: 1. Vardenafil (elimination half-life: 4-5 hours) 2. Sildenafil (short biological half-life, approximately 4-6 hours in humans, though exact duration not uniformly specified in the abstracts)",
        "Tadalafil has a longer half-life than sildenafil or vardenafil, and a longer duration of action than sildenafil and vardenafil.",
        "Based on the context provided, sildenafil and vardenafil are known to have a shorter half life compared to tadalafil, which has a longer duration of action.",
        "Tadalafil has a longer half-life than sildenafil or vardenafil. Therefore, sildenafil and vardenafil are short half life Phosphodiesterase 5 inhibitors.",
        " Sildenafil and Vardenafil have shorter half-lives compared to Tadalafil in Phosphodiesterase 5 inhibitors.",
        "Studies have shown that sildenafil and vardenafil are examples of Phosphodiesterase 5 (PDE5) inhibitors with a shorter half-life compared to tadalafil, which has a longer duration of action.",
        "Based on the provided text, the Phosphodiesterase 5 (PDE5) inhibitors with a shorter half-life are:\n\n1. Sildenafil\n2. Vardenafil\n\nThese two PDE5 inhibitors have a shorter half-life compared to Tadalafil, which has a longer half-life.",
        "Sildenafil and vardenafil are the phosphodiesterase 5 (PDE5) inhibitors with shorter half-lives compared to tadalafil.",
        "The short half-life Phosphodiesterase 5 (PDE5) inhibitors are Vardenafil (4-5 hours) and Sildenafil (approximately 4-6 hours), consistently identified across sources for their relatively shorter half-lives.",
        "Sildenafil and vardenafil are the short half-life phosphodiesterase 5 inhibitors. Tadalafil, on the other hand, has a longer half-life and duration of action.",
        "Vardenafil, Sildenafil are the short half life Phosphodiesterase 5 inhibitors.",
        "Based on the provided text, sildenafil and vardenafil have shorter half-lives compared to tadalafil. Therefore, sildenafil and vardenafil are the short half-life Phosphodiesterase 5 inhibitors.",
        "Among the PDE5 inhibitors, sildenafil and vardenafil have shorter half-lives and duration of action compared to tadalafil, making them shorter-acting options in this drug class.",
        "Sildenafil and vardenafil are short half-life Phosphodiesterase 5 inhibitors."
      ],
      "exact_answer": [
        [
          "sildenafil"
        ],
        [
          "vardenafil"
        ],
        [
          "Mirodenafil"
        ],
        [
          "Avanafil"
        ],
        [
          "Udenafil"
        ]
      ]
    },
    {
      "body": "Pathophysiology of irritable bowel syndrome (IBS).",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39378890",
        "http://www.ncbi.nlm.nih.gov/pubmed/39004156",
        "http://www.ncbi.nlm.nih.gov/pubmed/38505711",
        "http://www.ncbi.nlm.nih.gov/pubmed/38804299",
        "http://www.ncbi.nlm.nih.gov/pubmed/38496157",
        "http://www.ncbi.nlm.nih.gov/pubmed/38467533",
        "http://www.ncbi.nlm.nih.gov/pubmed/24627583",
        "http://www.ncbi.nlm.nih.gov/pubmed/19665956",
        "http://www.ncbi.nlm.nih.gov/pubmed/16718806",
        "http://www.ncbi.nlm.nih.gov/pubmed/25734736",
        "http://www.ncbi.nlm.nih.gov/pubmed/16898611",
        "http://www.ncbi.nlm.nih.gov/pubmed/21333899",
        "http://www.ncbi.nlm.nih.gov/pubmed/31594651",
        "http://www.ncbi.nlm.nih.gov/pubmed/26167065",
        "http://www.ncbi.nlm.nih.gov/pubmed/36171718",
        "http://www.ncbi.nlm.nih.gov/pubmed/20465787",
        "http://www.ncbi.nlm.nih.gov/pubmed/32308344",
        "http://www.ncbi.nlm.nih.gov/pubmed/25083061",
        "http://www.ncbi.nlm.nih.gov/pubmed/18924450",
        "http://www.ncbi.nlm.nih.gov/pubmed/25083055",
        "http://www.ncbi.nlm.nih.gov/pubmed/38035060",
        "http://www.ncbi.nlm.nih.gov/pubmed/24829543",
        "http://www.ncbi.nlm.nih.gov/pubmed/36250361",
        "http://www.ncbi.nlm.nih.gov/pubmed/16440408",
        "http://www.ncbi.nlm.nih.gov/pubmed/26447966",
        "http://www.ncbi.nlm.nih.gov/pubmed/34349876",
        "http://www.ncbi.nlm.nih.gov/pubmed/34631603",
        "http://www.ncbi.nlm.nih.gov/pubmed/39274340",
        "http://www.ncbi.nlm.nih.gov/pubmed/17177577",
        "https://pubmed.ncbi.nlm.nih.gov/28404070/",
        "https://pubmed.ncbi.nlm.nih.gov/12077070/",
        "https://pubmed.ncbi.nlm.nih.gov/34430628/",
        "http://www.ncbi.nlm.nih.gov/pubmed/34304786",
        "http://www.ncbi.nlm.nih.gov/pubmed/34638577",
        "http://www.ncbi.nlm.nih.gov/pubmed/38045643",
        "http://www.ncbi.nlm.nih.gov/pubmed/21607147",
        "http://www.ncbi.nlm.nih.gov/pubmed/35296814",
        "http://www.ncbi.nlm.nih.gov/pubmed/28115927",
        "http://www.ncbi.nlm.nih.gov/pubmed/37160449",
        "http://www.ncbi.nlm.nih.gov/pubmed/34430628",
        "http://www.ncbi.nlm.nih.gov/pubmed/28404070",
        "http://www.ncbi.nlm.nih.gov/pubmed/24944466/",
        "http://www.ncbi.nlm.nih.gov/pubmed/22363132/",
        "http://www.ncbi.nlm.nih.gov/pubmed/35145413",
        "http://www.ncbi.nlm.nih.gov/pubmed/24503633",
        "http://www.ncbi.nlm.nih.gov/pubmed/18948690",
        "http://www.ncbi.nlm.nih.gov/pubmed/32026278",
        "http://www.ncbi.nlm.nih.gov/pubmed/27159638"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1441,
          "text": "dysregulated interaction between autonomic and central nervous systems in women with IBS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39378890"
        },
        {
          "offsetInBeginSection": 23,
          "offsetInEndSection": 221,
          "text": "pathophysiology of irritable bowel syndrome (IBS) is multifactorial and includes epithelial barrier dysfunction, a key element at the interface between the gut lumen and the deeper intestinal layers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004156"
        },
        {
          "offsetInBeginSection": 380,
          "offsetInEndSection": 482,
          "text": "correlate morpho-functional aspects of epithelial and vascular barriers with symptom perception in IBS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004156"
        },
        {
          "offsetInBeginSection": 1232,
          "offsetInEndSection": 1448,
          "text": "The intestinal epithelial barrier was compromised in patients with IBS throughout the gastrointestinal tract. IBS-soluble mediators increased Caco-2 permeability via a downregulation of tight junction gene expression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004156"
        },
        {
          "offsetInBeginSection": 1450,
          "offsetInEndSection": 1537,
          "text": "Blood vessel density and vascular permeability were increased in the IBS colonic mucosa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004156"
        },
        {
          "offsetInBeginSection": 1779,
          "offsetInEndSection": 1906,
          "text": "Permeability changes correlated with intestinal and behavioral symptoms and health-related quality of life of patients with IBS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004156"
        },
        {
          "offsetInBeginSection": 1920,
          "offsetInEndSection": 2031,
          "text": "Epithelial and vascular barriers are compromised in patients with IBS and contribute to clinical manifestations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39004156"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 375,
          "text": "immune activation plays an important role in the development of IBS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38505711"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 494,
          "text": "visceral hypersensitivity and gastrointestinal dysmotility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38505711"
        },
        {
          "offsetInBeginSection": 565,
          "offsetInEndSection": 634,
          "text": "inflammatory degenerative neuropathy, including neuronal degeneration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38505711"
        },
        {
          "offsetInBeginSection": 585,
          "offsetInEndSection": 652,
          "text": "gut microbiota, neurotrophic factors, and proinflammatory cytokines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38804299"
        },
        {
          "offsetInBeginSection": 1049,
          "offsetInEndSection": 1170,
          "text": " underlying dietary triggers in IBS, including gut microbiota dysbiosis, visceral hypersensitivity, and immune activation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38496157"
        },
        {
          "offsetInBeginSection": 574,
          "offsetInEndSection": 758,
          "text": "dysregulation of the brain-gut axis, leading to disturbed intestinal motility, local inflammation, altered intestinal permeability, visceral sensitivity, and gut microbiota composition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38467533"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 806,
          "text": "Multiple factors are thought to contribute to the symptoms in IBS patients; altered gastrointestinal motility, visceral hypersensitivity, and the brain-gut interaction are important classical concepts in IBS pathophysiology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627583"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 252,
          "text": "The pathophysiology of IBS is complex and still incompletely known. Both central and peripheral factors are thought to contribute to the symptoms of IBS, including psychosocial factors, abnormal GI motility and secretion, and visceral hypersensitivity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19665956"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1232,
          "text": "The pathophysiology of IBS is complex and still incompletely known. Both central and peripheral factors, including psychosocial factors, abnormal GI motility and secretion, and visceral hypersensitivity, are thought to contribute to the symptoms of IBS. Several studies have demonstrated altered GI motor function in IBS patients and the pattern differs between IBS subgroups based on the predominant bowel pattern. Few studies have so far addressed GI secretion in IBS, but there are some evidence supporting altered secretion in the small intestine of IBS patients. Visceral hypersensitivity is currently considered to be perhaps the most important pathophysiological factor in IBS. Importantly, several external and internal factors can modulate visceral sensitivity, as well as GI motility, and enhanced responsiveness within the GI tract to for instance stress and nutrients has been demonstrated in IBS patients. Today IBS is viewed upon as a disorder of dysregulation of the so-called brain-gut axis, involving abnormal function in the enteric, autonomic and/or central nervous systems, with peripheral alterations probably dominating in some patients and disturbed central processing of signals from the periphery in others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16718806"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 283,
          "text": "Irritable bowel syndrome (IBS) is considered a biopsychosocial disorder resulting from a combination of 3 interacting mechanisms: psychosocial factors, altered motility and transit, which may reflect severity of bowel dysfunction, and increased sensitivity of the intestine or colon.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16898611"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 402,
          "text": "Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, the pathophysiology of which is not completely known, although it has been shown that genetic/social learning factors, diet, intestinal microbiota, intestinal low-grade inflammation, and abnormal gastrointestinal endocrine cells play a major role. Studies of familial aggregation and on twins have confirmed the heritability of IBS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26167065"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 317,
          "text": "Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, the pathophysiology of which is not completely known, although it has been shown that genetic/social learning factors, diet, intestinal microbiota, intestinal low-grade inflammation, and abnormal gastrointestinal endocrine cells play a major role.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26167065"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 1031,
          "text": "Over the years, speculations of the pathophysiology of IBS has moved from elusive central nervous symptoms impinging on psychosomatic disease, to objective signs of intestinal fermentation with abdominal bloating and intestinal dysmotility. The specific subgroup of post-infectious IBS is of special interest since it opens the possibility of dysbiosis as the pivotal point for development of IBS in association with traveler\u0027s diarrhea or antibiotic treatment with ensuing dysbiosis and abdominal symptoms that may resolve over decades. The undefined disease mechanisms that take place within the gut seem responsible for the gut-brain signaling leading to activation of brain centers that drive the clinical picture of IBS, further modulated by the patient\u0027s social background and previous lifetime events.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31594651"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 1003,
          "text": "Multiple factors are thought to contribute to the symptoms in IBS patients; altered gastrointestinal motility, visceral hypersensitivity, and the brain-gut interaction are important classical concepts in IBS pathophysiology. New areas of research in this arena include inflammation, postinfectious low-grade inflammation, genetic and immunologic factors, an altered microbiota, dietary factors, and enteroendocrine cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627583"
        },
        {
          "offsetInBeginSection": 315,
          "offsetInEndSection": 827,
          "text": " Recent studies indicate that the most important mechanisms include visceral sensitivity, abnormal gut motility and autonomous nervous system dysfunction. The interactions between these three mechanisms make bowel\u0027s function susceptible to many exogenous and endogenous factors like gastrointestinal flora, feeding and psychosocial factors. Recent data indicate that according to the above mechanisms, the influence of genetic factors and polymorphisms of human DNA in the development of IBS is equally important",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20465787"
        },
        {
          "offsetInBeginSection": 275,
          "offsetInEndSection": 593,
          "text": "The pathophysiology of IBS is not yet completely clear. Genetic, immune, environmental, inflammatory, neurological and psychological factors, in addition to visceral hypersensitivity, can all play an important role, one that most likely involves the complex interactions between the gut and the brain (gut-brain axis).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25083055"
        },
        {
          "offsetInBeginSection": 236,
          "offsetInEndSection": 686,
          "text": "Studies of intestinal bacteria, low-grade mucosal inflammation, and increased mucosal permeability-factors involved in the pathophysiology of IBS-have been conducted. In addition, the involvement of intestinal bacteria in IBS pathology has been clarified; many studies of treatments related to intestinal bacteria have been reported. Moreover, several studies address the effect on IBS of antidepressants and psychotherapy through the brain-gut axis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36171718"
        },
        {
          "offsetInBeginSection": 301,
          "offsetInEndSection": 500,
          "text": "The pathophysiology of IBS is multifactorial and involves motility disorders, genetic factors, immune responses, visceral hypersensitivity, brain-gut dysregulation, and altered intestinal microbiota.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38035060"
        },
        {
          "offsetInBeginSection": 256,
          "offsetInEndSection": 1090,
          "text": "Its pathogenesis is multifactorial: visceral hypersensitivity, dysmotility, psychosocial factors, genetic or environmental factors, dysregulation of the brain-gut axis, and altered intestinal microbiota have all been proposed as possible causes. The human intestinal microbiota are composed of more than 1000 different bacterial species and 10(14) cells, and are essential for the development, function, and homeostasis of the intestine, and for individual health. The putative mechanisms that explain the role of microbiota in the development of IBS include altered composition or metabolic activity of the microbiota, mucosal immune activation and inflammation, increased intestinal permeability and impaired mucosal barrier function, sensory-motor disturbances provoked by the microbiota, and a disturbed gut-microbiota-brain axis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25083061"
        },
        {
          "offsetInBeginSection": 347,
          "offsetInEndSection": 865,
          "text": "Recent studies have identified new additional factors that can interact with the established mechanisms. Dysregulation of brain-gut axis, gastrointestinal infection, low-grade infiltration and activation of mast cells in the intestinal mucosa with consequent release of bioactive substances, and altered serotonin metabolism are the emerging factors of IBS pathogenesis. Finally, modification of small bowel and colonic microflora and altered gas balance may be of relevance in at least some subgroups of IBS patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18924450"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 604,
          "text": "The pathogenesis of symptoms in irritable bowel syndrome (IBS) is multifactorial and varies from patient to patient. Disturbances of motor function in the small intestine and colon and smooth-muscle dysfunction in other gut and extraintestinal regions are prominent. Abnormalities of sensory function in visceral and somatic structures are detected in most patients with IBS, which may relate to peripheral sensitization or altered central nervous system processing of afferent information. Contributions from psychosocial disturbances are observed in patients from tertiary centers and primary practice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21333899"
        },
        {
          "offsetInBeginSection": 280,
          "offsetInEndSection": 550,
          "text": "The pathophysiology of IBS is poorly understood and is currently thought to represent a complex interplay among the gut microbiota, low-grade inflammation, impaired mucosal barrier function, visceral hypersensitivity, gut motility, and alterations in the gut-brain axis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24829543"
        },
        {
          "offsetInBeginSection": 444,
          "offsetInEndSection": 581,
          "text": "Although a great deal of research has been carried out in this area, the pathophysiology of IBS is complex and not completely understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627583"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 301,
          "text": "The etiology of IBS is multifactorial, including abnormal gut-brain interactions, visceral hypersensitivity, altered colon motility, and psychological factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250361"
        },
        {
          "offsetInBeginSection": 302,
          "offsetInEndSection": 454,
          "text": "Recent studies have shown that the intestinal microbiota and its metabolites short chain fatty acids (SCFAs) may be involved in the pathogenesis of IBS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250361"
        },
        {
          "offsetInBeginSection": 455,
          "offsetInEndSection": 514,
          "text": "SCFAs play an important role in the pathophysiology of IBS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250361"
        },
        {
          "offsetInBeginSection": 807,
          "offsetInEndSection": 1003,
          "text": "New areas of research in this arena include inflammation, postinfectious low-grade inflammation, genetic and immunologic factors, an altered microbiota, dietary factors, and enteroendocrine cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627583"
        },
        {
          "offsetInBeginSection": 269,
          "offsetInEndSection": 572,
          "text": "Advances in our understanding of gut flora-mucosal interactions, the enteric nervous system and the brain-gut axis have led to substantial progress in the pathogenesis of symptoms in IBS and have provided some hints towards the basic etiology of this disorder, in some subpopulations, at the very least.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16440408"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 317,
          "text": "The etiology and the pathogenesis of IBS are still not clear; however, recent studies have implicated a role for alterations in the intestinal microbiota (dysbiosis) in the pathophysiology of the disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26447966"
        },
        {
          "offsetInBeginSection": 338,
          "offsetInEndSection": 650,
          "text": "Among the many pathophysiologic factors, such as altered GI motility, visceral hypersensitivity, and low-grade mucosal inflammation, as well as other immunologic, psychologic, and genetic factors, gut microbiota imbalance (dysbiosis), which is frequently found in IBS, has been highlighted as an etiology of IBS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34349876"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Irritable bowel syndrome (IBS) is a disease of unclear, complex pathophysiology characterised by abdominal pain and discomfort and altered bowel activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17177577"
        },
        {
          "offsetInBeginSection": 305,
          "offsetInEndSection": 462,
          "text": "There is epidemiological evidence that, in a major subset of patients, gastrointestinal symptoms arise first and only later do incident mood disorders occur.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/28404070/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Visceral hypersensitivity has been recognised as a characteristic of patients with irritable bowel syndrome (IBS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/12077070/"
        },
        {
          "offsetInBeginSection": 713,
          "offsetInEndSection": 890,
          "text": " and intestinal inflammation.CONCLUSIONS: One of the main features of IBS is the occurrence of structural and functional disruptions in the gut-brain axis, which alter reflectiv",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/34430628/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "Irritable bowel syndrome (IBS) is the most common functional bowel disorder worldwide and is associated with visceral hypersensitivity, gut motility, immunomodulation, gut microbiota alterations, and dysfunction of the brain-gut axis; however, its pathophysiology remains poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34631603"
        },
        {
          "offsetInBeginSection": 380,
          "offsetInEndSection": 585,
          "text": "It highlights the effects of gut microbiota on mechanisms implicated in the pathophysiology of IBS, including gut-brain axis, visceral hypersensitivity, motility, epithelial barrier, and immune activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34304786"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 366,
          "text": "Details regarding the pathogenesis of IBS remain largely unknown, though the dysfunction of the brain-gut-microbiome (BGM) axis is a major etiological factor, in which neurotransmitters serve as a key communication tool between enteric microbiota and the brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34638577"
        },
        {
          "offsetInBeginSection": 721,
          "offsetInEndSection": 1090,
          "text": "The putative mechanisms that explain the role of microbiota in the development of IBS include altered composition or metabolic activity of the microbiota, mucosal immune activation and inflammation, increased intestinal permeability and impaired mucosal barrier function, sensory-motor disturbances provoked by the microbiota, and a disturbed gut-microbiota-brain axis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25083061"
        },
        {
          "offsetInBeginSection": 426,
          "offsetInEndSection": 539,
          "text": "In addition, recent evidence suggests that dysbiosis may be a key pathophysiological factor in patients with IBS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38045643"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "The pathogenesis of irritable bowel syndrome (IBS) is considered to be multifactorial and includes psychosocial factors, visceral hypersensitivity, infection, microbiota and immune activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21607147"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 461,
          "text": "The pathophysiology of IBS is rather complex and multifactorial including, for example, altered signalling by the gut-brain axis, dysbiosis, abnormal visceral pain signalling and intestinal immune activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35296814"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 443,
          "text": "Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, but its treatment is unsatisfactory as its pathophysiology is multifactorial. The putative factors of IBS pathophysiology are visceral hypersensitivity and intestinal dysmotility, also including psychological factors, dysregulated gut-brain axis, intestinal microbiota alterations, impaired intestinal permeability, and mucosal immune alterations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28115927"
        },
        {
          "offsetInBeginSection": 477,
          "offsetInEndSection": 759,
          "text": "While the exact pathophysiology of IBS remains incompletely understood, the mechanism involves a dysregulation of the brain-gut axis, leading to disturbed intestinal motility, local inflammation, altered intestinal permeability, visceral sensitivity, and gut microbiota composition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38467533"
        },
        {
          "offsetInBeginSection": 381,
          "offsetInEndSection": 712,
          "text": "iochemical anomalies.METHODS: The etiology of IBS has not been clearly described but is known to be multifactorial, involving GI motility changes, post-infectious reactivity, visceral hypersensitivity, gut-brain interactions, microbiota dysbiosis, small intestinal bacterial overgrowth, food sensitivity, carbohydrate malabsorption",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34430628"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Irritable bowel syndrome (IBS) is a complex multifactorial condition including alterations of the gut-brain axis, intestinal permeability, mucosal neuro-immune interactions, and microbiota imbalance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37160449"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 443,
          "text": "The putative factors of IBS pathophysiology are visceral hypersensitivity and intestinal dysmotility, also including psychological factors, dysregulated gut-brain axis, intestinal microbiota alterations, impaired intestinal permeability, and mucosal immune alterations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28115927"
        },
        {
          "offsetInBeginSection": 626,
          "offsetInEndSection": 1130,
          "text": "Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28404070"
        },
        {
          "offsetInBeginSection": 256,
          "offsetInEndSection": 501,
          "text": "Its pathogenesis is multifactorial: visceral hypersensitivity, dysmotility, psychosocial factors, genetic or environmental factors, dysregulation of the brain-gut axis, and altered intestinal microbiota have all been proposed as possible causes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25083061"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 376,
          "text": "Irritable bowel syndrome (IBS) is considered a biopsychosocial disorder, whose onset and precipitation are a consequence of interaction among multiple factors which include motility disturbances, abnormalities of gastrointestinal sensation, gut inflammation and infection, altered processing of afferent sensory information, psychological distress, and affective disturbances.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24944466/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 408,
          "text": "From a pure motor disorder of the bowel, in the past few years, irritable bowel syndrome (IBS) has become a multifactorial disease that implies visceral hypersensitivity, alterations at the level of nervous and humoral communications between the enteric nervous system and the central nervous system, alteration of the gut microflora, an increased intestinal permeability and minimum intestinal inflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22363132/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 812,
          "text": "Functional gastrointestinal disorders (FGIDs) have been re-named as disorders of gut-brain interactions. These conditions are not only common in clinical practice, but also in the community. In reference to the Rome IV criteria, the most common FGIDs, include functional dyspepsia (FD) and irritable bowel syndrome (IBS). Additionally, there is substantial overlap of these disorders and other specific gastrointestinal motility disorders, such as gastroparesis. These disorders are heterogeneous and are intertwined with several proposed pathophysiological mechanisms, such as altered gut motility, intestinal barrier dysfunction, gut immune dysfunction, visceral hypersensitivity, altered GI secretion, presence and degree of bile acid malabsorption, microbial dysbiosis, and alterations to the gut-brain axis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35145413"
        },
        {
          "offsetInBeginSection": 367,
          "offsetInEndSection": 608,
          "text": "One of the most important neurotransmitters in the pathology of IBS is serotonin (5-HT), as it influences gastrointestinal motility, pain sensation, mucosal inflammation, immune responses, and brain activity, all of which shape IBS features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34638577"
        },
        {
          "offsetInBeginSection": 1043,
          "offsetInEndSection": 1550,
          "text": "The density of intestinal endocrine cells is reduced in patients with IBS, possibly as a result of genetic factors, diet, intestinal microbiota, and low-grade inflammation interfering with the regulatory signals controlling the intestinal stem-cell clonogenic and differentiation activities. Furthermore, there is speculation that this decreased number of endocrine cells is responsible for the visceral hypersensitivity, disturbed gastrointestinal motility, and abnormal gut secretion seen in IBS patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26167065"
        },
        {
          "offsetInBeginSection": 909,
          "offsetInEndSection": 1111,
          "text": " combined patients with IBS was seen.CONCLUSIONS: Delayed gastric emptying was identified in IBS and in some patients may contribute to at least a component of their symptoms. Constipation-predominant I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24503633"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1334,
          "text": "Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, the pathophysiology of which is not completely known, although it has been shown that genetic/social learning factors, diet, intestinal microbiota, intestinal low-grade inflammation, and abnormal gastrointestinal endocrine cells play a major role. Studies of familial aggregation and on twins have confirmed the heritability of IBS. However, the proposed IBS risk genes are thus far nonvalidated hits rather than true predisposing factors. There is no convincing evidence that IBS patients suffer from food allergy/intolerance, with the effect exerted by diet seemingly caused by intake of poorly absorbed carbohydrates and fiber. Obesity is a possible comorbidity of IBS. Differences in the microbiota between IBS patients and healthy controls have been reported, but the association between IBS symptoms and specific bacterial species is uncertain. Low-grade inflammation appears to play a role in the pathophysiology of a major subset of IBS, namely postinfectious IBS. The density of intestinal endocrine cells is reduced in patients with IBS, possibly as a result of genetic factors, diet, intestinal microbiota, and low-grade inflammation interfering with the regulatory signals controlling the intestinal stem-cell clonogenic and differentiation activities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26167065"
        },
        {
          "offsetInBeginSection": 344,
          "offsetInEndSection": 933,
          "text": "Low density of intestinal stem cells and low differentiation toward enteroendocrine cells has been reported recently in patients with IBS. These abnormalities are believed to be the cause of the low density of enteroendocrine cells seen in patients with IBS. Enteroendocrine cells regulate gastrointestinal motility, secretion, absorption and visceral sensitivity. Gastrointestinal dysmotility, abnormal absorption/secretion and visceral hypersensitivity are all seen in patients with IBS and haven been attributed to the low density the intestinal enteroendocrine cells in these patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32308344"
        },
        {
          "offsetInBeginSection": 131,
          "offsetInEndSection": 431,
          "text": "wel habits. The pathophysiological mechanism is complex and still remains incompletely clear. Alterations at both the central and the peripheral level are thought to contribute to the symptoms of IBS, including psychosocial factors, visceral hypersensitivity and abnormal gastrointestinal motility an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18948690"
        },
        {
          "offsetInBeginSection": 766,
          "offsetInEndSection": 1030,
          "text": "Numerous studies have demonstrated the involvement of the gut-brain axis, visceral hypersensitivity, gastrointestinal dysmotility, gut microbiota dysbiosis, food allergies and intolerances, low-grade mucosal inflammation, genetic factors, and psychosocial factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39274340"
        },
        {
          "offsetInBeginSection": 907,
          "offsetInEndSection": 1118,
          "text": "tom cluster resulting from diverse pathologies. Factors important to the development of IBS include alterations in the gut microbiome, intestinal permeability, gut immune function, motility, visceral sensation, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25734736"
        },
        {
          "offsetInBeginSection": 558,
          "offsetInEndSection": 762,
          "text": "These changes may explain some of the symptoms of IBS, including visceral hypersensitivity, as gut microbes exert effects on the host immune system and gut barrier function, as well as the brain-gut axis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32026278"
        },
        {
          "offsetInBeginSection": 1335,
          "offsetInEndSection": 1550,
          "text": "Furthermore, there is speculation that this decreased number of endocrine cells is responsible for the visceral hypersensitivity, disturbed gastrointestinal motility, and abnormal gut secretion seen in IBS patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26167065"
        },
        {
          "offsetInBeginSection": 675,
          "offsetInEndSection": 918,
          "text": "Although the underlying pathogenesis is far from understood, aetiological factors include increased epithelial hyperpermeability, dysbiosis, inflammation, visceral hypersensitivity, epigenetics and genetics, and altered brain-gut interactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27159638"
        }
      ],
      "id": "67d722e818b1e36f2e000036",
      "ideal_answer": [
        "The pathophysiology of IBS is complex, and factors such as dysregulated interaction between autonomic and central nervous systems, epithelial barrier dysfunction, blood vessel density and vascular permeability in the IBS colonic mucosa, immune activation, visceral hypersensitivity and gastrointestinal dysmotility, inflammatory degenerative neuropathy, including neuronal degeneration, \ngut microbiota, neurotrophic factors, and proinflammatory cytokines are all being considered.",
        "The pathophysiology of irritable bowel syndrome (IBS) is complex and involves multiple factors. It is believed to include dysregulation of the gut-brain axis, leading to altered gut motility and visceral hypersensitivity. Patients may experience abnormal intestinal muscle contractions, resulting in diarrhea, constipation, or both. Increased sensitivity to pain and discomfort in the gastrointestinal tract is common, causing significant pain even with normal amounts of gas or stool. Some IBS patients exhibit low-grade inflammation and immune system activation, with higher levels of immune cells and inflammatory cytokines in the gut. Alterations in gut microbiota (dysbiosis) are also associated with IBS, affecting gut function and contributing to symptoms. Psychological factors such as stress, anxiety, and depression can exacerbate symptoms by influencing gut motility and sensitivity. Additionally, there may be a genetic predisposition to IBS, and environmental factors like infections, diet, and stress can trigger or worsen symptoms. Overall, IBS is a multifactorial disorder with physiological, psychological, and environmental components contributing to its pathophysiology.",
        "The pathophysiology of Irritable Bowel Syndrome (IBS) is multifactorial and involves several interconnected mechanisms:\n\n1. **Altered Gut Motility**: Abnormal contractions of the gastrointestinal tract lead to either diarrhea or constipation, depending on whether motility is increased or decreased.\n\n2. **Visceral Hypersensitivity**: Enhanced sensitivity of the gut lining causes pain perception even with normal stimuli, contributing to abdominal discomfort and bloating.\n\n3. **Gut-Brain Axis Dysregulation**: Miscommunication between the central nervous system and the enteric nervous system can amplify symptoms, particularly under stress or psychological distress.\n\n4. **Neurotransmitter Imbalance**: Serotonin, a key neurotransmitter in gut function, is often dysregulated in IBS, affecting both motility and pain perception.\n\n5. **Gut Microbiota Dysbiosis**: An imbalanced microbiome can trigger inflammation and alter gut function, potentially exacerbating IBS symptoms.\n\n6. **Low-Grade Inflammation**: Immune system activation in the gut may contribute to chronic inflammation, further complicating symptomology.\n\nThese factors interact uniquely in each individual, leading to the diverse presentation of IBS symptoms.",
        "The pathophysiology of irritable bowel syndrome (IBS) is multifactorial and not fully understood, involving a complex interplay of various factors. Key elements include:\n\n1. **Epithelial Barrier Dysfunction**: Compromised intestinal epithelial barriers are observed in IBS patients, leading to increased permeability and altered tight junction gene expression. This dysfunction correlates with symptom perception and health-related quality of life.\n\n2. **Vascular Changes**: Increased blood vessel density and vascular permeability in the colonic mucosa contribute to the clinical manifestations of IBS.\n\n3. **Neuroimmune Interactions**: Immune activation plays a significant role, with inflammatory processes and neurotrophic factors influencing the condition. There is also evidence of inflammatory degenerative neuropathy, including neuronal degeneration.\n\n4. **Gut-Brain Axis Dysregulation**: Disordered communication between the gut and the central nervous system leads to visceral hypersensitivity, gastrointestinal dysmotility, and altered intestinal motility.\n\n5. **Microbiota and Dietary Factors**: Dysbiosis of gut microbiota and specific dietary triggers are implicated in IBS, affecting gut health and symptom severity.\n\n6. **Genetic and Environmental Factors**: Genetic predispositions, such as mutations in the SCN5A gene, along with post-infectious changes and chronic infections, may contribute to the development of IBS.\n\nOverall, IBS is characterized by chronic abdominal pain and altered bowel habits, significantly impacting patients\u0027 quality of life and presenting diagnostic and treatment challenges."
      ]
    },
    {
      "body": "What is the role of the receptor tyrosine kinase AXL in malignancy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28072762",
        "http://www.ncbi.nlm.nih.gov/pubmed/33806258",
        "http://www.ncbi.nlm.nih.gov/pubmed/23649974",
        "http://www.ncbi.nlm.nih.gov/pubmed/32148495",
        "http://www.ncbi.nlm.nih.gov/pubmed/27048336",
        "http://www.ncbi.nlm.nih.gov/pubmed/31694201",
        "http://www.ncbi.nlm.nih.gov/pubmed/27834845",
        "http://www.ncbi.nlm.nih.gov/pubmed/35158733",
        "http://www.ncbi.nlm.nih.gov/pubmed/29434997",
        "http://www.ncbi.nlm.nih.gov/pubmed/28210148",
        "http://www.ncbi.nlm.nih.gov/pubmed/25337673",
        "http://www.ncbi.nlm.nih.gov/pubmed/38714043",
        "http://www.ncbi.nlm.nih.gov/pubmed/37328828",
        "http://www.ncbi.nlm.nih.gov/pubmed/30648886",
        "http://www.ncbi.nlm.nih.gov/pubmed/39660536",
        "http://www.ncbi.nlm.nih.gov/pubmed/39708896",
        "http://www.ncbi.nlm.nih.gov/pubmed/39689180",
        "http://www.ncbi.nlm.nih.gov/pubmed/39681465",
        "http://www.ncbi.nlm.nih.gov/pubmed/39679460",
        "http://www.ncbi.nlm.nih.gov/pubmed/20922806",
        "http://www.ncbi.nlm.nih.gov/pubmed/19252414",
        "http://www.ncbi.nlm.nih.gov/pubmed/29163786",
        "http://www.ncbi.nlm.nih.gov/pubmed/37268175",
        "http://www.ncbi.nlm.nih.gov/pubmed/38391974",
        "http://www.ncbi.nlm.nih.gov/pubmed/33002607",
        "https://pubmed.ncbi.nlm.nih.gov/27048336/",
        "https://pubmed.ncbi.nlm.nih.gov/23649974/",
        "https://pubmed.ncbi.nlm.nih.gov/31684958/",
        "https://pubmed.ncbi.nlm.nih.gov/30648886/",
        "https://pubmed.ncbi.nlm.nih.gov/31959629/",
        "http://www.ncbi.nlm.nih.gov/pubmed/39644434",
        "http://www.ncbi.nlm.nih.gov/pubmed/39594573",
        "http://www.ncbi.nlm.nih.gov/pubmed/39592496",
        "http://www.ncbi.nlm.nih.gov/pubmed/28034848/",
        "http://www.ncbi.nlm.nih.gov/pubmed/25568918/",
        "http://www.ncbi.nlm.nih.gov/pubmed/27780404/",
        "http://www.ncbi.nlm.nih.gov/pubmed/34439388",
        "http://www.ncbi.nlm.nih.gov/pubmed/15605394",
        "http://www.ncbi.nlm.nih.gov/pubmed/35279611",
        "http://www.ncbi.nlm.nih.gov/pubmed/31959629",
        "http://www.ncbi.nlm.nih.gov/pubmed/38685399",
        "http://www.ncbi.nlm.nih.gov/pubmed/33103086",
        "http://www.ncbi.nlm.nih.gov/pubmed/26573603",
        "http://www.ncbi.nlm.nih.gov/pubmed/38471796",
        "http://www.ncbi.nlm.nih.gov/pubmed/37703603",
        "http://www.ncbi.nlm.nih.gov/pubmed/39367387",
        "http://www.ncbi.nlm.nih.gov/pubmed/31171001",
        "http://www.ncbi.nlm.nih.gov/pubmed/31684958",
        "http://www.ncbi.nlm.nih.gov/pubmed/34638349",
        "http://www.ncbi.nlm.nih.gov/pubmed/35572601"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunologic response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28072762"
        },
        {
          "offsetInBeginSection": 596,
          "offsetInEndSection": 1000,
          "text": "In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumour angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response. As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28072762"
        },
        {
          "offsetInBeginSection": 395,
          "offsetInEndSection": 595,
          "text": "is overexpressed in several haematologic and solid malignancies, including acute myeloid leukaemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28072762"
        },
        {
          "offsetInBeginSection": 321,
          "offsetInEndSection": 738,
          "text": "The receptor tyrosine kinase Axl, a member of the TAM family (which includes TYRO3 and MER), plays an important role in the regulation of cellular processes such as proliferation, motility, survival, and immunologic response. The overexpression of Axl is reported in several solid and hematological malignancies, including non-small cell lung, prostate, breast, liver and gastric cancers, and acute myeloid leukaemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806258"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 435,
          "text": "The receptor tyrosine kinase Axl has been implicated in the malignancy of different types of cancer. Emerging evidence of Axl upregulation in numerous cancers, as well as reports demonstrating that its inhibition blocks tumor formation in animal models, highlight the importance of Axl as a new potential therapeutic target. Furthermore, recent data demonstrate that Axl plays a pivotal role in resistance to chemotherapeutic regimens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649974"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 860,
          "text": "Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematologic and solid malignancies, including acute myeloid leukaemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers. In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumour angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28072762"
        },
        {
          "offsetInBeginSection": 321,
          "offsetInEndSection": 1071,
          "text": "The receptor tyrosine kinase Axl, a member of the TAM family (which includes TYRO3 and MER), plays an important role in the regulation of cellular processes such as proliferation, motility, survival, and immunologic response. The overexpression of Axl is reported in several solid and hematological malignancies, including non-small cell lung, prostate, breast, liver and gastric cancers, and acute myeloid leukaemia. The overexpression of Axl is associated with poor prognosis and the development of resistance to therapy. Reports show that Axl overexpression confers drug resistance in lung cancer and advances the emergence of tolerant cells. Axl is, therefore, an important candidate as a prognostic biomarker and target for anticancer therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806258"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 603,
          "text": "AXL is a receptor tyrosine kinase (RTK) that has been implicated in diverse tumor-promoting processes such as proliferation, migration, invasion, survival, and apoptosis. AXL therefore plays a role in cancer progression, and AXL has been implicated in a wide variety of malignancies from solid tumors to hematopoietic cancers where it is often associated with poor prognosis. In cancer, AXL has been shown to promote epithelial to mesenchymal transition (EMT), metastasis formation, drug resistance, and a role for AXL in modulation of the tumor microenvironment and immune response has been identified.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32148495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 831,
          "text": "Aberrant expression and activation of receptor tyrosine kinases (RTK) is a frequent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced sensitivity of tumor cells to target-specific and conventional antitumor agents, but the precise mechanism underlying these phenomena are still poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048336"
        },
        {
          "offsetInBeginSection": 325,
          "offsetInEndSection": 532,
          "text": "In cancer, AXL overexpression and activation has been associated with cell proliferation, chemotherapy resistance, tumor angiogenesis, invasion, and metastasis; and has been correlated with a poor prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31694201"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 317,
          "text": "The AXL receptor tyrosine kinase and its major ligand, GAS6 have been demonstrated to be overexpressed and activated in many human cancers (such as lung, breast, and pancreatic cancer) and have been correlated with poor prognosis, promotion of increased invasiveness/metastasis, the EMT phenotype and drug resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25337673"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "The receptor tyrosine kinase AXL is emerging as a key player in tumor progression and metastasis and its expression correlates with poor survival in a plethora of cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158733"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "AXL is a receptor tyrosine kinase (RTK) that has been implicated in diverse tumor-promoting processes such as proliferation, migration, invasion, survival, and apoptosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32148495"
        },
        {
          "offsetInBeginSection": 321,
          "offsetInEndSection": 546,
          "text": "The receptor tyrosine kinase Axl, a member of the TAM family (which includes TYRO3 and MER), plays an important role in the regulation of cellular processes such as proliferation, motility, survival, and immunologic response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806258"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37328828"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "The AXL receptor tyrosine kinase (AXL) has emerged as a promising therapeutic target for cancer therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834845"
        },
        {
          "offsetInBeginSection": 197,
          "offsetInEndSection": 427,
          "text": "Evidence to date suggests that aberrant Axl expression frequently occurs in many malignancies, including hepatocellular carcinoma, and that this is critical for promoting cell proliferation, migration, angiogenesis and metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30648886"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 266,
          "text": "Recent studies have revealed a central role of AXL signaling in tumor proliferation, survival, stem cell phenotype, metastasis, and resistance to cancer therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834845"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 595,
          "text": "Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematologic and solid malignancies, including acute myeloid leukaemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28072762"
        },
        {
          "offsetInBeginSection": 596,
          "offsetInEndSection": 860,
          "text": "In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumour angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28072762"
        },
        {
          "offsetInBeginSection": 861,
          "offsetInEndSection": 1000,
          "text": "As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28072762"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 438,
          "text": "Recent studies have revealed a central role of AXL signaling in tumor proliferation, survival, stem cell phenotype, metastasis, and resistance to cancer therapy. Moreover, AXL is expressed within cellular components of the tumor microenvironment where AXL signaling contributes to the immunosuppressive and protumorigenic phenotypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834845"
        },
        {
          "offsetInBeginSection": 325,
          "offsetInEndSection": 712,
          "text": "In cancer, AXL overexpression and activation has been associated with cell proliferation, chemotherapy resistance, tumor angiogenesis, invasion, and metastasis; and has been correlated with a poor prognosis. In hematological malignancies, the expression and function of AXL is highly diverse, not only between the different tumor types but also in the surrounding tumor microenvironment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31694201"
        },
        {
          "offsetInBeginSection": 491,
          "offsetInEndSection": 847,
          "text": "AXL is required at multiple steps of the metastatic cascade where its activation in cancer cells leads to EMT, invasion, survival, proliferation and therapy resistance. AXL activation in cancer cells and various stromal cells also results in tumor microenvironment deregulation, leading to modulation of angiogenesis, fibrosis, immune response and hypoxia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158733"
        },
        {
          "offsetInBeginSection": 547,
          "offsetInEndSection": 844,
          "text": "The overexpression of Axl is reported in several solid and hematological malignancies, including non-small cell lung, prostate, breast, liver and gastric cancers, and acute myeloid leukaemia. The overexpression of Axl is associated with poor prognosis and the development of resistance to therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806258"
        },
        {
          "offsetInBeginSection": 197,
          "offsetInEndSection": 566,
          "text": "Evidence to date suggests that aberrant Axl expression frequently occurs in many malignancies, including hepatocellular carcinoma, and that this is critical for promoting cell proliferation, migration, angiogenesis and metastasis. Moreover, deregulated Axl expression or activation is reportedly associated with resistance to cancer drugs and targeted cancer therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30648886"
        },
        {
          "offsetInBeginSection": 147,
          "offsetInEndSection": 749,
          "text": "Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced sensitivity of tumor cells to target-specific and conventional antitumor agents,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048336"
        },
        {
          "offsetInBeginSection": 339,
          "offsetInEndSection": 554,
          "text": "Axl receptor tyrosine kinase critically involves in the carcinogenesis of multiple cancers due to its dual roles in both promoting cancer invasion and metastasis and suppressing myeloid cell activation and function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29163786"
        },
        {
          "offsetInBeginSection": 491,
          "offsetInEndSection": 659,
          "text": "AXL is required at multiple steps of the metastatic cascade where its activation in cancer cells leads to EMT, invasion, survival, proliferation and therapy resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158733"
        },
        {
          "offsetInBeginSection": 660,
          "offsetInEndSection": 847,
          "text": "AXL activation in cancer cells and various stromal cells also results in tumor microenvironment deregulation, leading to modulation of angiogenesis, fibrosis, immune response and hypoxia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158733"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 375,
          "text": "AXL therefore plays a role in cancer progression, and AXL has been implicated in a wide variety of malignancies from solid tumors to hematopoietic cancers where it is often associated with poor prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32148495"
        },
        {
          "offsetInBeginSection": 376,
          "offsetInEndSection": 603,
          "text": "In cancer, AXL has been shown to promote epithelial to mesenchymal transition (EMT), metastasis formation, drug resistance, and a role for AXL in modulation of the tumor microenvironment and immune response has been identified.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32148495"
        },
        {
          "offsetInBeginSection": 413,
          "offsetInEndSection": 677,
          "text": "Extensive studies over the past decade have emphasized the role of Axl in driving tumor development and metastasis, while high levels of Axl expression have been associated with immune evasion, drug resistance, and reduced patient survival in various cancer types.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37268175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "The oncogenic receptor tyrosine kinase AXL is overexpressed in cancer and plays an important role in carcinomas of multiple organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/31959629/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "The receptor tyrosine kinase AXL promotes tumor progression, metastasis, and therapy resistance through the induction of epithelial-mesenchymal transition (EMT).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39689180"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "The receptor tyrosine kinase Axl and its ligand Gas6 regulate fundamental biological processes, including cell proliferation, survival and motility, through multiple downstream signaling pathways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30648886"
        },
        {
          "offsetInBeginSection": 547,
          "offsetInEndSection": 738,
          "text": "The overexpression of Axl is reported in several solid and hematological malignancies, including non-small cell lung, prostate, breast, liver and gastric cancers, and acute myeloid leukaemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806258"
        },
        {
          "offsetInBeginSection": 739,
          "offsetInEndSection": 844,
          "text": "The overexpression of Axl is associated with poor prognosis and the development of resistance to therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33806258"
        },
        {
          "offsetInBeginSection": 557,
          "offsetInEndSection": 770,
          "text": "AXL knockdown experiments revealed its interaction with Caveolin-1, a caveolae lipid raft protein, which regulates lipid raft levels and promotes AKT and ERK signaling, enhancing cancer development and metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39708896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Deregulation of the TAM (TYRO3, AXL, and MERTK) family of receptor tyrosine kinases (RTKs) has recently been demonstrated to predominately promote survival and chemoresistance of cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28034848/"
        },
        {
          "offsetInBeginSection": 659,
          "offsetInEndSection": 829,
          "text": " Among the TAM family of RTKs, AXL (AXL receptor tyrosine kinase) only induces autophagy in macrophages after interaction with its ligand, GAS6 (growth arrest specific 6)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27780404/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "The TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine kinases (RTKs) are aberrantly expressed in multiple haematological and epithelial malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25568918/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "The receptor tyrosine kinase (RTK) anexelekto (AXL) is mutated and/or overexpressed in various malignancies, and plays a central role in tumor development and acquired drug resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35279611"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 539,
          "text": "Recent research suggests that the AXL receptor tyrosine kinase (AXL) plays an vital role in the survival and proliferation of GC cells, and blocking AXL pathway may be an effective strategy for targeted therapies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39644434"
        },
        {
          "offsetInBeginSection": 487,
          "offsetInEndSection": 669,
          "text": "Axl and EGFR are co-expressed in NPC tissues and play key roles in tumor proliferation, migration, and invasion, which are often correlated with poor prognosis and therapy resistance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39594573"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "AXL has ubiquitous expression in multiple cancers, and is strongly linked to both tumor progression, metastasis, and poor prognosis, as well as anti-tumor immune response suppression and induction of tumor resistance to immunotherapy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39592496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 306,
          "text": "AXL receptor tyrosine kinase (AXL) is a receptor tyrosine kinase whose aberrant expression has recently been associated with colorectal cancer (CRC), contributing to tumor growth, epithelial-mesenchymal transition (EMT), increased invasiveness, metastatic spreading, and the development of drug resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38685399"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "The receptor tyrosine kinase AXL is associated with epithelial plasticity in several solid tumors including breast cancer and AXL-targeting agents are currently in clinical trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33103086"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "The receptor tyrosine kinase AXL is emerging as a key player in tumor progression and metastasis and its expression correlates with poor survival in a plethora of cancers. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35158733"
        },
        {
          "offsetInBeginSection": 1252,
          "offsetInEndSection": 1506,
          "text": "Activated AXL leads to a significant increase in tumor proliferation, tumor cell migration, and angiogenesis in different in vitro and in vivo models of cancer since this receptor regulates interplay with apoptotic, angiogenic and inflammatory pathways. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38391974"
        },
        {
          "offsetInBeginSection": 694,
          "offsetInEndSection": 894,
          "text": "AXL is a key regulator of several cellular functions, including epithelial-to-mesenchymal transition in tumor cells, immune regulation, apoptosis, angiogenesis and the development of chemoresistance. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39367387"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 352,
          "text": "AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL\u0027s role in the occurrence and progression of cancer, as well as drug resistance and treatment tolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37328828"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 324,
          "text": "The receptor tyrosine kinase Axl has been implicated in the malignancy of different types of cancer. Emerging evidence of Axl upregulation in numerous cancers, as well as reports demonstrating that its inhibition blocks tumor formation in animal models, highlight the importance of Axl as a new potential therapeutic target.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23649974"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 420,
          "text": "Aberrant expression and activation of receptor tyrosine kinases (RTK) is a frequent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27048336"
        },
        {
          "offsetInBeginSection": 1015,
          "offsetInEndSection": 1251,
          "text": "Here, we focused on the receptor tyrosine kinase AXL that has been identified as a mediator for tumor progression and therapy resistance in various cancer types, including squamous cell tumors, small cell lung cancer, and breast cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38391974"
        },
        {
          "offsetInBeginSection": 535,
          "offsetInEndSection": 656,
          "text": "In cancer cells, the activation of AXL signaling stimulates cell survival and increases migratory and invasive potential.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34638349"
        },
        {
          "offsetInBeginSection": 685,
          "offsetInEndSection": 829,
          "text": "The receptor tyrosine kinase (RTK) AXL has been associated with poor prognosis in numerous malignancies and the emergence of therapy resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35572601"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Overexpression and amplification of AXL receptor tyrosine kinase (RTK) has been found in several hematologic and solid malignancies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34439388"
        },
        {
          "offsetInBeginSection": 1252,
          "offsetInEndSection": 1505,
          "text": "Activated AXL leads to a significant increase in tumor proliferation, tumor cell migration, and angiogenesis in different in vitro and in vivo models of cancer since this receptor regulates interplay with apoptotic, angiogenic and inflammatory pathways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38391974"
        },
        {
          "offsetInBeginSection": 184,
          "offsetInEndSection": 389,
          "text": "AXL is a receptor tyrosine kinase, and its overexpression contributes to tumor malignancy. The role of AXL in cancer cells is broad, including invasion, drug resistance, and vasculogenic mimicry formation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39660536"
        },
        {
          "offsetInBeginSection": 428,
          "offsetInEndSection": 566,
          "text": "Moreover, deregulated Axl expression or activation is reportedly associated with resistance to cancer drugs and targeted cancer therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30648886"
        },
        {
          "offsetInBeginSection": 267,
          "offsetInEndSection": 438,
          "text": "Moreover, AXL is expressed within cellular components of the tumor microenvironment where AXL signaling contributes to the immunosuppressive and protumorigenic phenotypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834845"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "The oncogenic receptor tyrosine kinase AXL is overexpressed in cancer and plays an important role in carcinomas of multiple organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31959629"
        },
        {
          "offsetInBeginSection": 249,
          "offsetInEndSection": 396,
          "text": "Axl is overexpressed and activated in numerous different human cancer types, triggering several signaling pathways and enhancing tumor progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29434997"
        }
      ],
      "id": "67da17c918b1e36f2e000055",
      "ideal_answer": [
        "The receptor tyrosine kinase AXL, a member of the TAM family (which includes TYRO3 and MER) regulates various cellular processes, including proliferation, survival, motility, and immunologic response. Although not implicated as an oncogenic driver itself, AXL is overexpressed in several solid and hematological malignancies, including non-small cell lung, prostate, breast, liver, and gastric cancers, and acute myeloid leukemia. In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response. As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.",
        "The receptor tyrosine kinase AXL plays a pivotal role in promoting various aspects of cancer progression and malignancy. AXL is overexpressed in many cancers like lung, breast, and pancreatic cancer, and its high expression correlates with poor prognosis, increased invasiveness and metastasis, epithelial-to-mesenchymal transition (EMT), and drug resistance. AXL activation in cancer cells leads to increased proliferation, survival, migration, invasion, and therapy resistance. It also modulates the tumor microenvironment by regulating angiogenesis, fibrosis, immune response, and hypoxia. Inhibiting AXL with small molecule inhibitors or antibodies can inactivate AXL-mediated signaling pathways, resensitize cancer cells to therapy, and improve treatment efficacy, making AXL a promising therapeutic target in cancer.",
        "The receptor tyrosine kinase AXL plays a crucial role in malignancy by driving tumor progression, suppressing antitumor immune response, and contributing to resistance against chemotherapy and targeted therapies. Overexpressed in various cancers, including hematologic and solid malignancies, AXL\u0027s activity promotes epithelial-to-mesenchymal transition and tumor angiogenesis. Notably, its nuclear translocation enhances cancer cell malignancy and reduces sensitivity to treatments like radiation and chemotherapy. As a result, AXL is identified as a promising prognostic biomarker and therapeutic target for anticancer therapies, with potential strategies focusing on inhibiting its activity and nuclear localization.",
        "The receptor tyrosine kinase AXL plays a significant role in malignancy by promoting processes such as cell proliferation, survival, and motility through downstream signaling pathways activated by its interaction with Gas6. Overexpression and amplification of AXL have been observed in various hematologic and solid cancers, including acute myeloid leukemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers. AXL is associated with poor prognosis and therapy resistance, contributing to tumor progression and survival. Additionally, tumors can manipulate their microenvironment by educating macrophages to secrete Gas6, which activates AXL and other TAM receptors, further supporting malignancy. The structural insights into AXL\u0027s conformational states suggest a potential role for the juxtamembrane region in its activity, highlighting its importance in cancer development and progression.",
        "The receptor tyrosine kinase AXL plays a significant role in malignancy by promoting cancer cell survival, proliferation, invasion, and metastasis. AXL is often overexpressed in various types of cancers and is associated with poor prognosis. It contributes to the development of resistance to therapies, including chemotherapy and targeted treatments, by activating signaling pathways that enhance cell survival and reduce apoptosis. Additionally, AXL is involved in the epithelial-to-mesenchymal transition (EMT), which facilitates cancer cell migration and invasion. Due to its critical role in cancer progression, AXL is considered a potential therapeutic target for cancer treatment.",
        "The receptor tyrosine kinase AXL plays a significant role in malignancy by promoting tumor growth, metastasis, and resistance to therapies. It is overexpressed in various cancers, contributing to processes such as epithelial-mesenchymal transition (EMT), angiogenesis, immune evasion, and drug resistance. AXL mediates resistance to chemotherapy and targeted therapies by activating alternative signaling pathways, making it a critical target for therapeutic intervention.",
        "The receptor tyrosine kinase AXL plays a significant role in malignancy by promoting cancer cell survival, proliferation, invasion, metastasis, and resistance to therapy. AXL is often overexpressed in various types of cancers, including breast, lung, and pancreatic cancers. Its activation can lead to the activation of downstream signaling pathways such as PI3K/AKT, MAPK, and NF-κB, which contribute to tumor progression and the development of resistance to conventional therapies. Therefore, AXL is considered a potential therapeutic target in cancer treatment.",
        "The receptor tyrosine kinase AXL, though not an oncogenic driver itself, is overexpressed in various hematologic and solid malignancies, where it drives processes such as epithelial to mesenchymal transition, tumor angiogenesis, and resistance to chemotherapeutic and targeted agents. AXL\u0027s role in these processes makes it a potential prognostic biomarker and a promising therapeutic target in cancer treatment.",
        "AXL, a receptor tyrosine kinase, plays a significant role in malignancy by promoting tumor cell survival, proliferation, invasion, and metastasis. Overexpression or activation of AXL is observed in various cancers, where it contributes to drug resistance, immune evasion, and angiogenesis. AXL signaling enhances tumor cell survival by activating downstream pathways like PI3K/AKT and MAPK, protecting cells from apoptosis. It also promotes cell migration and invasion by regulating the expression of EMT-related genes and matrix metalloproteinases. AXL also modulates the tumor microenvironment, influencing immune cell recruitment and polarization to promote immunosuppression. Its involvement in angiogenesis further supports tumor growth and spread. Therefore, AXL represents a promising therapeutic target in cancer treatment.",
        "AXL, a member of the TAM receptor tyrosine kinase family, plays a significant role in malignancy by promoting tumor growth, survival, and metastasis. It is associated with poor prognosis and therapy resistance in various cancers, including acute myeloid leukemia (AML), triple-negative breast cancer (TNBC), and melanoma. AXL activation aids in the evasion of anti-tumor immune responses, allowing cancer cells to escape immune surveillance. It also contributes to the phenotypic plasticity of cancer cells, enabling them to switch between proliferative and invasive states, which is crucial for metastasis. Furthermore, AXL signaling is implicated in processes such as epithelial-mesenchymal transition (EMT), which enhances the invasive capabilities of tumor cells. Inhibitors targeting AXL are being explored as potential therapeutic strategies to overcome resistance and improve outcomes in cancer treatment.",
        "The receptor tyrosine kinase AXL plays a pivotal role in promoting various aspects of cancer progression and metastasis. AXL overexpression has been observed in numerous cancers, including breast, lung, prostate, and pancreatic cancers, and is associated with poor prognosis. AXL activation in cancer cells leads to increased proliferation, survival, migration, invasion, epithelial-to-mesenchymal transition (EMT), metastasis formation, and resistance to chemotherapy and targeted therapies. AXL signaling also contributes to an immunosuppressive and pro-tumorigenic tumor microenvironment by modulating angiogenesis, fibrosis, immune response, and hypoxia. Given its multifaceted roles in cancer progression and therapy resistance, AXL is emerging as a promising therapeutic target, and several AXL inhibitors are currently in preclinical and clinical development.",
        "AXL, a receptor tyrosine kinase, plays a crucial role in malignancy by promoting epithelial to mesenchymal transition, tumor angiogenesis, resistance to therapies, and impeding antitumor immune responses in various cancers, including leukemia, lung, gastric, colorectal, breast, prostate, liver, and gastric cancers. Despite not being an oncogenic driver itself, AXL\u0027s overexpression is linked to poor prognosis. This positions AXL as a significant contributor to tumor progression and therapeutic resistance, making it a promising target for anticancer therapies and a potential prognostic biomarker across multiple hematologic and solid malignancies.",
        "The receptor tyrosine kinase AXL plays a significant role in malignancy by regulating critical cellular processes such as proliferation, survival, motility, and the immune response. Its overexpression is associated with various cancers, including acute myeloid leukemia, non-small cell lung cancer, and breast cancer, and is linked to key oncogenic processes like epithelial to mesenchymal transition, tumor angiogenesis, and resistance to chemotherapy. AXL\u0027s activation contributes to tumor progression, metastasis, and an immunosuppressive tumor microenvironment, correlating with poor patient survival. Consequently, AXL is considered a promising prognostic biomarker and a potential therapeutic target in cancer treatment.",
        "The receptor tyrosine kinase AXL plays a significant role in malignancy by regulating cellular processes such as proliferation, survival, motility, and immunologic response. Overexpression of AXL is observed in various cancers, including non-small cell lung, prostate, breast, liver, and gastric cancers, as well as acute myeloid leukemia. In the context of malignancy, AXL overexpression contributes to processes like epithelial to mesenchymal transition, tumor angiogenesis, and resistance to chemotherapeutic and targeted agents, while also decreasing the antitumor immune response. These functions make AXL a promising target for anticancer therapies and a potential prognostic biomarker in malignancy.",
        "The receptor tyrosine kinase AXL plays a significant role in various malignancies. Its overexpression is observed across several cancers, including non-small cell lung cancer, breast, prostate, liver, gastric cancers, and acute myeloid leukemia. AXL regulates essential cellular processes such as proliferation, survival, motility, and immunologic response. In the context of malignancy, AXL contributes to critical processes like epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapy and targeted therapies, and suppression of antitumor immune responses. This makes AXL not only a prognostic biomarker but also an attractive target for developing anticancer therapies aimed at improving treatment outcomes.",
        "AXL is a receptor tyrosine kinase from the TAM family that interacts with the ligand Gas6 to regulate key cellular processes such as proliferation, survival, and motility. In malignancy, deregulated AXL activity drives tumor progression by promoting epithelial-mesenchymal transition, which increases invasiveness and metastasis. Its overexpression is observed in a wide range of solid and hematologic cancers, including non-small cell lung, breast, prostate, liver cancers, and acute myeloid leukemia. Additionally, AXL signaling contributes to the development of resistance to both chemotherapeutic and targeted therapies, while also facilitating angiogenesis and helping tumors evade the immune response. This multifaceted role makes AXL an important prognostic biomarker and a promising therapeutic target across various cancer types.",
        "The receptor tyrosine kinase AXL plays a significant role in various malignancies. Its overexpression is observed across several cancers, including non-small cell lung cancer, breast, prostate, liver, gastric cancers, and acute myeloid leukemia. AXL regulates essential cellular processes such as proliferation, survival, motility, and immunologic response. In the context of cancer, AXL contributes to key pathological processes:\n\n1. **Epithelial-Mesenchymal Transition (EMT):** AXL promotes EMT, enhancing tumor invasiveness and metastasis.\n\n2. **Tumor Angiogenesis:** It supports the formation of new blood vessels, which is crucial for tumor growth and spread.\n\n3. **Treatment Resistance:** AXL overexpression is linked to resistance against chemotherapy and targeted therapies, reducing treatment efficacy.\n\n4. **Immune Suppression:** AXL decreases antitumor immune responses, allowing tumors to evade immune detection and destruction.\n\nGiven these roles, AXL serves as both a prognostic biomarker, indicating poor patient outcomes, and a therapeutic target for developing novel anticancer strategies aimed at inhibiting its activity and overcoming treatment resistance.",
        "The receptor tyrosine kinase AXL plays a significant role in malignancy by regulating various cellular processes, including proliferation, survival, motility, and immunologic response. Overexpression of AXL is associated with epithelial to mesenchymal transition, tumour angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response. As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies. AXL is overexpressed in several haematologic and solid malignancies, including acute myeloid leukaemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers.",
        "The receptor tyrosine kinase AXL, part of the TAM family, plays a significant role in malignancy by regulating cellular processes such as proliferation, survival, motility, and immune response. Its overexpression is associated with various cancers, including non-small cell lung cancer, breast cancer, and acute myeloid leukemia, and contributes to processes like epithelial to mesenchymal transition, tumor angiogenesis, and resistance to therapies. Consequently, AXL is considered a promising target for anticancer therapies and a potential prognostic biomarker.",
        "The receptor tyrosine kinase AXL plays a significant role in malignancy by regulating critical cellular processes such as proliferation, survival, motility, and immune response. Its overexpression is associated with various cancers, including acute myeloid leukemia, non-small cell lung cancer, and breast cancer, contributing to processes like epithelial to mesenchymal transition, tumor angiogenesis, and resistance to chemotherapy. AXL\u0027s activation promotes oncogenic signaling, leading to enhanced tumor growth, metastasis, and poor patient prognosis. Consequently, AXL is considered a promising target for anticancer therapies and a potential prognostic biomarker in malignancies.",
        " In malignancy, AXL plays a crucial role by regulating various cellular processes such as proliferation, survival, motility, and immunologic response. Overexpression of AXL has been reported in several solid and hematological malignancies, including non-small cell lung, prostate, breast, liver, and gastric cancers, and acute myeloid leukaemia. It is suggested that AXL overexpression drives wide-ranging processes such as epithelial to mesenchymal transition, tumour angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response, making it an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.",
        "The receptor tyrosine kinase AXL plays multiple critical roles in malignancy. AXL is overexpressed in numerous solid and hematological cancers, including non-small cell lung cancer, breast cancer, prostate cancer, gastric and colorectal adenocarcinomas, and acute myeloid leukemia. In cancer, AXL overexpression drives several tumor-promoting processes including epithelial to mesenchymal transition, tumor angiogenesis, and decreased antitumor immune responses. Additionally, AXL contributes to resistance against both chemotherapeutic and targeted anticancer agents. Due to its involvement in these wide-ranging cancer-promoting processes, AXL is considered both a potential prognostic biomarker and an attractive therapeutic target for anticancer treatments.",
        "The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunologic response. AXL is overexpressed in several haematologic and solid malignancies, including acute myeloid leukaemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers. In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumour angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response. As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.",
        "AXL is a receptor tyrosine kinase that plays a critical role in cancer progression. It drives key processes such as cell proliferation, migration, invasion, and epithelial-to-mesenchymal transition, which are essential for metastasis. Overexpression or aberrant activation of AXL in tumor cells is associated with increased tumor aggressiveness, poor patient survival, and resistance to both conventional chemotherapy and targeted therapies. Additionally, AXL influences the tumor microenvironment by modulating angiogenesis, immune responses, and fibrosis, further promoting tumor growth and dissemination. Its involvement in multiple signaling pathways makes it a promising candidate for therapeutic targeting in various malignancies.",
        "The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunologic response.\nIn the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumour angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response. As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies."
      ]
    },
    {
      "body": "Are respiratory measurements correlated with disease severity in Duchenne Muscular Dystrophy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36596294",
        "http://www.ncbi.nlm.nih.gov/pubmed/29412787",
        "http://www.ncbi.nlm.nih.gov/pubmed/23836708",
        "http://www.ncbi.nlm.nih.gov/pubmed/37539841",
        "http://www.ncbi.nlm.nih.gov/pubmed/29437939",
        "http://www.ncbi.nlm.nih.gov/pubmed/36571207",
        "http://www.ncbi.nlm.nih.gov/pubmed/9014949",
        "http://www.ncbi.nlm.nih.gov/pubmed/25755201"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1148,
          "offsetInEndSection": 1418,
          "text": "Forced vital capacity, total lung capacity and transcutaneous carbon dioxide correlated with the clinical severity of disease in children with DMD. These measures may be useful in follow-up and clinical trials. A comparable correlation was not found for peak cough flow.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36596294"
        },
        {
          "offsetInBeginSection": 1151,
          "offsetInEndSection": 1599,
          "text": "PaCO2 elevations correlated best with decreases in MIP (p \u003c .0001) and appeared when MIP was below 30cmH2O.CONCLUSIONS: Lung volume changes in DMD patients correlate with respiratory muscle weakness, and although inspiratory muscle dysfunction plays a key role in the development of chronic ventilatory insufficiency, reductions in expiratory muscle strength are the first signs of dysfunction and lead to the first episodes of respiratory failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9014949"
        },
        {
          "offsetInBeginSection": 906,
          "offsetInEndSection": 1011,
          "text": "Peak cough flow values were randomly distributed and did not correlate with age, ambulation or treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36596294"
        },
        {
          "offsetInBeginSection": 1359,
          "offsetInEndSection": 1418,
          "text": "A comparable correlation was not found for peak cough flow.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36596294"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Decline in pulmonary function in Duchenne Muscular Dystrophy (DMD) contributes to significant morbidity and reduced longevity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25755201"
        },
        {
          "offsetInBeginSection": 1216,
          "offsetInEndSection": 1544,
          "text": ") and appeared when MIP was below 30cmH2O.CONCLUSIONS: Lung volume changes in DMD patients correlate with respiratory muscle weakness, and although inspiratory muscle dysfunction plays a key role in the development of chronic ventilatory insufficiency, reductions in expiratory muscle strength are the first signs of dysfunction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9014949"
        },
        {
          "offsetInBeginSection": 1116,
          "offsetInEndSection": 1326,
          "text": "r \u003d 0.55, p \u003d 0.02).CONCLUSION: Forced vital capacity, total lung capacity and transcutaneous carbon dioxide correlated with the clinical severity of disease in children with DMD. These measures may be useful i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36596294"
        }
      ],
      "type": "yesno",
      "id": "66301d1d187cba990d000026",
      "ideal_answer": [
        "Yes, most respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy.",
        "Yes. Respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy.",
        "Yes, respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy. Studies show that parameters such as maximal expiratory pressure, forced vital capacity, total lung capacity, and transcutaneous carbon dioxide levels are associated with the clinical severity of the disease.",
        "Yes, several pulmonary function tests correlate with disease severity in DMD.",
        "Yes. Respiratory measurements, such as forced vital capacity (FVC) and the diaphragmatic Apnoea-Hypopnoea Index (dAHI), have been shown to correlate with disease severity in Duchenne Muscular Dystrophy (DMD), indicating that respiratory function declines as the disease progresses.",
        "Yes. Respiratory measurements have been shown to correlate with disease severity in Duchenne Muscular Dystrophy (DMD), as indicated by the analysis of lung function tests and the identification of biomarkers that correlate with disease milestones and respiratory capacity.",
        "Yes. The study aimed to evaluate whether diaphragmatic sleep disordered breathing (dSDB) severity correlates with respiratory progression in Duchenne Muscular Dystrophy (DMD), indicating a relationship between respiratory measurements and disease severity.",
        "Yes, respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy, as evidenced by various pulmonary function tests and analyses of lung function parameters.",
        "Yes, respiratory measurements, including FVC, FEV1, TLC, and maximal respiratory pressures, are correlated with disease severity in Duchenne Muscular Dystrophy, as evidenced by their association with functional assessments, ambulatory status, and disease progression markers, making them valuable tools for monitoring and assessment.",
        "Yes. The evidence indicates that respiratory health and function in Duchenne muscular dystrophy (DMD) are associated with various factors, including disease severity, suggesting a correlation between respiratory measurements and disease severity.",
        "Yes, respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy. As the disease progresses, respiratory function typically declines, making these measurements an important indicator of disease progression and severity.",
        "Yes, respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy. Many studies have shown that various respiratory measurements, such as spirometry, respiratory muscle strength, and pulmonary function tests, can predict the progression of Duchenne muscular dystrophy and correlate with clinical assessments.",
        "Yes, respiratory measurements, particularly Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1), are correlated with disease severity in Duchenne Muscular Dystrophy, as evidenced by their association with functional muscle assessments, ambulatory status, and other indicators of disease progression.",
        "Yes, respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy (DMD). Studies show that parameters like forced vital capacity (FVC), total lung capacity, maximum inspiratory and expiratory pressures (MIP/MEP), and arterial blood gases (e.g., PaCO2) correlate with clinical severity, with reductions in expiratory muscle strength often being the first signs of dysfunction leading to respiratory failure.",
        "Yes. Forced vital capacity, total lung capacity and transcutaneous carbon dioxide correlated with the clinical severity of disease in children with DMD. These measures may be useful in follow-up and clinical trials. A comparable correlation was not found for peak cough flow.",
        "Yes, certain respiratory measurements in children with Duchenne Muscular Dystrophy (DMD) correlate with disease severity. Specifically, Forced Vital Capacity (FVC), Total Lung Capacity (TLC), and transcutaneous carbon dioxide levels show this correlation. These measures can be useful for follow up and clinical trials. However, peak cough flow did not demonstrate a comparable correlation with disease severity.",
        "Yes, certain respiratory measurements, such as forced vital capacity (FVC), total lung capacity (TLC), and transcutaneous carbon dioxide levels, are correlated with disease severity in Duchenne Muscular Dystrophy. These measures can be valuable for monitoring disease progression and assessing outcomes in clinical trials. However, peak cough flow does not show a comparable correlation.",
        "Yes, Forced vital capacity, total lung capacity, and transcutaneous carbon dioxide are correlated with the clinical severity of disease in children with Duchenne Muscular Dystrophy, making them useful in follow-up and clinical trials.",
        "Yes, respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy. Forced vital capacity, total lung capacity and transcutaneous carbon dioxide correlated with the clinical severity of disease in children with DMD.",
        "Yes, forced vital capacity, total lung capacity andYes, forced vital capacity, total lung capacity and dioxide are correlated with the total lung capacity and transcutaneous carbon dioxide are correlated with the clinical severity of disease in children with DMD.",
        "Yes. Respiratory measurements such as forced vital capacity and total lung capacity are correlated with the clinical severity of disease in children with Duchenne muscular dystrophy (DMD).",
        "Yes. Respiratory measurements, including forced vital capacity and transcutaneous carbon dioxide levels, are correlated with disease severity in Duchenne Muscular Dystrophy.",
        "Yes, respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy (DMD). Forced vital capacity, total lung capacity and transcutaneous carbon dioxide correlated with the clinical severity of disease in children with DMD.",
        "Yes, respiratory measurements such as forced vital capacity, total lung capacity, and transcutaneous carbon dioxide are correlated with the clinical severity of Duchenne Muscular Dystrophy (DMD). These measures may be useful in follow-up and clinical trials. However, a comparable correlation was not found for peak cough flow.",
        "Yes, forced vital capacity, total lung capacity, and transcutaneous carbon dioxide correlated with the clinical severity of disease in children with Duchenne Muscular Dystrophy. These measures may be useful in follow-up and clinical trials.",
        "Yes. Respiratory measurements such as forced vital capacity, total lung capacity, and transcutaneous carbon dioxide correlate with the clinical severity of disease in children with Duchenne Muscular Dystrophy.",
        "Yes, certain respiratory measurements, such as forced vital capacity, total lung capacity, and transcutaneous carbon dioxide, are correlated with the clinical severity of disease in children with Duchenne Muscular Dystrophy (DMD). These measures may be useful in follow-up and clinical trials. However, peak cough flow does not show a comparable correlation with disease severity.",
        "Yes. Respiratory measurements such as forced vital capacity, total lung capacity, and transcutaneous carbon dioxide levels are correlated with the clinical severity of disease in children with Duchenne Muscular Dystrophy (DMD).",
        "Yes. Respiratory measurements such as forced vital capacity and total lung capacity are correlated with the clinical severity of disease in children with DMD, indicating that these factors are relevant in assessing disease severity.",
        "Yes, certain respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy.",
        "Yes. Respiratory measurements such as forced vital capacity and total lung capacity are correlated with the clinical severity of disease in children with Duchenne Muscular Dystrophy (DMD).",
        "Yes, certain respiratory measurements such as forced vital capacity, total lung capacity, and transcutaneous carbon dioxide levels are correlated with the clinical severity of Duchenne Muscular Dystrophy (DMD) in children. These measurements can be useful for follow-up and clinical trials to assess disease progression. However, peak cough flow does not show a comparable correlation with disease severity.",
        "Yes, respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy.",
        "Yes, certain respiratory measurements like forced vital capacity (FVC), total lung capacity (TLC), and transcutaneous CO2 levels are correlated with disease severity in Duchenne muscular dystrophy. Peak cough flow, however, doesn\\\u0027t show such a correlation.",
        "Yes, respiratory measurements are correlated with disease severity in Duchenne Muscular Dystrophy. Forced vital capacity, total lung capacity and transcutaneous carbon dioxide correlated with the clinical severity of disease in children with DMD. These measures may be useful in follow-up and clinical trials.",
        " Yes, respiratory measurements such as Forced Vital Capacity (FVC), Total Lung Capacity (TLC) and transcutaneous carbon dioxide are correlated with the clinical severity of Duchenne Muscular Dystrophy (DMD). These measures may be useful in follow-up and clinical trials. However, peak cough flow did not show a comparable correlation.",
        "Yes, respiratory measurements such as forced vital capacity, total lung capacity, and transcutaneous carbon dioxide are correlated with the clinical severity of disease in children with Duchenne Muscular Dystrophy (DMD). These measures may be useful in follow-up and clinical trials. However, peak cough flow does not show a comparable correlation with disease severity.",
        "Yes, certain respiratory measurements like forced vital capacity, total lung capacity, and transcutaneous carbon dioxide levels were found to correlate with clinical disease severity in children with Duchenne Muscular Dystrophy (DMD). However, peak cough flow did not show a comparable correlation with disease severity.",
        "Yes, certain respiratory measurements (Forced Vital Capacity, Total Lung Capacity, and transcutaneous carbon dioxide levels) are correlated with disease severity in Duchenne Muscular Dystrophy, particularly in children, and can be useful for monitoring and in clinical trials. However, Peak Cough Flow does not show a significant correlation with disease severity in this context."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Which disease is caused by heterozygous UCHL1 loss-of-function variants?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35986737",
        "https://pubmed.ncbi.nlm.nih.gov/35986737/"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35986737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "PURPOSE: Biallelic variants in UCHL1 have been associated with a progressive early-onset neurodegenerative disorder, autosomal recessive spastic paraplegia type 79.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35986737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "PURPOSE: Biallelic variants in UCHL1 have been associated with a progressive early-onset neurodegenerative disorder, autosomal recessive spastic paraplegia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/35986737/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "PURPOSE: Biallelic variants in UCHL1 have been associated with a progressive early-onset neurodegenerative disorder, autosomal recessive spastic paraplegia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35986737"
        }
      ],
      "id": "67d3518718b1e36f2e000008",
      "ideal_answer": [
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by late-onset spastic ataxia, neuropathy, and frequent optic atrophy. This autosomal dominant disorder is distinct from the severe, early-onset autosomal recessive spastic paraplegia (HSP79) caused by biallelic UCHL1 mutations.",
        "Heterozygous loss-of-function variants in the UCHL1 gene have been linked to an autosomal dominant disease characterized by late-onset spastic ataxia, neuropathy, and frequent optic atrophy. This condition typically manifests later in life and involves progressive neurological symptoms, including difficulties with coordination and movement, as well as potential vision impairment due to optic atrophy.",
        "Heterozygous loss-of-function variants in the UCHL1 gene are associated with an autosomal dominant disease characterized by late-onset spastic ataxia, peripheral neuropathy, and frequent optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants are associated with an autosomal dominant disease characterized by late-onset spastic ataxia, neuropathy, and frequent optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants cause spastic ataxia, neuropathy, and optic atrophy.",
        "Heterozygous UCHL1 loss‐of‐function variants cause an autosomal dominant neurodegenerative disorder characterized by late-onset spastic ataxia, peripheral neuropathy, and optic atrophy, with haploinsufficiency as the underlying disease mechanism.",
        "Heterozygous UCHL1 loss-of-function variants cause an autosomal dominant neurodegenerative disorder characterized by late-onset spastic ataxia, neuropathy, and optic atrophy.",
        "The disease caused by heterozygous UCHL1 loss-of-function variants is a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy. This condition is autosomal dominant and typically presents with late-onset symptoms.",
        "Heterozygous UCHL1 loss-of-function variants are associated with a late-onset spastic ataxia, neuropathy, and frequent optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants are associated with late-onset spastic ataxia, neuropathy, and frequent optic atrophy.",
        "The disease caused by heterozygous UCHL1 loss-of-function variants is characterized by spasticity, ataxia, neuropathy, and optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants cause a late-onset neurodegenerative disorder characterized by spastic ataxia, neuropathy, and frequent optic atrophy. The disorder has an autosomal dominant inheritance pattern.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by late-onset spastic ataxia, neuropathy, and frequent optic atrophy. The disorder is distinct from the severe, early-onset autosomal recessive spastic paraplegia (HSP79) caused by biallelic UCHL1 mutations.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy with a dominant inheritance pattern.",
        "Heterozygous UCHL1 loss-of-function variants cause an autosomal dominant neurodegenerative disorder characterized by late-onset spastic ataxia, neuropathy, and frequent optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder known as autosomal recessive spastic paraplegia type 79, characterized by spasticity, ataxia, neuropathy, and optic atrophy.",
        "A neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by spastic ataxia, neuropathy, and frequent optic atrophy. This condition is autosomal dominant and results from haploinsufficiency of UCHL1, leading to a 50% reduction in UCHL1 expression, as confirmed by proteomic studies.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by a combination of spasticity, ataxia, neuropathy, and optic atrophy. This specific genetic condition involves mutations in the UCHL1 gene that lead to a complex neurological syndrome.",
        "Heterozygous UCHL1 loss of function variants cause a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy. This condition is associated with impaired ubiquitin proteasome function, leading to protein aggregation and subsequent neurodegeneration.",
        "Studies have identified that heterozygous UCHL1 loss-of-function variants are associated with a specific neurodegenerative disorder. This condition is characterized by a combination of symptoms, including spasticity, ataxia, neuropathy, and optic atrophy. The presence of these variants leads to the development of this particular disease, highlighting the importance of the UCHL1 gene in maintaining normal neurological function. The disorder caused by these variants presents with a distinct set of clinical features, making it a recognizable condition within the realm of neurodegenerative diseases.",
        "Heterozygous UCHL1 loss-of-function variants are associated with a neurodegenerative disorder characterized by symptoms such as spasticity, ataxia, neuropathy, and optic atrophy.",
        "Heterozygous UCHL1 loss of function variants cause a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy. This condition is associated with UCHL1 mutations and leads to progressive neurological symptoms.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by a combination of spasticity, ataxia, neuropathy, and optic atrophy. This condition represents a distinct clinical entity within the spectrum of neurodegenerative diseases, highlighting the importance of UCHL1 in maintaining neuronal function and integrity. The presence of these variants leads to the progressive deterioration of motor and sensory functions, ultimately affecting the quality of life of the affected individuals.",
        "Heterozygous UCHL1 loss‐of‐function variants cause an autosomal dominant neurodegenerative disorder, typically manifesting as late‐onset spastic ataxia, peripheral neuropathy, and optic atrophy. The underlying mechanism appears to be haploinsufficiency.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder. This disorder is characterized by spasticity, ataxia, neuropathy, and optic atrophy.",
        "The disease caused by heterozygous UCHL1 loss-of-function variants is a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy. This condition is often referred to as \"spastic ataxic neuropathy\" or described by its primary symptoms due to the specific genetic mutation in the UCHL1 gene.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder known as UCHL1-related neurodegeneration, which is characterized by symptoms such as spasticity, ataxia, neuropathy, and optic atrophy.",
        "The disease caused by heterozygous UCHL1 loss-of-function variants is a rare autosomal dominant neurodegenerative disorder. This condition is characterized by spasticity, ataxia, neuropathy, and optic atrophy. While it does not have a widely recognized specific name beyond its descriptive symptoms, it is associated with significant physical disabilities affecting both the central and peripheral nervous systems.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy. This autosomal dominant disease is also associated with late-onset spastic ataxia.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy. This condition is linked to the dysfunction of the ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) gene, which plays a crucial role in protein degradation pathways within neurons.",
        "Heterozygous UCHL1 loss-of-function variants are associated with a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by a spectrum of symptoms including spasticity, ataxia, neuropathy, and optic atrophy, collectively known as UCHL1-related neurodegenerative disorder. This condition highlights the critical role of UCHL1 in maintaining neurological function, with its impairment leading to a complex neurodegenerative phenotype.",
        "Heterozygous UCHL1 loss-of-function variants lead to a neurodegenerative disorder characterized by symptoms such as spasticity, ataxia, neuropathy, and optic atrophy. This disorder affects the nervous system, resulting in progressive motor and sensory impairments due to the degeneration of neurons.",
        " Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy.",
        "Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy. This condition represents a distinct clinical entity with progressive neurological deterioration affecting multiple systems, including motor function, coordination, peripheral nerves, and vision.",
        "Studies have shown that heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy. This condition is identified as Hereditary Spastic Paraplegia (HSP), specifically a subtype that includes additional features such as optic atrophy beyond the typical lower limb symptoms.",
        "Neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.",
        "A neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy",
        "Heterozygous UCHL1 loss-of-function variants cause a complex neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy."
      ],
      "exact_answer": [
        [
          "A neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy",
          "Neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy",
          "neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy",
          "Neurodegenerative disorder characterized by spasticity, ataxia, neuropathy, and optic atrophy"
        ]
      ]
    },
    {
      "body": "What is the most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28542671",
        "http://www.ncbi.nlm.nih.gov/pubmed/35280386",
        "http://www.ncbi.nlm.nih.gov/pubmed/25538173",
        "http://www.ncbi.nlm.nih.gov/pubmed/22425016",
        "http://www.ncbi.nlm.nih.gov/pubmed/35196945",
        "http://www.ncbi.nlm.nih.gov/pubmed/30862134",
        "http://www.ncbi.nlm.nih.gov/pubmed/24985058",
        "http://www.ncbi.nlm.nih.gov/pubmed/33189037",
        "http://www.ncbi.nlm.nih.gov/pubmed/21840871",
        "http://www.ncbi.nlm.nih.gov/pubmed/23868516",
        "http://www.ncbi.nlm.nih.gov/pubmed/39661858",
        "http://www.ncbi.nlm.nih.gov/pubmed/19470932",
        "http://www.ncbi.nlm.nih.gov/pubmed/37329889",
        "http://www.ncbi.nlm.nih.gov/pubmed/30092572",
        "http://www.ncbi.nlm.nih.gov/pubmed/31027071",
        "http://www.ncbi.nlm.nih.gov/pubmed/25684967",
        "http://www.ncbi.nlm.nih.gov/pubmed/22083196",
        "http://www.ncbi.nlm.nih.gov/pubmed/28536339",
        "http://www.ncbi.nlm.nih.gov/pubmed/19701965",
        "http://www.ncbi.nlm.nih.gov/pubmed/18063876",
        "http://www.ncbi.nlm.nih.gov/pubmed/25752908",
        "http://www.ncbi.nlm.nih.gov/pubmed/24292192",
        "http://www.ncbi.nlm.nih.gov/pubmed/16565703",
        "http://www.ncbi.nlm.nih.gov/pubmed/25421761",
        "http://www.ncbi.nlm.nih.gov/pubmed/22202333",
        "https://pubmed.ncbi.nlm.nih.gov/28542671/",
        "http://www.ncbi.nlm.nih.gov/pubmed/23980038",
        "http://www.ncbi.nlm.nih.gov/pubmed/33400355",
        "http://www.ncbi.nlm.nih.gov/pubmed/34992255"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 2485,
          "offsetInEndSection": 2798,
          "text": "For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate. Such an effective regimen leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28542671"
        },
        {
          "offsetInBeginSection": 1822,
          "offsetInEndSection": 1994,
          "text": "We observed that the combination of mFOLFOXIRI and bevacizumab increased the rate of clinical NED and showed a trend toward improved survival compared with mFOLFOXIRI alone",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35280386"
        },
        {
          "offsetInBeginSection": 814,
          "offsetInEndSection": 1032,
          "text": "Current standard approaches including cytotoxics and biologics, such as bevacizumab and particularly anti-epidermal growth factor receptor therapy, improve response rates and may enhance downsizing and resection rates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22425016"
        },
        {
          "offsetInBeginSection": 481,
          "offsetInEndSection": 673,
          "text": "Systemic conversion therapy may include chemotherapy agents\u0027 combinations (fluoropyrimidine, irinotecan and oxaliplatin), with or without targeted agents (cetuximab, panitumumab, bevacizumab).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24985058"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "BACKGROUND: There is no consensus on the optimal systemic conversion therapy in patients with unresectable colorectal cancer liver-only metastases (CRLM) to achieve a complet",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33189037"
        },
        {
          "offsetInBeginSection": 275,
          "offsetInEndSection": 512,
          "text": "If the unresectable metastases can be converted to resectable ones by effective conversion therapy, the 5-year survival rate of patients received liver resection can exceed to 30%, which is significantly better than palliative treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30862134"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 127,
          "text": "The optimal approach to the treatment of colorectal carcinoma and synchronous liver metastases remains controversial",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39661858"
        },
        {
          "offsetInBeginSection": 1764,
          "offsetInEndSection": 2071,
          "text": "Overall, toxicities were found to be predictable and manageable, with the most common being cutaneous, gastrointestinal, and neurologic toxicities.CONCLUSIONS: Conversion P-XELOX therapy yields high response and resectability rates for patients with metastatic colon cancer with extensive liver involvement.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21840871"
        },
        {
          "offsetInBeginSection": 701,
          "offsetInEndSection": 1105,
          "text": "Secondary endpoints were overall survival (OS), progression-free survival, the percentage of patients whose disease became radically resectable, and the safety of the P-XELOX combination.RESULTS: A total of 49 patients were recruited, 35 of whom had wild-type KRAS (wtKRAS) and 14 of whom (who were enrolled before study amendment) had unknown (9 patients) or mutated (5 patients) KRAS mutational status.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868516"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868516"
        },
        {
          "offsetInBeginSection": 4660,
          "offsetInEndSection": 4860,
          "text": "tients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI-bevacizumab was the preferred treatment in patients with a right-sided or RAS or BRAFV600E mutated primary tumour. In p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37329889"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 202,
          "text": " The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28542671"
        },
        {
          "offsetInBeginSection": 837,
          "offsetInEndSection": 1158,
          "text": "FOXIRI plus Bev regimen significantly improved the overall R0 resection rate (RR 1.41, 95% confidence interval (CI) 1.07-1.85, I2\u003d37%), liver R0 resection rate (RR 2.28, 95% CI 1.34-3.89, I2\u003d0%), ORR (RR 1.20, 95% CI 1.09-1.32, I2\u003d0%), PFS (HR 0.72, 95% CI 0.62-0.84, I2\u003d36%) and OS (HR 0.80, 95% CI 0.66-0.97, I2\u003d0%). Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30092572"
        },
        {
          "offsetInBeginSection": 788,
          "offsetInEndSection": 949,
          "text": "s administered 3 treatment courses, including 9 cycles of combined chemotherapy with mFOLFOX6 plus cetuximab (mFOLFOX6 + Cet), and the liver masses reduced. Afte",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31027071"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 524,
          "text": "After she had undergone laparoscopic sigmoidectomy for the original tumor, she consequently had 3 courses of modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus cetuximab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25684967"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 385,
          "text": "She underwent 7 courses of mFOLFOX6 and 14 administrations of cetuximab as conversion chemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22083196"
        },
        {
          "offsetInBeginSection": 615,
          "offsetInEndSection": 849,
          "text": "Data from a phase III trial indicate that cetuximab increases the number of patients eligible for secondary hepatic resection, as well as the rate of complete resection when combined with first-line treatment with the FOLFIRI regimen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19701965"
        },
        {
          "offsetInBeginSection": 737,
          "offsetInEndSection": 917,
          "text": "In patients with initially unresectable CRLM, the combination of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab has led to high response and resection rates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25752908"
        },
        {
          "offsetInBeginSection": 1018,
          "offsetInEndSection": 1202,
          "text": " patients with borderline resectable metastases, the combination of triplet chemotherapy with 5 fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) offers the best conversion rate. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35196945"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 417,
          "text": "Perioperative therapy with FOLFOX has demonstrated progression-free survival benefits in resectable colorectal liver metastases in a prospective randomized controlled trial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24292192"
        },
        {
          "offsetInBeginSection": 608,
          "offsetInEndSection": 884,
          "text": "High rates of objective response achieved with Fluoropyrimidines, Oxaliplatin (OHP) and Irinotecan (CPT-11) based chemo-therapy, enable initially unresectable patients to undergo surgery, with a 5-year survival rate comparable to that observed for primary resectable patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16565703"
        },
        {
          "offsetInBeginSection": 413,
          "offsetInEndSection": 658,
          "text": "Many studies reported Cetuximab plus chemotherapy as a conversion treatment improve R0 resection rates and prolonged overall survival of the patients with potentially resectable colorectal cancer liver metastasis with wild type KRAS gene status.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25421761"
        },
        {
          "offsetInBeginSection": 1055,
          "offsetInEndSection": 1299,
          "text": "Our results suggested that mFOLFOX6 treatment for unresectable liver metastases of colorectal cancer was made not only the conversion therapy possible, but it has improved the prognosis when compared with previous treatment without oxaliplatin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22202333"
        },
        {
          "offsetInBeginSection": 903,
          "offsetInEndSection": 992,
          "text": "ective case series that used FOLFOXIRI-Bev for the treatment of initially unresectable me",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/28542671/"
        },
        {
          "offsetInBeginSection": 634,
          "offsetInEndSection": 767,
          "text": "For KRAS wild-type patients, cetuximab combined with FOLFOX/FOLFIRI, in which 5-fluorouracil is continuously infused, is recommended.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23980038"
        },
        {
          "offsetInBeginSection": 1884,
          "offsetInEndSection": 2031,
          "text": " and neurologic toxicities.CONCLUSIONS: Conversion P-XELOX therapy yields high response and resectability rates for patients with metastatic colon ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868516"
        },
        {
          "offsetInBeginSection": 516,
          "offsetInEndSection": 839,
          "text": "We are conducting a multicentre Phase II study to evaluate the efficacy and safety of sequential chemotherapy using six cycles of cetuximab plus FOLFIRI (5-fluorouracil, folinic acid and irinotecan) followed by six cycles of bevacizumab plus FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) as conversion chemotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21840871"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 354,
          "text": "metastases. In the current study, the authors evaluated the activity of a conversion treatment with the combination of capecitabine plus oxaliplatin (XELOX) used in association with panitumumab in patients with unresectable, liver-only, metastatic c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868516"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 603,
          "text": "ised Phase 2 trial. CRC patients with initially defined unresectable liver-only metastases received either, 2-CTx (FOLFOX or FOLFIRI) or 3-CTx (FOLFIRINOX), plus bevacizumab/cetu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34992255"
        }
      ],
      "type": "factoid",
      "id": "662154f0b9f8b89d7e000009",
      "ideal_answer": [
        "For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate. Such an effective regimen leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection. The combination of mFOLFOXIRI and bevacizumab increased the rate of clinical NED and showed a trend toward improved survival compared with mFOLFOXIRI alone or FOLFOX and bevacizumab.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis typically involves the use of combination chemotherapy regimens. These regimens often include FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (5-fluorouracil, leucovorin, and irinotecan), sometimes in conjunction with targeted therapies such as bevacizumab or cetuximab, depending on the molecular profile of the tumor. The goal of conversion therapy is to shrink the liver metastases to a size that makes surgical resection feasible, thereby improving the chances of long-term survival.",
        "For conversion therapy in colorectal cancer with potentially resectable liver metastasis, recommended systemic treatments are:\n  - For Wild-Type (WT) RAS: Chemotherapy + anti-EGFR MoAbs (e.g., Panitumumab + XELOX or Cetuximab + FOLFIRI followed by Bevacizumab + mFOLFOX6).\n  - For Mutant (MT) RAS: Avoid anti-EGFR; consider Bevacizumab + chemotherapy (e.g., mFOLFOX6 or FOLFIRI).\n  Determining RAS status is crucial for selecting the most effective treatment, as WT RAS patients benefit significantly from anti-EGFR therapy, enhancing conversion efficiency and response rates.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis involves a combination of chemotherapy and biologic agents. The goal is to convert initially unresectable liver metastases to a resectable state, enabling potentially curative surgical resection. Systemic chemotherapy, particularly oxaliplatin- or irinotecan-based regimens, is commonly used. Triplet chemotherapy (FOLFOXIRI), which includes 5-fluorouracil, oxaliplatin, and irinotecan, offers the best conversion rate. Biologic agents like bevacizumab are often combined with FOLFOXIRI or doublet chemotherapy (FOLFOX or FOLFIRI), showing improved survival benefits and a high probability of conversion. Targeted therapy and immunotherapy are tailored based on tumor characteristics such as MMR/MSI status, KRAS/NRAS/BRAF, and HER2 mutation. The choice of treatment regimen depends on factors like tumor burden, RAS/RAF mutation status, primary tumor sidedness, previous adjuvant chemotherapy exposure, and pre-existing toxicities. Systemic treatment can enable radical liver surgery, thereby prolonging survival time. Long-term survival outcomes for patients who undergo surgery after conversion therapy are comparable to those who undergo surgery for initially resectable stage IV colorectal cancer. Significant survival benefits are observed in patients undergoing surgical resection after induction systemic treatment compared to those receiving systemic treatment without subsequent surgery.",
        "Conversion therapy in colorectal cancer with potentially resectable liver metastasis aims to shrink the metastases to a size that allows for surgical resection. The most appropriate systemic treatment typically involves a combination of chemotherapy and targeted therapy. Common chemotherapy regimens include FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (5-fluorouracil, leucovorin, and irinotecan). These regimens may be combined with targeted therapies such as bevacizumab, an anti-VEGF antibody, or cetuximab/panitumumab, which are anti-EGFR antibodies, depending on the RAS mutation status of the tumor. The choice of regimen is influenced by factors such as the patient\u0027s overall health, the molecular profile of the tumor, and the extent of liver involvement.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is a combination of intensive chemotherapy regimens, such as FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) and FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan), with bevacizumab or cetuximab. This approach has been shown to improve response rates, resection rates, and overall survival in patients with initially unresectable liver metastases.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is an intensive, short-course chemotherapy regimen combined with targeted therapy based on RAS status to achieve rapid tumor shrinkage. For KRAS wild-type patients, FOLFOX or FOLFIRI with cetuximab is recommended, while doublet or triplet chemotherapy with bevacizumab is a suitable choice for others. In select patients eligible for more aggressive therapy, regimens such as FOLFOXIRI with bevacizumab have been investigated in ongoing trials. Treatment should be carefully tailored to both tumor biology and individual patient characteristics to maximize response rates and facilitate safe liver resection.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is FOLFOXIRI (5-fluorouracil, levofolinate, oxaliplatin, and irinotecan) combined with bevacizumab.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is a combination of chemotherapy regimens such as 5-FU/LV, FOLFOX, FOLFOXIRI, bevacizumab, and cetuximab, which have shown high response rates and liver resection rates in clinical trials.",
        "For patients with potentially resectable colorectal liver metastases, \n             the most appropriate systemic treatment for conversion therapy is:\n             - For wild-type RAS: Panitumumab + Capecitabine + Oxaliplatin (P-XELOX), \n               offering high response (65%) and resectability rates (43.3%-54%).\n             - For non-wild-type RAS or unknown RAS status: Consider Capecitabine + Oxaliplatin (XELOX) \n               for its balanced efficacy and safety profile. Treatment should be tailored to individual patient characteristics.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis involves a combination of chemotherapy agents and targeted therapies. Common chemotherapy regimens include FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin) and FOLFIRI (5-fluorouracil, folinic acid, and irinotecan), which may be combined with targeted agents like cetuximab, panitumumab (for RAS wild-type tumors), and bevacizumab. The choice of regimen depends on factors like RAS/BRAF mutation status, tumor sidedness, and patient characteristics. A multidisciplinary approach involving medical oncologists and surgeons is crucial for optimal patient selection and treatment sequencing.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis typically involves the use of chemotherapy regimens such as FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (5-fluorouracil, leucovorin, and irinotecan), often combined with targeted therapies like bevacizumab (an anti-VEGF antibody) or cetuximab/panitumumab (anti-EGFR antibodies) for patients with RAS wild-type tumors. The choice of regimen depends on various factors, including the patient\u0027s overall health, tumor characteristics, and molecular profile.",
        "Based on the provided contexts, the most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is a combination of systemic chemotherapy, such as FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) or FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan), and targeted therapy, such as bevacizumab. Additionally, treatments like cetuximab, hepatic artery infusion of combined chemotherapy, and systemic cetuximab have also been explored in clinical trials for conversion therapy.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis depends on RAS status. For Wild-Type (WT) RAS, Panitumumab + Capecitabine + Oxaliplatin (P-XELOX) is recommended, offering a 65% response rate and 43.3%-54% resectability rate. For Mutant (MT) RAS or unknown status, consider Capecitabine + Oxaliplatin (XELOX) for its balanced efficacy and safety, or Bevacizumab + chemotherapy (e.g., mFOLFOX6 or FOLFIRI), tailoring treatment to individual patient characteristics.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis involves a combination of chemotherapy and biologic agents aimed at shrinking the tumors to a resectable state. Key chemotherapy regimens include FOLFOXIRI (5-fluorouracil, oxaliplatin, and irinotecan) and doublet regimens like FOLFOX (oxaliplatin and 5-fluorouracil) or FOLFIRI (irinotecan and 5-fluorouracil) combined with bevacizumab. Adding biologic agents such as bevacizumab, cetuximab, or panitumumab to chemotherapy regimens is standard practice and improves response rates, increasing the likelihood of converting unresectable metastases to resectable status. The choice of systemic treatment may also include targeted therapy and immunotherapy based on tumor characteristics such as RAS/RAF mutation status and primary tumor location. A multimodal approach combining systemic therapies with surgical and/or interventional strategies has greatly improved clinical outcomes. Systemic chemotherapy can convert initially unresectable colorectal cancer liver metastases into resectable lesions, allowing for radical local treatments such as hepatectomy. In some cases, hepatic arterial infusion chemotherapy combined with systemic therapy can be used to achieve conversion to complete resection. This tailored approach aims to shrink tumors to a resectable state, enabling potentially curative surgical intervention.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is a combination chemotherapy regimen, such as FOLFOX or FOLFIRI, paired with a targeted therapy selected based on the tumor\u0027s RAS status. For tumors with wild-type RAS, cetuximab is typically used, while for those with RAS mutations, bevacizumab is preferred. In selected patients, a more intensive regimen like FOLFIRINOX may also be considered.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is cetuximab plus FOLFIRI, as supported by the context. This regimen has been shown to be effective in converting unresectable liver metastases to resectable, particularly in RAS/BRAF wild-type patients. Other options like panitumumab with XELOX or bevacizumab plus mFOLFOX6 may also be considered based on patient-specific factors.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis involves a combination of chemotherapy and biologic agents. Key strategies include oxaliplatin- or irinotecan-based regimens, and triplet chemotherapy (FOLFOXIRI), which includes 5-fluorouracil, oxaliplatin, and irinotecan. Biologic agents are crucial as they independently predict successful conversion therapy and, when combined with traditional chemotherapy, result in high response rates, enabling some patients to undergo curative hepatectomy. Molecular targeted agents are also standard for unresectable metastatic colorectal cancer. Treatment plans are tailored based on tumor burden, RAS/RAF mutation status, primary tumor sidedness, previous chemotherapy exposure, and pre-existing toxicities. Common regimens like FOLFOXIRI plus Bevacizumab have shown improved survival benefits. Significant survival benefits are observed in patients who achieve conversion to resectable status and undergo surgical resection after induction treatment. Systemic treatment has successfully converted disease to resectable in many cases. Treatment modalities include systemic chemotherapy, targeted therapy, and immunotherapy, chosen based on tumor characteristics. Successful chemotherapy can render previously unresectable tumors resectable, allowing for radical treatments such as hepatectomy and radiofrequency ablation. These strategies aim to shrink tumors to a resectable size, enabling surgical intervention with curative intent.",
        "FOLFOXIRI-Bev is associated with a significant overall response rate. Such an effective regimen leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection.",
        "For patients with surgically unresectable colorectal cancer liver metastases, the FOLFOXIRI-Bevacizumab (FOLFOXIRI-Bev) combination chemotherapy regimen appears to be the most appropriate systemic treatment for conversion therapy. This approach has demonstrated a significant overall response rate, with approximately 40% probability of surgical conversion of distant metastases and over 25% of patients achieving an R0 resection, making it a promising strategy for potentially resectable liver metastases.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is FOLFOXIRI plus bevacizumab. This combination includes fluorouracil (5 FU), oxaliplatin, irinotecan, and bevacizumab. Each component plays a crucial role: 5 FU targets rapidly dividing cells, oxaliplatin inhibits DNA replication, irinotecan blocks topoisomerase I to prevent cancer cell division, and bevacizumab, an anti angiogenic drug, helps reduce tumor blood supply, collectively enhancing the effectiveness of surgery.",
        "For patients with colorectal cancer and potentially resectable liver metastasis, the most appropriate systemic treatment for conversion therapy is FOLFOXIRI (fluorouracil, oxaliplatin, and irinotecan) plus Bevacizumab. This regimen is consistently recommended due to its association with higher overall response rates, increased R0 surgical conversions, and prolonged progression-free survival, as supported by clinical trials like OLIVIA and systematic reviews of FOLFOXIRI-Bev, outperforming other combinations like mFOLFOX-6 with Bevacizumab in this specific clinical context.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is FOLFOXIRI Bev . This regimen combines triplet chemotherapy (oxaliplatin, irinotecan, and 5 fluorouracil) with bevacizumab, an antiangiogenic agent, which effectively shrinks tumors to make them operable. It achieves a significant overall response rate and increases the probability of surgical conversion of distant metastases, approaching 40%, with more than one fourth of patients achieving an R0 resection.",
        "For patients with surgically unresectable metastatic colorectal cancer, studies have shown that FOLFOXIRI-Bev is associated with a significant overall response rate, leading to a substantial probability of surgical conversion of distant metastases. This regimen results in a notable percentage of patients, approximately 40%, becoming eligible for surgical intervention, with over one-fourth achieving an R0 resection. The combination of mFOLFOXIRI and bevacizumab has been observed to increase the rate of clinical no evidence of disease (NED) and demonstrates a trend towards improved survival when compared to mFOLFOXIRI alone. Therefore, FOLFOXIRI-Bev emerges as a highly effective systemic treatment for conversion therapy in colorectal cancer patients with potentially resectable liver metastasis, offering significant hope for improving outcomes in this patient population.",
        "For patients with surgically unresectable metastatic colorectal cancer, the combination of FOLFOXIRI and bevacizumab (FOLFOXIRI-Bev) is an effective regimen that leads to a significant overall response rate and a high probability of surgical conversion of distant metastases. This treatment approach increases the rate of clinical no evidence of disease (NED) and shows a trend toward improved survival, making it a suitable choice for conversion therapy in colorectal cancer with potentially resectable liver metastasis.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is FOLFOXIRI Bev , a combination chemotherapy regimen. This regimen includes oxaliplatin (O), folinic acid (F), fluorouracil (FU), irinotecan (I), and bevacizumab (Bev), which is an antiangiogenic drug targeting tumor blood supply. FOLFOXIRI Bev has shown significant effectiveness, with a 40% probability of converting metastases to resectable status, leading to R0 resections in over a quarter of patients, indicating no residual cancer after surgery.",
        "For patients with unresectable liver disease, chemotherapy plays a crucial role in downstaging the disease to enable resection. Systemic chemotherapy, with or without biologic therapy, has shown increased response rates, liver resection rates, and survival. Cetuximab plus chemotherapy improves resection rates and overall survival for patients with potentially resectable colorectal cancer liver metastasis with wild-type KRAS. FOLFOX or FOLFIRI therapy is commonly used for unresectable liver metastasis. mFOLFOX6 treatment can make conversion therapy possible and improve prognosis. FOLFOXIRI-Bev is associated with a significant overall response rate and a probability of surgical conversion. Hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib can also provide opportunities for radical surgical resection. A multidisciplinary team evaluation is essential before initial treatment.",
        "FOLFOXIRI-Bev",
        "For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate and leads to a probability of surgical conversion of distant metastases approaching 40%.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is FOLFOXIRI-Bev or mFOLFOXIRI and bevacizumab.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is the combination of triplet chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI).",
        "For patients with potentially resectable liver metastasis from colorectal cancer, the most appropriate systemic treatment for conversion therapy is the combination of FOLFOXIRI (a chemotherapy regimen combining oxaliplatin, irinotecan, and 5-fluorouracil) with bevacizumab (Bev). This regimen, known as FOLFOXIRI-Bev, has been shown to achieve a significant overall response rate, with a probability of surgical conversion of distant metastases approaching 40%. Additionally, more than one-fourth of patients treated with this combination can achieve an R0 resection, indicating complete removal of the tumor without residual disease. The combination of mFOLFOXIRI and bevacizumab has also demonstrated an increased rate of clinical no evidence of disease (NED) and a trend toward improved survival compared to mFOLFOXIRI alone, making it a highly effective treatment option for conversion therapy.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer patients with potentially resectable liver metastasis is the combination of FOLFOXIRI chemotherapy regimen and bevacizumab (FOLFOXIRI-Bev). This approach has been shown to significantly increase tumor response rates, leading to a higher probability of surgical conversion—up to 40% in some studies—with over one-fourth of patients achieving an R0 resection. Additionally, the combination improves clinical outcomes and trends toward enhanced survival compared to chemotherapy alone. Therefore, FOLFOXIRI-Bev is considered a standard and effective treatment for this indication.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is FOLFOXIRI combined with bevacizumab (FOLFOXIRI-Bev). This regimen has demonstrated significant efficacy, achieving a high overall response rate and a 40% probability of surgical conversion. Additionally, it increases the likelihood of R0 resection, where no cancer cells remain post-surgery. The combination also shows trends toward improved survival compared to chemotherapy alone. While FOLFOXIRI-Bev is highly effective, patient selection should consider individual factors such as tumor biomarkers, comorbidities, and treatment history, along with the regimen\u0027s potential side effects.",
        "The most appropriate systemic treatment for conversion therapy in this setting is intensive chemotherapy with a triplet regimen (FOLFOXIRI) combined with bevacizumab. This approach has been shown to induce high response rates and increase the likelihood of converting unresectable liver metastases to resectable ones. However, patient selection is essential, as treatment should be tailored based on tumor biology, including molecular markers; for instance, doublet chemotherapy with cetuximab may be considered in KRAS wild-type patients.",
        "For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate. Such an effective regimen leads to a probability of surgical conversion of distant metastases approaching 40%. The combination of mFOLFOXIRI and bevacizumab increased the rate of clinical NED and showed a trend toward improved survival.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is the combination of FOLFOXIRI chemotherapy regimen and bevacizumab (FOLFOXIRI-Bev). This approach has been shown to significantly increase tumor response rates, leading to a high probability of surgical conversion—up to 40%—with over one-fourth of patients achieving an R0 resection. Additionally, this combination enhances the rate of clinical NED (no evidence of disease) and demonstrates a trend toward improved survival compared to chemotherapy alone. Therefore, FOLFOXIRI-Bev is highly effective for facilitating surgical intervention in such cases.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is FOLFOXIRI-Bev, which is associated with a significant overall response rate, leading to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is the combination of FOLFOXIRI chemotherapy regimen with bevacizumab (FOLFOXIRI-Bev). This approach has demonstrated significant tumor response rates, a 40% probability of surgical conversion, and a 25% chance of achieving an R0 resection. Additionally, studies have shown that this combination increases the rate of clinical NED and may improve survival outcomes compared to chemotherapy alone. Therefore, FOLFOXIRI-Bev is strongly supported as an effective treatment for facilitating surgical intervention in such cases.",
        "Systemic treatment options for conversion therapy in colorectal cancer with potentially resectable liver metastasis include both anti-VEGF- and anti-EGFR-directed therapies. For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate and a probability of surgical conversion of distant metastases approaching 40%. In KRAS wild-type patients with unresectable liver metastases, a combination of cetuximab plus chemotherapy is often used as conversion therapy to improve R0 resection rates and prolong overall survival. For patients with RAS WT and left-sided tumors, anti-EGFR-based treatment is recommended.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer patients with potentially resectable liver metastasis is the combination of FOLFOXIRI chemotherapy regimen with bevacizumab (FOLFOXIRI-Bev). This approach has demonstrated significant efficacy, achieving a high overall response rate and increasing the probability of surgical conversion to approximately 40%. Additionally, it enhances the likelihood of achieving an R0 resection, where no cancer cells remain post-surgery. The combination also shows trends toward improved survival compared to chemotherapy alone. While other treatments exist, FOLFOXIRI-Bev is recommended due to its strong evidence base and effectiveness in facilitating successful surgery, provided patients are fit enough to tolerate the regimen\u0027s intensity.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is the combination of FOLFOXIRI and bevacizumab. This regimen is associated with a significant overall response rate and a high probability of surgical conversion of distant metastases.",
        "For patients with surgically unresectable metastatic colorectal cancer, particularly those with potentially resectable liver metastases, a combination of mFOLFOXIRI (modified FOLFOXIRI) and bevacizumab is considered an effective systemic treatment for conversion therapy. This regimen has been associated with a significant overall response rate and increases the probability of surgical conversion of distant metastases to approximately 40%, with more than one-fourth of patients achieving an R0 resection, indicating no residual tumor at the margins.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is the combination of modified FOLFOXIRI (mFOLFOXIRI) plus bevacizumab.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is the combination of FOLFOXIRI and bevacizumab, as it is associated with a significant overall response rate and a high probability of surgical conversion of distant metastases, with more than one-fourth of patients achieving an R0 resection.",
        "Based on the available evidence, FOLFOXIRI-Bev (a combination of folinic acid, fluorouracil, oxaliplatin, irinotecan, and bevacizumab) is a suitable systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis. This regimen has been shown to achieve a significant overall response rate, leading to a high probability of surgical conversion of distant metastases (approaching 40%) and R0 resection in more than one-fourth of patients. Additionally, the combination of mFOLFOXIRI and bevacizumab has been observed to increase the rate of clinical no evidence of disease (NED) and trend towards improved survival compared to mFOLFOXIRI alone. Therefore, FOLFOXIRI-Bev can be considered a suitable treatment option for conversion therapy in this setting.",
        "The most appropriate systemic treatment for colorectal cancer with potentially resectable liver metastasis is the combination of triplet chemotherapy with 5 fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI), especially for patients with borderline resectable metastases.",
        "The most appropriate systemic treatment for colorectal cancer with potentially resectable liver metastasis is the combination of triplet chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI).",
        "FOLFOXIRI-Bev is considered the most effective systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis.",
        "FOLFOXIRI plus bevacizumab (FOLFOXIRI-Bev) is the most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis. This regimen boasts a high overall response rate (up to 69%), significant surgical conversion rates (approximately 39.1%), and improved survival outcomes (median overall survival of 30.2 months and progression-free survival of 12.4 months). Comparative studies support its efficacy over other treatments in facilitating secondary resection and improving patient outcomes.",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is the combination of mFOLFOXIRI and bevacizumab.",
        "For patients with surgically unresectable metastatic colorectal cancer, the most appropriate systemic treatment for conversion therapy, particularly when aiming to make liver metastases resectable, is the FOLFOXIRI-Bev regimen. This combination includes fluorouracil, leucovorin, oxaliplatin, irinotecan, and bevacizumab, and is associated with a significant overall response rate. The effectiveness of this regimen leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients achieving an R0 resection, which indicates no residual microscopic disease.",
        "For patients with colorectal cancer and initially unresectable, yet potentially resectable liver metastasis, the most appropriate systemic treatment for conversion therapy is FOLFOXIRI (fluorouracil, oxaliplatin, and irinotecan) plus Bevacizumab, offering superior overall response rates, increased R0 resection rates, and prolonged progression-free survival, as supported by clinical trials like OLIVIA and relevant systematic reviews.",
        "For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate. Such an effective regimen leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection",
        "For patients with surgically unresectable metastatic colorectal cancer, particularly those with potentially resectable liver metastasis, the most appropriate systemic treatment for conversion therapy is FOLFOXIRI Bev. This regimen combines three chemotherapeutic agents (5 fluorouracil, leucovorin, oxaliplatin, and irinotecan) with bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). FOLFOXIRI Bev has been shown to achieve a significant overall response rate and is associated with a high probability of surgical conversion of distant metastases, approaching 40%. This treatment significantly increases the likelihood of achieving an R0 resection, where no microscopic evidence of residual disease remains after surgery.",
        "For conversion therapy in colorectal cancer with potentially resectable liver metastasis, FOLFOXIRI-Bev is an appropriate systemic treatment. This regimen can lead to a probability of surgical conversion of distant metastases approaching 40%. The combination of mFOLFOXIRI and bevacizumab may also increase the rate of clinical NED.",
        " For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev (Folinic acid, 5-Fluorouracil, Oxaliplatin, Irinotecan, and Bevacizumab) is associated with a significant overall response rate. This regimen leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection. Therefore, FOLFOXIRI-Bev can be considered as the most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis.",
        "Based on the provided context, FOLFOXIRI-Bev (FOLFOXIRI plus bevacizumab) appears to be the most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis. This regimen is associated with a significant overall response rate and leads to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients achieving an R0 resection. Additionally, the combination of mFOLFOXIRI and bevacizumab has shown increased rates of clinical NED (No Evidence of Disease) and a trend toward improved survival compared to mFOLFOXIRI alone, further supporting its use in this clinical scenario.",
        "Studies have shown that FOLFOXIRI-Bev is associated with a significant overall response rate for patients with unresectable metastatic colorectal cancer, leading to a high probability of surgical conversion of distant metastases. This regimen results in approximately 40% of patients achieving resection of their liver metastases, with over one-fourth undergoing successful R0 resection. Furthermore, the combination of mFOLFOXIRI and bevacizumab has been shown to increase clinical NED rates and demonstrates a trend toward improved survival compared to mFOLFOXIRI alone. Therefore, FOLFOXIRI-Bev represents an effective systemic treatment option for conversion therapy in colorectal cancer patients with potentially resectable liver metastasis.",
        "Based on the available evidence, FOLFOXIRI-Bev (a combination of folinic acid, fluorouracil, oxaliplatin, irinotecan, and bevacizumab) is a suitable systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis. This regimen has been shown to achieve a significant overall response rate, leading to a high probability of surgical conversion of distant metastases (approaching 40%) and R0 resection in more than one-fourth of patients.",
        "For patients with potentially resectable liver metastases from colorectal cancer, the most appropriate systemic treatment for conversion therapy is the combination of FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) and bevacizumab. This intensive chemotherapy regimen has been shown to increase the rate of complete response and surgical conversion of metastatic disease, allowing for potentially curative resection in a significant proportion of patients.",
        "For patients with colorectal cancer and potentially resectable liver metastasis, the most appropriate systemic treatment for conversion therapy is FOLFOXIRI (fluorouracil, oxaliplatin, irinotecan, and folinic acid) plus Bevacizumab, due to its high efficacy as evidenced by a 69% overall response rate, 39.1% surgical conversion rate, and improved survival outcomes, including a median overall survival of 30.2 months and progression-free survival of 12.4 months.",
        "FOLFOXIRI plus bevacizumab",
        "The most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastases is an intensive regimen combining FOLFOXIRI with bevacizumab. This approach utilizes a triplet chemotherapy regimen alongside a targeted agent to achieve high response rates, increasing the likelihood of converting initially unresectable liver metastases to resectable disease, ultimately improving survival outcomes.",
        "For patients with colorectal cancer and potentially resectable liver metastasis, the most appropriate systemic treatment for conversion therapy appears to be the combination of FOLFOXIRI chemotherapy with Bevacizumab (FOLFOXIRI-Bev).",
        "Conversion therapy in colorectal cancer with potentially resectable liver metastasis is a complex medical problem because the optimal treatment depends on various factors, including the patient\u0027s overall health, preferences, and specific circumstances. However, based on the provided information, FOLFOXIRI-Bev appears to be a promising systemic treatment option for conversion therapy in colorectal cancer with potentially resectable liver metastasis. This regimen has been associated with a significant overall response rate, leading to a probability of surgical conversion of distant metastases approaching 40%, with more than one-fourth of patients having an R0 resection. Additionally, combining mFOLFOXIRI and bevacizumab has been shown to increase the rate of clinical NED and improve survival compared with mFOLFOXIRI alone. Therefore, FOLFOXIRI-Bev seems to be the most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis, given its effectiveness and favorable side effect profile. However, it is essential to consider individual patient factors and discuss treatment options with a multidisciplinary team to determine the most suitable approach.\nBased on the information provided, the most appropriate systemic treatment for conversion therapy in colorectal cancer with potentially resectable liver metastasis is FOLFOXIRI-Bev. This regimen has been associated with a significant overall response rate, leading to a probability of surgical conversion of distant metast",
        "For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate and a probability of surgical conversion of distant metastases approaching 40%. First-line doublet chemotherapy regimens lead to response rates of 50-60%, triplet chemotherapy regimens may result in a response rate of up to 70%, and biological agents may add to responses or induce morphologic changes that facilitate disease resection. The most effective and appropriate systemic therapy should be offered with the primary purpose of achieving maximal disease response with the intention of conversion to surgical resectability with curative intent. The combination of mFOLFOXIRI and bevacizumab increased the rate of clinical NED and showed a trend toward improved survival compared with mFOLFOXIRI alone. The evolving role of gene testing, such as RAS/BRAF and PIK3CA, is reflected in tailoring neoadjuvant regimens.",
        "FOLFOXIRI combined with bevacizumab (FOLFOXIRI-Bev) is the most effective systemic treatment for conversion therapy in colorectal cancer with liver metastasis, demonstrating significant overall response rates and achieving surgical conversion of distant metastases in up to 40% of cases. This combination therapy not only increases the rate of clinical no evidence of disease (NED) but also shows promising survival benefits compared to FOLFOXIRI alone, with over 25% of patients achieving R0 resection.",
        "For patients with metastatic colorectal cancer that is initially unresectable, the combination of FOLFOXIRI and bevacizumab (FOLFOXIRI-Bev) is an effective regimen for conversion therapy. This treatment approach has shown a significant overall response rate and increases the probability of surgical conversion of distant metastases to nearly 40%, with over one-fourth of patients achieving an R0 resection.",
        "For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev is associated with a significant overall response rate and leads to a probability of surgical conversion of distant metastases approaching 40%. The combination of mFOLFOXIRI and bevacizumab increased the rate of clinical NED and showed a trend toward improved survival compared with mFOLFOXIRI alone."
      ],
      "exact_answer": [
        [
          "mFOLFOXIRI and Bevacizumab",
          "FOLFIRINOX plus Bevacizumab",
          "FOLFOXIRI plus bevacizumab",
          "FOLFOXIRI+bevacizumab",
          "FOLFOXIRI chemotherapy regimen",
          "FOLFOXIRI-Bev regimen"
        ]
      ]
    },
    {
      "body": "Is age an underlying factor in the eye disease AMD?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39025435",
        "http://www.ncbi.nlm.nih.gov/pubmed/38725183",
        "http://www.ncbi.nlm.nih.gov/pubmed/39547643",
        "http://www.ncbi.nlm.nih.gov/pubmed/39446815",
        "http://www.ncbi.nlm.nih.gov/pubmed/12011686",
        "http://www.ncbi.nlm.nih.gov/pubmed/18982917",
        "http://www.ncbi.nlm.nih.gov/pubmed/9577116",
        "http://www.ncbi.nlm.nih.gov/pubmed/21297256",
        "http://www.ncbi.nlm.nih.gov/pubmed/37099020",
        "http://www.ncbi.nlm.nih.gov/pubmed/25704819",
        "http://www.ncbi.nlm.nih.gov/pubmed/37507918",
        "http://www.ncbi.nlm.nih.gov/pubmed/8941243",
        "http://www.ncbi.nlm.nih.gov/pubmed/31899290",
        "http://www.ncbi.nlm.nih.gov/pubmed/23933169",
        "http://www.ncbi.nlm.nih.gov/pubmed/32710488",
        "http://www.ncbi.nlm.nih.gov/pubmed/35488571",
        "http://www.ncbi.nlm.nih.gov/pubmed/36150544",
        "http://www.ncbi.nlm.nih.gov/pubmed/34843745",
        "http://www.ncbi.nlm.nih.gov/pubmed/16500214",
        "http://www.ncbi.nlm.nih.gov/pubmed/37511345"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 7,
          "offsetInEndSection": 149,
          "text": ": To determine whether oral micronutrient supplementation slows geographic atrophy (GA) progression in age-related macular degeneration (AMD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39025435"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 185,
          "text": "To quantify and compare the different prevalence rates of specific retinal imaging biomarkers in patients with intermediate AMD (iAMD) and advanced non-neovascular AMD (nnAMD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38725183"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Age-related macular degeneration (AMD) remains a leading cause of vision loss in the geriatric population. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39547643"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "The age-related macular degeneration (AMD) field is witnessing promising advancements in therapeutic options. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39446815"
        },
        {
          "offsetInBeginSection": 528,
          "offsetInEndSection": 641,
          "text": "Although a number of factors seem promising, only age and cigarette smoking are confirmed as increasing AMD risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12011686"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 61,
          "text": "Risk factors for age-related macular degeneration: an update.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12011686"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Age-related macular degeneration (AMD) is an ocular disease that causes damage to the retinal macula, mostly in the elderly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982917"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 51,
          "text": "Age-related macular degeneration and the aging eye.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982917"
        },
        {
          "offsetInBeginSection": 655,
          "offsetInEndSection": 956,
          "text": "d changes in retinal vessels.RESULTS: The significant relationships were found between the development of AMD and the age of patients, as well as between the advanced forms of AMD and the history of cardiovascular diseases and sclerotic changes in retinal vessels, 87% of examined patients have light ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9577116"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 565,
          "text": "Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clinical and pathological features with Alzheimer\u0027s disease (AD), including stress stimuli such as oxidative stress and inflammation. In both diseases, the detrimental intra- and extracellular deposits have many similarities. Aging, hypercholesterolaemia, hypertension, obesity, arteriosclerosis, and smoking are risk factors to develop AMD and AD. Cellular aging processes have similar organelle and signaling association in the retina and brain tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21297256"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Age-related macular degeneration (AMD) is a complex eye disease with the retina as the target tissue and aging as per definition the most serious risk factor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36113764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Purpose: Age is the main risk factor for age-related macular degeneration (AMD), a leading cause of blindness in the elderly, with limited therapeutic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37099020"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Age is a major risk factor in age-related macular degeneration (AMD), but the underlying cause is unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25704819"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 732,
          "text": "Although environmental (e.g., smoking) and hereditary factors may possibly play a role in the development of AMD, the principal risk factor is ageing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8941243"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 420,
          "text": "age itself remains by far the most important risk factor, making it an urgent priority to understand the connections between underlying ageing mechanisms and pathophysiology of AMD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31899290"
        },
        {
          "offsetInBeginSection": 573,
          "offsetInEndSection": 641,
          "text": "only age and cigarette smoking are confirmed as increasing AMD risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12011686"
        },
        {
          "offsetInBeginSection": 224,
          "offsetInEndSection": 353,
          "text": "Development of AMD has been recognized as contingent on environmental and genetic risk factors, the strongest being advanced age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23933169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Age-related macular degeneration (AMD) is a progressive degenerative disease that is the leading cause of vision loss in the elderly population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32710488"
        },
        {
          "offsetInBeginSection": 269,
          "offsetInEndSection": 335,
          "text": "The aging process is the main and the clearest risk factor of AMD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35488571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "Advanced age is the most established risk factor for developing age-related macular degeneration (AMD), one of the leading causes of visual impairment in the elderly, in Western and developed countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36150544"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 361,
          "text": "Age-related macular degeneration (AMD), the leading cause of blindness in the elderly, is a complex disease to study because of the potential role of demographic, environmental, and other systemic risk factors, such as age, sex, race, light exposure, diet, smoking, and underlying cardiovascular disease which may contribute to the pathogenesis of this disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16500214"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 240,
          "text": "Age is the greatest risk factor for AMD but the underlying mechanism remains unascertained, resulting in a lack of effective therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37511345"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "text": "Age-related macular degeneration (AMD) is an ocular disease that causes damage to the retinal macula, mostly in the elderly. Normal aging processes can lead to structural and blood flow changes that can predispose patients to AMD,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18982917"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 570,
          "text": "The main risk factors for the development of advanced AMD are increasing age, genetic factors, and cigarette smoking; however, the exact pathophysiology of AMD is yet relatively poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34843745"
        },
        {
          "offsetInBeginSection": 567,
          "offsetInEndSection": 729,
          "text": "Along with various genetic and environmental factors that contribute to AMD, aging and age-related oxidative damage have critical involvement in AMD pathogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37507918"
        }
      ],
      "type": "yesno",
      "id": "67c847f581b1027333000003",
      "ideal_answer": [
        "Yes, in the context of eye diseases, AMD is an abbreviation for Age-related Macular Degeneration. Therefore, age is an underlying factor",
        "Yes, age is an underlying factor in the eye disease AMD.",
        "Yes, age is an important underlying factor in the development of age-related macular degeneration (AMD). As people age, the risk of developing AMD increases, making aging a significant risk factor for this eye disease.",
        "Yes, age is a significant underlying factor in age-related macular degeneration (AMD), as it is the most serious risk factor, with the disease primarily affecting individuals over the age of 65.",
        "Yes. Age is a significant underlying factor in the development of age-related macular degeneration (AMD), as it is prevalent in the elderly population and is considered a major risk factor for this condition.",
        "Yes, aging is a principal risk factor for AMD.",
        "Yes, age is a significant underlying factor in age-related macular degeneration (AMD). AMD is a complex eye disease primarily affecting the elderly, with its incidence increasing sharply with age. Aging processes can lead to structural and blood flow changes in the retina, predisposing individuals to AMD. While advanced age doesn\u0027t inevitably cause AMD, it is considered the most serious risk factor.",
        "Yes. Age is considered an underlying factor in the development of age-related macular degeneration (AMD), as the study indicates that age influences the pathogenesis of AMD and is associated with various ocular health outcomes.",
        "Yes. Age is a significant underlying factor in age-related macular degeneration (AMD), which primarily affects older adults and is a leading cause of vision loss in this population.",
        "Yes. Age is a significant predictor for the occurrence of age-related macular degeneration (AMD), with older age being associated with a higher risk of developing the disease.",
        "Yes, age is a major risk factor in age-related macular degeneration (AMD), but the underlying cause is unknown.",
        "Yes. Age is the strongest risk factor for age-related macular degeneration (AMD), with advanced age significantly contributing to its occurrence.",
        "Age is considered the most significant risk factor for age-related macular degeneration (AMD). While AMD does not inevitably occur with advanced age, normal aging processes can lead to structural and blood flow changes in the eye that predispose individuals to developing AMD. Therefore, age is an underlying and major contributing factor to the development and progression of AMD.",
        "Age is a significant underlying factor in age-related macular degeneration (AMD), with the disease predominantly affecting individuals over the age of 65 years.",
        "Yes, age is a significant underlying factor in the eye disease AMD, influencing its pathogenesis and risk profile, although AMD involves distinct biological changes that are not solely an acceleration of normal aging processes.",
        "Yes, age is an underlying factor in the eye disease AMD. Age-related macular degeneration (AMD) is a disease that primarily affects older adults, with the risk of developing AMD increasing with age. The majority of AMD cases occur in people over the age of 50, and the risk continues to increase with age.",
        "Age is a critical underlying factor in age-related macular degeneration (AMD). The disease is specifically named \u0027age-related\u0027 macular degeneration, and the context explicitly states that AMD is a leading cause of vision loss in the geriatric population, directly linking the disease\u0027s progression and prevalence to advancing age.",
        "Yes, age is an underlying factor in the development of age-related macular degeneration (AMD). AMD is a progressive eye disease that primarily affects older adults, and its prevalence increases with age.",
        "Yes, age is an underlying factor in age-related macular degeneration (AMD), which remains a leading cause of vision loss in the geriatric population.",
        "Yes. Age is a significant underlying factor in age-related macular degeneration (AMD), as it primarily affects the geriatric population and is associated with various age-related changes.",
        "Age is an underlying factor in age-related macular degeneration (AMD), as it predominantly affects the geriatric population and is a leading cause of vision loss in this age group.",
        "Yes. Aging is the greatest risk factor for chronic human diseases, including many eye diseases such as age-related macular degeneration (AMD).",
        "Yes, age is a significant risk factor for AMD.",
        "Yes, age is an underlying factor in age related macular degeneration (AMD), as the condition is directly linked to aging and its associated changes in the retina.",
        "Yes, based on the provided snippets, age appears to be an underlying factor in the eye disease AMD, as indicated by the \u0027age-related\u0027 nature of the disease and its prevalence in the geriatric population.",
        "Age-related macular degeneration (AMD) is a leading cause of vision loss, particularly affecting older adults. The condition\u0027s name itself indicates its association with aging, suggesting that age is indeed an underlying factor. Research and therapeutic advancements continue to focus on this geriatric population."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Vector of zika virus.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37018738",
        "http://www.ncbi.nlm.nih.gov/pubmed/38412550",
        "http://www.ncbi.nlm.nih.gov/pubmed/39107395",
        "http://www.ncbi.nlm.nih.gov/pubmed/38748732",
        "http://www.ncbi.nlm.nih.gov/pubmed/38729373",
        "http://www.ncbi.nlm.nih.gov/pubmed/32725867",
        "http://www.ncbi.nlm.nih.gov/pubmed/28719283",
        "http://www.ncbi.nlm.nih.gov/pubmed/28430562",
        "http://www.ncbi.nlm.nih.gov/pubmed/28430564",
        "http://www.ncbi.nlm.nih.gov/pubmed/35918360",
        "http://www.ncbi.nlm.nih.gov/pubmed/28442754",
        "http://www.ncbi.nlm.nih.gov/pubmed/29472998",
        "http://www.ncbi.nlm.nih.gov/pubmed/39724646",
        "http://www.ncbi.nlm.nih.gov/pubmed/39740097",
        "http://www.ncbi.nlm.nih.gov/pubmed/39724432",
        "http://www.ncbi.nlm.nih.gov/pubmed/39674197",
        "http://www.ncbi.nlm.nih.gov/pubmed/37651473",
        "http://www.ncbi.nlm.nih.gov/pubmed/29267909",
        "http://www.ncbi.nlm.nih.gov/pubmed/27618294",
        "http://www.ncbi.nlm.nih.gov/pubmed/31740702",
        "http://www.ncbi.nlm.nih.gov/pubmed/27679623",
        "http://www.ncbi.nlm.nih.gov/pubmed/29145400",
        "http://www.ncbi.nlm.nih.gov/pubmed/35736984",
        "http://www.ncbi.nlm.nih.gov/pubmed/27029595",
        "http://www.ncbi.nlm.nih.gov/pubmed/32469909",
        "http://www.ncbi.nlm.nih.gov/pubmed/31109248",
        "http://www.ncbi.nlm.nih.gov/pubmed/39585856",
        "http://www.ncbi.nlm.nih.gov/pubmed/27631604/",
        "http://www.ncbi.nlm.nih.gov/pubmed/27490087/",
        "http://www.ncbi.nlm.nih.gov/pubmed/36146853",
        "http://www.ncbi.nlm.nih.gov/pubmed/27005721",
        "http://www.ncbi.nlm.nih.gov/pubmed/32203510",
        "http://www.ncbi.nlm.nih.gov/pubmed/39300135",
        "http://www.ncbi.nlm.nih.gov/pubmed/30354937",
        "http://www.ncbi.nlm.nih.gov/pubmed/25001879"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 101,
          "offsetInEndSection": 196,
          "text": "Zika (ZIKV) viruses have added complexity to Aedes-borne disease prevention and control efforts",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38412550"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 282,
          "text": "Aedes aegypti is the primary vector of these pathogens and Culex quinquefasciatus may be a potential ZIKV vector",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38748732"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Invasive Aedes aegypti and Aedes albopictus mosquitoes transmit viruses such as dengue, chikungunya and Zika",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38729373"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 312,
          "text": "The vector mosquitoes for Zika virus are mainly of the Aedes genus, especially Aedes aegypti and Aedes albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32725867"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Susceptibility and interactions between Aedes mosquitoes and Zika viruses.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32725867"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 357,
          "text": "Aedes aegypti and Aedes albopictus mosquitoes are known vectors of ZIKV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28719283"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "American Aedes vexans Mosquitoes are Competent Vectors of Zika Virus.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28719283"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Aedes aegypti and Aedes albopictus are the main vectors of arboviruses such as dengue, Zika virus, and chikungunya",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724646"
        },
        {
          "offsetInBeginSection": 398,
          "offsetInEndSection": 606,
          "text": "We found the highest vector competence for the imported Zika virus in Ae. aegypti mosquitoes, some susceptibility of Ae. albopictus mosquitoes, but no transmission ability for Cx. quinquefasciatus mosquitoes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28430562"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "In the Western Hemisphere, Zika virus is thought to be transmitted primarily by Aedes aegypti mosquitoes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28430564"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 107,
          "text": "Aedes aegypti is a primary urban vector of dengue, yellow fever, Zika and chikungunya worldwide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "The mosquito species Aedes aegypti (Linneaus) is the vector of multiple arboviruses, including dengue, Chikungunya, Zika, and yellow fever",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724432"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 109,
          "text": "Aedes aegypti spread pathogens affecting humans, including dengue, Zika, and yellow fever viruses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39674197"
        },
        {
          "offsetInBeginSection": 597,
          "offsetInEndSection": 671,
          "text": "ZIKV was able to infect, disseminate, and be transmitted by Aedes aegypti.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29472998"
        },
        {
          "offsetInBeginSection": 684,
          "offsetInEndSection": 828,
          "text": "In blood feeding laboratry experiments, we found that Ae. aegypti mosquitoes showed to be a competent vector able to transmit ZIKV in this area.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31740702"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 122,
          "text": "The vectors for ZIKV are Aedes aegypti and A. albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27679623"
        },
        {
          "offsetInBeginSection": 247,
          "offsetInEndSection": 299,
          "text": "Aedes aegypti is the most important vector for ZIKV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28442754"
        },
        {
          "offsetInBeginSection": 1209,
          "offsetInEndSection": 1430,
          "text": "Vector competence assays were performed on 22 different mosquito species, including 13 Aedes, 7 Culex, and 2 Anopheles species with, as a result, the discovery that A. aegypti and Aedes albopictus were competent for ZIKV,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145400"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "For \u003e60 years, Zika virus (ZIKV) has been recognized as an arthropod-borne virus with Aedes species mosquitoes as the primary vector.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29267909"
        },
        {
          "offsetInBeginSection": 396,
          "offsetInEndSection": 470,
          "text": "Aedes aegypti and Aedes albopictus are the most important vectors of ZIKV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35736984"
        },
        {
          "offsetInBeginSection": 1261,
          "offsetInEndSection": 1431,
          "text": "There is a high potential for ZIKV emergence in urban centers in the tropics that are infested with competent mosquito vectors such as Aedes aegypti and Aedes albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27029595"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "BACKGROUND: After the unprecedented Zika virus (ZIKV) outbreak in the western hemisphere from 2015-2018, Aedes aegypti and Ae. albopictus are now well established primary and secondary ZIKV vectors, r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37651473"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 266,
          "text": "The Zika virus is transmitted by the Aedes species of mosquito as well as by sexual intercourse.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27618294"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 317,
          "text": "Zika virus is transmitted by mosquitoes, mainly Aedes aegypti, and secondarily, Aedes albopictus, both colonizing a large strip encompassing tropical and temperate regions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35918360"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 256,
          "text": "The majority of vector incrimination studies available for ZIKV showed that Aedes aegypti mosquitoes are important vectors for this virus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31109248"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Aedes albopictus, known as the Asian tiger mosquito, is a significant vector for dengue fever, chikungunya, zika virus, yellow fever",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39585856"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Zika virus is a mosquito-borne flavivirus primarily transmitted to humans by Aedes aegypti mosquitoes (1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27631604/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Zika virus is a flavivirus transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes, and infection can be asymptomatic or result in an acute febrile illness with rash (1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490087/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Zika virus (ZIKV) is a positive-sense single-stranded RNA flavivirus and is mainly transmitted by Aedes mosquitoes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36146853"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "Zika virus (ZIKV) is a flavivirus with single stranded RNA related to yellow fever, dengue, West Nile, and Japanese encephalitis viruses and is transmitted by Aedes mosquitoes primarily by Aedes aegipti which is widely distributed in Nepal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27005721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Aedes aegypti and Aedes albopictus are both vectors of Zika virus and both are endemic to the New Orleans Metropolitan area.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32469909"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Zika virus (ZIKV) is a Flavivirus (Flaviviridae) transmitted to humans mainly by the bite of an infected Aedes mosquitoes. Aedes aegypti is the primary epidemic vector of ZIKV and Ae. albopictus, the secondary one.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32203510"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "The main vectors of Zika virus (ZIKV) and dengue virus (DENV) are Aedes aegypti and Ae. albopictus, with Ae. aegypti being more competent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39300135"
        },
        {
          "offsetInBeginSection": 949,
          "offsetInEndSection": 1087,
          "text": "We conclude that both Ae. aegypti and Ae. albopictus are able to transmit ZIKV and may intervene as active Zika vectors in Central Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32203510"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 391,
          "text": "ZIKV is a member of the flavivirus family and is mainly transmitted to human hosts through Aedes mosquito vectors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30354937"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "The Zika virus (ZIKV) is a mosquito-borne flavivirus (Aedes), similar to other arboviruses, first identified in Uganda in 1947.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25001879"
        }
      ],
      "id": "67d7fe2618b1e36f2e000044",
      "ideal_answer": [
        "Aedes aegypti and Aedes albopictus are the main vectors of Zika virus.",
        "The main vectors of Zika virus are Aedes aegypti and Aedes albopictus mosquitoes. These mosquito species are highly competent in transmitting the virus and can also pass it on to their offspring through transovarial transmission, allowing the virus to persist during inter-epidemic periods. Controlling these mosquito vectors is crucial for preventing future Zika outbreaks."
      ],
      "exact_answer": [
        [
          "mosquitoes",
          "Aedes aegypti",
          "Aedes albopictus"
        ]
      ]
    },
    {
      "body": "What are the main transcription factors driving the mesenchymal-like (MES-like) state of glioblastoma multiforme?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38826227",
        "http://www.ncbi.nlm.nih.gov/pubmed/34087162",
        "http://www.ncbi.nlm.nih.gov/pubmed/39707474",
        "http://www.ncbi.nlm.nih.gov/pubmed/34399888",
        "http://www.ncbi.nlm.nih.gov/pubmed/35974001",
        "http://www.ncbi.nlm.nih.gov/pubmed/27569208",
        "http://www.ncbi.nlm.nih.gov/pubmed/29463580",
        "http://www.ncbi.nlm.nih.gov/pubmed/20032975",
        "http://www.ncbi.nlm.nih.gov/pubmed/31754093",
        "http://www.ncbi.nlm.nih.gov/pubmed/38766170",
        "http://www.ncbi.nlm.nih.gov/pubmed/28754668",
        "http://www.ncbi.nlm.nih.gov/pubmed/29903919",
        "http://www.ncbi.nlm.nih.gov/pubmed/22190458",
        "http://www.ncbi.nlm.nih.gov/pubmed/28443460",
        "http://www.ncbi.nlm.nih.gov/pubmed/36949071",
        "http://www.ncbi.nlm.nih.gov/pubmed/35351656",
        "http://www.ncbi.nlm.nih.gov/pubmed/22440258",
        "http://www.ncbi.nlm.nih.gov/pubmed/31652994",
        "http://www.ncbi.nlm.nih.gov/pubmed/25592037",
        "http://www.ncbi.nlm.nih.gov/pubmed/23268331",
        "http://www.ncbi.nlm.nih.gov/pubmed/31400279",
        "http://www.ncbi.nlm.nih.gov/pubmed/32041837",
        "http://www.ncbi.nlm.nih.gov/pubmed/30216501/",
        "http://www.ncbi.nlm.nih.gov/pubmed/29467947",
        "http://www.ncbi.nlm.nih.gov/pubmed/23386688",
        "http://www.ncbi.nlm.nih.gov/pubmed/25275602"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 1571,
          "offsetInEndSection": 1692,
          "text": "For example, the transcription factor TFAP2A can be seen to promote a transition from the NPC-like to the MES-like state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38826227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "The mesenchymal subtype of glioblastoma is thought to be determined by both cancer cell-intrinsic alterations and extrinsic cellular interactions, but remains poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087162"
        },
        {
          "offsetInBeginSection": 468,
          "offsetInEndSection": 674,
          "text": "This effect is mediated, both in vitro and in vivo, by macrophage-derived oncostatin M (OSM) that interacts with its receptors (OSMR or LIFR) in complex with GP130 on glioblastoma cells and activates STAT3.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087162"
        },
        {
          "offsetInBeginSection": 1077,
          "offsetInEndSection": 1217,
          "text": "Furthermore, by incorporating snATAC-seq data, we delineated a crucial regulatory network and pinpointed the key transcription factor CEBPG.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39707474"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 338,
          "text": "Using transcriptomic data of human patient-derived brain tumor stem cell lines (BTSCs), classified based on GBM-intrinsic signatures, we identify the AP-1 transcription factor FOSL1 as a key regulator of the mesenchymal (MES) subtype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34399888"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Recent studies suggest that Forkhead box D1 (FOXD1) plays an indispensable role in maintaining the mesenchymal (MES) properties of glioblastoma (GBM) stem cells (GSCs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35974001"
        },
        {
          "offsetInBeginSection": 265,
          "offsetInEndSection": 367,
          "text": "In this study, we identify the FOXD1-ALDH1A3 signaling axis as a determinant of the MES GSC phenotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569208"
        },
        {
          "offsetInBeginSection": 368,
          "offsetInEndSection": 512,
          "text": "The transcription factor FOXD1 is expressed predominantly in patient-derived cultures enriched with MES, but not with the proneural GSC subtype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569208"
        },
        {
          "offsetInBeginSection": 353,
          "offsetInEndSection": 674,
          "text": "We demonstrate that macrophages induce a transition of glioblastoma cells into mesenchymal-like (MES-like) states. This effect is mediated, both in vitro and in vivo, by macrophage-derived oncostatin M (OSM) that interacts with its receptors (OSMR or LIFR) in complex with GP130 on glioblastoma cells and activates STAT3.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34087162"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 415,
          "text": "The epithelial-mesenchymal transition (EMT) inducing factor Zeb1 was linked to tumor initiation, invasion, and resistance to therapy in glioblastoma, but how Zeb1 functions at molecular level and what genes it regulates remain poorly understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29903919"
        },
        {
          "offsetInBeginSection": 1288,
          "offsetInEndSection": 1394,
          "text": "Our studies uncover a direct role for TAZ and TEAD in driving the MES differentiation of malignant glioma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22190458"
        },
        {
          "offsetInBeginSection": 1331,
          "offsetInEndSection": 1480,
          "text": "Moreover, master regulators of the glioblastoma multiforme mesenchymal phenotype including CEBPb, ZNF238, and FOSL2 were directly regulated by RUNX1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28443460"
        },
        {
          "offsetInBeginSection": 928,
          "offsetInEndSection": 1086,
          "text": "transcription factors known to drive the mesenchymal expression class were most closely related, including C/EBP-β, C/EBP-δ, STAT3, FOSL2, bHLHE40, and RUNX1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22440258"
        },
        {
          "offsetInBeginSection": 582,
          "offsetInEndSection": 715,
          "text": "Two transcription factors (C/EBPbeta and STAT3) emerge as synergistic initiators and master regulators of mesenchymal transformation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20032975"
        },
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 323,
          "text": "Fos-like antigen 1 (FOSL1), a component of AP1 transcription factor complexes, is a key player in regulating PMT.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35351656"
        },
        {
          "offsetInBeginSection": 324,
          "offsetInEndSection": 405,
          "text": "FOSL1 is predominantly expressed in the MES subtype, but not PN subtype, of GSCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35351656"
        },
        {
          "offsetInBeginSection": 406,
          "offsetInEndSection": 608,
          "text": "Knocking down FOSL1 expression in MES GSCs leads to the loss of MES features and tumor-initiating ability, whereas ectopic expression of FOSL1 in PN GSCs is able to induce PMT and maintain MES features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35351656"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 267,
          "text": "Runt-related transcription factor 1 (RUNX1) was shown to support MES GBM, however, its underlying mechanisms are unclear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36949071"
        },
        {
          "offsetInBeginSection": 394,
          "offsetInEndSection": 530,
          "text": "Overexpression of USP10 upregulated RUNX1 and induced proneural-to-mesenchymal transition (PMT), thus maintaining MES properties in GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36949071"
        },
        {
          "offsetInBeginSection": 248,
          "offsetInEndSection": 503,
          "text": "Here, we report that transglutaminase 2 (TGM2) is upregulated in the perinecrotic region of GBM and triggered mesenchymal (MES) transdifferentiation of glioma stem cells (GSC) by regulating master transcription factors (TF), such as C/EBPβ, TAZ, and STAT3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28754668"
        },
        {
          "offsetInBeginSection": 715,
          "offsetInEndSection": 971,
          "text": "Moreover, we show that both mesenchymal GBMs and progenitor-like BTSCs are characterized by over-activated STAT3/EMT pathways and that SLUG is the primary epithelial to mesenchymal transition (EMT) transcription factor directly regulated by STAT3 in BTSCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31652994"
        },
        {
          "offsetInBeginSection": 1345,
          "offsetInEndSection": 1575,
          "text": "Single-cell sequencing of bevacizumab-resistant patient GBMs confirmed upregulated mesenchymal genes, particularly glycoprotein YKL-40 and transcription factor ZEB1, in later clones, implicating these changes as treatment-induced.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32041837"
        },
        {
          "offsetInBeginSection": 1570,
          "offsetInEndSection": 1691,
          "text": "For example, the transcription factor TFAP2A can be seen to promote a transition from the NPC-like to the MES-like state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38766170"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 380,
          "text": "We report here that truncated glioma-associated oncogene homolog 1 (tGLI1) is a tumor-specific transcription factor that facilitates GBM growth, is enriched in the mesenchymal subtype of GBM and glioma stem cells (GSC), and promotes mesenchymal GSC by upregulating transcription of CD44.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29463580"
        },
        {
          "offsetInBeginSection": 89,
          "offsetInEndSection": 283,
          "text": "The transcription factor signal transducer and activator of transcription 3 (STAT3) was recently identified as a master transcriptional regulator in the mesenchymal subtype of glioblastoma (GBM)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23386688"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 380,
          "text": "Here, we report that transforming growth factor-β (TGF-β) is able to induce a mesenchymal phenotype in GBM that involves activation of SMAD2 and ZEB1, a known transcriptional inducer of mesenchymal transition in epithelial cancer",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25275602"
        },
        {
          "offsetInBeginSection": 740,
          "offsetInEndSection": 867,
          "text": "High NFAT2 expression was significantly associated with mesenchymal (MES) subtype and recurrent GBM and predicted poor survival",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31400279"
        }
      ],
      "id": "67d7503018b1e36f2e00003e",
      "ideal_answer": [
        "The mesenchymal (MES) subtype of glioblastoma is thought to be determined by both cancer cell-intrinsic alterations and extrinsic cellular interactions but remains poorly understood. Major transcription factors underlying this MES-like cell state include FOSL1 (AP-1), CEBPG, STAT3, and TFAP2A, with the last one having been shown to promote a transition from the NPC-like to the MES-like state.",
        "The main transcription factors driving the mesenchymal-like (MES-like) state of glioblastoma multiforme are C/EBPbeta, STAT3, FoxM1, ZEB1, Snai1, Slug, Twist, and Notch. These transcription factors regulate the expression of mesenchymal genes and epithelial-to-mesenchymal transition (EMT) markers, leading to increased invasiveness, therapy resistance, and a more aggressive tumor phenotype.",
        "The mesenchymal-like (MES-like) state of glioblastoma multiforme (GBM) is driven by several key transcription factors. Among these, TAZ (WWTR1) and TEAD4 are significant contributors, as they are involved in the Hippo signaling pathway, which is crucial for the regulation of cell proliferation and apoptosis. Additionally, C/EBPβ and STAT3 are important transcription factors that promote the MES-like phenotype by influencing inflammatory responses and cellular differentiation. Other transcription factors such as ZEB1 and TWIST1 also play roles in epithelial-to-mesenchymal transition (EMT), further contributing to the mesenchymal characteristics of GBM. These transcription factors collectively drive the aggressive and invasive nature of the MES-like subtype of glioblastoma.",
        "The main transcription factors driving the mesenchymal-like (MES-like) state of glioblastoma multiforme (GBM) are CEBPG, FOSL1 (modulated by NF1), and the SOX8/JUN axis (influenced by HDAC7). TFAP2A is also predicted to promote transition to the MES-like state. These factors play crucial roles in GBM-M2 macrophage crosstalk and mesenchymal phenotype regulation. Understanding their interplay and associated signaling pathways (including HDAC7\u0027s role in LGALS3-mediated crosstalk) is essential for developing targeted therapies for the mesenchymal subtype of GBM.",
        "The main transcription factors driving the mesenchymal-like (MES-like) state in glioblastoma multiforme (GBM) are CEBPG, associated with adverse prognosis, the SOX8/JUN axis (regulated by HDAC7), and TFAP2A, which promotes state transition. Additionally, FOSL1 (modulated by NF1) is also implicated. These factors are crucial for GBM-M2 macrophage interactions and mesenchymal phenotype, offering potential therapeutic targets.",
        "The mesenchymal-like (MES-like) state of glioblastoma multiforme (GBM) is driven by several key transcription factors and regulatory mechanisms. The main factors identified include TFAP2A, which promotes the transition from the neural progenitor-like state to the MES-like state in GBM; FOSL1, a key transcription factor in the MES subtype of glioblastoma stem cells that regulates the proneural-to-mesenchymal transition through the UBC9/CYLD/NF-κB axis; and NF-κB transcriptional programs, with genetic abnormalities like NF1 mutations being major drivers of the MES-like state. Other important transcription factors include CEBPb, ZNF238, and FOSL2, regulated by RUNX1, which drives the mesenchymal gene expression signature in GBM. SOX8 and JUN are also significant, with HDAC7 inhibiting SOX8 expression and the SOX8/JUN complex regulating key genes promoting the MES transition. Additional factors such as CD44, BCL2A1, LYN, and WT1 have been identified through various studies. Conditions like high immune infiltration, NF1 mutation, and a hypoxic environment are also linked to the MES-like state. These transcription factors and associated conditions collectively contribute to the MES-like state in GBM, influencing its progression and response to therapies.",
        "The main transcription factors driving the mesenchymal like (MES like) state of glioblastoma multiforme include: 1. TFAP2A : This transcription factor promotes the transition from NPC like to MES like states, indicating a significant role in shaping the mesenchymal phenotype. 2. CEBPG : Identified through snATAC seq data analysis, CEBPG serves as a key regulator within the MES like state, highlighting its importance in this subtype of glioblastoma. 3. FOSL1 : As an AP 1 transcription factor, FOSL1 is crucial for regulating the mesenchymal subtype, underscoring its direct role in driving the MES like state. While STAT3 is involved through OSM signaling, it functions more as part of a broader signaling pathway rather than directly driving the MES like state. Thus, the primary drivers are TFAP2A, CEBPG, and FOSL1.",
        "TFAP2A, CEBPG, and FOSL1 are key transcription factors identified as drivers of the MES like state. TFAP2A promotes the transition from NPC like to MES like states. CEBPG is part of a crucial regulatory network identified through snATAC seq data. FOSL1 acts as a key regulator of the mesenchymal subtype, identified using transcriptomic data from brain tumor stem cell lines. Additionally, STAT3 plays a role in mediating effects that contribute to the mesenchymal phenotype, though it is more of a downstream effector activated by external signals such as OSM and LIFR.",
        "Studies have identified key transcription factors driving the mesenchymal-like (MES-like) state of glioblastoma multiforme. The transcription factor TFAP2A is found to promote a transition from the NPC-like to the MES-like state, while the AP-1 transcription factor FOSL1 is pinpointed as a key regulator of the mesenchymal subtype. Additionally, CEBPG has been identified as a crucial transcription factor in the regulatory network underlying this subtype. These findings suggest that the mesenchymal subtype of glioblastoma is driven by a complex interplay of transcription factors, including TFAP2A, FOSL1, and CEBPG, which are influenced by cellular interactions and signaling pathways such as those mediated by oncostatin M (OSM) and STAT3 activation.",
        "The mesenchymal subtype of glioblastoma is driven by key transcription factors such as FOSL1 and CEBPG, with TFAP2A also promoting a transition to this state. Additionally, macrophage-derived oncostatin M plays a significant role in activating STAT3, which contributes to the mesenchymal-like phenotype.",
        "The mesenchymal-like (MES-like) state of glioblastoma multiforme (GBM) is driven by several key transcription factors. FOSL1, a member of the AP-1 transcription factor family, plays a crucial role in regulating the MES subtype based on transcriptomic data from human patient-derived brain tumor stem cell lines. Additionally, TFAP2A promotes the transition from a neural progenitor cell-like (NPC-like) state to the MES-like state. Another important transcription factor identified through snATAC-seq data is CEBPG, which is part of a crucial regulatory network in this subtype. These transcription factors, along with extrinsic factors such as macrophage-derived oncostatin M (OSM), which activates STAT3 signaling, collectively contribute to the MES-like phenotype in GBM.",
        "The main transcription factors driving the mesenchymal-like (MES-like) state of glioblastoma multiforme are:\n\n1. **TFAP2A**: This transcription factor promotes the transition from the NPC-like state to the MES-like state.\n\n2. **STAT3**: Activated by macrophage-derived oncostatin M (OSM), STAT3 interacts with receptors OSMR or LIFR in complex with GP130, playing a role in mediating effects both in vitro and in vivo.\n\n3. **CEBPG**: Identified as a crucial transcription factor through snATAC-seq data, it is part of a key regulatory network influencing the MES-like state.\n\n4. **FOSL1**: An AP-1 transcription factor that serves as a key regulator of the mesenchymal (MES) subtype in glioblastoma multiforme, identified using transcriptomic data from patient-derived brain tumor stem cell lines.\n\nThese transcription factors collectively contribute to the regulation and promotion of the MES-like state in glioblastoma multiforme through various mechanisms.",
        "In glioblastoma the mesenchymal-like state is driven by an interconnected network of transcription factors. FOSL1, a key component of the AP-1 complex, is central in promoting proneural-to-mesenchymal transitions and associated features, while STAT3 plays a pivotal role by being activated through signals such as macrophage-derived oncostatin M. TFAP2A contributes by facilitating the transition towards a mesenchymal state. RUNX1 supports the mesenchymal phenotype, although its underlying mechanisms remain less defined, and CEBPG forms part of the broader regulatory network. Furthermore, NF-κB, which is activated downstream of FOSL1, along with EMT inducers like TWIST1, ZEB1/2, and SNAI1/2, also contribute to cell invasiveness and the mesenchymal phenotype. Although RBPJ is mentioned in some studies, its role is less established compared to the other key regulators in this network.",
        "The main transcription factors driving the mesenchymal-like (MES-like) state of glioblastoma multiforme include:\n\n1. **TFAP2A**: This transcription factor promotes the transition from a neural progenitor cell-like (NPC-like) state to a mesenchymal-like (MES-like) state, playing a key role in reprogramming cancer cells into a more aggressive form.\n\n2. **FOSL1**: Identified as a crucial regulator of the MES subtype, FOSL1 is essential for maintaining or establishing the mesenchymal characteristics in glioblastoma cells based on transcriptomic data from patient-derived brain tumor stem cell lines.\n\n3. **CEBPG**: This transcription factor is involved in regulating the chromatin structure and gene expression patterns associated with the MES-like state, as indicated by snATAC-seq data analysis.\n\nAdditionally, external factors such as oncostatin M (OSM) from macrophages influence these transcriptional networks by activating STAT3 in glioblastoma cells, further contributing to the mesenchymal phenotype. Understanding these transcription factors is crucial for developing targeted therapies aimed at disrupting the aggressive MES-like state in glioblastoma.",
        "The mesenchymal-like (MES-like) state of glioblastoma multiforme is driven by several key transcription factors identified through transcriptomic and regulatory network analyses:\n\n1. **TFAP2A**: Promotes the transition from a neural progenitor cell (NPC)-like to a MES-like state.\n2. **STAT3**: Activated by macrophage-derived oncostatin M (OSM) signaling, contributing to the maintenance of the mesenchymal subtype.\n3. **CEBPG**: Identified as a crucial regulator in the mesenchymal subtype through snATAC-seq data analysis.\n4. **FOSL1**: A key transcription factor regulating the MES-like state, identified using transcriptomic data from patient-derived brain tumor stem cell lines.\n\nThese transcription factors collectively contribute to the development and maintenance of the mesenchymal-like phenotype in glioblastoma multiforme.",
        "The main transcription factors driving the mesenchymal-like (MES-like) state of glioblastoma multiforme include FOSL1, identified as a key regulator of the MES subtype, TFAP2A, which promotes the transition to the MES-like state, and CEBPG, pinpointed as part of a crucial regulatory network. Additionally, macrophage-derived oncostatin M (OSM) activates STAT3 signaling in glioblastoma cells, further contributing to the MES-like state.",
        "Based on the provided abstracts, the main transcription factors driving the mesenchymal-like (MES-like) state of glioblastoma multiforme are:\n\n1. TFAP2A: promotes transition from NPC-like to MES-like state.\n2. FOSL1: identified as a key regulator of the MES subtype in brain tumor stem cell lines.\n3. CEBPG: pinpointed as a crucial transcription factor in the regulatory network underlying the MES state.\n\nAdditionally, STAT3 is activated by macrophage-derived oncostatin M (OSM) and its receptors OSMR or LIFR, which also contributes to the MES-like state.\n\nThese findings suggest that multiple transcription factors are involved in driving the mesenchymal-like state of glioblastoma multiforme, highlighting the complexity of this disease.",
        "The primary transcription factors driving the mesenchymal-like (MES-like) state of glioblastoma multiforme are TFAP2A, CEBPG, and FOSL1, with STAT3 also playing a significant role in this transition, particularly through activation by macrophage-derived oncostatin M. These factors are crucial for promoting cell state transitions and are closely associated with the mesenchymal subtype of glioblastoma, influencing its aggressiveness and plasticity through regulation of gene expression and signaling pathways.",
        "The mesenchymal-like (MES-like) state of glioblastoma multiforme is driven by several key transcription factors. TFAP2A is known to promote the transition to the MES-like state. Additionally, the AP-1 transcription factor FOSL1 has been identified as a key regulator of the MES subtype. The regulatory network also involves macrophage-derived oncostatin M (OSM) interacting with its receptors (OSMR or LIFR) in complex with GP130, which activates STAT3, contributing to the MES-like state. Furthermore, CEBPG has been pinpointed as a crucial transcription factor in the regulatory network associated with the MES subtype.",
        "Several key transcription factors have been identified as drivers of the mesenchymal-like (MES-like) state in glioblastoma multiforme. TFAP2A has been shown to promote the transition from neural progenitor cell-like (NPC-like) to mesenchymal-like state. The AP-1 transcription factor FOSL1 was identified as a key regulator of the mesenchymal subtype in human patient-derived brain tumor stem cell lines. Additionally, CEBPG was pinpointed as a crucial transcription factor within the regulatory network of the mesenchymal subtype. STAT3 activation, mediated by macrophage-derived oncostatin M (OSM), also plays a role in the mesenchymal phenotype, though STAT3 itself is a transcription factor that acts downstream of OSM signaling.",
        "The primary transcription factors driving the mesenchymal-like (MES-like) state in glioblastoma multiforme are TFAP2A, CEBPG, and FOSL1, with TFAP2A facilitating the transition from the neural progenitor-like state, CEBPG specifying the mesenchymal subtype with links to adverse prognosis and hypoxia, and FOSL1 regulating subtype plasticity and aggressiveness. Additionally, STAT3, activated by oncostatin M, contributes to the MES-like state transition, playing a nuanced role in mediating signaling pathways. These factors are crucial for understanding the subtype\u0027s aggressiveness and plasticity, influenced by both intrinsic and extrinsic cellular interactions.",
        "Several key transcription factors have been identified as regulators of the mesenchymal (MES) subtype in glioblastoma, including FOSL1 (an AP-1 transcription factor), TFAP2A which promotes transition to the MES-like state, and CEBPG which was identified through snATAC-seq analysis. This regulatory network is further influenced by STAT3 activation through macrophage-derived oncostatin M signaling.",
        "The mesenchymal (MES) subtype of glioblastoma is driven by key transcription factors such as FOSL1 and CEBPG, with TFAP2A also promoting a transition to this state. Additionally, macrophage-derived oncostatin M (OSM) plays a significant role in activating STAT3, which contributes to the mesenchymal-like phenotype."
      ],
      "exact_answer": [
        [
          "TFAP2A",
          "tfap2a"
        ],
        [
          "STAT3"
        ],
        [
          "CEBPG",
          "C/EBPbeta",
          "C/EBPβ",
          "C/EBP"
        ],
        [
          "FOSL1",
          "AP-1",
          "fosl1",
          "JUN"
        ],
        [
          "FOXD1"
        ],
        [
          "ZEB1",
          "Snai1",
          "Slug",
          "Twist",
          "ZEB"
        ],
        [
          "TEAD4",
          "TEAD2",
          "TEAD"
        ],
        [
          "RUNX1"
        ],
        [
          "NFAT2"
        ]
      ]
    },
    {
      "body": "Which role does AAAGG have in RFC1 repeat expansions?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37450567"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 643,
          "offsetInEndSection": 1219,
          "text": "While AAAAG, AAAGGG and AAGAG expansions appear to be benign, we revealed a pathogenic role for large AAAGG repeat configuration expansions (n \u003d 5). Long-read sequencing was used to characterize the entire repeat sequence, and six patients exhibited a pure AGGGC expansion, while the other patients presented complex motifs with AAGGG or AAAGG interruptions. All pathogenic motifs appeared to have arisen from a common haplotype and were predicted to form highly stable G quadruplexes, which have previously been demonstrated to affect gene transcription in other conditions. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37450567"
        }
      ],
      "id": "67d34fb318b1e36f2e000007",
      "ideal_answer": [
        "While AAAAG, AAAGGG and AAGAG expansions appear to be benign, a pathogenic role was revealed for large AAAGG repeat configuration expansions.",
        "AAAGG expansions in RFC1 have a context-dependent pathogenic role, particularly in large configurations (\u003e500 repeats) or in a compound heterozygous state with AAGGG, contributing to CANVAS (cerebellar ataxia, neuropathy, and vestibular areflexia syndrome). These repeats can form G-quadruplex structures, potentially impairing gene expression. However, AAAGG expansions are not associated with inflammatory neuropathies. Accurate assessment via long-read sequencing is recommended for CANVAS patients with negative or inconclusive genetic testing, especially for large or interrupted motifs.",
        "The AAAGG repeat expansion plays a pathogenic role in RFC1-related disorders when it is present in a large configuration, contributing to cerebellar ataxia, peripheral neuropathy, and vestibular areflexia syndrome (CANVAS). While smaller expansions of this motif may be benign, larger expansions are implicated in the disease. Additionally, AAAGG expansions can occur alongside other motifs such as AAGGG or ACAGG, further highlighting their significance in the genetic basis of late-onset ataxia.",
        "AAAGG is one of the repeat motifs found in the RFC1 (Replication Factor C subunit 1) gene, which is associated with certain neurological disorders when expanded. The expansion of these repeats, including AAAGG, can disrupt normal gene function, leading to conditions such as CANVAS (Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome) and other ataxia-related disorders. The presence of AAAGG repeat expansions in the RFC1 gene is a key factor in the pathogenesis of these diseases, as it can interfere with the normal replication and repair processes in cells.",
        "AAAGG is one of the repeat motifs involved in the replication factor C subunit 1 (RFC1) gene repeat expansions. These expansions, which also include motifs such as AAGGG and AAAAG, have been implicated in a neurodegenerative disorder known as cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS). The presence of these repeat expansions in the RFC1 gene disrupts normal gene function, contributing to the pathogenesis of the disease.",
        "Large AAAGG repeat configuration expansions (n \u003d 5) have a pathogenic role in RFC1 repeat expansions. Particular attention should be paid to carriers of compound AAGGG/AAAGG expansions when the AAAGG motif is very large (\u003e500 repeats) or the AAGGG motif is interrupted.",
        "Large AAAGG repeat expansions in RFC1 have a pathogenic role, particularly when the AAAGG motif is very large (\u003e500 repeats) or the AAGGG motif is interrupted, and they are associated with cerebellar ataxia, peripheral neuropathy, and vestibular areflexia syndrome (CANVAS).",
        "AAAGG has a pathogenic role in RFC1 repeat expansions, particularly when it is part of a compound expansion with AAGGG, especially when the AAAGG motif is very large (\u003e500 repeats).",
        "AAAGG repeat expansions in RFC1 can have a pathogenic role when they are very large (\u003e500 repeats) or in compound states with AAGGG.",
        "Large AAAGG repeat expansions in RFC1 are pathogenic, unlike other repeat motifs such as AAAAG and AAGAG that are generally benign. The evidence indicates that when AAAGG repeats expand significantly, especially in individuals with compound AAGGG/AAAGG configurations, the risk of disease increases. This risk is particularly pronounced when the AAAGG repeats are very large—exceeding thresholds like 500 repeats—or when the AAGGG motif is interrupted. The pathogenic AAAGG expansions tend to form abnormal nucleic acid structures, including quadruplexes and triplexes, which in turn impair DNA replication and gene expression. These toxic effects, through replication fork stalling and reduced polymerization efficiency, are likely key mediators of the disease phenotype associated with these large expansions.",
        "The role of AAAGG in RFC1 repeat expansions is significant as it has been identified as having a pathogenic role. Specifically, large AAAGG repeat configurations (n\u003d5) have been associated with contributing to genetic disorders. In contrast, other configurations such as AAAAG, AAAGGG, and AAGAG are considered benign. Therefore, while some repeat sequences in RFC1 may not cause issues, the presence of large AAAGG expansions can lead to disease, highlighting their importance in genetic research and diagnosis.",
        "Large AAAGG repeat expansions in RFC1 may have a pathogenic role, particularly when found in combination with AAGGG expansions. Particular attention should be paid to carriers of compound AAGGG/AAAGG expansions, especially when the AAAGG motif is very large (e.g., \u003e500 repeats) or interrupting the AAGGG motif.",
        "AAAGG is a specific pentanucleotide repeat configuration within intron 2 of the RFC1 gene. While some repeat expansions, such as AAAAG, AAAGGG, and AAGAG, are considered benign, large AAAGG repeats (n\u003d5) have been identified as pathogenic. These expansions contribute to diseases like Multiple System Atrophy when they exceed a certain threshold, unlike other configurations which may not cause harm. Thus, AAAGG plays a role in disease when it expands beyond a specific size.",
        "AAAGG expansions appear to be benign, but large AAAGG repeat configurations have been revealed to have a pathogenic role, particularly in conjunction with AAGGG expansions, which are associated with neurological disorders such as cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS).",
        "AAAGG interrupts the AAGGG motif in RFC1 repeat expansions, forming stable G quadruplexes and arising from a common haplotype, particularly when involved in compound expansions and when the motif is very large (\u003e500 repeats), playing a pathogenic role in the development of CANVAS.",
        "AAAGG has a potential pathogenic role in RFC1 repeat expansions, particularly in large configurations (\u003e500 repeats) or in compound heterozygous states with AAGGG, contributing to neurodegenerative diseases like CANVAS. While typically considered benign, large AAAGG repeats can impair gene expression, possibly through G-quadruplex formation. Accurate sizing and sequencing are crucial for molecular diagnosis in carriers, especially in cases with large AAAGG repeats or AAGGG interruptions. AAAGG expansions are identified in subsets of patients with CANVAS or sporadic late-onset ataxia, highlighting their relevance in genetic screening.",
        "AAAGG is one of the repeat motifs found in the RFC1 (Replication Factor C subunit 1) gene, which is associated with certain neurological disorders when expanded. The expansion of AAAGG repeats, along with other motifs like AAGGG, is implicated in conditions such as CANVAS (Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome) and late-onset ataxia. These repeat expansions can disrupt normal gene function, leading to the clinical manifestations observed in these disorders.",
        "The role of AAAGG in RFC1 repeat expansions is associated with CANVAS in the homozygous or compound heterozygous state with the common pathogenic AAGGG expansion. While AAAAG, AAAGGG, and AAGAG expansions appear to be benign, a pathogenic role for large AAAGG repeat configuration expansions has been revealed. Long-read sequencing characterized the entire repeat sequence, and patients exhibited a pure AGGGC expansion or complex motifs with AAGGG or AAAGG interruptions. All pathogenic motifs appeared to have arisen from a common haplotype and were predicted to form highly stable G quadruplexes, which have previously been demonstrated to affect gene transcription in other conditions. Therefore, AAAGG repeat expansions should be assessed in CANVAS patients with negative or inconclusive genetic testing, especially when the AAAGG motif is very large (\u003e500 repeats) or the AAGGG motif is interrupted.",
        "The AAAGG repeat motif in RFC1 appears to be pathogenic and associated with CANVAS (cerebellar ataxia, neuropathy, and vestibular areflexia syndrome) when present as a large expansion, particularly in compound heterozygous or homozygous states with the AAGGG expansion. However, smaller AAAGG expansions may be benign polymorphisms.",
        "The role of AAAGG in RFC1 repeat expansions is that of a pathogenic repeat expansion, which is associated with cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS).",
        "The AAAGG repeat motif in RFC1 appears to have a pathogenic role when present as a large expansion, particularly when present in a compound heterozygous state with the common AAGGG pathogenic expansion. Large AAAGG expansions (\u003e500 repeats) or AAGGG expansions interrupted by AAAGG motifs are associated with the CANVAS syndrome, a neurodegenerative disease caused by biallelic RFC1 repeat expansions.",
        "AAAGG expansions in the RFC1 gene have a context-dependent pathogenic role, particularly in large configurations (\u003e500 repeats) or when combined with AAGGG, contributing to conditions like CANVAS (cerebellar ataxia, neuropathy, and vestibular areflexia syndrome) and possibly sporadic late-onset ataxia. These expansions may form G-quadruplex structures, impairing gene expression. Despite being generally considered benign, accurate long-read sequencing is crucial for diagnosis, especially in large or interrupted motifs, to uncover their potential pathogenic impact.",
        "Large expansions of the AAAGG repeat in RFC1 are associated with disease, particularly in conditions such as CANVAS. In compound configurations, a moderate repeat stretch of AAAGG preceding an expanded AAGGG tract appears critical for pathogenicity. While some similar repeat motifs do not show adverse effects when expanded, large AAAGG expansions—especially when reaching over 500 repeats or when accompanied by interruptions in the AAGGG tract—can disrupt normal gene function. Consequently, the AAAGG component of the repeat configuration contributes to the overall pathogenic mechanism of the expansion in affected individuals.",
        "AAAGG has a potential pathogenic role in RFC1 repeat expansions, particularly in large configurations or in compound heterozygous states with AAGGG, contributing to neurodegenerative diseases like CANVAS.",
        "AAAGG repeat expansions in RFC1 have a pathogenic role, particularly when they are very large (\u003e500 repeats) or compound with AAGGG expansions. These expansions are associated with cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS), and their assessment is important in patients with negative or inconclusive genetic testing.",
        "Large AAAGG repeat configuration expansions have a pathogenic role in RFC1 repeat expansions. Particular attention should be paid to carriers of compound AAGGG/AAAGG expansions when the AAAGG motif is very large (\u003e500 repeats) or the AAGGG motif is interrupted.",
        "The AAAGG expansion in the RFC1 gene is associated with cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS), a late-onset, slow-progressing multisystem neurodegenerative disorder.",
        "Large AAAGG repeat configuration expansions are pathogenic.",
        "AAAGG repeat expansions in RFC1 can have a pathogenic role when they form large configurations. The research suggests that while some AAAGG expansions may be benign, certain AAAGG repeat configurations can be associated with disease, particularly when they form highly stable G quadruplexes that potentially affect gene transcription.",
        "AAAGG repeat expansions play a significant role in RFC1 related conditions. Specifically, large AAAGG expansions (n \u003d 5) have been identified as pathogenic. These expansions can occur alone or in combination with other motifs like AAGGG, forming complex configurations that originate from a common haplotype. The resulting repeats are predicted to form highly stable G quadruplexes, which interfere with gene transcription and contribute to disease development.",
        "In RFC1 repeat expansions, AAAGG plays a pathogenic role when expanded extensively. These expansions are associated with the formation of stable G quadruplex structures, which interfere with gene transcription and lead to pathological effects.",
        "Studies have revealed that large AAAGG repeat configuration expansions play a pathogenic role in RFC1 repeat expansions. Specifically, expansions of this motif with five or more repeats appear to be associated with disease. The entire repeat sequence was characterized using long-read sequencing, which showed that patients with pathogenic motifs had either pure AGGGC expansions or complex motifs with AAGGG or AAAGG interruptions. Notably, all pathogenic motifs seemed to originate from a common haplotype and were predicted to form highly stable G quadruplexes, which can affect gene transcription. This suggests that the AAAGG expansion has a significant impact on the formation of these stable structures, potentially leading to disrupted gene function.",
        "The AAAGG repeat configuration is identified as pathogenic when expanded (n \u003d 5), unlike the benign AAAAG and AAAGGG expansions. This expansion can form stable G-quadruplexes, which are known to impact gene transcription. The pathogenic AAAGG motifs originate from a common haplotype and may include complex motifs with AAGGG or AAAGG interruptions.",
        "In RFC1 repeat expansions, AAAGG configurations play a significant role. Specifically, large AAAGG expansions (n\u003d5) have been identified as pathogenic. These expansions contribute to the formation of highly stable G quadruplex structures, which interfere with gene transcription and are associated with disease development.",
        "AAAGG has a pathogenic role in RFC1 repeat expansions.",
        "While AAAAG, AAAGGG and AAGAG expansions appear to be benign, large AAAGG repeat configuration expansions have a pathogenic role.",
        "AAAGG expansions appear to be benign, but large AAAGG repeat configurations can have a pathogenic role when they are very large (\u003e500 repeats) or interrupted by other motifs.",
        "The AAAGG repeat expansion in RFC1 is associated with a pathogenic role, particularly when it occurs in large configurations (n \u003d 5). In contrast, other expansions such as AAAAG, AAAGGG, and AAGAG are considered benign. Long-read sequencing revealed that some patients exhibited a pure AGGGC expansion, while others had complex motifs with interruptions like AAGGG or AAAGG. These pathogenic motifs are predicted to form highly stable G-quadruplex structures, which can affect gene transcription, similar to their impact in other conditions. All pathogenic motifs seem to have originated from a common haplotype, indicating a specific genetic background associated with the disease.",
        "AAAGG plays a significant role in RFC1 repeat expansions as part of pathogenic motifs. Specifically, large AAAGG repeat configurations (n \u003d 5) are associated with disease. These motifs, along with others like AAGGG or AGGGC, form highly stable G quadruplexes, which can disrupt gene transcription and contribute to the pathological effects observed in affected individuals. The common haplotype from which these motifs arise suggests a shared genetic origin among patients. Thus, AAAGG expansions are integral to the pathogenicity of RFC1 repeat expansions due to their structural properties and impact on gene function.",
        "AAAGG expansions in RFC1 are pathogenic when large (\u003e500 repeats), interrupt the AAGGG motif, are involved in compound expansions, form stable G quadruplexes, and arise from a common haplotype.",
        "Large AAAGG repeat expansions in RFC1 are considered pathogenic only when present in high numbers, with one study noting a threshold of n \u003d 5 and another highlighting expansions of over 500 repeats. In this configuration, particularly when occurring with or interrupting other repeat motifs like AAGGG, the AAAGG expansions form abnormal nucleic acid structures such as triplex H-DNA and G-quadruplexes. These structures interfere with DNA polymerization and stall replication fork progression, ultimately impairing gene expression. In contrast, other repeats such as AAAAG, AAAGGG, and AAGAG typically appear benign.",
        "AAAGG expansions appear to be benign. However, complex motifs with AAGGG or AAAGG interruptions were present in patients with pathogenic motifs.",
        "AAAGG plays a significant role in RFC1 repeat expansions as part of pathogenic motifs. These motifs, which include AAAGG interruptions, arise from a common haplotype and are predicted to form highly stable G quadruplexes. These structures can interfere with normal gene transcription, contributing to disease. Unlike benign configurations such as AAAAG, the specific AAAGG repeats in larger expansions are associated with pathogenic effects due to their structural properties and potential impact on gene expression.",
        "In RFC1 repeat expansions, AAAGG is not pathogenic by itself, but large AAAGG repeat configurations (n \u003d 5) have been shown to have a pathogenic role. However, the pathogenic motifs often present complex motifs with AAGGG or AAAGG interruptions, and the pure AGGGC expansion is also pathogenic. All these pathogenic motifs are predicted to form highly stable G quadruplexes, which can affect gene transcription.",
        "Large AAAGG repeat configuration expansions can have a pathogenic role in RFC1 repeat expansions, particularly when the AAAGG motif is very large (\u003e500 repeats) or the AAGGG motif is interrupted. These pathogenic motifs are predicted to form highly stable G quadruplexes, which can affect gene transcription. In contrast, AAAAG, AAAGGG, and AAGAG expansions appear to be benign.",
        "AAAGG expansions play a significant role in RFC1 repeat expansions as they are associated with pathogenic effects. These expansions contribute to the formation of highly stable G quadruplexes, which can interfere with gene transcription and potentially lead to disease. The presence of AAAGG motifs is linked to a common haplotype, suggesting a shared genetic origin among affected individuals. Thus, AAAGG expansions are integral to the pathogenic mechanisms in RFC1 repeat expansions, influencing both genetic structure and potential clinical outcomes.",
        "AAAGG repeat expansions in the RFC1 gene have been revealed to have a pathogenic role. These expansions can form highly stable G quadruplexes, which can affect gene transcription.",
        "AAAGG repeat expansions in the context of RFC1 are generally considered benign; however, pathogenic effects were observed with large AAAGG configurations when they form part of complex motifs. Specifically, these pathogenic motifs often include interruptions by AAGGG or AAAGG within a larger AGGGC expansion and arise from a common haplotype. These expansions are predicted to form stable G quadruplexes, which can impact gene transcription similarly to other conditions.",
        "AAAGG expansions appear to have a pathogenic role in RFC1 repeat expansions, particularly when they are large (\u003e500 repeats) or interrupted by the AAGGG motif.",
        "AAAGG repeat expansions in RFC1 are generally benign, but pathogenic configurations arise when AAAGG repeats are part of larger expansions with specific motifs, such as AGGGC or complex interruptions. These pathogenic motifs are associated with a common haplotype and are predicted to form stable G quadruplexes, which can impact gene transcription.",
        "AAAGG repeat configuration expansions have a pathogenic role in RFC1 repeat expansions. Specifically, large AAAGG expansions are associated with disease pathology, whereas smaller expansions (AAAAG, AAAGGG, AAGAG) appear to be benign. The pathogenic motifs are predicted to form highly stable G quadruplexes, which can affect gene transcription.",
        "AAAGG repeat expansions in the RFC1 gene are associated with a pathogenic role in neurological disorders, particularly in cases with large expansions (\u003e500 repeats) and can interact with other motifs like AAGGG, contributing to conditions such as cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS).",
        "AAAGG expansions in RFC1 are associated with a pathogenic role when they are large (\u003e500 repeats) and can interact with AAGGG motifs, particularly in compound configurations, contributing to conditions like CANVAS and late-onset ataxia.",
        "AAAGG plays a pathogenic role in RFC1 repeat expansions, particularly in large configurations.",
        "AAAGG repeat expansions in the RFC1 gene play a pathogenic role in the development of CANVAS (cerebellar ataxia, neuropathy, and vestibular areflexia syndrome), especially in large configurations or in homozygous/compound heterozygous states. These expansions are predicted to form highly stable G quadruplexes, potentially disrupting gene transcription. Accurate assessment via long-read sequencing is recommended for CANVAS patients, particularly those with negative or inconclusive genetic testing, to enable precise molecular diagnosis and genetic counseling.",
        "AAAGG has a pathogenic role in RFC1 repeat expansions, particularly when the AAAGG motif is very large (\u003e500 repeats) or when it is present in combination with AAGGG expansions.",
        "In the context of RFC1 repeat expansions, AAAGG repeat configurations are generally considered benign. However, large expansions of AAAGG repeats, particularly when they form complex motifs with interruptions such as AAGGG or AAAGG, can have a pathogenic role. These pathogenic motifs are associated with a common haplotype and are predicted to form highly stable G quadruplexes. These structures can affect gene transcription, potentially leading to disease conditions.",
        "AAAGG plays a pathogenic role in RFC1 repeat expansions when its configuration exceeds 500 repeats, contributing to the development of Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome (CANVAS). This role is particularly pronounced in compound heterozygous states with AAGGG expansions, and possibly in homozygous states or when AAAGG acts as an interrupting motif. Notably, smaller AAAGG repeat configurations (\u003c500 repeats) are generally considered benign. The size-dependent pathogenicity of AAAGG highlights the importance of repeat length in assessing genetic risk for CANVAS.",
        "While AAAAG, AAAGGG and AAGAG expansions appear to be benign, we revealed a pathogenic role for large AAAGG repeat configuration expansions (n \u003d 5). Long-read sequencing was used to characterize the entire repeat sequence, and six patients exhibited a pure AGGGC expansion, while the other patients presented complex motifs with AAGGG or AAAGG interruptions. All pathogenic motifs appeared to have arisen from a common haplotype and were predicted to form highly stable G quadruplexes, which have previously been demonstrated to affect gene transcription in other conditions.",
        "Large AAAGG repeat configuration expansions have a pathogenic role. These expansions can form highly stable G quadruplexes. These quadruplexes have been demonstrated to affect gene transcription.",
        "AAAGG repeat expansions in the RFC1 gene play a pathogenic role in developing Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome (CANVAS), especially when exceeding 500 repeats or in compound heterozygous states with AAGGG expansions. These expansions form highly stable G quadruplexes, disrupting gene transcription. While smaller expansions (≥5 repeats) may also affect transcription, their clinical impact is less clear. Accurate diagnosis via long-read sequencing is recommended for CANVAS patients with significant AAAGG expansions or interruptions, highlighting the importance of precise genetic assessment in these cases.",
        "The AAAGG motif can be part of a complex repeat expansion in RFC1, and its role appears to depend on the size and configuration of the expansion. In moderate lengths it may be benign, but when present in compound configurations—especially alongside large AAGGG repeat segments or when the AAAGG expansion itself exceeds a threshold—it is associated with pathogenicity, as seen in conditions like CANVAS. In these cases, large AAAGG expansions may contribute to the formation of stable secondary structures that disrupt normal gene transcription.",
        "Large AAAGG repeat configuration expansions have a pathogenic role. Particular attention should be paid to carriers of compound AAGGG/AAAGG expansions when the AAAGG motif is very large (\u003e500 repeats) or the AAGGG motif is interrupted. All pathogenic motifs appeared to have arisen from a common haplotype and were predicted to form highly stable G quadruplexes, which have previously been demonstrated to affect gene transcription in other conditions.",
        "While AAAGG repeat configurations by themselves appear to be benign in RFC1, when present as interruptions within complex repeat motifs alongside AGGGC expansions, they can contribute to pathogenic outcomes. These complex repeat structures, which can form stable G quadruplexes, arise from a common haplotype and can affect gene transcription."
      ],
      "exact_answer": [
        [
          "Pathogenic",
          "pathogenic",
          "pathogenic when large (\u003e500 repeats)"
        ]
      ]
    },
    {
      "body": "Does the consensus molecular subtype (CMS) classification for colorectal cancer any use in routine clinical practice?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34909395",
        "http://www.ncbi.nlm.nih.gov/pubmed/36202996",
        "http://www.ncbi.nlm.nih.gov/pubmed/28825047",
        "http://www.ncbi.nlm.nih.gov/pubmed/34077519",
        "http://www.ncbi.nlm.nih.gov/pubmed/37345083",
        "http://www.ncbi.nlm.nih.gov/pubmed/32463385",
        "http://www.ncbi.nlm.nih.gov/pubmed/39227409",
        "http://www.ncbi.nlm.nih.gov/pubmed/29721154",
        "http://www.ncbi.nlm.nih.gov/pubmed/32694712",
        "http://www.ncbi.nlm.nih.gov/pubmed/36517022",
        "http://www.ncbi.nlm.nih.gov/pubmed/28505475",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831448",
        "http://www.ncbi.nlm.nih.gov/pubmed/35780916",
        "http://www.ncbi.nlm.nih.gov/pubmed/30073926",
        "http://www.ncbi.nlm.nih.gov/pubmed/32647253",
        "http://www.ncbi.nlm.nih.gov/pubmed/39115332",
        "http://www.ncbi.nlm.nih.gov/pubmed/28748988/",
        "http://www.ncbi.nlm.nih.gov/pubmed/28494874"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1122,
          "offsetInEndSection": 1350,
          "text": "Understanding CMS is a crucial step in personalized medicine, although prospective clinical trials selecting patients by CMS are required to pass proof-of-concept before becoming a routine clinical tool in oncology routine care.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34909395"
        },
        {
          "offsetInBeginSection": 264,
          "offsetInEndSection": 402,
          "text": ". A promising consensus molecular (CMS) classification with prognostic relevance has been developed, but it is not used in daily practice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36202996"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1028,
          "text": "The colorectal cancer (CRC) Subtyping Consortium has unified six independent molecular classification systems, based on gene expression data, into a single consensus system with four distinct groups, known as the Consensus Molecular Subtypes (CMS); clinical implications are discussed in this review. This article is based on a literature review relevant to the CMS of CRC indexed in PubMed (US National Library of Medicine) as well as the authors\u0027 own published data. The CMS were determined and correlated with epigenomic, transcriptomic, microenvironmental, genetic, prognostic and clinical characteristics. The CMS1 subtype is immunogenic and hypermutated. CMS2 tumors are activated by the WNT-β-catenin pathway and have the highest overall survival. CMS3 feature a metabolic cancer phenotype and CMS4 cancers have the worst survival and have a strong stromal gene signature. The Consensus Molecular Subtypes of CRC may better inform clinicians of prognosis, therapeutic response, and potential novel therapeutic strategies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28825047"
        },
        {
          "offsetInBeginSection": 819,
          "offsetInEndSection": 1021,
          "text": "For patients allocated to the CMS4 subgroup of stage III CRCs, elevated blood CEA concentrations may identify a subgroup with highly aggressive disease and contribute to improving therapeutic decisions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36517022"
        },
        {
          "offsetInBeginSection": 621,
          "offsetInEndSection": 775,
          "text": "However, genomic assessment of tumours is not readily translated into routine pathology with a need for standardisation and reproducibility of assessment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28505475"
        },
        {
          "offsetInBeginSection": 77,
          "offsetInEndSection": 248,
          "text": "In 2015, the Colorectal Cancer Subtyping Consortium classified CRC into four consensus molecular subtypes (CMS), but these CMS have had little impact on clinical practice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36831448"
        },
        {
          "offsetInBeginSection": 823,
          "offsetInEndSection": 1040,
          "text": "The Consensus Molecular Subtypes classification (CMS) is a good example of the efforts to combine different molecular features of this disease, although its relevance in clinical practice is still under investigation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35780916"
        },
        {
          "offsetInBeginSection": 661,
          "offsetInEndSection": 917,
          "text": "Recently, the Colorectal Cancer Subtyping Consortium identified four consensus molecular subtypes, CMS 1-4 in CRC; however, attempts to stratify CRC using molecular features for prognostic and predictive purposes in clinical conditions had limited success.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30073926"
        },
        {
          "offsetInBeginSection": 1316,
          "offsetInEndSection": 1494,
          "text": "AS wild-type CMS2 patients.CONCLUSIONS: The CMS classification holds clear potential for clinical use in predicting both prognosis and response to systemic therapy, which seems t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34077519"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39115332"
        },
        {
          "offsetInBeginSection": 221,
          "offsetInEndSection": 413,
          "text": "type (CIMP). Based on the new molecular classification, four consensus CRC molecular subtypes (CMS) are established, which are related to clinical, pathological and biological characteristics ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28748988/"
        },
        {
          "offsetInBeginSection": 291,
          "offsetInEndSection": 725,
          "text": " of time, it is sparingly incorporated as a determining factor in current clinical practice. Here we describe how unsupervised gene expression-based classification efforts, amongst which the consensus molecular subtypes (CMS), can stratify patients in biological subgroups associated with distinct disease outcome and responses to therapy. We will discuss what is needed to extend these subtyping efforts to the clinic and we will arg",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32647253"
        },
        {
          "offsetInBeginSection": 266,
          "offsetInEndSection": 402,
          "text": "A promising consensus molecular (CMS) classification with prognostic relevance has been developed, but it is not used in daily practice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36202996"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 335,
          "text": "Recent efforts help resolve this by sub-classification of CRC into natural molecular subtypes; however, this strategy is not yet able to provide clinicians with improved tools for decision making.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28494874"
        },
        {
          "offsetInBeginSection": 918,
          "offsetInEndSection": 1064,
          "text": "Adjuvant chemotherapy in stage II and III CRC was most beneficial for OS in CMS2 and CMS3 (HR range \u003d 0.16-0.45) and not effective in CMS4 tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34077519"
        },
        {
          "offsetInBeginSection": 251,
          "offsetInEndSection": 324,
          "text": "However, to date, there is no clinical diagnostic test for CMS subtyping.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32694712"
        }
      ],
      "type": "yesno",
      "id": "662fc277187cba990d000013",
      "ideal_answer": [
        "CMS classification is not used in daily practice / oncology routine care.",
        "No. The consensus molecular subtype (CMS) classification for colorectal cancer has not been widely adopted in routine clinical practice.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has potential clinical utility, but further prospective clinical trials are needed before it can be routinely used in clinical practice. The CMS classification captures the molecular heterogeneity of colorectal cancer and provides insights into prognosis, therapeutic response, and potential novel therapeutic strategies tailored to each subtype. However, most of the current evidence is from retrospective studies, and prospective validation in clinical trials is required to demonstrate improved patient outcomes and guide treatment decisions before the CMS classification can be widely adopted in routine oncology care.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer is a valuable tool in understanding the heterogeneity of the disease. It categorizes colorectal cancer into four distinct subtypes, each with unique biological characteristics and clinical outcomes. While it provides insights into tumor biology and potential therapeutic targets, its direct application in routine clinical practice is still limited. The CMS classification is primarily used in research settings to guide the development of personalized treatment strategies and to improve prognostic assessments. However, ongoing studies and advancements in precision medicine may enhance its utility in clinical practice in the future.",
        "No. The consensus molecular subtype (CMS) classification for colorectal cancer is a promising tool for personalized medicine, but it is not yet widely used in routine clinical practice.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer (CRC), based on RNA expression profiles, identifies four biologically distinct subtypes that capture tumor heterogeneity and could potentially guide clinical decisions such as adjuvant chemotherapy use in stage II CRC, personalized first-line treatment for metastatic disease, and targeted therapies. However, despite its biological relevance and potential to address key clinical questions, the CMS classification has had limited impact on routine clinical practice due to its reliance on complex gene expression data, which is not yet easily integrated into standard clinical workflows.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer (CRC) categorizes the disease into four subtypes: CMS1 (immune subtype), CMS2 (canonical subtype), CMS3 (metabolic subtype), and CMS4 (mesenchymal subtype) based on gene expression profiling. This classification has significant implications for prognosis and treatment decisions, although its routine clinical use is still under evaluation.\n\nThe CMS classification provides a framework for understanding the heterogeneity of CRC and is proposed to improve patient management by enhancing the understanding of the genomic and epigenomic landscapes of CRC. It involves using RNA-sequencing to generate gene expression profiles, which are then input into a CMS subtype classifier to determine the CMS subtype for each sample. A novel CMS classifier has been optimized for RNA-sequencing data from degraded RNA of clinical formalin-fixed paraffin-embedded (FFPE) tissue samples.\n\nThe CMS classification has been developed and validated for use in routine clinical practice, specifically in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, using an assay applicable to FFPE samples. The identification of the CMS4 subtype, associated with poor prognosis, has become a significant focus in routine clinical practice. The CMS classification can potentially be used as a predictive biomarker for the efficacy of IRI-based regimens, particularly for CMS4 patients, and may influence the choice of chemotherapy in routine clinical practice.\n\nIn summary, while the CMS classification for colorectal cancer holds promise for enhancing prognostic and therapeutic decision-making, its routine implementation in clinical practice is still evolving. Further validation through prospective clinical trials and integration into clinical guidelines will be necessary for its widespread adoption.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer is not yet widely used in routine clinical practice. While it provides valuable insights into the molecular heterogeneity of colorectal cancer and can help in understanding the disease\u0027s biology, its direct application in clinical settings is limited. The CMS classification can potentially guide treatment decisions and prognostic assessments in the future, but more research and validation are needed before it becomes a standard part of clinical practice.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer is not yet widely used in routine clinical practice. Although it offers valuable insights into the molecular heterogeneity of colorectal cancer and has potential implications for prognosis and treatment stratification, its application in everyday clinical settings is still limited. Further validation, standardization, and demonstration of clinical utility in guiding treatment decisions are needed before it can be integrated into routine practice. Currently, its use remains primarily in the research domain.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer (CRC) is widely accepted and constitutes a basis for patient stratification to improve clinical practice and has contributed to a better understanding of disease heterogeneity and prognosis. However, the CMS classification has yet to be fully integrated into routine clinical practice. Intratumoral heterogeneity restricts its clinical application, and appropriate risk stratification tools are still lacking. Prospective clinical trials selecting patients by CMS are required before becoming a routine clinical tool in oncology care. Refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer (CRC) is showing potential for clinical use, particularly in predicting prognosis and response to systemic therapy, but it is not yet routinely used in clinical practice as further validation through prospective clinical trials is needed.",
        "No. The Consensus Molecular Subtype (CMS) classification has yet to be integrated into clinical practice.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer (CRC) offers a detailed molecular categorization of CRC patients into four distinct subtypes through wide transcriptional genome analysis. While this classification provides valuable insights into the molecular heterogeneity of CRC, its current utility in routine clinical practice is limited due to the complexity and cost of the required genomic testing. However, as research progresses, the CMS classification may become increasingly relevant for personalized treatment strategies and prognostic assessments, potentially guiding therapeutic decisions and improving patient outcomes.",
        "CMS classification shows potential but is not yet a routine clinical tool.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer (CRC) is used in research and clinical practice to predict disease progression and outcomes. However, the direct clinical utility and routine application of CMS classification in CRC management is still being explored and developed.\n\nBased on the provided context, it appears that CMS classification is mainly used for biological interpretability and clinical stratification of CRC in primary tumors, but its application in metastases is still limited. Therefore, the answer to the question is:\n\nThe consensus molecular subtype (CMS) classification for colorectal cancer has some use in research and clinical practice, but its direct clinical utility and routine application in CRC management is still being explored and developed.",
        "Consensus molecular subtyping has advanced our understanding of colorectal cancer by offering insights into both prognosis and treatment prediction, but it is not yet routinely used in clinical practice. Its current application remains predominantly in research and clinical trial settings. Ongoing studies are refining CMS classifications through the integration of additional genomic and molecular features, aiming to more accurately identify patients who would benefit from specific targeted therapies. While it shows potential as both a prognostic and predictive tool, further validation and clinical evidence are needed before CMS can be reliably incorporated into everyday clinical decision-making.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer has shown potential in enhancing personalized treatment strategies by categorizing cancers based on molecular characteristics, which can predict prognosis and therapy response. However, its integration into routine clinical practice remains limited due to several factors:\n\n1. **Research Advancements**: Studies have developed tools like NanoCMSer to facilitate CMS classification using specific genes, indicating progress toward practical application.\n\n2. **Clinical Utility**: CMS has demonstrated the ability to predict patient outcomes and treatment responses, suggesting it could tailor therapies and improve outcomes by identifying those needing more aggressive treatments.\n\n3. **Barriers to Adoption**: Despite promising research, CMS hasn\u0027t been widely adopted. Challenges include complex or costly testing methods, clinician awareness gaps, and the need for integration into existing clinical workflows.\n\n4. **Need for Further Validation**: More prospective studies are required to validate CMS\u0027s effectiveness and establish standardized protocols for its use in clinical settings.\n\nIn conclusion, while CMS holds promise for personalized medicine, its adoption is still limited. Continued research and validation are essential to overcome current barriers and realize its potential in routine clinical practice.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer (CRC) has the potential for clinical use in predicting prognosis and response to systemic therapy, and may allow improved prognostication and targeted therapy in order to deliver more personalized treatment for CRC. CMS classification can be a meaningful step in providing possible answers to important issues in CRC, such as the use of adjuvant chemotherapy in stage II, personalized first-line chemotherapy for metastasic CRC, and possible new target treatments that address specific pathways in each molecular subtype. However, the CMS classification has yet to be integrated into routine clinical practice, and prospective clinical trials are required before it becomes a routine clinical tool in oncology care.",
        "The Consensus Molecular Subtypes (CMS) classification for colorectal cancer (CRC) represents an effort to integrate various molecular features of the disease, aiming to provide a more refined understanding of CRC\u0027s heterogeneity. While the CMS classification has established four molecular subtypes that correlate with clinical, pathological, and biological characteristics of tumors, its utility in routine clinical practice remains under investigation. The classification\u0027s potential to guide personalized treatment strategies is promising, but further validation and research are needed to fully integrate it into standard clinical management.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer has demonstrated potential in enhancing patient care by predicting prognosis and treatment response through molecular characterization. Studies indicate that CMS can differentiate patients with better prognoses, particularly in certain subtypes, which could influence treatment decisions. However, its integration into routine clinical practice remains pending due to challenges such as lack of standardization, validation, and adoption barriers. While tools like NanoCMSer show promise for standardized classification, further research and collaboration are necessary to overcome these hurdles and fully realize CMS\u0027s benefits in clinical settings.",
        "No. Although the consensus molecular subtype (CMS) classification has shown promise in prognostic relevance, it is not yet used in daily clinical practice due to challenges in its incorporation as a predictive biomarker and the need for further validation in prospective clinical trials.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has some potential uses in routine clinical practice, such as guiding the use of adjuvant chemotherapy in stage II and personalized first-line chemotherapy for metastatic CRC, but its clinical application is challenging due to high uncertainty of single-sample classification and associated costs.",
        "No. The consensus molecular subtypes (CMS) classification for colorectal cancer is not yet widely used in routine clinical practice.",
        "No. The molecular profiling of colorectal cancer has had limited impact in daily clinical practice, despite the establishment of the consensus molecular subtype classification.",
        "No. Although there has been progress in understanding consensus molecular subtypes (CMS) for colorectal cancer, the translation of this molecular knowledge into routine clinical practice faces several major challenges, and no RNA-based biomarkers from these classifications have entered routine clinical practice yet.",
        "No, CMS classification is not yet routinely used in clinical practice for colorectal cancer.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer has potential utility in routine clinical practice for prognosis and guiding personalized treatment decisions. CMS classification can predict overall survival, with CMS4 and CMS1 associated with worse outcomes in local and metastatic diseases, respectively. It can inform chemotherapy choices, such as adjuvant chemotherapy for CMS2/CMS3, irinotecan-based regimens for metastatic CMS4, and potential use of anti-EGFR therapy and immune checkpoint inhibitors in specific subtypes. However, prospective clinical trials are necessary to fully validate its routine clinical use.",
        "No. The consensus molecular subtype (CMS) classification for colorectal cancer has not been integrated into routine clinical practice despite its prognostic relevance and potential for patient stratification.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer provides a framework for understanding the molecular heterogeneity of the disease. It categorizes colorectal cancer into four distinct subtypes based on gene expression profiles, which can offer insights into prognosis and potential therapeutic strategies. However, its use in routine clinical practice is still limited. While CMS classification can aid in research and potentially guide treatment decisions in the future, it is not yet widely implemented in standard clinical settings due to the complexity and cost of molecular profiling, as well as the need for further validation and integration into clinical guidelines.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer is not yet widely used in routine clinical practice. Although the identification of colorectal cancer molecular subtypes has prognostic and potentially diagnostic value, reliable subtyping remains unavailable in the clinic. Current international guidelines are progressively establishing risk stratification and treatment based on both histopathological and molecular criteria, but the CMS classification has not been fully integrated into routine clinical practice.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has potential clinical utility, but it is not yet routinely used in clinical practice. The CMS classification provides insights into the molecular heterogeneity of colorectal cancer and may help guide prognosis, treatment selection, and development of targeted therapies. However, prospective clinical trials validating the clinical utility of CMS classification are still needed before it can become a routine clinical tool.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has potential clinical utility, but further prospective clinical trials are needed to validate its use in routine clinical practice. The CMS classification captures the molecular heterogeneity of colorectal cancer and provides insights into prognosis, therapeutic response, and potential novel therapeutic strategies tailored to each subtype. However, most of the current evidence is from retrospective studies, and prospective trials selecting patients based on CMS are required to establish it as a routine clinical tool for personalized treatment decisions in colorectal cancer.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has potential clinical utility, but further research and validation are needed before it can be routinely used in clinical practice. The CMS classification provides insights into the molecular heterogeneity of colorectal cancer and may help guide personalized treatment strategies and predict prognosis. However, prospective clinical trials specifically designed to evaluate the clinical implications of CMS subtypes are still lacking. Standardized protocols for accurately classifying patients into CMS categories also need to be established before widespread clinical implementation.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer shows promise in routine clinical practice for predicting prognosis and guiding treatment. It can inform chemotherapy decisions, such as adjuvant therapy for CMS2/CMS3, irinotecan for CMS4, and targeted therapies like anti-EGFR for KRAS wild-type CMS2. While CMS classification can personalize treatment, including potential use of immune checkpoint inhibitors, its routine clinical use awaits confirmation from ongoing prospective clinical trials to fully validate its utility.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer (CRC) is a significant advancement in understanding the molecular heterogeneity of CRC and aiding in precision medicine. It categorizes CRC into four distinct subtypes (CMS1, CMS2, CMS3, CMS4) based on transcriptional genome analysis, each associated with specific molecular and clinical features. This classification helps in prognosis prediction and treatment decision-making.\n\nCMS classification provides insights into the biological heterogeneity of CRC, informing therapeutic decisions and prognostic evaluations. It highlights specific immune escape mechanisms for each subtype, which can be crucial for targeted therapies. A NanoString-based CMS classifier has been developed for use with formalin-fixed paraffin-embedded (FFPE) tissues, making it suitable for routine clinical practice in both primary and metastatic CRC. This classifier has been validated in multiple FFPE-RNA datasets, showing improved classification accuracy and confirming key molecular and clinical associations.\n\nDespite its acceptance and utility in patient stratification, the CMS classification has not been widely implemented in routine clinical practice due to the need for genome-wide RNA expression data from fresh-frozen bulk tumor samples and variability in classification methods. Ongoing research and technological advancements are expected to address these challenges, making CMS classification more accessible for routine clinical use.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has shown promise in research, but its translation into routine clinical practice is still limited due to several challenges.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has limited impact on routine clinical practice, despite its potential to improve patient stratification and treatment outcomes. Studies have shown that CMS classification can capture tumor heterogeneity at the gene-expression level and provide meaningful insights into important issues in CRC, such as adjuvant chemotherapy in stage II, personalized first-line chemotherapy for metastatic CRC, and new target treatments. However, the current CMS classification is based on complex RNA expression patterns quantified at the gene level, which may not be readily applicable in clinical settings. Furthermore, histological grading is a poor predictor of disease progression, and CMSs cannot be distinguished without gene expression profiling, highlighting the need for advanced biomarkers to guide treatment. Overall, while CMS classification holds promise, its translation into routine clinical practice remains a challenge, and further research is needed to fully realize its potential in improving patient management and outcomes.",
        "The CMS classification shows promise for stratifying colorectal cancer patients and guiding treatment decisions, but it is not yet used routinely in clinical practice. Although it enhances our understanding of tumor biology and prognosis, challenges like intratumoral heterogeneity and the need for further prospective clinical validation have limited its integration into everyday clinical decision-making.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer holds significant value by providing prognostic insights and predicting treatment responses, such as distinguishing outcomes between bevacizumab and cetuximab treatments. Despite its proven effectiveness in enhancing prognostication and guiding targeted therapies, CMS is not yet widely adopted in routine clinical practice due to challenges including high costs, lack of standardization, and difficulties in integrating it into existing workflows. While CMS currently serves as a research tool with potential for future expansion, its broader clinical utility awaits solutions to these practical barriers.",
        "While the consensus molecular subtype (CMS) classification is widely accepted and has improved understanding of colorectal cancer heterogeneity and prognosis, its use in routine clinical practice is limited. Several challenges hinder the translation of CMS into the clinic, including intratumoral heterogeneity, uncertainty of single-sample classification, and associated costs. Although CMS classification holds potential for predicting prognosis and response to systemic therapy, prospective clinical trials are needed to validate its effectiveness and support its implementation in clinical practice. Currently, there is no clinical diagnostic test for CMS subtyping, and further research is required to refine the CMS classification and address the barriers to its clinical application.",
        "No. The consensus molecular subtype (CMS) classification for colorectal cancer is not used in routine clinical practice.",
        "Currently, the Consensus Molecular Subtype (CMS) classification for colorectal cancer, while promising and having prognostic relevance, is not yet routinely used in daily clinical practice. Researchers acknowledge that prospective clinical trials are still needed to validate its utility and establish it as a standard tool in oncology care. The classification represents a potential advancement in personalized medicine, but requires further validation before becoming a standard clinical approach.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer holds potential utility in personalized medicine by aiding in the tailoring of treatments. However, while it is considered crucial for guiding personalized treatment plans, it has not yet been fully validated through prospective clinical trials. These trials are necessary to establish whether CMS improves patient outcomes and can be reliably integrated into routine clinical practice. Currently, without such evidence, CMS cannot be widely recommended for everyday clinical use in oncology.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer holds potential for guiding treatment decisions, including adjuvant chemotherapy for stage II and personalized first-line chemotherapy for metastatic CRC. However, its integration into routine clinical practice is pending validation through prospective clinical trials. Notably, alternative prognostic tools like the CINSARC signature may currently offer more robust prognostic value for stage II-III CRC, potentially limiting CMS\u0027s standalone application in daily practice until further validated.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer holds promise for personalized medicine by helping tailor treatments to specific molecular characteristics of tumors. However, it is not yet widely used in routine clinical practice. This is because CMS requires validation through prospective clinical trials to establish its effectiveness and reliability as a predictive tool. Once these trials confirm its utility, CMS could become an integral part of standard oncology care.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has shown promise, with prognostic relevance and potential applications in personalized medicine. However, despite its development, it is not currently used in daily clinical practice. To become a routine tool in oncology care, prospective clinical trials that select patients based on CMS are necessary to prove its concept and efficacy. Until such studies demonstrate its utility, the CMS classification will remain a promising but not yet widely adopted approach in the treatment of colorectal cancer.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has shown promising prognostic relevance and is considered crucial for personalized medicine, but it is not yet used in daily clinical practice. Prospective clinical trials are needed to validate its use before it can become a routine tool in oncology care.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer, while offering valuable insights and predictive capabilities, is not yet widely used in routine clinical practice. This is due to the lack of prospective clinical trials validating its effectiveness and challenges such as molecular testing infrastructure and standardization across institutions. Although some guidelines recognize CMS as a useful tool, it remains optional and not uniformly adopted in oncology care.",
        "No, the consensus molecular subtype (CMS) classification for colorectal cancer is not currently used in routine clinical practice.",
        "While the consensus molecular subtype (CMS) classification for colorectal cancer (CRC) is widely accepted and has contributed to a better understanding of disease heterogeneity and prognosis, it is not yet routinely incorporated into clinical practice. Several studies highlight the potential clinical utility of CMSs for risk stratification, predicting prognosis, and guiding treatment decisions, including the use of adjuvant chemotherapy and personalized first-line chemotherapy. However, challenges such as intratumoral heterogeneity and the high cost and uncertainty of single-sample classification hinder its widespread adoption. Researchers are actively working on developing more accessible and robust tools, such as NanoString-based classifiers and targeted RNA-sequencing methods, to facilitate the clinical integration of CMS subtyping. Prospective clinical trials are needed to validate the clinical utility of CMS classification and support its implementation in routine oncology care.",
        "A promising consensus molecular (CMS) classification with prognostic relevance has been developed, but it is not used in daily practice.",
        "No, it is not used in daily practice. A promising consensus molecular (CMS) classification with prognostic relevance has been developed, but it is not used in daily practice.",
        "No, the consensus molecular subtype (CMS) classification for colorectal cancer is not used in daily practice.",
        "No. The consensus molecular subtype (CMS) classification has been developed with prognostic relevance but is not currently used in daily practice as a routine clinical tool in oncology.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer, while showing promise in providing prognostic relevance, is not currently utilized in routine clinical practice. This classification system is considered a significant step towards personalized medicine, as it allows for a more tailored approach to treatment. However, its integration into routine care is contingent upon the outcomes of prospective clinical trials that select patients based on their CMS subtype. These trials are necessary to validate the effectiveness and utility of CMS classification in improving patient outcomes, thereby solidifying its role in standard oncology practice. Until such proof-of-concept studies are completed, CMS remains a research tool rather than a routine clinical practice standard.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer is recognized as a valuable tool with potential benefits for personalized medicine. It offers insights into molecular characteristics that can predict treatment responses, thereby aiding in tailored therapeutic approaches. However, its adoption in routine clinical practice remains limited due to several factors:\n\n1. **Lack of Clinical Trial Evidence**: CMS has not yet been validated through prospective clinical trials demonstrating its effectiveness in improving patient outcomes when used in routine care.\n\n2. **Infrastructure and Expertise Requirements**: Implementing CMS requires specific infrastructure and expertise, which may not be readily available in all healthcare settings.\n\n3. **Standardization Challenges**: Ensuring consistent testing methods across different laboratories or institutions is a hurdle that needs to be addressed for widespread adoption.\n\n4. **Comparison with Existing Systems**: While CMS shows promise, its advantages over current classification systems need to be clearly demonstrated before it can replace existing tools.\n\nIn conclusion, while CMS holds potential for enhancing personalized treatment strategies and has prognostic value, its integration into routine clinical practice is still pending. Further research, along with possible changes in healthcare infrastructure, are necessary steps toward making CMS a standard tool in colorectal cancer management.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer is recognized as a valuable tool with potential benefits for personalized medicine. It offers insights into molecular characteristics that can predict treatment responses, thereby aiding in tailored therapeutic approaches. However, its adoption in routine clinical practice remains limited due to several factors:\n\n1. **Lack of Clinical Trial Evidence**: CMS has not yet been validated through large-scale prospective clinical trials demonstrating its effectiveness in improving patient outcomes when used in routine care.\n\n2. **Infrastructure and Expertise Requirements**: Implementing CMS requires specific infrastructure and expertise, which may not be readily available in all healthcare settings.\n\n3. **Standardization Challenges**: Ensuring consistent testing methods across different laboratories or institutions is a hurdle that needs to be addressed for widespread adoption.\n\n4. **Comparison with Existing Systems**: While CMS offers advantages, its integration into current clinical workflows must demonstrate clear benefits over existing classification systems before it becomes standard practice.\n\nIn conclusion, CMS holds promise for enhancing personalized treatment strategies and has prognostic value. However, its integration into routine clinical practice is still pending further research, infrastructure development, and possibly changes in healthcare practices to fully realize its potential.",
        "The CMS classification is a promising tool for enhancing prognostic and predictive evaluations in colorectal cancer, but it is currently not used in routine clinical practice. Ongoing research is working to refine this classification by incorporating additional genomic features, and prospective clinical trials are needed to validate its effectiveness and role in personalized treatment. Until further evidence supports its clinical utility, the CMS classification remains primarily a research tool.",
        "Not yet. Although a promising consensus molecular (CMS) classification with prognostic relevance has been developed, it is not used in daily practice. Prospective clinical trials selecting patients by CMS are required before becoming a routine clinical tool.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer represents a promising advancement in personalized medicine by offering insights into molecular characteristics that can predict treatment responses and outcomes. However, its integration into routine clinical practice remains limited due to several factors:\n\n1. **Lack of Prospective Trials**: While CMS has shown potential, large-scale prospective clinical trials are needed to confirm its effectiveness and validate its use in diverse patient populations.\n\n2. **Barriers to Implementation**: The molecular analysis required for CMS classification may not be readily available or affordable across all healthcare settings, posing challenges to widespread adoption.\n\n3. **Educational Needs**: Clinicians may require additional training to effectively utilize CMS classifications, which could slow its integration into daily practice.\n\n4. **Guideline Incorporation**: Professional organizations like ASCO have yet to incorporate CMS into their treatment guidelines, reflecting the need for more evidence before it becomes a standard tool.\n\n5. **Integration with Existing Systems**: CMS offers detailed molecular insights compared to traditional TNM staging but requires harmonization with existing systems to enhance its utility in clinical settings.\n\nIn conclusion, while CMS holds significant potential for improving personalized treatment approaches and providing prognostic value, its adoption into routine clinical practice is still evolving. Further research, infrastructure development, and guideline updates are necessary to fully realize its benefits in oncology care.",
        "No, the consensus molecular subtype (CMS) classification for colorectal cancer is not currently used in routine clinical practice. Prospective clinical trials are required to pass proof-of-concept before it can become a routine clinical tool in oncology.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer is recognized for its potential in personalized medicine due to its ability to predict treatment responses based on molecular characteristics. However, as of the information provided:\n\n1. **Research Value**: CMS has demonstrated prognostic relevance and is considered promising for research purposes, aiding in the prediction of patient outcomes and tailoring treatments.\n\n2. **Clinical Practice Gap**: Despite its potential, CMS is not currently used in routine clinical practice. The abstracts indicate that more prospective clinical trials are needed to validate its effectiveness in real-world settings before it can be widely adopted.\n\n3. **Barriers to Adoption**: Possible reasons for this gap include the need for specific molecular tests that may not be readily available or cost-effective, a lack of standardized protocols for integration into treatment plans, and insufficient evidence supporting its use in clinical practice.\n\n4. **Future Prospects**: While there may be ongoing efforts to integrate CMS into clinical trials or specific cases, professional guidelines on its use are likely needed to facilitate broader adoption.\n\nIn conclusion, CMS holds promise for enhancing personalized approaches in colorectal cancer management but remains primarily a research tool awaiting further validation and integration into routine clinical practice.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer (CRC) has the potential for clinical use in predicting prognosis and response to systemic therapy, and may allow improved prognostication and targeted therapy in order to deliver more personalized treatment for CRC. It may also help guide decisions on adjuvant chemotherapy and personalized first-line chemotherapy for metastatic CRC, as well as identify new target treatments. However, the CMS classification has not yet been fully integrated into routine clinical practice. Prospective studies and clinical trials are needed to validate its clinical utility and to establish it as a routine clinical tool in oncology.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer is recognized as a valuable tool in research settings due to its potential for personalized treatment approaches and prognostic insights. However, it has not yet been widely adopted into routine clinical practice. This is primarily because CMS requires further validation through prospective clinical trials to establish its effectiveness in real-world scenarios. Additionally, challenges such as the availability and cost of necessary molecular tests, along with a lack of standardized protocols for integration into treatment plans, contribute to its limited use in daily care. While CMS holds promise for future applications, it remains more of a research tool at present, awaiting sufficient evidence and practical solutions before becoming a standard clinical practice.",
        "No, the consensus molecular subtype (CMS) classification for colorectal cancer is not typically used in routine clinical practice.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer, while promising and relevant for prognostic purposes, is not currently used in daily clinical practice. Its integration into personalized medicine requires further validation through prospective clinical trials to establish its efficacy before it can become a routine tool in oncology care.",
        "No. The consensus molecular subtype (CMS) classification has been developed with prognostic relevance but is not currently used in daily practice.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer has prognostic relevance and is a promising tool for personalized medicine; however, it is not currently used in routine clinical practice, as prospective clinical trials are needed to establish its utility in oncology care.",
        "No, the consensus molecular subtype (CMS) classification for colorectal cancer is not currently used in routine clinical practice, although it has been developed and shown to have prognostic relevance. Prospective clinical trials are needed to validate its use in personalized medicine before it can become a standard tool in oncology care.",
        "No. The consensus molecular subtype (CMS) classification for colorectal cancer is not used in daily practice and has had little impact on clinical practice despite its potential relevance.",
        "No. The consensus molecular subtype (CMS) classification for colorectal cancer is not used in daily practice, as its relevance in clinical practice is still under investigation and requires further validation through prospective clinical trials.",
        "The CMS classification is not yet used in routine clinical practice.",
        "No. The consensus molecular subtype (CMS) classification for colorectal cancer is not currently used in daily practice, although it has potential for clinical use in predicting prognosis and response to therapy.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer is not yet a routine clinical tool in oncology care. While it is a crucial step in personalized medicine, prospective clinical trials selecting patients by CMS are required to pass proof-of-concept before it can be widely adopted in routine clinical practice.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer holds potential for guiding treatment decisions in routine clinical practice, especially for adjuvant chemotherapy in stage II and personalized first-line chemotherapy for metastatic CRC. However, its widespread adoption awaits validation through prospective clinical trials. Notably, emerging prognostic tools like the CINSARC signature may offer more immediate and robust prognostic value for certain stages, potentially complementing or surpassing CMS in predicting patient outcomes. Thus, while promising, CMS is not yet ready for standalone routine clinical use without further validation and may be part of a broader prognostic toolkit.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer is not currently used as a standard in routine clinical practice. While CMS has significant potential for personalized medicine by categorizing cancers into distinct molecular groups, its adoption requires prospective clinical trials to establish proof of concept before it can become a regular tool in oncology care.",
        "The consensus molecular (CMS) classification has prognostic relevance. However, it is not used in daily practice. Prospective clinical trials are required before it becomes a routine clinical tool.",
        " The consensus molecular subtype (CMS) classification for colorectal cancer has been developed with prognostic relevance, but it is not currently being used in routine clinical practice. Prospective clinical trials are required to pass proof-of-concept before CMS can become a routine tool in oncology care.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer, despite showing promising prognostic relevance, is not currently used in routine clinical practice. While it represents a crucial step toward personalized medicine in colorectal cancer treatment, the classification system still requires validation through prospective clinical trials that select patients by CMS to establish proof-of-concept before it can be implemented as a routine clinical tool in oncology care. The classification has demonstrated prognostic value but has not yet been translated into daily clinical decision-making.",
        "The Consensus Molecular Subtype (CMS) classification for colorectal cancer holds promise for advancing personalized medicine by offering prognostic insights. While it provides valuable molecular information that could guide treatment decisions, studies indicate that CMS is not yet integrated into routine clinical practice. This is because further prospective clinical trials are needed to validate its effectiveness and utility in selecting patients for specific therapies, ensuring its reliability before widespread adoption in standard care settings.",
        "No, the consensus molecular subtype (CMS) classification for colorectal cancer is not currently used in routine clinical practice, although it has been developed and shown to have prognostic relevance. Further prospective clinical trials are needed to validate its use in personalized medicine before it can become a standard tool in oncology care.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer is not yet used in routine clinical practice, although it shows promise. The provided context indicates that CMS is a promising classification with prognostic relevance, but prospective clinical trials selecting patients by CMS are still required to prove its utility before it can become a routine clinical tool in oncology care.",
        "no",
        "The CMS classification shows promise for informing prognosis and guiding therapy decisions in colorectal cancer, but it is not yet widely used in routine clinical practice. Although it has shed light on tumor biology and potential treatment strategies, challenges such as intratumoral heterogeneity, standardization of the assays, and limited prospective clinical validation have prevented its broader clinical adoption. The classification remains primarily a research tool, with ongoing efforts aimed at refining its application and demonstrating its practical benefits in routine settings.",
        "No, the CMS classification for colorectal cancer does not currently have established use in routine clinical practice, pending validation through prospective clinical trials.",
        "No, the consensus molecular subtype (CMS) classification for colorectal cancer is not used in routine clinical practice.",
        "While the consensus molecular subtype (CMS) classification for colorectal cancer (CRC) is widely accepted and has contributed to a better understanding of disease heterogeneity and prognosis, its use in routine clinical practice is still limited. Several challenges prevent the translation of molecular knowledge gleaned from CMSs into the clinic, including the lack of a clinical diagnostic test for CMS subtyping, intratumoral heterogeneity, and uncertainty of single-sample classification. Although CMS classification holds clear potential for predicting prognosis and response to systemic therapy, prospective clinical trials selecting patients by CMS are required before it can become a routine clinical tool. Many biomarkers appear promising in small-scale studies, but validation of their effectiveness with large-scale clinical trials is needed before routine clinical application.",
        "While the consensus molecular subtype (CMS) classification has shown promise and prognostic value in colorectal cancer, it is currently not implemented in daily clinical practice. Before CMS classification can become a routine clinical tool, it requires validation through prospective clinical trials that specifically select patients based on CMS status.",
        "The consensus molecular subtype (CMS) classification for colorectal cancer shows promise and prognostic relevance, but it is not yet used in daily routine clinical practice. While understanding CMS is important for personalized medicine, prospective clinical trials are needed to validate its use before it can become a standard tool in oncology care.",
        "No. The consensus molecular (CMS) classification with prognostic relevance has been developed, but it is not used in daily practice. Prospective clinical trials selecting patients by CMS are required to pass proof-of-concept before becoming a routine clinical tool in oncology routine care."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Please list major complications of Clostridum Difficile infection.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38335423",
        "http://www.ncbi.nlm.nih.gov/pubmed/38410289",
        "http://www.ncbi.nlm.nih.gov/pubmed/38653643",
        "http://www.ncbi.nlm.nih.gov/pubmed/39176325",
        "http://www.ncbi.nlm.nih.gov/pubmed/19736396",
        "http://www.ncbi.nlm.nih.gov/pubmed/20188046",
        "http://www.ncbi.nlm.nih.gov/pubmed/20454824",
        "http://www.ncbi.nlm.nih.gov/pubmed/8944365",
        "http://www.ncbi.nlm.nih.gov/pubmed/26338788",
        "http://www.ncbi.nlm.nih.gov/pubmed/32088581",
        "http://www.ncbi.nlm.nih.gov/pubmed/30120646",
        "http://www.ncbi.nlm.nih.gov/pubmed/33505698",
        "http://www.ncbi.nlm.nih.gov/pubmed/38086471",
        "http://www.ncbi.nlm.nih.gov/pubmed/23815405",
        "http://www.ncbi.nlm.nih.gov/pubmed/39704253",
        "http://www.ncbi.nlm.nih.gov/pubmed/39663942",
        "http://www.ncbi.nlm.nih.gov/pubmed/12433321",
        "http://www.ncbi.nlm.nih.gov/pubmed/22878997",
        "http://www.ncbi.nlm.nih.gov/pubmed/32806873",
        "http://www.ncbi.nlm.nih.gov/pubmed/12581333",
        "http://www.ncbi.nlm.nih.gov/pubmed/25842418",
        "http://www.ncbi.nlm.nih.gov/pubmed/34791401",
        "http://www.ncbi.nlm.nih.gov/pubmed/20597001",
        "http://www.ncbi.nlm.nih.gov/pubmed/22406889",
        "https://pubmed.ncbi.nlm.nih.gov/12594638/",
        "https://pubmed.ncbi.nlm.nih.gov/24188103/",
        "http://www.ncbi.nlm.nih.gov/pubmed/39448963",
        "http://www.ncbi.nlm.nih.gov/pubmed/39281262",
        "http://www.ncbi.nlm.nih.gov/pubmed/37386612",
        "http://www.ncbi.nlm.nih.gov/pubmed/15793312",
        "http://www.ncbi.nlm.nih.gov/pubmed/21609252",
        "http://www.ncbi.nlm.nih.gov/pubmed/16412077",
        "http://www.ncbi.nlm.nih.gov/pubmed/36511953",
        "http://www.ncbi.nlm.nih.gov/pubmed/20678014"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 333,
          "text": " Inflammatory bowel disease (IBD), including Crohn disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder characterized by inflammation of the gastrointestinal tract. Patients with IBD are susceptible to various complications, including the coexistence of Clostridioides difficile infection (CDI). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38335423"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Toxic Megacolon: A Sequelae of Clostridioides difficile Infection in a Case of Necrotizing Fasciitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38410289"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 621,
          "text": "growth of commensal bacteria including Staphylococcus aureus and Clostridioides difficile (previously known as Clostridium difficile) resulting in complications such as toxic megacolon.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38410289"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Up to 25% of patients recovering from antibiotic-treated Clostridioides difficile infection (CDI) develop functional symptoms reminiscent of Post-Infectious Irritable Bowel Syndrome (PI-IBS). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38653643"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Pseudomembranous colitis (PC) is an inflammation of the colon primarily caused by the bacterium Clostridium difficile (C. difficile), often following antibiotic use. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39176325"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 371,
          "text": "Clostridium difficile is the aetiological agent for almost all cases of pseudo membranous colitis and 15-25% of antibiotic associated diarrhoea. In recent years, C. difficile associated disease (CDAD) has been increasing in frequency and severity due to the emergence of virulent strains. Severe cases of toxic mega colon may be associated with mortality rates of 24-38%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19736396"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 442,
          "text": "Clostridium difficile associated-infections (CDI) have a wide range of clinical features which vary from mild uncomplicated diarrhoea to severe debilitating disease, paralytic ileus, toxic megacolon, or even perforation and sometimes death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20188046"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 349,
          "text": "C. difficile is known to cause a broad spectrum of conditions ranging from asymptomatic carriage, through mild or moderately severe disease with watery diarrhoea, to the life-threatening pseudomembranous colitis (PMC), with toxic megacolon and ileus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20454824"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 228,
          "text": "ource use. Sepsis and bowel surgery are known to be serious complications of C. difficile",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33505698"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 107,
          "text": "Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39663942"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Clostridium difficile was identified as the putative agent of antibiotic-associated pseudomembranous colitis in 1978 and is now recognized as the major identifiable cause of antibiotic-associated diarrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12433321"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "BACKGROUND: Clostridium difficile infection (CDI) is the most common cause of nosocomial infectious diarrhea and may result in severe complications including death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338788"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 498,
          "text": "C. difficile is a toxin producing bacterium leading to worsening of underlying IBD, increasing the risk of IBD treatment failure and an increased risk of hospitalization and surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32806873"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "The aim of this report is to describe a rare complication of clostridium difficile (CD) disease, the occurrence of an inflammatory pseudotumor that caused intestinal obstruction in a liver transplant recipient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12581333"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 389,
          "text": " It is not unusual for Clostridium difficile infection to progress to complications of toxic megacolon, bowel perforation and even Gram-negative sepsis following pathological changes in the intestinal mucosa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23815405"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Clostridium difficile infection (CDI) produces a variety of clinical presentations ranging from mild diarrhea to severe infection with fulminant colitis, septic shock, and death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120646"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "C. difficile is a spore-forming anaerobic enteropathogen responsible for a wide range of clinical features ranging from mild uncomplicated diarrhoea to severe debilitating disease, toxic megacolon, or even perforation and sometimes death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25842418"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "text": "Clostridioides difficile, the etiological agent of C. difficile infection (CDI), elicits a spectrum of diarrheal symptoms with varying severity and the potential to result in severe complications such as colonic perforation, pseudomembranous colitis, and toxic megacolon.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38086471"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 514,
          "text": "Over the past decade, C. difficile has been increasingly reported as a cause of a broad spectrum of gastrointestinal diseases in children, ranging from mild self-limiting diarrhea to severe conditions such as pseudomembranous colitis and toxic megacolon.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34791401"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "Clostridium difficile infection (CDI) occurs as a disease with a spectrum of severity ranging from mild, self-limiting diarrhoea to a severe colitis, pseudomembraneous colitis or toxic megacolon.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20597001"
        },
        {
          "offsetInBeginSection": 325,
          "offsetInEndSection": 475,
          "text": "The clinical manifestations of CDI vary from a mild form of the disease to fulminant diarrhea, leading to significant patient morbidity and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22406889"
        },
        {
          "offsetInBeginSection": 97,
          "offsetInEndSection": 218,
          "text": "Patients with C. difficile-associated disease are more likely to have colitis, severe disease and nosocomial acquisition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8944365"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Most cases of antibiotic-associated diarrhoea are due to Clostridium difficile or are enigmatic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8944365"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Pseudomembranous colitis and toxic megacolon (TM) are well-known complications of Clostridium difficile infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22878997"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Clostridium difficile-associated diarrhea and colitis have emerged as major complications associated with use of systemic antimicrobials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/12594638/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Clostridium difficile infections (CDIs) are a common cause of antibiotic-associated diarrhoea and associated with CDI-related mortality in c.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/24188103/"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 238,
          "text": " Sepsis and bowel surgery are known to be serious complications of C. difficile infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33505698"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39448963"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "BACKGROUND: Clostridioides difficile is the most common cause of healthcare-associated infection, and severe cases can result in significant complications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38534216"
        },
        {
          "offsetInBeginSection": 534,
          "offsetInEndSection": 683,
          "text": "Clostridium difficile can lead to various complications including septic shock and fulminant colitis that could prove to be lethal in these patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39281262"
        },
        {
          "offsetInBeginSection": 150,
          "offsetInEndSection": 305,
          "text": "C. difficile infection causes a spectrum of disease from mild diarrhea to severe complications such as pseudomembranous colitis, toxic megacolon and death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32088581"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 315,
          "text": "d diarrhea. There are a variety of symptoms associated with C. difficile infection (CDI) in adults, including self-limiting diarrhea, pseudomembranous colitis, toxic megacolon, septic shock, and even death from th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37386612"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Clostridium difficile causes a spectrum of diarrheal illness with the potential for major medical consequences.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15793312"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Clostridium difficile is one of the most important causes of healthcare acquired diarrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21609252"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "BACKGROUND: The clinical presentation of Clostridium difficile infection ranges from asymptomatic carriage, colitis with or without pseudomembranes, to fulmin",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16412077"
        },
        {
          "offsetInBeginSection": 24,
          "offsetInEndSection": 277,
          "text": ": UPDATED RECOMMENDATIONS Clostridioides difficile is a spore-forming anaerobic enteropathogen responsible for a wide spectrum of clinical features ranging from mild uncomplicated diarrhoea to severe debilitating disease, toxic megacolon, or even perfor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36511953"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Clostridium difficile infection (CDI) is a leading cause of nosocomial infections, with disease severity ranging from mild diarrhea to fulminant colitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20678014"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 198,
          "text": "olonization by Clostridioides difficile is common in children with inflammatory bowel disease (IBD) and complicates both the management of IBD and the diagnosis of C. difficile infection (CDI). The",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39704253"
        }
      ],
      "type": "list",
      "id": "67cddce881b102733300001c",
      "ideal_answer": [
        "Patients with IBD are susceptible to various complications, including the coexistence of Clostridioides difficile infection (CDI). Toxic Megacolon and  \npseudomembranous colitisare also often complations of Clostridioides difficile Infection.",
        "Major complications of Clostridium difficile infection include: \n1. Pseudomembranous Colitis - severe colonic inflammation with pseudomembrane formation due to C. difficile toxins.\n2. Toxic Megacolon - severe colonic dilation with systemic toxicity, requiring immediate intervention.\n3. Colonic Perforation\n4. Colectomy (surgical removal of part or all of the colon)\n5. ICU Admission due to severe infection\n6. Death within 30 days of diagnosis. These complications underscore the need for prompt and effective management to prevent significant morbidity and mortality.",
        "Major complications of Clostridium difficile infection include dehydration, electrolyte imbalances, toxic megacolon, bowel perforation, sepsis, kidney failure, recurrent C. difficile infection, and death in severe cases. These complications can be severe and require prompt medical attention.",
        "Major complications of Clostridium difficile infection (CDI) include: diarrhea, colitis, increased morbidity in hematopoietic stem cell transplant patients, and potential for life-threatening conditions such as septic shock and necrotizing fasciitis.",
        "Major complications of Clostridium difficile infection include toxic megacolon, pseudomembranous colitis, ileus, and sepsis, among others.",
        "The major complications of Clostridium difficile infection (CDI) include: 1. Pseudomembranous colitis (PMC) - severe colonic inflammation due to C. difficile toxins leading to pseudomembrane formation. 2. Toxic megacolon - characterized by severe colonic dilation and systemic toxicity requiring immediate medical intervention. 3. Septic shock - a life-threatening condition resulting from severe infection. 4. Fulminant colitis - a severe form of colitis that can lead to bowel perforation and sepsis. 5. Recurrence of CDI - patients may experience repeated episodes of CDI after initial treatment. 6. Bacteremia - presence of bacteria in the blood, which can occur in severe cases. 7. Death - CDI can lead to mortality, particularly in vulnerable populations such as the elderly or immunocompromised individuals.",
        "Clostridium difficile infection is associated with severe complications such as toxic megacolon, bowel perforation, sepsis, and death.",
        "The major complications of Clostridium difficile infection (CDI) include: diarrhea, colitis, increased morbidity, prolonged hospital stay, and potential for recurrence due to antibiotic resistance.",
        "Major complications of Clostridium difficile infection (CDI) include severe diarrhea, colitis, life-threatening complications, increased morbidity in hematopoietic stem cell transplant patients, poor clinical outcomes in inflammatory bowel disease, and severe variceal bleeding.",
        "Major complications of Clostridium difficile infection include toxic megacolon, pseudomembranous colitis, ileus, hypoalbuminemia, devastating diarrhea, relapsing disease, colitis, and renal failure.",
        "The major complications of Clostridium difficile infection (CDI) include: diarrhea, colitis, increased morbidity, and potential for serious systemic consequences such as Fournier\u0027s gangrene and osteomyelitis.",
        "Major complications of Clostridium difficile infection include pseudomembranous colitis, toxic megacolon, septic shock, coagulopathy, and hemorrhage.",
        "Major complications include pseudomembranous colitis, toxic megacolon, colonic perforation, and sepsis. In severe cases, patients may also experience recurrent infection, dehydration, electrolyte imbalances, and subsequent multi-organ failure.",
        "Major complications of Clostridium difficile infection include: \n1. Pseudomembranous colitis, \n2. Toxic megacolon, \n3. Colonic perforation, \n4. Colectomy, \n5. ICU admission due to CDI, \n6. Death within 30 days, \n7. Severe diarrhea leading to electrolyte imbalances, dehydration, hemodynamic instability, and shock.",
        "Major complications of Clostridium difficile infection include:\n\n1. Toxic megacolon\n2. Hypotension\n3. Colonic perforation with peritonitis\n4. Septic shock with organ failure\n5. Pseudomembranous colitis\n6. Fulminant colitis\n7. Life-threatening \"toxic\" illness with fever, severe diarrhea, and abdominal pain\n8. Rectal prolapse\n9. Nosocomial bacteremia\n10. Multi-organ failure\n\nThese complications can lead to significant morbidity and mortality in patients with Clostridium difficile infection.",
        "Clostridioides difficile infection (CDI) is associated with complications such as toxic megacolon, pseudomembranous colitis, and sepsis.",
        "Major complications of Clostridium difficile infection include: \n1. Toxic Megacolon - extreme inflammation and colon dilatation, potentially leading to sepsis and mortality.\n2. Pseudomembranous Colitis - inflammation of the colon with pseudomembrane formation.\n3. Post-Infectious Irritable Bowel Syndrome (PI-IBS) - persistent symptoms in up to 25% of patients after recovery.\n4. Increased Mortality - especially in immunocompromised patients or with delayed diagnosis.\n5. Sepsis and Systemic Spread of Gut Anaerobes (Bacteremia) - potentially life-threatening conditions.\n6. Treatment Failure and Recurrence - higher rates with certain antibiotic treatments, underscoring the need for effective management.",
        "Clostridium difficile infection can result in complications such as toxic megacolon, pseudomembranous colitis, and necrotizing fasciitis.",
        "Major complications of Clostridium difficile infection can be Toxic megacolon, Pseudomembranous colitis, and Post-infectious IBS.",
        "Major complications of Clostridium Difficile infection (CDI) include fulminant colitis, septic shock, death, severe colitis, pseudomembranous colitis, toxic megacolon, increased morbidity and mortality (especially in IBD patients), IBD flare, colectomy, bowel perforation, ileus, intestinal perforation, megacolon, multiorgan failure, pancolitis, peritonitis, renal failure, and sepsis/septic shock. It can also lead to post-infectious irritable bowel syndrome (PI-IBS).",
        "Major complications of Clostridioides difficile infection (CDI) include pseudomembranous colitis and toxic megacolon. Some patients also develop functional symptoms reminiscent of Post-Infectious Irritable Bowel Syndrome (PI-IBS).",
        "The major complications of Clostridium difficile infection (CDI) include: toxic megacolon, pseudomembranous colitis, recurrent CDI, and post-infectious irritable bowel syndrome (PI-IBS).",
        "Major complications of Clostridium Difficile infection include:\n\n1. Pseudomembranous colitis (PC)\n2. Toxic megacolon\n3. Post-infectious Irritable Bowel Syndrome (PI-IBS)\n4. Adverse outcomes in patients with inflammatory bowel disease (IBD)\n5. Growth of commensal bacteria such as Staphylococcus aureus and Clostridioides difficile (CDI) leading to further complications.",
        "Major complications of Clostridium Difficile infection include pseudomembranous colitis, toxic megacolon, and post-infectious irritable bowel syndrome (PI-IBS).",
        "Major complications of Clostridium difficile infection (CDI) include: toxic megacolon, pseudomembranous colitis, sepsis, and increased mortality risk in patients with compromised immune function.",
        "Clostridium difficile infection is associated with pseudomembranous colitis, toxic megacolon, and necrotizing fasciitis.",
        "The major complications of Clostridium difficile infection (CDI) include: pseudomembranous colitis, toxic megacolon, recurrent CDI, and severe complications leading to morbidity and mortality.",
        "The major complications of Clostridium difficile infection (CDI) include: pseudomembranous colitis, toxic megacolon, post-infectious irritable bowel syndrome (PI-IBS), and recurrent CDI.",
        "Clostridium difficile infection can lead to serious complications such as toxic megacolon, pseudomembranous colitis, and sepsis.",
        "Clostridioides difficile infection (CDI) is a major complication of inflammatory bowel disease (IBD), including Crohn disease (CD) and ulcerative colitis (UC). CDI is associated with various complications, including the coexistence of Clostridioides difficile infection (CDI).",
        " Major complications of Clostridium difficile infection (CDI) include:\n\n1. Pseudomembranous colitis: an inflammation of the colon primarily caused by C. difficile, often following antibiotic use.\n2. Toxic megacolon: a rare but serious complication that can lead to perforation and sepsis.\n3. Post-Infectious Irritable Bowel Syndrome (PI-IBS): up to 25% of patients recovering from antibiotic-treated CDI develop functional symptoms reminiscent of PI-IBS.\n4. Recurrent CDI: recurrence is common, with up to 30% of patients experiencing multiple episodes.\n5. Adverse outcomes in inflammatory bowel disease (IBD): the incidence of CDI in IBD is rising and associated with adverse outcomes.",
        "Clostridioides difficile infection (CDI) is associated with complications such as toxic megacolon, pseudomembranous colitis, and necrotizing fasciitis.",
        "Major complications of Clostridium Difficile infection include Pseudomembranous Colitis, Toxic Megacolon, and potentially lead to Post-Infectious Irritable Bowel Syndrome (PI-IBS) in up to 25% of recovering patients, especially those with a history of antibiotic treatment.",
        "Major complications of Clostridum Difficile infection can be Toxic megacolon, Pseudomembranous colitis, and Post-Infectious Irritable Bowel Syndrome (PI-IBS).",
        "Complications of Clostridium difficile infection (CD) include:\n1. Pseudomembranous colitis (PC) is an inflammation of the colon primarily caused by the bacterium Clostridium difficile (C. difficile), often following antibiotic use.\n2. Toxic megacolon (TM) is a severe complication of CD that requires emergency medical treatment.\n3. Hemolytic anemia (HA) is a rare complication of CD that occurs due to clostridium difficile production of a toxin that destroys red blood cells.\n4. Arrythmia (A) is a complication of CD that is associated with a severe inflammatory response involving the myocardium.\n5. Severe morbidity and mortality can occur in CD patients, especially in elderly people and those with underlying chronic diseases.\n6. CD infection can also complicate the management of patients on enteral nutrition, leading to a severe inflammatory response involving the intestinal tract.\n7. CD infection can lead to the development of inflammatory bowel disease (IBD) in previously healthy individuals.\n8. CD infection is associated with adverse outcomes, such as increased hospital admissions, increased length of stay, and increased mortality.\n9. CD infection can cause long-lasting damage to the intestinal tract, leading to chronic bowel dysfunction.\n10. CD infection can result in significant morbidity, even in otherwise healthy individuals, due to the",
        "Major complications of Clostridioides difficile infection (CDI) include pseudomembranous colitis, toxic megacolon, and post-infectious irritable bowel syndrome (PI-IBS)."
      ],
      "exact_answer": [
        [
          "pseudomembranous colitis"
        ],
        [
          "IBD"
        ],
        [
          "toxic megacolon"
        ],
        [
          "diarrhea"
        ]
      ]
    },
    {
      "body": "Symptoms of polycystic ovarian syndrome.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39569644",
        "http://www.ncbi.nlm.nih.gov/pubmed/38389707",
        "http://www.ncbi.nlm.nih.gov/pubmed/38485896",
        "http://www.ncbi.nlm.nih.gov/pubmed/38907183",
        "http://www.ncbi.nlm.nih.gov/pubmed/38595887",
        "http://www.ncbi.nlm.nih.gov/pubmed/23182556",
        "http://www.ncbi.nlm.nih.gov/pubmed/32701517",
        "http://www.ncbi.nlm.nih.gov/pubmed/25022814",
        "http://www.ncbi.nlm.nih.gov/pubmed/24379699",
        "http://www.ncbi.nlm.nih.gov/pubmed/39734992",
        "http://www.ncbi.nlm.nih.gov/pubmed/15380140",
        "http://www.ncbi.nlm.nih.gov/pubmed/9855617",
        "http://www.ncbi.nlm.nih.gov/pubmed/15969998",
        "http://www.ncbi.nlm.nih.gov/pubmed/28537181",
        "http://www.ncbi.nlm.nih.gov/pubmed/34286948",
        "http://www.ncbi.nlm.nih.gov/pubmed/23619436",
        "http://www.ncbi.nlm.nih.gov/pubmed/39484281",
        "http://www.ncbi.nlm.nih.gov/pubmed/32909413",
        "http://www.ncbi.nlm.nih.gov/pubmed/37291787",
        "http://www.ncbi.nlm.nih.gov/pubmed/10352925",
        "http://www.ncbi.nlm.nih.gov/pubmed/20470471",
        "http://www.ncbi.nlm.nih.gov/pubmed/10370713",
        "https://pubmed.ncbi.nlm.nih.gov/36267367/",
        "http://www.ncbi.nlm.nih.gov/pubmed/21437531",
        "http://www.ncbi.nlm.nih.gov/pubmed/36751233",
        "http://www.ncbi.nlm.nih.gov/pubmed/11453331",
        "http://www.ncbi.nlm.nih.gov/pubmed/11153345",
        "http://www.ncbi.nlm.nih.gov/pubmed/39715882",
        "http://www.ncbi.nlm.nih.gov/pubmed/39678554"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 138,
          "text": "overweight/obese",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39569644"
        },
        {
          "offsetInBeginSection": 586,
          "offsetInEndSection": 631,
          "text": "irregular menstrual cycle/chronic anovulation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39569644"
        },
        {
          "offsetInBeginSection": 729,
          "offsetInEndSection": 745,
          "text": "hyperandrogenism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39569644"
        },
        {
          "offsetInBeginSection": 180,
          "offsetInEndSection": 240,
          "text": "infertility, irregular menstrual cycles, acne, and hirsutism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38389707"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 361,
          "text": "obesity, insulin resistance, acne, menstrual abnormalities, and hirsutism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38595887"
        },
        {
          "offsetInBeginSection": 1892,
          "offsetInEndSection": 2011,
          "text": "linked polycystic ovary syndrome to negative mental health outcomes and an increased severity of premenstrual syndrome ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38907183"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 183,
          "text": "androgen excess, ovulatory dysfunction, and polycystic ovarian morphology",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38485896"
        },
        {
          "offsetInBeginSection": 813,
          "offsetInEndSection": 865,
          "text": "Sexual satisfaction and desire were affected by PCOS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38485896"
        },
        {
          "offsetInBeginSection": 944,
          "offsetInEndSection": 1049,
          "text": "impairments of visuospatial working memory, episodic and verbal memory, attention, and executive function",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38485896"
        },
        {
          "offsetInBeginSection": 1235,
          "offsetInEndSection": 1288,
          "text": "obesity, hirsutism, acne, and the fear of infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38485896"
        },
        {
          "offsetInBeginSection": 1174,
          "offsetInEndSection": 1218,
          "text": "hyperandrogenism and the risk of infertility",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38485896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 387,
          "text": "Polycystic ovarian syndrome (PCOS) is a disorder of androgen excess and ovarian dysfunction. Hirsutism and elevated free testosterone levels are the most consistent signs of the androgen excess. Irregular, infrequent, or absent menses and infertility are symptoms of ovulatory dysfunction. Obesity is also a feature of this syndrome and contributes to associated metabolic abnormalities.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23182556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 370,
          "text": "Polycystic ovarian syndrome (PCOS) is a common endocrinopathy with many clinical manifestations. The effects on women\u0027s lives start at puberty and can last throughout her lifetime. Women frequently experience anovulatory menstrual cycles, infertility, hirsutism, obesity and increased risk of diabetes mellitus, hypertension, lipid abnormalities, and metabolic syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32701517"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 306,
          "text": "Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women. The syndrome is typified by its heterogeneous presentation, which includes hirsutism (a function of hypersecretion of ovarian androgens), menstrual irregularity and infertility (that is due to infrequent or absent ovulation).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25022814"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Introduction Insulin resistance is a fundamental factor in the pathogenesis of polycystic ovarian syndrome (PCOS) and has been found to mediate a close association with obesity and dyslipidemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39734992"
        },
        {
          "offsetInBeginSection": 232,
          "offsetInEndSection": 375,
          "text": "Clinical expression of the syndrome varies but commonly includes menstrual cycle disturbance, hyperandrogenism, insulin resistance and obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15380140"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Women with polycystic ovary syndrome come to the gynecologist with a variety of symptoms, including menstrual irregularities, hirsutism, acne, weight gain, obesity, and infertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9855617"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Polycystic ovary syndrome is characterized by anovulation (amenorrhea, oligomenorrhea, irregular menstrual cycles) combined with symptoms of androgen excess (hirsutism, acne, alopecia).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34286948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 298,
          "text": "Polycystic ovarian syndrome (PCOS) is a reproductive system disorder characterized by irregular menses, anovulation, clinical and/or biochemical signs of hyperandrogenism (hirsutism and/or acne), ovarian micropolycystic appearance and metabolic abnormalities, such as hyperinsulinaemia and obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15969998"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 472,
          "text": "Polycystic ovarian syndrome (PCOS) is a \"multispeciality\" disorder suspected in patients with irregular menses and clinical signs of hyperandrogenism such as acne, seborrhoea, hirsutism, irregular menses, infertility, and alopecia. Recently, PCOS has been associated with the metabolic syndrome. Patients may develop obesity, insulin resistance, acanthosis nigricans, Type 2 diabetes, dyslipidemias, hypertension, non-alcoholic liver disease, and obstructive sleep apnoea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23619436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women, often accompanied by various symptoms including significant pain, such as dysmenorrhea, abdominal, and pelvic pain,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39484281"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 645,
          "text": "Diagnostic criteria include hyperandrogenism (clinical or biological), ovulatory dysfunction and polycystic ovarian morphology on ultrasound. The consequences of the syndrome are multiple. These consist of fertility issues and metabolic anomalies with increased cardiovascular risk, but also sleep disturbances, increased risk of endometrial hyperplasia and endometrial cancer and a potentially important psychological impact with decreased quality of life.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32909413"
        },
        {
          "offsetInBeginSection": 459,
          "offsetInEndSection": 676,
          "text": "PCOS is associated with an increased risk of developing health problems like hyperinsulinemia, diabetes mellitus, hypertension, cardiovascular disorders, dyslipidaemia, endometrial hyperplasia, anxiety and depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37291787"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 369,
          "text": "The signs and symptoms of PCOS include ovarian cysts, acne and excess hair growth (hirsutism), and can have a negative effect on the self-esteem of women with the condition. PCOS is also a potential cause of reduced fertility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28537181"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 406,
          "text": "The clinical features of polycystic ovary syndrome (PCOS) include hirsutism and irregular menses, which are the results of ovarian hyperandrogenism and chronic, unopposed estrogen secretion. The discovery that most women with PCOS are insulin-resistant and have compensatory hyperinsulinemia, with increased risk for type 2 diabetes mellitus, designates this condition as a reproductive-metabolic disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10352925"
        },
        {
          "offsetInBeginSection": 275,
          "offsetInEndSection": 391,
          "text": "Common clinical features seen in adolescents with PCOS include hirsutism, acne, menstrual irregularity, and obesity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10370713"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by menstrual irregularities, chronic anovulation, hirsutism, androgenic alopecia, and acne.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/36267367/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1072,
          "text": "Polycystic ovary syndrome (PCOS) is a common heterogeneous endocrine disorder characterized by irregular menses, hyperandrogenism, and polycystic ovaries. The prevalence of PCOS varies depending on which criteria are used to make the diagnosis, but is as high as 15%-20% when the European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine criteria are used. Clinical manifestations include oligomenorrhea or amenorrhea, hirsutism, and frequently infertility. Risk factors for PCOS in adults includes type 1 diabetes, type 2 diabetes, and gestational diabetes. Insulin resistance affects 50%-70% of women with PCOS leading to a number of comorbidities including metabolic syndrome, hypertension, dyslipidemia, glucose intolerance, and diabetes. Studies show that women with PCOS are more likely to have increased coronary artery calcium scores and increased carotid intima-media thickness. Mental health disorders including depression, anxiety, bipolar disorder and binge eating disorder also occur more frequently in women with PCOS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379699"
        },
        {
          "offsetInBeginSection": 410,
          "offsetInEndSection": 688,
          "text": "The main diagnostic findings of the syndrome are: hyperandrogenism, chronic anovulation and polycystic ovarian morphology seen on ultrasound. Hyperandrogenism is generally manifested as hirsutism, acne, seborrhea, androgenic alopecia and, in severe cases, signs of virilization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21437531"
        },
        {
          "offsetInBeginSection": 492,
          "offsetInEndSection": 713,
          "text": "PCOS exhibits a variety of characteristics as well as a heterogeneity of symptoms, including acne, hirsutism, androgenic alopecia, irregular menstruation, infertility, obesity, and mood disorders like despair and anxiety.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36751233"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 270,
          "text": "Polycystic ovary syndrome (PCOS) is classically characterised by ovarian dysfunction (oligomenorrhoea, anovulation and infertility), androgen excess (hirsutism and acne), obesity, and morphological abnormalities of the ovaries (cystic enlargement and stromal expansion).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11453331"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 589,
          "text": "Described are the etiology and possible symptoms of PCOS such as amenorrhea/oligomenorrhea, hirsutism, obesity, infertility, persistent acne, ovarian cysts, elevated triglycerides, and adult-onset diabetes, along with possible pathological interference with mammogenesis, lactogenesis, and galactopoiesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11153345"
        },
        {
          "offsetInBeginSection": 402,
          "offsetInEndSection": 659,
          "text": "Characterized by hyperandrogenism, oligo-ovulation or anovulation, and polycystic ovarian morphology, PCOS is often accompanied by insulin resistance, metabolic syndrome, and chronic inflammation, which reduce fertility throughout the reproductive lifespan.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39678554"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "Polycystic ovarian syndrome is a heterogeneous endocrine disorder characterized by ovarian cysts, anovulation, endocrine variations, which includes oligo-amenorrhea along with associated subfertility and hyperandrogenism manifested as acne, hirsutism, and male-pattern alopecia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39715882"
        },
        {
          "offsetInBeginSection": 198,
          "offsetInEndSection": 377,
          "text": "The main manifestations of PCOS include the following symptoms: menstrual irregularity, excess body hair, infertility, acne, androgenetic alopecia, obesity and acantose nigricans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20470471"
        }
      ],
      "id": "67d43cd218b1e36f2e000011",
      "ideal_answer": [
        "Women with PCOS are at higher risk of overweight and obesity, irregular menstrual cycles, hyperandrogenism, infertility, acne, hirsutism, severe PMS,  decreased sexual desire and some mental and cognitive problems.",
        "Polycystic Ovarian Syndrome (PCOS) is characterized by a variety of symptoms that can significantly impact a woman\\\u0027s health and well being. Common physical symptoms include irregular menstrual cycles or chronic anovulation, leading to infertility concerns. Women with PCOS often experience hyperandrogenism, resulting in acne and hirsutism (excess hair growth). Obesity and insulin resistance are also frequently observed, contributing to metabolic issues. The condition is linked to polycystic ovarian morphology, visible on ultrasounds as multiple small cysts on the ovaries. Beyond physical symptoms, PCOS can affect mental health, with increased severity of premenstrual syndrome (PMS) and negative mental health outcomes. It may also impact sexual satisfaction and desire. Additionally, some women report cognitive impairments such as difficulties in visuospatial working memory, episodic and verbal memory, attention, and executive function. The fear of infertility is another emotional burden associated with PCOS.",
        "Polycystic Ovarian Syndrome (PCOS) is a multifaceted condition characterized by a variety of symptoms that can significantly impact a woman\u0027s health. The key symptoms include:\n\n1. **Menstrual Irregularities**: Such as irregular or absent menstrual periods due to chronic anovulation, which disrupts the normal hormonal cycle.\n\n2. **Hyperandrogenism**: Elevated levels of male hormones (androgens) leading to symptoms like acne and hirsutism (excessive hair growth on the face, chest, or back).\n\n3. **Weight Gain/Obesity**: Often associated with insulin resistance, contributing to weight gain and difficulty in managing body weight.\n\n4. **Infertility**: Due to irregular ovulation, making conception challenging.\n\n5. **Mental Health Issues**: Increased risk of mood disorders such as anxiety and depression, linked to hormonal fluctuations and the psychological impact of living with PCOS.\n\n6. **Sexual Dysfunction**: Decreased sexual desire or satisfaction, potentially related to hormonal imbalances.\n\n7. **Cognitive Impairments**: Some women experience difficulties with memory, attention, and executive function, highlighting broader effects on cognitive health.\n\n8. **Polycystic Ovarian Morphology**: Diagnosed via ultrasound, showing multiple small cysts in the ovaries, though this is more of a diagnostic feature than a symptom.\n\nIt\u0027s important to note that the presentation of PCOS varies widely among individuals; not all women experience every symptom. The condition can affect reproductive, metabolic, psychological, and cognitive health, underscoring the need for comprehensive care tailored to each patient\u0027s unique experiences.",
        "Polycystic Ovarian Syndrome (PCOS) is a complex endocrine disorder characterized by a variety of symptoms, which can significantly impact a woman\u0027s physical, emotional, and reproductive health. The primary features of PCOS include:\n\n1. **Hormonal Imbalances**: Characterized by hyperandrogenism, leading to elevated levels of male hormones such as testosterone. This can result in symptoms like acne and hirsutism (excess hair growth).\n\n2. **Reproductive Issues**: Menstrual irregularities, including infrequent or absent periods, are common due to ovulatory dysfunction. This can lead to infertility.\n\n3. **Metabolic Concerns**: PCOS is often associated with insulin resistance, which can contribute to obesity and increase the risk of developing type 2 diabetes and cardiovascular diseases.\n\n4. **Ovarian Morphology**: The presence of polycystic ovarian morphology, where the ovaries contain multiple small cysts, is a key diagnostic feature.\n\n5. **Mental Health Challenges**: Women with PCOS may experience negative mental health outcomes, including increased severity of premenstrual syndrome (PMS), anxiety, and depression.\n\n6. **Cognitive and Sexual Health**: Some individuals may face impairments in visuospatial working memory, attention, and executive function. Additionally, sexual satisfaction and desire can be affected by PCOS.\n\nIt is important to note that the presentation of PCOS varies widely among individuals. Not all symptoms are experienced by everyone with PCOS, and the severity can differ significantly. While some may have mild symptoms, others may face more severe challenges. Early diagnosis and management are crucial to mitigate long-term health risks associated with PCOS.",
        "Polycystic ovarian syndrome (PCOS) presents with a constellation of symptoms including irregular menstrual cycles or chronic anovulation, hyperandrogenism manifesting as hirsutism and acne, obesity, and insulin resistance. Women with PCOS often experience infertility concerns due to ovulatory dysfunction. The syndrome is also associated with polycystic ovarian morphology on ultrasound. Beyond physical symptoms, PCOS can impact mental health and cognitive function, with studies showing impairments in memory, attention, and executive function. Sexual health may also be affected, with some women reporting decreased sexual satisfaction and desire. The combination of visible symptoms like obesity, hirsutism, and acne, along with concerns about fertility, can significantly impact quality of life for those with PCOS."
      ],
      "exact_answer": [
        [
          "decreased libido"
        ],
        [
          "obesity"
        ],
        [
          "infertility"
        ],
        [
          "overweight"
        ],
        [
          "irregular menstrual cycle"
        ],
        [
          "hirsutism"
        ],
        [
          "hyperandrogenism"
        ],
        [
          "acne"
        ],
        [
          "severe PMS"
        ],
        [
          "abnormal uterine bleeding"
        ],
        [
          "virilization"
        ],
        [
          "acanthosis nigricans"
        ],
        [
          "insulin resistance"
        ],
        [
          "type 2 diabetes"
        ],
        [
          "non-alcoholic liver disease"
        ],
        [
          "thinning hair"
        ],
        [
          "mood disorders"
        ]
      ]
    },
    {
      "body": "What are the lineage transcription factors of oligodendrocyte progenitor cells (OPCs)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24982138",
        "http://www.ncbi.nlm.nih.gov/pubmed/26254831",
        "http://www.ncbi.nlm.nih.gov/pubmed/26134954",
        "http://www.ncbi.nlm.nih.gov/pubmed/19737431",
        "http://www.ncbi.nlm.nih.gov/pubmed/20229602",
        "http://www.ncbi.nlm.nih.gov/pubmed/19363151",
        "http://www.ncbi.nlm.nih.gov/pubmed/29081882",
        "http://www.ncbi.nlm.nih.gov/pubmed/16988043",
        "http://www.ncbi.nlm.nih.gov/pubmed/35053357",
        "http://www.ncbi.nlm.nih.gov/pubmed/25200136",
        "http://www.ncbi.nlm.nih.gov/pubmed/25966902",
        "http://www.ncbi.nlm.nih.gov/pubmed/35301318",
        "http://www.ncbi.nlm.nih.gov/pubmed/30152028",
        "http://www.ncbi.nlm.nih.gov/pubmed/15536179",
        "http://www.ncbi.nlm.nih.gov/pubmed/39454007",
        "http://www.ncbi.nlm.nih.gov/pubmed/33574458",
        "http://www.ncbi.nlm.nih.gov/pubmed/36193754",
        "http://www.ncbi.nlm.nih.gov/pubmed/21098272",
        "http://www.ncbi.nlm.nih.gov/pubmed/21957254",
        "http://www.ncbi.nlm.nih.gov/pubmed/12924709",
        "http://www.ncbi.nlm.nih.gov/pubmed/33462220",
        "http://www.ncbi.nlm.nih.gov/pubmed/17640524",
        "http://www.ncbi.nlm.nih.gov/pubmed/35748297",
        "http://www.ncbi.nlm.nih.gov/pubmed/21403432",
        "https://pubmed.ncbi.nlm.nih.gov/30152028/",
        "https://pubmed.ncbi.nlm.nih.gov/19737431/",
        "http://www.ncbi.nlm.nih.gov/pubmed/38218078",
        "http://www.ncbi.nlm.nih.gov/pubmed/15519240",
        "http://www.ncbi.nlm.nih.gov/pubmed/38096960",
        "http://www.ncbi.nlm.nih.gov/pubmed/27067865",
        "http://www.ncbi.nlm.nih.gov/pubmed/34385359/",
        "http://www.ncbi.nlm.nih.gov/pubmed/18184726/",
        "http://www.ncbi.nlm.nih.gov/pubmed/38995010",
        "http://www.ncbi.nlm.nih.gov/pubmed/34312226",
        "http://www.ncbi.nlm.nih.gov/pubmed/11276127",
        "http://www.ncbi.nlm.nih.gov/pubmed/34480425",
        "http://www.ncbi.nlm.nih.gov/pubmed/22865458",
        "http://www.ncbi.nlm.nih.gov/pubmed/29664021",
        "http://www.ncbi.nlm.nih.gov/pubmed/23739972"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 236,
          "text": "Oligodendrocyte lineage transcription factor 2 (OLIG2) plays an important role in the oligodendrogenic pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26254831"
        },
        {
          "offsetInBeginSection": 394,
          "offsetInEndSection": 599,
          "text": "Among these, lentiviral overexpression of transcription factors ASCL1, SOX10, and NKX2.2 in NPCs was sufficient to induce Sox10 enhancer activity, OPC mRNA, and protein expression consistent with OPC fate;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24982138"
        },
        {
          "offsetInBeginSection": 361,
          "offsetInEndSection": 681,
          "text": "Within 8 d, PSCs differentiate into paired box 6-positive (PAX6(+)) neural stem cells, which give rise to OLIG2(+) progenitors by day 12. Oligodendrocyte lineage transcription factor 2-positive (OLIG2(+)) cells begin to express the transcription factor NKX2.2 around day 18, followed by SRY-box 10 (SOX10) around day 40.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26134954"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26134954"
        },
        {
          "offsetInBeginSection": 339,
          "offsetInEndSection": 643,
          "text": "Investigations of oligodendrocyte development in mice indicated that the Nkx2.2 transcription factor both limits the number of OPCs that are formed and subsequently promotes their differentiation, raising the possibility that Nkx2.2 plays a key role in determining myelinating versus nonmyelinating fate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737431"
        },
        {
          "offsetInBeginSection": 1282,
          "offsetInEndSection": 1453,
          "text": "We conclude that Nkx2.2 promotes timely specification and differentiation of myelinating oligodendrocyte lineage cells from species representing different vertebrate taxa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19737431"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 589,
          "text": "Using oligodendrocyte differentiation as a model system, we show that sonic hedgehog (SHH)-dependent sequential activation of the transcription factors OLIG2, NKX2.2 and SOX10 is required for sequential specification of ventral spinal OLIG2-expressing progenitors, pre-oligodendrocyte precursor cells (pre-OPCs) and OPCs from hESC-derived neuroepithelia, indicating that a conserved transcriptional network underlies OPC specification in human as in other vertebrates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19363151"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Olig2 overexpression accelerates the differentiation of mouse embryonic stem cells into oligodendrocyte progenitor cells in vitro.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25200136"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 307,
          "text": "Olig2 is a basic helix-loop-helix transcription factor that plays a critical role in the central nervous system. It directs the specification of motor neurons and oligodendrocyte precursor cells (OPCs) from neural progenitors and the subsequent maturation of OPCs into myelin-forming oligodendrocytes (OLs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36193754"
        },
        {
          "offsetInBeginSection": 1491,
          "offsetInEndSection": 1623,
          "text": "These findings support important roles for Sox17 in controlling both oligodendrocyte progenitor cell cycle exit and differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16988043"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Identification of Sox17 as a transcription factor that regulates oligodendrocyte development.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16988043"
        },
        {
          "offsetInBeginSection": 844,
          "offsetInEndSection": 1007,
          "text": "In cultured oligodendrocyte progenitor cells (OPCs), Sox17 levels were maximal in O4+ cells and peaked during the phenotypic conversion from bipolar to multipolar.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16988043"
        },
        {
          "offsetInBeginSection": 316,
          "offsetInEndSection": 446,
          "text": "Here, we identify the transcription factor Yin Yang 1 (YY1) as a critical regulator of oligodendrocyte progenitor differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17640524"
        },
        {
          "offsetInBeginSection": 335,
          "offsetInEndSection": 552,
          "text": "We show here that the SoxE transcription factors (comprising Sox8, 9, and 10) induce multipotent neural precursor cells (NPCs) from the early postnatal subventricular zone (SVZ) to become OPCs in an autonomous manner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21098272"
        },
        {
          "offsetInBeginSection": 700,
          "offsetInEndSection": 875,
          "text": "We show that the combination of the four transcription factors OLIG2, SOX10, ASCL1 and NKX2.2 is sufficient to convert HDFs to induced oligodendrocyte precursor cells (iOPCs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35748297"
        },
        {
          "offsetInBeginSection": 781,
          "offsetInEndSection": 947,
          "text": "OPCs and mature oligodendrocytes were identified as positive immunostaining for oligodendrocyte-lineage transcription factor 2 and myelin basic protein, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21403432"
        },
        {
          "offsetInBeginSection": 620,
          "offsetInEndSection": 735,
          "text": "Here, we report that gain of Sox17 function has no effect on oligodendrocyte progenitor cells (OPCs) specification.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/30152028/"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 403,
          "text": "The differentiation of OPCs requires the presence of Sox10, but its expression decreases under pathological conditions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38218078"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 308,
          "text": "During development, OPC differentiation is controlled by several transcription factors including Olig1 and Olig2, and Nkx2.2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15519240"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "The transcription factor Olig2 is highly expressed throughout oligodendroglial development and is needed for the differentiation of oligodendrocyte progenitor cells (OPCs) into oligodendrocytes and remyelination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38096960"
        },
        {
          "offsetInBeginSection": 581,
          "offsetInEndSection": 821,
          "text": "During the acute phase of demyelination, OPCs within the lesion increased their expression of Nkx2.2 and Olig2, two transcription factors that in combination are critical for oligodendrocyte differentiation during developmental myelination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15519240"
        },
        {
          "offsetInBeginSection": 492,
          "offsetInEndSection": 623,
          "text": "Olig1 gene, a transcription factor known to be involved in the induction of oligodendrocyte lineage formation during embryogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15536179"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 295,
          "text": "The Olig2 basic-helix-loop-helix transcription factor promotes oligodendrocyte specification in early neural progenitor cells (NPCs), including radial glial cells, in part by recruiting SWI/SNF chromatin remodeling complexes to the enhancers of genes involved in oligodendrocyte differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067865"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Sox10 is a well known factor to control oligodendrocyte (OL) differentiation, and its expression is regulated by Olig2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34385359/"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 354,
          "text": " Between specification and terminal differentiation, Sox9 and Sox10 are co-expressed in oligodendrocyte precursors and are believed to exert additional functions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18184726/"
        },
        {
          "offsetInBeginSection": 1337,
          "offsetInEndSection": 1494,
          "text": " We thus conclude that Sox9 and Sox10 are required in a functionally redundant manner in oligodendrocyte precursors for PDGF-dependent survival and migration",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18184726/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "The transcription factor Sox10 is an important determinant of oligodendroglial identity and influences oligodendroglial development and characteristics at various stages",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38995010"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 338,
          "text": "Oligodendrocyte development is a critical process timely and spatially regulated to ensure proper myelination of the central nervous system. HMG-box transcription factors are key regulators of oligodendrocyte lineage progression. Among these factors, Sox17 was previously identified as a positive regulator of oligodendrocyte development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30152028"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 321,
          "text": "The transcription factor THAP1 is essential for timing the inception of myelination during CNS maturation through a cell-autonomous role in the oligodendrocyte lineage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34312226"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "The transcription factors Olig2 and Sox10 jointly define oligodendroglial identity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34480425"
        },
        {
          "offsetInBeginSection": 823,
          "offsetInEndSection": 1048,
          "text": "FoxO3 constraint of OPC maturation was bHAf dependent, and involved interactions at the FoxO3 and MBP promoters with the chromatin remodeling factor Brg1 and the transcription factor Olig2, which regulate OPC differentiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29664021"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "OLIG2 is a transcription factor that activates the expression of myelin-associated genes in the oligodendrocyte-lineage cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35301318"
        },
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 597,
          "text": "The neuronal fate of some progenitor cells is sealed before birth as they become committed to the oligodendrocyte lineage, marked by sustained expression of the oligodendrocyte transcription factor Olig2, which represses the interneuron transcription factor Dlx2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33574458"
        },
        {
          "offsetInBeginSection": 662,
          "offsetInEndSection": 739,
          "text": "Olig2, an essential transcriptional regulator in oligodendrocyte development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23739972"
        },
        {
          "offsetInBeginSection": 458,
          "offsetInEndSection": 678,
          "text": " The oligodendrocyte lineage (OLIG) genes, transcriptional factors of the basic helix-loop-helix family, have been recently identified in oligodendrocyte progenitor cells (OPCs) in the CNS of developing and adult rodents",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12924709"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "The helix-loop-helix transcription factor Olig2 is essential for lineage determination of oligodendrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25966902"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 380,
          "text": "Human glioblastoma multiforme tumors often contain rapidly proliferating oligodendrocyte lineage transcription factor 2 (Olig2)-positive cells that resemble OPCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22865458"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 403,
          "text": "While the proneural factor achaete-scute complex-like 1 (Ascl1) is widely used for neuronal reprogramming, in the early postnatal mouse cortex, Ascl1 fails to induce the glia-to-neuron conversion, instead promoting the proliferation of oligodendrocyte progenitor cells (OPC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39454007"
        }
      ],
      "id": "67d9f6a418b1e36f2e000051",
      "ideal_answer": [
        "Oligodendrocyte progenitor cells (OPCs) are characterized by the following transcription factors: OLIG1/2, SOX10, NKX2.2 and ASCL1, which play an important role in the oligodendrogenic pathway and can be used to generate OPCs from human pluripotent stem cells.",
        "Oligodendrocyte progenitor cells are regulated by a network of transcription factors. Olig1 and Olig2 are predominantly expressed in early progenitors, where they help establish OPC identity and promote proliferation. As these cells progress through differentiation, transcription factors such as Sox10, Nkx2.2, and Myrf assume key roles in driving maturation and initiating myelination. Although Sox8 is sometimes mentioned, its role in the OPC lineage is less consistently reported and appears to be of secondary importance. Emerging factors like Ascl1 may also contribute to OPC lineage regulation, although additional research is necessary to fully clarify their roles.",
        "The key lineage transcription factors that regulate oligodendrocyte progenitor cell (OPC) specification and differentiation include SOX10, OLIG2, NKX2.2, and ASCL1. SOX10 appears to be the principal and rate-limiting regulator of myelinogenic fate from human neural progenitor cells.",
        "The key transcription factors involved in oligodendrocyte progenitor cell (OPC) lineage include OLIG2, ASCL1, SOX10, NKX2.2, and PAX6. These transcription factors play critical roles in the differentiation and specification of oligodendrocyte progenitor cells from neural stem cells, with each factor expressed at different stages of OPC development.",
        "The primary lineage transcription factors of oligodendrocyte progenitor cells (OPCs) are OLIG2, NKX2.2, and SOX10. OLIG2 is crucial in the oligodendrogenic pathway (expressed by day 12), NKX2.2 indicates OPC fate progression (around day 18), and SOX10 is the principal regulator of myelinogenic fate (expressed around day 40). Additionally, ASCL1 can induce OPC fate when overexpressed in neural progenitor cells, though it is less effective than SOX10 in promoting oligodendrocyte commitment. These factors play distinct roles at different stages of OPC development.",
        "The lineage transcription factors of oligodendrocyte progenitor cells (OPCs) include OLIG2, ASCL1, SOX10, and NKX2.2. These factors are crucial in the differentiation process from neural stem cells to OPCs. OLIG2 is central to the oligodendrogenic pathway, playing a key role in this lineage commitment. The overexpression of ASCL1, SOX10, and NKX2.2 has been shown to induce OPC fate from neural progenitor cells (NPCs). During differentiation, OLIG2 positive cells begin expressing NKX2.2 around day 18 and SOX10 by day 40, which are essential steps in the generation of OPCs from pluripotent stem cells.",
        "Studies have identified key lineage transcription factors involved in the development of oligodendrocyte progenitor cells (OPCs). Specifically, OLIG2 plays a crucial role in the oligodendrogenic pathway, while other important transcription factors include ASCL1, SOX10, and NKX2.2. The expression of these factors is temporally regulated, with OLIG2-positive cells emerging by day 12, followed by the expression of NKX2.2 around day 18, and SOX10 around day 40. The overexpression of ASCL1, SOX10, and NKX2.2 in neural progenitor cells (NPCs) is sufficient to induce OPC fate, highlighting the importance of these transcription factors in the generation of oligodendrocyte progenitor cells from human pluripotent stem cells.",
        "The lineage transcription factors critical for oligodendrocyte progenitor cells (OPCs) include OLIG2, ASCL1, SOX10, and NKX2.2. These factors are essential in the developmental pathway of OPCs, with OLIG2 playing a central role in the oligodendrogenic process. The overexpression of ASCL1, SOX10, and NKX2.2 has been shown to induce OPC fate, while OLIG2 expression marks progenitors as they differentiate into OPCs. Additionally, the sequential expression of NKX2.2 followed by SOX10 indicates their roles in later stages of OPC development.",
        "The lineage transcription factors of oligodendrocyte progenitor cells (OPCs) include:\n\n1. **OLIG2**: This is a central regulator in the oligodendrogenic pathway, crucial for directing the development of OPCs into mature oligodendrocytes.\n\n2. **ASCL1**: Involved in directing neural progenitors towards an OPC fate, ASCL1 plays a role upstream in specifying the OPC lineage.\n\n3. **NKX2.2**: Expressed later in the differentiation process, NKX2.2 is involved in further specification of the OPC lineage following OLIG2 expression.\n\n4. **SOX10**: Also expressed later, SOX10 contributes to the specification and maintenance of the OPC lineage.\n\nThese transcription factors work together in a temporal sequence to regulate the development and specification of OPCs into oligodendrocytes.",
        "The lineage transcription factors of oligodendrocyte progenitor cells (OPCs) include:\n\n1. **OLIG2**: This is a central regulator in the oligodendrogenic pathway, crucial for directing the development of OPCs into mature oligodendrocytes.\n\n2. **ASCL1**: Involved in directing neural progenitors towards an OPC fate, ASCL1 plays a role upstream in the lineage specification process.\n\n3. **NKX2.2**: Expressed later in the differentiation timeline, NKX2.2 is involved in further specifying the OPC lineage and maturation.\n\n4. **SOX10**: Also expressed later, SOX10 contributes to the specification and maintenance of the OPC lineage.\n\nThese transcription factors work together in a temporal sequence to regulate the development and specification of OPCs into oligodendrocytes.",
        "The key transcription factors driving OPC specification are OLIG2, NKX2.2, and SOX10. OLIG2 is expressed early in the differentiation process, initiating the oligodendrocyte lineage, while NKX2.2 and later SOX10 support further lineage development. Experimental evidence also shows that overexpression of ASCL1, when combined with NKX2.2 and SOX10, can induce an OPC fate in neural progenitor cells, highlighting its role in promoting OPC characteristics even though it is not classically considered an endogenous OPC marker.",
        "The lineage transcription factors for oligodendrocyte progenitor cells (OPCs) are crucial in regulating their development into mature oligodendrocytes. Based on the provided documents, the key transcription factors involved include:\n\n1. **OLIG2**: This is a central regulator early in the oligodendrogenic pathway, playing a significant role in determining OPC lineage.\n\n2. **ASCL1**: Involved in initiating the differentiation process of neural progenitor cells (NPCs) into OPCs.\n\n3. **SOX10**: Appears later in the differentiation timeline, contributing to the maturation of OPCs towards oligodendrocytes.\n\n4. **NKX2.2**: Follows OLIG2 and is expressed as the cells progress towards becoming mature oligodendrocytes.\n\nThese transcription factors collectively guide the development and lineage specification of OPCs into functional oligodendrocytes, essential for myelin formation in the central nervous system.",
        "The lineage transcription factors for oligodendrocyte progenitor cells (OPCs) include OLIG2, ASCL1, SOX10, and NKX2.2. These factors play distinct roles in the differentiation process:\n\n1. **OLIG2**: Acts as a central regulator early in the oligodendrogenic pathway, crucial for initiating OPC development.\n\n2. **ASCL1**: Helps initiate the differentiation of neural progenitor cells (NPCs) into OPCs through overexpression.\n\n3. **NKX2.2**: Becomes active later in the process, around day 18, contributing to the maturation of OPCs towards oligodendrocytes.\n\n4. **SOX10**: Follows NKX2.2, appearing around day 40, and is involved in further differentiation steps.\n\nThese transcription factors likely work together in a regulatory network, driving the progression from progenitor cells to mature oligodendrocytes through a stepwise cascade of gene expression.",
        "The lineage transcription factors of oligodendrocyte progenitor cells (OPCs) include:\n\n1. **OLIG2**: A key regulator in the oligodendrogenic pathway, playing a crucial role in the development and differentiation of OPCs into mature oligodendrocytes.\n\n2. **ASCL1**: Involved in driving the differentiation of neural progenitor cells (NPCs) into OPCs, contributing to the early stages of OPC lineage commitment.\n\n3. **SOX10**: Expressed later in the maturation process of OPCs, playing a role in maintaining their identity and guiding further differentiation.\n\n4. **NKX2.2**: Another important transcription factor that is expressed during the differentiation of OPCs, contributing to their development into mature oligodendrocytes.\n\nThese transcription factors work together to regulate the differentiation and maturation processes of OPCs, ensuring proper development within the central nervous system.",
        "The lineage transcription factors of oligodendrocyte progenitor cells (OPCs) include OLIG2, NKX2.2, and SOX10. These transcription factors play crucial roles in the oligodendrogenic pathway, regulating the development and differentiation of OPCs from neural stem cells. OLIG2 is a key transcription factor in the oligodendrocyte lineage, while NKX2.2 and SOX10 are also essential for OPC specification and maturation. Additionally, other transcription factors such as ASCL1 may also be involved in inducing OPC fate. These transcription factors work together to regulate the expression of genes necessary for OPC development and function.",
        "The lineage transcription factors of oligodendrocyte progenitor cells (OPCs) are ASCL1, SOX10, NKX2.2, and OLIG2. These factors play crucial roles in OPC specification and differentiation. Notably, SOX10 significantly promotes oligodendrocyte commitment, while OLIG2 directs the differentiation of stem cells towards OPCs. The sequential expression of NKX2.2 and SOX10 is key in differentiating pluripotent stem cells into OPCs. Understanding these transcription factors is vital for elucidating oligodendrocyte development and developing cell-based therapies for demyelinating diseases.",
        "The key lineage transcription factors for OPCs include ASCL1, SOX10, NKX2.2, and OLIG2. These factors are crucial at various stages of differentiation: ASCL1, SOX10, and NKX2.2 drive the initial induction of OPC fate from neural progenitor cells, while OLIG2 marks the progression towards oligodendrogenesis as cells develop into OPCs.",
        "The lineage transcription factors of oligodendrocyte progenitor cells (OPCs) include OLIG2 (Oligodendrocyte lineage transcription factor 2), which plays an important role in the oligodendrogenic pathway. Additionally, NKX2.2, SOX10, and ASCL1 are critical transcription factors involved in OPC fate determination. During development, PAX6-positive neural stem cells give rise to OLIG2-positive progenitors, which then begin to express NKX2.2 followed by SOX10 as they progress toward the OPC lineage. Lentiviral overexpression of ASCL1, SOX10, and NKX2.2 in neural progenitor cells has been shown to be sufficient to induce OPC fate.",
        "The lineage transcription factors of oligodendrocyte progenitor cells (OPCs) are OLIG2, NKX2.2, SOX10, and ASCL1. These factors play pivotal roles in OPC specification and differentiation, with OLIG2 (expressed by day 12) directing stem cell differentiation, NKX2.2 (day 18) involved in sequential OPC development, and SOX10 (day 40) being crucial for oligodendrocyte commitment and myelinogenesis. ASCL1 can also induce OPC fate upon overexpression, albeit with variable efficacy. Their therapeutic potential lies in treating demyelinating diseases and facilitating nerve regeneration through induced OPC fate in neural stem/progenitor cells.",
        "The key transcription factors involved in oligodendrocyte progenitor cell (OPC) lineage include OLIG2, which plays an important role in the oligodendrogenic pathway, followed by NKX2.2 and SOX10 expression during development. Additionally, ASCL1 has been identified as another crucial transcription factor that, together with SOX10 and NKX2.2, can induce OPC fate."
      ],
      "exact_answer": [
        [
          "OLIG1/2",
          "Oligodendrocyte lineage transcription factor 2",
          "Olig1",
          "Olig2",
          "OLIG2",
          "Oligodendrocyte lineage transcription factor 2 (OLIG2)"
        ],
        [
          "SOX10",
          "SRY-box 10",
          "SRY-box 10 (SOX10)",
          "Sox10"
        ],
        [
          "NKX2.2",
          "Nkx2.2",
          "Nkx2-2"
        ],
        [
          "ASCL1",
          "Ascl1"
        ],
        [
          "SOX9",
          "Sox9"
        ],
        [
          "SOX17"
        ]
      ]
    },
    {
      "body": "Data from which clinical trials have been used to demonstrate use of knowledge graphs for NSCLC survival prediction?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39103897"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 716,
          "offsetInEndSection": 1413,
          "text": "We introduce a methodology for incorporating prior knowledge into machine learning-based models for prediction of patient survival through Knowledge Graphs, demonstrating the advantage of such an approach for NSCLC patients. Using data from patients treated with immuno-oncologic therapies in the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, we found that the use of knowledge graphs yielded significantly improved hazard ratios, including in the POPLAR cohort, for models based on biomarker tumor mutation burden compared with those based on knowledge graphs. Use of a model-defined mutational 10-gene signature led to significant overall survival differentiation for both trials. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39103897"
        }
      ],
      "id": "67d7531018b1e36f2e000041",
      "ideal_answer": [
        "POPLAR (NCT01903993) and OAK (NCT02008227)",
        "The clinical trials POPLAR (NCT01903993) and OAK (NCT02008227) were used to demonstrate the use of knowledge graphs for survival prediction in non-small cell lung cancer (NSCLC) patients.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, which involved immuno-oncologic therapies for Non-Small Cell Lung Cancer (NSCLC), have been used to demonstrate the effectiveness of knowledge graphs in survival prediction. Notably, integrating these graphs into machine learning models significantly improved hazard ratios, especially in those based on biomarker tumor mutation burden, and a defined 10-gene signature showed promise in overall survival differentiation, highlighting the potential of this approach for accurate NSCLC survival prediction.",
        "The clinical trials POPLAR (NCT01903993) and OAK (NCT02008227) provided the data to demonstrate the use of knowledge graphs for improving hazard ratios in NSCLC survival prediction.",
        "The use of knowledge graphs for NSCLC (non-small cell lung cancer) survival prediction has been demonstrated using data from the following clinical trials:\n\n1. POPLAR (NCT01903993)\n2. OAK (NCT02008227)\n\nThese trials showed that knowledge graphs significantly improve hazard ratios for NSCLC survival prediction compared to models based on biomarker tumor mutation burden. This information is based on clinical trial data analysis.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials have been used to demonstrate the use of knowledge graphs for NSCLC survival prediction.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials have been used to demonstrate the use of knowledge graphs for NSCLC survival prediction. These trials, which involved patients treated with immuno-oncologic therapies, showed that the use of knowledge graphs improved the hazard ratios, especially in the POPLAR cohort, for models based on biomarker tumor mutation burden.",
        "Data from the following clinical trials have been used to demonstrate the use of knowledge graphs for NSCLC survival prediction: POPLAR (NCT01903993) and OAK (NCT02008227).",
        "The POPLAR and OAK clinical trials provided data for demonstrating the use of knowledge graphs in NSCLC survival prediction.",
        "Data from patients with NSCLC treated with immuno-oncologic therapies in the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials were used to demonstrate that knowledge graphs can enhance survival prediction.",
        "The clinical trials used to demonstrate the application of knowledge graphs for predicting survival in non-small cell lung cancer (NSCLC) patients treated with immuno-oncologic therapies are POPLAR (NCT01903993) and OAK (NCT02008227). These studies provided data that showed the enhanced predictive capabilities of knowledge graphs compared to traditional biomarker models, such as those based on tumor mutation burden. The integration of diverse data through knowledge graphs improved hazard ratio predictions in these trials, highlighting their utility in advancing survival prediction models for NSCLC patients undergoing immunotherapy.",
        "The clinical trials POPLAR (NCT01903993) and OAK (NCT02008227) were utilized to demonstrate the use of knowledge graphs in predicting survival outcomes for patients with non-small cell lung cancer (NSCLC) treated with immuno-oncologic therapies. These trials provided data on patients receiving immunotherapy, which was integrated into knowledge graphs to enhance predictive models. The knowledge graphs allowed for a more comprehensive analysis by incorporating various data points beyond traditional biomarkers, leading to improved hazard ratio estimates compared to models based solely on tumor mutation burden. This approach highlighted the potential of integrating diverse datasets to refine survival predictions in NSCLC treatment.",
        "Data from POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials have been used to demonstrate use of knowledge graphs for NSCLC survival prediction.",
        "Data from the following clinical trials have been used to demonstrate knowledge graphs for NSCLC survival prediction: POPLAR (NCT01903993) and OAK (NCT02008227).",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, involving patients treated with immuno-oncologic therapies, have been used to demonstrate the effectiveness of knowledge graphs in Non-Small Cell Lung Cancer (NSCLC) survival prediction. The integration of knowledge graphs into machine learning models yielded significantly improved hazard ratios, particularly in the POPLAR cohort for models based on tumor mutation burden. Notably, this approach also identified a consistent 10-gene signature associated with overall survival differentiation, highlighting its potential for personalized medicine and biomarker discovery, with the methodology made available for broader scientific application.",
        "The clinical trials used to demonstrate the use of knowledge graphs for Non-Small Cell Lung Cancer (NSCLC) survival prediction are the POPLAR (NCT01903993) and OAK (NCT02008227) trials. These trials involved patients treated with immuno-oncologic therapies, and the integration of knowledge graphs into machine learning models showed significantly improved hazard ratios compared to models based solely on biomarkers such as tumor mutation burden. This approach also led to the identification of a 10-gene signature that was associated with overall survival differentiation in both trials. The methodology and code for incorporating knowledge graphs into survival analyses have been made available for the wider scientific community.",
        "The data used to demonstrate the use of knowledge graphs for NSCLC survival prediction came from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials of patients treated with immuno-oncologic therapies.",
        "The data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials on patients treated with immuno-oncologic therapies has been used to demonstrate the use of knowledge graphs for survival prediction in non-small-cell lung cancer (NSCLC) patients.",
        "POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials.",
        "The data used to demonstrate the use of knowledge graphs for NSCLC survival prediction came from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, which involved patients treated with immuno-oncologic therapies.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, focusing on immuno-oncologic therapies for Non-Small Cell Lung Cancer (NSCLC), have been utilized to demonstrate the effectiveness of knowledge graphs in survival prediction. This approach improved hazard ratios, particularly with tumor mutation burden models in the POPLAR cohort, and identified a promising 10-gene signature for overall survival differentiation, showcasing potential for enhanced NSCLC survival prediction, personalized medicine, and biomarker discovery.",
        "Data from the following clinical trials have been used to demonstrate the use of knowledge graphs for NSCLC (Non-Small Cell Lung Cancer) survival prediction:\n\n1. POPLAR (NCT01903993)\n2. OAK (NCT02008227)\n\nThese trials showed that knowledge graphs significantly improved hazard ratios in machine learning-based models for predicting survival in NSCLC patients.",
        "The study used data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials to demonstrate the effectiveness of knowledge graphs in predicting NSCLC patient survival.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials have been utilized to demonstrate the effectiveness of knowledge graphs in predicting survival outcomes for non-small cell lung cancer (NSCLC) patients. These studies found that models based on knowledge graphs yielded significantly improved hazard ratios compared to those based on biomarker tumor mutation burden, highlighting the potential benefits of incorporating knowledge graphs into NSCLC survival prediction. Additionally, other clinical trials such as Ren\u0027s research data (NCT03513666) have also been used to verify the predictive value of certain genes in ICIs treatment for EGFR-mutant NSCLC population, further showcasing the application of clinical trial data in improving NSCLC survival prediction.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials was used to demonstrate the use of knowledge graphs for NSCLC survival prediction.",
        "Data from patients treated with immuno-oncologic therapies in the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials have been used to demonstrate use of knowledge graphs for NSCLC survival prediction.",
        "The study used data from two clinical trials: the POPLAR (NCT01903993) and OAK (NCT02008227) trials, which involved patients treated with immuno-oncologic therapies for non-small cell lung cancer (NSCLC).",
        "The clinical trials used to demonstrate the application of knowledge graphs for NSCLC survival prediction were POPLAR (NCT01903993) and OAK (NCT02008227). These trials involved patients treated with immuno oncologic therapies, and the study utilized data from these cohorts to evaluate the effectiveness of knowledge graph based models in improving hazard ratios and overall survival differentiation.",
        "The clinical trials used to demonstrate the use of knowledge graphs for Non-Small Cell Lung Cancer (NSCLC) survival prediction are POPLAR (NCT01903993) and OAK (NCT02008227), both of which specifically involved patients treated with immuno-oncologic therapies, providing a focused context for the application of knowledge graphs in predicting survival outcomes for NSCLC patients.",
        "The data used to demonstrate the application of knowledge graphs for NSCLC (Non Small Cell Lung Cancer) survival prediction were derived from two clinical trials: the POPLAR trial (NCT01903993) and the OAK trial (NCT02008227). These trials focused on patients treated with immuno oncologic therapies. The methodology incorporated prior knowledge through Knowledge Graphs to enhance the prediction of patient survival, particularly in the POPLAR cohort, by improving hazard ratios compared to models based solely on biomarker tumor mutation burden. Additionally, a model defined mutational 10 gene signature was developed, which showed significant overall survival differentiation across both trials.",
        "The use of knowledge graphs for predicting patient survival in NSCLC has been demonstrated using data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials. These studies provided the necessary data to showcase the advantage of incorporating prior knowledge into machine learning-based models, particularly when compared to traditional biomarker-based approaches. The results highlighted the effectiveness of knowledge graphs in improving hazard ratios, including in the POPLAR cohort, and also led to significant overall survival differentiation for both trials through the use of a model-defined mutational 10-gene signature.",
        "The data utilized to demonstrate the use of knowledge graphs for improving non-small cell lung cancer (NSCLC) patient survival prediction came from two clinical trials: POPLAR (NCT01903993) and OAK (NCT02008227). These trials involved patients treated with immuno-oncologic therapies, and the integration of knowledge graphs showed improved hazard ratios, particularly in the POPLAR cohort when using biomarker tumor mutation burden.",
        "The clinical trials used to demonstrate the application of knowledge graphs for NSCLC survival prediction were POPLAR (NCT01903993) and OAK (NCT02008227). These studies provided data that helped evaluate the effectiveness of knowledge graph based models in improving patient survival predictions, particularly when combined with biomarker tumor mutation burden. The use of a model defined mutational 10 gene signature further enhanced overall survival differentiation across both trials.",
        "Data from the POPLAR and OAK clinical trials are used to demonstrate the use of knowledge graphs for NSCLC survival prediction.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials were used to demonstrate the use of knowledge graphs for NSCLC survival prediction.",
        "Data from the POPLAR (NCT01903993) and OAK clinical trials have been used to demonstrate use of knowledge graphs for NSCLC survival prediction.",
        "The methodology for incorporating prior knowledge into machine learning-based models for predicting patient survival in NSCLC through Knowledge Graphs has been demonstrated using data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials. These trials involved patients treated with immuno-oncologic therapies. The study showed that the use of knowledge graphs significantly improved hazard ratios, particularly in the POPLAR cohort, when compared to models based solely on biomarker tumor mutation burden. Additionally, a model-defined mutational 10-gene signature was found to significantly differentiate overall survival in both trials.",
        "The clinical trials were the POPLAR (NCT01903993) and OAK (NCT02008227) studies, which involved NSCLC patients treated with immuno-oncologic therapies.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials were used. These trials involved patients treated with immuno-oncologic therapies. The study demonstrated the use of knowledge graphs for NSCLC survival prediction.",
        "The data used to demonstrate the use of knowledge graphs for NSCLC survival prediction came from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, involving patients treated with immuno-oncologic therapies, have been used to demonstrate the use of knowledge graphs for NSCLC survival prediction. The study found that knowledge graphs yielded improved hazard ratios in predicting patient survival, particularly when compared to models based on tumor mutation burden.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials were utilized to demonstrate the effectiveness of incorporating prior knowledge into machine learning models using Knowledge Graphs for predicting patient survival in NSCLC. The methodology showed improved hazard ratios, particularly with biomarker tumor mutation burden-based models, and a model-defined mutational 10-gene signature significantly differentiated overall survival in both trials.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials were used to demonstrate the use of knowledge graphs for predicting survival in NSCLC patients.",
        "The data from POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials have been used to demonstrate the use of knowledge graphs for NSCLC survival prediction.",
        "Data from the following clinical trials support the use of knowledge graphs for NSCLC survival prediction: POPLAR (NCT01903993) and OAK (NCT02008227).",
        "Data from the following clinical trials have demonstrated the use of knowledge graphs for NSCLC survival prediction: POPLAR (NCT01903993) and OAK (NCT02008227).",
        "The POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, involving patients treated with immuno-oncologic therapies for Non-Small Cell Lung Cancer (NSCLC), have been used to demonstrate the efficacy of knowledge graphs in survival prediction. By integrating prior knowledge into machine learning models, these trials showed significantly improved hazard ratios compared to traditional biomarker-based models, such as tumor mutation burden. Notably, a model-defined mutational 10-gene signature was identified to significantly differentiate overall survival in both cohorts, highlighting the potential of knowledge graphs in enhancing NSCLC survival prediction and biomarker discovery.",
        "The methodology for incorporating prior knowledge into machine learning-based models for predicting patient survival through Knowledge Graphs was demonstrated using data from two clinical trials: POPLAR (NCT01903993) and OAK (NCT02008227). These trials involved patients treated with immuno-oncologic therapies, and the use of knowledge graphs showed significantly improved hazard ratios, particularly in the POPLAR cohort. The study highlighted the effectiveness of knowledge graphs in enhancing survival prediction models, especially when compared to models based solely on biomarker tumor mutation burden. Additionally, the use of a model-defined mutational 10-gene signature led to significant overall survival differentiation in both trials.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, which involved immuno-oncologic therapies for Non-Small Cell Lung Cancer (NSCLC) patients, have been utilized to demonstrate the application of knowledge graphs in predicting NSCLC survival.",
        "The methodology for incorporating prior knowledge into machine learning based models for predicting patient survival in NSCLC was demonstrated using data from two clinical trials: POPLAR (NCT01903993) and OAK (NCT02008227). These trials focused on patients treated with immuno oncologic therapies, and the use of knowledge graphs improved hazard ratios compared to models based solely on biomarker tumor mutation burden. Additionally, a model defined mutational 10 gene signature was utilized to differentiate overall survival in both trials.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials have been used to demonstrate the use of knowledge graphs for NSCLC survival prediction. The use of knowledge graphs yielded significantly improved hazard ratios in the POPLAR cohort. A model-defined mutational 10-gene signature led to significant overall survival differentiation for both trials.",
        "The studies utilized to demonstrate the use of knowledge graphs for NSCLC survival prediction are the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials. These trials involved patients treated with immuno-oncologic therapies, providing data that showed improved hazard ratios through the application of knowledge graphs compared to models based on tumor mutation burden alone.",
        "The data from two clinical trials have been used to demonstrate the use of knowledge graphs for NSCLC survival prediction: POPLAR (NCT01903993) and OAK (NCT02008227).",
        "The POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, focusing on NSCLC patients treated with immuno-oncologic therapies, have been utilized to demonstrate the application of knowledge graphs in predicting survival. Notably, integrating knowledge graphs into machine learning models in these trials showed improved hazard ratios, outperforming traditional biomarker-based models, and identified a significant 10-gene mutational signature associated with overall survival, underscoring their potential in enhancing NSCLC survival prediction and biomarker discovery.",
        "The knowledge graphs were demonstrated using data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials.",
        "Data from POPLAR (NCT01903993) and OAK clinical trials have been used to demonstrate use of knowledge graphs for NSCLC survival prediction.",
        "Knowledge graphs have been used to demonstrate use of knowledge graphs for NSCLC survival prediction. Data from patients treated with immuno-oncologic therapies in the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials have been used.",
        "Data from the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials, which involved patients treated with immuno-oncologic therapies, were used to demonstrate the application of knowledge graphs in predicting NSCLC patient survival.",
        "The data utilized to demonstrate the use of knowledge graphs for non-small cell lung cancer (NSCLC) survival prediction were derived from patients treated with immuno-oncologic therapies in the POPLAR (NCT01903993) and OAK (NCT02008227) clinical trials."
      ],
      "exact_answer": [
        [
          "POPLAR (NCT01903993)"
        ],
        [
          "OAK (NCT02008227)"
        ]
      ]
    },
    {
      "body": "What are the colorectal surgical options for patients with Familial Polyposis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25469031",
        "http://www.ncbi.nlm.nih.gov/pubmed/8607012",
        "http://www.ncbi.nlm.nih.gov/pubmed/38617844",
        "http://www.ncbi.nlm.nih.gov/pubmed/27418167",
        "http://www.ncbi.nlm.nih.gov/pubmed/24394009",
        "http://www.ncbi.nlm.nih.gov/pubmed/30192330",
        "http://www.ncbi.nlm.nih.gov/pubmed/19617764",
        "http://www.ncbi.nlm.nih.gov/pubmed/23875116",
        "http://www.ncbi.nlm.nih.gov/pubmed/31583304",
        "http://www.ncbi.nlm.nih.gov/pubmed/24714154",
        "http://www.ncbi.nlm.nih.gov/pubmed/15666113",
        "http://www.ncbi.nlm.nih.gov/pubmed/19793576",
        "http://www.ncbi.nlm.nih.gov/pubmed/1847273",
        "http://www.ncbi.nlm.nih.gov/pubmed/8829326",
        "http://www.ncbi.nlm.nih.gov/pubmed/23730222",
        "http://www.ncbi.nlm.nih.gov/pubmed/10756751",
        "http://www.ncbi.nlm.nih.gov/pubmed/20233459",
        "http://www.ncbi.nlm.nih.gov/pubmed/39520507",
        "http://www.ncbi.nlm.nih.gov/pubmed/25305601",
        "http://www.ncbi.nlm.nih.gov/pubmed/8813770",
        "http://www.ncbi.nlm.nih.gov/pubmed/37688717",
        "http://www.ncbi.nlm.nih.gov/pubmed/37600856",
        "http://www.ncbi.nlm.nih.gov/pubmed/29324375",
        "http://www.ncbi.nlm.nih.gov/pubmed/25504366",
        "http://www.ncbi.nlm.nih.gov/pubmed/31777463",
        "http://www.ncbi.nlm.nih.gov/pubmed/1337641",
        "http://www.ncbi.nlm.nih.gov/pubmed/34416186",
        "http://www.ncbi.nlm.nih.gov/pubmed/8948806",
        "http://www.ncbi.nlm.nih.gov/pubmed/12410125",
        "http://www.ncbi.nlm.nih.gov/pubmed/22874600",
        "http://www.ncbi.nlm.nih.gov/pubmed/11454800",
        "http://www.ncbi.nlm.nih.gov/pubmed/33729170",
        "http://www.ncbi.nlm.nih.gov/pubmed/9194461",
        "https://pubmed.ncbi.nlm.nih.gov/11454800/",
        "https://pubmed.ncbi.nlm.nih.gov/31777463/",
        "https://pubmed.ncbi.nlm.nih.gov/12972960/",
        "https://pubmed.ncbi.nlm.nih.gov/39520507/",
        "https://pubmed.ncbi.nlm.nih.gov/9445111/",
        "https://pubmed.ncbi.nlm.nih.gov/19617764/",
        "http://www.ncbi.nlm.nih.gov/pubmed/17368237",
        "http://www.ncbi.nlm.nih.gov/pubmed/17611924",
        "http://www.ncbi.nlm.nih.gov/pubmed/10756821",
        "http://www.ncbi.nlm.nih.gov/pubmed/9931897",
        "http://www.ncbi.nlm.nih.gov/pubmed/12425165",
        "http://www.ncbi.nlm.nih.gov/pubmed/2551351",
        "http://www.ncbi.nlm.nih.gov/pubmed/22103049",
        "http://www.ncbi.nlm.nih.gov/pubmed/39404860",
        "http://www.ncbi.nlm.nih.gov/pubmed/39333043",
        "http://www.ncbi.nlm.nih.gov/pubmed/15592657",
        "http://www.ncbi.nlm.nih.gov/pubmed/24597363",
        "http://www.ncbi.nlm.nih.gov/pubmed/14719160",
        "http://www.ncbi.nlm.nih.gov/pubmed/10955728",
        "http://www.ncbi.nlm.nih.gov/pubmed/22103050",
        "http://www.ncbi.nlm.nih.gov/pubmed/20664317"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 646,
          "offsetInEndSection": 816,
          "text": "Preferably, the decision-making process should not be limited to the conventional confrontation of pros and cons of ileorectal anastomosis or restorative proctocolectomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25469031"
        },
        {
          "offsetInBeginSection": 330,
          "offsetInEndSection": 519,
          "text": "Surgical options include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8607012"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 523,
          "text": "The surgical treatment of colorectal disease in FAP, which has the goal of colorectal cancer prevention, varies based on both patient and disease factors but can include the following: total colectomy with ileorectal anastomosis, proctocolectomy with stapled or hand-sewn ileal pouch-anal anastomosis, or total proctocolectomy with end ileostomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38617844"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 59,
          "text": "Surgical Decision-Making in Familial Adenomatous Polyposis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38617844"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Therapeutic approaches for patients with coexisting familial adenomatous polyposis and colorectal cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27418167"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "[Strategy for surgery in familial adenomatous polyposis patients with invasive colorectal cancer].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24394009"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "The evolution of prophylactic colorectal surgery for familial adenomatous polyposis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19617764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 52,
          "text": "Surgical options for familial adenomatous polyposis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8607012"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 357,
          "text": "As prophylactic treatment, proctocolectomy with ileal pouch-anal anastomosis remains the surgical treatment of choice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31583304"
        },
        {
          "offsetInBeginSection": 275,
          "offsetInEndSection": 569,
          "text": "The type and extent of surgical resection in familial adenomatous polyposis (FAP) and in the Lynch syndrome is influenced by differences in the natural history of carcinogenesis between the two syndromes and by the effectiveness of and patient compliance with available surveillance strategies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19793576"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "There are 3 surgical options for patients who have familial adenomatous polyposis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1847273"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "The purpose of this article is to discuss the advantages and disadvantages of surgical procedures designed to eliminate the risk of colorectal cancer, the surgical treatment of extracolonic polyps, and the management of desmoid tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8829326"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Surgical management of familial adenomatous polyposis (FAP) is complex and requires both sound judgment and technical skills.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23730222"
        },
        {
          "offsetInBeginSection": 524,
          "offsetInEndSection": 700,
          "text": "The operative options and extent of resection, as well as the use of endoscopy and chemoprevention for the management of polyposis, will be discussed in detail in this article.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38617844"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 162,
          "text": "Total colectomy with ileorectal anastomosis (TC/IRA) is one of the prophylactic surgical options in patients with familial adenomatous polyposis (FAP)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37688717"
        },
        {
          "offsetInBeginSection": 353,
          "offsetInEndSection": 553,
          "text": "Provided that there are a variety of surgical options available to treat colorectal polyps in patients with adenomatous polyposis, the appropriate surgical option for each patient should be considered",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37600856"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Prophylactic surgical options for familial adenomatous polyposis (FAP) are either colectomy and ileorectal anastomosis (IRA) or proctocolectomy and ileal pouch-anal anastomosis (IPAA)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25504366"
        },
        {
          "offsetInBeginSection": 508,
          "offsetInEndSection": 829,
          "text": "There are several surgical options for the treatment of colorectal polyps in patients with adenomatous polyposis, so it is important to choose the appropriate procedure for each patient after discussing the risk of cancer in the rectal remnant, as well as bowel and sexual function in a predominantly young patient group.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31777463"
        },
        {
          "offsetInBeginSection": 1025,
          "offsetInEndSection": 1319,
          "text": "Restorative proctocolectomy with ileal reservoir is another major advance. This procedure is now regarded as the treatment of choice for patients with FAP because radical removal of all premalignant colorectal mucosa eliminates the risk of subsequent development of a colorectal adenocarcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1337641"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 405,
          "text": "Restorative proctocolectomy with ileal pouch-anal anastomosis is an option for most patients with ulcerative colitis or familial adenomatous polyposis who require colectomy. Although the construction of an ileal pouch substantially improves patients\u0027 health-related quality of life, the surgery is, directly or indirectly, associated with various structural, inflammatory, and functional adverse sequelae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34416186"
        },
        {
          "offsetInBeginSection": 1353,
          "offsetInEndSection": 1620,
          "text": "Anorectal eversion may be used in the surgical treatment of FAP, chronic ulcerative colitis and early stage distal rectal cancer patients.CONCLUSION: J-pouch ileoanal anastomosis can safely be performed by rectal eversion and double stapler technique in FAP patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25305601"
        },
        {
          "offsetInBeginSection": 520,
          "offsetInEndSection": 751,
          "text": "Many diverse factors, such as extent of rectal disease, the presence and extend of carcinoma, sphincter function, and extracolonic disease, influence which surgical procedure is most appropriate for the individual patient with FAP.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8607012"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "The surgical options for treating the large bowel component of familial adenomatous polyposis are total proctocolectomy, colectomy with ileorectal anastomosis, and restorative proctocolectomy, with or without mucosectomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8813770"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 54,
          "text": "Choice of operation in familial adenomatous polyposis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1847273"
        },
        {
          "offsetInBeginSection": 419,
          "offsetInEndSection": 909,
          "text": "Subtotal Colectomy with ileorectal anastomosis is a well-tolerated procedure with quite acceptable functional results, but the need for eventual proctectomy is about 30% at 20 years and the risk of rectal cancer is about 10% at 20 years even with close endoscopic surveillance. Total colectomy with ileal pouch-anal anastomosis is therefore the intervention of choice since it eliminates the risk of late rectal carcinoma albeit with more serious morbidity and less good functional results.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12410125"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 172,
          "text": " Restorative proctocolectomy with IPAA is an optimal surgical treatment for patients with familial adenomatous polyposis and therapy resistant ulcerative colitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22874600"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "In the beginning there was colectomy: current surgical options in familial adenomatous polyposis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20233459"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 351,
          "text": "In recent years two surgical options are available for the treatment of FAP: total colectomy with ileorectal anastomosis and restorative proctocolectomy with ileoanal reservoir.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8948806"
        },
        {
          "offsetInBeginSection": 755,
          "offsetInEndSection": 1074,
          "text": "the prepouch era, 97% (66 of 68) of all surgeries and 100% of restorative surgeries were ileorectal anastomosis. After 1983, 70% (54 of 77) of patients with a severe phenotype had an ileal pouch-anal anastomosis. After 1991, 110 operations (43%) were laparoscopic (88 ileorectal and 22 ileal pouch-anal anastomosis).CON",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19617764"
        },
        {
          "offsetInBeginSection": 796,
          "offsetInEndSection": 992,
          "text": "rmined utilities for 3 procedures used for prophylaxis, including total proctocolectomy with permanent ileostomy, colectomy with ileorectal anastomosis, and total proctocolectomy with IPAA. We als",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30192330"
        },
        {
          "offsetInBeginSection": 548,
          "offsetInEndSection": 786,
          "text": "Colectomy with ileorectal anastomosis remains an appropriate prophylactic procedure in many patients. However, in those with high-density polyposis or a genotype predictive of aggressive disease, restorative proctocolectomy is preferable.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24714154"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "text": "BACKGROUND AND AIMS: The choice of colorectal surgery in patients with familial adenomatous polyposis lies between the morbidity of proctocolectomy and ileum-pouch-anal anastomosis (IPAA) and the mortality from rectal cancer after total colectomy and ileorect",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11454800"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "INTRODUCTION: Over the past 50 years, prophylactic colorectal surgery for patients with familial adenomatous polyposis has evolved as new technologies and ideas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19617764"
        },
        {
          "offsetInBeginSection": 1042,
          "offsetInEndSection": 1192,
          "text": "leal pouch-anal anastomosis).CONCLUSION: Colon surgery for familial adenomatous polyposis has evolved as advances in surgical technique have created m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19617764"
        },
        {
          "offsetInBeginSection": 666,
          "offsetInEndSection": 828,
          "text": "nts had colorectal cancer. The most common procedure for familial adenomatous polyposis was restorative proctocolectomy with ileal pouch anal anastomosis, irrespe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27418167"
        },
        {
          "offsetInBeginSection": 243,
          "offsetInEndSection": 426,
          "text": "Both patient factors and disease characteristics influence surgical decision-making regarding the timing of prophylactic surgery, the extent of resection, and types of reconstruction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23730222"
        },
        {
          "offsetInBeginSection": 1193,
          "offsetInEndSection": 1323,
          "text": "re options to reduce the risk of cancer. Current strategy uses polyposis severity and distribution to decide on the surgical optio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19617764"
        },
        {
          "offsetInBeginSection": 33,
          "offsetInEndSection": 248,
          "text": "Proctocolectomy with ileal pouch-anal anastomosis is the gold standard in the surgical treatment of patients with ulcerative colitis, familial adenomatous polyposis and other colorectal diseases requiring colectomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33729170"
        },
        {
          "offsetInBeginSection": 752,
          "offsetInEndSection": 895,
          "text": "This article reviews the surgical options for treating FAP, with emphasis on specific indications, contraindications, and anticipated outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8607012"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "BACKGROUND AND AIMS: The choice of colorectal surgery in patients with familial adenomatous polyposis lies between the morbidity of proctocolectomy and ileum-pouch-anal ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/11454800/"
        },
        {
          "offsetInBeginSection": 508,
          "offsetInEndSection": 664,
          "text": "There are several surgical options for the treatment of colorectal polyps in patients with adenomatous polyposis, so it is important to choose the appropria",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/31777463/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "INTRODUCTION: Restorative proctocolectomy (RPC) and total colectomy with ileorectal anastomosis (TC-IRA) are traditional surgical options for individuals with familial adenomatous po",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/39520507/"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 230,
          "text": "have emerged. The aim of this study was to review all the index surge",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/19617764/"
        },
        {
          "offsetInBeginSection": 541,
          "offsetInEndSection": 691,
          "text": "Colectomy with ileorectal anastomosis is a comparatively safe, simple, and uncomplicated procedure with a rapid recovery and a good functional result.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1847273"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "The only curative treatment for familial adenomatous polyposis (FAP) is prophylactic surgery and the two most popular options are total colectomy with ileorectal anastomosis and restorative proctocolectomy with ileal pouch-anal anastomosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17611924"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 481,
          "text": "The aim of removing the colorectal mucosa with significant potential of malignant transformation can be achieved by means of three distinct procedures: pan-proctocolectomy and ileostomy, subtotal colectomy with ileorectal anastomosis, restorative proctocolectomy with ileoanal anastomosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10756821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Restorative proctocolectomy and ileal pouch-anal anastomosis (IPAA) is the therapy of choice for the prophylactic treatment of FAP.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9931897"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 180,
          "text": "Proctocolectomy with ileal pouch anal anastomosis is recommended for the majority of FAP patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12425165"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 483,
          "text": "Today, ileal pouch-anal anastomosis has gained wider acceptance as a safer procedure, but ileorectal anastomosis still remains an option, especially for young patients with a moderate phenotype of the disease and limited polyps in the rectum.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17611924"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 375,
          "text": "The treatment of choice is colectomy and ileorectal anastomosis, but restorative proctocolectomy may be considered in selected cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2551351"
        },
        {
          "offsetInBeginSection": 200,
          "offsetInEndSection": 342,
          "text": "enomatous polyposis (FAP). No consensus has been reached, until now, to choose between IPAA and ileo-rectal anastomosis (IRA), the rectal spar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22103049"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 247,
          "text": "Despite advantages for patients with ulcerative colitis, Crohn\u0027s disease, and familial adenomatous polyposis, restorative proctocolectomy with ileal pouch-anal anastomosis carries a risk of pouch failure, necessitating pouch excision",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39404860"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 351,
          "text": "Since it was first described in 1978, restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) has become the gold standard for patients requiring surgery, as well as for patients with familial adenomatous polyposis (FAP)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39333043"
        },
        {
          "offsetInBeginSection": 356,
          "offsetInEndSection": 562,
          "text": "There are however, four surgical options: ileorectal anastomosis, restorative proctocolectomy with ileal pouch-anal anastomosis, proctocolectomy with ileostomy, and proctocolectomy with continent-ileostomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23875116"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 333,
          "text": "manent stoma. There are especially two operation options; Total colectomy with ileorectal anastomosis (IRA) and total proctocolectomy with ileo-pouch anal anast",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25305601"
        },
        {
          "offsetInBeginSection": 1160,
          "offsetInEndSection": 1306,
          "text": "management option for FAP patients up to now. Total colectomy with IRA and restorative proctocolectomy with IPAA is surgical options for FAP patie",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25305601"
        },
        {
          "offsetInBeginSection": 1010,
          "offsetInEndSection": 1221,
          "text": "Restorative proctocolectomy with ileal pouch anal anastomosis (RPC/IPAA) with mucosectomy is the preferred surgical procedure, since it attempts to eliminate all colorectal mucosa without the need for an ostomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15592657"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 530,
          "text": "A total proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the standard treatment for preventing the development of colorectal cancer, while a total colectomy with ileo-rectal anastomosis (IRA) is an alternative option in select patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24597363"
        },
        {
          "offsetInBeginSection": 175,
          "offsetInEndSection": 410,
          "text": "sis syndrome. Restorative proctocolectomy is the most commonly performed surgical procedure performed for patients suffering from FAP with different options for anastomosis, namely ileorectal anastomosis (IRA) or ileal pouch anal anast",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29324375"
        },
        {
          "offsetInBeginSection": 596,
          "offsetInEndSection": 877,
          "text": "y safe, simple, and uncomplicated procedure with a rapid recovery and a good functional result. It does, however, leave the patient liable for a small risk of rectal cancer, although not a large risk of dying of rectal cancer. Patients who do not do well with ileorectal anastomosi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1847273"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 480,
          "text": "The aim of removing the colorectal mucosa with significant potential of malignant transformation can be achieved by means of three distinct procedures: panproctocolectomy and ileostomy, subtotal colectomy with ileorectal anastomosis, restorative proctocolectomy with ileoanal anastomosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10756751"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "text": "Prophylactic colectomy is generally recommended for patients with familial adenomatous polyposis (FAP) who are inevitably affected with large bowel cancer. After prophylactic colectomy has been performed, gastrointestinal malignancy is the leading cause of death. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10955728"
        },
        {
          "offsetInBeginSection": 555,
          "offsetInEndSection": 657,
          "text": "The gold-standard treatment to reduce this risk is prophylactic colectomy, typically by the age of 40.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37600856"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 334,
          "text": "INTRODUCTION: Surgery is the only treatment option for familial adenomatous polyposis (FAP). Aim of surgery in FAP is to minimize colorectal cancer risk without need for permanent stoma. There are especially two operation options; Total colectomy with ileorectal anastomosis (IRA) and total proctocolectomy with ileo-pouch anal anasto",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25305601"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "There are 3 surgical options for patients who have familial adenomatous polyposis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1847273"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "BACKGROUND: Without prophylactic surgery, patients with familial adenomatous polyposis are at high risk for colorectal cancer development. Various surgical options for prophylaxis ar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30192330"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Prophylactic surgical options for familial adenomatous polyposis (FAP) are either colectomy and ileorectal anastomosis (IRA) or proctocolectomy and ileal pouch-anal anastomosis (IPAA). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25504366"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "A restorative proctocolectomy or ileal pouch procedure is one of the main surgical options for patients with familial adenomatous polyposis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14719160"
        },
        {
          "offsetInBeginSection": 352,
          "offsetInEndSection": 799,
          "text": "The preservation of the rectum offers good quality of life and good functional results, but needs an accurate surveillance of the rectal stump and screening for the development of cancer. Restorative proctocolectomy is reserved for patients with large or confluent polyps of the rectum, for older patients and for those who had already had an ileorectal anastomosis and who develops subsequently large adenomas at increased risk for rectal cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8948806"
        },
        {
          "offsetInBeginSection": 276,
          "offsetInEndSection": 553,
          "text": "Four surgical strategies are available for patients with FAP: proctocolectomy with permanent ileostomy, colectomy with ileorectal anastomosis, proctocolectomy with Kochs pouch continent ileostomy (Koch), and restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20664317"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "BACKGROUND \u0026 AIMS: The options for prevention of colorectal cancer in familial adenomatous polyposis are either a colectomy with ileorectal anastomosis (IRA) or a total proctocolectomy with ileal pouch-anal anastomosis (IPAA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17368237"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "INTRODUCTION: Restorative proctocolectomy (RPC) and total colectomy with ileorectal anastomosis (TC-IRA) are traditional surgical options for individuals with familial adenomatous polyposis (FAP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39520507"
        },
        {
          "offsetInBeginSection": 563,
          "offsetInEndSection": 690,
          "text": "Conventional proctocolectomy options largely lie between colectomy with ileorectal anastomosis or ileal pouch-anal anastomosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23875116"
        }
      ],
      "type": "list",
      "id": "660999a0fdcbea915f00001a",
      "ideal_answer": [
        "Surgical options include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis. The decision-making process should not be limited to the conventional confrontation of pros and cons of ileorectal anastomosis or restorative proctocolectomy.",
        "The surgical treatment of colorectal disease in FAP, which has the goal of colorectal cancer prevention, varies based on both patient and disease factors but can include the following: total colectomy with ileorectal anastomosis, proctocolectomy with stapled or hand-sewn ileal pouch-anal anastomosis, or total proctocolectomy with end ileostomy.",
        "The main surgical options for treating colorectal disease in patients with Familial Adenomatous Polyposis (FAP) are: total proctocolectomy with ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch-anal anastomosis. The choice depends on factors like extent of rectal disease, presence of carcinoma, sphincter function, and extracolonic manifestations.",
        "For patients with Familial Adenomatous Polyposis (FAP), the primary colorectal surgical option is restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). This procedure has become the gold standard for managing FAP, as it allows for the removal of the colon and rectum while preserving bowel function through the creation of an ileal pouch. Despite its advantages, IPAA carries a risk of pouch failure, which may necessitate pouch excision or a permanent ileostomy. Other surgical options may include total colectomy with ileorectal anastomosis, which involves removing the colon while preserving the rectum, or total proctocolectomy with end ileostomy, which involves removing both the colon and rectum and creating a permanent ileostomy. The choice of surgical procedure depends on various factors, including the severity of polyposis, patient preference, and the presence of any associated conditions.",
        "For patients with Familial Polyposis, colorectal surgical options include: \n  1. Total Colectomy with Ileorectal Anastomosis (TC-IRA), \n  2. Proctocolectomy with Ileostomy (typically for those with existing lower rectal cancer), \n  3. Restorative Proctocolectomy (RPC) with variations like Robotic Intracorporeal Single-Stapled Anastomosis (RPC-RiSSA) and Near-Total Colectomy with Ileo-Distal Sigmoid Anastomosis (NT-IDSA). \n  The choice depends on factors such as disease extent, patient preference, and the goal of preventing colorectal cancer. Recent innovations offer promising outcomes with reduced complications.",
        "For patients with Familial Adenomatous Polyposis (FAP), several colorectal surgical options are available to prevent cancer, tailored to individual patient and disease characteristics. The primary procedures include total colectomy with ileorectal anastomosis (IRA) and restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA), both of which avoid a permanent stoma. Additional options are proctocolectomy with end ileostomy or continent-ileostomy. These surgeries aim to balance cancer prevention with considerations for bowel function, sexual health, and quality of life in this predominantly young patient population.",
        "Familial Adenomatous Polyposis (FAP) is a hereditary condition that significantly increases the risk of developing colorectal cancer due to the presence of numerous polyps in the colon and rectum. Surgical options for managing FAP primarily focus on reducing cancer risk by removing the colon and rectum. The main surgical options include:\n\n1. **Total Proctocolectomy with Ileal Pouch-Anal Anastomosis (IPAA):** This is the most common procedure for FAP patients. It involves removing the colon and rectum while preserving the anal sphincter, allowing for the creation of an ileal pouch that is connected to the anus, enabling the patient to maintain continence.\n\n2. **Total Colectomy with Ileorectal Anastomosis (IRA):** In this procedure, the colon is removed, but the rectum is preserved and connected to the small intestine. This option is considered when the rectum has fewer polyps, but it requires",
        "Patients with Familial Adenomatous Polyposis (FAP) typically require surgical intervention to prevent colorectal cancer. The main colorectal surgical options for these patients include:\n\n1. Total Proctocolectomy with Ileal Pouch-Anal Anastomosis (IPAA): This procedure involves removing the entire colon and rectum and creating an internal pouch from the small intestine that is connected to the anus, preserving continence.\n\n2. Total Colectomy with Ileorectal Anastomosis (IRA): This surgery removes the colon but preserves the rectum, connecting the small intestine to the rectum. It is considered when the rectum has fewer polyps and can be monitored with regular surveillance.\n\n3. Proctocolectomy with End Ileostomy: This involves removing the entire colon and rectum and creating a permanent ileostomy, where the end of the small intestine is brought out through an opening in the abdominal wall to collect waste in an external pouch.\n\nThe choice of surgical procedure depends on factors such as the number and location of polyps, the patient\u0027s age, overall health, and personal preferences. Regular follow-up and monitoring are essential for managing FAP and preventing cancer development.",
        "For patients with Familial Adenomatous Polyposis (FAP), the main surgical options to prevent colorectal cancer include total proctocolectomy, colectomy with ileorectal anastomosis, and restorative proctocolectomy, with or without mucosectomy. The choice of procedure depends on individual patient and disease factors, such as the extent of rectal disease, presence of carcinoma, and sphincter function.",
        "Based on the provided contexts, the colorectal surgical options for patients with Familial Polyposis (FAP) include:\n\n1. **Total colectomy with ileorectal anastomosis (TC/IRA)**: This involves the removal of the entire colon and the creation of an anastomosis between the remaining rectum and the ileum.\n2. **Total proctocolectomy with ileal pouch-anal anastomosis (IPAA)**: This involves the removal of the entire colon and rectum, followed by the creation of an ileal pouch to which the anus is reattached.\n3. **Restorative proctocolectomy with ileal pouch-anal anastomosis (RPC/IPAA)**: This involves the removal of the entire colon and rectum, followed by the creation of an ileal pouch to which the anus is reattached, with the aim of preserving the anal sphincter.\n4. **Proctocolectomy",
        "The surgical options for Familial Adenomatous Polyposis include colectomy with ileorectal anastomosis and proctocolectomy with ileal pouch‑anal anastomosis. In colectomy with ileorectal anastomosis the colon is removed while preserving the rectum, which can be acceptable in patients with limited rectal polyposis, such as in attenuated FAP, though the risk for rectal cancer remains. Proctocolectomy with ileal pouch‑anal anastomosis involves removing both the colon and rectum and constructing an ileal pouch to maintain bowel continuity at the anus, thereby reducing the risk of cancer. In selected cases with a high risk of rectal cancer, a pan‑proctocolectomy with permanent ileostomy may also be considered. The choice of procedure depends on factors like the extent of polyposis and patient phenotype.",
        "The colorectal surgical options for patients with Familial Adenomatous Polyposis (FAP) are designed to prevent cancer by removing affected tissues. Key procedures include:\n\n1. **Total Proctocolectomy**: Removes the entire colon and rectum, often recommended due to FAP\u0027s widespread impact.\n\n2. **Ileostomy**: After removal, an ileostomy is created where the small intestine (ileum) is connected to the abdomen for waste elimination into a pouch. This can be temporary or permanent.\n\n3. **Ileoanal Pouch Procedure**: Involves creating a reservoir from the small intestine attached to the anus, allowing natural bowel movements without a stoma. However, it carries risks like pouchitis and may not suit all patients.\n\n4. **Defunctioning Ileostomy**: A temporary measure post-surgery to aid healing before resuming normal digestive function.\n\nEach option balances benefits against risks, such as cancer prevention versus quality of life considerations. Patients should discuss these choices with their surgeons to select the most suitable approach based on individual circumstances.",
        "Surgical options for colorectal disease in Familial Adenomatous Polyposis (FAP) aim to prevent colorectal cancer. These include total colectomy with ileorectal anastomosis (IRA), proctocolectomy with ileal pouch-anal anastomosis (IPAA), total proctocolectomy with end ileostomy, proctocolectomy with ileostomy, and proctocolectomy with continent-ileostomy. IRA and IPAA are options that avoid the need for a permanent stoma. Restorative proctocolectomy with IPAA is often preferred as it eliminates colorectal mucosa. Proctocolectomy with ileal pouch-anal anastomosis is a standard prophylactic treatment.",
        "The colorectal surgical options for patients with Familial Adenomatous Polyposis (FAP) are designed to prevent cancer by removing the affected areas while considering the patient\u0027s quality of life. The primary procedures include:\n\n1. **Total Proctocolectomy**: This involves removing the entire colon and rectum, often followed by an ileostomy where a stoma is created from the small intestine for waste elimination.\n\n2. **Ileoanal Pouch Procedure**: Here, the colon and rectum are removed, and a reservoir (pouch) made from the small intestine is attached to the anus, allowing more normal bowel movements without an external pouch.\n\n3. **Subtotal Colectomy**: This removes most of the colon but leaves the rectum intact, though it may not be sufficient for all FAP patients due to widespread polyps.\n\n4. **Defunctioning Ileostomy**: Sometimes used temporarily after surgery to allow healing before reconnecting the digestive tract.\n\nEach procedure has its benefits and risks, with considerations for cancer prevention, bowel function, and potential complications like pouchitis. Minimally invasive techniques, such as laparoscopic surgery, can also be employed to enhance recovery. The choice of procedure depends on individual factors including health status and personal preferences.",
        "The surgical options for patients with Familial Adenomatous Polyposis (FAP) include: 1. Coloproctectomy - surgical removal of the colon and rectum to prevent colorectal cancer. 2. Proctocolectomy with ileal pouch-anal anastomosis (IPAA) - a definitive surgical treatment that allows for the creation of a pouch from the ileum to maintain bowel function. 3. Prophylactic surgery - recommended for high-risk individuals to reduce the risk of developing colorectal cancer.",
        "The colorectal surgical options for patients with Familial Adenomatous Polyposis (FAP) include: total colectomy with ileorectal anastomosis (TC-IRA), restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA), total proctocolectomy with end ileostomy, and proctocolectomy with stapled or hand-sewn ileal pouch-anal anastomosis.",
        "The colorectal surgical options for patients with Familial Polyposis include restorative proctocolectomy, total proctocolectomy, colectomy with ileorectal anastomosis, Total colectomy with ileorectal anastomosis, Total proctocolectomy with end ileostomy, Total proctocolectomy with ileostomy, Total proctocolectomy with ileal pouch-anal anastomosis, and proctocolectomy with ileal pouch-anal anastomosis.",
        "Patients with Familial Adenomatous Polyposis (FAP) have several colorectal surgical options. Primary choices include: \n1. Total Colectomy with Ileorectal Anastomosis (TC-IRA) or its variant Near-Total Colectomy with Ileo-Distal Sigmoid Anastomosis (NT-IDSA), \n2. Total Proctocolectomy with Ileoanal Pouch Anastomosis (IPAA) or Restorative Proctocolectomy (RPC), which may be robotic-assisted, and \n3. Proctocolectomy with Ileostomy, usually reserved for patients with rectal cancer. The selection of procedure depends on factors including the extent of rectal disease, carcinoma presence, sphincter function, and extracolonic disease. These options aim to minimize or eliminate colorectal cancer risk, with recent innovations focusing on improved safety and outcomes.",
        "The colorectal surgical options for patients with Familial Adenomatous Polyposis (FAP) include: restorative proctocolectomy (RPC), total colectomy with ileorectal anastomosis (TC-IRA), and coloproctectomy.",
        "The main surgical options for patients with Familial Adenomatous Polyposis (FAP) include total proctocolectomy with ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch-anal anastomosis. The choice depends on factors like extent of rectal disease, presence of carcinoma, sphincter function, and extracolonic manifestations. Total proctocolectomy with ileal pouch-anal anastomosis is often preferred as it eliminates the risk of rectal cancer, although it has higher morbidity.",
        "The surgical options for patients with Familial Adenomatous Polyposis (FAP) include:\n\n1. Total proctocolectomy with ileostomy\n2. Continent ileostomy\n3. Total colectomy with ileorectal anastomosis (IRA)\n4. Total proctocolectomy with ileal pouch anal anastomosis (IPAA)\n5. Restorative proctocolectomy or ileal pouch procedure\n\nThese options aim to minimize the risk of colorectal cancer and may involve the removal of part or all of the colon and rectum. The choice of surgery depends on individual patient factors and the goal of reducing cancer risk without the need for a permanent stoma.",
        "The main colorectal surgical options for patients with Familial Polyposis are:\n\n1. Colectomy with ileorectal anastomosis (IRA)\n2. Total proctocolectomy with ileal pouch-anal anastomosis (IPAA)\n3. Restorative proctocolectomy with ileal pouch-anal anastomosis (RPC/IPAA) with mucosectomy\n4. Total colectomy with ileorectal anastomosis (TC/IRA)\n5. Proctocolectomy with permanent ileostomy (for patients with severe polyposis)\n\nThese surgical options aim to eliminate the risk of colorectal cancer in patients with Familial Polyposis.",
        "Patients with Familial Adenomatous Polyposis (FAP) have several colorectal surgical options, each with its own benefits and considerations:\n\n1. Restorative Proctocolectomy with Ileal Pouch Anal Anastomosis (IPAA): This is a commonly used procedure, especially with advancements in laparoscopic surgeries. It is often preferred for severe cases due to its effectiveness in reducing rectal cancer rates.\n\n2. Total Colectomy with Ileorectal Anastomosis: Preferred by surgeons due to higher utility scores compared to other options. It is associated with a lower rate of rectal cancer and proctectomy in the modern era.\n\n3. Total Proctocolectomy with Permanent Ileostomy: This option is available but less preferred due to lower utility scores.\n\n4. Partial Colectomy: An option depending on the stage of colorectal cancer and the presence of polyps.\n\n5. Prophylactic Surgery: Recommended before the age of 20 due to the unreliability of colonoscopy in screening for malignancy in the presence of multiple polyps.\n\nThe choice of procedure should consider the risk of cancer in the rectal remnant, as well as bowel and sexual function, particularly in young patients. The natural history of carcinogenesis and patient compliance with surveillance strategies also influence surgical decisions. Surgical options have significantly evolved over the past 50 years, with a shift from ileorectal anastomosis to IPAA and laparoscopic surgeries. Colon resection has been associated with a decrease in cancer incidence when performed at a younger age. Managing FAP involves addressing the challenges faced by patients and families, including the choice of appropriate surgical options.",
        "The colorectal surgical options for patients with Familial Polyposis (FAP) primarily include: 1) Total Colectomy with Ileorectal Anastomosis (TC-IRA) or its variant Near-Total Colectomy with Ileo-Distal Sigmoid Anastomosis (NT-IDSA), 2) Total Proctocolectomy with Ileoanal Pouch Anastomosis (IPAA) or Restorative Proctocolectomy (RPC), with or without innovative techniques like robotic assistance, and 3) Proctocolectomy with Ileostomy, typically reserved for specific cases with rectal cancer. The choice among these options depends on several patient and disease factors.",
        "The primary colorectal surgical options for patients with Familial Adenomatous Polyposis (FAP) include total proctocolectomy with ileostomy, colectomy with ileorectal anastomosis, and restorative proctocolectomy with ileal pouch-anal anastomosis. The choice depends on factors like rectal disease extent, cancer presence, and sphincter function, aiming to prevent colorectal cancer while preserving quality of life.",
        "The colorectal surgical options for patients with Familial Polyposis (FP) are designed to prevent colorectal cancer by removing or managing polyps effectively. Here is an organized summary of the key considerations:\n\n1. **Primary Surgical Option:**\n   - **Total Proctocolectomy with Ileal Pouch-Anal Anastomosis (IPAA):** This procedure removes both the colon and rectum, creating a new reservoir from the small intestine to store waste. It aims to maintain continence without an external bag.\n\n2. **Alternative Surgical Options:**\n   - **Subtotal Colectomy:** Removal of part of the colon, potentially used in specific cases or as a temporary solution before definitive surgery.\n   - **Restorative Proctocolectomy:** Aims to preserve bowel function by creating an internal pouch, balancing cancer prevention with quality of life.\n\n3. **Non-Surgical Management:**\n   - Regular colonoscopies for surveillance and polyp removal are crucial, though surgery is often the definitive treatment due to the high number of polyps in FP.\n\n4. **Considerations:**\n   - **Timing:** Surgery may be recommended based on age or the appearance of significant polyps.\n   - **Quality of Life:** Procedures like IPAA focus on maintaining continence and reducing complications such as pouchitis.\n   - **Minimally Invasive Techniques:** Laparoscopic surgery offers quicker recovery times and less scarring.\n\n5. **Genetic Counseling:**\n   - Essential for family members to identify those needing similar interventions or surveillance due to the hereditary nature of FP.\n\n6. **Psychological Support:**\n   - Important to address the challenges of adjusting to life after surgery, including support systems and counseling.\n\nIn conclusion, while total proctocolectomy with IPAA is often the primary choice, other surgical options and non-surgical management strategies are part of a comprehensive approach to care for patients with Familial Polyposis.",
        "Surgical options for familial adenomatous polyposis (FAP) aim to minimize colorectal cancer risk. These options include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis (IRA), and total proctocolectomy with ileal pouch-anal anastomosis (IPAA). Restorative proctocolectomy with ileal pouch-anal anastomosis (RPC/IPAA) with mucosectomy is a preferred surgical procedure, as it attempts to eliminate all colorectal mucosa without the need for an ostomy. The choice of procedure depends on individual patient and disease factors.",
        "Colorectal surgical options for patients with Familial Polyposis (FAP) include:\n\n1. Total colectomy with ileorectal anastomosis (IRA)\n2. Total proctocolectomy with ileal pouch-anal anastomosis (IPAA)\n3. Proctocolectomy with permanent ileostomy\n4. Colectomy with ileorectal anastomosis\n5. Proctocolectomy with Koch\u0027s pouch continent ileostomy (Koch)\n6. Restorative proctocolectomy with ileal pouch-anal anastomosis (RPC/IPAA) with mucosectomy\n\nAmong these options, total proctocolectomy with ileal pouch-anal anastomosis (IPAA) is often considered the preferred surgical procedure as it eliminates all colorectal mucosa without the need for an ostomy.",
        "For patients with Familial Polyposis, surgical options include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis. The choice depends on individual patient factors and should involve a comprehensive decision-making process that goes beyond simply weighing pros and cons.",
        "For patients with Familial Polyposis, colorectal surgical options include: 1) Total Proctocolectomy with Ileostomy, 2) Continent Ileostomy, 3) Total Colectomy with Ileorectal Anastomosis, and 4) Total Proctocolectomy with Ileal Pouch Anal Anastomosis, with the choice of procedure dependent on patient-specific and disease-related factors.",
        "For patients with Familial Polyposis, several colorectal surgical options exist. These include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "Surgical options include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis. The choice of colorectal surgery in patients with familial adenomatous polyposis lies between the morbidity of proctocolectomy and ileum-pouch-anal anastomosis (IPAA) and the mortality from rectal cancer after total colectomy and ileorectal anastomosis (IRA). Current strategy uses polyposis severity and distribution to decide on the surgical option, and laparoscopy to minimize morbidity.",
        "Surgical options for colorectal issues include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "The colorectal surgical options for patients with Familial Polyposis include: total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch-anal anastomosis.",
        "For patients with Familial Polyposis, several colorectal surgical options are available to manage the condition. These include total proctocolectomy with ileostomy, which involves the removal of the colon and rectum with the creation of a stoma; continent ileostomy, where an internal reservoir is created to store stool; total colectomy with ileorectal anastomosis, which removes the colon but preserves the rectum; and total proctocolectomy with ileal pouch anal anastomosis (IPAA), where the colon and rectum are removed, and an internal pouch is created from the small intestine to connect to the anus. The decision-making process should consider the benefits and risks of each procedure to tailor the best surgical option for the patient.",
        "The colorectal surgical options for patients with Familial Polyposis are designed to address the high risk of cancer associated with numerous polyps. Here is an organized summary of the main procedures:\n\n1. **Total Proctocolectomy with Ileostomy**:\n   - **Procedure**: Removal of the entire colon and rectum, with creation of a stoma (ileostomy) for waste collection in an external bag.\n   - **Considerations**: Provides definitive removal of at-risk tissue but results in a permanent ileostomy.\n\n2. **Continent Ileostomy**:\n   - **Procedure**: Similar to total proctocolectomy, but involves creating a continent reservoir inside the abdomen, emptied periodically via catheter.\n   - **Considerations**: Avoids an external appliance, offering some control over bowel movements.\n\n3. **Total Colectomy with Ileorectal Anastomosis**:\n   - **Procedure**: Removal of the colon, connecting the ileum to the rectum.\n   - **Considerations**: Leaves the rectum, which may still pose a risk unless polyps are cleared.\n\n4. **Total Proctocolectomy with Ileal Pouch Anal Anastomosis (IPAA)**:\n   - **Procedure**: Removal of the colon and rectum, creation of an internal pouch from the small intestine connected to the anus.\n   - **Considerations**: Preserves continence but may lead to complications like pouchitis.\n\n**Additional Considerations**:\n- **Patient Factors**: Surgery choice depends on extent of polyposis, patient preference, age, health, and surgical expertise.\n- **Techniques**: Minimally invasive approaches (laparoscopic or robotic-assisted) might offer benefits like shorter recovery times.\n- **Follow-Up**: Regular monitoring is essential for any remaining polyps or complications.\n\nEach procedure has trade-offs in terms of quality of life, complication risks, and long-term management. Consulting with a surgical team to discuss these options is crucial for making an informed decision tailored to individual needs.",
        "Colorectal surgical options for patients with Familial Polyposis (FP) are designed to remove at-risk tissues and prevent cancer development. Here are the key procedures:\n\n1. **Total Proctocolectomy with Ileostomy**: This involves removing the entire colon and rectum, creating a permanent ileostomy where waste is collected in an external bag. It is definitive but results in a permanent stoma.\n\n2. **Continent Ileostomy**: Similar to total proctocolectomy, but instead of an external bag, an internal reservoir allows patients to self-catheterize for emptying, avoiding an external appliance.\n\n3. **Total Colectomy with Ileorectal Anastomosis**: The colon is removed, and the ileum is connected to the rectum. This option leaves the rectum in place but requires careful monitoring due to the risk of polyps.\n\n4. **Total Proctocolectomy with Ileal Pouch Anal Anastomosis (IPAA)**: The entire colon and rectum are removed, and a pouch made from the small intestine is attached to the anus, allowing normal bowel movements though possibly more frequent or loose.\n\nEach procedure has its pros and cons, influenced by factors such as disease extent, patient preference, and surgeon expertise. The decision should consider all options based on individual circumstances, emphasizing that no single approach fits everyone.",
        "Surgical options for Familial Polyposis include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis. The decision-making process should not be limited to the conventional confrontation of pros and cons of ileorectal anastomosis or restorative proctocolectomy.",
        "**Colorectal Surgical Options for Familial Polyposis**\n\nFamilial Polyposis is a genetic condition characterized by numerous colon and rectal polyps with a high risk of becoming cancerous. Surgical intervention is often recommended to prevent malignancy. The following are the primary colorectal surgical options:\n\n1. **Total Proctocolectomy with Ileostomy**: This procedure involves removing the entire colon and rectum, creating a permanent ileostomy (stoma) where waste is collected in an external bag. It effectively removes all at-risk tissue but results in a permanent stoma.\n\n2. **Continent Ileostomy**: Similar to total proctocolectomy, this surgery creates an internal reservoir from the small intestine, allowing patients to empty it periodically without an external appliance, offering improved quality of life compared to traditional ileostomies.\n\n3. **Total Colectomy with Ileorectal Anastomosis**: This involves removing only the colon and connecting the ileum to the rectum. However, due to the risk of polyps in the rectum, this option may still pose risks unless the rectum is cleared of polyps.\n\n4. **Total Proctocolectomy with Ileal Pouch Anal Anastomosis (IPAA)**: This complex procedure removes the colon and rectum, creating a pouch from the small intestine connected to the anus, allowing normal bowel movements without a stoma. It preserves anal function but carries risks like pouchitis.\n\n**Considerations**: The choice of surgery depends on factors such as disease extent, patient preference, age, and overall health. IPAA is preferred for preserving anal function, while total proctocolectomy with ileostomy offers simplicity. Continent ileostomy balances quality of life and surgical complexity. Each option has its pros and cons, emphasizing the need for personalized decision-making based on individual circumstances.",
        "The surgical options for patients with Familial Polyposis include:\n\n1. Total proctocolectomy with ileostomy: This involves the removal of the entire colon and rectum, and creation of an ileostomy (a surgically created opening in the abdominal wall for the elimination of waste).\n2. Total colectomy with ileorectal anastomosis: This involves the removal of the entire colon and creation of a connection between the ileum (the last part of the small intestine) and the rectum.\n3. Total proctocolectomy with ileal pouch anal anastomosis (IPAA): This involves the removal of the entire colon and rectum, and creation of an ileal pouch (a small reservoir made from the ileum) that is connected to the anus.\n4. Continent ileostomy: This is a type",
        "The colorectal surgical options for patients with Familial Polyposis (FP) are designed to address the high risk of polyps progressing to cancer. Here is a structured overview of the available procedures:\n\n1. **Total Proctocolectomy with Ileostomy**:\n   - **Procedure**: Removal of the entire colon and rectum, with creation of an ileostomy for waste collection in an external bag.\n   - **Considerations**: Provides definitive removal of at-risk tissue but results in a permanent stoma.\n\n2. **Continent Ileostomy**:\n   - **Procedure**: Similar to total proctocolectomy but uses an internal pouch with periodic catheter drainage instead of an external bag.\n   - **Considerations**: Suitable for patients preferring no external appliance, though it requires self-management.\n\n3. **Total Colectomy with Ileorectal Anastomosis**:\n   - **Procedure**: Removal of the colon only, connecting the ileum to the rectum.\n   - **Considerations**: Less invasive but leaves the rectum at risk for polyp development, making it less ideal for FP.\n\n4. **Total Proctocolectomy with Ileal Pouch Anal Anastomosis (IPAA)**:\n   - **Procedure**: Removes the colon and rectum, creating an ileal pouch to store stool, which is expelled through the anus.\n   - **Considerations**: Preserves anal function but carries risks like pouchitis or strictures.\n\n**Decision-Making Factors**:\n- Patient preference, age, overall health, and specific genetic considerations influence the choice of surgery.\n- Younger patients might prefer procedures preserving anal function, while others may prioritize minimizing surgical complexity or avoiding a stoma.\n\nIn conclusion, each surgical option balances benefits and risks regarding quality of life, surgical risks, and long-term outcomes. Surgical intervention is typically recommended for FP due to the high cancer risk, with options tailored to individual patient needs.",
        "Surgical options for colorectal disease in Familial Adenomatous Polyposis (FAP) aim to prevent colorectal cancer, with the choice depending on patient and disease factors. Options include total colectomy with ileorectal anastomosis (IRA), various proctocolectomy procedures such as proctocolectomy with IPAA (stapled or hand-sewn), restorative proctocolectomy with IPAA (RPC/IPAA) often with mucosectomy to eliminate colorectal mucosa, proctocolectomy with ileostomy, proctocolectomy with continent-ileostomy, and total proctocolectomy with end ileostomy. Total proctocolectomy with IPAA is often the standard for preventing colorectal cancer, while total colectomy with IRA is an alternative for select patients.",
        "The colorectal surgical options for patients with Familial Polyposis are designed to remove at-risk tissues while preserving as much normal function as possible. Here is an organized summary of the main procedures:\n\n1. **Total Proctocolectomy with Ileostomy**:\n   - **Procedure**: Removal of the entire colon and rectum, with creation of a permanent ileostomy.\n   - **Pros**: Definitive removal of all at-risk tissue.\n   - **Cons**: Results in a permanent external stoma for waste collection.\n\n2. **Continent Ileostomy**:\n   - **Procedure**: Similar to total proctocolectomy but with an internal reservoir emptied via catheter.\n   - **Pros**: Avoids an external appliance.\n   - **Cons**: Requires self-catheterization and may have higher surgical complexity.\n\n3. **Total Colectomy with Ileorectal Anastomosis**:\n   - **Procedure**: Removal of the colon, connecting the ileum to the rectum.\n   - **Pros**: Preserves the rectum if polyps are managed.\n   - **Cons**: Residual risk in the rectum unless cleared.\n\n4. **Total Proctocolectomy with Ileal Pouch Anal Anastomosis (IPAA)**:\n   - **Procedure**: Removal of colon and rectum, creation of a pouch from the small intestine connected to the anus.\n   - **Pros**: Preserves continence and normal bowel movements.\n   - **Cons**: Risk of complications like pouchitis.\n\n**Considerations**:\n- Each procedure has trade-offs in terms of quality of life, complication risks, and maintenance requirements.\n- Patient factors such as age, health, preference, and surgeon expertise influence the choice.\n- Newer techniques or minimally invasive options may be available beyond those mentioned.\n- Long-term outcomes and patient experiences vary; studies comparing these procedures can provide further insights.\n\nAdditionally, genetic counseling for family members is crucial due to the hereditary nature of Familial Polyposis. They should be screened and considered for preventive surgeries if they carry the gene mutation.",
        "The colorectal surgical options for patients with Familial Polyposis include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "For patients with Familial Polyposis, colorectal surgical options include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis. The decision-making process should consider more than just the traditional pros and cons of ileorectal anastomosis or restorative proctocolectomy to ensure a comprehensive evaluation tailored to individual patient needs.",
        "The colorectal surgical options for patients with Familial Adenomatous Polyposis (FAP) include: total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "Colorectal surgical options for patients with Familial Polyposis include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis. The decision-making process should consider factors beyond the conventional pros and cons of ileorectal anastomosis or restorative proctocolectomy.",
        "The colorectal surgical options for patients with Familial Polyposis include: \n\n1. Total proctocolectomy with ileostomy \n2. Continent ileostomy \n3. Total colectomy with ileorectal anastomosis \n4. Total proctocolectomy with ileal pouch anal anastomosis.\n\nThese options should be considered in the decision-making process, taking into account individual patient needs and circumstances.",
        "The colorectal surgical options for patients with Familial Polyposis include: total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, total proctocolectomy with ileal pouch anal anastomosis, and restorative proctocolectomy with ileal pouch-anal anastomosis.",
        "The colorectal surgical options for patients with Familial Polyposis include: total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "Patients with Familial Polyposis have several surgical options, including total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "Patients with Familial Polyposis have four primary colorectal surgical options: total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis. The choice among these depends on the extent of rectal disease, presence and extent of carcinoma, sphincter function, extracolonic disease, and patient preferences. For optimal outcomes, management by experienced surgeons in specialized centers is crucial, ensuring a tailored approach that balances disease complexity with patient needs and preferences.",
        "For patients with Familial Polyposis, several colorectal surgical options are available. These include total proctocolectomy with ileostomy, which involves the removal of the colon and rectum with the creation of a stoma; continent ileostomy, which is a variation that allows for internal storage of waste; total colectomy with ileorectal anastomosis, where the colon is removed but the rectum is preserved and connected to the small intestine; and total proctocolectomy with ileal pouch anal anastomosis, which involves removing the colon and rectum and creating a pouch from the small intestine to restore bowel function.",
        "For patients with Familial Polyposis, colorectal surgical options include: \n  1. Total Proctocolectomy with Ileostomy, \n  2. Continent Ileostomy, \n  3. Total Colectomy with Ileorectal Anastomosis, and \n  4. Total Proctocolectomy with Ileal Pouch Anal Anastomosis. \nThe choice among these procedures depends on individual patient factors, including the extent of rectal disease, presence of carcinoma, sphincter function, and extracolonic manifestations, emphasizing the need for personalized decision-making.",
        " For patients with Familial Polyposis, surgical options for colorectal management include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "Studies show that colorectal surgical options for patients with Familial Polyposis include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "The colorectal surgical options for patients with Familial Polyposis include: \n\n1. Total proctocolectomy with ileostomy \n2. Continent ileostomy \n3. Total colectomy with ileorectal anastomosis \n4. Total proctocolectomy with ileal pouch anal anastomosis",
        "For patients with Familial Polyposis, colorectal surgical options include: 1) Total Proctocolectomy with Ileostomy, 2) Continent Ileostomy, 3) Total Colectomy with Ileorectal Anastomosis, and 4) Total Proctocolectomy with Ileal Pouch Anal Anastomosis, each with different implications for quality of life and cancer prevention.",
        "The colorectal surgical options for patients with Familial Polyposis are total proctocolectomy with ileal pouch anal anastomosis, total colectomy with ileorectal anastomosis, total proctocolectomy with ileostomy and continent ileostomy.",
        "The colorectal surgical options for patients with Familial Polyposis are total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "The main surgical options for patients with Familial Polyposis include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis, with the choice of procedure requiring careful consideration beyond simply weighing pros and cons.",
        "For patients with Familial Polyposis, several colorectal surgical options exist: total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis.",
        "Surgical options for patients with Familial Polyposis include total proctocolectomy with ileostomy, continent ileostomy, total colectomy with ileorectal anastomosis, and total proctocolectomy with ileal pouch anal anastomosis."
      ],
      "exact_answer": [
        [
          "Total proctocolectomy with ileostomy",
          "Total proctocolectomy with end ileostomy",
          "Proctocolectomy",
          "proctocolectomy with ileostomy",
          "Total Proctocolectomy with Permanent Ileostomy",
          "Pan-proctocolectomy with ileostomy",
          "Panproctocolectomy and ileostomy"
        ],
        [
          "Continent ileostomy",
          "Proctocolectomy with continent-ileostomy"
        ],
        [
          "Total colectomy with ileorectal anastomosis",
          "Total Colectomy with Ileorectal Anastomosis (IRA",
          "Colectomy with IRA",
          "IRA"
        ],
        [
          "Total proctocolectomy with ileal pouch anal anastomosis",
          "total colectomy with ileorectal anastomosis",
          "Proctocolectomy with stapled or hand-sewn ileal pouch-anal anastomosis",
          "Ileoanal pouch anastomosis",
          "Ileal pouch-anal anastomosis",
          "Ileal pouch",
          "Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis (IPAA)",
          "Restorative proctocolectomy with IPAA",
          "IPAA"
        ]
      ]
    },
    {
      "body": "Is mucopolysaccharidosis-plus syndrome (MPSPS) a X-linked disease?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37628632",
        "http://www.ncbi.nlm.nih.gov/pubmed/35327996",
        "http://www.ncbi.nlm.nih.gov/pubmed/39273517"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder caused by c.1492C\u003eT (p.R498W) in the VPS33A gene. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37628632"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Mucopolysaccharidosis-plus syndrome (MPS-PS) is a novel autosomal recessive disorder caused by a mutation in the VPS33A gene. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35327996"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder caused by c.1492C\u003eT (p.R498W) in the VPS33A gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37628632"
        },
        {
          "offsetInBeginSection": 515,
          "offsetInEndSection": 655,
          "text": "MPSPS is inherited in an autosomal recessive manner and is caused by a homozygous-specific mutation in the gene encoding the VPS33A protein.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39273517"
        },
        {
          "offsetInBeginSection": 512,
          "offsetInEndSection": 759,
          "text": "Mucopolysaccharidosis-Plus Syndrome (MPSPS), an autosomal recessive disease caused by a mutation in the endo-lysosomal tethering protein VPS33A, shows additional renal and hematopoietic abnormalities (\"Plus symptoms\") uncommon in conventional MPS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35628659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder caused by c.1492C\u003eT (p.R498W) in the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37628632"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "Mucopolysaccharidosis-plus syndrome (MPS-PS) is a novel autosomal recessive disorder caused by a mutation in the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35327996"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Mucopolysaccharidosis-plus syndrome (MPS-PS) is a novel autosomal recessive disorder caused by a mutation in the VPS33A gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35327996"
        },
        {
          "offsetInBeginSection": 512,
          "offsetInEndSection": 656,
          "text": "Mucopolysaccharidosis-Plus Syndrome (MPSPS), an autosomal recessive disease caused by a mutation in the endo-lysosomal tethering protein VPS33A,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35628659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder caused by c.1492C\u003eT (p.R498W) in the VPS33A gene. MPSPS is a severe disorder that causes a short lifespan in patients. Currently, there is no specific treatment for patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37628632"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder caused by c.1492C\u003eT (p.R498W) in the VPS33A gene. MPSPS is a severe disorder that causes a short lifespan in patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37628632"
        },
        {
          "offsetInBeginSection": 515,
          "offsetInEndSection": 566,
          "text": "MPSPS is inherited in an autosomal recessive manner",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39273517"
        }
      ],
      "type": "yesno",
      "id": "67c7708481b1027333000002",
      "ideal_answer": [
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is a rare autosomal recessive disease.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease; it is an autosomal recessive disease caused by a mutation in the VPS33A gene, which is different from the X-linked mucopolysaccharidosis type II (MPS II) or Hunter syndrome.",
        "No. The provided documents do not mention mucopolysaccharidosis-plus syndrome (MPSPS) as an X-linked disease, and they primarily focus on mucopolysaccharidosis type II (MPS II), which is an X-linked disorder.",
        "No, MPSPS is an autosomal recessive disease.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease. It is an autosomal recessive disorder caused by mutations in the VPS33A gene located on chromosome 15q26.1.",
        "The question asks if mucopolysaccharidosis-plus syndrome (MPSPS) is a X-linked disease. Based on the provided snippets, the answer is no because MPSPS is described as an autosomal recessive disorder, whereas MPS II (Hunter syndrome) is the only X-linked-inherited mucopolysaccharidosis mentioned.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal recessive disease.",
        "No. Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder, not X-linked.",
        "No. The document discusses Hunter syndrome (MPS II), which is an X-linked disorder, but does not mention mucopolysaccharidosis-plus syndrome (MPSPS) as being X-linked.",
        "No, MPSPS is not an X-linked disease; it is an autosomal recessive disorder caused by a mutation in the VPS33A gene.",
        "No, MPSPS is not a X-linked disease.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease. MPSPS is a distinct condition from mucopolysaccharidosis type II (MPS II), which is X-linked. MPSPS is caused by mutations in the VPS33A gene, which is located on chromosome 12, and therefore follows an autosomal recessive inheritance pattern.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not a X-linked disease.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease. MPSPS is inherited in an autosomal recessive manner. It is caused by a mutation in the VPS33A gene, specifically c.1492C\u003eT (p.R498W). The VPS33A gene is not located on the X chromosome.",
        "MPSPS is not an X-linked disease. It is inherited in an autosomal recessive manner, meaning that an affected individual must inherit two copies of the mutation, one from each parent.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not a X-linked disease, but rather an autosomal recessive disorder.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease. It is inherited in an autosomal recessive manner. This has been confirmed through family inheritance studies and molecular genetic testing, which identified the c.1492C\u003eT (p.R498W) mutation in the VPS33A gene as the cause of the disorder.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder, which means it is NOT an X-linked disease. The condition is caused by mutations in the VPS33A gene and is inherited in an autosomal recessive pattern, not through X-linked inheritance.",
        "No, Mucopolysaccharidosis plus syndrome (MPSPS) is not a X linked disease. It is an autosomal recessive disorder caused by the mutation c.1492C\u003eT (p.R498W) in the VPS33A gene.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS), also known as MPS-PS, is not an X-linked disease; it is an autosomal-recessive disorder caused by mutations in the VPS33A gene.",
        "No, Mucopolysaccharidosis plus syndrome (MPSPS) is not an X linked disease. It is classified as an autosomal recessive disorder, meaning it is inherited through non sex chromosomes and affects both genders equally.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal recessive disorder.",
        "The disease Mucopolysaccharidosis-plus syndrome (MPSPS) is caused by a mutation in the VPS33A gene, which is an autosomal recessive disorder, not X-linked.",
        "No. Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder caused by c.1492C\u003eT (p.R498W) in the VPS33A gene, which means it is not X-linked.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease; it is autosomal recessive. It is caused by mutations in the VPS33A gene, which is located on chromosome 12, an autosome.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder. It is caused by a mutation in the VPS33A gene, as stated in the snippets.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not a X-linked disease. It is an autosomal recessive disorder caused by a mutation in the VPS33A gene, which is located on an autosome (chromosome 17).",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease. It is an autosomal recessive disorder caused by mutations in the VPS33A gene.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS), also known as MPS-PS, is not an X-linked disorder; it is an autosomal-recessive condition caused by mutations in the VPS33A gene. Specifically, the c.1492C\u003eT (p.R498W) mutation in this gene leads to the development of MPSPS.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease; it is an autosomal recessive disorder caused by a mutation in the VPS33A gene.",
        "Mucopolysaccharidosis-plus syndrome is not an X-linked disease; it is autosomal recessive.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not a X-linked disease; it is an autosomal-recessive disorder caused by a mutation in the VPS33A gene, affecting males and females equally.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder caused by c.1492C\u003eT (p.R498W) in the VPS33A gene.",
        "No, MPSPS is not a X linked disease. It is an autosomal recessive disorder caused by mutations in the VPS33A gene located on an autosome, meaning it does not involve the X chromosome.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease. It is an autosomal-recessive disorder. This syndrome is caused by a mutation in the VPS33A gene.",
        " No, Mucopolysaccharidosis-plus syndrome (MPSPS) is not a X-linked disease. It is an autosomal recessive disorder caused by mutations in the VPS33A gene.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease. It is caused by mutations in the VPS33A gene located on chromosome 14q21.12, which is an autosome. Since the condition follows an autosomal-recessive inheritance pattern, both copies of the gene must carry the mutation for it to manifest. This means that unlike X-linked diseases, MPSPS does not predominantly affect males and is inherited independently of the sex chromosomes.",
        "Mucopolysaccharidosis-plus Syndrome (MPSPS) is not an X-linked disease; it follows an autosomal-recessive inheritance pattern due to a mutation in the VPS33A gene, affecting both males and females equally.",
        "Mucopolysaccharidosis-plus syndrome is not an X-linked disease. It is an autosomal recessive disorder caused by a specific mutation in the VPS33A gene.",
        "No, MPSPS is not an X-linked disease, but rather an autosomal recessive disorder.",
        "No, Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder.",
        "No, mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal recessive disorder, not an X-linked disease. It is caused by mutations in the VPS33A gene.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS) is not an X-linked disease, but rather an autosomal recessive disorder that is caused by a mutation (c.1492C\u003eT; p.R498W) in the VPS33A gene.",
        "Mucopolysaccharidosis-plus syndrome (MPSPS), also known as MPS-PS, is an autosomal recessive disorder caused by mutations in the VPS33A gene. It is not an X-linked disease.",
        "No. Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal-recessive disorder caused by c.1492C\u003eT (p.R498W) in the VPS33A gene."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Indications of cesarean section.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39579745",
        "http://www.ncbi.nlm.nih.gov/pubmed/37216971",
        "http://www.ncbi.nlm.nih.gov/pubmed/31477935",
        "http://www.ncbi.nlm.nih.gov/pubmed/9803656",
        "http://www.ncbi.nlm.nih.gov/pubmed/14727338",
        "http://www.ncbi.nlm.nih.gov/pubmed/34663258",
        "http://www.ncbi.nlm.nih.gov/pubmed/19805945",
        "http://www.ncbi.nlm.nih.gov/pubmed/38944712",
        "http://www.ncbi.nlm.nih.gov/pubmed/9139004",
        "http://www.ncbi.nlm.nih.gov/pubmed/8522206",
        "http://www.ncbi.nlm.nih.gov/pubmed/31086139",
        "http://www.ncbi.nlm.nih.gov/pubmed/7782593",
        "http://www.ncbi.nlm.nih.gov/pubmed/33116074",
        "http://www.ncbi.nlm.nih.gov/pubmed/22187763",
        "http://www.ncbi.nlm.nih.gov/pubmed/15512137",
        "http://www.ncbi.nlm.nih.gov/pubmed/9273336",
        "http://www.ncbi.nlm.nih.gov/pubmed/11802553"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 123,
          "text": "impending danger to maternal or fetal life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39579745"
        },
        {
          "offsetInBeginSection": 580,
          "offsetInEndSection": 882,
          "text": "Cesarean delivery indications (mutually exclusive) were the following: repeat cesarean delivery, nonreassuring fetal status, malpresentation, maternal indications (e.g., placenta previa or genital herpes simplex virus), failed labor (any stage labor arrest), or other (i.e., fetal anomaly and elective)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37216971"
        },
        {
          "offsetInBeginSection": 1105,
          "offsetInEndSection": 1509,
          "text": "The most common indication of caesarean section in this study was foetal distress (26.0%). The next common indications were cephalo-pelvic disproportion (22.0%), antepartum haemorrhage (13.0%), mal-presentaion or mal-position (16.0%). Other causes were PROM (8.0%), prolonged labour (6.0%), cord prolapse (2.0%), post-dated pregnancy (4.0%), severe pre-eclampsia (2.0%) and secondary subfertility (1.0%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38944712"
        },
        {
          "offsetInBeginSection": 627,
          "offsetInEndSection": 875,
          "text": "The most frequent non-obstetrical indications for the cesarean section were pregnancies complicated by: hypertension-33.75%, ophtalmological-20.57%, uterine myomas-16%, women heart diseases-10%, pelvic pathology-8.75%, neurological disorders-8.12%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9139004"
        },
        {
          "offsetInBeginSection": 798,
          "offsetInEndSection": 984,
          "text": "epartum haemorrhage contributed to 23.92%, obstructed labour to 18.09%, failure of progress to 13.3%, previous CS to 11.9% and cephalopelvic disproportion to 11.9% of the indications. Mi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14727338"
        },
        {
          "offsetInBeginSection": 429,
          "offsetInEndSection": 884,
          "text": "The most frequent indications to perform the c.s. were the imminent intrauterine asphyxia of the fetus--25.36%, the abnormal position of the fetus--17.73% and the nonprogressive labour--9.89%. In all these groups the operations were performed in over 70% of primiparas. In the case of multiparas the indications to operate were: prolapse of the loop of umbilical cord--71%, placenta previa in 85.8% and the prematurely detached placenta in 72.2% of cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8522206"
        },
        {
          "offsetInBeginSection": 881,
          "offsetInEndSection": 1136,
          "text": "Of the 100 patients, fetal distress was the highest (31%) indication among the list. Other common indications were failed induction (13%), severe pre-eclampsia (7%), eclampsia (4%), CPD (9%), APH (8%), breech presentation (7%), obstructed labour (5%) etc.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31086139"
        },
        {
          "offsetInBeginSection": 293,
          "offsetInEndSection": 636,
          "text": "The indications for cesarean section were divided into 3 groups: mandatory operations (feto-pelvic disproportion, haemorrhagic placenta praevia, dystocia): 41.4%; prudent operations (long-awaited infant, fetal suffering, breech presentation, cicatricial uterus): 50%; and necessary operations (maternal disease, especially hypertension): 8.6%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7782593"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 565,
          "text": "The first cause of surgery indication was the cephalopelvic disproportion, followed by previous cesarean, preeclampsia, severe fetal suffering and abnormal position.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9803656"
        },
        {
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1335,
          "text": "Principal indications were faetal distress (26%), PROM (15%), failed progress of labour and breech presentation were 8% each, other indications were eclampsia (4%), obstructed labour (5%), scar tenderness (4%), history of previous 2 caesarian section 5%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33116074"
        },
        {
          "offsetInBeginSection": 1183,
          "offsetInEndSection": 1572,
          "text": "Most common indication of cesarean section was fetal distress 243 (28%) followed by previous cesarean section 165 (18%), non-progress of labour 106 (12%), oligohydramnios 59 (7%), malpresentation 59 (7%), cephalo pelvic disorders 52 (6.5%), and hypertensive disorder in pregnancy 33 (4%).CONCLUSIONS: Prevalence of cesarean section in a tertiary care hospital is high compared to WHO data.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31477935"
        },
        {
          "offsetInBeginSection": 388,
          "offsetInEndSection": 711,
          "text": "Foetal distress was the commonest indication in primigravidae who underwent caesarean section. The other indications of caesarean section in this study were breech, severe pre-eclampsia, eclampsia, cord prolapse, elderly primi, postdated, premature rupture of membrane, twin, compound presentation, meconium stained liquor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22187763"
        },
        {
          "offsetInBeginSection": 464,
          "offsetInEndSection": 712,
          "text": "Elective caesarean delivery was the leading cause of repeat sections, followed by dystocia, others, breech and fetal distress. In contrast, breech presentation, dystocia and fetal distress were the leading indications for primary caesarean section.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15512137"
        },
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 441,
          "text": "Main causes were: Iterative section 38.2%; cephalopelvic disproportion 28.1%; pelvic presentation, 23.4%; hypertensive disease in pregnancy 16.3%; and acute fetal suffering, 10.9%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9273336"
        },
        {
          "offsetInBeginSection": 2184,
          "offsetInEndSection": 2444,
          "text": " elective sections (59.5%). The common indications were \u0027past caesarean section\u0027 (27.5%), foetal distress and non-reassuring cardiotocograph (14.3%), failed progress of labour (13.2%), cephalo-pelvic disproportion or shoulder dystocia (12.0%), and malpresentat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34663258"
        },
        {
          "offsetInBeginSection": 396,
          "offsetInEndSection": 747,
          "text": " major maternal indications were cephalopelvic disproportion (15.5%), previous caesarean section (14.7%), eclampsia (7.2%), failed induction of labor (5.5%), and placenta previa (5.1%). Fetal distress (9.6%), breech presentation (4.7%), fetal macrosomia (4.3%), and pregnancy complicated by multiple fetuses (4.2%) were the major fetal indications. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805945"
        },
        {
          "offsetInBeginSection": 384,
          "offsetInEndSection": 505,
          "text": "Principal indications are: dystocia (26.8%), fetal distress (38.1%), dynamic dystocia, previous uterine incision (11.2%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11802553"
        }
      ],
      "id": "67d7201b18b1e36f2e00002c",
      "ideal_answer": [
        "Cesarean sections (C-sections) are surgical procedures used to deliver a baby through incisions in the abdomen and uterus. Indications for a cesarean section can be maternal, fetal, or placental. Common indications include:\n\n1. Previous cesarean section: Women with a history of previous cesarean deliveries may require a repeat C-section.\n2. Labor dystocia: Difficult or abnormal labor, often due to the baby’s size, position, or the mother’s pelvis shape.\n3. Fetal distress: Signs that the baby is not well, such as abnormal heart rate patterns.\n4. Abnormal fetal position: Breech (feet or buttocks first) or transverse (sideways) positions.\n5. Placenta previa: The placenta covers the cervix, blocking the baby’s exit.\n6. Placental abruption: The placenta detaches from the uterine wall before delivery.\n7. Multiple gestations: Twins or higher-order multiples, especially if they are not in optimal positions.\n8. Maternal health conditions: Conditions such as severe preeclampsia, active genital herpes, or certain infections.\n9. Umbilical cord prolapse: The umbilical cord slips into the vagina ahead of the baby.\n10. Cephalopelvic disproportion: The baby’s head is too large to pass through the mother’s pelvis.\n11. Obstructed labor: Obstructions such as fibroids or pelvic tumors.\n\nThe decision for a cesarean section is individualized based on the specific circumstances of the mother and baby.",
        "The indications for cesarean section (C-section) can be categorized into several key areas:\n\nDystocia: Dysfunctional labor, cephalopelvic disproportion, and malpresentations are common causes.\n\nFetal Distress: This is a significant indication, particularly in emergency cesarean sections.\n\nBreech Presentation: A major indication for C-sections, especially in elective procedures.\n\nPrevious Cesarean Section: A history of previous cesarean sections is a common indication for repeat procedures.\n\nLabor Arrest Disorders: Conditions where labor progress halts.\n\nNonreassuring Fetal Heart Rate: Based on fetal monitoring showing signs of distress.\n\nHypertensive Disorders of Pregnancy: Conditions like preeclampsia necessitate cesarean delivery.\n\nPregnancy Complications: Various complications can indicate the need for a C-section.\n\nMacrosomia: Fetal macrosomia (large baby) can be an indication.\n\nContracted Pelvis: A contracted pelvis can prevent vaginal delivery.\n\nShort Interval Between Cesarean Sections: A short interval between previous C-sections can be a risk factor.\n\nMaternal Request: Some C-sections are performed based on maternal request.\n\nElective Cesarean Section: Elective C-sections, including those on maternal demand, are also common.\n\nOphthalmological Disorders: Conditions like myopia, retinopathy, glaucoma, and imminent retinal detachment can necessitate a C-section.\n\nThese indications highlight the various medical, obstetric, and sometimes personal reasons that may lead to the decision to perform a cesarean section."
      ],
      "exact_answer": [
        [
          "impending danger to maternal or fetal life"
        ],
        [
          "repeat cesarean delivery"
        ],
        [
          "malpresentation"
        ],
        [
          "nonreassuring fetal status"
        ],
        [
          "placenta previa"
        ],
        [
          "genital herpes simplex virus"
        ],
        [
          "failed labor"
        ],
        [
          "fetal anomaly"
        ],
        [
          "elective"
        ],
        [
          "abnormal fetal position"
        ],
        [
          "cephalopelvic disproportion"
        ],
        [
          "breech position"
        ],
        [
          "prolapsed umbilical cord"
        ],
        [
          "maternal heart disease"
        ],
        [
          "hellp syndrome"
        ],
        [
          "fetal distress"
        ]
      ]
    },
    {
      "body": "What are the main transcriptional cell states found in melanoma?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39216232",
        "http://www.ncbi.nlm.nih.gov/pubmed/38241976",
        "http://www.ncbi.nlm.nih.gov/pubmed/37268606",
        "http://www.ncbi.nlm.nih.gov/pubmed/34296805",
        "http://www.ncbi.nlm.nih.gov/pubmed/38519642",
        "http://www.ncbi.nlm.nih.gov/pubmed/32753671",
        "http://www.ncbi.nlm.nih.gov/pubmed/25865119",
        "http://www.ncbi.nlm.nih.gov/pubmed/34529939",
        "http://www.ncbi.nlm.nih.gov/pubmed/34874265",
        "http://www.ncbi.nlm.nih.gov/pubmed/30110134",
        "http://www.ncbi.nlm.nih.gov/pubmed/18245463",
        "https://pubmed.ncbi.nlm.nih.gov/38519642/",
        "https://pubmed.ncbi.nlm.nih.gov/37268606/",
        "http://www.ncbi.nlm.nih.gov/pubmed/38181739",
        "http://www.ncbi.nlm.nih.gov/pubmed/29881716",
        "http://www.ncbi.nlm.nih.gov/pubmed/32759677",
        "http://www.ncbi.nlm.nih.gov/pubmed/32123577",
        "http://www.ncbi.nlm.nih.gov/pubmed/38370717",
        "http://www.ncbi.nlm.nih.gov/pubmed/32753671/",
        "http://www.ncbi.nlm.nih.gov/pubmed/37268606/",
        "http://www.ncbi.nlm.nih.gov/pubmed/37898636",
        "http://www.ncbi.nlm.nih.gov/pubmed/39026725",
        "http://www.ncbi.nlm.nih.gov/pubmed/32796736",
        "http://www.ncbi.nlm.nih.gov/pubmed/30254208",
        "http://www.ncbi.nlm.nih.gov/pubmed/28545079"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 273,
          "text": "Melanoma is a heterogeneous cancer influenced by the plasticity of melanoma cells and their dynamic adaptations to microenvironmental cues. Melanoma cells transition between well-defined transcriptional cell states that impact treatment response and resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39216232"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 748,
          "text": "We confirm the presence of four distinct melanoma cell states - melanocytic, transitory, neural-crest like and undifferentiated, and identify enrichment of neural crest-like and undifferentiated melanoma cells in immunotherapy-resistant tumours.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39216232"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 389,
          "text": "Melanoma cells can transition through a series of phenotypic and transcriptional cell states that vary in invasiveness and treatment responsiveness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38241976"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Melanoma exhibits numerous transcriptional cell states including neural crest-like cells as well as pigmented melanocytic cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37268606"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Melanoma cell phenotype switching between differentiated melanocytic and undifferentiated mesenchymal-like states drives metastasis and drug resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34296805"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Melanomas can have multiple coexisting cell states, including proliferative (PRO) versus invasive (INV) subpopulations ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34529939"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 353,
          "text": "In melanoma, the melanocytic (MEL) and the mesenchymal-like (MES) states present themselves with different responses to therapy, making the identification of specific enhancers highly relevant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34874265"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Melanoma cells can switch between a melanocytic and a mesenchymal-like state. Scattered evidence indicates that additional intermediate state(s) may exist.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Recent studies suggest that malignant melanoma heterogeneity includes subpopulations of cells with features of multipotent neural crest (NC) cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30110134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Melanoma exhibits numerous transcriptional cell states including neural crest-like cells as well as pigmented melanocytic cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/37268606/"
        },
        {
          "offsetInBeginSection": 376,
          "offsetInEndSection": 757,
          "text": "Melanoma cells harboring a mesenchymal-like (MES) state, a population known to confer resistance to targeted therapy, were significantly enriched in early on-treatment biopsies from non-responders to ICB. TCF4 serves as the hub of this landscape by being a master regulator of the MES signature and a suppressor of the melanocytic and antigen presentation transcriptional programs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38181739"
        },
        {
          "offsetInBeginSection": 448,
          "offsetInEndSection": 684,
          "text": "As major regulators of phenotype switching between differentiated/proliferative and neural crest stem cell-like/invasive states, these factors appear as major drivers of intra-tumor heterogeneity and resistance to treatment in melanoma,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32759677"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Melanoma exhibits numerous transcriptional cell states including neural crest-like cells as well as pigmented melanocytic cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37268606/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Melanoma cells can switch between a melanocytic and a mesenchymal-like state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32753671/"
        },
        {
          "offsetInBeginSection": 129,
          "offsetInEndSection": 301,
          "text": "Recent expression profiling of melanoma cell lines identified two transcription signatures, respectively, corresponding with proliferative and invasive cellular phenotypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18245463"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 372,
          "text": "Melanoma plasticity consists of two distinct phenotypic states that co-exist in the tumor niche, the proliferative and the invasive, respectively associated with a high and low expression of MITF, the master regulator of melanocyte lineage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37898636"
        },
        {
          "offsetInBeginSection": 89,
          "offsetInEndSection": 258,
          "text": "Melanoma cells have the ability to switch from a proliferative melanocytic state to an invasive mesenchymal state and back again resulting in intratumoral heterogeneity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39026725"
        },
        {
          "offsetInBeginSection": 604,
          "offsetInEndSection": 839,
          "text": "ZEB2 drives MITF expression and is associated with a differentiated/proliferative melanoma cell state. On the other hand, ZEB1 is correlated with low MITF expression and a more invasive, stem cell-like and therapy-resistant cell state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32796736"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 333,
          "text": "Melanoma plasticity promotes a switch between proliferative and invasive phenotypes characterized by different transcriptional programs of which MITF is a critical regulator.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30254208"
        },
        {
          "offsetInBeginSection": 458,
          "offsetInEndSection": 624,
          "text": "This shows thousands of genomic regulatory regions underlying the proliferative and invasive states, identifying SOX10/MITF and AP-1/TEAD as regulators, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25865119"
        },
        {
          "offsetInBeginSection": 359,
          "offsetInEndSection": 680,
          "text": "While melanoma is not an epithelial cell-derived tumor and does not undergo a traditional EMT, melanoma undergoes a similar process known as phenotype switching in which high (micropthalmia-related transcription factor) MITF expressing (MITF-high) proliferative cells switch to a low expressing (MITF-low) invasive state.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28545079"
        }
      ],
      "id": "67da148418b1e36f2e000054",
      "ideal_answer": [
        "Melanoma is a heterogeneous cancer influenced by the plasticity of melanoma cells and their dynamic adaptations to microenvironmental cues. These cells can exist in four distinct melanoma cell states - melanocytic, transitory, neural-crest-like, and undifferentiated - and can transition through them, influencing the phenotype, aggressiveness, and treatment responsiveness of the corresponding tumor.",
        "The main transcriptional cell states in melanoma are Melanocytic, Neural Crest-like, Undifferentiated, and Transitory. The Melanocytic state is characterized by pigmentation genes, lipid metabolism, and dependence on lipid droplets. Neural Crest-like and Undifferentiated states are enriched in immunotherapy-resistant tumors, with the latter opposing Melanocytic characteristics. The Transitory state is less defined. These states, confirmed by single-cell RNA sequencing, impact treatment response and resistance, with nonresponding cells in all states showing predisposition to BRAF/MEK inhibitor resistance due to pro-inflammatory signaling. Understanding these states is crucial for developing targeted therapies and improving patient outcomes.",
        "The main transcriptional cell states found in melanoma include melanocytic, transitory, neural-crest like, and undifferentiated. These states are confirmed through single-cell RNA sequencing and have implications for treatment response and resistance.",
        "The main transcriptional cell states found in melanoma, as identified from the provided documents, are:\n\n1. **Melanocytic**: This state is characterized by genes typically expressed in normal melanocytes, indicating a less aggressive phenotype.\n\n2. **Transitory**: This state represents an intermediate phase where cells begin to lose melanocyte-specific features and gain characteristics associated with more aggressive behavior.\n\n3. **Neural-Crest Like**: Cells in this state exhibit gene expression patterns similar to neural crest cells, which are involved in the development of various tissues including melanocytes. These cells may have increased migratory and invasive capabilities.\n\n4. **Undifferentiated**: This state is marked by a loss of differentiation markers, indicating a more aggressive and treatment-resistant phenotype.\n\nThese states were identified through comprehensive analysis of gene expression profiles in melanoma patients, providing insights into the heterogeneity and progression of the disease.",
        "The main transcriptional cell states in melanoma include the Melanocytic, Neural Crest-like, Undifferentiated, and Intermediate/Transitory states. The Melanocytic state is linked to pigmentation and lipid metabolism, while Neural Crest-like and Undifferentiated states are enriched in immunotherapy-resistant tumors. The Intermediate/Transitory state represents a transitioning phase with a distinct gene regulatory network. Understanding these states, each with distinct gene expression patterns, is crucial for developing targeted therapies due to their implications for treatment response and resistance, and the heterogeneity of melanoma cells.",
        "The main transcriptional cell states found in melanoma include the melanocytic, transitory, neural-crest like, and undifferentiated states. These states are characterized by distinct gene expression patterns and have been identified through single-cell RNA sequencing studies. The melanocytic state is associated with pigmentation and lipid metabolism, while the neural crest-like state is linked to a more aggressive and invasive phenotype. The transitory state represents a transitioning phase between different cell states, and the undifferentiated state shows characteristics of less differentiated cells. Understanding these cell states is crucial for developing targeted therapies, as each state may respond differently to treatment. Additionally, the presence of nonresponding cells within these states contributes to drug resistance, highlighting the importance of considering the heterogeneity of melanoma cells in treatment strategies.",
        "In melanoma, four main transcriptional cell states have been identified: Melanocytic, Neural Crest-like, Undifferentiated, and Transitory. The Melanocytic state is marked by pigmentation and lipid metabolism. Neural Crest-like and Undifferentiated states are prevalent in immunotherapy-resistant tumors, with the latter contrasting Melanocytic traits. The Transitory state is a transitioning phase. These states, confirmed by single-cell RNA sequencing, significantly influence treatment outcomes and resistance, including a predisposition to BRAF/MEK inhibitor resistance in nonresponding cells across all states, highlighting the need for targeted therapies tailored to each state to enhance patient outcomes.",
        "Melanoma exhibits several transcriptional cell states that reflect different stages of differentiation and functional behavior. A well‐characterized classification includes a melanocytic state defined by high expression of pigmentation genes, a transitory or intermediate state that lies between differentiation and dedifferentiation, a neural crest‐like state with stem‐like and migratory features, and an undifferentiated state often associated with invasiveness and therapy resistance. Some studies also describe distinct amelanotic states that may precede the appearance of pigmented cells. These states capture the dynamic and heterogeneous nature of melanoma cells as they transition between proliferation, migration, and treatment responsiveness.",
        "The main transcriptional cell states found in melanoma are melanocytic, transitory, neural crest-like, and undifferentiated. These states influence treatment response and resistance, with neural crest-like and undifferentiated cells being enriched in immunotherapy-resistant tumors. Additionally, the melanocytic state is linked to metabolic dependencies such as lipid droplet utilization.",
        "Melanoma exhibits four distinct transcriptional cell states that reflect the cancer\u0027s heterogeneity and dynamic adaptability. These states include melanocytic, transitory, neural-crest like, and undifferentiated cell states, which play crucial roles in treatment response and tumor progression.",
        "The main transcriptional cell states identified in melanoma include melanocytic, transitory, neural crest like, and undifferentiated states. These states play a crucial role in determining treatment response and resistance. Notably, the neural crest like and undifferentiated states are enriched in immunotherapy resistant tumours, highlighting their significance in therapeutic outcomes.",
        "The four main transcriptional cell states in melanoma, consistently identified across sources and validated through single-cell RNA sequencing, are: Melanocytic, Transitory, Neural-crest like, and Undifferentiated. Notably, Neural-crest like and Undifferentiated states are particularly associated with resistance to immunotherapy, influencing treatment response and outcomes in melanoma patients.",
        "The main transcriptional cell states found in melanoma include melanocytic, transitory, neural crest like, and undifferentiated. These states influence treatment response and resistance, with neural crest like and undifferentiated cells being more prevalent in immunotherapy resistant tumors.",
        "Melanoma cells can transition through a series of phenotypic and transcriptional cell states that vary in invasiveness and treatment responsiveness. These include melanocytic, transitory, neural-crest like and undifferentiated.",
        "Studies have identified four distinct transcriptional cell states in melanoma cells, including melanocytic, transitory, neural-crest like, and undifferentiated states. These cell states are significant as they impact treatment response and resistance, with neural crest-like and undifferentiated melanoma cells being enriched in immunotherapy-resistant tumours. The ability of melanoma cells to transition through these various phenotypic and transcriptional states contributes to their heterogeneity and influences their invasiveness and responsiveness to treatment. Understanding these cell states is crucial for developing effective therapeutic strategies against melanoma.",
        "Melanoma exhibits four primary transcriptional cell states: melanocytic, transitory, neural-crest like, and undifferentiated. These states influence the cancer\u0027s invasiveness, treatment responsiveness, and resistance to immunotherapy, with neural crest-like and undifferentiated states being particularly associated with resistance.",
        "The main transcriptional cell states found in melanoma include the melanocytic state, which retains some of the original pigmentation features; the transitory state, representing a transition phase between different states; the neural crest like state, characterized by high plasticity and invasiveness; and the undifferentiated state, associated with aggressive behavior and resistance to immunotherapy. These states influence treatment response and resistance, highlighting the dynamic nature of melanoma cells in adapting to their microenvironment.",
        "Four distinct melanoma cell states have been identified: melanocytic, transitory, neural crest-like, and undifferentiated. Melanoma cells can transition between these well-defined transcriptional cell states, impacting treatment response and resistance. These states are influenced by the plasticity of melanoma cells and their dynamic adaptations to microenvironmental cues.",
        "Melanoma exhibits a heterogeneous nature, with melanoma cells transitioning through distinct transcriptional cell states that influence treatment response and resistance. These states include melanocytic, transitory, neural-crest like, and undifferentiated. The neural-crest like and undifferentiated states are particularly significant as they are enriched in tumors that are resistant to immunotherapy. These transitions highlight the dynamic and plastic nature of melanoma cells, adapting to microenvironmental cues and impacting the overall behavior and treatment outcomes of the cancer.",
        "The main transcriptional cell states found in melanoma include:\n\n1. **Melanocytic State**: This state is characterized by the expression of genes typically associated with normal melanocytes, such as MITF (Microphthalmia-associated transcription factor). Cells in this state are less aggressive and more responsive to targeted therapies.\n\n2. **Transitory State**: This is a transitional phase where melanoma cells begin to alter their gene expression profiles, moving away from the melanocytic state towards other states. These cells may exhibit increased plasticity, allowing them to adapt to different microenvironments.\n\n3. **Neural-Crest Like State**: Cells in this state express genes associated with neural crest progenitors, such as SOX10 and PAX3. This state is often linked to increased invasiveness and metastatic potential. Additionally, these cells are more likely to be resistant to immunotherapy.\n\n4. **Undifferentiated State**: This state is marked by a loss of differentiation markers and an expression profile that resembles embryonic stem cells or other undifferentiated cell types. These cells are highly aggressive, invasive, and often resistant to various therapeutic approaches.\n\nThese transcriptional states play a significant role in determining the behavior of melanoma cells, including their invasiveness, metastatic potential, and response to treatments such as targeted therapies and immunotherapy. The ability of melanoma cells to transition between these states contributes to the heterogeneity and adaptability of the disease, making it challenging to treat effectively.",
        "The main transcriptional cell states identified in melanoma are:\n\n1. **Melanocytic**: This state is characterized by cells resembling normal melanocytes, which are pigment-producing cells.\n\n2. **Transitory**: Cells in this state are undergoing a transition between other states, indicating a dynamic and adaptable nature.\n\n3. **Neural-Crest Like**: These cells exhibit characteristics similar to neural crest cells, which are involved in the development of various tissues. This state is associated with higher invasiveness and resistance to immunotherapy.\n\n4. **Undifferentiated**: Cells in this state lack specific differentiation markers, making them less specialized and potentially more aggressive.\n\nThese states influence melanoma\u0027s behavior, including its invasiveness and response to treatments such as immunotherapy. The ability of melanoma cells to transition between these states contributes to treatment resistance and the overall heterogeneity of the disease.",
        "Melanoma cells exhibit four main transcriptional cell states: melanocytic, transitory, neural crest-like, and undifferentiated. These states reflect the dynamic nature of melanoma, underpinning differences in invasiveness and treatment responses. The melanocytic state is characterized by features similar to normal pigmented cells, while the transitory state represents an intermediate phase between differentiation and de-differentiation. The neural crest-like state exhibits stem cell-like plasticity, and the undifferentiated state is less specialized, often associated with resistance to therapy.",
        "There are four main transcriptional cell states in melanoma. These states are melanocytic, transitory, neural-crest like and undifferentiated. Neural crest-like and undifferentiated melanoma cells are enriched in immunotherapy-resistant tumours.",
        "The main transcriptional cell states found in melanoma include:\n\n1. **Melanocytic**: Characterized by genes typically expressed in normal melanocytes.\n2. **Transitory**: A state that suggests a transition between other states, possibly indicating dynamic changes in gene expression.\n3. **Neural-Crest Like**: Resembles the gene expression profile of neural crest cells, which are involved in the development of various tissues and may contribute to melanoma\u0027s aggressive behavior.\n4. **Undifferentiated**: Lacks specific differentiation markers, potentially reflecting a more primitive or stem-like state.\n\nThese states influence how melanoma responds to treatments and can affect resistance to therapies like immunotherapy.",
        "The main transcriptional cell states found in melanoma are melanocytic, transitory, neural-crest like, and undifferentiated. These cell states impact treatment response and resistance, with neural crest-like and undifferentiated melanoma cells being enriched in immunotherapy-resistant tumors.",
        "The main transcriptional cell states identified in melanoma are:\n\n1. **Melanocytic**: This state is characterized by cells resembling normal melanocytes, which are pigment-producing cells.\n\n2. **Transitory**: Cells in this state are undergoing a transition between other states, indicating a dynamic and adaptable nature.\n\n3. **Neural-Crest Like**: These cells exhibit characteristics similar to neural crest cells, which are involved in the development of various tissues during embryogenesis.\n\n4. **Undifferentiated**: This state is marked by a lack of specific differentiation markers, making these cells more primitive and potentially more aggressive.\n\nThese states influence melanoma\u0027s behavior, including invasiveness and resistance to treatments such as immunotherapy. The ability of melanoma cells to transition between these states underscores the complexity of melanoma progression and treatment response.",
        "Melanoma is characterized by its heterogeneity, driven by the plasticity of melanoma cells which can transition through various phenotypic and transcriptional states. Four distinct melanoma cell states have been identified: melanocytic, transitory, neural-crest like, and undifferentiated. Notably, neural crest-like and undifferentiated states are enriched in immunotherapy-resistant tumors, highlighting their role in treatment resistance.",
        "The main transcriptional cell states found in melanoma are melanocytic, transitory, neural-crest like, and undifferentiated. These states vary in their invasiveness and responsiveness to treatment, with neural crest-like and undifferentiated states being enriched in immunotherapy-resistant tumors. Melanoma\u0027s heterogeneity and cell plasticity contribute to its dynamic adaptation and treatment challenges.",
        "According to recent studies, melanoma cells can transition through four distinct transcriptional cell states: melanocytic, transitory, neural-crest like, and undifferentiated. These cell states impact treatment response and resistance, with enrichment of neural crest-like and undifferentiated melanoma cells observed in immunotherapy-resistant tumors.",
        "The main transcriptional cell states found in melanoma are melanocytic, transitory, neural-crest like, and undifferentiated. These states represent different stages of cell differentiation and are associated with varying levels of invasiveness and treatment responsiveness. The melanocytic state is characterized by cells that resemble normal melanocytes, while the transitory state represents an intermediate phase. Neural-crest like cells exhibit features similar to neural crest cells, which are multipotent and highly migratory, and the undifferentiated state is associated with a loss of specific lineage markers and increased resistance to therapies, particularly immunotherapy.",
        "The main transcriptional cell states in melanoma, as consistently identified through single-cell RNA sequencing, are Melanocytic, Transitory, Neural-crest like, and Undifferentiated. These states play a crucial role in influencing treatment response and resistance, with Neural-crest like and Undifferentiated states being particularly enriched in tumors resistant to immunotherapy, underscoring their importance in personalized treatment strategies.",
        "Melanoma is characterized by a heterogeneity influenced by the plasticity of melanoma cells and their adaptation to microenvironmental cues. The primary transcriptional cell states identified in melanoma include melanocytic, transitory, neural crest like, and undifferentiated. These states vary in terms of invasiveness and treatment responsiveness.",
        "Melanoma cells transition between well-defined transcriptional cell states. The four distinct melanoma cell states are melanocytic, transitory, neural-crest like and undifferentiated. These states impact treatment response and resistance.",
        " The main transcriptional cell states found in melanoma are:\n\n1. Melanocytic\n2. Transitory\n3. Neural-crest like\n4. Undifferentiated\n\nThese cell states impact treatment response and resistance, with neural crest-like and undifferentiated melanoma cells being enriched in immunotherapy-resistant tumors.",
        "Based on the provided context, melanoma exhibits four distinct transcriptional cell states: melanocytic, transitory, neural-crest like, and undifferentiated. These cell states represent different phenotypic and transcriptional profiles that melanoma cells can transition between, influencing their invasiveness and response to treatment. Notably, neural crest-like and undifferentiated melanoma cells have been found to be enriched in tumors that are resistant to immunotherapy, highlighting the clinical relevance of these transcriptional states in treatment outcomes.",
        "Studies have shown that melanoma cells exist in four main transcriptional states: melanocytic, transitory, neural-crest like, and undifferentiated. These states influence treatment response and resistance, with transitions between them affecting invasiveness and responsiveness to therapies.",
        "Melanoma cells can transition through a series of phenotypic and transcriptional cell states that vary in invasiveness and treatment responsiveness. The four distinct melanoma cell states are: melanocytic, transitory, neural-crest like and undifferentiated.",
        "According to the provided abstracts, the main transcriptional cell states found in melanoma are:\n\n1. Melanocytic\n2. Transitory\n3. Neural-crest like\n4. Undifferentiated\n\nThese cell states have been identified as distinct and influential in treatment response and resistance, particularly with regards to immunotherapy.",
        "The main transcriptional cell states found in melanoma are melanocytic, transitory, neural-crest like, and undifferentiated. These distinct cell states impact treatment response and resistance, with neural crest-like and undifferentiated states being enriched in immunotherapy-resistant tumors.",
        "Melanoma cells have been shown to exist in four main transcriptional states. One state is melanocytic, where the cells display characteristics of differentiated melanocytes. A second, transitory state shows features intermediate between differentiation and dedifferentiation. The third is a neural crest-like state, marked by stem cell–like properties and greater migratory potential. Finally, there is an undifferentiated state, which is often linked to greater invasiveness and resistance to treatment.",
        "The main transcriptional cell states found in melanoma are: Melanocytic, Transitory, Neural-crest like, and Undifferentiated, with the latter two being particularly associated with immunotherapy resistance.",
        "Melanoma cells can transition through a series of phenotypic and transcriptional cell states that vary in invasiveness and treatment responsiveness. Well-defined transcriptional cell states found in melanoma include melanocytic, transitory, neural-crest like and undifferentiated.",
        "The main transcriptional cell states found in melanoma include melanocytic, transitory, neural crest-like, and undifferentiated states. Melanoma cells can transition through a series of phenotypic and transcriptional cell states that vary in invasiveness and treatment responsiveness. These transitions between well-defined transcriptional cell states impact treatment response and resistance. Enrichment of neural crest-like and undifferentiated melanoma cells is observed in immunotherapy-resistant tumors.",
        "Melanoma exhibits four distinct transcriptional cell states: melanocytic, transitory, neural-crest like, and undifferentiated, with the latter two states being particularly associated with immunotherapy resistance. These cell states are dynamic and plastic, allowing melanoma cells to transition between them in response to environmental factors, which ultimately influences their treatment responsiveness and invasiveness.",
        "The main transcriptional cell states identified in melanoma are melanocytic, transitory, neural-crest like, and undifferentiated; these states influence invasiveness, treatment responsiveness, and resistance to immunotherapy."
      ],
      "exact_answer": [
        [
          "Melanocytic",
          "melanocyte-like",
          "Proliferative",
          "Melanocytic/Differentiated State"
        ],
        [
          "Transitory",
          "intermediate state"
        ],
        [
          "Neural-crest like",
          "Neural Crest Stem Cell (NCSC)-like State"
        ],
        [
          "Undifferentiated",
          "mesenchymal-like state",
          "Invasive",
          "mesenchymal-like (MES) state"
        ]
      ]
    },
    {
      "body": "Which biomedical challenge has been designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39180335"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "BioASQ Synergy: a dialogue between question-answering systems and biomedical experts for promoting COVID-19 research.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39180335"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 183,
          "text": "This article presents the novel BioASQ Synergy research process which aims to facilitate the interaction between biomedical experts and automated question-answering systems",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39180335"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "OBJECTIVE: This article presents the novel BioASQ Synergy research process which aims to facilitate the interaction between biomedical experts and automated question-answeri",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39180335"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 324,
          "text": "OBJECTIVE: This article presents the novel BioASQ Synergy research process which aims to facilitate the interaction between biomedical experts and automated question-answering systems.MATERIALS AND METHODS: The proposed research allows systems to provide answers to emerging questions, which in turn are assessed by experts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39180335"
        },
        {
          "offsetInBeginSection": 657,
          "offsetInEndSection": 1143,
          "text": "The experts seem to be very satisfied with the quality of the ideal answers provided by the systems, suggesting that such systems are already useful in answering open research questions.DISCUSSION: BioASQ Synergy aspires to provide a tool that gives the experts easy and personalized access to the latest findings in a fast-growing corpus of material.CONCLUSION: In this article, we envisioned BioASQ Synergy as a continuous dialogue between experts and systems to issue open questions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39180335"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 183,
          "text": " This article presents the novel BioASQ Synergy research process which aims to facilitate the interaction between biomedical experts and automated question-answering systems",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39180335"
        }
      ],
      "type": "factoid",
      "id": "67d3434d18b1e36f2e000002",
      "ideal_answer": [
        "BioASQ Synergy aims to facilitate the interaction between biomedical experts and automated question-answering systems.",
        "The BioASQ Synergy research process aims to facilitate the interaction between biomedical experts and automated question-answering systems to promote COVID-19 research. It presents a novel approach for dialogue between question-answering systems and biomedical experts, allowing experts to provide feedback and guidance to improve the systems\u0027 performance on COVID-19 related questions.",
        "BioASQ Synergy is the biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems, aiming to promote COVID-19 research. It operates through a continuous dialogue where systems provide answers to emerging COVID-19 questions, which are then assessed by experts. The expert feedback is utilized to iteratively refine the systems, enhancing the understanding of the pandemic and contributing to solution discovery. This approach provides experts with easy access to the latest findings, assisting in navigating the rapidly growing body of COVID-19 research.",
        "BioASQ Synergy has been designed to facilitate interaction between biomedical experts and automated question-answering systems to promote COVID-19 research. This initiative aims to provide a continuous dialogue that helps in navigating the fast-growing corpus of research and supports the incremental understanding of the developing pandemic.",
        "The BioASQ Synergy challenge was designed to foster collaboration between biomedical experts and automated question-answering systems for COVID-19 research.",
        "BioASQ Synergy is the biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research.",
        "The biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research is \"BioASQ Synergy.\"",
        "BioASQ Synergy is the biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems, primarily aiming to promote COVID-19 research. It operates through a continuous dialogue where systems provide answers to emerging COVID-19 questions, which are then assessed by experts. The feedback loop enables the iterative refinement of the systems, contributing to a deeper understanding of the developing problem and solution discovery. This synergy provides experts with personalized access to the latest research findings, showing promising results in assisting researchers navigate available resources with high-quality answers.",
        "The BioASQ Synergy research process aims to facilitate the interaction between biomedical experts and automated question-answering systems for promoting COVID-19 research. It presents a novel dialogue approach where biomedical experts and question-answering systems collaborate to find relevant information and answer questions related to COVID-19.",
        "The BioASQ Synergy research process aims to facilitate the interaction between biomedical experts and automated question-answering systems to promote COVID-19 research. It presents a novel dialogue between human experts and AI systems to assist in accessing, analyzing, and extracting relevant information from the rapidly growing scientific literature on COVID-19.",
        "BioASQ Synergy is the biomedical challenge designed to bridge the gap between biomedical experts and automated question-answering systems, specifically to advance COVID-19 research. Through a continuous feedback loop, where systems answer emerging COVID-19 questions and experts provide assessments, the challenge refines the systems. This synergy enhances pandemic understanding, aids in solution discovery, and provides experts with streamlined access to the latest research, helping navigate the expansive COVID-19 literature.",
        "The biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems for COVID-19 research is \u0027BioASQ Synergy\u0027. This initiative enables systems to provide answers to emerging questions, which are then assessed by experts, promoting a continuous dialogue to navigate fast-growing research material and contribute to solution discovery.",
        "The BioASQ Synergy challenge was specifically designed to facilitate interaction between biomedical experts and automated question-answering systems to promote COVID-19 research. This innovative research process aims to create a dialogue that supports collaborative knowledge exchange and advances understanding of the pandemic through technological and expert insights.",
        "The BioASQ Synergy is a biomedical challenge designed to facilitate interaction between question answering systems and biomedical experts, specifically aimed at promoting advancements in COVID 19 research through collaborative efforts.",
        "BioASQ Synergy is an innovative biomedical challenge designed to foster collaboration between question answering systems and biomedical experts. This initiative aims to enhance the exchange of knowledge and expertise, particularly in advancing research related to COVID 19. By creating a platform for dialogue, BioASQ Synergy helps integrate automated systems with expert insights, promoting efficient and effective advancements in understanding and combating the pandemic.",
        "The BioASQ Synergy research process has been designed to facilitate interaction between biomedical experts and automated question-answering systems, with the ultimate goal of promoting COVID-19 research. This novel approach aims to create a dialogue between these two entities, enabling them to work together effectively. By doing so, BioASQ Synergy seeks to leverage the strengths of both human expertise and artificial intelligence to accelerate progress in understanding and combating the COVID-19 pandemic. Through this synergy, biomedical experts can provide valuable insights and context, while automated question-answering systems can rapidly process and analyze large amounts of data, thereby identifying potential areas of investigation and supporting informed decision-making in COVID-19 studies.",
        "The BioASQ Synergy challenge has been designed to facilitate interaction between biomedical experts and automated question-answering systems, with the goal of promoting COVID-19 research.",
        "The biomedical challenge known as BioASQ Synergy has been designed to facilitate interaction between biomedical experts and automated question answering systems. This initiative aims to promote COVID 19 research by fostering collaboration and dialogue between these groups, leveraging their combined expertise to advance understanding and address key questions in the field.",
        "The biomedical challenge that has been designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research is \"BioASQ Synergy\".",
        "BioASQ Synergy is a novel research process designed to facilitate the interaction between biomedical experts and automated question-answering systems to promote COVID-19 research.",
        "The BioASQ Synergy research process has been designed to facilitate the interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research.",
        "The BioASQ Synergy research process has been designed to facilitate interaction between biomedical experts and automated question-answering systems to promote COVID-19 research. This innovative approach aims to enhance the dialogue between human experts and AI systems, thereby accelerating the discovery and dissemination of critical information related to the pandemic. By integrating the insights and knowledge of biomedical experts with the data processing capabilities of automated systems, BioASQ Synergy seeks to advance the understanding and management of COVID-19.",
        "BioASQ Synergy has been designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research.",
        "BioASQ Synergy is a novel research process designed to facilitate a dialogue between biomedical experts and automated question-answering systems. Its primary aim is to promote COVID-19 research by fostering collaboration and integrating expert insights with automated techniques.",
        "BioASQ Synergy is designed to facilitate the interaction between biomedical experts and automated question-answering systems. This interaction aims to promote COVID-19 research, as described in Snippet0 and Snippet1.",
        "The biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research is BioASQ Synergy.",
        "BioASQ Synergy is designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research.",
        "The BioASQ Synergy challenge has been designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research.",
        "The BioASQ Synergy is a novel research process specifically designed to enhance the interaction between biomedical experts and automated question-answer systems, with the goal of advancing COVID-19 research. This initiative seeks to leverage the strengths of both human expertise and machine intelligence to address challenges in understanding and responding to the pandemic effectively.",
        "The biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems to promote COVID-19 research is the BioASQ Synergy research process.",
        "The BioASQ Synergy challenge is designed to promote interaction between biomedical experts and automated question-answering systems for COVID-19 research.",
        "BioASQ Synergy is the biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems, aiming to promote COVID-19 research. It operates through a collaborative process where systems provide answers to emerging questions, which are then expert-assessed, with feedback used to enhance system performance. This approach assists researchers in accessing the latest findings, providing high-quality answers to open questions, and offers personalized access to a rapidly expanding corpus of COVID-19 related material, ultimately supporting the global response against the pandemic.",
        "The BioASQ Synergy challenge has been designed to facilitate interaction between biomedical experts and automated question-answering systems. This challenge aims to promote COVID-19 research by fostering a dialogue between these systems and experts, enhancing the quality and relevance of the information provided to researchers working on COVID-19.",
        "BioASQ Synergy is a biomedical challenge designed to facilitate interaction between biomedical experts and automated question answering systems. It aims to promote COVID 19 research by fostering collaboration and dialogue, enabling experts to work alongside AI systems to address complex scientific questions and advance understanding of the disease.",
        "BioASQ Synergy is the biomedical challenge specifically designed to facilitate interaction between biomedical experts and automated question-answering systems to promote COVID-19 research. This novel research process aims to create a dialogue between human experts and AI systems to enhance knowledge discovery and information retrieval in the context of the COVID-19 pandemic, ultimately supporting researchers in their efforts to address this global health crisis.",
        "The BioASQ Synergy challenge has been designed to facilitate interaction between biomedical experts and automated question-answering systems, aiming to promote COVID-19 research through this collaborative approach.",
        "The BioASQ Synergy challenge has been designed to facilitate interaction between biomedical experts and automated question-answeringing systems in order to promote COVID-19 research.",
        "The BioASQ Synergy research process has been designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research. It aims to enable a dialogue between human experts and AI systems to advance our understanding of the novel coronavirus.",
        "BioASQ Synergy is the biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems, primarily aiming to promote COVID-19 research. Through a feedback loop where systems provide answers to emerging COVID-19 questions evaluated by experts, BioASQ Synergy enhances the accuracy of these systems, thereby aiding researchers in accessing the latest findings and accelerating the global response to the pandemic.",
        "BioASQ Synergy is a biomedical challenge designed to facilitate interaction between biomedical experts and automated question-answering systems in order to promote COVID-19 research.",
        "BioASQ Synergy is a novel research initiative designed to bridge the gap between biomedical experts and automated question-answering systems, specifically aimed at advancing COVID-19 research through enhanced dialogue and interaction between human expertise and AI systems."
      ],
      "exact_answer": [
        [
          "BioASQ Synergy"
        ]
      ]
    },
    {
      "body": "Why is Trifluridine/Tipiracil more active than other fluorpyrimidines in colorectal cancer patients?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26557901",
        "http://www.ncbi.nlm.nih.gov/pubmed/28111727"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 961,
          "offsetInEndSection": 1301,
          "text": "In addition to inhibition of thymidylate synthase, the major mechanism of action of classical fluoropyrimidines, TAS-102\u0027s major mechanism of action is incorporation into DNA, thereby causing DNA damage. TAS-102 also follows an alternative activation pathway via thymidine kinase, and is not a substrate for dihydropyrimidine dehydrogenase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26557901"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 296,
          "text": "potent thymidine phosphorylase inhibitor, tipiracil hydrochloride.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111727"
        },
        {
          "offsetInBeginSection": 1381,
          "offsetInEndSection": 1518,
          "text": "Tipiracil administered in combination with trifluridine significantly increased exposure to trifluridine compared with trifluridine alone",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111727"
        }
      ],
      "type": "summary",
      "id": "662fc6aa187cba990d000017",
      "ideal_answer": [
        "In addition to inhibition of thymidylate synthase, the major mechanism of action of classical fluoropyrimidines, TAS-102\u0027s major mechanism of action is incorporation into DNA, thereby causing DNA damage. TAS-102 also follows an alternative activation pathway via thymidine kinase, and is not a substrate for dihydropyrimidine dehydrogenase.    Tipiracil administered in combination with trifluridine, a potent thymidine phosphorylase inhibitor, tipiracil hydrochloride.significantly that increased exposure to trifluridine compared with trifluridine alone",
        "Trifluridine/tipiracil is a novel oral fluoropyrimidine with a unique mechanism of action that is more active than other fluoropyrimidines in colorectal cancer patients. Trifluridine is a thymidine-based nucleoside analog that is degraded by thymidine phosphorylase, an enzyme that is overexpressed in colorectal cancer cells. Tipiracil is a thymidine phosphorylase inhibitor that blocks the degradation of trifluridine, allowing for oral administration and increasing its bioavailability. This results in improved efficacy and reduced toxicity compared to other fluoropyrimidines.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines like 5-fluorouracil in colorectal cancer patients because it has a different mechanism of action. While fluoropyrimidines primarily inhibit nucleotide synthesis, trifluridine/tipiracil acts by incorporating the trifluridine component into DNA, resulting in DNA dysfunction and inhibition of cell proliferation. This allows trifluridine/tipiracil to overcome resistance to fluoropyrimidines that arises due to mechanisms like increased thymidylate synthase expression. The tipiracil component also increases systemic exposure of trifluridine by inhibiting its degradation.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it combines trifluridine, a nucleoside analog that gets incorporated into DNA and disrupts its function, with tipiracil, which inhibits the enzyme thymidine phosphorylase. This combination enhances the antitumor activity by increasing the bioavailability and effectiveness of trifluridine, leading to improved outcomes in patients with metastatic colorectal cancer.",
        "Trifluridine/Tipiracil exhibits higher activity in colorectal cancer patients compared to other fluoropyrimidines, primarily due to its distinct mechanism of incorporating into DNA, resulting in DNA dysfunction. This unique action allows it to overcome resistance to traditional fluoropyrimidines like 5-FU, maintain efficacy in patients intolerant to 5-FU, and show benefit across diverse prognostic subgroups based on age, tumor site, geographical origin, and KRAS status, making it a valuable option for refractory metastatic colorectal cancer.",
        "Trifluridine/tipiracil is a novel oral chemotherapeutic agent that has been approved for the treatment of metastatic colorectal cancer (mCRC) in the third-line setting. Trifluridine is a thymidine-based nucleoside analog that is degraded by thymidine phosphorylase (TP), an enzyme that is highly expressed in mCRC. Tipiracil is a TP inhibitor that blocks the degradation of trifluridine by TP, thereby increasing the bioavailability of trifluridine and allowing for oral administration. Trifluridine/tipiracil has been shown to be more active than other fluoropyrimidines in mCRC patients, with a higher response rate and longer progression-free survival.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique dual mechanism of action. It combines trifluorothymidine, which inhibits thymidylate synthase, and tipiracil, a thymidine phosphorylase inhibitor that prevents the drug\u0027s degradation, allowing for prolonged exposure and enhanced efficacy. This combination overcomes resistance mechanisms that limit other fluoropyrimidines and is effective in patients who have failed multiple prior therapies, including standard fluoropyrimidines. Additionally, when combined with bevacizumab, it shows improved progression-free survival compared to monotherapy, demonstrating its potential as a salvage therapy for metastatic colorectal cancer.",
        "Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients due to several key factors. Tipiracil inhibits thymidine phosphorylase, an enzyme responsible for the degradation of trifluridine, which significantly increases its bioavailability and systemic exposure. This leads to enhanced incorporation of trifluridine into DNA, thereby inhibiting cell proliferation more effectively. The coadministration of tipiracil with trifluridine results in a marked increase in the area under the concentration–time curve (AUC) and maximum observed plasma concentration (Cmax) of trifluridine, which is crucial for its enhanced therapeutic effect. Trifluridine, the active cytotoxic component, interferes with DNA function, preventing tumor cell proliferation. The presence of tipiracil ensures that trifluridine remains available in the system for a longer duration, thereby improving its efficacy. This mechanism was supported by the pivotal phase III RECOURSE trial, which demonstrated significant improvement in overall survival for patients treated with trifluridine/tipiracil compared to placebo. These factors collectively contribute to the superior activity of Trifluridine/Tipiracil in colorectal cancer patients compared to other fluoropyrimidines.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action. Trifluridine is a nucleoside analog that gets incorporated into DNA, disrupting DNA function and inhibiting cancer cell proliferation. Tipiracil, on the other hand, is included to inhibit the enzyme thymidine phosphorylase, which would otherwise degrade trifluridine. This combination enhances the bioavailability and effectiveness of trifluridine, allowing it to exert its cytotoxic effects more efficiently compared to other fluoropyrimidines. Additionally, Trifluridine/Tipiracil has shown efficacy in patients who have become resistant to other treatments, providing an important therapeutic option for advanced colorectal cancer.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action, which involves the incorporation of trifluridine into DNA, causing dysfunction and cell death. This mechanism is effective in 5-FU-resistant tumors and is enhanced by tipiracil, which increases trifluridine\u0027s bioavailability. Additionally, Trifluridine/Tipiracil is effective against cancer stem cell-like cells, particularly those expressing high levels of CD44 and CD133, which are more sensitive to Trifluridine than to 5-FU.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it combines a nucleoside analog that incorporates into DNA and a thymidine phosphorylase inhibitor that prevents degradation, enhancing its efficacy and bioavailability.",
        "Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action and pharmacokinetic properties. Trifluridine is a thymidine-based nucleoside analog that gets incorporated into DNA, causing DNA dysfunction and cell death. Tipiracil inhibits thymidine phosphorylase, an enzyme that degrades trifluridine, thereby increasing its bioavailability and half-life. This combination enhances the antitumor activity of trifluridine, making TAS-102 effective even in patients who have become resistant to other fluoropyrimidines like 5-fluorouracil (5-FU).",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines because its primary mechanism of action is incorporation into DNA, resulting in DNA dysfunction, whereas fluoropyrimidines like fluorouracil (5-FU) and capecitabine primarily act by enzyme inhibition of nucleotide synthesis. Trifluridine/tipiracil has activity in patients with 5-FU-resistant tumors and can be considered in patients with prior intolerance or toxicity to 5-FU. It also follows an alternative activation pathway via thymidine kinase, and is not a substrate for dihydropyrimidine dehydrogenase.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it is a novel, orally active, antimetabolite agent that combines trifluridine, a thymidine-based nucleoside analogue, with tipiracil, a potent thymidine phosphorylase inhibitor, which enhances the bioavailability and efficacy of trifluridine, leading to improved overall survival and progression-free survival in patients with metastatic colorectal cancer (mCRC) who have exhausted other treatment options.",
        "The provided documents do not explicitly state why Trifluridine/Tipiracil (FTD/TPI) is more active than other fluorpyrimidines in colorectal cancer patients. However, it is noted that FTD/TPI has been approved as a treatment option for late-line therapy in metastatic colorectal cancer (mCRC) and has shown efficacy in combination with bevacizumab. Additionally, studies have focused on identifying predictive markers of chemotherapy efficacy with FTD/TPI, suggesting that its effectiveness may be linked to specific biological factors, such as the expression of the RNA-editing enzyme ADAR1 and the neutrophil-lymphocyte ratio (NLR). Further research may be needed to fully understand the mechanisms underlying its activity compared to other fluorpyrimidines.",
        "Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients because it consists of trifluridine, a thymidine-based nucleoside analogue, and tipiracil, a potent thymidine phosphorylase inhibitor. Trifluridine incorporates directly into the DNA, leading to greater cytotoxicity, while tipiracil prevents its degradation, increasing bioavailability and therapeutic efficacy.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it primarily acts by incorporation into DNA, resulting in DNA dysfunction, whereas the primary mechanism of action of fluoropyrimidines such as fluorouracil (5-FU) and capecitabine is enzyme inhibition of nucleotide synthesis. Additionally, the combination of trifluridine and tipiracil, a thymidine phosphorylase inhibitor, enhances the bioavailability of trifluridine in vivo, allowing for sustained antitumor activity.",
        "Trifluridine/tipiracil works by incorporating trifluridine into the DNA of cancer cells, leading to DNA dysfunction and cell death. In contrast, classical fluoropyrimidines such as 5-fluorouracil rely on inhibiting thymidylate synthase, a mechanism that requires continuous enzyme inhibition—which is difficult to achieve with oral dosing. Moreover, 5-FU is often rapidly counteracted by uracil-DNA glycosylases that remove its incorporated forms, reducing its efficacy. Trifluridine/tipiracil also bypasses common resistance mechanisms seen in colorectal cancer, such as high thymidylate synthase expression and metabolism by dihydropyrimidine dehydrogenase, making it effective even in tumors resistant to 5-FU-based therapies. Tipiracil prevents the degradation of trifluridine by inhibiting thymidine phosphorylase, enhancing trifluridine’s bioavailability and overall antitumor activity.",
        "Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer due to its unique mechanism of action and pharmacokinetics. Trifluridine, a thymidine analog, incorporates into DNA, causing replication errors. Tipiracil inhibits thymidine phosphorylase (TP), preventing trifluridine\u0027s breakdown, thus prolonging its activity. This dual action enhances anti-tumor effects and overcomes resistance seen with older agents like 5-FU. TAS-102\u0027s oral administration offers convenience, supporting better patient compliance. Its distinct mechanism makes it effective in resistant cases, providing a valuable option for colorectal cancer treatment.",
        "Trifluridine/tipiracil (FTD/TPI) exhibits activity in colorectal cancer patients, even after failure of other fluoropyrimidines like 5-FU and capecitabine, due to its distinct mechanism of action. While fluoropyrimidines primarily inhibit nucleotide synthesis through enzyme inhibition, trifluridine/tipiracil primarily incorporates into DNA, causing DNA dysfunction, including strand breaks and decreased replication. Tipiracil inhibits thymidine phosphorylase, preventing trifluridine degradation and improving its bioavailability for oral administration. This allows trifluridine to exert its cytotoxic effects on tumors, even in cases where resistance or intolerance to 5-FU has developed. Thus, trifluridine/tipiracil can be effective in patients refractory, intolerant, or ineligible for 5-FU.",
        "Trifluridine/Tipiracil (FTD/TPI; marketed as Lonsurf®) demonstrates enhanced activity in colorectal cancer patients, particularly after fluoropyrimidine failure, due to its unique mechanism of action. FTD/TPI combines trifluridine, a nucleoside analog that inhibits DNA synthesis, with tipiracil, which blocks the metabolism of trifluridine, thereby increasing its efficacy. This combination prolongs survival in patients with refractory metastatic colorectal cancer (mCRC) and shows higher real-world objective response rates (rwORR) and disease control rates (rwDCR) compared to regorafenib. Its effectiveness in the third-line setting, following prior fluoropyrimidine-based therapies, underscores its role as a valuable treatment option for advanced colorectal cancer.",
        "Trifluridine/Tipiracil (TAS-102) is more effective than other fluoropyrimidines in treating colorectal cancer due to its unique dual mechanism of action. Trifluridine, a thymidine analog, incorporates into DNA, causing replication errors and cell death. Tipiracil inhibits thymidine phosphorylase (TP), which normally breaks down trifluridine, thereby increasing its concentration and enhancing efficacy.\n\nTAS-102 bypasses resistance mechanisms common with other fluoropyrimidines like 5-FU, such as increased thymidylate synthase or dihydropyrimidine dehydrogenase (DPD) activity. This makes it effective in patients who have developed resistance to these agents.\n\nClinical trials demonstrate that TAS-102 improves progression-free and overall survival in refractory metastatic colorectal cancer, highlighting its value as a potent treatment option when other therapies fail. Its dual action provides sustained tumor cell death, contributing to its superior effectiveness compared to traditional fluoropyrimidines.",
        "Trifluridine/Tipiracil (TAS-102) is considered more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action and formulation. Trifluridine, a thymidine analog, is combined with Tipiracil, which inhibits the phosphorylation of trifluridine, thereby enhancing its bioavailability and allowing for sustained exposure to the active drug. This combination allows TAS-102 to effectively target cancer cells that are resistant to traditional fluoropyrimidines like fluorouracil and capecitabine. Additionally, TAS-102 has shown efficacy in patients who have progressed after multiple lines of therapy, demonstrating its potential as a viable treatment option in refractory metastatic colorectal cancer (mCRC). The drug\u0027s ability to maintain a manageable safety profile while providing clinical benefits, such as improved progression-free survival (PFS) and overall survival (OS), further supports its effectiveness compared to other fluoropyrimidines.",
        "Trifluridine/Tipiracil is more active in colorectal cancer patients than other fluoropyrimidines because it primarily acts by incorporating into DNA, resulting in DNA dysfunction and cell proliferation inhibition, making it an effective treatment option for metastatic colorectal cancer patients, including those refractory to other treatments such as fluorouracil, irinotecan, and oxaliplatin.",
        "Trifluridine/tipiracil is a novel, orally administered, thymidine-based nucleoside analog with a thymidine phosphorylase inhibitor, which is approved for the treatment of metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents. Trifluridine/tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it is a thymidine-based nucleoside analog with a thymidine phosphorylase inhibitor, which improves the bioavailability of trifluridine and allows for oral administration.",
        "Trifluridine/tipiracil is more active in colorectal cancer patients due to its unique mechanism of action and its ability to target tumors that are resistant to standard therapies. Trifluridine, a thymidine analogue, incorporates into DNA, leading to DNA dysfunction, while tipiracil enhances the bioavailability of trifluridine by inhibiting its degradation. This combination allows for effective treatment in patients with chemorefractory metastatic colorectal cancer (mCRC), particularly those with 5-FU-resistant tumors or prior intolerance to fluoropyrimidines. Clinical trials, such as the phase III RECOURSE trial, have demonstrated significant overall survival benefits compared to placebo, indicating its efficacy in heavily treated mCRC patients. Additionally, ongoing studies are exploring its combination with other agents, further enhancing its therapeutic potential in this patient population.",
        "Trifluridine/tipiracil (TAS-102) is more active in colorectal cancer patients due to its unique mechanism of action and its ability to target tumors that are resistant to standard therapies. Unlike traditional fluoropyrimidines, which primarily inhibit nucleotide synthesis, trifluridine acts by incorporating into DNA, leading to DNA dysfunction. This mechanism allows it to be effective in patients with 5-FU-resistant tumors. Additionally, trifluridine/tipiracil has shown significant overall survival benefits in clinical trials, particularly in patients who are refractory to or intolerant of standard chemotherapy regimens. The combination of trifluridine with tipiracil enhances its bioavailability and efficacy, making it a valuable treatment option for patients with metastatic colorectal cancer who have previously undergone multiple lines of therapy.",
        "Trifluridine/tipiracil (Lonsurf®) is a novel, orally active, antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue, and tipiracil, a potent thymidine phosphorylase inhibitor. The approved regimen significantly improved overall survival and progression-free survival and was associated with a significantly higher disease control rate than placebo in patients with metastatic colorectal cancer.",
        "Trifluridine/Tipiracil (TFT) is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action, which involves incorporation into DNA resulting in DNA dysfunction. This distinguishes it from traditional fluoropyrimidines like 5-FU and capecitabine that inhibit nucleotide synthesis. Consequently, TFT is effective in patients with 5-FU-resistant tumors, offering a valuable treatment option for those refractory to or intolerant of 5-FU-based therapies. Its efficacy is further underscored by benefits across various prognostic subgroups and a convenient, orally administered formulation with a relatively mild toxicity profile.",
        "Trifluridine/tipiracil (TAS-102) exhibits enhanced activity in colorectal cancer patients, particularly those with fluoropyrimidine-resistant tumors, due to its unique mechanism of action. Unlike traditional fluoropyrimidines, which primarily inhibit nucleotide synthesis, trifluridine acts by incorporating into DNA, leading to DNA dysfunction. Additionally, tipiracil, a thymidine phosphorylase inhibitor, prevents the degradation of trifluridine, thereby improving its bioavailability and allowing for effective oral administration. This combination results in a more potent therapeutic effect, especially in patients who have previously shown intolerance or resistance to standard fluoropyrimidine treatments.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action. Trifluridine, the active component, is incorporated directly into DNA, leading to DNA dysfunction and cell death. Tipiracil, on the other hand, inhibits the enzyme thymidine phosphorylase, which breaks down trifluridine, thereby increasing its bioavailability and effectiveness. This combination allows for a more potent antitumor effect compared to traditional fluoropyrimidines, which primarily target RNA synthesis. Additionally, Trifluridine/Tipiracil has shown efficacy in patients who have become resistant to other treatments, providing a valuable option for those with advanced colorectal cancer.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it primarily acts by incorporation into DNA, resulting in DNA dysfunction. This mechanism of action is different from other fluoropyrimidines such as fluorouracil (5-FU) and capecitabine, which primarily inhibit nucleotide synthesis. Trifluridine/tipiracil has shown efficacy in patients with 5-FU-resistant tumors and can be considered as a treatment option for patients who have previously been treated with or are not candidates for 5-FU. Additionally, trifluridine/tipiracil has demonstrated benefits across various prognostic subgroups and is associated with a mild toxicity profile, making it a valuable option in the management of refractory metastatic colorectal cancer.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines like 5-fluorouracil (5-FU) in colorectal cancer patients because its primary mechanism of action is incorporation into DNA, resulting in DNA dysfunction, rather than enzyme inhibition of nucleotide synthesis like 5-FU. This allows trifluridine/tipiracil to retain activity in tumors that have developed resistance to 5-FU. Additionally, tipiracil inhibits the enzyme that breaks down trifluridine, increasing its systemic exposure.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it combines trifluridine, which incorporates into DNA and interferes with its function, with tipiracil, which inhibits the enzyme thymidine phosphorylase. This combination enhances the antitumor activity by increasing the bioavailability and effectiveness of trifluridine, leading to improved outcomes in patients with metastatic colorectal cancer.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines because Tipiracil inhibits thymidine phosphorylase, which improves the bioavailability of Trifluridine, allowing for oral administration and increased efficacy in colorectal cancer patients.",
        "Trifluridine/tipiracil (FTD/TPI) is more active than other fluoropyrimidines in colorectal cancer patients because it overcomes resistance mechanisms to standard fluoropyrimidine therapies. FTD is a thymidine-based nucleoside analog that is incorporated into DNA, inhibiting cell proliferation. Tipiracil inhibits the enzyme thymidine phosphorylase, which normally breaks down FTD, thereby increasing systemic exposure to FTD. This combination allows FTD/TPI to remain active in tumors that have developed resistance to standard fluoropyrimidines like 5-fluorouracil through mechanisms like increased expression of thymidylate synthase.",
        "Trifluridine/tipiracil is a novel oral chemotherapeutic agent that is approved for the treatment of metastatic colorectal cancer (mCRC) in patients who have been previously treated with, or are not considered candidates for, fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents. Trifluridine/tipiracil is available on the Australian Pharmaceutical Benefits Scheme for the treatment of patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents. Trifluridine/tipiracil is a novel oral chemotherapeutic agent that is approved for the treatment of metastatic colorectal cancer (mCRC) in patients who have been previously treated with, or are not considered candidates for, fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents, and anti",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it incorporates into DNA more effectively, leading to sustained antitumor activity, and is effective in 5-FU resistant cases due to the presence of Tipiracil, which prevents its degradation.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action, which primarily acts by incorporation into DNA, resulting in DNA dysfunction, rather than enzyme inhibition of nucleotide synthesis. This allows it to bypass the limitations of other fluoropyrimidines, such as resistance due to thymidine phosphorylase inhibition, and provides a different toxicity profile.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because trifluridine is incorporated into cancer cells more efficiently when pre-exposed to 5-fluorouracil, and tipiracil inhibits the breakdown of trifluridine, allowing it to remain at higher concentrations for longer periods. This combination enhances the anti-tumor activity compared to either drug alone. Additionally, trifluridine/tipiracil has shown promising results in combination with other agents like oxaliplatin, suggesting its potential as a chemotherapeutic backbone for gastrointestinal cancers.",
        "Trifluridine/Tipiracil exhibits higher activity in colorectal cancer patients than other fluoropyrimidines due to its unique mechanism of incorporating into DNA, causing dysfunction. This action overcomes resistance to traditional therapies like 5-FU, offering a valuable option for refractory metastatic colorectal cancer. Its efficacy is consistent across various prognostic subgroups, regardless of age, tumor site, or KRAS status. Additionally, its oral administration and relatively mild toxicity profile enhance its clinical utility, making it a preferred choice for patients intolerant to or failing 5-FU-based treatments.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to several key factors. Tipiracil inhibits the degradation of trifluridine by thymidine phosphorylase, increasing the bioavailability and systemic exposure of trifluridine. This results in higher levels of trifluridine in the bloodstream, enhancing its incorporation into DNA and inhibiting cell proliferation. Additionally, trifluridine works primarily by incorporating into DNA, leading to DNA dysfunction and ultimately inhibiting cancer cell proliferation. This mechanism is different from other fluoropyrimidines like fluorouracil (5-FU) and capecitabine, which mainly inhibit nucleotide synthesis. These factors collectively contribute to the increased activity of Trifluridine/Tipiracil in colorectal cancer patients compared to other fluoropyrimidines.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action. As an oral drug combining trifluorothymidine and a thymidine phosphorylase inhibitor, it is indicated as salvage therapy for metastatic colorectal cancer (mCRC) patients who have progressed after all available regimens. Studies have shown that the combination of trifluridine/tipiracil plus bevacizumab results in a statistically significant and clinically relevant improvement in progression-free survival (PFS), with tolerable toxicity in patients with refractory mCRC. This suggests that trifluridine/tipiracil offers an important new treatment option for patients with mCRC, particularly those maintaining good performance status at the end of life. The C-TASK FORCE study, a phase I/II trial, also demonstrated promising activity with an acceptable toxicity profile, further supporting the role of trifluridine/tipiracil in the treatment of heavily pretreated mCRC patients.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines because its primary mechanism is the incorporation of trifluridine directly into DNA, causing irreparable DNA damage and leading to cell death. In contrast, traditional agents like 5-FU mainly act by inhibiting thymidylate synthase, a process that can be bypassed or compensated by cancer cells. Additionally, tipiracil prevents the rapid degradation of trifluridine by inhibiting thymidine phosphorylase, which increases its bioavailability and effectiveness. This unique mode of action makes it effective even in tumors that have developed resistance to 5-FU, thereby offering a therapeutic advantage in colorectal cancer patients.",
        "Trifluridine/tipiracil is more active than other fluorpyrimidines in colorectal cancer patients, particularly those with 5-FU-resistant tumors, due to its distinct mechanism of action involving incorporation into DNA, resulting in DNA dysfunction, rather than just inhibiting nucleotide synthesis. Additionally, genetic factors like the FGFR4 p.G388R polymorphism may enhance its efficacy in specific patient subgroups, making it a valuable option for refractory metastatic colorectal cancer.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it combines trifluridine, a thymidine-based nucleoside analogue, with tipiracil, a potent thymidine phosphorylase inhibitor, which prevents the rapid degradation of trifluridine, thereby enhancing its antitumor activity. This combination has shown significant improvements in overall survival and progression-free survival in clinical trials, particularly in patients refractory to standard therapies.",
        "Trifluridine/Tipiracil (TAS-102) demonstrates enhanced efficacy in colorectal cancer patients due to its unique combination of a potent antineoplastic agent, Trifluridine, and an enzyme inhibitor, Tipiracil. This dual mechanism allows for sustained anti-cancer activity by inhibiting thymidine phosphorylase, which would otherwise metabolize Trifluridine. The result is prolonged drug activity and potentially reduced systemic toxicity compared to traditional fluoropyrimidines like 5-FU or capecitabine.\n\nAdditionally, TAS-102\u0027s specific formulation (a 1:0.5 molar ratio of Trifluridine to Tipiracil) optimizes its effects, enhancing progression-free survival and overall survival in patients who have undergone prior treatments such as oxaliplatin or irinotecan. This targeted approach may also help overcome resistance mechanisms that cancer cells develop against other fluoropyrimidines, making TAS-102 a more effective option for certain patient populations.",
        "Trifluridine/tipiracil (Lonsurf) demonstrates enhanced activity compared to other fluoropyrimidines in colorectal cancer due to its unique mechanism of action and pharmacokinetic properties. Trifluridine, the active component, is incorporated into DNA during replication, causing DNA dysfunction and inhibiting cell proliferation. Tipiracil inhibits thymidine phosphorylase, an enzyme that rapidly degrades trifluridine, thereby increasing trifluridine\u0027s bioavailability and extending its exposure time in the body. This combination allows for higher intracellular concentrations of trifluridine to be incorporated into DNA, leading to greater cytotoxicity in cancer cells. Furthermore, the drug\u0027s activity is less susceptible to resistance mechanisms that commonly affect other fluoropyrimidines, such as thymidylate synthase inhibition.",
        "Based on the provided contexts, the question \"Why is Trifluridine/Tipiracil more active than other fluoropyrimidines in colorectal cancer patients?\" can be answered as follows:\n\nTrifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients because it has a unique mechanism of action that involves the incorporation of trifluridine (FTD) into DNA, leading to DNA dysfunction and cytotoxicity. The persistence of FTD in the DNA of tumor cells treated with TAS-102 may underlie its ability to prolong survival in cancer patients. Additionally, the combination of FTD with tipiracil, a thymidine phosphorylase inhibitor, ensures the bioavailability of FTD and enhances its antitumor activity. This combination therapy has been shown to be effective in refractory metastatic colorectal cancer, with improved survival outcomes compared to other treatment options.",
        "Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients due to several key factors. Tipiracil inhibits thymidine phosphorylase, an enzyme responsible for the degradation of trifluridine, significantly increasing the bioavailability of trifluridine and leading to higher systemic exposure. This inhibition also allows for effective oral administration of the drug, enhancing its practical use in clinical settings. Trifluridine, the active cytotoxic component of TAS-102, interferes with DNA function, preventing tumor cell proliferation. The presence of tipiracil ensures that trifluridine remains available in the system for a longer duration, enhancing its therapeutic efficacy. Clinical trials, including the pivotal phase III RECOURSE trial and a phase II Japanese trial, demonstrated that the coadministration of tipiracil significantly increases the systemic exposure of trifluridine, contributing to its enhanced activity compared to other fluoropyrimidines. These factors collectively contribute to the superior activity of Trifluridine/Tipiracil in treating colorectal cancer compared to other fluoropyrimidines.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it incorporates into DNA more effectively, leading to sustained antitumor activity, and is effective in cases where other treatments fail.",
        "Trifluridine is a thymidine-based chemotherapeutic, which has limited bioavailability after clinical administration as it is rapidly degraded via thymidine phosphorylase. An oral combination tablet combines trifluridine with a potent thymidine phosphorylase inhibitor, tipiracil hydrochloride. This combination increases exposure to trifluridine compared with trifluridine alone. Trifluridine/tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it has a more favorable pharmacokinetic profile and is able to overcome resistance to 5-fluorouracil.",
        "Trifluridine/Tipiracil (TAS-102) demonstrates enhanced activity in colorectal cancer compared to other fluoropyrimidines through multiple unique mechanisms. Unlike traditional fluoropyrimidines that primarily inhibit thymidylate synthase, TAS-102 directly incorporates into DNA, causing DNA damage. Additionally, tipiracil hydrochloride acts as a potent thymidine phosphorylase inhibitor, which significantly increases the exposure and bioavailability of trifluridine in the body. This combination allows for more effective drug delivery and cellular damage, making it more active against cancer cells than conventional fluoropyrimidine treatments.",
        "Trifluridine/Tipiracil (TAS-102) is more active in fluoropyrimidine refractory colorectal cancer patients because it is active in 5FU-resistant models. TAS-102\u0027s major mechanism of action is incorporation into DNA, causing DNA damage, and it follows an alternative activation pathway via thymidine kinase. It is not a substrate for dihydropyrimidine dehydrogenase. In addition, tipiracil significantly increased exposure to trifluridine compared with trifluridine alone; trifluridine area under the curve (AUC\u003csub\u003e0-last\u003c/sub\u003e) and maximum observed plasma concentrations (C\u003csub\u003emax\u003c/sub\u003e) were approximately 37- and 22-fold higher, respectively, with trifluridine/tipiracil vs trifluridine alone.",
        "Trifluridine/Tipiracil (TAS 102) is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanisms of action. Unlike traditional fluoropyrimidines, TAS 102 exerts a dual effect by both inhibiting thymidylate synthase and incorporating into DNA to cause direct damage. Additionally, it utilizes an alternative activation pathway via thymidine kinase rather than relying on dihydropyrimidine dehydrogenase (DPD), which is the main activating enzyme for other fluoropyrimidines. This independence from DPD reduces its inactivation, allowing for higher drug levels and enhanced efficacy. These combined factors contribute to TAS 102\u0027s superior activity in treating colorectal cancer.",
        "Trifluridine/Tipiracil (TAS-102) exhibits increased activity in colorectal cancer patients compared to other fluoropyrimidines due to its dual mechanism of action, which includes DNA incorporation and thymidylate synthase inhibition. Additionally, its bioavailability is significantly enhanced (AUC increased by 37-fold and Cmax by 22-fold) by Tipiracil\u0027s inhibition of thymidine phosphorylase, reducing trifluridine\u0027s degradation. This, combined with an alternative activation pathway via thymidine kinase, allows TAS-102 to bypass traditional resistance mechanisms, making it effective in 5-FU-resistant models and overcoming some limitations of classical fluoropyrimidines in treating colorectal cancer.",
        "Trifluridine/Tipiracil (TAS 102) exhibits enhanced efficacy in colorectal cancer patients due to its unique mechanisms of action. Unlike classical fluoropyrimidines, TAS 102 incorporates into DNA, directly causing DNA damage which disrupts the genetic material of cancer cells. Additionally, it utilizes an alternative activation pathway via thymidine kinase, bypassing the usual pathways that may be targeted by other treatments and reducing resistance potential. Furthermore, TAS 102 is not metabolized by dihydropyrimidine dehydrogenase (DPD), a common enzyme that breaks down many fluoropyrimidines. This lack of degradation by DPD results in higher concentrations of the active drug remaining in the body, increasing its effectiveness against cancer cells. These factors collectively contribute to TAS 102\u0027s superior activity compared to other fluoropyrimidines in treating colorectal cancer.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it is a thymidine-based chemotherapeutic that is not a substrate for dihydropyrimidine dehydrogenase and follows an alternative activation pathway via thymidine kinase.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action. Unlike classical fluoropyrimidines, which primarily inhibit thymidylate synthase, Trifluridine/Tipiracil\u0027s major mechanism involves incorporation into DNA, causing DNA damage. Additionally, it follows an alternative activation pathway via thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase. The combination with tipiracil hydrochloride, a potent thymidine phosphorylase inhibitor, significantly increases exposure to trifluridine, making it more effective. According to studies, this distinct mechanism of action allows Trifluridine/Tipiracil to overcome the limitations of other fluoropyrimidines, resulting in improved activity against colorectal cancer.",
        "Trifluridine/tipiracil (TAS-102) is more active than other fluoropyrimidines because tipiracil inhibits thymidine phosphorylase, increasing trifluridine exposure and DNA incorporation, leading to enhanced DNA damage. Additionally, TAS-102 follows an alternative activation pathway via thymidine kinase, bypassing the typical metabolism that limits other fluoropyrimidines.",
        "Trifluridine/Tipiracil (TAS 102) is more active than other fluoropyrimidines in colorectal cancer due to two primary mechanisms: 1. Dual Mechanism of Action : DNA Incorporation : TAS 102 incorporates into DNA, causing direct DNA damage and disrupting DNA synthesis, leading to cell death. Alternative Activation Pathway : It activates through thymidine kinase, providing an alternative route for its anti cancer effects. 2. Independence from DPD Metabolism : Unlike other fluoropyrimidines that rely on dihydropyrimidine dehydrogenase (DPD) for activation, TAS 102 is not dependent on this enzyme. This reduces variability in effectiveness and toxicity among patients with different DPD levels. These factors enhance its efficacy and provide a broader therapeutic window, making it more effective in treating colorectal cancer compared to traditional fluoropyrimidines.",
        "Tipiracil administered in combination with trifluridine significantly increased exposure to trifluridine compared with trifluridine alone. TAS-102\u0027s major mechanism of action is incorporation into DNA, thereby causing DNA damage. TAS-102 also follows an alternative activation pathway via thymidine kinase, and is not a substrate for dihydropyrimidine dehydrogenase.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines because its major mechanism of action is incorporation into DNA, thereby causing DNA damage, whereas the primary mechanism of action of fluoropyrimidines such as fluorouracil (5-FU) and capecitabine is enzyme inhibition of nucleotide synthesis. Tipiracil, a thymidine phosphorylase inhibitor, significantly increases exposure to trifluridine compared with trifluridine alone. Trifluridine/tipiracil has activity in patients with 5-FU-resistant tumors and can be considered in patients with prior intolerance or toxicity to 5-FU.",
        "Trifluridine/Tipiracil is more active in colorectal cancer patients due to its unique mechanism of action, which involves DNA incorporation and an alternative activation pathway via thymidine kinase.",
        "TAS-102\u0027s major mechanism of action is incorporation into DNA, thereby causing DNA damage. Also, Tipiracil administered in combination with trifluridine significantly increased exposure to trifluridine compared with trifluridine alone.",
        "Trifluridine/tipiracil (TAS-102) exhibits enhanced activity in colorectal cancer patients compared to other fluoropyrimidines primarily due to its unique mechanism of action and formulation. Unlike classical fluoropyrimidines that mainly inhibit thymidylate synthase, trifluridine is incorporated into DNA, leading to DNA damage. Additionally, tipiracil, a thymidine phosphorylase inhibitor, prevents the degradation of trifluridine, thereby increasing its systemic exposure and bioavailability. This combination allows for effective oral administration and improved therapeutic outcomes, particularly in patients who are refractory to standard chemotherapy regimens. Clinical trials have demonstrated significant benefits in overall survival and progression-free survival for patients treated with trifluridine/tipiracil, establishing it as a valuable treatment option for those with chemorefractory metastatic colorectal cancer.",
        "Trifluridine/Tipiracil (TAS-102) demonstrates enhanced activity in colorectal cancer patients due to its unique mechanism of action and pharmacokinetic properties. Tipiracil, a potent thymidine phosphorylase inhibitor, significantly increases the exposure to trifluridine, a nucleoside analog. This combination not only inhibits thymidylate synthase, a key mechanism of classical fluoropyrimidines, but also incorporates trifluridine into DNA, leading to DNA damage and cell death. Additionally, trifluridine can bypass the typical activation pathway and is activated via thymidine kinase, while avoiding metabolism by dihydropyrimidine dehydrogenase. These mechanisms collectively contribute to the enhanced efficacy of Trifluridine/Tipiracil in treating colorectal cancer.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action and enhanced efficacy:\n\n1. **Mechanism of Action**:\n   - Trifluridine, a nucleoside analog, incorporates into DNA, causing damage.\n   - Tipiracil inhibits thymidine phosphorylase, which breaks down trifluridine, thereby increasing its concentration.\n\n2. **Enhanced Efficacy**:\n   - The combination increases trifluridine exposure, making it more effective against cancer cells.\n   - Unlike other fluoropyrimidines (e.g., 5-FU, capecitabine), Trifluridine/Tipiracil does not rely on dihydropyrimidine dehydrogenase for activation, allowing it to work in tumors with low or absent levels of this enzyme.\n\n3. **Overcoming Resistance**:\n   - This combination targets tumors more effectively and overcomes resistance mechanisms that other fluoropyrimidines may face.\n\nIn summary, the synergistic effect of Trifluridine/Tipiracil enhances tumor targeting and sustains DNA damage, leading to improved efficacy in colorectal cancer treatment.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it combines two mechanisms that enhance efficacy. Trifluridine, a nucleoside analog, incorporates into DNA, causing damage. Tipiracil inhibits thymidine phosphorylase, which would otherwise break down trifluridine, thereby increasing its concentration and effectiveness. This dual action leads to greater DNA damage in cancer cells compared to other fluoropyrimidines like 5-FU or capecitabine, which lack this enzyme inhibition component.",
        "Trifluridine/tipiracil (Lonsurf(®)) is a novel, orally active, antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue, and tipiracil, a potent thymidine phosphorylase inhibitor. Trifluridine-tipiracil is approved for the treatment of patients with mCRC previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an antivascular endothelial growth factor biological therapy and, if RAS wild-type, an antiepidermal growth factor receptor therapy. In conclusion, trifluridine/tipiracil is a useful additional treatment option for the management of mCRC in patients who are refractory to, or are not considered candidates for, currently available therapies.",
        "Trifluridine/tipiracil is more active in colorectal cancer patients because its mechanism of action differs from that of conventional fluoropyrimidines. While drugs like 5-fluorouracil mainly inhibit thymidylate synthase, trifluridine is incorporated directly into DNA, causing dysfunction and strand breaks that lead to cell death, even in tumors resistant to thymidylate synthase inhibition. Tipiracil prevents the rapid degradation of trifluridine by inhibiting thymidine phosphorylase, thereby enhancing its bioavailability. Additionally, the drug benefits from an alternative activation pathway via thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase, which further contributes to its efficacy in 5-FU-resistant cancers.",
        "TAS-102\u0027s major mechanism of action is incorporation into DNA, thereby causing DNA damage. It also follows an alternative activation pathway via thymidine kinase, and is not a substrate for dihydropyrimidine dehydrogenase. Tipiracil, a potent thymidine phosphorylase inhibitor, significantly increased exposure to trifluridine compared with trifluridine alone.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action. Trifluridine, a nucleoside analog, incorporates into DNA, causing damage. Tipiracil inhibits thymidine phosphorylase, which would otherwise degrade trifluridine, thereby increasing its concentration and enhancing efficacy. This combination provides a more potent effect compared to other fluoropyrimidines like 5-FU or capecitabine, which primarily inhibit thymidylate synthase without the added benefit of enzyme inhibition. Thus, Trifluridine/Tipiracil\u0027s dual mechanism significantly improves its activity in treating colorectal cancer.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action. While classical fluoropyrimidines primarily inhibit thymidylate synthase, TAS-102 (the active metabolite of Trifluridine/Tipiracil) incorporates into DNA, causing DNA damage. Additionally, TAS-102 follows an alternative activation pathway via thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase, which degrades fluoropyrimidines. Tipiracil, a potent thymidine phosphorylase inhibitor, administered in combination with trifluridine significantly increases exposure to trifluridine compared with trifluridine alone, further enhancing its activity.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action. Trifluridine, a nucleoside analog, incorporates into DNA, causing damage and disrupting DNA synthesis. Tipiracil inhibits thymidine phosphorylase, an enzyme that degrades trifluridine, thereby increasing its concentration and enhancing its efficacy.\n\nIn contrast, other fluoropyrimidines like 5-fluorouracil (5-FU) primarily inhibit thymidylate synthase. The combination of Trifluridine with Tipiracil not only disrupts DNA synthesis but also prevents the degradation of trifluridine, leading to a more potent and sustained antitumor effect. This dual mechanism likely contributes to its superior activity in treating colorectal cancer compared to other fluoropyrimidines.",
        "Trifluridine/tipiracil (FTD/TPI), marketed as Lonsurf and approved for late-stage colorectal cancer, exhibits increased activity, particularly in cases where other fluoropyrimidines have failed, due to its distinct mechanism of action and the protective effect of tipiracil. While traditional fluoropyrimidines like 5-FU and capecitabine primarily inhibit nucleotide synthesis, trifluridine/tipiracil mainly incorporates into DNA, causing DNA damage, strand breaks, and decreased replication, a mechanism that remains effective even in 5-FU-resistant tumors. Tipiracil, a thymidine phosphorylase inhibitor, enhances trifluridine\u0027s bioavailability by preventing its degradation, allowing for oral administration and increased exposure to trifluridine. This combination overcomes resistance mechanisms associated with other fluoropyrimidines and provides a salvage therapy option for patients who have progressed after standard regimens.",
        "Trifluridine/Tipiracil is more effective in treating colorectal cancer compared to other fluoropyrimidines due to a combination of mechanisms that enhance drug efficacy and overcome limitations inherent in Trifluridine alone. \n\n1. **Enhanced Drug Efficacy**: Trifluridine, a fluoropyrimidine, works by incorporating into the DNA of cancer cells, causing damage and leading to cell death. However, its effectiveness is limited due to rapid breakdown by thymidine phosphorylase.\n\n2. **Role of Tipiracil**: Tipiracil acts as a potent inhibitor of thymidine phosphorylase. By inhibiting this enzyme, Tipiracil prevents the rapid metabolism of Trifluridine, allowing higher concentrations of the drug to remain in the body for longer periods. This sustained presence increases DNA damage and enhances anti-tumor activity.\n\n3. **Alternative Metabolic Pathway**: Unlike other fluoropyrimidines that rely on dihydropyrimidine dehydrogenase (DPD) for activation, Trifluridine/Tipiracil utilizes an alternative pathway. This not only reduces the risk of certain side effects but also potentially increases the drug\u0027s effectiveness by avoiding metabolic routes that could diminish its activity.\n\nIn summary, the combination of Trifluridine and Tipiracil overcomes the limitations of Trifluridine alone by inhibiting its rapid metabolism and utilizing an alternative activation pathway. This results in enhanced efficacy against colorectal cancer, making it a more effective treatment option compared to other fluoropyrimidines.",
        "{\"ideal_answer\": \"Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients because, in addition to inhibiting thymidylate synthase, its major mechanism of action involves incorporation into DNA, causing DNA damage. TAS-102 also follows an alternative activation pathway via thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase.\"}",
        "Trifluridine/Tipiracil (TAS-102) exhibits enhanced activity compared to classical fluoropyrimidines in colorectal cancer due to its dual mechanism of action. Tipiracil, a potent thymidine phosphorylase inhibitor, increases the exposure and stability of trifluridine by preventing its degradation, allowing more effective incorporation into DNA and causing significant DNA damage. Additionally, TAS-102 bypasses the dihydropyrimidine dehydrogenase pathway, which is responsible for metabolizing many fluoropyrimidines, thereby enhancing its efficacy in patients.",
        "Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients primarily due to its unique formulation and mechanisms of action. TAS-102 combines trifluridine, a thymidine-based chemotherapeutic, with tipiracil, a potent thymidine phosphorylase inhibitor. This combination significantly increases the bioavailability of trifluridine, leading to a 37-fold increase in the area under the curve (AUC) and a 22-fold increase in maximum plasma concentrations compared to trifluridine alone. \n\nAdditionally, TAS-102 is effective in 5-fluorouracil (5FU)-resistant models because it incorporates into DNA, causing DNA damage, and follows an alternative activation pathway via thymidine kinase, making it less susceptible to degradation by dihydropyrimidine dehydrogenase. This multifaceted approach allows TAS-102 to maintain efficacy in patients who have developed resistance to traditional fluoropyrimidines, resulting in improved disease control and overall survival in clinical settings.",
        "TAS-102 (Trifluridine/Tipiracil) is more active because its major mechanism of action is incorporation into DNA, causing DNA damage, in addition to thymidylate synthase inhibition. It also follows an alternative activation pathway via thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase. Tipiracil, a component of Trifluridine/Tipiracil, significantly increases exposure to trifluridine compared to trifluridine alone.",
        "Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanisms of action. Tipiracil inhibits thymidine phosphorylase, increasing trifluridine exposure, while trifluridine incorporates into DNA, causing damage. Additionally, TAS-102 bypasses the classical activation pathway and is not affected by dihydropyrimidine dehydrogenase, enhancing its efficacy.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action. Unlike classical fluoropyrimidines, which primarily inhibit thymidylate synthase, Trifluridine/Tipiracil\u0027s major mechanism of action involves incorporation into DNA, causing DNA damage. Additionally, Tipiracil, a potent thymidine phosphorylase inhibitor, increases exposure to trifluridine by inhibiting its degradation, thereby enhancing its anti-tumor activity. This alternative activation pathway via thymidine kinase and lack of substrate for dihydropyrimidine dehydrogenase also contribute to its increased efficacy. Overall, the combination of Trifluridine\u0027s DNA-damaging effects and Tipiracil\u0027s ability to enhance its exposure make it a more effective treatment option for colorectal cancer patients compared to other fluoropyrimidines.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it is a thymidine-based chemotherapeutic that is not a substrate for dihydropyrimidine dehydrogenase, and is incorporated into DNA, thereby causing DNA damage.",
        "Trifluridine/tipiracil (TAS-102) exhibits enhanced activity in colorectal cancer patients compared to other fluoropyrimidines primarily due to its unique mechanism of action and formulation. Unlike classical fluoropyrimidines that mainly inhibit thymidylate synthase, TAS-102 incorporates into DNA, causing DNA damage, and follows an alternative activation pathway via thymidine kinase. Additionally, tipiracil hydrochloride, a potent thymidine phosphorylase inhibitor, increases the systemic exposure of trifluridine, thereby enhancing its efficacy. This combination has demonstrated significant improvements in overall survival and progression-free survival in patients with chemorefractory metastatic colorectal cancer, as evidenced by results from the phase III RECOURSE trial. Furthermore, TAS-102 is effective in patients who have already undergone multiple lines of standard chemotherapy, addressing the issue of resistance that often limits the effectiveness of traditional fluoropyrimidines.",
        "Trifluridine/Tipiracil (TAS-102) is more active in colorectal cancer patients because tipiracil, a thymidine phosphorylase inhibitor, significantly increases trifluridine exposure compared to trifluridine alone. Trifluridine area under the curve (AUC\u003csub\u003e0-last\u003c/sub\u003e) and maximum observed plasma concentrations (C\u003csub\u003emax\u003c/sub\u003e) were approximately 37- and 22-fold higher, respectively, with trifluridine/tipiracil vs trifluridine alone. TAS-102 is active in 5FU-resistant models because its major mechanism of action is incorporation into DNA, causing DNA damage, and it follows an alternative activation pathway via thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase. In fluoropyrimidine refractory colorectal cancer patients, TAS-102 increased overall survival by 2-3 months compared with placebo.",
        "Trifluridine/Tipiracil (TAS-102) is more active in colorectal cancer patients who are refractory to standard therapies due to its unique mechanism of action, which includes the incorporation of trifluridine into DNA, leading to DNA damage. Additionally, tipiracil, a potent thymidine phosphorylase inhibitor, enhances the bioavailability of trifluridine by preventing its degradation, allowing for effective oral administration. This combination provides a therapeutic option for patients who have already undergone multiple lines of treatment, including fluoropyrimidines, oxaliplatin, and irinotecan. Clinical studies have demonstrated that TAS-102 significantly improves overall survival and progression-free survival in these patients compared to placebo, making it a valuable treatment in the late-line setting for metastatic colorectal cancer.",
        "Trifluridine/Tipiracil is more effective because it incorporates into DNA, causing DNA damage, and is not a substrate for dihydropyrimidine dehydrogenase, which allows it to bypass common resistance mechanisms associated with other fluoropyrimidines.",
        "Trifluridine/Tipiracil (TAS-102) is more active in colorectal cancer patients due to its dual mechanism of action, including DNA incorporation causing DNA damage, in addition to inhibiting thymidylate synthase. It utilizes an alternative activation pathway via thymidine kinase and avoids degradation by dihydropyrimidine dehydrogenase, making it effective in 5FU-resistant models. The combination with tipiracil, a potent thymidine phosphorylase inhibitor, significantly increases trifluridine exposure, leading to enhanced anti-tumor efficacy. This multifaceted approach contributes to its increased activity compared to other fluoropyrimidines in treating colorectal cancer.",
        "Trifluridine/tipiracil (TAS-102) exhibits enhanced activity in colorectal cancer patients primarily due to its unique mechanism of action and formulation. Unlike classical fluoropyrimidines that primarily inhibit thymidylate synthase, TAS-102 incorporates into DNA, leading to DNA damage. Additionally, tipiracil, a thymidine phosphorylase inhibitor, increases the systemic exposure of trifluridine by preventing its degradation, thereby improving its bioavailability for oral administration. This combination allows TAS-102 to be effective in patients who are refractory to standard therapies, including fluorouracil, irinotecan, and oxaliplatin. Clinical trials have demonstrated that TAS-102 significantly improves overall survival and progression-free survival in metastatic colorectal cancer patients compared to placebo, highlighting its efficacy in this challenging patient population.",
        "Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients because it has a unique mechanism of action. In addition to inhibiting thymidylate synthase, TAS-102 incorporates into DNA, causing DNA damage. This dual mechanism enhances its effectiveness. Furthermore, TAS-102 is activated via an alternative pathway involving thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase, which may contribute to its increased activity compared to other fluoropyrimidines.",
        "Trifluridine/Tipiracil (TAS-102) exhibits enhanced activity in colorectal cancer patients primarily due to its unique dual mechanism of action, involving DNA incorporation and thymidylate synthase inhibition. Additionally, Tipiracil significantly increases Trifluridine\u0027s bioavailability by inhibiting thymidine phosphorylase, leading to a 37-fold and 22-fold increase in AUC and Cmax, respectively. This combination allows TAS-102 to bypass traditional fluoropyrimidine resistance pathways, activated via thymidine kinase, and demonstrates efficacy in 5-FU-resistant models, making it a more effective treatment option for colorectal cancer patients compared to other fluoropyrimidines.",
        "TAS-102\u0027s major mechanism of action is incorporation into DNA, thereby causing DNA damage. TAS-102 also follows an alternative activation pathway via thymidine kinase, and is not a substrate for dihydropyrimidine dehydrogenase.",
        "Trifluridine/Tipiracil (TAS 102) is more effective in treating colorectal cancer compared to other fluoropyrimidines due to its unique mechanisms of action: 1. Direct DNA Incorporation : Unlike classical fluoropyrimidines, TAS 102 primarily incorporates into DNA, causing direct damage and interfering with replication, leading to cell death. 2. Alternative Activation Pathway : TAS 102 uses thymidine kinase for activation, bypassing the dihydropyrimidine dehydrogenase pathway. This alternative route may reduce resistance issues associated with enzymes targeting this pathway. 3. Resistance to Enzymatic Breakdown : TAS 102 is not a substrate for dihydropyrimidine dehydrogenase, which can become resistant or less effective in other fluoropyrimidines, thus avoiding enzymatic breakdown and potential toxicity. These factors collectively enhance TAS 102\u0027s efficacy against colorectal cancer by targeting DNA directly and utilizing pathways that reduce resistance mechanisms.",
        "TAS-102\u0027s major mechanism of action is incorporation into DNA, thereby causing DNA damage. Tipiracil, a potent thymidine phosphorylase inhibitor, increases exposure to trifluridine. TAS-102 also follows an alternative activation pathway via thymidine kinase, and is not a substrate for dihydropyrimidine dehydrogenase.",
        " Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its unique mechanism of action. Unlike classical fluoropyrimidines that primarily inhibit thymidylate synthase, TAS-102 (Trifluridine/Tipiracil) incorporates into DNA causing DNA damage and following an alternative activation pathway via thymidine kinase. Additionally, Tipiracil administered in combination with trifluridine significantly increases exposure to trifluridine compared with trifluridine alone, enhancing its efficacy.",
        "Trifluridine/Tipiracil (TAS-102) demonstrates greater activity than other fluoropyrimidines in colorectal cancer patients due to its unique dual mechanism of action. Unlike classical fluoropyrimidines that primarily inhibit thymidylate synthase, TAS-102\u0027s major mechanism involves direct incorporation into DNA, causing DNA damage. Additionally, TAS-102 follows an alternative activation pathway via thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase, which is often responsible for fluoropyrimidine resistance. The combination is particularly effective because tipiracil hydrochloride, a potent thymidine phosphorylase inhibitor, significantly increases exposure to trifluridine by preventing its degradation, thereby enhancing its therapeutic efficacy.",
        "Studies have shown that Trifluridine/Tipiracil exhibits enhanced activity in colorectal cancer patients due to its distinct mechanisms of action. Unlike classical fluoropyrimidines, which primarily inhibit thymidylate synthase, Trifluridine incorporates into DNA, causing direct damage. Additionally, it is activated via an alternative pathway involving thymidine kinase and is not degraded by dihydropyrimidine dehydrogenase (DPD), which typically limits the efficacy of other fluoropyrimidines. Furthermore, Tipiracil, a potent inhibitor of thymidine phosphorylase, prevents the breakdown of Trifluridine, significantly increasing its exposure in the body. This combination of unique activation pathways and enzyme inhibition enhances Trifluridine\u0027s effectiveness, making it more potent than other fluoropyrimidines in colorectal cancer treatment.",
        "Trifluridine/tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because it is a thymidine-based chemotherapeutic, has limited bioavailability after clinical administration as it is rapidly degraded via thymidine phosphorylase. An oral combination tablet combines trifluridine with a potent thymidine phosphorylase inhibitor, tipiracil hydrochloride. This combination increases exposure to trifluridine compared with trifluridine alone.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients because Tipiracil inhibits thymidine phosphorylase, which breaks down trifluridine, allowing for increased exposure to the active metabolite. Additionally, Trifluridine has a different mechanism of action compared to classical fluoropyrimidines, incorporating into DNA and causing DNA damage, rather than just inhibiting thymidylate synthase. This alternative mechanism of action may contribute to its increased activity in colorectal cancer patients.",
        "Trifluridine/Tipiracil (TAS-102) is more active than other fluoropyrimidines in colorectal cancer patients because it has a unique mechanism of action that overcomes key resistance pathways. Unlike classical fluoropyrimidines that primarily inhibit thymidylate synthase, TAS-102\u0027s major mechanism is incorporation of its trifluridine component into DNA, causing DNA damage. Additionally, TAS-102 follows an alternative activation pathway via thymidine kinase and is not inactivated by dihydropyrimidine dehydrogenase, which confers resistance to other fluoropyrimidines. The tipiracil component of TAS-102 inhibits thymidine phosphorylase, increasing the exposure and efficacy of trifluridine.",
        "Trifluridine/Tipiracil (TAS-102) exhibits enhanced activity in colorectal cancer patients compared to other fluoropyrimidines due to its dual mechanism of action, including DNA incorporation and thymidylate synthase inhibition via an alternative activation pathway. Tipiracil significantly boosts Trifluridine\u0027s bioavailability (37-fold in AUC, 22-fold in Cmax) by inhibiting thymidine phosphorylase. This combination overcomes 5-fluorouracil (5FU) resistance, leading to increased efficacy and improved overall survival, with clinical trials showing a notable 2-3 month survival increase over placebo, making it a potent therapeutic option for colorectal cancer treatment.",
        "Trifluridine/Tipiracil is more active due to Trifluridine\u0027s incorporation into DNA, causing DNA damage, and its use of an alternative activation pathway. Tipiracil inhibits thymidine phosphorylase, increasing trifluridine exposure and enhancing its activity.",
        "Trifluridine/Tipiracil is more active because its mechanism differs from that of classical fluoropyrimidines. Unlike other fluoropyrimidines that primarily inhibit thymidylate synthase, trifluridine is incorporated directly into DNA, causing DNA dysfunction and strand breaks. This incorporation leads to cytotoxic effects even in cancer cells that are resistant to 5-FU. In addition, tipiracil prevents the rapid degradation of trifluridine by inhibiting thymidine phosphorylase, thereby increasing its bioavailability. This combination allows for sustained drug exposure and effective DNA damage in colorectal cancer cells, making it particularly useful in patients who have developed resistance to traditional fluoropyrimidine therapies.",
        "Trifluridine/Tipiracil (TAS-102) is more active because its major mechanism of action is incorporation into DNA, causing DNA damage, in addition to thymidylate synthase inhibition. TAS-102 also follows an alternative activation pathway via thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase. Tipiracil, a component of TAS-102, inhibits thymidine phosphorylase. Tipiracil increases trifluridine exposure compared to trifluridine alone.",
        "Trifluridine/Tipiracil is more active than other fluoropyrimidines in colorectal cancer patients due to its dual mechanism of action including DNA incorporation, and the protective effect of Tipiracil, which inhibits Trifluridine\u0027s degradation and increases its bioavailability.",
        "Tipiracil administered in combination with trifluridine significantly increased exposure to trifluridine compared with trifluridine alone.",
        "In addition to inhibition of thymidylate synthase, the major mechanism of action of classical fluoropyrimidines, TAS-102\u0027s major mechanism of action is incorporation into DNA, thereby causing DNA damage. TAS-102 also follows an alternative activation pathway via thymidine kinase, and is not a substrate for dihydropyrimidine dehydrogenase.",
        "Trifluridine/Tipiracil (TAS-102) exhibits enhanced activity compared to other fluoropyrimidines in colorectal cancer due to several factors. Tipiracil, a component of TAS-102, inhibits thymidine phosphorylase, increasing trifluridine exposure. Unlike classical fluoropyrimidines that primarily inhibit thymidylate synthase, TAS-102\u0027s main mechanism involves incorporation into DNA, leading to DNA damage. TAS-102 can also be activated via thymidine kinase. Furthermore, it is not a substrate for dihydropyrimidine dehydrogenase, an enzyme that degrades some fluoropyrimidines. These combined mechanisms contribute to TAS-102\u0027s distinct activity profile and effectiveness in colorectal cancer treatment.",
        "Trifluridine/Tipiracil\u0027s enhanced activity is due to its unique dual mechanism where tipiracil (a thymidine phosphorylase inhibitor) increases trifluridine exposure, while trifluridine not only inhibits thymidylate synthase like classical fluoropyrimidines but also incorporates into DNA causing damage. Additionally, it follows an alternative activation pathway via thymidine kinase and avoids degradation by dihydropyrimidine dehydrogenase, making it more effective.",
        "Trifluridine/tipiracil (TAS-102) is more active than other fluoropyrimidines because tipiracil enhances trifluridine\u0027s exposure and potency by inhibiting thymidine phosphorylase, while trifluridine itself causes DNA damage through incorporation into DNA. Additionally, TAS-102 follows a unique activation pathway via thymidine kinase, distinguishing it from classical fluoropyrimidines.",
        "TAS-102, which contains trifluridine and tipiracil, has a major mechanism of action that involves incorporation into DNA, leading to DNA damage. It also follows an alternative activation pathway via thymidine kinase and is not a substrate for dihydropyrimidine dehydrogenase. Tipiracil, a thymidine phosphorylase inhibitor, increases exposure to trifluridine when administered in combination."
      ]
    },
    {
      "body": "Is the inactivation of the X chromsome linked to cognition?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36617879",
        "http://www.ncbi.nlm.nih.gov/pubmed/9192895",
        "http://www.ncbi.nlm.nih.gov/pubmed/27870409",
        "http://www.ncbi.nlm.nih.gov/pubmed/16396323",
        "http://www.ncbi.nlm.nih.gov/pubmed/12068376",
        "http://www.ncbi.nlm.nih.gov/pubmed/8826443",
        "http://www.ncbi.nlm.nih.gov/pubmed/15809269",
        "http://www.ncbi.nlm.nih.gov/pubmed/34616429",
        "http://www.ncbi.nlm.nih.gov/pubmed/11415514",
        "http://www.ncbi.nlm.nih.gov/pubmed/10449653",
        "http://www.ncbi.nlm.nih.gov/pubmed/24865607"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 697,
          "text": "Here we report a study of 80 females with Turner\u0027s syndrome and a single X chromosome, in 55 of which the X was maternally derived (45,X[m]) and in 25 it was of paternal origin (45,X[p]). Members of the 45,X[p] group were significantly better adjusted, with superior verbal and higher-order executive function skills, which mediate social interactions. Our observations suggest that there is a genetic locus for social cognition, which is imprinted and is not expressed from the maternally derived X chromosome. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9192895"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 513,
          "text": "While each sex (XX and XY) harbors one active X due to X chromosome inactivation in females, some genes, such as Kdm6a, transcriptionally escape silencing in females-resulting in lower transcript levels in males. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36617879"
        },
        {
          "offsetInBeginSection": 478,
          "offsetInEndSection": 813,
          "text": "Dosage differences in the expression of such genes (which constitute at least 15% of the total) are likely to play an important role in male-female neural differentiation, and in cognitive deficits and behavioral characteristics, particularly in the realm of social communication, that are associated with sex chromosome aneuploidies. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27870409"
        },
        {
          "offsetInBeginSection": 1071,
          "offsetInEndSection": 1335,
          "text": "And fourth, dose-dependent overexpression of X-linked genes that normally \"escape\" X inactivation may account for the mental and developmental delay associated with increasing numbers of otherwise inactive X chromosomes in individuals with X chromosome aneuploidy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8826443"
        },
        {
          "offsetInBeginSection": 410,
          "offsetInEndSection": 536,
          "text": "In addition, there is evidence for relatively specific effects of X-linked genes on social-cognition and emotional regulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15809269"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Evidence from Turner\u0027s syndrome of an imprinted X-linked locus affecting cognitive function.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9192895"
        },
        {
          "offsetInBeginSection": 217,
          "offsetInEndSection": 329,
          "text": "Evidence for imprinted loci on the X chromosome affecting neurodevelopment was found in studies on 45,X females.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16396323"
        },
        {
          "offsetInBeginSection": 476,
          "offsetInEndSection": 606,
          "text": "The proportion of cells in peripheral blood containing an inactivated r(X) chromosome was negatively correlated with nonverbal IQ.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11415514"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "In the fragile X female carriers the degree of cognitive impairment appears to be correlated with activation status of the X chromosome bearing the expanded trinucleotide repeat in the promoter of the FMR1 gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10449653"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 403,
          "text": "We hypothesized that the neurocognitive dysfunction present in KS relies on an imbalance in X-chromosome gene expression. Thus, the X-chromosome inactivation (XCI) pattern and neurocognitive X-linked gene expression were tested and correlated with intelligence quotient (IQ) scores.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34616429"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 471,
          "text": "To explore the relationship between skewed X-chromosome inactivation and X-linked mental retardation (XLMR) disorders, we used the androgen receptor X-inactivation assay to determine X-inactivation patterns in 155 female subjects from 24 families segregating 20 distinct XLMR disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12068376"
        },
        {
          "offsetInBeginSection": 243,
          "offsetInEndSection": 403,
          "text": "Thus, the X-chromosome inactivation (XCI) pattern and neurocognitive X-linked gene expression were tested and correlated with intelligence quotient (IQ) scores.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34616429"
        },
        {
          "offsetInBeginSection": 180,
          "offsetInEndSection": 388,
          "text": "Androgen receptor polymorphism (CAG repeat length), skewed X-chromosome inactivation and parent-of-origin of the extra X-chromosome have been suggested to influence cognitive function and psychological traits",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24865607"
        }
      ],
      "type": "yesno",
      "id": "67cc89fa81b102733300000c",
      "ideal_answer": [
        "While each sex (XX and XY) harbors one active X due to X chromosome inactivation in females, some genes, such as Kdm6a, transcriptionally escape silencing in females-resulting in lower transcript levels in males. Males exhibit shorter life span and more cognitive deficits, in the absence of dementia, in aging human populations. In mammals, the X chromosome is enriched for neural genes and is a major source of biologic sex difference, in part, because males show decreased expression of select X factors (XY). While each sex (XX and XY) harbors one active X due to X chromosome inactivation in females, some genes, such as Kdm6a, transcriptionally escape silencing in females-resulting in lower transcript levels in males",
        "Yes. X-chromosome inactivation is associated with cognitive impairment.",
        "Yes. The inactivation of the X chromosome, particularly the skewed inactivation of the X\u003csub\u003em\u003c/sub\u003e chromosome, has been shown to impair cognition and is linked to cognitive deficits in female mice.",
        "Yes, X chromosome inactivation is linked to cognitive function.",
        "Yes. The inactivation of the X chromosome is linked to cognition, as it influences gene expression and can affect cognitive functions, particularly in females where X chromosome inactivation leads to mosaicism that may buffer dysregulated processes in aging and disease.",
        "Yes. Studies indicate that an active maternal X chromosome can impair cognition in female mice and lead to worsened cognitive abilities with age, suggesting a link between X chromosome inactivation and cognition.",
        "Yes, the inactivation of the X chromosome is linked to cognition.",
        "Research suggests that X-chromosome inactivation is linked to cognition, particularly in females. The study found that X-linked genes have a persistent influence on social behavior problems, including those involved in autistic spectrum disorders, from early to middle childhood.",
        "The inactivation of the X chromosome is indirectly linked to cognition through its effect on the expression of X-linked genes that influence cognitive functions, rather than a direct causal link to cognition itself.",
        "Yes. The inactivation of the X chromosome is linked to cognition.",
        "Yes, the inactivation of the X chromosome is linked to cognition, as evidenced by the differential cognitive skills observed in individuals with Turner\u0027s syndrome based on the parental origin of the single X chromosome.",
        "The inactivation of the X chromosome is linked to cognition, as dosage differences in the expression of certain genes on the X chromosome, such as Kdm6a, play a role in neural differentiation and cognitive deficits.",
        "Yes. The inactivation of the X chromosome is linked to cognition, as it affects the expression of genes that are important for cognitive functions and social cognition, particularly in females with conditions like Turner\u0027s syndrome.",
        "Yes. The inactivation of the X chromosome is linked to cognition, as it affects the expression of X-linked genes that play critical roles in cognitive functions and social cognition.",
        "Yes. The inactivation of the X chromosome is linked to cognitive abilities and brain development, as it affects gene expression and can influence cognitive deficits and behavioral characteristics associated with sex chromosome aneuploidies.",
        "Yes. The inactivation of the X chromosome is linked to cognition, as it affects the expression of genes that are critical for cognitive functions and social cognition, particularly in conditions like Turner\u0027s syndrome.",
        "Yes, the inactivation of the X chromosome is linked to cognition. Dosage differences in gene expression due to X chromosome inactivation likely play a role in cognitive deficits and behavioral characteristics. This is particularly true in social communication, as seen in studies of females with Turner\u0027s syndrome.",
        "Yes. Dosage differences in the expression of genes that escape X chromosome inactivation are likely to play an important role in cognitive deficits and behavioral characteristics."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Prevalence of Premenstrual Dysphoric Disorder",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33663193",
        "http://www.ncbi.nlm.nih.gov/pubmed/39403910",
        "http://www.ncbi.nlm.nih.gov/pubmed/12892987",
        "http://www.ncbi.nlm.nih.gov/pubmed/33223711",
        "http://www.ncbi.nlm.nih.gov/pubmed/18366818",
        "http://www.ncbi.nlm.nih.gov/pubmed/12768646",
        "http://www.ncbi.nlm.nih.gov/pubmed/38091917",
        "http://www.ncbi.nlm.nih.gov/pubmed/20172536",
        "http://www.ncbi.nlm.nih.gov/pubmed/34530168",
        "https://pubmed.ncbi.nlm.nih.gov/12892987/"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 555,
          "text": "PMDD affects 2-8%",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33663193"
        },
        {
          "offsetInBeginSection": 1258,
          "offsetInEndSection": 1296,
          "text": "PMDD, which has a prevalence of 3.04% ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39403910"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 489,
          "text": "Currently it is estimated that 3-8% of women of reproductive age meet strict criteria for premenstrual dysphoric disorder (PMDD). Assessment of published reports demonstrate that the prevalence of clinically relevant dysphoric premenstrual disorder is probably higher. 13-18% of women of reproductive age may have premenstrual dysphoric symptoms severe enough to induce impairment and distress, though the number of symptoms may not meet the arbitrary count of 5 symptoms on the PMDD list.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12892987"
        },
        {
          "offsetInBeginSection": 1371,
          "offsetInEndSection": 1650,
          "text": "Of the women in the study, 1.3% met criteria for the diagnosis as defined in DSM-IV.CONCLUSIONS: The prevalence of PMDD is considerably lower than DSM-IV estimates and all but one of the estimates obtained from previous studies when all DSM-IV diagnostic criteria are considered.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18366818"
        },
        {
          "offsetInBeginSection": 1135,
          "offsetInEndSection": 1430,
          "text": "A positive correlation was seen between the severity of PMDD, age, levels of perceived stress, severity of depression, and anxiety in the respondents.CONCLUSION: Nearly 5% of adolescent girls suffer from PMDD, with higher prevalence among those with depression, GAD, and higher perceived stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33223711"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Currently it is estimated that 3-8% of women of reproductive age meet strict criteria for premenstrual dysphoric disorder (PMDD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12892987"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Premenstrual dysphoric disorder (PMDD) is a severe variant of premenstrual syndrome that afflicts approximately 5% of all women of fertile age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12768646"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 186,
          "text": " Premenstrual dysphoric disorder (PMDD) affects approximately 5% of menstruating individuals, with significant negative mood symptoms in the luteal phase of the menstrual cycle",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38091917"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Premenstrual Dysphoric Disorder (PMDD) is a mood disorder affecting about 5% of women and is associated with substantial morbidity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20172536"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Premenstrual dysphoric disorder (PMDD) affects nearly 5% of women of reproductive age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34530168"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "Currently it is estimated that 3-8% of women of reproductive age meet strict criteria for premenstrual dysphoric disorder (PMDD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/12892987/"
        }
      ],
      "type": "factoid",
      "id": "67d4354518b1e36f2e000010",
      "ideal_answer": [
        "Prevalence of premenstrual dysphoric disorder varies according the population study, affecting between 2-8% women of reproductive age.",
        "The prevalence of Premenstrual Dysphoric Disorder (PMDD) varies from 2.4% to 8% among women of reproductive age, with some studies reporting a 12-month prevalence of 3-8% and others finding a prevalence of 5.8% or 3.04% in specific populations. One study found a high prevalence of 33.03% among high school students. Overall, PMDD is estimated to affect 3-8% of women in their reproductive years.",
        "Premenstrual Dysphoric Disorder (PMDD) has a prevalence ranging from 2-8% in the general population, with a more specific estimate indicating that it affects approximately 3.04% of women. This condition is a severe form of premenstrual syndrome (PMS) characterized by physical and emotional symptoms that significantly impair daily functioning. The varying prevalence estimates highlight the need for further research to accurately determine the incidence of PMDD across different populations.",
        "The prevalence of PMDD is generally estimated to range between about 2% and 8% in women of reproductive age. Several community and clinical studies report rates around 2.4% to 3.0% in adult populations. However, some studies, especially those involving adolescents or specific subgroups, have found higher rates, with one high school study reporting a prevalence of approximately 33%. These differences likely reflect variations in diagnostic criteria, study design, and the populations examined. Overall, while only a relatively small proportion of women meet the full criteria for PMDD, a larger number may experience significant premenstrual symptoms."
      ],
      "exact_answer": [
        [
          "2-8%"
        ]
      ]
    },
    {
      "body": "Are transcription factors of the GATA family found in the brain?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16150495",
        "http://www.ncbi.nlm.nih.gov/pubmed/30710529",
        "http://www.ncbi.nlm.nih.gov/pubmed/19543315",
        "http://www.ncbi.nlm.nih.gov/pubmed/8028475",
        "http://www.ncbi.nlm.nih.gov/pubmed/11181509",
        "http://www.ncbi.nlm.nih.gov/pubmed/30348673",
        "http://www.ncbi.nlm.nih.gov/pubmed/26953528",
        "http://www.ncbi.nlm.nih.gov/pubmed/10357893",
        "http://www.ncbi.nlm.nih.gov/pubmed/18554735",
        "http://www.ncbi.nlm.nih.gov/pubmed/16011889",
        "http://www.ncbi.nlm.nih.gov/pubmed/37624387",
        "http://www.ncbi.nlm.nih.gov/pubmed/19371385",
        "https://pubmed.ncbi.nlm.nih.gov/30710529/",
        "http://www.ncbi.nlm.nih.gov/pubmed/8114750",
        "http://www.ncbi.nlm.nih.gov/pubmed/9177206"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "The mammalian GATA family of transcription factors comprises of 6 members that are involved in diverse roles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16150495"
        },
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 282,
          "text": "In this report, we identify GATA6 expression in the normal mouse and human CNS,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16150495"
        },
        {
          "offsetInBeginSection": 370,
          "offsetInEndSection": 481,
          "text": "GATA6 is expressed as a 2.2 kb transcript in the adult mouse brain and several regions of the adult human brain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16150495"
        },
        {
          "offsetInBeginSection": 483,
          "offsetInEndSection": 634,
          "text": "Furthermore, cellular characterization demonstrates GATA6 nuclear expression in neurons, astrocytes, choroids plexus epithelium, and endothelial cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16150495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "GATA-binding protein 4 (GATA-4)，a member of the GATA family of transcription factors, is expressed in the normal brain and participates in the neural inflammatory response and senescence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30710529"
        },
        {
          "offsetInBeginSection": 1236,
          "offsetInEndSection": 1383,
          "text": "Collectively, we show that GATA4 is expressed in the embryonic and adult CNS and acts as a negative regulator of astrocyte proliferation and growth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19543315"
        },
        {
          "offsetInBeginSection": 337,
          "offsetInEndSection": 473,
          "text": "We now show GATA4, a family member of GATA6, to be expressed in the neurons and glia of normal murine and human embryonic and adult CNS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19543315"
        },
        {
          "offsetInBeginSection": 187,
          "offsetInEndSection": 335,
          "text": "Using retroviral gene trapping on transgenic mouse glioma models, we identified GATA6 to be a novel tumor suppressor gene in glioblastoma multiforme",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19543315"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "GATA-4 regulates neuronal apoptosis after intracerebral hemorrhage via the NF-κB/Bax/Caspase-3 pathway both in vivo and in vitro.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30710529"
        },
        {
          "offsetInBeginSection": 375,
          "offsetInEndSection": 641,
          "text": "We show here that two of the members of this gene family, GATA-2 and GATA-3, are expressed within discrete cell populations of the chicken optic tectum during embryogenesis, and that they have highly restricted patterns of expression in the developing chicken brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8028475"
        },
        {
          "offsetInBeginSection": 832,
          "offsetInEndSection": 1187,
          "text": "The observation that both the timing of appearance and the localization of expression of GATA-2 and GATA-3 are correlated with optic tectum development suggest that these transcription factors may be associated with the initiation of gene transcription required for the determination of specific neuronal fates within visual areas of the vertebrate brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8028475"
        },
        {
          "offsetInBeginSection": 187,
          "offsetInEndSection": 350,
          "text": "The six vertebrate GATA factors are expressed in a broad spectrum of tissues, including the hemopoietic system, heart, gut, brain, placenta, pituitary, and gonads.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11181509"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 372,
          "text": "GATA proteins are essential for the development of tissues derived from all three germ layers, including the skin, brain, gonads, liver, hematopoietic, cardiovascular and urogenital systems.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30348673"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 294,
          "text": "GATA1/2/3 are required for differentiation of mesoderm and ectoderm-derived tissues, including the haematopoietic and central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26953528"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "GATA-binding protein 4 (GATA-4)，a member of the GATA family of transcription factors, is expressed in the normal brain and participates in the neural inflammatory response and senescence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30710529"
        },
        {
          "offsetInBeginSection": 370,
          "offsetInEndSection": 482,
          "text": "GATA6 is expressed as a 2.2 kb transcript in the adult mouse brain and several regions of the adult human brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16150495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "GATA-binding protein 4 (GATA-4)，a member of the GATA family of transcription factors, is expressed in the normal brain and participates in the neural inflammatory response and senescence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/30710529/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 318,
          "text": "GATA-3 is a zinc finger transcription factor which is expressed in a highly restricted and strongly conserved tissue distribution pattern in vertebrate organisms, specifically, in a subset of hematopoietic cells, in cells within the central and peripheral nervous systems, in the kidney, and in placental trophoblasts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8114750"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 278,
          "text": "GATA-2 is a transcription factor required for hematopoiesis and is dynamically expressed in hematopoietic tissues and in the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9177206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 294,
          "text": "The GATA family of transcription factors consists of six proteins (GATA1-6) which are involved in a variety of physiological and pathological processes. GATA1/2/3 are required for differentiation of mesoderm and ectoderm-derived tissues, including the haematopoietic and central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26953528"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "GATA binding protein 3 (GATA3) is an important regulator of central nervous system (CNS) development, but its expression pattern in the postnatal CNS has not been studied.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18554735"
        },
        {
          "offsetInBeginSection": 417,
          "offsetInEndSection": 645,
          "text": "Although GATA2 is essential for hematopoiesis and lymphangiogenesis, it is also expressed in other tissues such as the lung, prostate gland, gastrointestinal tract, central nervous system, placenta, fetal liver, and fetal heart.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37624387"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "GATA4 is a regulator of astrocyte cell proliferation and apoptosis in the human and murine central nervous system.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19543315"
        },
        {
          "offsetInBeginSection": 310,
          "offsetInEndSection": 622,
          "text": "During the first 2 weeks of postnatal development, numerous GATA3-expressing cells were found in the intergeniculate leaf, ventral lateral geniculate nucleus, pretectal nucleus, nucleus of the posterior commissure, superior colliculus, inferior colliculus, periaqueductal grey, substantia nigra and raphe nuclei.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18554735"
        },
        {
          "offsetInBeginSection": 1001,
          "offsetInEndSection": 1135,
          "text": "In the substantia nigra, GATA3 was exclusively expressed in cells of the reticulate part and some of which were found to be GABAergic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18554735"
        }
      ],
      "id": "67d74a9b18b1e36f2e00003a",
      "ideal_answer": [
        "Yes, the GATA family of transcription factors comprises 6 members that are involved in diverse roles, including normal brain development, neural inflammatory responses, and tumor suppression. For example, GATA4 has been found in the neurons and glia of normal human embryonic and adult CNS to act as a negative regulator of astrocyte proliferation and growth. In addition, GATA4 regulates neuronal apoptosis after intracerebral hemorrhage via the NF-κB/Bax/Caspase-3 pathway, confirming its participation in the inflammatory response. Finally, GATA6 nuclear expression has also been found in neurons, astrocytes, choroid plexus epithelium, and endothelial cells.",
        "Yes, transcription factors of the GATA family are found in the brain. Several studies have shown that GATA2, GATA3, and GATA6 are expressed in various regions of the developing and adult brain in both mice and humans. They play important roles in neurogenesis, neuronal differentiation, and brain development.",
        "Yes, transcription factors of the GATA family, specifically GATA6 and GATA4, are found in the brain. GATA6 is expressed in neurons, astrocytes, choroid plexus epithelium, and endothelial cells of both adult mouse and human central nervous systems. GATA4 plays roles in neural inflammatory response, senescence, and regulates neuronal apoptosis via the NF-κB/Bax/Caspase-3 pathway after intracerebral hemorrhage. Additionally, GATA4 influences astrocyte proliferation and apoptosis, functioning as a tumor suppressor in glioblastoma multiforme. These findings highlight the significant presence and functional roles of GATA family transcription factors within the brain.",
        "Yes, transcription factors of the GATA family are found in the brain. Specifically, GATA-binding protein 4 (GATA-4) is expressed in the normal brain and plays a role in neural inflammatory responses and senescence. Additionally, GATA-2 and GATA-3 have been implicated in optic tectum development, suggesting their involvement in determining specific neuronal fates within visual areas of the vertebrate brain. This highlights the importance of GATA transcription factors in both brain function and development.",
        "Yes, transcription factors of the GATA family are found in the brain. Specifically, GATA-binding protein 4 (GATA-4), a member of the GATA family of transcription factors, is expressed in the normal brain and plays a role in the neural inflammatory response and senescence. The GATA family of transcription factors, in general, has critical roles in various cell types and is of crucial importance during embryonic development, influencing cell fate decisions and tissue morphogenesis. These factors are essential regulators of gene expression across different tissues, including neural tissues.",
        "Only certain GATA transcription factors, specifically GATA2 and GATA3, are found in the brain. Their expression is confined to particular neuronal subtypes and brain regions, rather than being widespread across all brain cells. Typically, their activity is associated with specific stages of neuronal development and differentiation, where they help regulate gene expression during key periods of brain formation and function. It is important to recognize that this involvement is specific to these members and that not all GATA factors are expressed in the brain.",
        "Yes, transcription factors from the GATA family are present in the brain. They contribute to various neurological processes, including the regulation of neuronal identity and function. For instance, Gata2 is involved in regulating striatal identity genes, which are crucial for reward and movement-related functions in the brain. Additionally, GATAD1 plays a role in epigenetic repression linked to puberty, highlighting its involvement in brain-mediated hormonal changes. While research into their specific roles continues, these findings confirm the presence and significance of GATA factors in brain function.",
        "Yes, transcription factors of the GATA family are found in the brain, with GATA6, GATA4, and GATA1 identified in various brain regions. GATA4 regulates astrocyte proliferation, apoptosis, and neural inflammatory responses. GATA1 is involved in synaptic regulation and immune activation in the context of depression. The presence of FOG-2, a GATA cofactor, in the brain suggests its role in modulating GATA-mediated gene expression. These findings highlight the significant, albeit diverse, roles of GATA transcription factors in brain function and pathology.",
        "Yes, transcription factors of the GATA family are found in the brain. GATA6 is expressed in the normal mouse and human CNS, as demonstrated by Northern blot analyses, immunohistochemistry, and immunofluorescence. It is present in neurons, astrocytes, choroids plexus epithelium, and endothelial cells. Additionally, GATA4, another member of the GATA family, is involved in neuronal apoptosis after intracerebral hemorrhage and regulates astrocyte cell proliferation and apoptosis in the human and murine CNS. Furthermore, FOG-2, a cofactor for GATA transcription factors, is expressed predominantly in the developing and adult heart, brain, and testis. GATA1, typically associated with hematopoietic system development, has also been found to be increased in the dorsolateral prefrontal cortex of patients with depression and plays a role in synaptic regulation. These findings indicate the presence and functional significance of GATA transcription factors in the brain.",
        "Yes, transcription factors of the GATA family are present in the brain, with identified members including GATA6, GATA4, and GATA1. These factors play diverse roles: GATA6 is broadly expressed in various brain cell types, GATA4 regulates astrocyte and neuronal processes including inflammation and apoptosis, and GATA1 is involved in synaptic and immune functions, notably in depression. The presence of the GATA cofactor FOG-2 further suggests complex gene expression modulation in brain function and pathology.",
        "Studies have shown that transcription factors of the GATA family are indeed found in the brain, where they participate in the neural inflammatory response and senescence. Specifically, GATA-binding protein 4 (GATA-4) is expressed in the normal brain, highlighting the importance of this family of transcription factors in brain function. Additionally, other members of the GATA family, such as GATA-2 and GATA-3, have been correlated with optic tectum development, suggesting a role in determining specific neuronal fates within visual areas of the vertebrate brain. Overall, these findings indicate that the GATA family of transcription factors plays a significant role in brain development and function.",
        "Yes, transcription factors of the GATA family, specifically GATA4 and GATA6, are found in the brain. They are expressed in various cell types within the human and mouse Central Nervous System (CNS), including neurons, astrocytes, choroid plexus epithelium, and endothelial cells. These transcription factors play crucial roles in regulating neuronal apoptosis, astrocyte proliferation, and response to brain injury, with implications in several brain-related pathologies, such as glioblastoma multiforme and intracerebral hemorrhage, highlighting their significance in both normal brain function and disease.",
        "Studies have identified the presence of transcription factors from the GATA family in the brain, specifically highlighting the expression of GATA6 in both normal mouse and human central nervous systems (CNS). GATA6 is expressed as a 2.2 kb transcript in various regions of the adult mouse and human brains, with nuclear expression observed in neurons, astrocytes, choroid plexus epithelium, and endothelial cells. Additionally, another member of the GATA family, GATA4, has been found to be expressed in the embryonic and adult CNS, playing a role as a negative regulator of astrocyte proliferation and growth, while also regulating neuronal apoptosis after intracerebral hemorrhage via specific pathways. These findings collectively demonstrate that transcription factors from the GATA family are indeed present and functional in the brain, with potential implications for understanding neural development, function, and disease.",
        "Yes, transcription factors of the GATA family are found in the brain. Specifically, GATA4 and GATA6 are expressed in both murine and human central nervous systems (CNS), including the neurons and glia of the embryonic and adult brain. GATA4, a member of the GATA family, is involved in neural inflammatory responses and senescence in the brain. Similarly, GATA6 is expressed in the adult mouse brain and various regions of the adult human brain, as evidenced by a 2.2 kb transcript. These findings indicate that GATA family members play significant roles in neural development and function.",
        "Yes, transcription factors of the GATA family are present in the brain. Specifically, GATA4 and GATA6 have been identified as members of this family that are expressed within the central nervous system (CNS). \n\nGATA6 is found in various regions of the adult mouse and human brain, including neurons, astrocytes, choroid plexus epithelium, and endothelial cells. It plays a role in normal brain function and has been implicated as a tumor suppressor gene in glioblastoma multiforme.\n\nSimilarly, GATA4 is expressed in both embryonic and adult CNS tissues, where it regulates processes such as neuronal apoptosis through pathways like NF-κB/Bax/Caspase-3. It also acts as a negative regulator of astrocyte proliferation and growth.\n\nThese findings indicate that multiple GATA family members contribute to brain function and are involved in both normal physiological processes and pathological conditions within the CNS.",
        "Yes, transcription factors of the GATA family are present in the brain. Specifically, GATA4 and GATA6 have been identified in various regions of the central nervous system (CNS), including neurons, astrocytes, choroid plexus epithelium, and endothelial cells. These proteins play roles in regulating gene expression during development, participating in neural inflammatory responses, and acting as tumor suppressors in conditions like glioblastoma multiforme. Their presence underscores the importance of GATA family members in both normal brain functions and pathological processes.",
        "Yes, transcription factors of the GATA family, including GATA6 and GATA4, are found in the brain. They are expressed in both embryonic and adult central nervous systems. Specifically, GATA6 is present in neurons, astrocytes, choroid plexus epithelium, and endothelial cells, while GATA4 is expressed in neurons and glia. These factors are involved in several cellular processes, including the regulation of astrocyte proliferation, neural inflammatory responses, and neuronal apoptosis.",
        "Yes, transcription factors of the GATA family are found in the brain. Multiple studies have demonstrated the expression of various GATA factors, including GATA-2, GATA-3, GATA-4, and GATA-6, in the central nervous system (CNS) of different organisms, including humans and mice. These factors are expressed in various cell types within the brain, such as neurons, astrocytes, choroid plexus epithelium, and endothelial cells. GATA factors participate in neural development, inflammatory response, and regulation of astrocyte proliferation. Some GATA factors, like GATA-4, regulate neuronal apoptosis after intracerebral hemorrhage.",
        "Yes, transcription factors of the GATA family are present in the brain. Specifically, GATA4 and GATA6 have been identified in various regions of the adult human and mouse CNS (central nervous system). These proteins are expressed in neurons, astrocytes, choroid plexus epithelium, and endothelial cells within the brain. Additionally, GATA4 plays a role in neural inflammatory responses and senescence, while GATA6 has been implicated as a tumor suppressor gene in glioblastoma multiforme. These findings demonstrate that GATA family members are integral to diverse functions within the brain.",
        "Yes, transcription factors of the GATA family, including GATA4 and GATA6, are expressed in the brain. GATA4 is found in neurons and glia of the central nervous system (CNS) and plays roles in neural inflammation, senescence, and astrocyte regulation, while GATA6 is expressed in neurons, astrocytes, and other cell types in the CNS and has been identified as a tumor suppressor in glioblastoma multiforme.",
        "Yes, transcription factors of the GATA family are found in the brain. Specifically, GATA6 and GATA4 have been identified as being expressed in the central nervous system (CNS) of mice and humans. GATA6 is expressed in neurons, astrocytes, choroids plexus epithelium, and endothelial cells, while GATA4 is expressed in neurons and glia of embryonic and adult CNS. Additionally, GATA4 has been shown to play a role in regulating neuronal apoptosis after intracerebral hemorrhage. These findings suggest that GATA transcription factors may have important functions in the development and maintenance of the brain, as well as in response to injury or disease.",
        "Yes, transcription factors of the GATA family, specifically GATA6 and GATA4, are found in the brain. They are expressed in various regions of the adult mouse and human central nervous system (CNS), with roles in neuronal and astrocytic functions, inflammation, and senescence. GATA4 is notably involved in regulating neuronal apoptosis after intracerebral hemorrhage and astrocyte proliferation/apoptosis, underscoring the importance of GATA family transcription factors in both CNS development and response to injury.",
        "Yes, transcription factors of the GATA family, specifically GATA4 and GATA6, are found in the brain. They are expressed in various central nervous system (CNS) cell types, including neurons, astrocytes, choroid plexus epithelium, and endothelial cells, in both human and mouse models. These factors play crucial roles in regulating cellular processes such as neuronal apoptosis, astrocyte proliferation, and response to brain injury, with implications in several neurological conditions. Their widespread expression and functional significance underscore their importance in brain physiology and pathology.",
        " Yes, transcription factors of the GATA family are found in the brain. Specifically, GATA6 and GATA-4 have been identified as being expressed in both the normal mouse and human CNS (central nervous system). These proteins play diverse roles in the brain, including participation in neural inflammatory response, senescence, regulation of astrocyte proliferation and growth, and acting as a negative regulator of neuronal apoptosis after intracerebral hemorrhage.",
        "Yes, transcription factors of the GATA family are found in the brain. Multiple studies have demonstrated that GATA6 is expressed as a 2.2 kb transcript in the adult mouse brain and several regions of the adult human brain, with nuclear expression in neurons, astrocytes, choroid plexus epithelium, and endothelial cells. Similarly, GATA4, another member of the GATA family, is expressed in the normal brain, specifically in neurons and glia of both murine and human embryonic and adult central nervous system (CNS). GATA4 has been shown to participate in neural inflammatory response, senescence, and acts as a negative regulator of astrocyte proliferation and growth. Additionally, GATA4 regulates neuronal apoptosis after intracerebral hemorrhage via specific molecular pathways.",
        "The studies demonstrate that transcription factors of the GATA family, specifically GATA4 and GATA6, are present in both murine and human central nervous systems (CNS). These factors are expressed in various cell types within the brain, including neurons, astrocytes, choroid plexus epithelium, and endothelial cells. GATA4 plays roles in neural inflammatory responses, senescence, and acts as a negative regulator of astrocyte proliferation. Additionally, GATA6 has been identified as a tumor suppressor in glioblastoma multiforme. Both factors are involved in critical processes such as apoptosis regulation and cellular growth control within the CNS.",
        "Yes, transcription factors of the GATA family, notably GATA4 and GATA6, are expressed in the human and mouse brain, localized in neurons, astrocytes, choroid plexus epithelium, and endothelial cells. They play crucial roles in regulating neuronal apoptosis, astrocyte proliferation, response to brain injury, neural inflammation, and senescence. Their dysregulation has implications in neurological conditions such as glioblastoma multiforme and intracerebral hemorrhage, highlighting their significance in CNS development and pathology across species."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Is there any role between AGRN and Myasthenia gravis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34400559"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Myasthenia gravis genome-wide association study implicates AGRN as a risk locus.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34400559"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 790,
          "text": "We confirmed the previously reported MG association with TNFRSF11A (rs4369774; p\u003d1.09×10-13, OR\u003d1.4). Furthermore, gene-based analysis revealed AGRN as a novel MG susceptibility gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34400559"
        },
        {
          "offsetInBeginSection": 1247,
          "offsetInEndSection": 1510,
          "text": "G and correlated disorders.DISCUSSION: Our gene-based analysis identifies AGRN as a novel MG susceptibility gene, implicating for the first time a locus encoding a protein (agrin) that is directly relevant to NMJ activation. Mutations in AGRN have been found to u",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34400559"
        },
        {
          "offsetInBeginSection": 1247,
          "offsetInEndSection": 1432,
          "text": "G and correlated disorders.DISCUSSION: Our gene-based analysis identifies AGRN as a novel MG susceptibility gene, implicating for the first time a locus encoding a protein (agrin) that ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34400559"
        },
        {
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1471,
          "text": "Cross-disorder meta-analysis reveals multiple risk loci that appear pleiotropic across MG and correlated disorders.DISCUSSION: Our gene-based analysis identifies AGRN as a novel MG susceptibility gene, implicating for the first time a locus encoding a protein (agrin) that is directly relevant to NMJ activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34400559"
        },
        {
          "offsetInBeginSection": 709,
          "offsetInEndSection": 790,
          "text": "Furthermore, gene-based analysis revealed AGRN as a novel MG susceptibility gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34400559"
        },
        {
          "offsetInBeginSection": 1291,
          "offsetInEndSection": 1476,
          "text": "ene-based analysis identifies AGRN as a novel MG susceptibility gene, implicating for the first time a locus encoding a protein (agrin) that is directly relevant to NMJ activation. Muta",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34400559"
        },
        {
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1549,
          "text": "Furthermore, we find MG to be genetically correlated with type 1 diabetes (T1D), rheumatoid arthritis (RA), late-onset vitiligo and autoimmune thyroid disease (ATD). Cross-disorder meta-analysis reveals multiple risk loci that appear pleiotropic across MG and correlated disorders.DISCUSSION: Our gene-based analysis identifies AGRN as a novel MG susceptibility gene, implicating for the first time a locus encoding a protein (agrin) that is directly relevant to NMJ activation. Mutations in AGRN have been found to underlie congenital myasthenic syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34400559"
        }
      ],
      "id": "67d41b8518b1e36f2e00000d",
      "ideal_answer": [
        "Yes. Gene-based analysis revealed AGRN as a novel Myasthenia gravis (MG) susceptibility gene.",
        "Yes. Agrin is a protein that is involved in the formation of the neuromuscular junction and is associated with myasthenia gravis.",
        "Yes, there is a role between AGRN (the gene encoding the agrin protein) and myasthenia gravis. Several studies have identified autoantibodies against agrin in some patients with myasthenia gravis, particularly those who do not have antibodies against the acetylcholine receptor, muscle-specific kinase, or LRP4. Agrin is essential for the formation and maintenance of neuromuscular junctions, and anti-agrin antibodies can impair this process, leading to neuromuscular junction dysfunction characteristic of myasthenia gravis. Animal studies have also shown that inducing anti-agrin antibodies can cause myasthenia gravis-like symptoms.",
        "Yes, there is a role between AGRN (agrin) and myasthenia gravis. Agrin is a protein that plays a crucial role in the neuromuscular junction, where it helps in the clustering of acetylcholine receptors. Myasthenia gravis is an autoimmune disorder characterized by weakness and rapid fatigue of muscles, which is caused by antibodies that attack acetylcholine receptors at the neuromuscular junction. Disruption in agrin\u0027s function can contribute to the pathophysiology of myasthenia gravis, as it affects the stability and function of the neuromuscular junction.",
        "Yes. AGRN is associated with Myasthenia gravis.",
        "Yes, AGRN (agrin) plays a role in the neuromuscular junction, and its dysfunction can be associated with myasthenia gravis. Agrin is a protein that helps in the clustering of acetylcholine receptors at the neuromuscular junction, which is crucial for effective muscle contraction. In myasthenia gravis, an autoimmune disorder, antibodies target components of the neuromuscular junction, including acetylcholine receptors, leading to muscle weakness. While agrin itself is not directly targeted by these antibodies, its role in receptor clustering makes it an important part of the neuromuscular junction\u0027s function, and any disruption in its activity can contribute to the symptoms of myasthenia gravis.",
        "Yes, there is a role between AGRN and Myasthenia gravis. Research has identified AGRN as a risk locus and a novel susceptibility gene for Myasthenia gravis, indicating that it plays a significant part in the disease\u0027s development, particularly in its connection to neuromuscular junction activation.",
        "Yes. Mutations in AGRN have been found to underlie congenital myasthenic syndrome, and AGRN is implicated as a novel susceptibility gene for myasthenia gravis, indicating a significant role in the disease.",
        "Yes, AGRN is implicated as a susceptibility gene for Myasthenia Gravis.",
        "Yes, agrin plays a significant role in myasthenia gravis. Agrin, an extracellular matrix protein essential for neuromuscular junction formation and maintenance, has been identified as an autoantigen in some MG patients. Autoantibodies targeting agrin disrupt the agrin/LRP4/MuSK signaling cascade by directly inhibiting agrin-induced MuSK phosphorylation and acetylcholine receptor clustering. This disruption impairs neuromuscular transmission and leads to muscle weakness. Experimental studies, including those using mice immunized with N-agrin, support the pathogenic role of these antibodies, and findings suggest a distinction between anti-N-agrin and anti-M-agrin antibodies. The presence of agrin autoantibodies provides valuable insight into the molecular mechanisms underlying MG pathogenesis.",
        "Yes, AGRN (agrin) plays a significant role in Myasthenia gravis (MG). Agrin is crucial for organizing acetylcholine receptors at the neuromuscular junction (NMJ), facilitating nerve-muscle communication. In MG, the immune system typically targets these receptors or related proteins like MuSK. However, some MG cases involve antibodies against LRP4 and agrin, indicating that AGRN can be a target in certain forms of the disease. This highlights AGRN\u0027s role in MG pathophysiology, particularly in antibody-mediated neuromuscular junction dysfunction.",
        "Yes, AGRN (agrin) plays a significant role in Myasthenia gravis (MG). AGRN is crucial for neuromuscular junction (NMJ) development and maintenance. In MG, antibodies often target acetylcholine receptors at the NMJ, disrupting nerve-muscle communication. Some MG cases involve antibodies against AGRN or related proteins like LRP4, impairing NMJ function. Additionally, mutations in AGRN cause congenital myasthenic syndromes, highlighting its importance in NMJ integrity. Thus, AGRN is implicated in both autoimmune and genetic forms of MG, contributing to muscle weakness through NMJ dysfunction.",
        "Yes. Agrin (AGRN) plays a significant role in myasthenia gravis (MG) as it is involved in the neuromuscular junction (NMJ) formation and maintenance, and antibodies against agrin have been identified in patients with MG.",
        "Yes. Mutations in AGRN have been found to underlie congenital myasthenic syndrome, and AGRN is implicated as a novel susceptibility gene for myasthenia gravis (MG).",
        "Yes. Anti-agrin antibodies have been detected in patients with myasthenia gravis (MG), suggesting a potential role in the pathogenesis of the disease.",
        "Yes, AGRN has been identified as a novel Myasthenia gravis susceptibility gene, indicating a role between AGRN and the disease.",
        "Yes, a link between AGRN and Myasthenia Gravis (MG) exists. Genome-wide association studies implicate AGRN as a novel MG susceptibility gene, suggesting a genetic correlation. Agrin, encoded by AGRN, is crucial for neuromuscular junction activation. Experimental models show that anti-agrin antibodies can induce MG-like symptoms, potentially contributing to MG pathogenesis, especially in \u0027triple-negative\u0027 cases. While AGRN mutations also underlie congenital myasthenic syndromes, the evidence collectively supports a role for AGRN in MG susceptibility and immunological mechanisms.",
        "Yes. Mutations in AGRN have been implicated in myasthenia gravis, and anti-agrin antibodies have been identified in patients with this condition, indicating a role for AGRN in the disease.",
        "Yes, AGRN (agrin) plays a role in the neuromuscular junction, and its dysfunction can be associated with myasthenia gravis. Myasthenia gravis is an autoimmune disorder characterized by weakness and rapid fatigue of muscles. Agrin is crucial for the clustering of acetylcholine receptors at the neuromuscular junction, which is essential for effective muscle contraction. In myasthenia gravis, antibodies may target components of the neuromuscular junction, including agrin, leading to impaired synaptic transmission and muscle weakness.",
        "Yes, there is evidence that mutations in the AGRN gene, which encodes the agrin protein, can play a role in the development of myasthenia gravis (MG). Agrin is a critical protein for the formation and maintenance of the neuromuscular junction. Some studies have identified autoantibodies against agrin in MG patients who lack antibodies against other known targets like the acetylcholine receptor. Additionally, animal studies have shown that inducing anti-agrin antibodies can cause MG-like symptoms and disrupt neuromuscular junction function. Therefore, agrin and anti-agrin antibodies appear to be implicated in the pathogenesis of certain subtypes of MG.",
        "Yes, there is evidence that the AGRN gene, which encodes the agrin protein, plays a role in myasthenia gravis. Several studies have found autoantibodies against agrin in some patients with myasthenia gravis. Agrin is essential for the formation and maintenance of the neuromuscular junction, and anti-agrin autoantibodies may disrupt this process, contributing to the pathogenesis of myasthenia gravis.",
        "Yes. Agrin is a novel MG susceptibility gene.",
        "Yes, a role exists between AGRN and Myasthenia Gravis (MG). Genome-wide association studies link AGRN to MG susceptibility, with agrin crucial for neuromuscular junction activation. AGRN\u0027s involvement is suggested in both the genetic architecture of MG and its immunological mechanisms, particularly in \u0027triple-negative\u0027 cases. While AGRN mutations underlie Congenital Myasthenic Syndromes, its broader role in autoimmune MG is indicated, with potential treatment implications, such as the use of pseudoephedrine, though further research is needed to establish efficacy in AGRN-related MG cases.",
        "Yes, there is a suggested role between AGRN and Myasthenia Gravis (MG). Genome-wide association studies implicate AGRN as a novel MG susceptibility gene, and experimental models demonstrate that anti-agrin antibodies can induce MG-like symptoms, potentially contributing to MG pathogenesis, particularly in triple-negative MG cases. However, it is essential to distinguish this from the established role of AGRN mutations in causing Congenital Myasthenic Syndromes, a separate clinical entity.",
        "Yes, AGRN (agrin) is implicated in Myasthenia gravis (MG) as a susceptibility gene, with genome-wide association studies identifying it as a risk locus. Agrin is directly relevant to neuromuscular junction (NMJ) activation, and autoantibodies to agrin have been found in MG patients, further supporting its role in the disease.",
        "Yes, there appears to be a role between AGRN (agrin) and Myasthenia gravis (MG). AGRN has been identified as a risk locus in genome-wide association studies for MG, suggesting a genetic link. Additionally, autoantibodies targeting agrin have been detected in some MG patients, though their diagnostic value and pathogenic effects are not yet fully understood.\n\nAgrin is crucial for clustering nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction. Disruptions or mutations in AGRN can affect this process, potentially contributing to MG symptoms. While AGRN\u0027s role may involve genetic predisposition and immune targeting, further research is needed to clarify its exact mechanisms and significance in MG pathogenesis.",
        "Yes, AGRN plays a role in Myasthenia Gravis. Genome wide association studies have identified AGRN as a risk locus for the disease, suggesting that it contributes to its development, possibly through immune mediated mechanisms or structural roles at the neuromuscular junction.",
        "Yes, AGRN has been implicated as a risk locus in Myasthenia Gravis through genome wide association studies (GWAS). This suggests that variations or mutations in the AGRN gene may contribute to an increased susceptibility to developing Myasthenia Gravis. The GWAS findings highlight the potential role of AGRN in the pathogenesis of this autoimmune disorder, indicating a genetic association between the two.",
        "Yes, AGRN has been implicated in Myasthenia Gravis through genome wide association studies, suggesting a potential role. However, further research may be needed to establish causation.",
        "Yes. AGRN has been identified as a novel susceptibility gene associated with Myasthenia gravis.",
        "Yes. Gene-based analysis revealed AGRN as a novel MG susceptibility gene.",
        "Yes, AGRN is a novel susceptibility gene for Myasthenia gravis.",
        "Yes. AGRN has been identified as a novel susceptibility gene for myasthenia gravis, implicating its role in the disease.",
        "Yes, AGRN has been identified as a novel susceptibility gene for Myasthenia gravis, implicating a direct relevance to neuromuscular junction activation.",
        "Yes, there is a role between AGRN and Myasthenia gravis. A genome-wide association study has implicated AGRN as a risk locus for Myasthenia gravis.",
        "Yes, there is a role between AGRN and Myasthenia gravis (MG). A genome-wide association study (GWAS) identified AGRN as a novel MG susceptibility gene. The study integrated three different data sets (total of 1401 cases and 3508 controls) in a GWAS meta-analysis. The research also confirmed the previously reported MG association with TNFRSF11A. Myasthenia gravis (MG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ).",
        "Yes, AGRN has been implicated as a risk locus in Myasthenia gravis according to genome-wide association studies.",
        "Yes. The gene-based analysis revealed AGRN as a novel susceptibility gene for Myasthenia gravis, implicating it in the disease\u0027s genetic architecture.",
        "Yes, AGRN has been identified as a novel susceptibility gene for Myasthenia gravis (MG). This means that genetic variations in the AGRN gene may contribute to an individual\u0027s risk of developing MG. The exact role of AGRN in MG is not yet fully understood, but its identification as a risk locus suggests that it may play a role in the pathogenesis of the disease.",
        "Yes. AGRN has been implicated as a novel susceptibility gene for Myasthenia gravis (MG), and autoantibodies can target agrin, affecting acetylcholine receptor clustering at the neuromuscular junction.",
        "Yes. AGRN is implicated as a novel susceptibility gene in myasthenia gravis (MG), and autoantibodies against agrin can interfere with acetylcholine receptor clustering, which is crucial for neuromuscular transmission.",
        "Yes, AGRN is implicated as a risk locus for Myasthenia Gravis.",
        "Yes, there is a definitive role between AGRN (Agrin) and Myasthenia gravis. Genome-wide association studies have identified AGRN as a novel susceptibility gene for this autoimmune neuromuscular disorder. Variations in the AGRN gene are implicated in contributing to the development of Myasthenia gravis, primarily by affecting the function of the neuromuscular junction. This association is further supported by AGRN\u0027s involvement in congenital myasthenic syndrome, underscoring its importance in neuromuscular health. The consensus across studies confirms AGRN\u0027s role in the pathogenesis of Myasthenia gravis.",
        "Yes, there is a role between AGRN and Myasthenia gravis. A genome-wide association study has implicated AGRN as a risk locus for Myasthenia gravis, suggesting that variations in the AGRN gene may contribute to the susceptibility or development of this autoimmune disorder.",
        "Yes, AGRN plays a significant role in Myasthenia Gravis (MG), identified as a novel MG susceptibility gene through genome-wide association studies. Its encoded protein, agrin, is crucial for neuromuscular junction activation. Notably, mutations in AGRN are linked to Congenital Myasthenic Syndrome, a related neuromuscular disorder, underscoring AGRN\u0027s implication in the pathology of MG, particularly in neuromuscular junction dysfunction.",
        "Yes, AGRN is a risk locus for Myasthenia gravis.",
        "Yes, there is a role between AGRN and Myasthenia gravis. A genome-wide association study implicates AGRN as a risk locus. Gene-based analysis revealed AGRN as a novel MG susceptibility gene.",
        "Yes, there is evidence supporting a role between AGRN (agrin) and Myasthenia gravis (MG). According to genome-wide association studies, AGRN has been identified as a novel MG susceptibility gene through gene-based analysis. This finding suggests that genetic variations in AGRN may contribute to the risk of developing Myasthenia gravis. This is significant because agrin is a protein known to be involved in neuromuscular junction formation and maintenance, which is directly relevant to the pathophysiology of MG, a disorder characterized by neuromuscular transmission defects.",
        "Yes, genome-wide studies have identified AGRN as a novel susceptibility gene for Myasthenia Gravis (MG), implicating it as a risk locus. These studies confirmed the previously known association with TNFRSF11A and revealed that variations in the AGRN gene contribute to the risk of developing MG.",
        "Yes, AGRN has been identified as a novel susceptibility gene for Myasthenia gravis (MG), suggesting a role in the development or progression of the disease.",
        "Yes, AGRN (Agrin) plays a significant role in Myasthenia Gravis (MG). Genome-wide association studies have identified AGRN as a novel MG susceptibility gene, crucial for neuromuscular junction (NMJ) activation. Variations in AGRN can impair NMJ function, contributing to MG\u0027s development. This genetic link is further supported by AGRN\u0027s association with congenital myasthenic syndrome, a related neuromuscular disorder, underscoring its importance in neuromuscular health and disease, particularly in the context of autoimmune disorders affecting the NMJ.",
        "Yes, according to both a genome-wide association study and gene-based analysis, AGRN is implicated as a risk locus and a novel susceptibility gene for Myasthenia gravis, indicating a genetic role in the disease.",
        "Yes, there is a role between AGRN and Myasthenia Gravis (MG). A genome-wide association study (GWAS) identified AGRN as a novel MG susceptibility gene. The study involved a meta-analysis of three different datasets, encompassing a total of 1401 cases and 3508 controls. This implicated AGRN as a risk locus for MG.",
        "Yes. AGRN is a novel MG susceptibility gene and Myasthenia gravis genome-wide association study implicates AGRN as a risk locus."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Please list the 4 problems that are found in the tetrology of Fallot.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31258874",
        "http://www.ncbi.nlm.nih.gov/pubmed/19144126",
        "http://www.ncbi.nlm.nih.gov/pubmed/38884737",
        "http://www.ncbi.nlm.nih.gov/pubmed/6822115",
        "http://www.ncbi.nlm.nih.gov/pubmed/38277413",
        "http://www.ncbi.nlm.nih.gov/pubmed/30592107",
        "http://www.ncbi.nlm.nih.gov/pubmed/17078912",
        "http://www.ncbi.nlm.nih.gov/pubmed/10218082",
        "http://www.ncbi.nlm.nih.gov/pubmed/26283594",
        "http://www.ncbi.nlm.nih.gov/pubmed/19717356",
        "http://www.ncbi.nlm.nih.gov/pubmed/32049433",
        "http://www.ncbi.nlm.nih.gov/pubmed/24778798",
        "http://www.ncbi.nlm.nih.gov/pubmed/38222209",
        "http://www.ncbi.nlm.nih.gov/pubmed/32462941",
        "http://www.ncbi.nlm.nih.gov/pubmed/39702213",
        "http://www.ncbi.nlm.nih.gov/pubmed/39063597",
        "http://www.ncbi.nlm.nih.gov/pubmed/33305230",
        "http://www.ncbi.nlm.nih.gov/pubmed/24888422",
        "http://www.ncbi.nlm.nih.gov/pubmed/15488093",
        "http://www.ncbi.nlm.nih.gov/pubmed/22176554",
        "http://www.ncbi.nlm.nih.gov/pubmed/31803303",
        "http://www.ncbi.nlm.nih.gov/pubmed/37042764",
        "http://www.ncbi.nlm.nih.gov/pubmed/24473430",
        "http://www.ncbi.nlm.nih.gov/pubmed/31660488",
        "http://www.ncbi.nlm.nih.gov/pubmed/12698517"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Tetralogy of Fallot is the most common cyanotic congenital heart disease. It consists of right ventricular outflow tract obstruction, a ventricular septal defect, abnormally located aorta and right ventricular hypertrophy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31258874"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 293,
          "text": "Tetralogy of Fallot is a congenital cardiac malformation that consists of an interventricular communication, also known as a ventricular septal defect, obstruction of the right ventricular outflow tract, override of the ventricular septum by the aortic root, and right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19144126"
        },
        {
          "offsetInBeginSection": 68,
          "offsetInEndSection": 459,
          "text": "TOF consists of the combination of four anomalies (Fig. 35.1): (1) a large malalignment ventricular septal defect, (2) an obstruction of the right ventricular outflow tract (usually infundibular and valvular pulmonary stenosis with a small pulmonary valve annulus and supravalvular stenosis, (3) an aorta that \"overrides\" the ventricular septal defect, and (4) right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38884737"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 357,
          "text": "Several late sequelae of corrected tetralogy of Fallot have been found, including residual ventricular septal defect, restenosis of the pulmonary outflow tract, ventricular tachycardia, and right ventricular failure from pulmonary insufficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6822115"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "BACKGROUND: Tetralogy of Fallot (ToF) is a cyanotic congenital heart disease, composed of four malformations: persistent communication between the right and the left ventricle, pulmonary stenosis, overriding aorta, and right ventricle ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38277413"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 235,
          "text": "Tetralogy of Fallot (TOF) has four anatomic features: right ventricular hypertrophy (RVH), ventriculoseptal defect (VSD), overriding aorta and right ventricular outflow tract obstruction (RVOT) with an occurrence of 3.9 /10,000 births.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30592107"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "Tetralogy of Fallot is the most common cyanotic congenital heart disease. It consists of right ventricular outflow tract obstruction, a ventricular septal defect, abnormally located aorta and right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31258874"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 280,
          "text": "The four characteristic findings in tetralogy of Fallot (TOF) include the following: 1) a malaligned ventricular septal defect; 2) right ventricular outflow and/or pulmonary valve/artery stenosis or atresia; 3) a dextraposed overriding aorta; and 4) right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17078912"
        },
        {
          "offsetInBeginSection": 245,
          "offsetInEndSection": 478,
          "text": "The four features that comprise tetralogy of Fallot--right ventricular hypertrophy, VSD, overriding aorta, and subpulmonary stenosis--are all secondary to a single morphogenetic defect: failure of expansion of the subpulmonary conus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10218082"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "Tetralogy of Fallot (TOF) classically consists of four characteristic features-right ventricular outflow obstruction, right ventricular hypertrophy, ventricular septal defect and an overriding aorta.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26283594"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "Tetralogy of Fallot (TOF) has four anatomic features: right ventricular hypertrophy (RVH), ventriculoseptal defect (VSD), overriding aorta and right ventricular outflow tract obstruction (RVOT) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30592107"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "Tetralogy of Fallot (TOF), one of the most common congenital heart diseases, has four major components: right ventricular hypertrophy, overriding aorta, membranous ventricular septal defect, and right ventricular outflow tract obstruction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19717356"
        },
        {
          "offsetInBeginSection": 829,
          "offsetInEndSection": 1063,
          "text": "New guidelines suggest screening for a 22q11.2 deletion in the patient with tetralogy of Fallot, truncus arteriosus, interrupted aortic arch type B, conoventricular septal defects as well as those with an isolated aortic arch anomaly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32049433"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "Tetralogy of Fallot (TOF) is one of the most common congenital heart malformations comprising a ventricular septal defect, right ventricular outflow tract obstruction, right ventricular hypertrophy, and overriding aorta.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24778798"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 361,
          "text": "Tetralogy of Fallot (TOF) is a congenital heart defect characterized by four distinct heart abnormalities, which include an overriding aorta (where the aorta crosses both ventricles), a ventricular septal defect (VSD), right ventricular hypertrophy (the right ventricle muscle is thickened), and pulmonary stenosis (the pulmonary valve and artery are narrowed).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38222209"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Tetralogy of Fallot is the most common cyanotic congenital heart defect consisting of an overriding aorta, right ventricular outflow obstruction, ventricular septal defect, and right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32462941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 284,
          "text": "Tetralogy of Fallot (TOF) is the most common congenital cyanotic heart disease and is characterized by an antero-superior deviation of the infundibular septum with a consequent large malaligned ventricular septal defect (VSD) and a pulmonary and sub-pulmonary (infundibular) stenosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39702213"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 459,
          "text": "Tetralogy of Fallot (TOF) is the most common cyanotic heart defect. TOF consists of the combination of four anomalies (Fig. 35.1): (1) a large malalignment ventricular septal defect, (2) an obstruction of the right ventricular outflow tract (usually infundibular and valvular pulmonary stenosis with a small pulmonary valve annulus and supravalvular stenosis, (3) an aorta that \"overrides\" the ventricular septal defect, and (4) right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38884737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Tetralogy of Fallot is a congenital heart disease comprised of a tetrad of ventricular septal defect, pulmonary stenosis, overriding aorta, and right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33305230"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Tetralogy of Fallot (TOF) is a cyanotic heart disease consisting of nonrestrictive ventricular septal defect, overriding aorta, pulmonary stenosis, and right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24888422"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Tetralogy of Fallot is the most common cyanotic congenital heart defect during infancy. It is composed of a ventricular septal defect, an overriding aorta, obstruction of right ventricular outflow, and right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15488093"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Tetralogy of Fallot is the most common heart defect associated with cyanosis characterized by the co-occurrence of pulmonary stenosis, right ventricular hypertrophy, and ventricular septal defect with over-riding of the aorta.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39063597"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 360,
          "text": "Tetralogy of Fallot (TOF) is a congenital heart defect characterized by four distinct heart abnormalities, which include an overriding aorta (where the aorta crosses both ventricles), a ventricular septal defect (VSD), right ventricular hypertrophy (the right ventricle muscle is thickened), and pulmonary stenosis (the pulmonary valve and artery are narrowed)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38222209"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Tetralogy of Fallot is a congenital heart disease comprised of a tetrad of ventricular septal defect, pulmonary stenosis, overriding aorta, and right ventricular hypertrophy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33305230"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Tetralogy of Fallot is characterized by a ventricular septal defect, a large, overriding aorta, subpulmonic stenosis, and right ventricular hypertrophy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176554"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 318,
          "text": "It consists of four different defects of the heart: ventricular septal defect, pulmonary artery stenosis (blockage of blood flow from the right ventricle to the lungs), right ventricle hypertrophy and dextroposition of aorta.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31803303"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "Tetralogy of Fallot was classically described as the combination of pulmonary stenosis, right ventricle hypertrophy, perimembranous ventricular septal defect and an aortic root that overrides the ventricular septal defect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37042764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Tetralogy of Fallot is a cyanotic congenital heart disease characterised by a tetrad of four anomalies including ventricular septal defect, pulmonary stenosis, over-riding of aorta and right ventricular hypertrophy ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24473430"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "BACKGROUND: Tetralogy of Fallot is a congenital heart defect characterized by pulmonary valve stenosis, ventricular septal defect (VSD), overriding aorta, and right ventricular ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31660488"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Tetralogy of Fallot is characterized by a ventricular septal defect, a large, overriding aorta, subpulmonic stenosis, and right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22176554"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 378,
          "text": "We diagnosed adult tetralogy of Fallot, which included all four characteristic anomalies: ventricular septal defect, overriding aorta, pulmonary artery stenosis, and right ventricular hypertrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12698517"
        }
      ],
      "type": "list",
      "id": "67cdbe0c81b1027333000019",
      "ideal_answer": [
        "Tetralogy of Fallot is the most common cyanotic congenital heart disease. It consists of right ventricular outflow tract obstruction, a ventricular septal defect, abnormally located aorta and right ventricular hypertrophy",
        "The four problems that make up the tetralogy of Fallot are: 1) ventricular septal defect (a hole between the two ventricles), 2) pulmonary stenosis (narrowing of the pulmonary valve and outflow tract), 3) an overriding aorta (the aorta is shifted over the ventricular septal defect), and 4) right ventricular hypertrophy (thickening of the right ventricular muscle).",
        "Tetralogy of Fallot (TOF) is characterized by four key problems: \n1. Right Ventricular Outflow Tract Obstruction, blocking blood flow to the lungs, \n2. Ventricular Septal Defect, allowing ventricular blood mixing, \n3. An abnormally located aorta positioned over the septal defect, and \n4. Right Ventricular Hypertrophy due to increased workload. \nThese defects cause cyanotic congenital heart disease, with symptoms like shortness of breath and cyanosis. Surgical correction is often necessary, and if left untreated, can lead to complications such as brain abscesses. Associated anomalies and long-term effects can also impact noncardiac surgeries.",
        "Tetralogy of Fallot is a congenital heart disease that consists of four main problems: pulmonary stenosis, ventricular septal defect, aorta overriding the ventricular septum, and right ventricular hypertrophy.",
        "The four characteristic problems found in Tetralogy of Fallot (ToF) are: 1) Ventricular Septal Defect (VSD), 2) Pulmonary Stenosis or Atresia, 3) Right Ventricular Hypertrophy, and 4) An overriding aorta. These anomalies are central to the condition and are consistently highlighted as key features of ToF.",
        "The four problems found in the tetralogy of Fallot are ventricular septal defect (VSD), pulmonary stenosis, right ventricular hypertrophy, and an overriding aorta.",
        "Tetralogy of Fallot classically consists of four characteristic features: right ventricular outflow obstruction, right ventricular hypertrophy, ventricular septal defect, and an overriding aorta.",
        "The four problems found in the tetralogy of Fallot are: 1) a malaligned ventricular septal defect, 2) right ventricular outflow and/or pulmonary valve/artery stenosis or atresia, 3) a dextraposed overriding aorta, and 4) right ventricular hypertrophy. These cardiac anomalies typically lead to a cyanotic congenital heart condition.",
        "The four characteristic problems in tetralogy of Fallot are a malaligned ventricular septal defect, right ventricular outflow tract obstruction, an overriding aorta, and right ventricular hypertrophy.",
        "Tetralogy of Fallot is characterized by a membranous ventricular septal defect, an overriding aorta, right ventricular outflow tract obstruction commonly caused by pulmonary stenosis, and right ventricular hypertrophy.",
        "Tetralogy of Fallot is characterized by four heart defects: ventricular septal defect, pulmonary stenosis (or right ventricular outflow obstruction), overriding aorta, and right ventricular hypertrophy.",
        "Tetralogy of Fallot is a congenital heart disease that consists of four main problems: ventricular septal defect, pulmonary stenosis, right ventricular hypertrophy, and an overriding aorta.",
        "The four major anatomical abnormalities found in Tetralogy of Fallot (TOF) are: 1) ventricular septal defect (VSD), 2) pulmonary stenosis, 3) right ventricular hypertrophy (RVH), and 4) overriding aorta.",
        "The four problems that are found in the tetralogy of Fallot include right ventricular hypertrophy, malaligned ventricular septal defect, overriding aorta, and right ventricular outflow obstruction.",
        "The four characteristic problems of Tetralogy of Fallot (TOF) are: \n1. Ventricular Septal Defect (VSD) - a hole between the heart\u0027s two ventricles.\n2. Obstruction to Right Ventricular Outflow - blockage affecting blood flow from the right ventricle to the lungs, which can manifest as pulmonary stenosis.\n3. Abnormally Located Aorta (Overriding Aorta) - positioned over the VSD, receiving blood from both ventricles.\n4. Right Ventricular Hypertrophy - thickening of the right ventricle muscle due to increased workload.",
        "The four major anatomical abnormalities found in Tetralogy of Fallot (TOF) are: 1. Ventricular septal defect (VSD) - a hole between the heart\u0027s lower chambers. 2. Pulmonary stenosis - narrowing of the outflow tract from the right ventricle to the pulmonary artery. 3. Overriding aorta - the aorta is positioned directly over the ventricular septal defect instead of over the left ventricle. 4. Right ventricular hypertrophy - thickening of the muscular walls of the right ventricle due to increased workload.",
        "Tetralogy of Fallot consists of four main defects: a ventricular septal defect (hole between the ventricles), pulmonary stenosis (obstruction of blood flow from the right ventricle to the lungs), right ventricular hypertrophy (thickening of the right ventricular muscle), and an overriding aorta (aorta positioned over the ventricular septal defect).",
        "The four characteristic findings in Tetralogy of Fallot (TOF) are:\n\n1. Ventricular septal defect (malaligned or anterior malaligned)\n2. Right ventricular outflow obstruction (stenosis or atresia)\n3. Overriding aorta (aortic root overrides the ventricular septal defect)\n4. Right ventricular hypertrophy",
        "The four cardinal features of tetralogy of Fallot, as described by Etienne-Louis Arthur Fallot, are: 1) stenosis (narrowing) of the pulmonary artery, 2) a ventricular septal defect (hole between the ventricles), 3) an overriding aorta (aorta situated over the ventricular septal defect), and 4) right ventricular hypertrophy (thickening of the right ventricular muscle).",
        "The tetralogy of Fallot consists of four anatomical abnormalities: 1) ventricular septal defect, 2) pulmonary stenosis, 3) overriding aorta, and 4) right ventricular hypertrophy.",
        "The four anatomic features of tetralogy of Fallot are: 1) right ventricular hypertrophy, 2) ventricular septal defect, 3) overriding aorta, and 4) right ventricular outflow tract obstruction.",
        "The Tetralogy of Fallot (TOF) is characterized by four key problems: \n1. Right Ventricular Outflow Tract Obstruction, blocking lung blood flow and potentially causing pulmonary stenosis.\n2. Ventricular Septal Defect, a hole between the ventricles allowing blood mixing.\n3. An abnormally located (overriding) aorta, positioned over the septal defect and receiving blood from both ventricles.\n4. Right Ventricular Hypertrophy, a thickening of the right ventricle muscle due to increased workload. These defects lead to cyanotic congenital heart disease, necessitating often surgical correction to prevent complications.",
        "Tetralogy of Fallot is characterized by four specific problems: a ventricular septal defect, an overriding aorta, pulmonary stenosis, and right ventricular hypertrophy.",
        "The four problems found in the tetralogy of Fallot are: \n1. Right ventricular outflow tract obstruction, \n2. Ventricular septal defect, \n3. Abnormally located aorta, \n4. Right ventricular hypertrophy.",
        "The four problems found in tetralogy of Fallot are: 1) a malaligned ventricular septal defect, 2) right ventricular outflow obstruction (including pulmonary valve/artery stenosis or atresia), 3) an overriding aorta, and 4) right ventricular hypertrophy. These anatomical abnormalities collectively lead to cyanotic congenital heart disease due to diminished pulmonary blood flow.",
        "The four problems found in Tetralogy of Fallot are: ventricular septal defect (VSD), overriding aorta, pulmonary stenosis or right ventricular outflow tract obstruction, and right ventricular hypertrophy.",
        "Tetralogy of Fallot is the most common cyanotic congenital heart disease. It consists of right ventricular outflow tract obstruction, a ventricular septal defect, abnormally located aorta and right ventricular hypertrophy.",
        "Tetralogy of Fallot is characterized by four main cardiac abnormalities: right ventricular outflow tract obstruction, a ventricular septal defect, an abnormally positioned aorta, and right ventricular hypertrophy.",
        "The problems found in Tetralogy of Fallot are right ventricular outflow tract obstruction, ventricular septal defect, abnormally located aorta, and right ventricular hypertrophy.",
        "Tetralogy of Fallot consists of four main problems: right ventricular outflow tract obstruction, a ventricular septal defect, abnormally located aorta and right ventricular hypertrophy.",
        "The four anatomical problems found in Tetralogy of Fallot (TOF) are: 1) Ventricular Septal Defect (VSD), 2) Right Ventricular Outflow Tract (RVOT) obstruction (pulmonic stenosis), 3) Overriding Aorta (dextroposition of the aorta), and 4) Right Ventricular Hypertrophy (RVH).",
        "The four problems that are found in tetralogy of Fallot are: 1) a malaligned ventricular septal defect, 2) right ventricular outflow obstruction, 3) a dextraposed overriding aorta, and 4) right ventricular hypertrophy.",
        "Tetralogy of Fallot consists of four defects: an overriding aorta, a ventricular septal defect, right ventricular outflow tract obstruction (pulmonary stenosis), and right ventricular hypertrophy.",
        "Tetralogy of Fallot consists of four problems. These are right ventricular outflow tract obstruction, a ventricular septal defect, abnormally located aorta and right ventricular hypertrophy.",
        "Tetralogy of Fallot consists of the following four problems:\n\n1. Right ventricular outflow tract obstruction: This is a narrowing of the blood vessels that carry blood from the right ventricle to the lungs.\n2. Ventricular septal defect: This is a hole in the wall between the two lower chambers of the heart, allowing oxygen-rich blood to mix with oxygen-poor blood.\n3. Abnormally located aorta: The aorta, the main blood vessel that carries oxygen-rich blood from the heart to the body, is positioned over the ventricular septal defect, receiving some of the oxygen-poor blood.\n4. Right ventricular hypertrophy: The right ventricle becomes thickened and enlarged due to the increased pressure it must exert to pump blood through the narrowed outflow tract and against the ventricular septal defect.",
        "The four problems found in Tetralogy of Fallot are ventricular septal defect, pulmonary stenosis or right ventricular outflow obstruction, overriding aorta, and right ventricular hypertrophy.",
        "The tetralogy of Fallot consists of four problems: right ventricular outflow tract obstruction, a ventricular septal defect, an abnormally located aorta, and right ventricular hypertrophy.",
        "The four problems found in Tetralogy of Fallot are: right ventricular outflow tract obstruction, ventricular septal defect, abnormally located aorta, and right ventricular hypertrophy.",
        "Tetralogy of Fallot consists of four key abnormalities: right ventricular outflow tract obstruction, a ventricular septal defect, an abnormally located aorta, and right ventricular hypertrophy.",
        "The four problems found in Tetralogy of Fallot are: right ventricular outflow tract obstruction, ventricular septal defect (VSD), overriding aorta, and right ventricular hypertrophy.",
        "The four problems found in Tetralogy of Fallot are: right ventricular outflow tract obstruction, ventricular septal defect, overriding aorta, and right ventricular hypertrophy.",
        "Tetralogy of Fallot consists of four heart defects: right ventricular outflow tract obstruction, a ventricular septal defect, an overriding aorta, and right ventricular hypertrophy.",
        "Tetralogy of Fallot is characterized by four key problems: \n  1. Right Ventricular Outflow Tract Obstruction - blockage of blood flow to the pulmonary artery, \n  2. Ventricular Septal Defect (VSD) - a hole in the wall between the ventricles, \n  3. Abnormally Located Aorta - positioned over the VSD, receiving blood from both ventricles, \n  4. Right Ventricular Hypertrophy - thickening of the right ventricle muscle due to increased workload.",
        "Tetralogy of Fallot includes four problems. These are right ventricular outflow tract obstruction, a ventricular septal defect, abnormally located aorta and right ventricular hypertrophy.",
        " Tetralogy of Fallot consists of four problems:\n\n1. Right ventricular outflow tract obstruction\n2. Ventricular septal defect\n3. Abnormally located aorta\n4. Right ventricular hypertrophy",
        "Tetralogy of Fallot is a congenital heart defect characterized by four main problems: right ventricular outflow tract obstruction, ventricular septal defect, abnormally located aorta overriding the ventricular septal defect, and right ventricular hypertrophy.",
        "Tetralogy of Fallot consists of a ventricular septal defect, an overriding aorta, right ventricular outflow tract obstruction (typically pulmonary stenosis), and right ventricular hypertrophy.",
        "the 4 problems that are found in the tetrology of Fallot can be right ventricular outflow tract obstruction, a ventricular septal defect, abnormally located aorta and right ventricular hypertrophy.",
        "The four problems found in Tetralogy of Fallot are: ventricular septal defect, overriding aorta, right ventricular hypertrophy, and right ventricular outflow tract obstruction or pulmonary stenosis.",
        "Tetralogy of Fallot is characterized by four key defects: right ventricular outflow tract obstruction, ventricular septal defect (a hole between the ventricles), abnormally positioned aorta, and right ventricular hypertrophy (thickened right ventricle wall).",
        "The four problems found in the Tetralogy of Fallot are: right ventricular outflow tract obstruction, a ventricular septal defect, abnormally located aorta, and right ventricular hypertrophy."
      ],
      "exact_answer": [
        [
          "right ventricular outflow tract obstruction,"
        ],
        [
          "ventricular septal defect,"
        ],
        [
          "abnormally located aorta"
        ],
        [
          "right ventricular hypertrophy"
        ],
        [
          "Overriding Aorta"
        ]
      ]
    },
    {
      "body": "Regarding genetic transmission of bipolar disorder, has any specific gene/mutation been identified?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39003412",
        "http://www.ncbi.nlm.nih.gov/pubmed/39278467",
        "http://www.ncbi.nlm.nih.gov/pubmed/39403837",
        "http://www.ncbi.nlm.nih.gov/pubmed/39299598",
        "http://www.ncbi.nlm.nih.gov/pubmed/26972125",
        "http://www.ncbi.nlm.nih.gov/pubmed/39561923",
        "http://www.ncbi.nlm.nih.gov/pubmed/8723051",
        "http://www.ncbi.nlm.nih.gov/pubmed/11519143",
        "http://www.ncbi.nlm.nih.gov/pubmed/14699425"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 4,
          "offsetInEndSection": 195,
          "text": "single nucleotide polymorphism rs13166360, causing a substitution of valine (Val) 147 to leucine (Leu) in the adenylyl cyclase 2 (ADCY2), has previously been associated with bipolar disorder ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39003412"
        },
        {
          "offsetInBeginSection": 1513,
          "offsetInEndSection": 1587,
          "text": "CNVs in RNF216 and postsynaptic membrane-related genes confer a risk of BD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39403837"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 503,
          "text": "Affective disorders and, in particular, bipolar affective disorder (BPAD) have been examined in many molecular genetic studies which have covered a large part of the genome. Specific hypotheses such as mutations have also been studied. Most recent studies indicate that several chromosomal regions may be involved in the aetiology of BPAD. These include genes on chromosomes 18, 21, 4, 5, 11 and X.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26972125"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "MIR218 polygenic risk score is associated with cognitive function and neurochemical metabolites among patients with depressed bipolar disorders.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39561923"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 581,
          "text": "Linkage studies have defined several BPD susceptibility loci. The findings to date suggested the candidate regions on 4p16, 12q23-24, 18p11, 18q22, 21q22, Xq24-27 for BPD, although no genes has yet been definitively identified. There are also many reports on the analyses of candidate genes, using association studies. But none of gene polymorphisms have been established as firm disease alleles with sufficient replications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11519143"
        },
        {
          "offsetInBeginSection": 1492,
          "offsetInEndSection": 1728,
          "text": "The association between manic-depressive illness and IMPA2 variants supports several reports on the linkage of bipolar disorder to chromosome 18p11.2, and sustains the possible role of IMPA2 as a susceptibility gene in bipolar disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14699425"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "The serotonin transporter (HTT) is an important candidate gene for the genetic transmission of bipolar disorder. It is the site of action of many antidepressants, and plays a key role in the regulation of serotonin neurotransmission.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723051"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "The serotonin transporter (HTT) is an important candidate gene for the genetic transmission of bipolar disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8723051"
        }
      ],
      "type": "summary",
      "id": "67d7238518b1e36f2e000038",
      "ideal_answer": []
    },
    {
      "body": "How does hypoxia influence the cell states of glioblastoma multiforme (GBM)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38538643",
        "http://www.ncbi.nlm.nih.gov/pubmed/38653236",
        "http://www.ncbi.nlm.nih.gov/pubmed/34956900",
        "http://www.ncbi.nlm.nih.gov/pubmed/26724617",
        "http://www.ncbi.nlm.nih.gov/pubmed/25592037"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 511,
          "text": "Glioblastoma (GBM) is the most common primary malignant cancer of the central nervous system. Insufficient oxygenation (hypoxia) has been linked to GBM invasion and aggression, leading to poor patient outcomes. Hypoxia induces gene expression for cellular adaptations. However, GBM is characterized by high intertumoral (molecular subtypes) and intratumoral heterogeneity (cell states), and it is not well understood to what extent hypoxia triggers patient-specific gene responses and cellular diversity in GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38538643"
        },
        {
          "offsetInBeginSection": 1061,
          "offsetInEndSection": 1671,
          "text": "Hypoxia gene signature to single cell RNA-seq datasets of glioma patients, which showed that hypoxic cells displayed a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. Interestingly, in response to hypoxia, tumor cells in IDH-mutant gliomas displayed a strong shift to the AC state, whereas tumor cells in IDH-wildtype gliomas mainly shifted to the MES state. This distinct hypoxia response of IDH-mutant gliomas may contribute to its more favorable prognosis. Our transcriptomic studies provide a basis for future approaches to better understand the diversity of hypoxic niches in gliomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38538643"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 737,
          "text": "We find three prominent modes of organization. First, gliomas are composed of small local environments, each typically enriched with one major cellular state. Second, specific pairs of states preferentially reside in proximity across multiple scales. This pairing of states is consistent across tumors. Third, these pairwise interactions collectively define a global architecture composed of five layers. Hypoxia appears to drive the layers, as it is associated with a long-range organization that includes all cancer cell states.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38653236"
        },
        {
          "offsetInBeginSection": 889,
          "offsetInEndSection": 1040,
          "text": "In summary, we provide a conceptual framework for the organization of cellular states in glioma, highlighting hypoxia as a long-range tissue organizer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38653236"
        },
        {
          "offsetInBeginSection": 1027,
          "offsetInEndSection": 1541,
          "text": "We further applied the Shared GBM Hypoxia gene signature to single cell RNA-seq datasets of glioma patients, which showed that hypoxic cells displayed a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. Interestingly, in response to hypoxia, tumor cells in IDH-mutant gliomas displayed a strong shift to the AC state, whereas tumor cells in IDH-wildtype gliomas mainly shifted to the MES state. This distinct hypoxia response of IDH-mutant gliomas may contribute to its more favorable prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38538643"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Hypoxia Contributes to Poor Prognosis in Primary IDH-wt GBM by Inducing Tumor Cells MES-Like Transformation Trend and Inhibiting Immune Cells Activity.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34956900"
        },
        {
          "offsetInBeginSection": 836,
          "offsetInEndSection": 937,
          "text": "In addition, there are links between hypoxia and the phenomenon of mesenchymal transition in gliomas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26724617"
        },
        {
          "offsetInBeginSection": 292,
          "offsetInEndSection": 1051,
          "text": "The exposure of non-mesenchymal SNB75 and U87 cells to hypoxia induced a strong change in cell morphology that was accompanied by enhanced invasive capacity and the acquisition of mesenchymal marker expression. Further analyses showed the induction of HIF1α and HIF2α by hypoxia and exposure to digoxin, a cardiac glycoside known to inhibit HIF1/2 expression, was able to prevent hypoxia-induced mesenchymal transition. ShRNA-mediated knockdown of HIF1α, and not HIF2α, prevented this transition, as well as the knockdown of the EMT transcription factor ZEB1. We provide further evidence for a hypoxia-induced mesenchymal shift in GBM primary material by showing co-localization of GLUT1, ZEB1 and the mesenchymal marker YKL40 in hypoxic regions of the tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25592037"
        },
        {
          "offsetInBeginSection": 1027,
          "offsetInEndSection": 1248,
          "text": "We further applied the Shared GBM Hypoxia gene signature to single cell RNA-seq datasets of glioma patients, which showed that hypoxic cells displayed a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38538643"
        }
      ],
      "id": "67d74b0418b1e36f2e00003b",
      "ideal_answer": [
        "Glioblastoma multiforme (GBM) is the most common primary malignant cancer of the central nervous system. Insufficient oxygenation (hypoxia) has been linked to GBM invasion and aggression, leading to poor patient outcomes. However, GBM is characterized by high intratumoral heterogeneity (cell states), and it is not well understood to what extent hypoxia triggers patient-specific gene responses and cellular diversity in GBM. A study of hypoxia gene signature in scRNA-seq data of glioma patients showed that hypoxic cells displayed a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. Interestingly, in response to hypoxia, tumor cells in IDH-mutant gliomas displayed a strong shift to the AC state, whereas tumor cells in IDH-wildtype gliomas mainly shifted to the MES state. This distinct hypoxia response of IDH-mutant gliomas may contribute to its more favorable prognosis. In addition, hypoxia has also been shown - using spatial transcriptomics - to act as a tissue cell state organizer both in small local environments and in long-range interactions.",
        "Hypoxia induces a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. In response to hypoxia, tumor cells in IDH-mutant gliomas display a strong shift to the AC state, whereas tumor cells in IDH-wildtype gliomas mainly shift to the MES state. This distinct hypoxia response of IDH-mutant gliomas may contribute to its more favorable prognosis.",
        "Hypoxia, or low oxygen levels, plays a significant role in driving glioblastoma multiforme (GBM) progression and therapeutic resistance. Hypoxia induces the expression of hypoxia-inducible factors (HIFs) which regulate genes involved in cellular adaptations like increased glycolysis, angiogenesis, autophagy, and invasion. Hypoxia promotes a shift towards more aggressive mesenchymal-like and astrocyte-like cell states in GBM. Interestingly, in IDH-mutant gliomas, hypoxia drives a stronger shift towards the astrocyte-like state, while in IDH-wildtype gliomas, it promotes a mesenchymal-like state. This distinct hypoxia response may contribute to the more favorable prognosis of IDH-mutant gliomas. Hypoxia also maintains glioblastoma stem cells which are resistant to therapy and can initiate tumor recurrence.",
        "Hypoxia significantly influences glioblastoma multiforme (GBM) cell states, driving them towards more aggressive, stem-like phenotypes. This is characterized by shifts towards Mesenchymal-like (MES) and Astrocyte-like (AC) states, with IDH-mutant gliomas predominantly adopting the AC state. Key changes include upregulation of stemness factors (SOX2, Oct4), dysregulation of microRNAs and survival genes, and alterations in metabolism, angiogenesis, and autophagy. Notably, a phase transition occurs in the mTORC1 signaling network near 1.5% oxygen partial pressure. These adaptations contribute to increased self-renewal, drug resistance, and patient-specific responses, highlighting the complexity of hypoxia\u0027s impact on GBM.",
        "Hypoxia significantly influences glioblastoma multiforme (GBM) cell states, driving a shift towards a stem-like phenotype with increased expression of stemness factors. This is accompanied by cell state transitions to mesenchymal-like (MES) and astrocyte-like (AC) states, with IDH-mutant gliomas favoring the AC state, potentially contributing to a more favorable prognosis. Hypoxia also induces dedifferentiation of non-stem cells, affects mTORC1 signaling, and leads to patient-specific gene expression changes. Reoxygenation triggers a shift towards a more differentiated state. Understanding hypoxia\u0027s impact on GBM cell states is crucial for developing effective treatment strategies.",
        "Hypoxia plays a significant role in the progression and aggressiveness of glioblastoma multiforme (GBM). It induces gene expression changes related to glucose metabolism, angiogenesis, and autophagy, which are shared across different patient-derived GBM stem cell lines. However, there is also a large set of patient-specific hypoxia-induced genes that are associated with cell migration and anti-inflammation, highlighting the intertumoral diversity of hypoxia responses in GBM.  Furthermore, hypoxia drives GBM cells towards a stem-like state, characterized by the upregulation of stemness factors such as SOX2 and Oct4. This stem-like state is associated with increased metabolism, altered angiogenesis, and apoptotic escape, contributing to GBM aggressiveness.  In terms of cell states, hypoxic GBM cells display a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. Interestingly, IDH-mutant gliomas show a strong shift to the AC state in response to hypoxia, which may contribute to their more favorable prognosis compared to IDH-wildtype gliomas.  Overall, understanding the impact of hypoxia on GBM cell states is crucial for developing effective treatment strategies for this aggressive cancer.",
        "Hypoxia, or low oxygen levels, plays a significant role in driving the aggressive and treatment-resistant nature of glioblastoma multiforme (GBM). Hypoxia induces changes in gene expression that promote cellular adaptations like increased glycolysis, angiogenesis, and autophagy. It also triggers a shift towards more invasive and stem-like cell states, such as the mesenchymal and astrocyte-like states. Notably, the hypoxia response differs between IDH-mutant and IDH-wildtype GBMs, with IDH-mutant tumors showing a stronger shift towards the astrocyte-like state under hypoxia, which may contribute to their relatively better prognosis compared to IDH-wildtype GBMs that tend to shift more towards the mesenchymal state.",
        "Hypoxia significantly influences glioblastoma multiforme (GBM) cell states, driving a shift towards a more aggressive, stem-like phenotype. This is characterized by increased expression of stemness factors (e.g., SOX2, Oct4) and transitions to Mesenchymal-like (MES) and Astrocyte-like (AC) states. Notably, IDH-mutant gliomas favor the AC state, potentially impacting prognosis. Hypoxia also affects mTORC1 signaling and induces dedifferentiation. Reoxygenation reverses this, shifting cells towards a more differentiated state. These complex adaptations contribute to increased self-renewal, drug resistance, and varied patient responses, underscoring the need for tailored treatment strategies.",
        "Hypoxia influences the cell states of glioblastoma multiforme (GBM) by driving shifts towards mesenchymal-like (MES) and astrocyte-like (AC) states, with IDH-mutant gliomas favoring the AC state. It also induces stemness, dedifferentiates cells, and alters signaling pathways, including mTORC1, with reoxygenation leading to subsequent differentiation processes.",
        "Hypoxia significantly influences glioblastoma cell states by driving cellular transformations and organizational patterns. Specifically, hypoxic conditions induce shifts in cellular states, with IDH-wildtype gliomas predominantly transitioning to mesenchymal-like (MES) states, while IDH-mutant gliomas shift more towards astrocyte-like (AC) states. Hypoxia acts as a long-range tissue organizer, creating small local environments enriched with specific cellular states and establishing predictable interactions between different cell states across tumor tissues. These hypoxia-driven changes contribute to the high intertumoral and intratumoral heterogeneity characteristic of glioblastoma, potentially impacting tumor aggression and patient outcomes.",
        "Hypoxia influences glioblastoma multiforme (GBM) cell states, driving shifts towards mesenchymal-like (MES) and astrocyte-like (AC) states. The IDH mutation status dictates the direction of this shift, with IDH-mutant gliomas favoring the AC state (potentially linked to a more favorable prognosis) and IDH-wildtype gliomas favoring the MES state. Hypoxia also acts as a long-range tissue organizer, influencing the multi-layered spatial structure of GBM, with different cellular states being spatially coordinated in response to hypoxic conditions. This dual role of hypoxia in shaping both cell state and tumor architecture is crucial for understanding GBM\u0027s complex biology.",
        "Hypoxia significantly influences the cell states of glioblastoma multiforme (GBM), triggering patient-specific gene responses and cellular diversity. Studies have shown that hypoxic cells in GBM display a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. Notably, the response to hypoxia differs between IDH-mutant and IDH-wildtype gliomas, with IDH-mutant gliomas shifting strongly to the AC state and IDH-wildtype gliomas mainly shifting to the MES state. This distinct hypoxia response may contribute to the more favorable prognosis of IDH-mutant gliomas. Furthermore, hypoxia drives a long-range organization of cellular states in glioma, defining a global architecture composed of five layers that includes all cancer cell states. Overall, hypoxia acts as a key regulator of cellular diversity and organization in GBM, highlighting its importance in understanding the complex biology of this disease.",
        "Hypoxia in glioblastoma multiforme (GBM) influences cellular states by inducing shifts towards mesenchymal-like and astrocyte-like states, with IDH-mutant gliomas predominantly shifting to the astrocyte-like state and IDH-wildtype gliomas to the mesenchymal-like state. This hypoxic response contributes to the tumor\u0027s organization into distinct layers and local environments, potentially impacting patient prognosis.",
        "Hypoxia induces gene expression for cellular adaptations in GBM, leading to a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. In IDH-mutant gliomas, hypoxic cells display a strong shift to the AC state, while in IDH-wildtype gliomas, the shift is mainly towards the MES state.",
        "Hypoxia induces gene expression for cellular adaptations and appears to drive the layers of cellular organization in glioma. Hypoxic cells displayed a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. In IDH-mutant gliomas, tumor cells displayed a strong shift to the AC state, whereas tumor cells in IDH-wildtype gliomas mainly shifted to the MES state.",
        "Hypoxia significantly influences the cell states of glioblastoma multiforme (GBM) by inducing shifts in cellular phenotypes. In response to hypoxic conditions, GBM cells exhibit a transition towards mesenchymal-like (MES) and astrocyte-like (AC) states, with distinct responses observed based on the IDH mutation status. Specifically, IDH-mutant gliomas show a strong shift towards the AC state, which may correlate with a more favorable prognosis, while IDH-wildtype gliomas predominantly shift to the MES state. This hypoxia-driven cellular diversity contributes to the tumor\u0027s invasive potential and is associated with the organization of cellular states within the tumor microenvironment. Hypoxia acts as a long-range organizer, influencing the spatial arrangement and interactions of different cell states, thereby impacting tumor progression and therapeutic resistance.",
        "Hypoxia significantly influences the cell states of glioblastoma multiforme (GBM) by inducing gene expression changes that promote cellular adaptations and contribute to tumor invasion and aggression. In GBM, hypoxia can drive cells towards distinct states, such as mesenchymal-like (MES) and astrocyte-like (AC) states, with IDH-mutant gliomas predominantly shifting towards the AC state and IDH-wildtype gliomas towards the MES state. This shift is associated with the molecular heterogeneity observed within GBM tumors and contributes to their diverse cellular architecture. Hypoxia appears to act as a long-range tissue organizer, influencing the spatial organization of cellular states and contributing to the complex, layered structure of GBM. Understanding these hypoxia-induced changes can provide insights into the mechanisms underlying GBM\u0027s aggressive behavior and potential therapeutic targets.",
        "Hypoxia significantly influences glioblastoma multiforme (GBM) by driving cellular adaptation through gene expression changes, leading to shifts in cell states towards mesenchymal-like (MES) or astrocyte-like (AC) characteristics. The response varies based on IDH mutation status: IDH-mutant gliomas tend toward AC states, while IDH-wildtype gliomas shift to MES states. This difference contributes to the prognosis, as AC states may be less aggressive.\n\nAdditionally, hypoxia affects the spatial organization of cells within the tumor, creating a complex environment that influences GBM\u0027s aggressive behavior and treatment resistance. Understanding these mechanisms could lead to new therapeutic strategies targeting both cancer cells and the tumor microenvironment.",
        "Hypoxia significantly influences the cellular states of glioblastoma multiforme (GBM) by driving tumor cells into specific phenotypes, which in turn affects their behavior and the tumor\u0027s overall structure. Here\u0027s a concise summary of how hypoxia impacts GBM:\n\n1. **Cellular Adaptations**: Hypoxia induces gene expression changes that lead to cellular adaptations. In GBM, this results in shifts towards mesenchymal-like (MES) and astrocyte-like (AC) states. These states are characterized by increased invasiveness in MES cells and a more differentiated phenotype in AC cells.\n\n2. **IDH Mutation Influence**: The response to hypoxia varies based on IDH mutation status. In IDH-mutant gliomas, tumor cells predominantly shift towards the AC state, which is associated with a better prognosis. Conversely, IDH-wildtype gliomas show a stronger shift towards the MES state, contributing to their aggressive nature.\n\n3. **Tumor Architecture**: Hypoxia drives long-range tissue organization, creating distinct zones within the tumor where certain cell types dominate. This spatial arrangement can influence treatment response and resistance mechanisms.\n\n4. **Therapeutic Implications**: Understanding these hypoxia-induced cellular states could aid in developing targeted therapies that address specific phenotypes or pathways activated under low oxygen conditions.\n\nIn summary, hypoxia plays a crucial role in shaping the cellular landscape of GBM, influencing both the behavior and organization of cancer cells within the tumor. This knowledge is pivotal for advancing therapeutic strategies against this aggressive brain cancer.",
        "Hypoxia triggers gene expression changes in GBM that not only shift tumor cells toward specific states but also organize the tumor’s overall spatial architecture. In low oxygen conditions, GBM cells tend to transition toward mesenchymal-like and astrocyte-like states. This shift is influenced by the tumor’s IDH status, with IDH-mutant gliomas predominantly adopting an astrocyte-like state and IDH-wildtype tumors leaning toward a mesenchymal-like state. Additionally, hypoxia drives a long-range structural organization within the tumor, contributing to a layered architecture and paired cellular interactions that enhance intratumoral heterogeneity.",
        "Hypoxia influences the cell states of glioblastoma multiforme (GBM) by driving a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. In IDH-mutant gliomas, hypoxia induces a strong shift towards the AC state, while in IDH-wildtype gliomas, the MES state is predominantly affected. This distinct hypoxia response of IDH-mutant gliomas may contribute to its more favorable prognosis. Hypoxia appears to drive the organization of cellular states in glioma, acting as a long-range tissue organizer.",
        "Hypoxia significantly influences the behavior and structure of glioblastoma multiforme (GBM) by inducing specific cellular adaptations and contributing to tumor heterogeneity. Here\u0027s a structured summary of its effects:\n\n1. **Cellular Adaptations**: Hypoxia triggers shifts in GBM cells towards mesenchymal-like (MES) and astrocyte-like (AC) states. The MES state enhances invasiveness, allowing cancer cells to penetrate surrounding tissues, while the AC state may involve interactions with other brain cells.\n\n2. **Tumor Heterogeneity**: Hypoxia contributes to intratumoral heterogeneity, where different regions of the tumor exhibit varying cell behaviors. This diversity is influenced by gene expression changes in response to low oxygen levels.\n\n3. **Molecular Subtype Differences**: IDH-mutant gliomas respond differently to hypoxia compared to IDH-wildtype gliomas. For instance, IDH-mutant tumors show a stronger shift towards the AC state, potentially affecting prognosis and treatment strategies.\n\n4. **Transcriptomic Impact**: Hypoxia affects gene expression across the tumor, influencing cellular organization at multiple scales. This leads to a complex global architecture with distinct zones or layers within the tumor, each dominated by specific cell states.\n\n5. **Therapeutic Implications**: Understanding hypoxia\u0027s role in GBM could aid in developing targeted therapies that address both cancer cells and their supportive microenvironment, potentially improving treatment outcomes.\n\nIn summary, hypoxia is a critical factor in shaping GBM\u0027s aggressive behavior, cellular diversity, and structural organization, offering insights for future therapeutic approaches.",
        "Hypoxia acts as a long-range organizer of cellular states in GBM, influencing tumor architecture. It significantly impacts glioma stem cells (GSCs), promoting stemness, TMZ resistance, and invasion. Hypoxic conditions induce a shift in cell states: cells tend towards mesenchymal-like (MES) and astrocyte-like (AC) states, with IDH-mutant gliomas showing a stronger shift to the AC state, while IDH-wildtype gliomas shift mainly to the MES state.",
        "Hypoxia significantly influences the cell states of glioblastoma multiforme (GBM) by inducing gene expression changes that lead to shifts in cellular phenotypes. In GBM, low oxygen levels drive tumor cells towards specific states, such as mesenchymal-like (MES) or astrocyte-like (AC), depending on genetic mutations like IDH status. This variation contributes to the tumor\u0027s aggressive behavior and heterogeneity, making treatment challenging. Hypoxia also organizes cellular interactions across different scales, creating a complex environment that influences all cancer cell states collectively. Understanding these mechanisms could aid in developing targeted therapies to disrupt adaptive responses to hypoxia, potentially improving patient outcomes.",
        "Hypoxia significantly influences the cellular states in glioblastoma multiforme (GBM) by inducing gene expression changes that lead to adaptations such as shifts towards mesenchymal-like and astrocyte-like states. In IDH-mutant gliomas, hypoxia predominantly drives a shift to an astrocyte-like state, which may contribute to a more favorable prognosis compared to the mesenchymal-like shift observed in IDH-wildtype gliomas. This hypoxic influence is part of a broader organizational framework where GBMs are structured into small local environments enriched with specific cellular states, and these interactions define a global architecture across five layers driven by hypoxia.",
        "Hypoxia influences the cell states of glioblastoma multiforme (GBM) by inducing a diverse set of gene responses that vary between patients. In a study of patient-derived GBM stem cell lines, hypoxia was found to increase invasiveness in certain lines and trigger a shared set of hypoxia response genes related to glucose metabolism, angiogenesis, and autophagy. Additionally, there were significant patient-specific hypoxia-induced genes associated with cell migration and anti-inflammation, indicating intertumoral diversity in responses to hypoxia.\n\nSingle-cell RNA sequencing revealed that hypoxic cells in gliomas tend to shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. Notably, IDH-mutant gliomas showed a strong shift to the AC state in response to hypoxia, while IDH-wildtype gliomas predominantly shifted to the MES state. This differential response may contribute to the more favorable prognosis observed in IDH-mutant gliomas. Overall, hypoxia acts as a critical factor in shaping the cellular states and organization within GBM, influencing tumor behavior and patient outcomes.",
        "Hypoxia influences the cell states of glioblastoma multiforme (GBM) by inducing gene expression changes that lead to cellular adaptations and shifts in cell states. Specifically, hypoxic conditions drive tumor cells towards mesenchymal-like (MES) and astrocyte-like (AC) states, with IDH-mutant gliomas favoring the AC state and IDH-wildtype gliomas favoring the MES state. This response contributes to the organization of cellular states in gliomas and highlights hypoxia as a key factor in the tissue architecture and diversity of GBM.",
        "Hypoxia influences the cell states of glioblastoma multiforme (GBM) by triggering patient-specific gene responses and cellular diversity. In response to hypoxia, GBM cells display a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. Notably, IDH-mutant gliomas exhibit a strong shift to the AC state, whereas IDH-wildtype gliomas mainly shift to the MES state. This distinct hypoxia response may contribute to the more favorable prognosis of IDH-mutant gliomas. Hypoxia also drives the organization of cellular states in GBM, defining a global architecture composed of five layers. The pairwise interactions between specific cell states are consistent across tumors and are influenced by hypoxia. Overall, hypoxia plays a crucial role in shaping the cellular heterogeneity of GBM, which is characterized by high intertumoral and intratumoral diversity.",
        "Hypoxia significantly influences the cell states of glioblastoma multiforme (GBM) by driving tumor-associated macrophages (TAMs) reprogramming, promoting immune evasion, and maintaining glioma stem cells (GSCs). In the hypoxic microenvironment, GBM cells exhibit a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states, with IDH-mutant gliomas showing a stronger shift to the AC state, which may correlate with better prognosis. Hypoxia enhances the invasive potential of a hypoxic subpopulation within GBM, which is crucial for tumor progression. Additionally, hypoxia contributes to the immunosuppressive nature of GBM by affecting the phenotypic and activation states of myeloid cells, including TAMs, thereby facilitating immune evasion. The interaction between hypoxia and GSCs is also critical, as hypoxia regulates metabolic alterations and gene expression that support GSC maintenance, further complicating treatment resistance and disease progression. Overall, hypoxia serves as a key organizer of cellular states in GBM, influencing tumor behavior and therapeutic responses.",
        "Hypoxia significantly influences the cell states of glioblastoma multiforme (GBM) by promoting tumor invasion, enhancing cellular heterogeneity, affecting immune cell interactions, and contributing to therapeutic resistance. In GBM, hypoxia drives tumor cells to adopt mesenchymal-like (MES) and astrocyte-like (AC) states, with IDH-mutant gliomas showing a strong shift towards the AC state, potentially leading to better prognoses. This hypoxic environment fosters a diverse cellular landscape, characterized by distinct local environments enriched with specific cellular states and long-range organizational patterns driven by hypoxia.\n\nMoreover, hypoxia enhances the invasive potential of glioblastoma stem-like cells (GSCs), which produce higher levels of glutamate that activate local neurons, further facilitating tumor spread. The tumor microenvironment, dominated by hypoxia, also plays a crucial role in immune evasion, as myeloid cells exhibit varied activation states influenced by hypoxic conditions. This complexity contributes to therapeutic resistance, as hypoxia is linked to autophagy and other protective mechanisms against chemotherapy. Targeting hypoxia and understanding its interactions with GSCs and the immune microenvironment may offer novel therapeutic strategies to improve patient outcomes in GBM.",
        "Hypoxia influences GBM by inducing a shift in cellular states towards mesenchymal-like (MES) and astrocyte-like (AC) states. In IDH-mutant gliomas, hypoxia causes a strong shift to the AC state, while in IDH-wildtype gliomas, it mainly shifts to the MES state.",
        "Hypoxia influences glioblastoma multiforme (GBM) cell states by driving shared and distinct transcriptomic changes, leading to shifts towards mesenchymal-like (MES) and astrocyte-like (AC) states. IDH-mutant gliomas show a stronger shift to the AC state, whereas IDH-wildtype gliomas mainly shift to the MES state. Hypoxia induces gene expressions related to glucose metabolism, angiogenesis, autophagy, and patient-specific responses. Notably, it acts as a long-range tissue organizer, shaping the global architecture of glioma cellular states. This differential response to hypoxia may contribute to the more favorable prognosis in IDH-mutant gliomas, highlighting the complex interplay between hypoxia, cell state, and prognosis in GBM.",
        "Hypoxia significantly influences the cell states of glioblastoma multiforme (GBM) by inducing a shift in cellular adaptations and gene expression. In response to hypoxia, GBM cells exhibit a transition towards mesenchymal-like (MES) and astrocyte-like (AC) states, with distinct responses observed between IDH-mutant and IDH-wildtype gliomas. IDH-mutant gliomas tend to shift strongly towards the AC state, which may correlate with a more favorable prognosis, while IDH-wildtype gliomas predominantly shift to the MES state, associated with aggressive invasion and therapeutic resistance. Additionally, hypoxia drives the organization of cellular states within the tumor microenvironment, creating a complex architecture that influences tumor behavior and patient outcomes. Overall, hypoxia acts as a critical factor in shaping the heterogeneity and adaptability of GBM cells.",
        "Hypoxia significantly influences the cell states of glioblastoma multiforme (GBM), driving shifts towards mesenchymal-like (MES) and astrocyte-like (AC) states. The direction of this shift is determined by the IDH mutation status: IDH-mutant gliomas favor AC states, potentially leading to a more favorable prognosis, whereas IDH-wildtype gliomas predominantly shift towards the more aggressive MES state. Additionally, hypoxia plays a crucial role as a long-range tissue organizer, shaping the tumor\u0027s multi-layered spatial structure and coordinating the arrangement of these cellular states. This process involves transcriptomic changes, affecting metabolism, angiogenesis, and patient-specific responses in cell migration and inflammation.",
        " Hypoxia influences the cell states of glioblastoma multiforme (GBM) by triggering gene expression for cellular adaptations, leading to a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. This response is patient-specific, with tumor cells in IDH-mutant gliomas displaying a strong shift to the AC state, while tumor cells in IDH-wildtype gliomas mainly shifting to the MES state. Hypoxia appears to drive long-range organization of cancer cell states in GBM, and is associated with a global architecture composed of five layers.",
        "Hypoxia significantly influences the cell states of glioblastoma multiforme (GBM) by triggering shifts toward specific cellular phenotypes. Under hypoxic conditions, GBM cells predominantly transition toward mesenchymal-like (MES) and astrocyte-like (AC) states. Notably, there are distinct hypoxic responses based on molecular subtypes: IDH-mutant gliomas strongly shift toward the AC state under hypoxia, while IDH-wildtype gliomas primarily shift to the MES state, which may explain the more favorable prognosis of IDH-mutant gliomas. Hypoxia also functions as a long-range tissue organizer in gliomas, influencing the spatial organization of tumor cells into specific microenvironments where certain cellular states preferentially co-locate. This creates a global architecture composed of five layers, with hypoxia driving a long-range organization that encompasses all cancer cell states, contributing to the heterogeneity and aggressive nature of GBM.",
        "Hypoxia influences the cell states of glioblastoma multiforme (GBM) by driving shifts towards mesenchymal-like (MES) or astrocyte-like (AC) states, with distinct responses based on IDH status. Studies show that hypoxic cells in IDH-mutant gliomas predominantly shift to the AC state, while those in IDH-wildtype gliomas mainly transition to the MES state. This differential response may underlie the more favorable prognosis observed in IDH-mutant gliomas. Additionally, hypoxia appears to act as a long-range tissue organizer, shaping the global architecture of glioma cellular states into five distinct layers, with specific pairwise interactions across multiple scales. These findings highlight hypoxia\u0027s role in driving cellular diversity and spatial organization in GBM.",
        "Hypoxia in glioblastoma multiforme (GBM) triggers patient-specific gene responses and cellular diversity, leading to distinct cell states. In response to hypoxia, tumor cells in IDH-mutant gliomas shift towards an astrocyte-like (AC) state, whereas those in IDH-wildtype gliomas mainly shift towards a mesenchymal-like (MES) state. Hypoxia drives the organization of cellular states in GBM, creating a long-range tissue architecture composed of five layers, with specific pairs of cell states preferentially residing in proximity across multiple scales. This hypoxia-driven reorganization is associated with changes in gene expression, leading to adaptations that promote GBM invasion and aggression. Overall, hypoxia plays a crucial role in shaping the heterogeneous cellular landscape of GBM, influencing tumor behavior and patient outcomes.",
        "Hypoxia (low oxygen levels) induces changes in gene expression that drive glioblastoma (GBM) cells to shift towards more aggressive mesenchymal-like and astrocyte-like cellular states. The specific hypoxic response differs between IDH-mutant and IDH-wildtype GBMs, with IDH-mutant tumors shifting more towards the astrocyte-like state and IDH-wildtype tumors shifting towards the mesenchymal-like state. Hypoxia appears to organize GBM tumors into distinct local environments enriched for particular cellular states, with preferential spatial pairings of certain states across multiple scales, collectively defining a layered global architecture driven by hypoxia.",
        "Hypoxia in glioblastoma multiforme (GBM) drives cell state shifts towards mesenchymal-like (MES) and astrocyte-like (AC) states, with IDH mutation status being a key determinant. IDH-mutant gliomas favor the AC state, potentially leading to a better prognosis, while IDH-wildtype gliomas shift towards the more aggressive MES state. This process, acting as a long-range tissue organizer, influences the tumor\u0027s spatial structure and is accompanied by changes in metabolism (including glucose metabolism and autophagy), angiogenesis, cell migration, and inflammation patterns, which may vary patient-to-patient.",
        "[\"Hypoxia induces shifts in glioblastoma multiforme (GBM) cell states, driving IDH-mutant gliomas toward astrocyte-like (AC) states and IDH-wildtype gliomas toward mesenchymal-like (MES) states, which may influence prognosis. Hypoxia also reorganizes the tumor\u0027s cellular architecture into distinct layered structures and modulates interactions between cell states.\"]",
        "Hypoxia acts as a key tissue organizer in glioblastoma, influencing cellular states and tumor heterogeneity. In response to hypoxic conditions, tumor cells undergo distinct state transitions: IDH-mutant gliomas shift towards astrocyte-like states, while IDH-wildtype gliomas predominantly shift to mesenchymal-like states, potentially explaining differences in prognosis. This hypoxia-driven organization creates a complex five-layer architecture where specific cell state pairs interact across multiple scales, demonstrating how oxygen insufficiency shapes the tumor\u0027s cellular diversity and spatial structure.",
        "Hypoxia in glioblastoma multiforme (GBM) influences cellular states by inducing shifts towards mesenchymal-like and astrocyte-like states, with IDH-mutant gliomas predominantly shifting to the astrocyte-like state and IDH-wildtype gliomas to the mesenchymal-like state. This hypoxia-driven response contributes to the tumor\u0027s organization into distinct layers and local environments, potentially impacting patient prognosis.",
        "Hypoxia influences the cell states of glioblastoma multiforme (GBM) by inducing gene expression for cellular adaptations. Hypoxic cells display a shift towards mesenchymal-like (MES) and astrocyte-like (AC) states. Hypoxia appears to drive the layers, as it is associated with a long-range organization that includes all cancer cell states."
      ]
    },
    {
      "body": "What\u0027s the increase in CORE profiles in JASPAR 2024 compared to the previous version?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37962376"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 542,
          "text": "JASPAR (https://jaspar.elixir.no/) is a widely-used open-access database presenting manually curated high-quality and non-redundant DNA-binding profiles for transcription factors (TFs) across taxa. In this 10th release and 20th-anniversary update, the CORE collection has expanded with 329 new profiles. We updated three existing profiles and provided orthogonal support for 72 profiles from the previous release\u0027s UNVALIDATED collection. Altogether, the JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37962376"
        }
      ],
      "id": "67d496ed18b1e36f2e000019",
      "ideal_answer": [
        "JASPAR (https://jaspar.elixir.no/) is a widely-used open-access database presenting manually curated high-quality and non-redundant DNA-binding profiles for transcription factors (TFs) across taxa. In JASPAR 2024, the CORE collection has expanded with 329 new profiles. Altogether, the JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release.",
        "The JASPAR 2024 update provided a 20% increase in CORE profiles from the previous release, with 329 new profiles added to the CORE collection.",
        "The JASPAR 2024 update results in a 20% increase in CORE profiles compared to the previous version.",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release.",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles compared to the previous release. This increase is part of the broader expansion and refinement of the JASPAR CORE sub-database.",
        "The increase in CORE profiles in JASPAR 2024 compared to the previous version is 20%.",
        "The JASPAR 2024 update includes a 20% increase in CORE profiles compared to the previous version. This expansion is part of the fifth major release, which significantly enhances the JASPAR CORE sub-database, representing the heart of the JASPAR database. Additionally, the update introduces three new specialized sub-databases, further enriching the resource for researchers studying transcription factor binding sites.",
        "The CORE profiles in JASPAR 2024 increased by 20% compared to the previous release.",
        "The increase in CORE profiles for JASPAR 2024 compared to the previous version is 329 profiles, representing a 20% growth from the prior release.",
        "20% increase in CORE profiles.",
        "The JASPAR 2024 update features a 20% increase in CORE profiles, adding 329 new profiles to the database, alongside updates to 3 existing profiles. Additionally, 72 previously unvalidated profiles now have orthogonal support, enhancing database quality. This expansion, part of JASPAR\u0027s 10th release, refines the database with improved metadata and a trimming algorithm for more accurate TF-DNA interaction modeling, further aiding in predicting TF binding sites and understanding gene regulation across various taxa.",
        "The JASPAR 2024 update includes a 20% increase in CORE profiles compared to the previous release. This expansion is part of the 10th release and 20th-anniversary update of the JASPAR database, which provides open-access, manually curated, and non-redundant DNA-binding profiles for transcription factors across various taxa. The new profiles were enhanced using a trimming algorithm that removed low information content flanking base pairs, likely uninformative for TFBS predictions and modeling TF-DNA interactions. Additionally, the update features enhanced metadata with a refined classification for plant TFs\u0027 structural DNA-binding domains. The increased CORE profiles in JASPAR 2024 contribute to the database\u0027s continued growth and utility in predicting TF binding sites and understanding gene regulation.",
        "The CORE collection has expanded with 329 new profiles in the 10th release and 20th-anniversary update.",
        "In the JASPAR 2024 release, the CORE collection of transcription factor binding profiles has expanded by 329 new profiles, representing a 20% increase compared to the previous release.",
        "JASPAR 2024 features a 20% increase in CORE profiles, with 329 new high-quality, non-redundant DNA-binding profiles for transcription factors across taxa, alongside updates to 3 existing profiles. Notably, 72 previously unvalidated profiles now have orthogonal support, enhancing database quality. This growth builds upon previous updates, following 19% and 18% increases in JASPAR 2022 and 2020, respectively, and is part of JASPAR\u0027s 10th release, further refining gene regulation understanding with improved metadata and tools.",
        "JASPAR 2024 shows a 20% increase in CORE profiles compared to the previous version.",
        "20%",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles compared to the previous release, as stated in the context. This expansion reflects the ongoing growth and refinement of the database\u0027s curated transcription factor binding profiles.",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release. The CORE collection has expanded with 329 new profiles.",
        "The JASPAR 2024 update includes a 20% increase in CORE profiles compared to the previous release.",
        "The CORE collection has expanded with 329 new profiles. Altogether, the JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release.",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles compared to the previous release, adding 329 new profiles and updating three existing ones while providing orthogonal support for 72 previously unvalidated profiles.",
        "In recent studies, the JASPAR database has undergone its 10th release and 20th-anniversary update, resulting in a significant expansion of its CORE collection. Specifically, this update has introduced 329 new profiles, updated three existing ones, and provided additional support for 72 previously unvalidated profiles. Overall, these changes have led to a notable increase in the number of CORE profiles, with a 20% rise compared to the previous release, thereby enhancing the database\u0027s capabilities and resources for users.",
        "The JASPAR 2024 update includes a 20% increase in CORE profiles compared to the previous release, with 329 new profiles added and three existing ones updated.",
        "The JASPAR 2024 update includes a 20% increase in CORE profiles compared to the previous release. This expansion adds 329 new DNA binding profiles for transcription factors across various taxa. Additionally, three existing profiles were updated, and orthogonal support was provided for 72 previously unvalidated profiles.",
        "The JASPAR 2024 update, marking its 20th anniversary, has significantly expanded its CORE collection of DNA-binding profiles for transcription factors (TFs) with a 20% increase compared to the previous version. This expansion includes 329 new profiles, updates to three existing profiles, and orthogonal support for 72 profiles previously listed in the UNVALIDATED collection. This enhancement underscores JASPAR\u0027s commitment to providing high-quality, non-redundant data for researchers studying TF binding across various taxa.",
        "JASPAR 2024 has increased its CORE collection by 20% compared to the previous version. This update includes the addition of 329 new profiles, as well as updates to three existing profiles and support for 72 previously unvalidated profiles from the UNVALIDATED collection.",
        "The JASPAR 2024 update increased the CORE profiles by 20% compared to the previous release, corresponding to the addition of 329 new profiles.",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release. This update includes 329 new profiles in the CORE collection.",
        "The increase in CORE profiles in JASPAR 2024 compared to the previous version is a 20% rise. This expansion was achieved by adding 329 new profiles, updating three existing ones, and providing support for 72 profiles from the UNVALIDATED collection.",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles compared to the previous release.",
        "JASPAR 2024 experienced a 20% increase in its CORE collection of DNA-binding profiles for transcription factors compared to the previous release. This expansion was achieved by adding 329 new profiles, updating three existing ones, and providing support for 72 profiles previously categorized as UNVALIDATED. The result is an enhanced resource that reflects significant growth and validation efforts within the database.",
        "The JASPAR 2024 update has expanded its CORE collection by adding 329 new DNA-binding profiles for transcription factors, resulting in a 20% increase from the previous release. Additionally, three existing profiles were updated and orthogonal support was provided for 72 profiles previously categorized as UNVALIDATED.",
        "The CORE profiles in JASPAR 2024 increased by 20% compared to the previous version.",
        "The JASPAR 2024 database update is characterized by a uniform 20% increase in CORE (Core promoter elements of transcription regulation) profiles compared to its previous version, as consistently reported across all provided sources.",
        "JASPAR is a widely-used open-access database that provides high-quality DNA-binding profiles for transcription factors across various species. In its 10th release, marking the 20th anniversary, JASPAR 2024 has expanded its CORE collection by adding 329 new profiles. This update represents a 20% increase in the number of CORE profiles compared to the previous version, enhancing the database\u0027s utility for researchers studying transcription factors.",
        "JASPAR 2024 features a 20% increase in CORE profiles compared to its previous version, incorporating 329 new profiles into the CORE collection. Additionally, the update includes at least 3 profile updates and the validation of 72 previously unvalidated profiles, now supported with orthogonal evidence, enhancing the database\u0027s depth and reliability.",
        "JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release.",
        "The increase in CORE profiles for JASPAR 2024 compared to the previous version is a 20% increase, which includes 329 new profiles, updates to three existing profiles, and orthogonal support for 72 profiles from the UNVALIDATED collection.",
        " The JASPAR 2024 update provides a 20% increase in CORE profiles compared to the previous release.",
        "The JASPAR 2024 update has resulted in a 20% increase in CORE profiles compared to the previous release. This expansion includes the addition of 329 new profiles, updates to three existing ones, and orthogonal support provided for 72 profiles from the prior UNVALIDATED collection.",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release, with 329 new profiles added to the CORE collection.",
        "The JASPAR 2024 release features a confirmed 20% increase in CORE profiles compared to its predecessor. This growth encompasses the addition of 329 new profiles to the CORE collection, updates to at least 3 existing profiles, and the validation of 72 previously unvalidated profiles with orthogonal support, enhancing the database\u0027s depth and reliability.",
        "20% increase in CORE profiles",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles compared to the previous version.",
        "JASPAR (https://jaspar.elixir.no/) is a widely-used open-access database presenting manually curated high-quality and non-redundant DNA-binding profiles for transcription factors (TFs) across taxa. In this 10th release and 20th-anniversary update, the CORE collection has expanded with 329 new profiles. We updated three existing profiles and provided orthogonal support for 72 profiles from the previous release\u0027s UNVALIDATED collection. Altogether, the JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release.",
        "The JASPAR 2024 update provides a 20% increase in CORE profiles from the previous release. Additionally, the CORE collection has expanded with 329 new profiles."
      ],
      "exact_answer": [
        [
          "20%"
        ]
      ]
    },
    {
      "body": "What is the mode of action for baclofen?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39754631",
        "http://www.ncbi.nlm.nih.gov/pubmed/39108680",
        "http://www.ncbi.nlm.nih.gov/pubmed/38533288",
        "http://www.ncbi.nlm.nih.gov/pubmed/36735548",
        "http://www.ncbi.nlm.nih.gov/pubmed/32710152",
        "http://www.ncbi.nlm.nih.gov/pubmed/27237806",
        "http://www.ncbi.nlm.nih.gov/pubmed/1651889",
        "http://www.ncbi.nlm.nih.gov/pubmed/30371538",
        "http://www.ncbi.nlm.nih.gov/pubmed/7852758",
        "http://www.ncbi.nlm.nih.gov/pubmed/30459646",
        "http://www.ncbi.nlm.nih.gov/pubmed/21255061",
        "http://www.ncbi.nlm.nih.gov/pubmed/25494007",
        "http://www.ncbi.nlm.nih.gov/pubmed/8532848",
        "http://www.ncbi.nlm.nih.gov/pubmed/8862467",
        "http://www.ncbi.nlm.nih.gov/pubmed/2858176",
        "http://www.ncbi.nlm.nih.gov/pubmed/6085175",
        "https://pubmed.ncbi.nlm.nih.gov/30459646/",
        "https://pubmed.ncbi.nlm.nih.gov/2858176/",
        "https://pubmed.ncbi.nlm.nih.gov/8881981/",
        "http://www.ncbi.nlm.nih.gov/pubmed/15659108",
        "http://www.ncbi.nlm.nih.gov/pubmed/11543948",
        "http://www.ncbi.nlm.nih.gov/pubmed/27303599",
        "http://www.ncbi.nlm.nih.gov/pubmed/8328901",
        "http://www.ncbi.nlm.nih.gov/pubmed/3725833",
        "http://www.ncbi.nlm.nih.gov/pubmed/1685343",
        "http://www.ncbi.nlm.nih.gov/pubmed/32142228",
        "http://www.ncbi.nlm.nih.gov/pubmed/35345746",
        "http://www.ncbi.nlm.nih.gov/pubmed/15138913",
        "http://www.ncbi.nlm.nih.gov/pubmed/17764008",
        "http://www.ncbi.nlm.nih.gov/pubmed/12824810",
        "http://www.ncbi.nlm.nih.gov/pubmed/3034654",
        "http://www.ncbi.nlm.nih.gov/pubmed/2558756",
        "http://www.ncbi.nlm.nih.gov/pubmed/12220972",
        "http://www.ncbi.nlm.nih.gov/pubmed/1663195",
        "http://www.ncbi.nlm.nih.gov/pubmed/13680072",
        "http://www.ncbi.nlm.nih.gov/pubmed/19641339",
        "http://www.ncbi.nlm.nih.gov/pubmed/3797419",
        "http://www.ncbi.nlm.nih.gov/pubmed/20655489",
        "http://www.ncbi.nlm.nih.gov/pubmed/11436597"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "PURPOSE OF REVIEW: Baclofen, a muscle relaxant that reduces the release of excitatory neurotransmitters in the pre-synaptic neurons stimulating inhibitory neuronal signals in post-synaptic neurons, has been around for over 5 decades",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39754631"
        },
        {
          "offsetInBeginSection": 199,
          "offsetInEndSection": 275,
          "text": "Baclofen, a gamma-aminobutyric acid derivative, relies on renal excretion, r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39108680"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 290,
          "text": "Baclofen, a gamma-aminobutyric acid receptor agonist, can help regulate sex hormones and reduce harmful blood lipids by protecting against morphine-induced gamma-aminobutyric acid inhibition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38533288"
        },
        {
          "offsetInBeginSection": 175,
          "offsetInEndSection": 264,
          "text": "Baclofen, a gamma-aminobutyric acid B receptor agonist structurally related to phenibut, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36735548"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Baclofen is a structural analogue of gamma-amino-butyric acid (GABA), which reduces spastic hypertonia of striated muscle due to a mechanism of GABA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32710152"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Baclofen is an agonist of peripheral and central B gamma-aminobutyric acid receptors, whose activation causes a myorelaxation and a powerfull depression of the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27237806"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "BACKGROUND: Baclofen is a lipophilic γ-aminobutyric acid (GABA) derivative that exhibits strong intrinsic activity and a high affinity for GABA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30371538"
        },
        {
          "offsetInBeginSection": 547,
          "offsetInEndSection": 625,
          "text": "Baclofen was shown to be a selective agonist for this novel GABAB recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1651889"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Baclofen, a beta-chlorophenyl derivative of gamma-aminobutyric acid (GABA), depresses neuronal excitability in various parts of the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1651889"
        },
        {
          "offsetInBeginSection": 547,
          "offsetInEndSection": 919,
          "text": "Baclofen was shown to be a selective agonist for this novel GABAB recognition. Baclofen also directly hyperpolarizes the membrane of mammalian brain neurons, in addition to its presynaptic action. This postsynaptic action of baclofen was shown to result from an increase in K+ conductance when studied in hippocampal pyramidal neurons through postsynaptic GABAB receptors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1651889"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 371,
          "text": "Baclofen is an agonist that reduces [(3)H]GABA, whilst the antagonist (+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid (Sch 50911) enhances [(3)H]GABA release in electrically-stimulated rat neocortical brain slices preloaded with [(3)H]GABA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21255061"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Baclofen is a γ-aminobutyric acid (GABA)-β receptor agonist with a muscle relaxant effect. It increases GABA activity and reduces the production of glutamate and dopamine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25494007"
        },
        {
          "offsetInBeginSection": 427,
          "offsetInEndSection": 1059,
          "text": "Baclofen, a selective GABAB receptor agonist, as well as GABA itself have pre- and post-synaptic effects. Pre-synaptic effects comprise the reduction of the release of excitatory and inhibitory transmitters. GABAergic receptors on GABAergic terminals may regulate GABA release, however, in most instances spontaneous inhibitory synaptic activity is not modulated by endogenous GABA. Post-synaptic GABAB receptor-mediated inhibition is likely to occur through a membrane delimited pathway activating K+ channels, while baclofen, in some neurons, may activate K+ channels through a second messenger pathway involving arachidonic acid.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8532848"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "The possible anticonvulsant action of baclofen, a GABAB (gamma-aminobutyric acid) receptor agonist, was studied using two types of motor seizures (m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8862467"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Baclofen, a GABA-B receptor agonist, is a promising treatment for alcohol use disorder (AUD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/30459646/"
        },
        {
          "offsetInBeginSection": 648,
          "offsetInEndSection": 724,
          "text": "Baclofen activates GABAB receptors putatively located on the same terminals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/2858176/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Baclofen, a gamma-aminobutyric acid agonist, acts at the spinal cord level to impede the release of excitatory neurotransmitters that cause spasticity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/8881981/"
        },
        {
          "offsetInBeginSection": 622,
          "offsetInEndSection": 877,
          "text": "re examined.RESULTS: Superfusion of baclofen, a GABA(B) receptor agonist, significantly reduced the frequency of GABA(A) receptor-mediated miniature IPSCs (mIPSCs), in a Cd2+-sensitive manner, with no effect on the amplitude, indicating presynaptic inhibi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15659108"
        },
        {
          "offsetInBeginSection": 1451,
          "offsetInEndSection": 1782,
          "text": "Taken together, the results suggest that baclofen-sensitive GABA(B) receptor is expressed pre- and postsynaptically on primary afferent fibers and neurons in the spinal dorsal horn; activation of GABA(B) receptor in the dorsal horn postsynaptically hyperpolarizes dorsal horn neurons and presynaptically inhibits primary afferents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11543948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Baclofen, a GABA-B receptor agonist, is a promising treatment for alcohol use disorder (AUD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459646"
        },
        {
          "offsetInBeginSection": 1220,
          "offsetInEndSection": 1431,
          "text": "plasma corticosterone levels. Sulpiride (selective D2-receptor antagonist), p-CPA (tryptophan hydroxylase inhibitor), and baclofen (GABAB agonist) significantly attenuated the oil-induced antidepressant-like eff",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27303599"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Baclofen (Lioresal) is a derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8328901"
        },
        {
          "offsetInBeginSection": 49,
          "offsetInEndSection": 84,
          "text": "baclofen (a GABAb receptor agonist)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3725833"
        },
        {
          "offsetInBeginSection": 1521,
          "offsetInEndSection": 2059,
          "text": "The present results suggest that baclofen, by activating GABAB receptors, may modulate spinal afferent processing in the superficial dorsal horn by at least two mechanisms: (1) baclofen depresses excitatory synaptic transmission primarily by a presynaptic mechanism involving a decrease in the release of excitatory amino acids, and (2) at higher concentrations, the hyperpolarization and increased membrane conductance may contribute to the depressant effect of baclofen on excitatory synaptic transmission in the rat spinal dorsal horn.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1685343"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Baclofen (Lioresal) is a derivative of gamma-aminobutyric acid and is used in both adults and children mainly for symptomatic treatment of muscle spasticity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32142228"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Baclofen is a presynaptic gamma-aminobutyric acid agonist, which has been used to treat muscle spasms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35345746"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Baclofen is a GABA(B) agonist that is administered spinally via an implanted drug delivery device to treat spasticity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15138913"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "BACKGROUND: Baclofen is a centrally acting gamma-aminobutyric acid agonist used for spasticity of spinal origin and mainly excreted unchanged by ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17764008"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "BACKGROUND: Baclofen, a gamma-aminobutyric acid type B agonist, has been proposed as a pharmacotherapeutic agent in the treatment of addictive disorders such as",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824810"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "The effect of GABA receptor agonists (THIP and baclofen) on the hypnotic activity (loss of righting reflex and sleep time) of pentobarbital in mice was investigated. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3034654"
        },
        {
          "offsetInBeginSection": 3,
          "offsetInEndSection": 204,
          "text": "The effects of gamma-aminobutyric acid (GABA), 3-aminopropane sulphonic acid (3-APS) and baclofen on spontaneous, electrically-induced and propulsive motility were investigated in rabbit distal colon. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2558756"
        },
        {
          "offsetInBeginSection": 823,
          "offsetInEndSection": 979,
          "text": "The data suggest that the antinociceptive effect of baclofen is GABA(B) receptor-mediated and reveal a central location of the analgesic effect of baclofen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12220972"
        },
        {
          "offsetInBeginSection": 721,
          "offsetInEndSection": 914,
          "text": "The data suggest that the antinociceptive effect of baclofen is GABAB receptor-mediated and that there may be a GABAergic and opiate/or non-opiate interaction in eliciting the analgesic effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1663195"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "RATIONALE: Since baclofen, the prototypical GABA(B) receptor agonist, is known to reduce the activity of dopaminergic mesolimbic neurons, a putative antipsychotic property of this compound has been suggested, but the evidence for this is still con",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/13680072"
        },
        {
          "offsetInBeginSection": 648,
          "offsetInEndSection": 904,
          "text": "Baclofen activates GABAB receptors putatively located on the same terminals. Activation of these receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2858176"
        },
        {
          "offsetInBeginSection": 494,
          "offsetInEndSection": 798,
          "text": "Baclofen (a GABAB agonist) acts at both supraspinal and spinal sites. Supraspinal mechanisms include inhibition of ascending noradrenergic and dopaminergic pathways but activation of descending noradrenergic pathways. The spinal mechanism may involve postsynaptic inhibition of the effect of substance P.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6085175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "BACKGROUND: Baclofen, a specific GABA(B) receptor agonist, is used to treat spasticity and its off-label use includes the treatm",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641339"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Baclofen, a GABA B agonist, inhibits prolactin release due to different kinds of stress.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3797419"
        },
        {
          "offsetInBeginSection": 496,
          "offsetInEndSection": 628,
          "text": "The studies reviewed have used the GABA(B) receptor agonist baclofen, which is currently the only GABA(B) agonist for use in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20655489"
        },
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 295,
          "text": "Baclofen, a GABAB receptor agonist, directly restores physiologic inhibition of alpha motoneuron, that is blocked by tetanus toxin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11436597"
        }
      ],
      "type": "summary",
      "id": "67cdca3881b102733300001b",
      "ideal_answer": [
        "Baclofen, a muscle relaxant that reduces the release of excitatory neurotransmitters in the pre-synaptic neurons stimulating inhibitory neuronal signals in post-synaptic neurons, has been around for over 5 decades. Baclofen is a gamma-aminobutyric acid receptor agonist",
        "Baclofen is a GABA receptor agonist.",
        "Baclofen acts as a GABA_B receptor agonist, which inhibits excitatory neurotransmitter release and reduces neuronal excitability.",
        "Baclofen acts as a GABA-B receptor agonist, reducing neurotransmitter release presynaptically and causing postsynaptic hyperpolarization.",
        "Baclofen works by activating GABAB receptors, which reduces the release of excitatory amino acids and helps alleviate spasticity.",
        "The mode of action for baclofen is as a GABA(B) receptor agonist, reducing neurotransmitter release presynaptically and increasing potassium conductance postsynaptically.",
        "Baclofen is a gamma-aminobutyric acid B receptor agonist.",
        "Baclofen is a gamma-aminobutyric acid derivative that reduces the release of excitatory neurotransmitters in the pre-synaptic neurons, stimulating inhibitory neuronal signals in post-synaptic neurons.",
        "Baclofen is a muscle relaxant that reduces the release of excitatory neurotransmitters in the pre-synaptic neurons stimulating inhibitory neuronal signals in post-synaptic neurons. It is also a gamma-aminobutyric acid B receptor agonist.",
        "Baclofen, a gamma-aminobutyric acid receptor agonist, can help regulate sex hormones and reduce harmful blood lipids by protecting against morphine-induced gamma-aminobutyric acid inhibition.",
        "Baclofen is a gamma-aminobutyric acid (GABA) derivative that acts as a GABA receptor agonist. It reduces the release of excitatory neurotransmitters in pre-synaptic neurons, stimulating inhibitory neuronal signals in post-synaptic neurons.",
        "Baclofen\u0027s mode of action involves activating GABA B receptors, thereby enhancing inhibitory neurotransmission. This mechanism reduces muscle spasms and promotes relaxation by diminishing excitatory nerve signals.",
        "{\"ideal_answer\": \"Baclofen is a gamma-aminobutyric acid B (GABA-B) receptor agonist that reduces the release of excitatory neurotransmitters in pre-synaptic neurons and stimulates inhibitory neuronal signals in post-synaptic neurons.\"}",
        "Baclofen is a gamma-aminobutyric acid B (GABA-B) receptor agonist that acts by reducing the release of excitatory neurotransmitters in pre-synaptic neurons and stimulating inhibitory signals in post-synaptic neurons, leading to muscle relaxation and other effects.",
        "Baclofen acts as a gamma-aminobutyric acid (GABA) B receptor agonist. It primarily works by inhibiting the release of excitatory neurotransmitters in the central nervous system, which leads to muscle relaxation and reduced spasticity.",
        "Baclofen acts as a muscle relaxant by reducing the release of excitatory neurotransmitters in pre-synaptic neurons and stimulating inhibitory neuronal signals in post-synaptic neurons.",
        "Baclofen, a gamma-aminobutyric acid derivative, relies on renal excretion, r",
        "Baclofen is a muscle relaxant that reduces the release of excitatory neurotransmitters in pre-synaptic neurons. It stimulates inhibitory neuronal signals in post-synaptic neurons. It is also a gamma-aminobutyric acid B receptor agonist.",
        "Baclofen\u0027s mode of action involves agonizing GABA_B receptors, thereby reducing the release of excitatory neurotransmitters and stimulating inhibitory neuronal signals, leading to a net decrease in neuronal excitation.",
        "Baclofen is a gamma-aminobutyric acid derivative that reduces the release of excitatory neurotransmitters in the pre-synaptic neurons stimulating inhibitory neuronal signals in post-synaptic neurons."
      ]
    },
    {
      "body": "Adverse effects of metformin.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39447350",
        "http://www.ncbi.nlm.nih.gov/pubmed/37272660",
        "http://www.ncbi.nlm.nih.gov/pubmed/37167532",
        "http://www.ncbi.nlm.nih.gov/pubmed/38417132",
        "http://www.ncbi.nlm.nih.gov/pubmed/10392666",
        "http://www.ncbi.nlm.nih.gov/pubmed/31769886",
        "http://www.ncbi.nlm.nih.gov/pubmed/18536788",
        "http://www.ncbi.nlm.nih.gov/pubmed/11045134",
        "http://www.ncbi.nlm.nih.gov/pubmed/8726592",
        "http://www.ncbi.nlm.nih.gov/pubmed/35602825",
        "http://www.ncbi.nlm.nih.gov/pubmed/21236717",
        "http://www.ncbi.nlm.nih.gov/pubmed/24299454",
        "http://www.ncbi.nlm.nih.gov/pubmed/36484892",
        "http://www.ncbi.nlm.nih.gov/pubmed/25954799",
        "http://www.ncbi.nlm.nih.gov/pubmed/29351716",
        "http://www.ncbi.nlm.nih.gov/pubmed/26773926",
        "http://www.ncbi.nlm.nih.gov/pubmed/39182908",
        "http://www.ncbi.nlm.nih.gov/pubmed/26605869",
        "http://www.ncbi.nlm.nih.gov/pubmed/35914764",
        "http://www.ncbi.nlm.nih.gov/pubmed/15082849",
        "http://www.ncbi.nlm.nih.gov/pubmed/39055480",
        "http://www.ncbi.nlm.nih.gov/pubmed/8835050",
        "http://www.ncbi.nlm.nih.gov/pubmed/35598993",
        "http://www.ncbi.nlm.nih.gov/pubmed/24674102",
        "http://www.ncbi.nlm.nih.gov/pubmed/36384864",
        "http://www.ncbi.nlm.nih.gov/pubmed/38662670",
        "http://www.ncbi.nlm.nih.gov/pubmed/29189867",
        "http://www.ncbi.nlm.nih.gov/pubmed/23436666",
        "http://www.ncbi.nlm.nih.gov/pubmed/39711126",
        "http://www.ncbi.nlm.nih.gov/pubmed/39421288"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 22,
          "text": "Sarcopenia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39447350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 35,
          "text": "Metfomin-associated lactic acidosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37272660"
        },
        {
          "offsetInBeginSection": 787,
          "offsetInEndSection": 860,
          "text": "Metformin therapy has adversely affected serum vitamin B12 concentrations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37167532"
        },
        {
          "offsetInBeginSection": 850,
          "offsetInEndSection": 1771,
          "text": "The most serious complication associated with metformin is lactic acidosis which has an incidence of about 0.03 cases per 1000 patients years of treatment and a mortality risk of about 0.015 per 1000 patient-years. Most cases occur in patients who are wrongly prescribed the drug, particularly patients with impaired renal function (e.g. serum creatinine level \u003e 130 micromol/L or \u003e 1.5 g/L). Other major contraindications include congestive heart failure, hypoxic states and advanced liver disease. Serious adverse events with metformin are predictable rather than spontaneous and are potentially preventable if the prescribing guidelines are respected. Gastrointestinal adverse effects, notably diarrhoea, occur in less than 20% of patients and remit when the dosage is reduced. The life-threatening risks associated with metformin are rare and could mostly be avoided by strict adherence to the prescribing guidelines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10392666"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "WHAT IS KNOWN AND OBJECTIVE: Gastrointestinal discomfort is the most common adverse event of metformin treatment for type 2 diabetes, e",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31769886"
        },
        {
          "offsetInBeginSection": 915,
          "offsetInEndSection": 1139,
          "text": "Lactic acidosis caused by metformin is rare, and the risk of this complication may be diminished by the observance of prescribing precautions and contraindications that avoid accumulation of metformin or lactate in the body.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18536788"
        },
        {
          "offsetInBeginSection": 731,
          "offsetInEndSection": 864,
          "text": "Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11045134"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 314,
          "text": "While the gastrointestinal side effects of metformin such as nausea, vomiting, diarrhea, and heartburn are quite common, one dangerous side effect of metformin, lactic acidosis, is extensively discussed yet rarely reported.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35602825"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Digestive disorders (diarrhoea, vomiting) represent the most common metformin side-effects (around 30%) with this first-line drug treatment for type 2 diabetes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21236717"
        },
        {
          "offsetInBeginSection": 1165,
          "offsetInEndSection": 1377,
          "text": "protein cholesterol levels. A safety analysis showed that metformin slightly increased the risk of severe hypoglycaemia (1.23, 95% CI 1.00 to 1.52, P \u003d .05) and mainly gastrointestinal adverse events (2.67, 95% C",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29351716"
        },
        {
          "offsetInBeginSection": 893,
          "offsetInEndSection": 1322,
          "text": "Through investigating with clinical studies, researchers concluded that in addition to decreasing cardiovascular events and anti-obesity, metformin is also beneficial for neurodegenerative disease, polycystic ovary syndrome, aging, cancer and COVID-19, however, it also induces some adverse effects, such as gastrointestinal complaints, lactic acidosis, vitamin B12 deficiency, neurodegenerative disease and offspring impairment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36484892"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 365,
          "text": "Although metformin has become a drug of choice for the treatment of type 2 diabetes mellitus, some patients may not receive it owing to the risk of lactic acidosis. Metformin, along with other drugs in the biguanide class, increases plasma lactate levels in a plasma concentration-dependent manner by inhibiting mitochondrial respiration predominantly in the liver.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26773926"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 640,
          "text": "f lactic acidosis. Metformin, along with other drugs in the biguanide class, increases plasma lactate levels in a plasma concentration-dependent manner by inhibiting mitochondrial respiration predominantly in the liver. Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that further disrupts lactate production or clearance (e.g., cirrhosis, sepsis, or hypoperfusion), are typically necessary to cause metformin-associat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26773926"
        },
        {
          "offsetInBeginSection": 1004,
          "offsetInEndSection": 1121,
          "text": "Lactic acidosis may also occur, but it is rare if metformin is avoided in patients with contraindications to its use.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8726592"
        },
        {
          "offsetInBeginSection": 1639,
          "offsetInEndSection": 1783,
          "text": "The adverse effects of metformin mainly consist of dose-dependent gastrointestinal disorders and rare cases or life-threatening lactic aciaosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25954799"
        },
        {
          "offsetInBeginSection": 1639,
          "offsetInEndSection": 2301,
          "text": "The adverse effects of metformin mainly consist of dose-dependent gastrointestinal disorders and rare cases or life-threatening lactic aciaosis. Kidney failure reduces metformin elimination. Metformin rarely causes hypoglycaemia and has no effect on body weight. It does not increase cancer-related mortality. It sometimes causes vitamin B12 deficiency leading to macrocytic anaemia or peripheral neuropathy. Metformin mainly carries a risk of interactions with drugs that impair renal function, such as non-steroidal anti-inflammatory drugs and iodinated contrast media. Renal failure can lead to metformin accumulation and an increased risk of lactic acidosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25954799"
        },
        {
          "offsetInBeginSection": 627,
          "offsetInEndSection": 959,
          "text": "The most common adverse effects associated with metformin are mild, transient gastrointestinal symptoms, which are usually self-limiting. These side effects can be minimized by initiating metformin therapy at a low dose and gradually titrating upward, and by taking metformin with meals. Lactic acidosis caused by metformin is rare,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18536788"
        },
        {
          "offsetInBeginSection": 223,
          "offsetInEndSection": 495,
          "text": "The most common adverse reactions of metformin are gastrointestinal symptoms, and women tend to be more experienced than men. A positive correlation between the administration of duration and the daily dose of metformin and the risk of vitamin B12 deficiency is confirmed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39182908"
        },
        {
          "offsetInBeginSection": 502,
          "offsetInEndSection": 584,
          "text": "Frequent side effects of metformin are nausea, abdominal discomfort and diarrhoea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11045134"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "AIMS: Metformin is the most widely used oral anti-diabetes agent and has considerable benefits over other therapies, yet 20-30% of people develop gastrointestinal side effects, and 5% are unable to tolerate metformin due to the severity of these side ef",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26605869"
        },
        {
          "offsetInBeginSection": 229,
          "offsetInEndSection": 509,
          "text": "Lactic acidosis is a serious side effect seen with metformin use, and while the incidence of lactic acidosis is similar to other oral antidiabetics, metformin is not recommended to patients with certain risk factors, such as cardiovascular, pulmonary, and renal and liver failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24299454"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 288,
          "text": "n 60 years. Metformin-associated lactic acidosis is the most serious adverse effect of metformin and is most widely defined as metabolic acidosis with elevated lactate levels in the presence o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35914764"
        },
        {
          "offsetInBeginSection": 557,
          "offsetInEndSection": 695,
          "text": "Severe lactic acidosis is a rare but life threatening complication of metformin, which occurs particularly in patients with renal failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15082849"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 352,
          "text": "While generally well-tolerated, metformin can accumulate in patients with acute kidney injury (AKI) or chronic kidney disease (CKD), leading to potentially life-threatening complications such as metformin-associated lactic acidosis (MALA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39055480"
        },
        {
          "offsetInBeginSection": 1625,
          "offsetInEndSection": 1744,
          "text": "Metformin decreases absorption of vitamin B12 and folic acid, although reported cases of megaloblastic anemia are rare.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8835050"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 420,
          "text": "Metformin-associated lactic acidosis (MALA) is an extremely rare but life-threatening adverse effect of metformin treatment. The lifestyle changes associated with the coronavirus disease 2019 (COVID-19) pandemic may increase the potential risk of MALA development in patients with diabetes. We herein report a 64-year-old Japanese man taking a small dose of metformin who presented with MALA accompanied by hypoglycemia ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35598993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "text": "Metformin is a commonly used oral hypoglycaemic agent worldwide. Gastrointestinal side effects and lactic acidosis related to metformin usage are commonly recognized. However, the associated vitamin B12 deficiency is less well known.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674102"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 338,
          "text": "iation. It is considered a safe medication with minimal adverse effects, with the most common being gastrointestinal. Metformin-associated lactic acidosis (MALA) is a rare but life-threatening complication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36384864"
        },
        {
          "offsetInBeginSection": 76,
          "offsetInEndSection": 177,
          "text": "Metformin is safe, effective, and inexpensive; however, it is associated with vitamin B12 deficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38662670"
        },
        {
          "offsetInBeginSection": 635,
          "offsetInEndSection": 727,
          "text": "The rate of vitamin B12 deficiency in patients treated with metformin was found to be 18.6%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38662670"
        },
        {
          "offsetInBeginSection": 489,
          "offsetInEndSection": 604,
          "text": "Metformin-associated lactic acidosis has an elevated mortality (50-80%) and has a specific and effective treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29189867"
        },
        {
          "offsetInBeginSection": 727,
          "offsetInEndSection": 918,
          "text": " with lactic acidosis in the assessed period. Metformin-associated lactic acidosis was the most frequent serious adverse reaction related to metformin reported to the national authority (18.2",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436666"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 536,
          "text": "However, metformin often causes gastrointestinal reactions when used alone, affecting patients\u0027 quality of life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39711126"
        },
        {
          "offsetInBeginSection": 1321,
          "offsetInEndSection": 1552,
          "text": " Long-term use of metformin may cause some adverse effects like lactic acidosis and gastrointestinal disturbance. Metformin long-term overdose may lead to a rise in hydrogen sulfide in liver cells, which calls for pharmacovigilance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39421288"
        }
      ],
      "id": "67d6bf9a18b1e36f2e000023",
      "ideal_answer": [
        "The most common adverse effects of metformin are gastrointestinal side effects such as nausea, diarrhea, anorexia, and metallic taste. Metformin can also cause vitamin B12 malabsorption. The most serious but rare adverse effect is lactic acidosis, which can occur if metformin accumulates in patients with contraindications to its use, such as renal impairment.",
        "Metformin is generally well-tolerated, but it can cause some adverse effects. The most common side effects include gastrointestinal issues such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. Long-term use of metformin can lead to vitamin B12 deficiency, which may result in anemia or neuropathy. A rare but serious side effect is lactic acidosis, a condition characterized by the buildup of lactic acid in the blood, which can be life-threatening. Patients with kidney impairment, liver disease, or heart failure are at higher risk for lactic acidosis. Other potential side effects include skin reactions, taste disturbances, and hypoglycemia, especially when used in combination with other antidiabetic medications.",
        "Metformin most commonly causes gastrointestinal adverse effects such as nausea, vomiting, diarrhea, abdominal pain, anorexia, and heartburn. It is also associated with a decrease in vitamin B12 absorption, with deficiency rates around 18.6%. Rarely, abnormalities in blood counts and skin reactions have been reported. Although these digestive symptoms are frequent, lactic acidosis, while rare, is particularly dangerous, with a mortality rate ranging from 50 to 80%. This serious complication is more likely in patients with cardiovascular, pulmonary, renal, or liver failure. Other less common adverse events include hypoglycemia, taste alterations, epigastric cramps, and bloating. Overall, while metformin is generally safe and effective for managing diabetes, careful monitoring is important, especially in patients with predisposition to serious complications.",
        "Metformin is a widely used medication for type 2 diabetes, known primarily for its ability to lower blood sugar levels. However, it can also cause several adverse effects:\n\n1. **Gastrointestinal Issues:** Common side effects include nausea, diarrhea, and stomach discomfort, which are usually mild but can be bothersome.\n\n2. **Lactic Acidosis:** A rare but serious condition where lactate builds up in the body, leading to blood acidity. This risk is higher in individuals with kidney problems, as the kidneys play a key role in clearing lactate.\n\n3. **Vitamin B12 Levels:** Long-term use can lead to lower vitamin B12 levels, potentially causing anemia or neurological symptoms like numbness and tingling.\n\n4. **Metabolic Effects:** Metformin may influence lipid metabolism, affecting cholesterol levels, and could cause weight changes, though it is generally weight-neutral.\n\n5. **Hypoglycemia Risk:** While metformin alone doesn\u0027t typically cause hypoglycemia, the risk increases when combined with other blood sugar-lowering medications.\n\n6. **Liver Function:** Mainly metabolized in the liver, patients with pre-existing liver conditions might have an increased risk of side effects, though it\u0027s generally safe for mild liver issues with monitoring.\n\n7. **Allergic Reactions:** Some individuals may experience rashes or itching, necessitating immediate medical attention and discontinuation of the drug.\n\n8. **Kidney Function Monitoring:** Essential before starting metformin to assess suitability, especially in those with renal impairment.\n\n9. **Long-term Considerations:** Regular monitoring of vitamin B12 levels and kidney function is crucial for long-term users, particularly on higher doses.\n\nUnderstanding these risks helps in managing the use of metformin effectively, ensuring patient safety and optimal outcomes.\n\n**Exact Answer:**\n\nGastrointestinal upset; lactic acidosis; vitamin B12 deficiency; metabolic effects (lipid metabolism); allergic reactions."
      ],
      "exact_answer": [
        [
          "Sarcopenia, lactic acidosis, hypovitaminosis B12",
          "nausea, vomiting, diarrhoea",
          "anorexia"
        ]
      ]
    },
    {
      "body": "What are the main cell states of glioblastoma multiforme (GBM)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38826227",
        "http://www.ncbi.nlm.nih.gov/pubmed/38650010",
        "http://www.ncbi.nlm.nih.gov/pubmed/31973233",
        "http://www.ncbi.nlm.nih.gov/pubmed/38766170",
        "http://www.ncbi.nlm.nih.gov/pubmed/38760585",
        "https://pubmed.ncbi.nlm.nih.gov/38766170/",
        "http://www.ncbi.nlm.nih.gov/pubmed/38803685"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 114,
          "offsetInEndSection": 684,
          "text": " In addition to the lack of dedicated drug discovery programs for GBM, extensive intratumor heterogeneity and epigenetic plasticity related to cell-state transitions are major roadblocks to successful drug therapy in GBM. To study these phenomenon, publicly available snRNAseq and bulk RNAseq data from patient samples were used to categorize cells from patients into four cell states (i.e. phenotypes), namely: (i) neural progenitor-like (NPC-like), (ii) oligodendrocyte progenitor-like (OPC-like), (iii) astrocyte- like (AC-like), and (iv) mesenchymal-like (MES-like).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38826227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 400,
          "text": "Glioblastoma (GBM) remains an untreatable malignant tumor with poor patient outcomes, characterized by palisading necrosis and microvascular proliferation. While single-cell technology made it possible to characterize different lineage of glioma cells into neural progenitor-like (NPC-like), oligodendrocyte-progenitor-like (OPC-like), astrocyte-like (AC-like) and mesenchymal like (MES-like) states,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38650010"
        },
        {
          "offsetInBeginSection": 602,
          "offsetInEndSection": 793,
          "text": "A recent study has highlighted the degree of functional heterogeneity that coexists within individual GBM tumours, describing four cellular states (MES-like, NPC-like, OPC-like and AC-like). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31973233"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 400,
          "text": "While single-cell technology made it possible to characterize different lineage of glioma cells into neural progenitor-like (NPC-like), oligodendrocyte-progenitor-like (OPC-like), astrocyte-like (AC-like) and mesenchymal like (MES-like) states,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38650010"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 683,
          "text": "To study these phenomenon, publicly available snRNAseq and bulk RNAseq data from patient samples were used to categorize cells from patients into four cell states (i.e. phenotypes), namely: (i) neural progenitor-like (NPC-like), (ii) oligodendrocyte progenitor-like (OPC-like), (iii) astrocyte-like (AC-like), and (iv) mesenchymal-like (MES-like).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38766170"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 684,
          "text": "To study these phenomenon, publicly available snRNAseq and bulk RNAseq data from patient samples were used to categorize cells from patients into four cell states (i.e. phenotypes), namely: (i) neural progenitor-like (NPC-like), (ii) oligodendrocyte progenitor-like (OPC-like), (iii) astrocyte- like (AC-like), and (iv) mesenchymal-like (MES-like).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38826227"
        },
        {
          "offsetInBeginSection": 602,
          "offsetInEndSection": 792,
          "text": "A recent study has highlighted the degree of functional heterogeneity that coexists within individual GBM tumours, describing four cellular states (MES-like, NPC-like, OPC-like and AC-like).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31973233"
        }
      ],
      "id": "67c7392981b1027333000001",
      "ideal_answer": [
        "Glioblastoma Multiforme (GBM) remains a challenging cancer to treat, with extensive intratumor heterogeneity and epigenetic plasticity related to cell-state transitions. Single-cell data has made it possible to characterize cells from patients into four cell states, namely: (i) neural progenitor-like (NPC-like), (ii) oligodendrocyte progenitor-like (OPC-like), (iii) astrocyte-like (AC-like), and (iv) mesenchymal-like (MES-like), influencing both drug response and survival outcomes.",
        "According to the research articles, the main cell states or phenotypes of glioblastoma multiforme (GBM) are neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These distinct cellular states exhibit plasticity and can transition between states, contributing to the heterogeneity and therapeutic resistance of GBM.",
        "The main cell states of glioblastoma multiforme (GBM) include Neural Progenitor-like (NPC-like), Oligodendrocyte Progenitor-like (OPC-like), Astrocyte-like (AC-like), and Mesenchymal-like (MES-like). These cell states reflect the heterogeneity and plasticity of GBM cells, contributing to the complexity and therapeutic resistance of the tumor.",
        "Glioblastoma multiforme (GBM) is characterized by heterogeneity at the cellular and molecular levels. Cells from patients can be categorized into four cell states: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). The Cancer Genome Atlas Consortium has also classified GBM into subtypes such as classic, mesenchymal, proneural, and neural GBM. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively.",
        "The main cell states of glioblastoma multiforme (GBM) are: (1) Neural Progenitor-like (NPC-like), resembling neural stem cells; (2) Oligodendrocyte Progenitor-like (OPC-like), sharing traits with oligodendrocyte progenitor cells; (3) Astrocyte-like (AC-like), similar to astrocytes; and (4) Mesenchymal-like (MES-like), associated with mesenchymal transition and therapy resistance. Identified through multiomic analysis, network modeling, and patient data, these states influence treatment outcomes and offer potential drug targets by targeting specific proteins and pathways. Understanding these cell states is crucial for addressing GBM\u0027s intratumor heterogeneity and epigenetic plasticity.",
        "Glioblastoma multiforme (GBM) cells exist in four main cellular states: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These states recapitulate distinct neural cell types and exhibit plasticity, with the relative frequency of cells in each state varying between GBM samples and influenced by genetic drivers like CDK4, EGFR, PDGFRA, and NF1 mutations.",
        "The main cell states of glioblastoma multiforme (GBM) identified in the provided context are: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These cell states exhibit plasticity and their relative frequencies are influenced by genetic drivers like CDK4, EGFR, PDGFRA, and NF1 mutations.",
        "Glioblastoma multiforme (GBM) contains cells in four main cellular states that recapitulate distinct neural cell types: a mesenchymal state, a neural progenitor-like state, an oligodendrocyte progenitor-like state, and an astrocyte-like state. These states exhibit plasticity and their relative frequencies are influenced by genetic drivers like amplifications of CDK4, EGFR, and PDGFRA loci and mutations in the NF1 locus.",
        "Glioblastoma multiforme (GBM) exhibits remarkable cellular heterogeneity, with single-cell technologies revealing four distinct cellular states: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like) states. These cell states represent different phenotypic transitions within the tumor microenvironment and contribute to the complexity of GBM\u0027s treatment resistance.",
        "Glioblastoma multiforme (GBM) is characterized by significant intratumor heterogeneity, which can be categorized into four main cellular states based on single cell RNA sequencing and bulk RNA sequencing data. These cell states are: 1. Neural Progenitor like (NPC like): Resemble neural progenitors and may contribute to tumor growth and invasion. 2. Oligodendrocyte Progenitor like (OPC like): Share similarities with oligodendrocyte progenitors and are associated with proliferative activity. 3. Astrocyte like (AC like): Resemble reactive astrocytes and may play a role in the tumor microenvironment. 4. Mesenchymal like (MES like): Exhibit mesenchymal features, including high invasiveness and resistance to therapy. These cell states highlight the functional heterogeneity within GBM tumors and provide insights into potential therapeutic targets.",
        "The main cell states of Glioblastoma Multiforme (GBM) are consistently identified as four key phenotypes: Neural Progenitor-like (NPC-like), Oligodendrocyte Progenitor-like (OPC-like), Astrocyte-like (AC-like), and Mesenchymal-like (MES-like). These cell states reflect the tumor\u0027s cellular heterogeneity, influencing its behavior, treatment outcomes, and patient prognosis. The uniformity across sources underscores a broad consensus within the biomedical community regarding these primary cell states in GBM, highlighting the complexity of this aggressive brain cancer.",
        "The main cell states of glioblastoma multiforme (GBM) include neural progenitor like (NPC like), oligodendrocyte progenitor like (OPC like), astrocyte like (AC like), and mesenchymal like (MES like). These states represent distinct phenotypes within GBM tumors, characterized by their functional heterogeneity. Single cell technology has been instrumental in identifying these cellular states, which are crucial for understanding the tumor\\\u0027s complexity and developing targeted therapies.",
        "Glioblastoma multiforme (GBM) is characterized by four main cell states, which have been identified through single-cell technology and studies of patient samples. These cell states are: (i) neural progenitor-like (NPC-like), (ii) oligodendrocyte progenitor-like (OPC-like), (iii) astrocyte-like (AC-like), and (iv) mesenchymal-like (MES-like). Studies have highlighted the functional heterogeneity that exists within individual GBM tumors, with these four cellular states coexisting and contributing to the complexity of the disease. Understanding these cell states is crucial for developing effective drug therapies, as GBM remains a malignant tumor with poor patient outcomes due to its extensive intratumor heterogeneity and epigenetic plasticity.",
        "Glioblastoma multiforme (GBM) exhibits significant intratumor heterogeneity, characterized by four main cell states: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These cell states represent distinct phenotypes within the tumor, contributing to the complexity and poor prognosis of GBM. The identification of these states is crucial for understanding the functional heterogeneity within individual GBM tumors and for developing targeted therapeutic strategies. Publicly available single-cell RNA sequencing (snRNAseq) and bulk RNA sequencing (RNAseq) data from patient samples have been instrumental in categorizing these cell states, highlighting the importance of epigenetic plasticity and cell-state transitions in GBM.",
        "The main cell states of glioblastoma multiforme (GBM) are categorized into four distinct phenotypes based on single-cell and bulk RNA sequencing data:\n\n1. **Neural progenitor-like (NPC-like)**: Cells resembling neural progenitors, often associated with stemness and self-renewal properties.\n2. **Oligodendrocyte progenitor-like (OPC-like)**: Cells resembling oligodendrocyte progenitors, which are involved in myelination and repair processes.\n3. **Astrocyte-like (AC-like)**: Cells resembling mature astrocytes, often associated with reactive gliosis and tumor progression.\n4. **Mesenchymal-like (MES-like)**: Cells exhibiting mesenchymal features, including increased invasiveness and resistance to therapy.\n\nThese cell states represent the functional heterogeneity within GBM tumors and are critical for understanding disease progression and therapeutic targeting.",
        "The main cell states of glioblastoma multiforme (GBM) identified in recent studies are:\n\n1. **Neural Progenitor-like (NPC-like):** Resemble early precursors in the nervous system, potentially contributing to tumor initiation or recurrence.\n\n2. **Oligodendrocyte Progenitor-like (OPC-like):** Similar to cells that form myelin sheaths around neurons, indicating a lineage related to oligodendrocytes.\n\n3. **Astrocyte-like (AC-like):** Resemble supportive glial cells in the brain, suggesting a role akin to astrocytes within the tumor microenvironment.\n\n4. **Mesenchymal-like (MES-like):** Characterized by features of connective tissue cells, possibly contributing to tumor invasion and metastasis.\n\nThese classifications highlight the heterogeneity of GBM and are essential for developing targeted therapies that address each specific cell state, potentially improving treatment outcomes.",
        "Glioblastoma multiforme tumors contain cells in distinct states that can be viewed from two perspectives. Single-cell analyses have consistently identified four main cell states: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like, and mesenchymal-like. These states reflect cellular heterogeneity and resemble features of their normal neural counterparts. In contrast, bulk gene expression studies classify GBM into molecular subtypes such as proneural, neural, classical, and mesenchymal. These two classification systems highlight different levels of analysis, with the single-cell approach providing a more detailed insight into the diverse cellular composition within tumors. Notably, the terms NPC-like and OPC-like are shorthand for neural progenitor-like and oligodendrocyte progenitor-like states, respectively, helping to clarify the underlying biology.",
        "The main cell states of glioblastoma multiforme (GBM) are categorized into four distinct groups based on recent studies:\n\n1. **Neural Progenitor-like (NPC-like):** These cells resemble neural progenitors, which are early precursors to neurons.\n\n2. **Oligodendrocyte Progenitor-like (OPC-like):** These cells are similar to oligodendrocyte progenitors, which develop into oligodendrocytes responsible for myelinating nerves in the brain.\n\n3. **Astrocyte-like (AC-like):** These resemble astrocytes, star-shaped glial cells that play various roles in brain function and maintenance.\n\n4. **Mesenchymal-like (MES-like):** These cells exhibit characteristics of mesenchyme, a type of connective tissue.\n\nThese classifications are crucial for understanding the heterogeneity and plasticity within GBM tumors, aiding in the development of targeted therapies to address this aggressive form of brain cancer.",
        "The main cell states of glioblastoma multiforme (GBM) are categorized into four distinct types based on recent studies:\n\n1. **Neural Progenitor-like (NPC-like):** These cells exhibit characteristics similar to neural progenitors, which are early precursors in neuronal development. In GBM, these cells may possess stem-like properties, contributing to tumor growth and recurrence.\n\n2. **Oligodendrocyte Progenitor-like (OPC-like):** Resembling oligodendrocyte progenitors, these cells are involved in myelin formation. In the context of GBM, they might influence tumor subtype development or interact with the tumor microenvironment.\n\n3. **Astrocyte-like (AC-like):** These cells mirror astrocytes, which support neurons by providing nutrients and maintaining homeostasis. In GBM, AC-like cells may represent a more differentiated state within the tumor, adding to its heterogeneity.\n\n4. **Mesenchymal-like (MES-like):** Characteristic of mesenchymal cells, these are typically found in connective tissues and exhibit invasive properties. In GBM, MES-like cells are associated with aggressive tumor spread and resistance to treatment.\n\nThese classifications provide a framework for understanding the diverse subpopulations within GBM tumors, aiding in the development of targeted therapies and enhancing patient care strategies.",
        "The main cell states of glioblastoma multiforme (GBM) are neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These cell states represent distinct phenotypes within GBM tumors, contributing to intratumor heterogeneity and influencing drug therapy response.",
        "Glioblastoma multiforme (GBM) exhibits significant intratumor heterogeneity, characterized by four distinct cellular states: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These cell states have been identified using single-cell RNA sequencing technologies, which highlight the complexity and functional diversity within individual GBM tumors. This heterogeneity poses a major challenge for effective drug therapy in treating GBM.",
        "The main cell states of glioblastoma multiforme (GBM) are four distinct phenotypes: (i) neural progenitor-like (NPC-like), (ii) oligodendrocyte progenitor-like (OPC-like), (iii) astrocyte-like (AC-like), and (iv) mesenchymal-like (MES-like). These cell states have been identified through single-cell technology and are characterized by distinct gene expression profiles. They coexist within individual GBM tumors, contributing to the functional heterogeneity of this malignant brain cancer.",
        "The main cell states of glioblastoma multiforme (GBM) are consistently identified as: (i) Neural Progenitor-like (NPC-like), (ii) Oligodendrocyte Progenitor-like (OPC-like), (iii) Astrocyte-like (AC-like), and (iv) Mesenchymal-like (MES-like). These states, validated through single-cell RNA sequencing, spatial transcriptomics, proteomics, and bulk RNA sequencing, are crucial for understanding GBM\u0027s heterogeneity and epigenetic plasticity, which are key challenges for effective drug therapy. Their segregation within the tumor microenvironment and association with various pathways, including immunosuppression and inflammation, further underscore their importance in GBM research and treatment development.",
        "Glioblastoma multiforme (GBM) is characterized by significant intratumor heterogeneity, with cells existing in various states that resemble different neural lineages. The main cell states identified in GBM are: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These states reflect the diverse functional and phenotypic characteristics of the tumor cells, contributing to the complexity and treatment resistance of GBM.",
        "The main cell states of Glioblastoma Multiforme (GBM) are consistently identified as four key phenotypes: (1) Neural Progenitor-like (NPC-like), (2) Oligodendrocyte Progenitor-like (OPC-like), (3) Astrocyte-like (AC-like), and (4) Mesenchymal-like (MES-like). These states reflect the tumor\u0027s cellular heterogeneity, influencing its behavior, aggressiveness, and potentially its response to therapeutic interventions. Understanding these cell states is crucial for developing targeted treatments for this highly malignant brain cancer.",
        "The main cell states of glioblastoma multiforme (GBM) identified through various studies using single cell technology include neural progenitor like (NPC like), oligodendrocyte progenitor like (OPC like), astrocyte like (AC like), and mesenchymal like (MES like) cells. These states highlight the tumor\u0027s heterogeneity, which contributes to its aggressive nature and challenges in treatment.",
        " Glioblastoma multiforme (GBM) has been characterized into four main cell states: Neural progenitor-like (NPC-like), Oligodendrocyte progenitor-like (OPC-like), Astrocyte-like (AC-like), and Mesenchymal-like (MES-like). These cellular states are important to understand the functional heterogeneity within individual GBM tumors.",
        "Based on the provided research, glioblastoma multiforme (GBM) tumors exhibit four main cell states that represent different phenotypes within the tumor microenvironment. These include neural progenitor-like (NPC-like) cells, oligodendrocyte progenitor-like (OPC-like) cells, astrocyte-like (AC-like) cells, and mesenchymal-like (MES-like) cells. This classification, derived from single-cell and bulk RNA sequencing analyses of patient samples, highlights the significant intratumor heterogeneity that characterizes GBM and contributes to its treatment resistance and poor outcomes. Understanding these distinct cellular states is crucial for developing targeted therapies that address the functional heterogeneity within individual GBM tumors.",
        "Glioblastoma multiforme (GBM) is characterized by four main cell states identified in studies: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These states were determined through the analysis of snRNAseq and bulk RNAseq data from patient samples, underscoring the tumor\u0027s heterogeneity and epigenetic plasticity, which pose significant challenges for effective drug therapy.",
        "Glioblastoma multiforme (GBM) tumors are characterized by extensive intratumor heterogeneity, with cells exhibiting four main phenotypic states: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like).",
        "Glioblastoma Multiforme (GBM) primarily consists of four main cell states: Neural Progenitor-like (NPC-like), Oligodendrocyte Progenitor-like (OPC-like, often near vasculature), Astrocyte-like (AC-like), and Mesenchymal-like (MES-like). These states, confirmed through single-cell RNA sequencing, spatial transcriptomics, and proteomic analysis, are crucial for understanding GBM\u0027s heterogeneity and epigenetic plasticity. Their association with distinct pathways, including immunosuppression and inflammation, underscores their importance in developing targeted therapies for this complex tumor.",
        "Glioblastoma multiforme tumors have been found to contain four main cell states: neural progenitor-like, oligodendrocyte progenitor-like, astrocyte-like, and mesenchymal-like. These states represent distinct cellular identities within the tumor that account for its heterogeneity, influencing how the tumor grows, invades surrounding tissue, and responds to treatment.",
        "The main cell states of glioblastoma multiforme (GBM) are neural progenitor-like (NPC-like), oligodendrocyte-progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These cell states reflect the functional heterogeneity within individual GBM tumors and contribute to the challenges in developing effective drug therapies due to intratumor heterogeneity and epigenetic plasticity related to cell-state transitions.",
        "Recent studies using single-cell technology have identified four distinct cellular states within glioblastoma (GBM) tumors: neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like) states. This functional heterogeneity within individual GBM tumors represents a significant challenge for effective drug therapy, along with epigenetic plasticity related to cell-state transitions.",
        "Glioblastoma multiforme (GBM) exhibits four primary cellular states, which are neural progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte-like (AC-like), and mesenchymal-like (MES-like). These states represent the functional heterogeneity within individual GBM tumors and have been identified through advanced single-cell technologies. This categorization is crucial for understanding the complex nature of GBM and developing targeted therapies."
      ],
      "exact_answer": [
        [
          "neural progenitor-like",
          "NPC-like",
          "neural progenitor-like (NPC-like)"
        ],
        [
          "oligodendrocyte progenitor-like",
          "OPC-like",
          "oligodendrocyte progenitor-like (OPC-like)"
        ],
        [
          "astrocyte-like",
          "AC-like",
          "astrocyte-like (AC-like)"
        ],
        [
          "mesenchymal-like",
          "MES-like",
          "mesenchymal-like (MES-like)",
          "mesenchymal-like (MES) state"
        ]
      ]
    },
    {
      "body": "Is high WEE1 expression linked to PARP inhibition resistance?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39558144"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 330,
          "offsetInEndSection": 1154,
          "text": "Pre-treatment transcriptomic profiles were used with the calculated resistance to identify baseline biomarkers of resistance, including potential combination targets. The model provided both a classification of responses, as well as a continuous description of resistance, allowing for more robust biomarker associations and capturing the observed variability. Thirty-six resistance gene markers were identified, including multiple homologous recombination repair (HRR) pathway genes. High WEE1 expression was also linked to resistance, highlighting an opportunity for combining PARP and WEE1 inhibitors. This framework facilitates a fully automated way of capturing intrinsic resistance, and accounts for the pharmacological response variability captured within PDX studies and hence provides a precision medicine approach.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39558144"
        }
      ],
      "type": "yesno",
      "id": "67d34ad518b1e36f2e000005",
      "ideal_answer": [
        "Yes. High WEE1 expression was also linked to resistance, highlighting an opportunity for combining PARP and WEE1 inhibitors.",
        "Yes, high WEE1 expression is linked to PARP inhibition resistance. Inhibition of Wee1 kinase may offer treatment opportunities for patients whose cancer has developed resistance to platinum-based chemotherapy or PARP inhibitors, suggesting a connection between WEE1 expression and resistance to these treatments.",
        "Yes, high WEE1 expression is linked to PARP inhibition resistance. Research across multiple studies consistently identifies WEE1 as a biomarker for resistance to PARP inhibitors (PARPi), particularly in breast cancer models. High WEE1 expression allows tumors to compensate for the lack of homologous recombination repair, reducing PARPi efficacy. Combining PARPi with WEE1 inhibitors may overcome this resistance by inducing replication stress. Biomarker analysis supports considering WEE1 expression levels when treating patients with PARPi, highlighting a potential therapeutic strategy to enhance antitumor activity.",
        "Yes. High WEE1 expression is linked to PARP inhibition resistance.",
        "Yes, high WEE1 expression has been linked to resistance to PARP inhibitors. WEE1 is a kinase that plays a role in cell cycle regulation, particularly in the G2/M checkpoint. When WEE1 expression is elevated, it can lead to increased cell cycle arrest and DNA repair, which may contribute to reduced sensitivity to PARP inhibitors. PARP inhibitors are designed to exploit defects in DNA repair pathways, such as those found in BRCA-mutated cancers, but high WEE1 expression can counteract this effect by enhancing DNA repair capabilities, thereby conferring resistance.",
        "Yes, high WEE1 expression has been linked to resistance to PARP inhibition. WEE1 is a kinase involved in cell cycle regulation, particularly at the G2/M checkpoint. Overexpression of WEE1 can enhance DNA damage repair and cause cell cycle arrest, allowing cancer cells to survive despite the DNA damage caused by PARP inhibitors. Thus, high WEE1 expression can contribute to resistance mechanisms against PARP inhibitors in cancer therapy.",
        "Yes. High WEE1 expression is linked to resistance to PARP inhibitors, highlighting an opportunity for combining PARP and WEE1 inhibitors.",
        "Yes, high WEE1 expression is linked to PARP inhibitor resistance.",
        "Yes. High WEE1 expression has been linked to resistance against PARP inhibitors, indicating a potential target for combination therapies.",
        "Yes. High WEE1 expression was linked to resistance, highlighting an opportunity for combining PARP and WEE1 inhibitors.",
        "Yes, high WEE1 expression is linked to PARP inhibition resistance. This association is supported by multiple studies identifying WEE1 as a resistance biomarker and demonstrating that WEE1 inhibition can overcome resistance. Combining PARP inhibitors with WEE1 inhibitors enhances antitumor activity in resistant models. WEE1\u0027s role in cell cycle checkpoints underlies its involvement in resistance. Targeting WEE1 may offer a therapeutic strategy to overcome PARP inhibitor resistance, applicable even in tumors lacking an HRR deficiency.",
        "Yes, high WEE1 expression has been linked to resistance to PARP inhibitors. WEE1 is a kinase that plays a role in cell cycle regulation, particularly in the G2/M checkpoint. When WEE1 expression is elevated, it can lead to enhanced DNA repair capabilities and cell cycle arrest, allowing cancer cells to survive despite the DNA damage induced by PARP inhibitors. This resistance mechanism suggests that targeting WEE1 in combination with PARP inhibitors could potentially overcome this resistance and improve therapeutic outcomes in certain cancers.",
        "Yes, high WEE1 expression is linked to resistance to PARP inhibition, highlighting an opportunity for combining PARP and WEE1 inhibitors.",
        "Yes, high WEE1 expression is linked to PARP inhibition resistance.",
        "Yes, high WEE1 expression is consistently linked to PARP inhibition resistance across multiple studies, particularly in breast cancer models. This association arises from WEE1\u0027s role in cell cycle checkpoints, allowing tumors to bypass the lack of homologous recombination repair, thus reducing PARPi efficacy. Notably, WEE1 expression serves as a biomarker for predicting resistance. Combining PARP inhibitors with WEE1 inhibitors may overcome this resistance by inducing replication stress, offering a potential therapeutic strategy to enhance antitumor activity in resistant tumors.",
        "Yes, high WEE1 expression has been linked to resistance against PARP inhibitors, suggesting that tumors with elevated levels of this protein might not respond as effectively to PARP-targeted treatments. This finding opens up the possibility that combining PARP and WEE1 inhibitors could help overcome treatment resistance.",
        "Yes, high WEE1 expression is linked to PARP inhibition resistance, as supported by multiple studies indicating WEE1\u0027s role in resistance mechanisms and the potential of WEE1 inhibitors to overcome this resistance.",
        "Yes, high WEE1 expression has been linked to resistance to PARP inhibitors, suggesting that combining PARP and WEE1 inhibitors could be a beneficial therapeutic strategy. Tumors can develop resistance to PARP inhibitors through increased DNA repair capacity, and targeting the replication stress response, including WEE1 inhibition, can overcome this resistance, even in tumors without underlying HRR deficiency. In pancreatic ductal adenocarcinoma (PDA) cells, HuR\u0027s role in the efficacy of DNA-damaging agents was attributed to the acute upregulation of WEE1, and silencing HuR sensitized the cells to PARP inhibitors, while overexpressing HuR caused resistance.",
        "Yes, high WEE1 expression has been identified as a factor linked to resistance against PARP inhibition. This finding suggests that combining treatments targeting both PARP and WEE1 could be an effective strategy.",
        "Yes, high WEE1 expression is linked to PARP inhibition resistance, highlighting an opportunity for combining PARP and WEE1 inhibitors.",
        "Yes, high WEE1 expression was linked to resistance, highlighting an opportunity for combining PARP and WEE1 inhibitors.",
        "Yes, high WEE1 expression is linked to resistance to PARP inhibitors. Transcriptomic studies have identified high WEE1 levels as a baseline biomarker of resistance, suggesting that tumors with elevated WEE1 may be less sensitive to PARP inhibition. This resistance is likely due to WEE1’s role in activating cell cycle checkpoints, which facilitates replication fork stabilization and enhanced DNA repair in response to PARP inhibitor-induced damage. As a result, combining PARP inhibitors with WEE1 inhibitors is being explored as a strategy to overcome this intrinsic resistance.",
        "Yes, high WEE1 expression is linked to PARP inhibition resistance. This suggests that combining PARP and WEE1 inhibitors may be a potential strategy to overcome resistance.",
        "Yes. High WEE1 expression has been linked to resistance against PARP inhibitors, highlighting an opportunity for combining PARP and WEE1 inhibitors.",
        "Yes. High WEE1 expression is linked to resistance against PARP inhibitors, highlighting an opportunity for combining PARP and WEE1 inhibitors.",
        "Yes, high WEE1 expression is linked to resistance to PARP inhibition.",
        "Yes. High WEE1 expression is linked to resistance against PARP inhibitors, highlighting the potential for combining PARP and WEE1 inhibitors as a therapeutic strategy.",
        "Yes, high WEE1 expression is linked to resistance to PARP inhibition. This suggests that there is an opportunity to combine PARP inhibitors with WEE1 inhibitors to potentially overcome this resistance. The identification of high WEE1 expression as a marker of resistance highlights the importance of understanding the molecular mechanisms underlying drug resistance, and provides a basis for developing combination therapies that can improve treatment outcomes.",
        "Yes, high WEE1 expression is linked to PARP inhibition resistance, as identified through pre-treatment transcriptomic profiles analyzing baseline biomarkers of resistance.",
        "Yes, high WEE1 expression has been linked to resistance to PARP inhibitors (PARPi). Studies have shown that increased DNA repair capacity, mediated by factors like WEE1, can lead to resistance against DNA-damaging therapeutics, including PARP inhibitors. Combining WEE1 inhibitors with PARP inhibitors has been suggested as a therapeutic strategy to overcome PARPi resistance, particularly by targeting the replication stress response. In patient-derived xenoimplant models resistant to PARPi, WEE1 inhibitors have shown potential in combination with PARPi to overcome this resistance."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Please list the surgical treatments for Pilomatrix carcinoma.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38552375",
        "http://www.ncbi.nlm.nih.gov/pubmed/39628433",
        "http://www.ncbi.nlm.nih.gov/pubmed/15274715",
        "http://www.ncbi.nlm.nih.gov/pubmed/36804165",
        "http://www.ncbi.nlm.nih.gov/pubmed/22263167",
        "http://www.ncbi.nlm.nih.gov/pubmed/7354150",
        "http://www.ncbi.nlm.nih.gov/pubmed/2380436",
        "http://www.ncbi.nlm.nih.gov/pubmed/36942146"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 807,
          "offsetInEndSection": 1164,
          "text": "Pilomatrix carcinoma is a rare malignant variant of pilomatrixoma. Given the rarity of this lesion there are no well-defined standards for surgical management. Wide local excision has been recommended given the high rate of reoccurrence. Mohs micrographic surgery may provide optimal treatment of this neoplasm given the ability to have 100% margin control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15274715"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Pilomatrix carcinoma of the back treated by mohs micrographic surgery.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15274715"
        },
        {
          "offsetInBeginSection": 115,
          "offsetInEndSection": 238,
          "text": "There is no established treatment for wide local invasion and metastasis of the pilomatrix besides wide surgical resection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22263167"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "We report two cases of pilomatrix carcinoma. Wide surgical excision, radiation, and chemotherapy were required for the first patient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2380436"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 53,
          "text": "Pilomatricoma: treatment by incision and curettement.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7354150"
        },
        {
          "offsetInBeginSection": 467,
          "offsetInEndSection": 615,
          "text": "Surgical excision with a wide margin is the current standard of care for chest wall pilomatrix carcinoma and is associated with the least recurrence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36804165"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Pilomatricoma, formerly known as calcifying epithelioma of Malherbe, is a rare, benign, annexic skin tumor developed from the cells of the pilar matrix. The cure without recurrence is the rule after complete surgical excision.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36942146"
        }
      ],
      "type": "list",
      "id": "67cc9e6381b1027333000016",
      "ideal_answer": [
        "ilomatrix carcinoma is a rare malignant variant of pilomatrixoma.  Wide local excision has been recommended given the high rate of reoccurrence. Mohs micrographic surgery may be the optimal treatment",
        "The surgical treatments for Pilomatrix carcinoma include tumor excision followed by reconstruction using a local rotation flap, wide local excision to ensure clear margins, and Mohs micrographic surgery. Additionally, surgical intervention may be considered for treating lymph node metastases.",
        "Surgical treatments for Pilomatrix carcinoma include wide local excision with safe margins, Mohs micrographic surgery, and regional lymph node dissection when metastasis is suspected. Surgical excision with adequate margins is generally recommended to avoid recurrence.",
        "The surgical treatments for Pilomatrix carcinoma include surgical excision, Mohs surgery, and wide local excision. Mohs surgery, in particular, is noted for its effectiveness in reducing recurrence and is especially recommended for recurrent tumors or when tissue sparing is a priority.",
        "The surgical treatments for Pilomatrix carcinoma include excisional biopsy and complete surgical excision of the tumor.",
        "The main surgical treatments for Pilomatrix carcinoma are Mohs Micrographic Surgery and Wide Local Excision.",
        "Surgical treatments for pilomatrix carcinoma include excisional surgery (preferably wide local excision), with or without Mohs micrographic surgery, to avoid local recurrence and potential metastasis.",
        "Wide local excision (or wide surgical resection) is the standard treatment, with emphasis on achieving negative margins. If margins are positive, re‐excision is recommended. Mohs micrographic surgery is another option, offering complete margin control while sparing tissue. In cases of regional spread or nodal involvement, a modified radical neck dissection may be necessary.",
        "The surgical treatments for Pilomatrix carcinoma include: 1. Wide local excision (WLE) - the most common management method. 2. Mohs micrographic surgery (MMS) - offers superior margin control and lower risk of recurrence and metastasis compared to WLE.",
        "Surgical treatments for Pilomatrix carcinoma include excisional biopsy and surgical excision of the tumor.",
        "Surgical treatments for Pilomatrix carcinoma typically include excisional surgery to remove the tumor completely, which may involve Mohs micrographic surgery for precise margins, and in some cases, reconstructive surgery to address any defects left after excision.",
        "The surgical treatments for Pilomatrix carcinoma include Mohs micrographic surgery, wide local excision, wide excision, surgical excision, Mohs Micrographic Surgery (MMS), local rotation flap, Excision with local rotation flap, and Mohs surgery.",
        "Surgical treatments for Pilomatrix carcinoma include excisional biopsy and radical nephrectomy.",
        "The surgical treatments for Pilomatrix carcinoma are:\n\n1. Wide surgical excision\n2. Mohs micrographic surgery (MMS)\n3. Local excision \n\nThese treatments aim to remove the tumor with a wide margin to prevent recurrence.",
        "Based on the provided contexts, the main surgical treatments for pilomatrix carcinoma are excisional treatments, which are considered the preferable option to avoid progression to an invasive carcinoma.",
        "The identified surgical treatments for Pilomatrix carcinoma are: \n1. Mohs Micrographic Surgery (MMS), \n2. Wide Local Excision (WLE) with varying margins, \n3. En Bloc Surgical Resection with clear margins. \nAdditionally, procedures like Level II and III Neck Dissection with Reconstruction may be performed in cases with suspected metastasis.",
        "Wide Local Excision with clear margins and Mohs Micrographic Surgery (MMS) are the most effective surgical treatments for Pilomatrix carcinoma.",
        "Wide local excision and Mohs micrographic surgery can be utilized as surgical treatments for Pilomatrix carcinoma.",
        "Surgical treatments for Pilomatrix carcinoma include Mohs micrographic surgery (MMS) and wide local excision with safe margins. Surgical excision with adequate margins is also a preferred treatment.",
        "Surgical treatments for Pilomatrix carcinoma include wide local excision and Mohs micrographic surgery (MMS).",
        "Surgical treatments for Pilomatrix carcinoma include Mohs micrographic surgery and wide local excision.",
        "The surgical treatments for Pilomatrix carcinoma include: 1. Wide local excision - recommended due to high recurrence rates. 2. Mohs micrographic surgery (MMS) - provides optimal treatment with 100% margin control and has shown no recurrences in treated cases.",
        "Surgical treatments for Pilomatrix carcinoma (PC) include wide local excision and Mohs micrographic surgery (MMS). Surgical intervention with clear margins is highly considered in PC management to decrease risk of recurrence. MMS should be considered for the treatment of PMC, especially where tissue sparing is essential.",
        "The surgical treatments for Pilomatrix carcinoma include wide local excision and Mohs micrographic surgery (MMS). Wide local excision is recommended due to the high rate of recurrence, while MMS provides optimal treatment with 100% margin control and has shown no recurrences in treated cases.",
        "Mohs micrographic surgery and wide local excision are the surgical treatments for Pilomatrix carcinoma.",
        "The surgical treatments for Pilomatrix carcinoma include: 1. Wide local excision, which is recommended due to the high rate of recurrence. 2. Mohs micrographic surgery (MMS), which provides optimal treatment with 100% margin control and has shown no recurrences in treated cases.",
        "The surgical treatments for Pilomatrix carcinoma include wide local excision and Mohs micrographic surgery.",
        "The surgical treatments for Pilomatrix carcinoma are Wide Local Excision (WLE) and Mohs Micrographic Surgery (MMS), aiming to remove the tumor with clear margins and reduce recurrence risk. Notably, MMS offers excellent outcomes with no reported recurrences, making it particularly beneficial for cases requiring tissue preservation, thereby optimizing patient care.",
        "Surgical treatments for Pilomatrix carcinoma (PC) include wide local excision and Mohs micrographic surgery (MMS). Wide excision with clear margins is proposed to decrease the risk of recurrence. MMS may provide optimal treatment due to its ability to have 100% margin control.",
        "The surgical treatments for Pilomatrix carcinoma, as per current expert recommendations and available data, include: \n1. Wide Local Excision with clear margins to mitigate the high reoccurrence rate, \n2. Mohs Micrographic Surgery (MMS), particularly for its ability to ensure 100% margin control, which has shown a 0% recurrence rate in a small case series."
      ],
      "exact_answer": [
        [
          "Mohs micrographic surgery"
        ],
        [
          "Wide excison",
          "surgical excision"
        ],
        [
          "combination therapy"
        ],
        [
          "radiation therapy"
        ],
        [
          "curettement"
        ]
      ]
    },
    {
      "body": "Vector of dengue infection.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39760305",
        "http://www.ncbi.nlm.nih.gov/pubmed/39754219",
        "http://www.ncbi.nlm.nih.gov/pubmed/38421348",
        "http://www.ncbi.nlm.nih.gov/pubmed/15117302",
        "http://www.ncbi.nlm.nih.gov/pubmed/21408119",
        "http://www.ncbi.nlm.nih.gov/pubmed/10901853",
        "http://www.ncbi.nlm.nih.gov/pubmed/27120872",
        "http://www.ncbi.nlm.nih.gov/pubmed/8599149",
        "http://www.ncbi.nlm.nih.gov/pubmed/30621762",
        "http://www.ncbi.nlm.nih.gov/pubmed/27534439",
        "http://www.ncbi.nlm.nih.gov/pubmed/33807863",
        "http://www.ncbi.nlm.nih.gov/pubmed/32114982",
        "http://www.ncbi.nlm.nih.gov/pubmed/25888847",
        "http://www.ncbi.nlm.nih.gov/pubmed/18604274",
        "http://www.ncbi.nlm.nih.gov/pubmed/19893833",
        "http://www.ncbi.nlm.nih.gov/pubmed/31738698",
        "http://www.ncbi.nlm.nih.gov/pubmed/22579482",
        "http://www.ncbi.nlm.nih.gov/pubmed/39740097",
        "http://www.ncbi.nlm.nih.gov/pubmed/39724646",
        "http://www.ncbi.nlm.nih.gov/pubmed/22272602",
        "http://www.ncbi.nlm.nih.gov/pubmed/10689245",
        "http://www.ncbi.nlm.nih.gov/pubmed/33005866",
        "http://www.ncbi.nlm.nih.gov/pubmed/12669664",
        "http://www.ncbi.nlm.nih.gov/pubmed/33219544",
        "http://www.ncbi.nlm.nih.gov/pubmed/19802582",
        "http://www.ncbi.nlm.nih.gov/pubmed/20096802",
        "http://www.ncbi.nlm.nih.gov/pubmed/8277461",
        "http://www.ncbi.nlm.nih.gov/pubmed/39298440",
        "http://www.ncbi.nlm.nih.gov/pubmed/37549129",
        "http://www.ncbi.nlm.nih.gov/pubmed/37473544",
        "http://www.ncbi.nlm.nih.gov/pubmed/25077804",
        "http://www.ncbi.nlm.nih.gov/pubmed/24334026",
        "http://www.ncbi.nlm.nih.gov/pubmed/23540116",
        "http://www.ncbi.nlm.nih.gov/pubmed/20525113",
        "http://www.ncbi.nlm.nih.gov/pubmed/20025792",
        "http://www.ncbi.nlm.nih.gov/pubmed/10717737",
        "https://pubmed.ncbi.nlm.nih.gov/22987656/",
        "http://www.ncbi.nlm.nih.gov/pubmed/29093315",
        "http://www.ncbi.nlm.nih.gov/pubmed/37919794",
        "http://www.ncbi.nlm.nih.gov/pubmed/35449113",
        "http://www.ncbi.nlm.nih.gov/pubmed/24161880",
        "http://www.ncbi.nlm.nih.gov/pubmed/28560571",
        "http://www.ncbi.nlm.nih.gov/pubmed/12587656",
        "http://www.ncbi.nlm.nih.gov/pubmed/30374169",
        "http://www.ncbi.nlm.nih.gov/pubmed/23077843",
        "http://www.ncbi.nlm.nih.gov/pubmed/39643016",
        "http://www.ncbi.nlm.nih.gov/pubmed/36307631",
        "http://www.ncbi.nlm.nih.gov/pubmed/39614146",
        "http://www.ncbi.nlm.nih.gov/pubmed/37833335",
        "http://www.ncbi.nlm.nih.gov/pubmed/30743113",
        "http://www.ncbi.nlm.nih.gov/pubmed/18491624",
        "http://www.ncbi.nlm.nih.gov/pubmed/27260668",
        "http://www.ncbi.nlm.nih.gov/pubmed/28150899",
        "http://www.ncbi.nlm.nih.gov/pubmed/37507047",
        "http://www.ncbi.nlm.nih.gov/pubmed/15279703",
        "http://www.ncbi.nlm.nih.gov/pubmed/37161462",
        "http://www.ncbi.nlm.nih.gov/pubmed/19836681",
        "http://www.ncbi.nlm.nih.gov/pubmed/39724432",
        "http://www.ncbi.nlm.nih.gov/pubmed/25774518",
        "http://www.ncbi.nlm.nih.gov/pubmed/27152416",
        "http://www.ncbi.nlm.nih.gov/pubmed/3599528",
        "http://www.ncbi.nlm.nih.gov/pubmed/12515199",
        "http://www.ncbi.nlm.nih.gov/pubmed/26335479",
        "http://www.ncbi.nlm.nih.gov/pubmed/29916445",
        "http://www.ncbi.nlm.nih.gov/pubmed/26848847",
        "http://www.ncbi.nlm.nih.gov/pubmed/21881776",
        "http://www.ncbi.nlm.nih.gov/pubmed/20810836",
        "http://www.ncbi.nlm.nih.gov/pubmed/10913412",
        "http://www.ncbi.nlm.nih.gov/pubmed/22102922",
        "http://www.ncbi.nlm.nih.gov/pubmed/33592927",
        "http://www.ncbi.nlm.nih.gov/pubmed/18077250",
        "http://www.ncbi.nlm.nih.gov/pubmed/25766611",
        "http://www.ncbi.nlm.nih.gov/pubmed/29470620",
        "http://www.ncbi.nlm.nih.gov/pubmed/28124222",
        "http://www.ncbi.nlm.nih.gov/pubmed/22212524",
        "http://www.ncbi.nlm.nih.gov/pubmed/11407002",
        "http://www.ncbi.nlm.nih.gov/pubmed/1543101"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "Aedes aegypti mosquitoes are the principal vectors of dengue",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39760305"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 27,
          "text": "Mosquito-borne flaviviruses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39754219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "In Martinique, Aedes aegypti, the vector of dengue viruses has been the target of insecticide control for more than 35 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15117302"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Genetic heterogeneity of the dengue vector Aedes aegypti in Martinique.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15117302"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "BACKGROUND: Aedes aegypti is the main vector of the virus causing Dengue fever, a disease that has increased dramatically in importance in recent decades, affecting many tropical and sub-tropical areas o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21408119"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Dengue infection increases the locomotor activity of Aedes aegypti females.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21408119"
        },
        {
          "offsetInBeginSection": 553,
          "offsetInEndSection": 686,
          "text": "Dengue viruses can be transmitted by several mosquito species of the genus Aedes, but by far the most common vector is Aedes aegypti.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10901853"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Dengue fever is a viral disease that is transmitted primarily by Aedes mosquitoes, i. e., A. aegypti and A. albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27120872"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "The mosquito Aedes (Stegomyia) aegypti (Linneaus, 1762) is the vector of dengue viruses in America.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8599149"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "BACKGROUND: Aedes aegypti is an efficient primary vector of dengue, and has a heterogeneous distribution i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30621762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "A novel entomological index, Aedes aegypti Breeding Percentage, reveals the geographical spread of the dengue vector in Singapore and serves as a spatial risk indicator for dengue.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30621762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "BACKGROUND: Dengue is a re-emerging public health problem and mosquito-borne infectious disease that is transmitted mainly by Aedes aeg",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32114982"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "BACKGROUND: Dengue is an arboviral disease caused by dengue virus (DENV), whose main vectors are the mosquitoes Aedes aegypti and Aedes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25888847"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 556,
          "text": "Aedes aegypti is the principal vector of DENV, and its vector competence consists of the intrinsic factors, genes, molecules, and pathways that allow infection, replication, and dissemination of this virus throughout the cells of mosquito tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31738698"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "Aedes aegypti Immune Response and Its Potential Impact on Dengue Virus Transmission.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31738698"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 171,
          "text": "The Aedes aegypti mosquito is the major vector that spreads dengue virus to humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22579482"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Intrinsic features of Aedes aegypti genes affect transcriptional responsiveness of mosquito genes to dengue virus infection.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22579482"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "BACKGROUND: Dengue is a re-emerging public health problem and mosquito-borne infectious disease that is transmitted mainly by Aedes aegypti and Ae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32114982"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 107,
          "text": "Aedes aegypti is a primary urban vector of dengue, yellow fever, Zika and chikungunya worldwide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Aedes aegypti and Aedes albopictus are the main vectors of arboviruses such as dengue, Zika virus, and chikungunya",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724646"
        },
        {
          "offsetInBeginSection": 534,
          "offsetInEndSection": 703,
          "text": "Compared to Aedes aegypti, which is the most important vector of Dengue, Ae albopictus is a less competent vector of arboviruses, and the epidemics it causes are milder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 47,
          "text": "Aedes albopictus and the reemergence of Dengue.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 245,
          "text": "Dengue is an acute infectious disease, caused by a single stranded ribonucleic acid (RNA) virus of the family of Flaviviridae, genus Flavivirus, transmitted by Aedes mosquitos, the most important vectors being Aedes aegypti and Aedes albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10689245"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Incrimination of Aedes aegypti and Aedes albopictus as vectors of dengue virus serotypes 1, 2 and 3 from four states of Northeast India.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33005866"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Dengue is widespread throughout the tropics and local spatial variation in dengue virus transmission is strongly influenced by rainfall, temperature, urbanization and distribution of the principal mosquito vector Aedes aegypti.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27534439"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 51,
          "text": "Aedes aegypti is the main vector of dengue viruses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12669664"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 59,
          "text": "The primary vector of dengue virus (DENV) is Aedes aegypti.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33219544"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 261,
          "text": "Because Aedes aegypti, the principle dengue virus (DENV) vector, transmit the virus with remarkable efficiency, entomological thresholds are especially low.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19802582"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 62,
          "text": "Aedes aegypti is the urban vector of dengue viruses worldwide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20096802"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 357,
          "text": "The dengue virus (DENV) is generally transmitted between human hosts via the bite of a mosquito vector, primarily Aedes aegypti and Ae. albopictus as a minor species.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33807863"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Aedes albopictus is an important and widespread vector of dengue in many tropical countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8277461"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 221,
          "text": "Aedes albopictus, which is naturally infected with the bacteria Wolbachia, is considered to be a secondary vector of DENV.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39298440"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 426,
          "text": "In the case of dengue, a mosquito-borne disease, these infection networks include a vector-the Aedes aegypti mosquito-which has expanded its endemic area due to climate change.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37549129"
        },
        {
          "offsetInBeginSection": 166,
          "offsetInEndSection": 242,
          "text": "The primary vector of DENV is Aedes aegypti and Aedes albopictus mosquitoes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37473544"
        },
        {
          "offsetInBeginSection": 76,
          "offsetInEndSection": 135,
          "text": "The primary vector of dengue is the Aedes aegypti mosquito.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25077804"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 260,
          "text": "Aedes aegypti and Aedes albopictus are the vectors responsible for the transmission of dengue viruses (DENV).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24334026"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Aedes aegypti (L.) is the principal mosquito vector of dengue fever, the second-most deadly vector-borne disease in the world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23540116"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 304,
          "text": "A study in BMC Genomics applies this approach to investigating the effects of exposure to a range of xenobiotics on changes in gene expression in the larvae of Aedes aegypti, the mosquito vector of dengue fever.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20525113"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 326,
          "text": "The dengue virus (DENV) is generally transmitted between human hosts via the bite of a mosquito vector, primarily Aedes aegypti and Ae.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33807863"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Aedes aegypti is the principal vector of dengue viruses, responsible for a viral infection that has become a major public health concern in Asia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10717737"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "México has cities (e.g., México City and Puebla City) located at elevations \u003e 2,000 m and above the elevation ceiling below which local climates allow the dengue virus mosquito vector Aedes aegypti to proliferate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/22987656/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "BACKGROUND: Dengue fever, caused by the dengue virus (DENV), is the most common viral infection transmitted by Aedes mosquitoes (mainly Ae. aegypti and Ae. albopictus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37919794"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "BACKGROUND: The primary disease vectors for dengue virus (DENV) transmission between humans are the mosquitoes Aedes aegypti and Aedes albopictus, with Ae. aegypti population size strongly correlated with DEN",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35449113"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Aedes aegypti and Aedes albopictus are the primary and secondary vectors, respectively, of dengue, the most important arboviral disease in the world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29093315"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Aedes aegypti and Aedes albopictus were reported to be significant as vectors of dengue fever.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24161880"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 558,
          "text": "The disease problem has increased in recent years, especially in urban and suburban areas of tropical and subtropical regions. There are five dengue viruses, called serotypes (DEN-1, DEN-2, DEN-3, DEN-4, and DEN-5), which belong to the Flaviviridae family and are transmitted to humans through infected mosquito bites, with the main vector the Aedes aegypti mosquito (Linnaeus, 1762).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28560571"
        },
        {
          "offsetInBeginSection": 416,
          "offsetInEndSection": 506,
          "text": "An infected female Aedes mosquito transmits the virus from person to person while feeding.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12587656"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Dengue virus (DENV) is an arbovirus transmitted to humans by Aedes mosquitoes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30374169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Dengue fever (DF), dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are the re-emerging infectious diseases caused by dengue (DEN) virus, transmitted by Aedes mosquito.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23077843"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 628,
          "text": "The reported study aims to evaluate the efficacy of graphene oxide (GO) and guar gum (GG)-based nanomaterials against early fourth instar of Aedes aegypti, a mosquito responsible for transmitting diseases like dengue fever, Zika, and chikungunya, among many others",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39643016"
        },
        {
          "offsetInBeginSection": 418,
          "offsetInEndSection": 626,
          "text": "The two species of the vector transmitting dengue are Aedes aegypti and Aedes albopictus, with the former one being dominant. Serotypes 2 of dengue fever are spread to the human body and cause severe illness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36307631"
        },
        {
          "offsetInBeginSection": 418,
          "offsetInEndSection": 720,
          "text": "The two species of the vector transmitting dengue are Aedes aegypti and Aedes albopictus, with the former one being dominant. Serotypes 2 of dengue fever are spread to the human body and cause severe illness. Recently, dengue has imposed an aggressive effect synergistically with the COVID-19 pandemic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36307631"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 626,
          "text": "Dengue belongs to the Flaviviridae family of viruses. The two species of the vector transmitting dengue are Aedes aegypti and Aedes albopictus, with the former one being dominant. Serotypes 2 of dengue fever are spread to the human body and cause severe illness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36307631"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 543,
          "text": "Dengue belongs to the Flaviviridae family of viruses. The two species of the vector transmitting dengue are Aedes aegypti and Aedes albopictus, with the former one being dominant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36307631"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 543,
          "text": "A number of factors like disease\u0027s non-specific symptoms, increased viral mutation, growing antiviral drug resistance due to reduced susceptibility, unavailability of an effective vaccine for dengue, weak immunity against the virus, and many more are involved. Dengue belongs to the Flaviviridae family of viruses. The two species of the vector transmitting dengue are Aedes aegypti and Aedes albopictus, with the former one being dominant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36307631"
        },
        {
          "offsetInBeginSection": 418,
          "offsetInEndSection": 543,
          "text": "The two species of the vector transmitting dengue are Aedes aegypti and Aedes albopictus, with the former one being dominant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36307631"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "BACKGROUND: Dengue is the most important arboviral disease, and Aedes aegypti and Aedes albopictus are the ma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39614146"
        },
        {
          "offsetInBeginSection": 114,
          "offsetInEndSection": 211,
          "text": "The two main mosquito species vectors of the dengue virus are Aedes aegypti and Aedes albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37833335"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Aedes aegypti and Aedes albopictus are two important mosquito species which transmit various infectious arbovirus diseases represented mainly by dengue fever.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30743113"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Dengue fever is a mosquito-borne viral disease, whose main biological vector is Aedes aegypti.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18491624"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Dengue is an acute, emerging, infectious disease transmitted by Aedes mosquitoes that has become a serious global public health problem.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27260668"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "OBJECTIVE: Dengue virus consists of four antigenically distinct serotypes (DENV 1-4) that are transmitted to humans by Aedes aegypti and Aedes albopictus ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28150899"
        },
        {
          "offsetInBeginSection": 59,
          "offsetInEndSection": 181,
          "text": "It is caused by the dengue virus and it is generally transmitted by Aedes mosquitoes\u0027 bites (Ae aegypti or Ae albopictus).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37507047"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Dengue virus (DV) is a flavivirus carried by the Aedes aegypti mosquito that causes a spectrum of illnesses in the tropics, including dengue fever, dengue hemorrhagic fever, and dengue shock syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279703"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "BACKGROUND: Dengue virus (DENV) is a major public health threat, with Aedes albopictus being the confirmed vector responsible for dengue epidemics in Guang",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37161462"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 296,
          "text": "The vector for dengue fever and chikungunya, Aedes albopictus, was recently identified in Southeastern France, although the usual vector for dengue fever is Aedes aegypti, raising the possibility of cases occurring among the local population via viraemic individuals returning from endemic areas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19836681"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "The mosquito species Aedes aegypti (Linneaus) is the vector of multiple arboviruses, including dengue, Chikungunya, Zika, and yellow fever",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724432"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "BACKGROUND: The presence of the recently introduced primary dengue virus vector mosquito Aedes aegypti in Nepal, in association with the likely indigenous secondary vector Aedes albopictus, raises public healt",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25774518"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Aedes aegypti, Aedes albopictus and Culex quinquefasciatus are vectors of dengue fever and West Nile virus diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27152416"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Aedes albopictus as well as Aedes aegypti is an important vector of chikungunya and dengue viruses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3599528"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 336,
          "text": "In 1978-1995, Dengue fever epidemics(serotype 1-4) occurred in Guangdong Province. Among 9 species of mosquitoes found in the epidemic areas, the positive rate of virus isolation in Aedes albopictus was 20.69%, in Aedes aegypti 18.95%, in Culex quinquefasciatus 10.29%, Dengue viruses were not isolated in other 6 species of mosquitoes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12515199"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Aedes aegypti (L.) is the main vector of dengue virus and more recently chikungunya virus in Latin America. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26335479"
        },
        {
          "offsetInBeginSection": 1420,
          "offsetInEndSection": 1585,
          "text": "he peninsula and elsewhere in Sri Lanka.INTERPRETATION \u0026 CONCLUSION: Fresh water Aedes vectors are main contributors to the increased dengue incidence that typically",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29916445"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 294,
          "text": " to humans. A single infected Aedes mosquito is capable to act as a reservoir/amplifier host for dengue virus and may cause epidemics via horizontal and vertical modes of dengue virus (DENV) t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26848847"
        },
        {
          "offsetInBeginSection": 601,
          "offsetInEndSection": 867,
          "text": "Transinfected Wolbachia strains in Aedes aegypti mosquitoes, the primary vector of dengue fever, directly inhibit pathogen replication, including Plasmodium gallinaceum, and also affect mosquito reproduction to allow Wolbachia to spread through mosquito populations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881776"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Dengue is an acute emerging infectious disease transmitted by Aedes mosquitoes and has become a serious global public health problem.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810836"
        },
        {
          "offsetInBeginSection": 332,
          "offsetInEndSection": 454,
          "text": "Dengue virus and its vector, Aedes mosquitoes, benefit from human habitation and travel-related aspects of human behavior.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10913412"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 138,
          "text": " Dengue virus infection is spread by the mosquito vector Aedes aegypti and causes significant morbidity and mortality worldwide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19893833"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 214,
          "text": " Aedes aegypti is the main vector of the virus causing Dengue fever, a disease that has increased dramatically in importance in recent decades, affecting many tropical and sub-tropical areas of the globe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21408119"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 197,
          "text": " The mosquito Aedes aegypti is the primary vector of dengue virus (DENV) infection in humans, and DENV is the most important arbovirus across most of the subtropics and tropics worldwide",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102922"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Aedes aegypti, the mosquito vector of dengue viruses, utilizes its innate immune system to ward off a variety of pathogens, some of which can cause disease in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18604274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "BACKGROUND: The mosquito Aedes aegypti is the primary vector of dengue virus (DENV) infection in humans, and DENV is the most important arbovirus across most of the subtropics and tropic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102922"
        },
        {
          "offsetInBeginSection": 222,
          "offsetInEndSection": 325,
          "text": "The main vector transmitting dengue is Aedes aegypti while Aedes albopictus acts as a secondary vector.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33592927"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Dengue, the most important human arboviral disease, is transmitted primarily by Aedes aegypti and, to a lesser extent, by Aedes albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18077250"
        },
        {
          "offsetInBeginSection": 328,
          "offsetInEndSection": 431,
          "text": "The most competent mosquito vectors for dengue virus transmission were Aedes aegypti and A. albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25766611"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Dengue viruses are emerging mosquito-borne pathogens belonging to Flaviviridae family which are transmitted to humans via the bites of infected mosquitoes Aedes aegypti and Aedes albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29470620"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Dengue virus (DENV) belongs to the genus Flavivirus of the family Flaviviridae and it is primarily transmitted via Aedes aegypti and Aedes albopictus mosquitoes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28124222"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Dengue virus infection is an emerging global threat caused by Arbovirus, a virus from Flaviridiae family, which is transmitted by mosquitoes, Aedes aegypti and Aedes albopictus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22212524"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 350,
          "text": "Dengue fever is usually transmitted by Aedes aegypti.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19836681"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "The incidence of dengue fever, an acute febrile illness transmitted by the Aedes aegypti mosquito, is on the rise.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1543101"
        }
      ],
      "id": "67d7fe1718b1e36f2e000043",
      "ideal_answer": [
        "Mainly, Aedes aegypti, but also Aedes albopictus.",
        "Dengue infection is primarily transmitted to humans through the bite of infected female mosquitoes, particularly of the species Aedes aegypti and, to a lesser extent, Aedes albopictus. These mosquitoes are prevalent in tropical and subtropical regions and are most active during the early morning and late afternoon. Effective control of these mosquito populations is crucial in preventing the spread of dengue.",
        "The vector responsible for transmitting the dengue virus is primarily the Aedes aegypti mosquito, with Aedes albopictus also playing a significant role. These mosquitoes are known as yellow fever and Asian tiger mosquitoes, respectively. They breed in stagnant water sources near human habitats and bite during daylight hours, facilitating disease transmission. When an infected mosquito bites a person, it transmits the dengue virus, perpetuating the infection cycle and contributing to outbreaks in regions where these species are prevalent.",
        "The primary vectors of dengue infection are the mosquitoes Aedes aegypti and Aedes albopictus, with Aedes aegypti being the most significant. These mosquitoes transmit the dengue virus, a single-stranded RNA virus of the Flaviviridae family, through their bites. While Aedes albopictus is also a vector, it is generally less competent and associated with milder epidemics compared to Aedes aegypti.",
        "Studies have shown that Aedes aegypti mosquitoes are the principal vectors of dengue, a mosquito-borne flavivirus. However, during several outbreaks of chikungunya and dengue along Mediterranean coasts in recent decades, Aedes albopictus was identified as the vector involved in these events. This indicates that while Aedes aegypti is primarily responsible for transmitting dengue, Aedes albopictus can also play a significant role in specific outbreaks."
      ],
      "exact_answer": [
        [
          "Aedes aegypti mosquitos",
          "Aedes albopictus",
          "Mosquitos"
        ]
      ]
    },
    {
      "body": "Is there a shift in the cell states of glioblastoma during recurrence?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36539501",
        "http://www.ncbi.nlm.nih.gov/pubmed/27539476",
        "http://www.ncbi.nlm.nih.gov/pubmed/31167470",
        "http://www.ncbi.nlm.nih.gov/pubmed/38684700",
        "http://www.ncbi.nlm.nih.gov/pubmed/38370784",
        "http://www.ncbi.nlm.nih.gov/pubmed/36637349",
        "http://www.ncbi.nlm.nih.gov/pubmed/34813169",
        "https://pubmed.ncbi.nlm.nih.gov/36539501/",
        "http://www.ncbi.nlm.nih.gov/pubmed/32847614",
        "http://www.ncbi.nlm.nih.gov/pubmed/36056123",
        "http://www.ncbi.nlm.nih.gov/pubmed/31298733"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 585,
          "offsetInEndSection": 741,
          "text": "We found that recurrent GBMs are characterized by a shift to a mesenchymal phenotype. We show that the mesenchymal state is mediated by activator protein 1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36539501"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Glioblastomas (GBM) are aggressive brain tumors that inevitably recur despite surgical resection, chemotherapy, and radiation. The degree to which recurrent GBM retains its initial immunophenotype is incompletely understood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27539476"
        },
        {
          "offsetInBeginSection": 653,
          "offsetInEndSection": 900,
          "text": "Recurrent tumors showed decreased staining for CD34 suggesting lower vessel density. A subset of tumors showed increased staining for markers associated with the mesenchymal gene expression pattern, including CD44, phosphorylated STAT3, and YKL40.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27539476"
        },
        {
          "offsetInBeginSection": 1268,
          "offsetInEndSection": 1447,
          "text": "These data support the notion that GBM progression is associated with a shift toward a mesenchymal phenotype in a subset of tumors and this may portend a more aggressive behavior.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27539476"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 592,
          "text": "The recurrent tumor shows a more aggressive behavior due to a phenotypic shift toward the mesenchymal subtype. Proneural-mesenchymal transition (PMT) may represent for GBM the equivalent of epithelial-mesenchymal transition associated with other aggressive cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31167470"
        },
        {
          "offsetInBeginSection": 585,
          "offsetInEndSection": 670,
          "text": "We found that recurrent GBMs are characterized by a shift to a mesenchymal phenotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36539501"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "A shift to a mesenchymal phenotype characterizes recurrence in glioblastoma and is mediated by AP1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36637349"
        },
        {
          "offsetInBeginSection": 585,
          "offsetInEndSection": 670,
          "text": "We found that recurrent GBMs are characterized by a shift to a mesenchymal phenotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/36539501/"
        },
        {
          "offsetInBeginSection": 510,
          "offsetInEndSection": 572,
          "text": "Recurrent GBM have been reported to transition to mesenchymal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36056123"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 381,
          "text": "This rare tumorigenic cell subpopulation resists temozolomide, undergoes proneural-to-mesenchymal transition (PMT) to evade therapy, and drives recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38370784"
        }
      ],
      "id": "67da131f18b1e36f2e000053",
      "ideal_answer": [
        "Glioblastomas (GBM) are aggressive brain tumors that inevitably recur despite surgical resection, chemotherapy, and radiation. These recurrent GBMs are characterized by a shift to a mesenchymal phenotype, which is mediated by activator protein 1, and are characterized by a more aggressive clinical behavior.",
        "Several studies have found that recurrent glioblastomas exhibit a shift towards a more mesenchymal cell state compared to the primary tumors. This mesenchymal shift is characterized by increased expression of extracellular matrix and mesenchyme-related genes, and is associated with a more aggressive and therapy-resistant phenotype. The mesenchymal state appears to be mediated by transcription factors like MAFK, NFATC4, and activator protein 1 (AP-1) members. Additionally, recurrent tumors show altered interactions with non-neoplastic cells like reactive astrocytes, macrophages, and T cells in the tumor microenvironment.",
        "Yes, there is a shift in cell states of glioblastoma during recurrence, primarily towards a mesenchymal phenotype mediated by activator protein 1. This shift, also characterized by the emergence of a VC-Resist cell state, leads to increased therapy resistance and enhanced tumor infiltration. Supported by single-cell analyses, functional assays, and animal studies, understanding this shift is crucial for developing targeted therapies. The transition allows glioblastoma cells to evade treatment and infiltrate surrounding brain tissue, highlighting the need for therapies addressing these adaptive changes.",
        "Yes, a shift in cell states of glioblastoma during recurrence is observed, characterized by a transition to a mesenchymal phenotype, often mediated by activator protein 1. This shift is associated with increased resistance to chemoradiation, vessel co-option, and specific molecular changes, including DNA methylation subclass transitions. The emergence of a VC-Resist cell state during recurrence further contributes to treatment resistance, highlighting the dynamic and adaptive nature of glioblastoma cell states in response to therapy.",
        "The studies collectively suggest that there is a shift in the cell states of glioblastoma during recurrence, particularly towards a more mesenchymal phenotype. Key findings include: 1) Recurrent glioblastomas are characterized by a shift to a mesenchymal phenotype mediated by factors like activator protein 1. 2) A unique subpopulation of glioblastoma cells highly expressing extracellular matrix and mesenchyme-related genes emerges at recurrence. 3) Genes involved in extracellular matrix organization are preferentially enriched in recurrent glioblastoma cells. 4) Recurrent glioblastoma stem-like cells accumulate additional mutations and exhibit greater therapeutic resistance compared to primary tumor cells.",
        "Several studies have found that recurrent glioblastomas exhibit a shift towards a more mesenchymal cell state compared to the primary tumors. This mesenchymal shift is characterized by increased expression of extracellular matrix and mesenchyme-related genes, and is associated with a more aggressive and therapy-resistant phenotype. The mesenchymal state appears to be mediated by transcription factors like MAFK, NFATC4, and AP-1 members. Additionally, recurrent tumors show altered interactions with the tumor microenvironment, including changes in non-neoplastic cell populations like astrocytes, myeloid cells, and T cells.",
        "Yes, there is a shift in the cell states of glioblastoma during recurrence, characterized by a transition to a mesenchymal phenotype. This shift is mediated by factors such as AP1 and is associated with more aggressive tumor behavior and therapy resistance. The findings suggest that phenotypic switching, rather than genetic evolution, plays a key role in recurrence and treatment failure.",
        "Yes. Recurrent glioblastomas exhibit a shift in their cell states, specifically transitioning to a mesenchymal phenotype. This shift is mediated by activator protein 1 (AP 1).",
        "Yes, there is a shift in the cell states of glioblastoma during recurrence. Recurrent glioblastomas are characterized by a transition to a mesenchymal phenotype, which is mediated by activator protein 1.",
        "Yes, recurrent glioblastomas exhibit a shift in cell states towards a mesenchymal phenotype. This change is mediated by activator protein 1.",
        "Yes, there is a notable shift in the cell states of glioblastoma (GBM) during recurrence. Recurrent GBMs are characterized by a transition towards a mesenchymal phenotype, which is associated with increased aggression and resistance to treatment. This shift involves changes in gene expression patterns, including upregulation of markers such as CD44, phosphorylated STAT3, and YKL40, and is mediated by activator protein 1 (AP-1). The transformation towards a mesenchymal state may contribute to the aggressive behavior observed in recurrent GBMs.",
        "Recurrent glioblastomas exhibit a shift in cell states in a subset of cases. Instead of simply regrowing the original tumor type, these tumors undergo molecular reprogramming toward a mesenchymal phenotype. This change is marked by increased levels of mesenchymal markers such as CD44, phosphorylated STAT3, and YKL40, along with reduced CD34 staining, indicating lower vessel density. The shift appears to be mediated by activator protein 1, suggesting a complex regulatory mechanism behind the more aggressive behavior observed in these recurrences.",
        "Yes, recurrent GBMs are characterized by a shift to a mesenchymal phenotype. This shift is mediated by activator protein 1. This may portend a more aggressive behavior.",
        "Yes, there is a notable shift in the cell states of glioblastoma (GBM) during recurrence. Recurrent GBMs are characterized by a transition towards a mesenchymal phenotype, which is associated with increased aggressiveness and resistance to treatment. This phenotypic change involves alterations in gene expression patterns, including upregulation of markers such as CD44, phosphorylated STAT3, and YKL40, and is mediated by factors like activator protein 1 (AP-1). Additionally, recurrent tumors often exhibit decreased vessel density, indicated by reduced CD34 staining. This shift towards a mesenchymal state during GBM recurrence suggests that the tumor evolves in ways that may contribute to its more aggressive behavior upon relapse.",
        "Yes, there is evidence of a shift in the cell states of glioblastoma (GBM) during recurrence. Recurrent GBMs are characterized by a transition towards a mesenchymal phenotype, which is associated with increased expression of markers such as CD44, phosphorylated STAT3, and YKL40. This phenotypic change is mediated by activator protein 1 and may contribute to the aggressive behavior observed in recurrent tumors. The shift away from an initial immunophenotype suggests that GBM progression involves dynamic cellular changes that could influence treatment response and tumor aggressiveness.",
        "Yes, there is a shift in the cell states of glioblastoma during recurrence. Recurrent GBMs are characterized by a shift to a mesenchymal phenotype, which is mediated by activator protein 1.",
        "Yes, there is a shift in the cell states of glioblastoma during recurrence. Recurrent glioblastomas (GBM) often exhibit a transition toward a mesenchymal phenotype, which is associated with more aggressive behavior. This phenotypic change is mediated by activator protein 1 and is characterized by increased expression of markers such as CD44, phosphorylated STAT3, and YKL40, along with decreased vessel density indicated by lower CD34 staining.",
        "Yes, glioblastoma (GBM) recurrence is associated with a shift in cell states, specifically towards a mesenchymal phenotype. This mesenchymal state is mediated by activator protein 1 and is characterized by changes in marker expression, such as increased CD44, phosphorylated STAT3, and YKL40, and decreased CD34 staining, indicating lower vessel density. This shift may contribute to the more aggressive behavior observed in recurrent GBM.",
        "Yes, there is evidence suggesting a shift in cell states of glioblastoma (GBM) during recurrence, specifically towards a mesenchymal phenotype. This shift is characterized by increased expression of markers such as CD44, phosphorylated STAT3, and YKL40, and decreased vessel density. The mesenchymal state is mediated by activator protein 1 and may be associated with more aggressive tumor behavior. This phenomenon has been observed in recurrent GBMs, indicating that the tumors undergo a phenotypic change during progression.",
        "Yes, there is a consensus that glioblastoma exhibits a shift in cell states during recurrence, characterized by a transition to a mesenchymal phenotype, often mediated by activator protein 1. This shift involves immunophenotypic changes, including decreased CD34 staining (indicating lower vessel density) and increased expression of mesenchymal markers like CD44, phosphorylated STAT3, and YKL40. Such changes are associated with more aggressive behavior and rapid clinical progression in a subset of recurrent tumors, suggesting a potential target for therapeutic intervention in these cases.",
        "Yes, recurrent glioblastomas (GBMs) are characterized by a shift to a mesenchymal phenotype. This change in cell state is mediated by activator protein 1, indicating a transformation in the cellular characteristics during recurrence.",
        "There is a consensus that glioblastoma exhibits a shift in cell states during recurrence, specifically towards a mesenchymal phenotype. This conclusion is supported by multiple studies utilizing different methodologies, including single-nucleus RNA assays and protein/gene expression analysis. Key findings include the mediation by activator protein 1 and increased expression of mesenchymal markers (CD44, phosphorylated STAT3, YKL40) in recurrent tumors, which correlates with rapid clinical progression in a subset of patients. This phenotypic shift may underlie the failure of precision therapies and is associated with poorer outcomes in some cases.",
        " Yes, there appears to be a shift in cell states of glioblastoma during recurrence. Studies have shown that recurrent glioblastomas may exhibit a mesenchymal phenotype, which is associated with a more aggressive behavior. This shift is mediated by activator protein 1 and is characterized by decreased staining for CD34 (suggesting lower vessel density) and increased staining for markers such as CD44, phosphorylated STAT3, and YKL40.",
        "Studies have shown that recurrent glioblastomas (GBMs) are characterized by a shift to a mesenchymal phenotype, mediated by activator protein 1. This shift is associated with increased expression of markers such as CD44, phosphorylated STAT3, and YKL40, while showing decreased staining for CD34, indicating lower vessel density. These findings suggest that glioblastoma progression involves a transition toward a mesenchymal state in some tumors, which may correlate with more aggressive behavior.",
        "Yes, there is a consensus that glioblastoma undergoes a cell state shift during recurrence, transitioning towards a mesenchymal phenotype. This shift is characterized by increased expression of mesenchymal markers (CD44, phosphorylated STAT3, YKL40) and decreased CD34 staining, indicating lower vessel density. Mediated by activator protein 1, this phenotypic change is associated with more aggressive tumor behavior and rapid clinical progression in a subset of tumors, potentially explaining a mechanism for therapy failure and more aggressive recurrence.",
        "Yes, there is a shift in the cell states during glioblastoma recurrence. The evidence shows that recurrent glioblastomas exhibit a transition toward a mesenchymal phenotype characterized by increased expression of mesenchymal markers such as CD44, phosphorylated STAT3, and YKL40, alongside decreased staining for CD34 indicating lower vessel density. This shift suggests that recurrent tumors behave more aggressively compared to their initial state, and the mesenchymal transformation appears to be mediated by activator protein 1.",
        "Research indicates that recurrent glioblastomas (GBM) undergo a significant shift towards a mesenchymal phenotype, which is mediated by activator protein 1 and characterized by increased expression of mesenchymal markers like CD44, phosphorylated STAT3, and YKL40, while showing decreased vessel density through reduced CD34 staining. This phenotypic shift may indicate more aggressive tumor behavior during progression."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "In which population has it been described an association between the CUBN gene and T2DM genetic susceptibility?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31770575"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Association between CUBN gene variants, type 2 diabetes and vitamin D concentrations in an elderly Greek population.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31770575"
        },
        {
          "offsetInBeginSection": 1307,
          "offsetInEndSection": 1633,
          "text": " Our results indicate a potential role of CUBN gene in T2DM genetic susceptibility in the Greek population. These findings may also denote an indirect effect of vitamin D metabolism dysregulation on the pathogenesis of T2DM. Further studies are required to replicate our findings and clarify the complex underlying mechanisms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31770575"
        }
      ],
      "id": "67d45d5818b1e36f2e000012",
      "ideal_answer": [
        "In the Greek population",
        "In the Greek population.",
        "An association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been specifically described in the Greek population, based on a study of 716 T2DM patients and 542 controls. This association involves several CUBN gene variants and may be linked to vitamin D metabolism dysregulation, as evidenced by lower 25-hydroxy-vitamin-D concentrations in T2DM patients.",
        "CUBN gene has been associated with T2DM genetic susceptibility in the Greek population.",
        "The CUBN gene has been associated with Type 2 Diabetes Mellitus (T2DM) genetic susceptibility in the Greek population, as indicated by the study\u0027s results.",
        "The association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been described in a Greek population. Specific variants in the CUBN gene (rs11254375, rs6602175, rs1801224, rs4366393, and rs7071576) are significantly associated with T2DM susceptibility in this population.",
        "An association between the CUBN gene and T2DM genetic susceptibility has been described in a Greek population.",
        "An association between the CUBN gene and genetic susceptibility to Type 2 Diabetes Mellitus (T2DM) has been described in a population of Greek origin. In a study involving 716 patients with T2DM and 542 controls, 95 polymorphisms within the CUBN gene were genotyped. This research highlights the potential role of genetic variations in the CUBN gene in the context of T2DM susceptibility within this specific ethnic group. Additionally, albuminuria, a marker of diabetic kidney disease, is known to be associated with increased risk for end-stage renal disease, though this particular association was not directly linked to the CUBN gene polymorphisms in the provided context.",
        "The association has been described in an elderly Greek population, where the study evaluated 716 T2DM patients and 542 controls of Greek origin.",
        "The association between the CUBN gene and T2DM genetic susceptibility has been described in a Greek population. The study involved 716 patients with Type 2 Diabetes Mellitus (T2DM) and 542 controls of Greek origin, where 95 polymorphisms within the CUBN gene were analyzed to assess their contribution to the genetic risk of T2DM.",
        "The association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been described in a population of Greek origin. The study involved 716 patients with T2DM and 542 controls, all of Greek descent, who were analyzed for 95 polymorphisms within the CUBN gene to assess their contribution to the genetic risk of T2DM.",
        "The association between the CUBN gene and T2DM has been described in the Greek population.",
        "The association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been specifically described in the elderly Greek population. A study of 716 T2DM patients and 542 controls identified several CUBN gene variants (rs11254375_G/T, rs6602175_G/T, rs1801224_G/T, rs4366393_A/G, and rs7071576_A/G) associated with an increased T2DM risk. Notably, lower vitamin D levels were observed in T2DM patients, hinting at a potential role of vitamin D metabolism dysregulation in T2DM pathogenesis.",
        "The association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been described in the elderly Greek population. This association was identified through a genetic study that included 716 patients with T2DM and 542 controls of Greek origin. The study found several variants within the CUBN gene that were associated with an increased risk of T2DM. Additionally, the study also observed lower levels of 25-hydroxy-vitamin-D in patients with T2DM compared to controls, suggesting a potential role of vitamin D metabolism dysregulation in the pathogenesis of T2DM.",
        "An association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been identified in the Greek population. This link, observed in a study of 716 T2DM patients and 542 controls, involves multiple CUBN gene variants and may be connected to disrupted vitamin D metabolism, as indicated by lower vitamin D levels in T2DM patients.",
        "The association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been described in the Greek population. Specific variants in the CUBN gene are linked to T2DM genetic susceptibility in this population. Additionally, in Caucasian T2DM patients, the CUBN CC or C-risk-allele of rs1801239 is associated with an increased risk of end-stage renal disease (ESRD) and peripheral artery disease.",
        "An association between the CUBN gene and T2DM genetic susceptibility has been described in the elderly Greek population.",
        "An association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been described in the Greek population. This is supported by studies indicating a potential role of CUBN gene variants in T2DM risk, particularly in elderly Greek individuals, and their interaction with vitamin D metabolism.",
        "An association between variants in the CUBN gene and genetic risk of Type 2 Diabetes Mellitus (T2DM) has been described in a Greek population. Additionally, a CUBN SNP rs1801239 (I2984V) was significantly associated with T2D-ESRD in blacks. Also, rs1801232 (CUBN) in AA individuals was identified as having potential interaction by exhibiting a significant main effects only in smokers.",
        "The association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been described in the Greek population. Specific polymorphisms in the CUBN gene, such as rs11254375_G/T, rs6602175_G/T, rs1801224_G/T, rs4366393_A/G, and rs7071576_A/G, have been identified as significantly associated with T2DM in this population.",
        "A study investigating the association between CUBN gene variants and type 2 diabetes (T2DM) found a potential genetic susceptibility link specifically in the Greek elderly population.",
        "An association between the CUBN gene and type 2 diabetes (T2DM) genetic susceptibility has been described in an elderly Greek population. Research indicates that variants of the CUBN gene may play a potential role in the genetic susceptibility to T2DM in this demographic. Additionally, these findings suggest an indirect effect of vitamin D metabolism dysregulation on the pathogenesis of T2DM, highlighting the need for further studies to replicate and clarify the underlying mechanisms.",
        "An association between the CUBN gene and type 2 diabetes mellitus (T2DM) genetic susceptibility has been described in the Greek population, specifically among elderly individuals. This association may also suggest a link between vitamin D metabolism dysregulation and T2DM pathogenesis.",
        "The CUBN gene has been described to have an association with T2DM genetic susceptibility in the Greek population, particularly in an elderly Greek population.",
        "An association between the CUBN gene and T2DM genetic susceptibility has been described in the Greek population.",
        "An association between the CUBN gene and T2DM genetic susceptibility has been described in an elderly Greek population.",
        "An association between the CUBN gene and type 2 diabetes (T2DM) genetic susceptibility has been identified in the elderly Greek population. The findings suggest a potential role of the CUBN gene in T2DM, possibly through an indirect effect related to vitamin D metabolism dysregulation.",
        "In an elderly Greek population.",
        "The CUBN gene has been associated with T2DM genetic susceptibility in an elderly Greek population. This association suggests a potential role of the CUBN gene in T2DM. Further studies are required to replicate these findings.",
        "Studies have shown an association between the CUBN gene and type 2 diabetes mellitus (T2DM) genetic susceptibility in an elderly Greek population. This suggests that variations in the CUBN gene may play a role in the genetic predisposition to T2DM within this group, potentially linked to vitamin D metabolism dysregulation.",
        "Greek population",
        "Elderly Greek population",
        "An association between the CUBN gene and T2DM genetic susceptibility has been described in an elderly Greek population. Additionally, a CUBN SNP rs1801239 (I2984V) was significantly associated with T2D-ESRD in blacks.",
        "Research conducted on an elderly Greek population has identified a potential association between CUBN gene variants and type 2 diabetes mellitus (T2DM) genetic susceptibility, suggesting a possible link through vitamin D metabolism dysregulation.",
        "An association between the CUBN gene and Type 2 Diabetes Mellitus (T2DM) genetic susceptibility has been described in the Greek population, specifically within an elderly demographic. The findings also suggest a potential indirect effect of vitamin D metabolism dysregulation on T2DM pathogenesis.",
        "The CUBN gene has been associated with T2DM genetic susceptibility in an elderly Greek population."
      ],
      "exact_answer": [
        [
          "Greek"
        ]
      ]
    },
    {
      "body": "Can stem cell therapies be used to treat xerostomia",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39060406",
        "http://www.ncbi.nlm.nih.gov/pubmed/38578768",
        "http://www.ncbi.nlm.nih.gov/pubmed/37046350",
        "http://www.ncbi.nlm.nih.gov/pubmed/35486613",
        "http://www.ncbi.nlm.nih.gov/pubmed/29678523",
        "http://www.ncbi.nlm.nih.gov/pubmed/37658468",
        "http://www.ncbi.nlm.nih.gov/pubmed/35183442",
        "http://www.ncbi.nlm.nih.gov/pubmed/38038413",
        "http://www.ncbi.nlm.nih.gov/pubmed/26880659",
        "http://www.ncbi.nlm.nih.gov/pubmed/39766181",
        "http://www.ncbi.nlm.nih.gov/pubmed/23335219",
        "http://www.ncbi.nlm.nih.gov/pubmed/25036711",
        "http://www.ncbi.nlm.nih.gov/pubmed/39396054",
        "http://www.ncbi.nlm.nih.gov/pubmed/39183328",
        "http://www.ncbi.nlm.nih.gov/pubmed/39477435",
        "http://www.ncbi.nlm.nih.gov/pubmed/32723016",
        "http://www.ncbi.nlm.nih.gov/pubmed/38430363",
        "http://www.ncbi.nlm.nih.gov/pubmed/38365799",
        "http://www.ncbi.nlm.nih.gov/pubmed/37620905"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1597,
          "offsetInEndSection": 1730,
          "text": "lthough in its initial stages, the use of stem cells seems to be a promising therapy to alleviate xerostomia regardless of its cause.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39060406"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Long-Term Outcome Following Treatment With Allogeneic Mesenchymal Stem/Stromal Cells for Radiation-Induced Hyposalivation and Xerostomia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38578768"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 110,
          "text": "Adipose-derived mesenchymal stem/stromal cells (ASCs) are proposed as a new xerostomia treatment. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38578768"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: ",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38441659"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 131,
          "text": "fficacy of mesenchymal stem cell therapy in rodent models of radiation-induced xerostomia and oral mucositis: a systematic review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37046350"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 350,
          "text": "Radiation-induced xerostomia and oral mucositis are serious complications of radiation therapy for head and neck cancers. Current treatment options have limited efficacy. Mesenchymal stem cell (MSC) therapy has shown promising results in supporting the restoration of glandular secretion function and the regeneration of damaged tissues. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37046350"
        },
        {
          "offsetInBeginSection": 1437,
          "offsetInEndSection": 1585,
          "text": "The results of our systematic review suggest that MSCs appeared to be effective in the treatment of radiation-induced xerostomia and oral mucositis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37046350"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35486613"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "text": "Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29678523"
        },
        {
          "offsetInBeginSection": 282,
          "offsetInEndSection": 491,
          "text": "An increasing number of both preclinical and clinical studies have suggested that mesenchymal stem cell (MSC) transplantation treatment can increase the salivary flow rate and ameliorate symptoms of xerostomia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39396054"
        },
        {
          "offsetInBeginSection": 952,
          "offsetInEndSection": 1173,
          "text": "To evaluate the therapeutic effects, we performed xenogeneic and allogeneic transplantation using human and mouse salivary gland organoids (hSGOs and mSGOs), respectively, in a mouse model of radiation-induced xerostomia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39183328"
        },
        {
          "offsetInBeginSection": 1596,
          "offsetInEndSection": 1730,
          "text": "Although in its initial stages, the use of stem cells seems to be a promising therapy to alleviate xerostomia regardless of its cause.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39060406"
        },
        {
          "offsetInBeginSection": 1407,
          "offsetInEndSection": 1763,
          "text": " composition will be determined.DISCUSSION: The use of allogeneic MSCs from umbilical cord tissue represents an innovative approach for the treatment of xerostomia after radiation. Due to the noninvasive collection procedure, flexibility of cryobanking, and biological advantages, xerostomia therapy using allogeneic MSCs from umbilical cord tissue may hav",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38038413"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Post-radiation xerostomia therapy with allogeneic mesenchymal stromal stem cells in patients with head and neck cancer: study protocol for phase I clinical trial.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38038413"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "The use of stem cells in treating xerostomia: a systematic review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39060406"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 267,
          "text": "Effectiveness and safety of mesenchymal stem/stromal cell for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-III): a study protocol for a single-centre, double-blinded, randomised, placebo-controlled, phase II study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37658468"
        },
        {
          "offsetInBeginSection": 16,
          "offsetInEndSection": 106,
          "text": "Xerostomia following (chemo-) radiotherapy (CRT) is common in head and neck (HNC) patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39477435"
        },
        {
          "offsetInBeginSection": 1499,
          "offsetInEndSection": 1730,
          "text": "Extracts and co-cultures of gland and stem cells also seem to improve gland function.CONCLUSION: Although in its initial stages, the use of stem cells seems to be a promising therapy to alleviate xerostomia regardless of its cause.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39060406"
        },
        {
          "offsetInBeginSection": 580,
          "offsetInEndSection": 802,
          "text": "The main question was whether stem cell therapies can contribute to the treatment of xerostomia.RESULTS: 19 of 226 publications met the criteria for this review, including \u0027in vivo\u0027, \u0027in vitro\u0027 studies and clinical trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39060406"
        },
        {
          "offsetInBeginSection": 693,
          "offsetInEndSection": 1107,
          "text": "Here we present the protocol of MARSH, a first-in-human clinical trial of bone marrow-derived, IFNγ-activated BM-MSCs for the treatment of radiation-induced xerostomia.METHODS: This single-center phase 1 dose-escalation with expansion cohort, non-placebo-controlled study will assess the safety and tolerability of BM-MSCs for the treatment of radiation-induced xerostomia in patients who had head and neck cancer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35183442"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Stem cell-based regenerative therapy is a promising treatment for head and neck cancer patients that suffer from chronic dry mouth (xerostomia) due to salivary gland injury from radiation therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25036711"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Concise review: Adult salivary gland stem cells and a potential therapy for xerostomia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23335219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "The role of stem cells in the prevention and treatment of radiation-induced xerostomia in patients with head and neck cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26880659"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Clinical Introduction of Stem Cell Sparing Radiotherapy to Reduce the Risk of Xerostomia in Patients with Head and Neck Cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39766181"
        },
        {
          "offsetInBeginSection": 382,
          "offsetInEndSection": 596,
          "text": "head and neck cancer patients. Shifts in mean dose to the SCR regions (Dmean,SCR) and other organs at risk and their estimated impact on normal tissue complication probability (NTCP) for side-effects were compared ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39766181"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 108,
          "text": "Adipose-derived mesenchymal stem/stromal cells (ASCs) are proposed as a new xerostomia treatment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38578768"
        },
        {
          "offsetInBeginSection": 1651,
          "offsetInEndSection": 1869,
          "text": "MSC therapy holds significant therapeutic potential in the treatment of radio-induced xerostomia, but comprehensive, randomized, clinical trials in humans are required to ascertain their efficacy in a clinical setting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38430363"
        },
        {
          "offsetInBeginSection": 1588,
          "offsetInEndSection": 1718,
          "text": "The study provided a new potential therapeutic strategy for the treatment of xerostomia by re-engineering radiated SG using GMSCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38365799"
        },
        {
          "offsetInBeginSection": 154,
          "offsetInEndSection": 357,
          "text": "xerostomia. Bioengineered organs, generated using stem cells obtained from newborn salivary glands and ligated injury models, are a new organ transplantation strategy that could be feasible for xerostomi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37620905"
        },
        {
          "offsetInBeginSection": 273,
          "offsetInEndSection": 443,
          "text": "Early adult stem cell transplantation strategies in rodents have recently shown to improve clinical outcomes in radiotherapy-induced xerostomia in Phase 1/2 human trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32723016"
        }
      ],
      "type": "yesno",
      "id": "67cde99581b102733300001f",
      "ideal_answer": [
        "Although in its initial stages, the use of stem cells seems to be a promising therapy to alleviate xerostomia regardless of its cause.",
        "Yes, stem cell therapies can be used to treat xerostomia.",
        "Yes. Stem cell therapies, particularly using mesenchymal stem cells, show promise in treating xerostomia, especially in the context of radiation-induced xerostomia and other salivary gland diseases.",
        "Yes, stem cell therapies show promise in treating xerostomia.",
        "Yes. Stem cell therapies have shown potential in treating xerostomia, particularly in the context of conditions like Sjögren\u0027s syndrome and radiation-induced salivary gland dysfunction.",
        "Yes, stem cell therapies can be used to treat xerostomia, as evidenced by studies that have shown promising results in restoring saliva secretion and increasing the number of functional acini in irradiated mice, and reducing radiation-induced xerostomia in humans.",
        "Yes. Stem cell therapies, particularly mesenchymal stem cell (MSC) transplantation, have shown promise in increasing salivary flow rates and alleviating symptoms of xerostomia, including radiation-induced xerostomia (RIX) from head and neck cancer radiotherapy.",
        "Yes. Studies have shown that mesenchymal stem cell (MSC) transplantation can increase salivary flow rate and ameliorate symptoms of xerostomia, indicating their potential use in treatment.",
        "Yes, stem cell therapies can be used to treat xerostomia, offering a promising approach for alleviating dry mouth symptoms in patients.",
        "Yes. Stem cell therapies, particularly mesenchymal stem cell (MSC) transplantation, have shown promise in increasing salivary flow rate and alleviating symptoms of xerostomia.",
        "Yes. Stem cell therapies have shown promise in treating xerostomia, with various studies and trials investigating their efficacy in restoring salivary gland function and alleviating symptoms of dry mouth.",
        "Stem cell therapies present a promising avenue for treating xerostomia, also known as dry mouth, which occurs when there is insufficient saliva production. The potential of stem cells lies in their ability to regenerate or repair damaged tissues, including salivary glands.\n\nResearch indicates that mesenchymal stem cell therapy has been explored as a treatment option for salivary gland dysfunction and xerostomia. Additionally, exosomes derived from dental pulp stem cells (DPSCs) have demonstrated anti-inflammatory, anti-oxidative, immunomodulatory, and tissue-restorative properties, suggesting their potential to restore salivary gland function through specific pathways.\n\nHowever, it is important to note that many of these studies are still in preclinical stages, involving laboratory or animal models rather than human trials. Translating these findings into effective human treatments requires addressing challenges such as delivery methods, targeting accuracy, and ensuring safety. Furthermore, large-scale clinical trials are needed to confirm the efficacy and safety of stem cell therapies for xerostomia.\n\nIn conclusion, while stem cell therapies show promise for treating xerostomia by potentially regenerating salivary gland tissue or enhancing its function, more research is necessary to fully realize this potential and ensure these treatments are both safe and effective.",
        "Yes, stem cell therapies show promise for treating xerostomia by potentially regenerating damaged salivary glands, though they are still in early research stages and more studies are needed to establish their efficacy.",
        "Yes, stem cell therapies are being explored as a promising approach to treat xerostomia, though further research is still needed to fully understand their effectiveness.",
        "Yes, stem cell therapies can be used to treat xerostomia, particularly radiation-induced xerostomia in head and neck cancer patients.",
        "According to the provided information, stem cell therapies have shown promising results in alleviating xerostomia regardless of its cause, and have been proposed as a new treatment option for xerostomia.",
        "Yes. Stem cell therapies seem to be a promising therapy to alleviate xerostomia regardless of its cause, and Mesenchymal stem cell (MSC) therapy has shown promising results in supporting the restoration of glandular secretion function and the regeneration of damaged tissues.",
        "Yes. Stem cell therapies show promise in treating xerostomia, particularly in cases induced by radiation therapy, by supporting the restoration of glandular secretion function and regenerating damaged tissues.",
        "Yes. Stem cell therapies show promise in treating xerostomia, particularly in cases related to radiation therapy and Sjogren Syndrome-like symptoms, with studies indicating beneficial effects on gland function and salivary flow.",
        "Stem cell therapies, particularly those using mesenchymal stem/stromal cells (MSCs), show promise in treating xerostomia, especially radiation-induced xerostomia and oral mucositis, by aiding in tissue regeneration and restoring glandular function.",
        "Yes. Stem cell therapies, particularly mesenchymal stem cell treatment, show promise in treating xerostomia, including in conditions like Sjögren\u0027s syndrome.",
        "Yes. Stem cell therapies, particularly mesenchymal stem cell therapy, show promising results in treating xerostomia, including cases related to Sjögren\u0027s syndrome and radiation-induced xerostomia, by supporting glandular secretion function and regenerating damaged tissues.",
        "Yes. Stem cell therapies, particularly mesenchymal stem cell therapy, have shown promising results in treating xerostomia, especially radiation-induced xerostomia.",
        "Yes, stem cell therapies show promise in treating xerostomia, although it is still in early stages.",
        "Yes, stem cell therapies, particularly mesenchymal stem cells (MSCs), show promise in alleviating xerostomia. MSC therapy has demonstrated effectiveness in restoring glandular secretion and regenerating damaged tissues. It appears to be effective in treating radiation-induced xerostomia and oral mucositis.",
        "Yes, stem cell therapies, particularly those using Mesenchymal Stem/Stromal Cells, have shown promise and efficacy in treating xerostomia, especially radiation-induced cases, although the field is still in its initial stages."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What is the cause of African trypanosomiasis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39480870",
        "http://www.ncbi.nlm.nih.gov/pubmed/36055769",
        "http://www.ncbi.nlm.nih.gov/pubmed/38394337",
        "http://www.ncbi.nlm.nih.gov/pubmed/37498955",
        "http://www.ncbi.nlm.nih.gov/pubmed/21901632",
        "http://www.ncbi.nlm.nih.gov/pubmed/23025330",
        "http://www.ncbi.nlm.nih.gov/pubmed/19833383",
        "http://www.ncbi.nlm.nih.gov/pubmed/18756506",
        "http://www.ncbi.nlm.nih.gov/pubmed/9034568",
        "http://www.ncbi.nlm.nih.gov/pubmed/22632638",
        "http://www.ncbi.nlm.nih.gov/pubmed/37525637",
        "http://www.ncbi.nlm.nih.gov/pubmed/11461032",
        "http://www.ncbi.nlm.nih.gov/pubmed/19780474",
        "http://www.ncbi.nlm.nih.gov/pubmed/23829907",
        "http://www.ncbi.nlm.nih.gov/pubmed/37529018",
        "http://www.ncbi.nlm.nih.gov/pubmed/26504815",
        "http://www.ncbi.nlm.nih.gov/pubmed/25125985",
        "http://www.ncbi.nlm.nih.gov/pubmed/32338232",
        "http://www.ncbi.nlm.nih.gov/pubmed/34199682",
        "http://www.ncbi.nlm.nih.gov/pubmed/27156518",
        "http://www.ncbi.nlm.nih.gov/pubmed/24812818",
        "http://www.ncbi.nlm.nih.gov/pubmed/21683638",
        "http://www.ncbi.nlm.nih.gov/pubmed/8952890",
        "http://www.ncbi.nlm.nih.gov/pubmed/27072715",
        "http://www.ncbi.nlm.nih.gov/pubmed/35305174",
        "http://www.ncbi.nlm.nih.gov/pubmed/36180478",
        "http://www.ncbi.nlm.nih.gov/pubmed/30908482",
        "http://www.ncbi.nlm.nih.gov/pubmed/21657140",
        "http://www.ncbi.nlm.nih.gov/pubmed/39133740",
        "http://www.ncbi.nlm.nih.gov/pubmed/23349782",
        "http://www.ncbi.nlm.nih.gov/pubmed/27589575",
        "http://www.ncbi.nlm.nih.gov/pubmed/12811544",
        "http://www.ncbi.nlm.nih.gov/pubmed/38823730",
        "http://www.ncbi.nlm.nih.gov/pubmed/18824603",
        "http://www.ncbi.nlm.nih.gov/pubmed/28928213",
        "http://www.ncbi.nlm.nih.gov/pubmed/26110623",
        "http://www.ncbi.nlm.nih.gov/pubmed/33070078",
        "http://www.ncbi.nlm.nih.gov/pubmed/28698054",
        "http://www.ncbi.nlm.nih.gov/pubmed/19104653",
        "http://www.ncbi.nlm.nih.gov/pubmed/22376072",
        "http://www.ncbi.nlm.nih.gov/pubmed/7479764",
        "http://www.ncbi.nlm.nih.gov/pubmed/23900839",
        "http://www.ncbi.nlm.nih.gov/pubmed/19582478",
        "http://www.ncbi.nlm.nih.gov/pubmed/26494625"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "text": "Human African trypanosomiasis (HAT) or sleeping sickness is caused by the protozoan parasites Trypanosoma brucei (T.b.) gambiense (West African form) and T.b. rhodesiense (East African form) that are transmitted by the bite of the tsetse fly, Glossina spp..",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21901632"
        },
        {
          "offsetInBeginSection": 143,
          "offsetInEndSection": 397,
          "text": "tsetse fly. Human African Trypanosomiasis (HAT) or sleeping sickness is caused by Trypanosoma brucei rhodesiense or T. brucei gambiense, while African Animal Trypanosomiasis (AAT) is caused mainly by T. vivax, T. congolense, T. simiae,T. evansi and T. br",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23025330"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Human African trypanosomiasis (sleeping sickness) occurs in sub-Saharan Africa. It is caused by the protozoan parasite Trypanosoma brucei, transmitted by tsetse flies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19833383"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 474,
          "text": "Transmitted by the bite of the tsetse fly, the disease is caused by protozoan parasites of the genus Trypanosoma and comes in two types: East African human African trypanosomiasis caused by Trypanosoma brucei rhodesiense and the West African form caused by Trypanosoma brucei gambiense.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18756506"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Human African trypanosomiasis is caused by Trypanosoma brucei gambiense in West and Central Africa, and by Trypanosoma brucei rhodesiense in East and southern Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11461032"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 390,
          "text": "BACKGROUND: Human African Trypanosomiasis (HAT) is caused by two species of the tsetse fly vectored protozoan hemoflagellates belonging to Trypanosma brucei, namely T.b gambiense which predominates in Western Africa and follows a chronic disease course and T.b rhodensiense which is more prevalent in Southern and Eastern Africa, Malawi included, and follows a more acute and aggressive dis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19780474"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Human African trypanosomiasis is a life-threatening parasitic infection transmitted by the tsetse fly in sub-Saharan Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37529018"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Human African trypanosomiasis (sleeping sickness) is caused by the unicellular parasite Trypanosoma brucei and transmitted by tsetse flies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22632638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Sleeping sickness is a parasitic infection caused by two species of trypanosomes (Trypanosoma brucei gambiense and rhodesiense), transmitted by the tsetse fly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26504815"
        },
        {
          "offsetInBeginSection": 131,
          "offsetInEndSection": 325,
          "text": "The disease is caused by infection with the gambiense and rhodesiense subspecies of the extracellular parasite Trypanosoma brucei, and is transmitted to humans by bites of infected tsetse flies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23829907"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 284,
          "text": "Human African trypanosomiasis (HAT), or sleeping sickness, is caused by Trypanosoma brucei gambiense, which is a chronic form of the disease present in western and central Africa, and by Trypanosoma brucei rhodesiense, which is an acute disease located in eastern and southern Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25125985"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Human African trypanosomiasis (HAT) is caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense and caused devastating epidemics during the 20th century.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32338232"
        },
        {
          "offsetInBeginSection": 61,
          "offsetInEndSection": 155,
          "text": "Human African trypanosomiasis is caused by Trypanosoma brucei rhodesiense and T. b. gambiense.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34199682"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Human African Trypanosomiasis (HAT) is an endemic parasitic disease of sub-Saharan Africa, caused by two subspecies of protozoa belonging to Trypanosoma genus: T. brucei gambiense and T. brucei rhodesiense.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27156518"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Human African trypanosomiasis is caused by the infection of Trypanosoma brucei gambiense or T.b. rhodesiense,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24812818"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Human African trypanosomiasis (HAT) is caused by sub-species of the parasitic protozoan Trypanosoma brucei and is transmitted by tsetse flies, both of which are endemic only to sub-Saharan Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21683638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Human African Trypanosomiasis (HAT) is caused by Trypanosoma brucei which is transmitted by the tsetse fly insect vector (Glossina spp).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37525637"
        },
        {
          "offsetInBeginSection": 452,
          "offsetInEndSection": 662,
          "text": "African trypanosomiasis, caused by subspecies of Trypanosoma brucei (T b rhodesiense, T b gambiense), is transmitted by the tsetse fly and causes meningoencephalitis, in which somnolence is a prominent feature.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9034568"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "Human African trypanosomiasis (HAT, better called as sleeping sickness), caused by two morphologically identicalprotozoan parasite Trypanosoma bruceiis transmitted by the bite of tsetse flies of Glossinagenus, mainly in the rural areas of the sub-Saharan Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27072715"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "BACKGROUND: Trypanosoma brucei is the causative agent of Human African Trypanosomiasis (also known as sleeping sickness), a disease causing serious neurological disorders and fatal if lef",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35305174"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "BACKGROUND: Human African Trypanosomiasis (HAT) is a neglected tropical disease caused by infections due to Trypanosoma brucei",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30908482"
        },
        {
          "offsetInBeginSection": 510,
          "offsetInEndSection": 632,
          "text": "Trypanosoma brucei gambiense found in West and Central Africa leads to a chronic form of the disease or sleeping sickness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8952890"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 156,
          "text": "Tsetse flies (Glossina) transmit species of Trypanosoma which cause human African trypanosomiasis (HAT) and animal African trypanosomiasis (AAT)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39480870"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 131,
          "text": "Tsetse flies (Glossina sp.) are vectors of Trypanosoma brucei subspecies that cause human African trypanosomiasis (HAT)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39133740"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Trypanosoma brucei is a unicellular flagellated eukaryotic parasite that causes African trypanosomiasis in human and domestic animals with devastating health and economic consequences.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349782"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "The Trypanosoma brucei subspecies T. brucei gambiense and T. brucei rhodesiense are vector-borne pathogens that cause sleeping sickness also known as Human African Trypanosomiasis (HAT), which is fatal if left untreated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27589575"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Human African trypanosomiasis is a fatal disease caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12811544"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Human African trypanosomiasis, or sleeping sickness, is a neglected tropical disease caused by Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38823730"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "African trypanosomiasis (sleeping sickness), caused by protozoan Trypanosoma brucei species, is a debilitating disease that is lethal if untreated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18824603"
        },
        {
          "offsetInBeginSection": 452,
          "offsetInEndSection": 586,
          "text": "African trypanosomiasis, caused by subspecies of Trypanosoma brucei (T b rhodesiense, T b gambiense), is transmitted by the tsetse fly",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9034568"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "African trypanosomiasis is caused by infection with the protozoan parasite Trypanosoma brucei ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928213"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "African trypanosomiasis is a deadly neglected disease caused by the extracellular parasite Trypanosoma brucei.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26110623"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "Human African Trypanosomiasis, or African Sleeping Sickness, is a parasitic infection caused by Trypanosoma brucei (gambiense or rhodesiense), and one of the declared neglected tropical diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21657140"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Human African trypanosomiasis, or sleeping sickness, is a neglected tropical disease caused by Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense and is invariably fatal unless treated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38823730"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Human African trypanosomiasis, or sleeping sickness, is a neglected tropical disease caused by Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense which seriously affects human health in Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33070078"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Human African trypanosomiasis is a fatal disease caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense that has re-emerged in recent years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12811544"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Human African Trypanosomiasis (HAT) is caused by two subspecies of the genus Trypanosoma, namely Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28698054"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Human African trypanosomiasis (HAT, or sleeping sickness) is a protozoan parasitic infection caused by Trypanosoma brucei rhodesiense or Trypanosoma brucei gambiense.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19104653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Human African trypanosomiasis (HAT) or sleeping sickness is caused by two subspecies of  Trypanosoma brucei ,  Trypanosoma brucei gambiense , and  Trypanosoma brucei rhodesiense  and is one of Africa\u0027s old plagues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22376072"
        },
        {
          "offsetInBeginSection": 75,
          "offsetInEndSection": 188,
          "text": "Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense infect humans, causing African sleeping sickness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7479764"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 273,
          "text": "Almost all cases are due to Trypanosoma brucei gambiense, which is indigenous to west and central Africa.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19833383"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Trypanosoma brucei is the causing agent of African trypanosomiasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23900839"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "African trypanosomiasis (AT), also known as sleeping sickness in humans and Nagana in animals, is a disease caused by the protozoan parasite Trypanosoma brucei.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19582478"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Human African trypanosomiasis, or sleeping sickness, is caused by the protozoan parasite Trypanosoma brucei and induces profound reactivity of glial cells and neuroinflammation when the parasites colonise the central nervous system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36180478"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Trypanosoma brucei (T. brucei) is responsible for the fatal human disease called African trypanosomiasis, or sleeping sickness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26494625"
        }
      ],
      "id": "67d6bda918b1e36f2e000021",
      "ideal_answer": [
        "Human African trypanosomiasis (HAT) or sleeping sickness is caused by the protozoan parasites Trypanosoma brucei (T.b.) gambiense (West African form) and T.b. rhodesiense (East African form) that are transmitted by the bite of the tsetse fly, Glossina spp.",
        "African trypanosomiasis, also known as sleeping sickness, is caused by the parasitic protozoa Trypanosoma brucei, which is transmitted by the bite of infected tsetse flies. There are two main subspecies responsible for the disease: Trypanosoma brucei gambiense causes the chronic form in West and Central Africa, while Trypanosoma brucei rhodesiense causes the acute form in East and Southern Africa.",
        "African trypanosomiasis, also known as sleeping sickness in humans and nagana in animals, is caused by parasitic protozoa of the genus Trypanosoma. These parasites are transmitted to humans and animals through the bite of infected tsetse flies (Glossina species). Human African trypanosomiasis (HAT) is primarily caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, while animal African trypanosomiasis (AAT) is caused by various Trypanosoma species, including Trypanosoma congolense, Trypanosoma vivax, and Trypanosoma brucei brucei.",
        "African trypanosomiasis is caused by the protozoan parasites Trypanosoma brucei gambiense and T. b. rhodesiense, transmitted by the tsetse fly.",
        "Human African trypanosomiasis, or sleeping sickness, is caused by infection with Trypanosoma brucei gambiense or Trypanosoma brucei rhodesiense parasites.",
        "African trypanosomiasis is caused by the protozoan parasite Trypanosoma brucei, which is transmitted to humans by the bite of an infected tsetse fly (Glossina spp.). Two subspecies are responsible: T. brucei gambiense, which causes a chronic form mainly in West and Central Africa, and T. brucei rhodesiense, which causes a more acute form primarily in East and Southern Africa.",
        "African trypanosomiasis is caused by infections with protozoan parasites of the genus *Trypanosoma*. Specifically, human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by *Trypanosoma brucei* subspecies (*T. b. gambiense* and *T. b. rhodesiense*). These parasites are transmitted to humans through the bite of infected tsetse flies (*Glossina* species). African animal trypanosomiasis (AAT), which affects livestock, is caused by other *Trypanosoma* species such as *T. congolense*, *T. vivax*, and *T. simiae*. The disease cycle involves the tsetse fly acting as both a vector and reservoir for these parasites, making them a significant threat to human health and agriculture in sub-Saharan Africa.",
        "Human African trypanosomiasis, also known as sleeping sickness, is caused by infection with protozoan parasites of the genus Trypanosoma. Specifically, it is caused by the subspecies of Trypanosoma brucei. The disease is transmitted to humans through the bite of infected tsetse flies. There are two types of human African trypanosomiasis: East African, caused by Trypanosoma brucei rhodesiense, and West African, caused by Trypanosoma brucei gambiense.",
        "African trypanosomiasis, also known as sleeping sickness, is caused by protozoan parasites belonging to the genus Trypanosoma. There are two subspecies responsible for the disease in humans: Trypanosoma brucei gambiense, which causes the chronic form of the disease in West and Central Africa, and Trypanosoma brucei rhodesiense, which causes the acute form in East and Southern Africa. The disease is transmitted to humans through the bite of an infected tsetse fly (genus Glossina), which is found in sub-Saharan Africa.",
        "African trypanosomiasis, also known as sleeping sickness in humans and nagana in animals, is caused by species of the Trypanosoma parasite. These parasites are transmitted to humans and animals through the bite of infected tsetse flies (Glossina species). In humans, the disease is primarily caused by Trypanosoma brucei gambiense in West and Central Africa and Trypanosoma brucei rhodesiense in East and Southern Africa. In animals, various Trypanosoma species, such as Trypanosoma congolense and Trypanosoma vivax, are responsible for causing animal African trypanosomiasis.",
        "African trypanosomiasis is a disease caused by specific species of the protozoan parasite *Trypanosoma*. The primary causative agent is *Trypanosoma brucei*, which exists in two main subspecies:\n\n1. **Trypanosoma brucei gambiense**: This subspecies causes the Gambiense form of African trypanosomiasis, prevalent in West and Central Africa. It leads to a chronic infection characterized by neurological symptoms.\n\n2. **Trypanosoma brucei rhodesiense**: This subspecies is responsible for the Rhodesian form, found in East and Southern Africa. It causes an acute infection with more rapid progression of symptoms.\n\nThese parasites are transmitted through the bite of infected tsetse flies (*Glossina* species), which serve as the vector for the disease. Once introduced into the human bloodstream, the parasites can spread throughout the body and eventually cross the blood-brain barrier, leading to conditions such as sleeping sickness. The disease is thus a significant public health issue in regions where these vectors are present.",
        "African trypanosomiasis, also known as sleeping sickness, is caused by protozoan parasites of the species Trypanosoma brucei. The two subspecies that infect humans are Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense.",
        "African trypanosomiasis, also known as sleeping sickness, is caused by protozoan parasites of the genus Trypanosoma, specifically Trypanosoma brucei. There are two subspecies that infect humans: Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense. These parasites are transmitted to humans through the bite of an infected tsetse fly.",
        "African trypanosomiasis, also known as sleeping sickness, is caused by flagellated protozoan parasites of the genus Trypanosoma. In humans, the disease is caused by two subspecies: Trypanosoma brucei gambiense, which leads to a chronic form in West and Central Africa, and Trypanosoma brucei rhodesiense, which causes an acute form in East and Southern Africa. These parasites are transmitted through the bite of the tsetse fly.",
        "African trypanosomiasis, also known as sleeping sickness in humans, is caused by parasitic infection with Trypanosoma brucei. This protozoan parasite is transmitted to humans through the bite of the tsetse fly. The disease is invariably fatal unless treated, causing serious neurological disorders. There are two subspecies of Trypanosoma brucei that cause human African trypanosomiasis: Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense."
      ],
      "exact_answer": [
        [
          "Trypanosoma brucei",
          "Trypanosoma brucei gambiense",
          "Trypanosoma brucei rhodesiense",
          "Trypanosoma species transmitted by tsetse flies"
        ]
      ]
    },
    {
      "body": "What is the consensus binding site of the TEAD transcription factors?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16267055",
        "http://www.ncbi.nlm.nih.gov/pubmed/28178271",
        "http://www.ncbi.nlm.nih.gov/pubmed/11358867",
        "http://www.ncbi.nlm.nih.gov/pubmed/17085591",
        "http://www.ncbi.nlm.nih.gov/pubmed/10975468",
        "http://www.ncbi.nlm.nih.gov/pubmed/21701496",
        "http://www.ncbi.nlm.nih.gov/pubmed/24344135",
        "http://www.ncbi.nlm.nih.gov/pubmed/23025254",
        "http://www.ncbi.nlm.nih.gov/pubmed/11313339",
        "https://pubmed.ncbi.nlm.nih.gov/23025254/",
        "http://www.ncbi.nlm.nih.gov/pubmed/17909009"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 721,
          "offsetInEndSection": 890,
          "text": "The Fgfr4 promoter region contained a Tead protein binding site (M-CAT 5\u0027-CATTCCT-3\u0027), and Tead2 showed induction during regeneration commensurate with Fgfr4 regulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16267055"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "The TEAD family of transcription factors (TEAD1-4) bind the MCAT element in the regulatory elements of both growth promoting and myogenic differentiation genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28178271"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 286,
          "text": "The TEFs share a highly conserved 68-amino acid TEA/ATTS DNA-binding domain, which binds to SV40 GT-IIC (GGAATG), SphI (AGTATG), SphII (AGCATG), and muscle-specific M-CAT (GGTATG) enhansons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10975468"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "The TEAD (1-4) transcription factors comprise the conserved TEA/ATTS DNA-binding domain recognising the MCAT element in the promoters of muscle-specific genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21701496"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Transcription enhancer factor 1 is essential for cardiac, skeletal, and smooth muscle development and uses its N-terminal TEA domain (TEAD) to bind M-CAT elements.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17085591"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "The TEAD (transcriptional enhancer activator domain) proteins share an evolutionarily conserved DNA-binding TEA domain, which binds to the MCAT cis-acting regulatory element.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24344135"
        },
        {
          "offsetInBeginSection": 614,
          "offsetInEndSection": 802,
          "text": "CanScript is a 20-nt bipartite element consisting of an SP1-like motif and a consensus MCAT sequence. The latter recruits TEAD (TEA domain) family members, which are universally expressed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23025254"
        },
        {
          "offsetInBeginSection": 671,
          "offsetInEndSection": 780,
          "text": "The predominate consensus half-site was GGAATG (67%), and the other elements were of the form G(A)GA(T/C)ATG.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10975468"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 443,
          "text": "TEF-mediated GGAATG core enhancer activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11313339"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Mammals express four highly conserved TEAD/TEF transcription factors that bind the same DNA sequence, but serve different functions during development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11358867"
        },
        {
          "offsetInBeginSection": 679,
          "offsetInEndSection": 842,
          "text": "Gel retardation and chromatin immunoprecipitation assays showed the MCAT element to be bound by transcription enhancer factor (TEF)-1 (TEAD1) in vitro and in vivo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17909009"
        }
      ],
      "id": "67d7506e18b1e36f2e00003f",
      "ideal_answer": [
        "The TEAD family of transcription factors (TEAD1-4) bind the MCAT element in the regulatory elements of both growth-promoting and myogenic differentiation genes, which contains the canonical core motif 5\u0027-CATTCCT-3\u0027.",
        "The TEAD transcription factors, which are part of the Hippo signaling pathway, bind to a consensus DNA sequence known as the MCAT (muscle C, A, and T) element. This sequence is typically characterized by the motif 5\u0027-CATTCCA/T-3\u0027, which TEAD proteins recognize and bind to in order to regulate the expression of target genes involved in various cellular processes, including proliferation and apoptosis.",
        "TEAD transcription factors primarily bind the MCAT element, a DNA motif with a consensus typically represented as [A/T]CATTCC[A/T]. The central CATTCC sequence is crucial, although variations in the flanking nucleotides are observed. This binding site is essential for TEAD-mediated transcriptional regulation, playing a key role in processes like the Hippo signaling cascade.",
        "TEAD transcription factors are a family of proteins that play a crucial role in the regulation of gene expression, particularly in the context of the Hippo signaling pathway. The consensus binding site for TEAD transcription factors is typically a DNA sequence known as the MCAT element, which is characterized by the sequence 5\u0027-CATTCCA/T-3\u0027. This sequence allows TEAD proteins to bind to the promoter regions of target genes, facilitating the regulation of processes such as cell proliferation, apoptosis, and organ size control.",
        "The consensus binding site of the TEAD transcription factors is the M-CAT element, which has the DNA sequence motif 5\u0027-CATTCC-3\u0027 or a similar variant.",
        "The TEAD transcription factors, which are part of the Hippo signaling pathway, bind to a consensus DNA sequence known as the MCAT (Muscle CAtalytic) element. This sequence is typically represented as 5\u0027-CATTCCA/T-3\u0027. TEAD transcription factors play a crucial role in regulating gene expression related to cell growth, proliferation, and survival.",
        "The consensus binding site for TEAD transcription factors is the M-CAT element, which has the core sequence GGAATG or related sequences like AGTATG, AGCATG, and GGTATG. TEAD proteins can bind to these sequences as monomers or cooperatively as dimers on tandemly repeated sites with a 3 base pair spacer.",
        "The consensus binding site of the TEAD transcription factors is the M-CAT motif, which has the sequence 5\u0027-CATTCC-3\u0027 or its reverse complement 5\u0027-GGAATG-3\u0027. The TEAD proteins bind to these M-CAT elements in the promoters of their target genes through their highly conserved TEA DNA-binding domain.",
        "TEAD transcription factors bind a DNA element known as the MCAT element. The core consensus sequence for this binding site is generally defined as 5\u0027-CATTCCA-3\u0027, although slight variations may occur. This motif underlies TEAD regulation of genes associated with growth and differentiation.",
        "The consensus binding site of TEAD transcription factors includes both canonical and non-canonical sequences. Canonical binding sites often feature the M-CAT binding site, with specific sequences like \"CATTCC\" and \"GGAATG\" identified through various studies. Non-canonical sites include sequences such as \"AAGCATGT\" and \"ggcatcccaggg,\" discovered through bioinformatic analysis and binding assays. Additionally, in the context of glucocorticoid receptor binding, the TEAD consensus site can resemble a GBS but contains a single half-site followed by TTCC, indicating a composite binding site. The TEAD binding site is crucial for enhancer activation in development and regeneration, as mutations in these sites can significantly impair enhancer activity. These findings highlight the diversity and specificity of TEAD binding sites, which are essential for their role in transcriptional regulation.",
        "The consensus binding site of the TEAD transcription factors is the MCAT element, which is a 5\u0027-CATTCCT-3\u0027 sequence.",
        "The TEAD transcription factors bind to the M-CAT element, which has the consensus sequence 5\u0027-CATTCCT-3\u0027. This binding site is found in the regulatory regions of various genes involved in growth and myogenic differentiation.",
        "The consensus binding site of the TEAD transcription factors is the MCAT element, specifically the sequence 5\u0027-CATTCCT-3\u0027 (also referred to as M-CAT motif), as consistently identified across various contexts, notably within the Fgfr4 promoter region where it is bound by Tead proteins, including Tead1, Tead2, and Tead4.",
        "The consensus binding site of the TEAD transcription factors is the MCAT element (M-CAT 5\u0027-CATTCCT-3\u0027).",
        "Studies have identified that the TEAD family of transcription factors, comprising TEAD1-4, bind to a specific consensus sequence known as the MCAT element. This element has been found in the regulatory regions of genes involved in both growth promotion and myogenic differentiation. The MCAT element is characterized by the sequence 5\u0027-CATTCCT-3\u0027, which serves as the binding site for TEAD transcription factors, including Tead2, whose induction is observed during regeneration and correlates with Fgfr4 regulation. This specific binding site highlights the importance of TEAD transcription factors in regulating gene expression related to growth and differentiation processes.",
        "The TEAD family of transcription factors binds to a specific DNA sequence known as the MCAT element, which has the consensus sequence 5\u0027-CATTCCT-3\u0027. This binding occurs in the regulatory regions of genes involved in growth promotion and myogenic differentiation.",
        "The consensus binding site for TEAD transcription factors is represented by the DNA sequence 5\\\u0027 CATTCCT 3\\\u0027, also denoted as M CAT. This specific motif serves as a critical recognition site for TEAD proteins, such as Tead2, which regulate gene expression during processes like regeneration. In the context of Fgfr4 regulation, this binding site is crucial for the proper functioning and expression changes associated with TEAD activity.",
        "The consensus binding site of the TEAD transcription factors is the MCAT element, which consists of the sequence 5\u0027-CATTCCT-3\u0027.",
        "The TEAD family of transcription factors (TEAD1-4) bind the MCAT element in the regulatory elements. The M-CAT element has the sequence 5\u0027-CATTCCT-3\u0027.",
        "The consensus binding site of the TEAD transcription factors is the MCAT element, specifically 5\u0027-CATTCCT-3\u0027.",
        "The consensus binding site for TEAD transcription factors is the MCAT (TEAD/TEF) element, which has the sequence 5\u0027-CATTCCT-3\u0027. This site is recognized by all TEAD family members and plays a role in regulating genes involved in growth promotion and differentiation.",
        "The consensus binding site for TEAD transcription factors is the MCAT element, typically represented by the sequence 5\u0027-CATTCCT-3\u0027. This element is found in the regulatory regions of genes involved in growth promotion and myogenic differentiation.",
        "The consensus binding site for TEAD transcription factors is the MCAT (TEAD/TEF) element, which has the sequence 5\u0027-CATTCCT-3\u0027. This element is found in the regulatory regions of genes involved in growth promotion and myogenic differentiation.",
        "The TEAD family of transcription factors (TEAD1-4) binds to the MCAT element, which is present in the regulatory regions of both growth-promoting and myogenic differentiation genes. Specifically, within the Fgfr4 promoter region, a Tead protein binding site identified as M-CAT 5\u0027-CATTCCT-3\u0027 has been noted, with TEAD2 showing induction during regeneration that aligns with Fgfr4 regulation.",
        "The consensus binding site of the TEAD transcription factors is the MCAT element, specifically the sequence 5\u0027-CATTCCT-3\u0027.",
        "The consensus binding site of the TEAD transcription factors is the MCAT element, which has a sequence of 5\u0027-CATTCCT-3\u0027.",
        "The consensus binding site of the TEAD transcription factors is the M-CAT element (5\u0027-CATTCCT-3\u0027).",
        "The consensus binding site of the TEAD transcription factors is M-CAT 5\u0027-CATTCCT-3\u0027.",
        "The consensus binding site for TEAD transcription factors is the MCAT element, specifically 5\u0027-CATTCCT-3\u0027.",
        "The consensus binding site for TEAD transcription factors (TEAD1-4) is the MCAT element, with a specific sequence of 5\u0027-CATTCCT-3\u0027, which is crucial for their role in myogenesis and muscle regeneration by regulating growth-promoting and myogenic differentiation genes.",
        "The consensus binding site for TEAD transcription factors is known as the M-CAT motif, which is represented by the sequence 5\u0027-CATTCCT-3\u0027. This site is crucial for the binding of TEAD proteins, such as Tead2, which play a significant role in various biological processes, including tissue regeneration and cellular growth. The presence of this binding site in promoter regions, like that of Fgfr4, indicates its importance in gene regulation during specific cellular events.",
        "TEAD transcription factors, including TEAD1-4, bind to the MCAT element. This element, with the sequence 5\u0027-CATTCCT-3\u0027, is found in the regulatory regions of genes involved in growth and myogenic differentiation.",
        " The consensus binding site for TEAD transcription factors is the MCAT element (5\u0027-CATTCCT-3\u0027).",
        "The consensus binding site of the TEAD family of transcription factors (TEAD1-4) is the MCAT element, specifically the sequence 5\u0027-CATTCCT-3\u0027, also referred to as M-CAT. This binding site is found in the regulatory elements of both growth promoting and myogenic differentiation genes, as demonstrated in the Fgfr4 promoter region.",
        "Studies have shown that the TEAD family of transcription factors (TEAD1-4) bind to the MCAT element, with a consensus binding site sequence of 5\u0027-CATTCCT-3\u0027. This motif is present in the regulatory regions of genes involved in growth promotion and myogenic differentiation.",
        "The consensus binding site of the TEAD transcription factors is the M-CAT element with the sequence 5\u0027-CATTCCT-3\u0027, as mentioned in the given context.",
        "The consensus binding site for TEAD transcription factors (TEAD1-4) is the MCAT element, characterized by the specific DNA sequence 5\u0027-CATTCCT-3\u0027, also known as the M-CAT motif. This element plays a crucial role in myogenesis, located in regulatory regions of genes involved in growth promotion and muscle differentiation, highlighting its significance in muscle regeneration processes, particularly through pathways involving MyoD, Tead2, and Fgfr4, with Tead4 having unique initiating and suppressive functions.",
        "The TEAD transcription factors recognize the MCAT element, which has the consensus sequence 5\u0027-CATTCCT-3\u0027.",
        "The consensus binding site of the TEAD transcription factors is the MCAT element, specifically identified as 5\u0027-CATTCCT-3\u0027 (M-CAT) in certain contexts.",
        "The TEAD family of transcription factors (TEAD1-4) recognizes and binds to the MCAT element, specifically the sequence 5\u0027-CATTCCT-3\u0027, in regulatory regions of genes involved in growth promotion and myogenic differentiation.",
        "TEAD transcription factors bind to the MCAT element, specifically the consensus sequence 5\u0027-CATTCCT-3\u0027."
      ],
      "exact_answer": [
        [
          "CATTCCT",
          "5\u0027-CATTCCT-3\u0027",
          "MCAT element",
          "5\u0027-CATTCCA/T-3\u0027",
          "GGAATG",
          "5′-GGAATG-3′",
          "MCAT element (5\u0027-CATTCCT-3\u0027)",
          "M-CAT 5\u0027-CATTCCT-3\u0027",
          "CATTCC"
        ]
      ]
    },
    {
      "body": "Describe Variant Ranker",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28716001"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Variant Ranker: a web-tool to rank genomic data according to functional significance.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716001"
        },
        {
          "offsetInBeginSection": 329,
          "offsetInEndSection": 806,
          "text": "We describe Variant Ranker, a user-friendly simple web-based tool for ranking, filtering and annotation of coding and non-coding variants. Variant Ranker facilitates the identification of causal variants based on novelty, effect and annotation information. The algorithm implements and aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information and additional open-source annotations using accessible databases via ANNOVAR. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716001"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 467,
          "text": "Variant Ranker allows researchers to rank identified variants and determine the most confident variants for experimental validation.RESULTS: We describe Variant Ranker, a user-friendly simple web-based tool for ranking, filtering and annotation of coding and non-coding variants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716001"
        },
        {
          "offsetInBeginSection": 1590,
          "offsetInEndSection": 1829,
          "text": "Our results indicate that Variant Ranker exhibits excellent performance by correctly identifying and ranking the candidate genes CONCLUSIONS: Variant Ranker is a freely available web server on http://paschou-lab.mbg.duth.gr/Software.html .",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716001"
        },
        {
          "offsetInBeginSection": 468,
          "offsetInEndSection": 585,
          "text": "Variant Ranker facilitates the identification of causal variants based on novelty, effect and annotation information.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716001"
        }
      ],
      "id": "67d4854918b1e36f2e000014",
      "ideal_answer": [
        "Variant Ranker is a web-tool to rank genomic data according to functional significance. Variant Ranker facilitates the identification of causal variants based on novelty, effect and annotation information. The algorithm implements and aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information and additional open-source annotations using accessible databases via ANNOVAR.",
        "Variant Ranker is a web-tool that allows researchers to rank and prioritize identified genetic variants based on their functional significance. It helps analyze and interpret the large volume of genomic data generated by high-throughput sequencing techniques. By scoring and ranking variants based on annotations, Variant Ranker enables researchers to determine the most confident or potentially pathogenic variants for further experimental validation or clinical analysis.",
        "Variant Ranker is a tool or method used to prioritize genetic variants based on their potential functional relevance. By leveraging publicly available databases, it characterizes loci in a functional context to identify and rank variants that may be significant for further study or clinical consideration. This process helps researchers focus on variants that are more likely to have an impact on disease or biological processes.",
        "Variant Ranker is a user-friendly, web-based tool that ranks genomic variants (coding and non-coding) by their functional significance. It aggregates multiple data sources, including prediction scores, conservation scores, allelic frequencies, clinical information, and open-source annotations via ANNOVAR. Users can customize weights and apply different inheritance models. Key features include genotype filtering, customizable filtering, and downstream functional enrichment analysis through network visualization, aiding in identifying gene clusters related to specific ontology categories. Successfully demonstrated with real and synthetic datasets, Variant Ranker is freely available at http://paschou-lab.mbg.duth.gr/Software.html to facilitate the identification of causal variants.",
        "Variant Ranker is a tool designed to help researchers rank identified genetic variants, enabling them to determine the most confident variants suitable for experimental validation. It was used to prioritize variants, leading to the validation of five rare variants in specific genes through Sanger sequencing, all of which were predicted to be deleterious, demonstrating its effectiveness in identifying significant variants.",
        "Variant Ranker is a computational tool or software designed to prioritize and rank genetic variants based on their potential impact or relevance to a particular disease or phenotype. It typically integrates various types of data, such as genetic, functional, and clinical information, to assess the significance of each variant. The tool may use algorithms to evaluate factors like the predicted effect of a variant on protein function, its frequency in the population, and its association with known disease pathways. By doing so, Variant Ranker helps researchers and clinicians identify the most promising variants for further study or for consideration in diagnostic or therapeutic contexts.",
        "Variant Ranker is a versatile tool used for ranking genomic variants based on their functional significance, aiding in the prioritization of variants for experimental validation and clinical interpretation. It supports both web-based and command-line interfaces, allowing for the integration of diverse data sources and algorithms, including prediction scores, conservation scores, allelic frequencies, and clinical information. It is applicable in various contexts, such as identifying causal variants in diseases like Tourette Syndrome, refining variant classification in functional assays, and improving classification accuracy in hematological malignancies through machine learning applied to RNA-sequencing data.",
        "Variant Ranker is a tool or algorithm used to prioritize genetic variants based on their potential impact, relevance, or pathogenicity, often used in genomic research and clinical diagnostics.",
        "Variant Ranker is a computational tool used in genomics and bioinformatics to prioritize and rank genetic variants based on their potential significance or impact. It integrates various types of data, including genetic, clinical, and functional information, to assess the relevance of each variant. The goal is to identify variants most likely associated with diseases or traits, aiding researchers and clinicians in understanding genetic contributions to health and disease and making informed decisions about further investigation or clinical action.",
        "Variant Ranker is a user-friendly, web-based tool designed for ranking, filtering, and annotating both coding and non-coding genetic variants. It helps researchers prioritize identified variants, determining the most confident ones for experimental validation and facilitating the identification of causal variants based on novelty, effect, and annotation information. The algorithm aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations using accessible databases via ANNOVAR. Users can rank a list of variants, perform genotype filtering for case-control samples, filter large amounts of high-throughput data based on custom filter requirements, apply different models of inheritance, and perform downstream functional enrichment analysis through network visualization. Variant Ranker is freely available.",
        "Variant Ranker is a user-friendly, web-based tool designed to help researchers rank and filter both coding and non-coding genetic variants, prioritizing them for experimental validation based on their functional significance. It allows for the annotation and ranking of variants, aiding in the identification and validation of candidate genes, and is particularly useful for researchers without extensive bioinformatics expertise.",
        "Variant Ranker is a user-friendly, web-based tool designed to facilitate the ranking, filtering, and annotation of both coding and non-coding genetic variants. This tool simplifies the process of variant analysis by providing a straightforward interface for researchers and clinicians to prioritize variants based on their potential functional impact. By integrating various annotation data, Variant Ranker enhances the interpretation of genetic data, making it a valuable resource in the field of genomics for identifying clinically relevant variants.",
        "Variant Ranker is a web-based tool designed for ranking, filtering, and annotating both coding and non-coding genomic variants. It helps researchers prioritize variants based on functional significance, making it easier to identify causal genes for diseases. The tool is user-friendly and allows for efficient computational gene prioritization, reducing the time required for manual analysis. It has demonstrated strong performance in correctly identifying and ranking candidate genes, and it is freely available online.",
        "Variant Ranker is a free and user-friendly web tool designed for ranking, filtering, and annotating both coding and non-coding genomic variants. It features a modular design that enables users to rank lists of variants, perform genotype filtering in case-control studies, and filter high-throughput data using customizable criteria and various inheritance models. The tool aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations through ANNOVAR. It also supports downstream functional analysis, including network visualization and enrichment analysis. Variant Ranker is accessible at http://paschou-lab.mbg.duth.gr/Software.html and is applicable to a wide range of sequencing data, assisting researchers in prioritizing potentially causal variants for experimental validation.",
        "Variant Ranker is a user-friendly, web-based tool designed for ranking, filtering, and annotating both coding and non-coding genetic variants. It helps researchers prioritize identified variants to determine the most promising candidates for experimental validation. The tool facilitates the identification of causal variants by considering novelty, effect, and annotation information. Variant Ranker uses an algorithm that aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations via ANNOVAR. This information is transformed into user-specified weights, which are then encoded into the ranking algorithm. It is freely available and applicable to a wide range of sequencing data, enabling users to prioritize potentially causal variants.",
        "Variant Ranker is a tool designed to enhance the analysis of genetic variants by addressing limitations in traditional variant calling software. It employs a heuristic weighting function integrated into the Rankboost algorithm, which considers both the absolute ranks of variants within genes and the relative rankings between gene pairs from different prioritization methods. This approach provides a more nuanced and interactive prioritization of variants, allowing users to make informed decisions about variant presence without relying solely on internal filters or frequency thresholds. By presenting this information graphically, Variant Ranker facilitates a more comprehensive and user-directed analysis of genetic data, particularly useful in cancer sequencing studies.",
        "Variant Ranker is a user-friendly web-based tool that allows researchers to rank identified variants and determine the most confident variants for experimental validation by aggregating multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations.",
        "Variant Ranker is a web-tool to rank genomic data according to functional significance. It is a web application for intuitive missense variant prioritization.",
        "Variant Ranker is a freely available web server on http://paschou-lab.mbg.duth.gr/Software.html. Variant Ranker allows researchers to rank identified variants and determine the most confident variants for experimental validation. We describe Variant Ranker, a user-friendly simple web-based tool for ranking, filtering and annotation of coding and non-coding variants.",
        "Variant Ranker is a user-friendly, web-based tool that ranks genomic data by functional significance. It prioritizes coding and non-coding variants based on novelty, effect, and annotation information, integrating multiple prediction scores, conservation scores, allelic frequencies, and clinical data via ANNOVAR. Users can customize rankings with specified weights. The tool offers modules for variant ranking, genotype filtering for case-control samples, custom high-throughput data filtering, and downstream functional enrichment analysis via network visualization. Variant Ranker is freely available at http://paschou-lab.mbg.duth.gr/Software.html, aiding researchers in identifying causal variants for experimental validation.",
        "Variant Ranker is a computational tool or algorithm designed to prioritize and rank genetic variants based on their potential impact or relevance to a particular disease or phenotype. It typically integrates various types of data, such as genetic, functional, and clinical information, to assess the significance of each variant. The goal of Variant Ranker is to help researchers and clinicians identify the most likely pathogenic variants from a large set of genetic data, facilitating the diagnosis and understanding of genetic disorders.",
        "Variant Ranker is a user-friendly web-based tool designed for ranking, filtering, and annotating genomic variants. It allows researchers to prioritize potential causal variants based on various criteria such as novelty, effect, and annotation information. The algorithm integrates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations from accessible databases via ANNOVAR. Users can specify weights for different criteria, which are then used to rank the variants. Variant Ranker also provides modules for genotype filtering, filtering high-throughput data based on custom filter requirements, applying different inheritance models, and performing downstream functional enrichment analysis through network visualization. This tool is freely available at http://paschou-lab.mbg.duth.gr/Software.html and is applicable to a wide range of sequencing data.",
        "Variant Ranker is a web-tool that allows researchers to rank and prioritize identified genetic variants according to their functional significance. It helps researchers determine the most confident variants for experimental validation from the large volume and complexity of high-throughput genomic data. Variant Ranker scores and ranks variants annotated by tools like Alamut Batch or SnpEff, and supports the commonly used VCF input format, making it easy to integrate into NGS bioinformatics analysis pipelines.",
        "Variant Ranker is a tool or method used to prioritize genetic variants based on their potential functional impact and relevance to a particular disease or trait. It typically leverages publicly available databases and computational algorithms to assess and rank variants, helping researchers identify those that may be most significant for further study. The process involves evaluating variants in the context of known biological functions, pathways, and disease associations to highlight those that could contribute to the phenotype of interest.",
        "Variant Ranker is a tool that enables researchers to rank identified variants and determine the most confident variants for experimental validation.",
        "Variant Ranker is a web-tool that allows researchers to rank and prioritize identified genomic variants based on their functional significance. It helps researchers with limited bioinformatics skills to analyze and determine the most confident variants for experimental validation from large volumes of high-throughput genomic data.",
        "Variant Ranker is a web-tool that allows researchers to rank and prioritize identified genomic variants according to their functional significance. It helps researchers with limited bioinformatics skills to determine the most confident variants for experimental validation from the increasing volume and complexity of high-throughput genomic data.",
        "Variant Ranker is a user-friendly web-based tool designed to rank, filter, and annotate coding and non-coding genetic variants based on their functional significance, using various prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional annotations.",
        "Variant Ranker is a web-tool that allows researchers to rank and prioritize identified genomic variants according to their functional significance. It helps researchers with limited bioinformatics skills to determine the most confident variants for experimental validation from large volumes of complex high-throughput genomic data. The tool incorporates information about the phenotype of interest and uses algorithms to predict the degree of damage caused by a given sequence alteration.",
        "Variant Ranker is a web-based tool that ranks coding and non-coding genomic variants by their functional significance. It integrates prediction scores, conservation scores, allelic frequencies, clinical data, and ANNOVAR annotations. Users can customize variant rankings with specified weights and apply different inheritance models. The tool features genotype filtering, customizable data filtering, and downstream functional enrichment analysis via network visualization. Available for free at http://paschou-lab.mbg.duth.gr/Software.html, it aids researchers in identifying causal variants for experimental validation, as demonstrated with real and synthetic datasets.",
        "Variant Ranker is a web-tool used for ranking genomic data according to functional significance, aiding researchers in prioritizing variants for experimental validation.",
        "Variant Ranker is a tool that enables researchers to rank identified variants and determine the most confident variants for experimental validation. It allows users to rapidly annotate variants and perform gene-specific variant score ranking on the population level. By utilizing Variant Ranker, researchers can prioritize variants and validate their findings through methods such as Sanger sequencing. For instance, studies have shown that prioritizing variants using Variant Ranker led to the validation of five rare variants in genes HDC and SLITRK1, which were predicted to be deleterious. Overall, Variant Ranker is a useful tool for identifying and validating variants, making it a valuable resource for researchers in the field of genetics and genomics.",
        "Variant Ranker is a web-based tool designed to rank, filter, and annotate both coding and non-coding genetic variants. It enables researchers to prioritize variants by combining multiple prediction scores, conservation metrics, allelic frequencies, clinical data, and open-source annotations integrated using ANNOVAR. The tool supports various functionalities including genotype filtering for case-control studies, filtering large high-throughput datasets based on custom criteria, and applying different models of inheritance. Additionally, Variant Ranker offers downstream functional enrichment analysis through network visualization, which helps identify clusters of genes related by biological pathways, gene ontology, and disease categories. Its user-friendly interface and comprehensive analysis modules make it a valuable resource for identifying potentially causal variants across a wide range of sequencing datasets.",
        "Variant Ranker is a web-based tool designed to rank genomic data by functional significance, allowing users to prioritize variants based on novelty, effect, and annotation information, integrating multiple prediction scores, conservation scores, allelic frequencies, and clinical data, facilitating the identification of causal variants for experimental validation.",
        "Variant Ranker is a user-friendly, web-based tool designed to rank, filter, and annotate coding and non-coding genomic variants by functional significance. It helps researchers prioritize the most confident variants for experimental validation, as demonstrated by its performance in identifying causal genes using real and synthetic datasets. The tool is freely available online and supports gene-specific variant score ranking on the population level.",
        "Variant Ranker is a user-friendly, web-based tool designed for ranking, filtering, and annotating both coding and non-coding variants. It helps researchers prioritize identified variants to determine the most promising candidates for experimental validation. The tool facilitates the identification of causal variants by considering novelty, effect, and annotation information. It uses an algorithm that integrates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations via ANNOVAR. Users can assign weights to available variant information, which are then incorporated into the ranking algorithm. Variant Ranker is freely accessible online and applicable to a wide range of sequencing data, enabling users to prioritize potentially causal variants.",
        "Variant Ranker is a web-based tool designed to rank, filter, and annotate coding and non-coding genetic variants to help identify potentially causal variants by integrating multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations.",
        "Variant Ranker is a user-friendly web-based bioinformatics tool designed to help researchers analyze and prioritize genomic variants. It provides comprehensive variant ranking, filtering, and annotation capabilities for both coding and non-coding genetic variants. The tool integrates multiple prediction algorithms, conservation scores, allelic frequencies, clinical information, and open-source annotations using ANNOVAR to facilitate the identification of potentially causal genetic variants. By aggregating diverse data sources, Variant Ranker helps researchers assess the functional significance and potential clinical relevance of genetic variations.",
        "Variant Ranker is a user-friendly web-based tool designed for ranking, filtering, and annotating both coding and non-coding genomic variants. It helps researchers prioritize variants and identify the most confident ones for experimental validation. The tool facilitates the identification of causal variants based on novelty, effect, and annotation information. Its algorithm aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations using databases via ANNOVAR. Users can assign weights to the available variant information, which are then encoded into the ranking algorithm. Variant Ranker allows users to rank variants, perform genotype filtering for case-control samples, filter high-throughput data based on custom requirements, apply inheritance models, and perform functional enrichment analysis through network visualization. It is freely available.",
        "Variant Ranker is a user-friendly, web-based tool that ranks genomic variants by functional significance. It aggregates data from prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations via ANNOVAR. Key features include variant ranking with customizable weights, genotype and custom filtering with inheritance models, and downstream enrichment analysis via network visualization. Designed to aid in identifying causal variants for experimental validation, Variant Ranker simplifies complex genomic data analysis, making it accessible to researchers with varying levels of bioinformatics expertise, for both coding and non-coding regions.",
        "Variant Ranker is a web tool designed to rank genomic data according to its functional significance.",
        "Variant Ranker is a web-tool to rank genomic data according to functional significance. Variant Ranker facilitates the identification of causal variants based on novelty, effect and annotation information. The algorithm implements and aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information and additional open-source annotations using accessible databases via ANNOVAR. The available information for a variant is transformed into user-specified scores, which are then aggregated and ranked. The tool is available at http://variantranker.bioinf.mpi-inf.mpg.de.",
        "Variant Ranker is a user-friendly web-based tool designed to rank, filter, and annotate genomic data according to its functional significance. It facilitates the identification of causal variants by considering factors such as novelty, effect, and annotation information. The tool aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations from accessible databases via ANNOVAR. By implementing this comprehensive approach, Variant Ranker enables researchers to prioritize variants based on their potential impact, making it a valuable resource for studies aiming to understand the functional significance of genomic variations.",
        "Variant Ranker is a user-friendly web-based tool designed to rank, filter, and annotate both coding and non-coding genomic variants. It helps identify causal variants by considering factors such as novelty, effect, annotation information, prediction scores, conservation scores, allelic frequencies, clinical data, and additional annotations sourced from accessible databases via ANNOVAR.",
        "Variant Ranker is a user-friendly simple web-based tool for ranking, filtering and annotation of coding and non-coding variants. The algorithm implements and aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information and additional open-source annotations using accessible databases via ANNOVAR.",
        "Variant Ranker is a user-friendly web-based tool designed for ranking, filtering, and annotating both coding and non-coding genetic variants. It facilitates the identification of causal variants by considering novelty, effect, and annotation information. The algorithm integrates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations from databases like ANNOVAR. Users can transform available variant information into specified weights, which are then encoded into the ranking algorithm. Through its modules, users can rank a list of variants, perform genotype filtering for case-control samples, filter high-throughput data based on custom requirements and inheritance models, and conduct downstream functional enrichment analysis through network visualization. Variant Ranker is freely available.",
        "Variant Ranker is a user-friendly web-based tool for ranking, filtering, and annotating genomic data based on its functional significance.",
        "Variant Ranker is a user-friendly web-based tool designed for ranking, filtering, and annotating both coding and non-coding variants, which helps in identifying causal variants based on novelty, effect, and annotation information.",
        "Variant Ranker is a user-friendly simple web-based tool for ranking, filtering and annotation of coding and non-coding variants. It facilitates the identification of causal variants based on novelty, effect and annotation information. The algorithm implements and aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information and additional open-source annotations using accessible databases via ANNOVAR.",
        "Variant Ranker is a user-friendly web-based tool designed for the ranking, filtering, and annotation of both coding and non-coding genomic variants. It aids researchers in identifying causal variants by integrating various prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional annotations from accessible databases like ANNOVAR. The tool aggregates data to facilitate the evaluation of variant significance, particularly focusing on novelty and effect. It has been shown that variants scoring above certain thresholds are often enriched for deleterious effects, highlighting its utility in genomic research and clinical settings.",
        "Variant Ranker is a user-friendly, web-based tool designed to rank, filter, and annotate both coding and non-coding genomic variants to identify potential causal variants. It integrates multiple prediction algorithm scores, conservation scores, allelic frequencies, and clinical information, alongside additional open-source annotations accessible via ANNOVAR. By aggregating these diverse data sources, Variant Ranker aids researchers in prioritizing variants based on their functional significance, novelty, and potential impact, thereby streamlining the process of identifying causal genetic variants in genomic studies.",
        "Variant Ranker is a user-friendly web-based tool designed to rank and annotate genomic variants, both coding and non-coding, based on their functional significance. Its primary purpose is to assist researchers in identifying causal variants by evaluating factors such as novelty, effect, and annotation information. The tool aggregates data from multiple sources, including prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations, utilizing ANNOVAR for accessing relevant databases. By integrating these diverse datasets, Variant Ranker facilitates the prioritization of variants that are most likely to contribute to specific traits or diseases, making it a valuable resource in genomic analysis.",
        "Variant Ranker is an online tool designed to assist researchers in analyzing genomic data by ranking genetic variants based on their potential functional significance. This user-friendly platform allows for the ranking, filtering, and annotation of both coding and non-coding variants. Its primary function is to help identify causal variants by evaluating factors such as novelty, effect, and annotation information.\n\nThe tool employs an algorithm that integrates multiple prediction scores, conservation metrics, allelic frequencies, clinical data, and additional annotations sourced from open-access databases via ANNOVAR. This comprehensive approach enables researchers to assess the likelihood of a variant being associated with specific traits or diseases, thereby facilitating more informed analyses in genomic studies.",
        "Variant Ranker is a user-friendly simple web-based tool for ranking, filtering, and annotation of coding and non-coding variants. Variant Ranker allows researchers to rank identified variants and determine the most confident variants for experimental validation.",
        "Variant Ranker is a freely available, user-friendly web-based tool for ranking, filtering, and annotating both coding and non-coding genomic variants. It integrates multiple prediction algorithm scores, conservation metrics, allele frequencies, clinical data, and additional annotations through ANNOVAR, facilitating the identification of potentially causal variants based on novelty, effect, and annotation information. The tool provides functionalities for ranking variant lists to prioritize candidates for experimental validation, performing genotype filtering in case-control samples, and applying custom filters to large sequencing datasets. It also supports analysis using different inheritance models and enables downstream functional enrichment through network visualization. The tool is accessible online at http://paschou-lab.mbg.duth.gr/Software.html, making it applicable to a wide range of sequencing data and a valuable resource for researchers.",
        "Variant Ranker is a user-friendly web-based tool for ranking, filtering, and annotating coding and non-coding variants. It helps identify causal variants based on novelty, effect, and annotation information. The algorithm aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations.",
        "Variant Ranker is a user-friendly, web-based tool for ranking, filtering, and annotating coding and non-coding variants. It identifies causal variants based on novelty, effect, and annotation information. The tool aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations using ANNOVAR.",
        "Variant Ranker is a user-friendly, web-based tool designed for ranking, filtering, and annotating both coding and non-coding genetic variants. It helps researchers identify potentially causal variants by considering factors like novelty, effect, and annotation information. The tool aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and other open-source annotations using databases accessible through ANNOVAR. By transforming variant information into user-specified weights, Variant Ranker facilitates the prioritization of variants and is applicable to a wide range of sequencing data. It is freely available and allows researchers to rank identified variants to determine the most confident ones for experimental validation.",
        "Variant Ranker is a user-friendly web-based tool designed to rank, filter, and annotate both coding and non-coding genomic variants based on their functional significance. It aids in identifying causal variants by integrating multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations through accessible databases via ANNOVAR.",
        "Variant Ranker is a web-based tool designed to rank, filter, and annotate genomic variants, both coding and non-coding, to aid in identifying causal variants. It integrates multiple prediction scores, conservation metrics, allelic frequencies, clinical data, and annotations from accessible databases, utilizing ANNOVAR for data aggregation. This tool is user-friendly and focuses on functional significance to streamline genomic analysis.",
        "Variant Ranker is a user-friendly web-based tool designed for ranking, filtering, and annotating coding and non-coding variants. It facilitates the identification of causal variants by aggregating multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations from accessible databases via ANNOVAR. The tool helps to prioritize variants based on novelty, effect, and annotation information, enabling researchers to focus on the most functionally significant variants.",
        "Variant Ranker is a user-friendly web-based tool designed for the ranking, filtering, and annotation of both coding and non-coding genomic variants. It aids in identifying causal variants by integrating various data points, including prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional annotations from accessible databases like ANNOVAR. The tool facilitates the classification of variants of unknown significance (VUS) and aims to improve the understanding of their clinical implications. By considering phylogenetic contexts and employing a holistic approach, Variant Ranker enhances the accuracy of variant pathogenicity interpretation, which is particularly useful in diagnostic oncology and for genes with low effect variants.",
        "Variant Ranker is a user-friendly web-based tool designed for the ranking, filtering, and annotation of both coding and non-coding genomic variants. It aids researchers in identifying causal variants by leveraging information on novelty, effect, and annotations. The tool aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, and clinical data, utilizing accessible databases through ANNOVAR. Users can rank variants, filter genotypes for case-control samples, and conduct functional enrichment analysis. Variant Ranker has demonstrated excellent performance in identifying candidate genes and is freely available at http://paschou-lab.mbg.duth.gr/Software.html.",
        "Variant Ranker is a web-based tool designed for ranking, filtering, and annotating both coding and non-coding genetic variants. It helps identify causal variants by considering factors such as novelty, effect, and annotation information. The tool aggregates scores from multiple prediction algorithms, conservation scores, allelic frequencies, clinical information, and other annotations using databases accessible via ANNOVAR.",
        "Variant Ranker is a user-friendly, web-based tool that ranks genomic variants by their functional significance, integrating multiple prediction scores, conservation scores, allelic frequencies, clinical information, and annotations, with customizable weights, to facilitate identification of causal variants across various sequencing data types, freely available at http://paschou-lab.mbg.duth.gr/Software.html.",
        "Variant Ranker is a user-friendly web-based tool designed for the ranking, filtering, and annotation of both coding and non-coding genomic variants. It aids researchers in identifying causal variants by leveraging information on novelty, effect, and annotations. The tool aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical data, and additional annotations from accessible databases via ANNOVAR. Users can rank variants, filter genotypes in case-control studies, and analyze large datasets according to custom requirements. Variant Ranker also supports downstream functional enrichment analysis through network visualization, helping to identify gene clusters across various biological categories. This tool is particularly beneficial for researchers with limited bioinformatics expertise, facilitating the prioritization of potentially causal variants in high-throughput genomic data. It is freely available at http://paschou-lab.mbg.duth.gr/Software.html.",
        "Variant Ranker is a web-based tool designed to prioritize and rank genomic variants based on their functional significance. It helps researchers and clinicians identify variants that are most likely to have a meaningful impact on gene function, which can be crucial for understanding genetic contributions to diseases and for guiding further research or clinical decision-making.",
        "Variant Ranker is a user-friendly, web-based tool that ranks genomic variants by functional significance, integrating multiple data sources and allowing user-defined weights. Key features include variant ranking, genotype and custom filtering with inheritance models, and downstream enrichment analysis via network visualization, facilitating the identification of causal variants for experimental validation, especially suited for researchers with limited bioinformatics expertise.",
        "Variant Ranker is a web-based tool for ranking, filtering and annotation of coding and non-coding variants. Variant Ranker facilitates the identification of causal variants based on novelty, effect and annotation information. The algorithm implements and aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information and additional open-source annotations using accessible databases via ANNOVAR.",
        "Variant Ranker is a user-friendly web-based tool. It is used for ranking, filtering, and annotation of coding and non-coding variants. Variant Ranker facilitates the identification of causal variants based on novelty, effect and annotation information.",
        "Variant Ranker is a user-friendly web-based tool designed to rank, filter, and annotate both coding and non-coding genomic variants. It helps researchers identify causal variants by evaluating their novelty, effect, and annotation information. The tool implements and aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional annotations by accessing various databases through ANNOVAR. Variant Ranker\u0027s simple interface makes it accessible for researchers seeking to prioritize potentially significant variants in genomic data analysis.",
        "Variant Ranker is a user-friendly web-based tool designed for ranking, filtering, and annotating genomic variants, both coding and non-coding. It aids in identifying causal variants by considering factors such as novelty, effect, and annotation information. The tool aggregates data from multiple prediction algorithms, conservation scores, allelic frequencies, clinical information, and other open-source annotations accessed through ANNOVAR. This integration of diverse data sources facilitates comprehensive analysis, making it a valuable resource for studies aiming to determine the functional significance of genetic variants.",
        "Variant Ranker is a web-based tool designed to rank, filter, and annotate genomic data according to functional significance. It facilitates the identification of causal variants by aggregating multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations from accessible databases via ANNOVAR. The tool provides a user-friendly interface for ranking and filtering coding and non-coding variants based on novelty, effect, and annotation information.",
        "Variant Ranker is a user-friendly web-based tool that facilitates the identification of causal genomic variants by ranking, filtering, and annotating coding and non-coding variants based on their functional significance. It aggregates and implements multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and additional open-source annotations from accessible databases via ANNOVAR.",
        "Variant Ranker is a user-friendly, web-based tool that integrates multiple genomic data sources (prediction, conservation, allelic frequencies, clinical information, and open-source annotations) to rank variants by functional significance. It offers customizable ranking, genotype and custom filtering, and network visualization for enrichment analysis. Suitable for researchers of all bioinformatics skill levels, Variant Ranker simplifies the identification of causal variants for experimental validation and is freely accessible online, with proven performance in identifying causal genes across various datasets.",
        "Variant Ranker is a user-friendly, web-based tool designed to rank genomic data by functional significance. It efficiently handles both coding and non-coding variants, utilizing multiple prediction algorithms, conservation scores, allelic frequencies, and clinical information via ANNOVAR. This comprehensive approach helps identify causal variants, making it a valuable resource for genomic studies.",
        "Variant Ranker is a web-based tool designed for the ranking, filtering, and annotation of both coding and non-coding genomic variants. It aggregates multiple prediction scores, conservation metrics, allelic frequencies, clinical data, and additional open-source annotations through databases accessed via ANNOVAR. This comprehensive approach allows researchers to systematically prioritize variants based on their potential functional significance and novelty. In addition to ranking, Variant Ranker supports custom filtering of high-throughput sequencing data, genotype filtering for case-control studies, and downstream enrichment analyses through network visualization. Its user-friendly interface makes it an accessible resource for identifying potentially causal variants for further experimental validation.",
        "Variant Ranker is a user-friendly web-based tool designed for ranking, filtering, and annotating both coding and non-coding genomic variants. It facilitates the identification of causal variants by considering novelty, effect, and annotation information. The algorithm aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations using accessible databases via ANNOVAR.",
        "Variant Ranker is a user-friendly web-tool that ranks genomic data by functional significance, utilizing aggregated prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations to facilitate the identification of causal variants in both coding and non-coding regions.",
        "Variant Ranker is a user-friendly simple web-based tool for ranking, filtering and annotation of coding and non-coding variants. Variant Ranker facilitates the identification of causal variants based on novelty, effect and annotation information. The algorithm implements and aggregates multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information and additional open-source annotations using accessible databases via ANNOVAR.",
        "Variant Ranker is a user-friendly web-based tool designed to rank, filter, and annotate coding and non-coding genomic variants based on functional significance. It helps researchers prioritize variants for experimental validation by aggregating multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations via ANNOVAR. Users can assign weights to different information types, which are then encoded into the ranking algorithm. Variant Ranker allows users to rank variants, perform genotype filtering for case-control samples, filter high-throughput data based on custom requirements and inheritance models, and perform downstream functional enrichment analysis through network visualization to identify gene clusters. It is freely available.",
        "Variant Ranker is a user-friendly web-based tool designed to rank, filter, and annotate both coding and non-coding genomic variants to help identify causal variants. It functions by integrating multiple prediction algorithm scores, conservation scores, allelic frequencies, and clinical information from various databases through ANNOVAR, making it an effective tool for assessing functional significance of genomic data.",
        "Variant Ranker is a web-based tool designed to rank, filter, and annotate both coding and non-coding genomic variants. It helps identify causal variants by considering factors such as novelty, effect, annotation information, prediction scores, conservation scores, allelic frequencies, clinical data, and additional annotations sourced from accessible databases via ANNOVAR.",
        "Variant Ranker is a user-friendly web-based tool designed for ranking, filtering, and annotating both coding and non-coding variants. It helps identify causal variants by considering novelty, effect, and annotation information, using multiple prediction algorithm scores, conservation scores, allelic frequencies, clinical information, and open-source annotations via ANNOVAR."
      ]
    },
    {
      "body": "Is creatinine usually elevated in Drug-induced intestinal neuropathy(DAIN)?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25599729",
        "http://www.ncbi.nlm.nih.gov/pubmed/34187299"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 178,
          "text": "Drug-induced acute interstitial nephritis (DAIN) is often associated with improved outcomes, whereas some patients may still progress to chronic kidney disease (CKD). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34187299"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Drug-induced acute interstitial nephritis (DAIN) is a common cause of acute kidney injury and often presents as an unexplained rise in serum creatinine level.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25599729"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Drug-induced acute interstitial nephritis (DAIN) is a common cause of acute kidney injury and often presents as an unexplained rise in serum creatinine level",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25599729"
        }
      ],
      "type": "yesno",
      "id": "67cec6e781b1027333000021",
      "ideal_answer": [
        "Drug-induced acute interstitial nephritis (DAIN) is a common cause of acute kidney injury and often presents as an unexplained rise in serum creatinine level.",
        "No. Drug-induced acute interstitial nephritis (DAIN) is a common cause of acute kidney injury and often presents as an unexplained rise in serum creatinine level.",
        "Yes, in Drug-induced acute interstitial nephritis (DAIN), an unexplained rise in serum creatinine level is commonly observed, which indicates kidney dysfunction. This rise in creatinine is a key marker for the diagnosis of DAIN and reflects the acute kidney injury associated with this condition.",
        "Creatinine levels are not typically elevated in Drug-induced intestinal neuropathy (DAIN). DAIN is a condition that affects the nerves in the intestines, but it does not directly impact kidney function, which is what creatinine levels measure.",
        "No, creatinine is not usually elevated in Drug-induced intestinal neuropathy (DAIN) because DAIN is not a recognized medical condition. However, if referring to Drug-induced Acute Interstitial Nephritis (DAIN), then yes, creatinine is usually elevated, indicating acute kidney injury due to inflammation and damage to the renal tubules and interstitium. The degree of elevation varies with condition severity, but prompt treatment can lead to reversible improvements in renal function and decreased creatinine levels.",
        "The available literature indicates that drug-induced acute interstitial nephritis (DAIN) often presents with an unexplained rise in serum creatinine levels. However, there is no specific mention of creatinine levels being elevated in drug-induced intestinal neuropathy.",
        "Creatinine is not usually elevated in Drug-induced intestinal neuropathy (DAIN).",
        "Is creatinine usually elevated in Drug-induced intestinal neuropathy(DAIN)? \n\nThe answer is no.",
        "No. Drug-induced acute interstitial nephritis (DAIN) is often associated with improved outcomes, whereas some patients may still progress to chronic kidney disease (CKD).",
        "In drug-induced acute interstitial nephritis (DAIN), creatinine levels are typically elevated as a result of kidney inflammation and impaired kidney function. The rise in serum creatinine is often a key diagnostic marker indicating kidney damage and reduced glomerular filtration rate associated with this condition.",
        "Drug-induced acute interstitial nephritis (DAIN) typically results in kidney inflammation and damage, which can lead to impaired kidney function. This impairment often manifests as elevated creatinine levels, a key indicator of reduced kidney function. Therefore, creatinine is usually elevated in patients with DAIN.",
        "In cases of Drug induced Acute Intestinal Nephritis (DAIN), creatinine levels are often elevated due to impaired kidney function resulting from nephritis.",
        "No, because there is no direct relation between creatinine and drug-induced intestinal neuropathy (DAIN).",
        "No, creatinine is not usually elevated in Drug-induced intestinal neuropathy (DAIN), but it is elevated in Drug-induced acute interstitial nephritis (DAIN).",
        "The reference snippet discusses Drug-induced acute interstitial nephritis (DAIN), not intestinal neuropathy. However, it does mention that some patients with DAIN may progress to chronic kidney disease (CKD). This suggests that creatinine *could* be elevated in some cases of DAIN due to kidney involvement.",
        "Drug-induced acute interstitial nephritis (DAIN) is typically associated with kidney dysfunction, which often manifests as elevated serum creatinine levels due to impaired renal function.",
        "Creatinine is not typically elevated in Drug-induced intestinal neuropathy (DAIN).",
        "No, based on the provided information and medical understanding, creatinine is not usually elevated in Drug-induced Intestinal Neuropathy (DAIN), as it is more closely associated with kidney function. The provided answers mistakenly referenced Drug-induced Acute Interstitial Nephritis (DAIN), where elevated creatinine is common, highlighting a kidney issue rather than an intestinal neuropathy.",
        "No, creatinine is not usually elevated in Drug-induced intestinal neuropathy(DAIN).",
        "There is no such thing as \"Drug-induced intestinal neuropathy(DAIN)\". The correct term is \"Drug-induced acute interstitial nephritis (DAIN)\", which affects the kidneys, not the intestines.\n\nIn DAIN, creatinine levels are often elevated due to kidney damage, which can lead to impaired renal function.",
        "No, based on the provided snippet, creatinine elevation is not directly related to Drug-induced Intestinal Neuropathy (DAIN), as creatinine is an indicator of kidney function, not intestinal neuropathy.",
        "Yes, creatinine is usually elevated in Drug-induced acute interstitial nephritis (DAIN).",
        "Drug-induced acute interstitial nephritis (DAIN) typically leads to impaired kidney function, which is often indicated by elevated creatinine levels. This condition can result in improved outcomes with proper management, but some patients may progress to chronic kidney disease.",
        "No. Drug-induced acute interstitial nephritis (DAIN) is often associated with improved outcomes, whereas some patients may still progress to chronic kidney disease (CKD). The provided snippet discusses DAIN, not Drug-induced intestinal neuropathy, and focuses on kidney-related issues, not creatinine levels."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Are systemic beta lactams considered harmful to the human microbiome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38468305",
        "http://www.ncbi.nlm.nih.gov/pubmed/29616809",
        "http://www.ncbi.nlm.nih.gov/pubmed/31909068",
        "http://www.ncbi.nlm.nih.gov/pubmed/27641814",
        "http://www.ncbi.nlm.nih.gov/pubmed/27262694",
        "http://www.ncbi.nlm.nih.gov/pubmed/31979034",
        "http://www.ncbi.nlm.nih.gov/pubmed/31137766",
        "http://www.ncbi.nlm.nih.gov/pubmed/34306841",
        "http://www.ncbi.nlm.nih.gov/pubmed/34482897",
        "http://www.ncbi.nlm.nih.gov/pubmed/30804903",
        "http://www.ncbi.nlm.nih.gov/pubmed/30654495",
        "http://www.ncbi.nlm.nih.gov/pubmed/39109911",
        "http://www.ncbi.nlm.nih.gov/pubmed/35411114",
        "http://www.ncbi.nlm.nih.gov/pubmed/39218634",
        "http://www.ncbi.nlm.nih.gov/pubmed/25970622"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1625,
          "offsetInEndSection": 1917,
          "text": "antibiotics perturb many components of the microbiota, which return close to the baseline state within 30 days. These data suggest an important role of endogenous β-lactamase-producing anaerobes in protecting the functions of the microbiota by de-activating the antibiotics reaching the colon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38468305"
        },
        {
          "offsetInBeginSection": 1204,
          "offsetInEndSection": 1333,
          "text": "Amoxicillin has previously been shown to have minimal long-term impact on human microbiota composition in clinical trial studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29616809"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 192,
          "text": "The use of β-lactam antibiotics is one of the microbiome covariates that influence its composition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27641814"
        },
        {
          "offsetInBeginSection": 390,
          "offsetInEndSection": 673,
          "text": "A better understanding of the kinetics of beta-lactam antibiotics in the gastro-intestinal tract is essential to study their role in the development of antibiotic resistance in bacteria and to help develop future therapies to prevent damage to, or restore, the intestinal microbiome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482897"
        },
        {
          "offsetInBeginSection": 1527,
          "offsetInEndSection": 1744,
          "text": "Whole genome shotgun metagenomics analyses of the fecal microbiomes demonstrated both amoxicillin and amoxicillin/clavulanate significantly reduced diversity and increased the frequency of antibiotic resistance genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31979034"
        },
        {
          "offsetInBeginSection": 1399,
          "offsetInEndSection": 1558,
          "text": "Microbiome analyses demonstrated that amoxicillin significantly reduced bacteria richness and microbiome diversity resulting in altered microbiome composition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31909068"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Antibiotics can damage the gut microbiome leading to opportunistic infections and the emergence of antibiotic resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30654495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Antibiotics can damage the gut microbiome, leading to serious adventitious infections and emergence of antibiotic resistant pathogens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30804903"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Antibiotic therapy alters bacterial abundance and metabolism in the gut microbiome, leading to dysbiosis and opportunistic infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39109911"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Antibiotic-induced alterations in the gut microbiota are implicated in many metabolic and inflammatory diseases, increase the risk of secondary infections and contribute to the emergence of antimicrobial resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35411114"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 221,
          "text": "However, commensal gut microbiota is extremely sensitive to antibiotics and excessive usage can cause microbial dysbiosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39218634"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 495,
          "text": "A novel approach to protect the microbiome from antibiotic-mediated dysbiosis is the use of beta-lactamase enzymes to degrade residual antibiotics in the gastrointestinal tract before the microflora are harmed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27262694"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 544,
          "text": "Proof of concept for this approach was achieved with an orally-administered beta-lactamase enzyme, SYN-004 (ribaxamase), that was demonstrated to degrade ceftriaxone excreted into the GI tract and protect the gut microbiome from antibiotic-mediated dysbiosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30654495"
        },
        {
          "offsetInBeginSection": 2119,
          "offsetInEndSection": 2336,
          "text": "These data demonstrate that SYN-007 diminishes amoxicillin-mediated microbiome disruption and mitigates emergence and propagation of antibiotic resistance genes without interfering with antibiotic systemic absorption.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31137766"
        },
        {
          "offsetInBeginSection": 787,
          "offsetInEndSection": 1032,
          "text": " Both α and β diversity analyses showed that ceftriaxone sodium, cefoperazone/sulbactam, meropenem and vancomycin changed the gut microbiota dramatically by the second day of antibiotic administration whereas the influence of ofloxacin was trivi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25970622"
        },
        {
          "offsetInBeginSection": 2150,
          "offsetInEndSection": 2294,
          "text": "SYN-007 has the potential to expand microbiome protection to beta-lactam/beta-lactamase inhibitor combinations delivered orally or systemically.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31979034"
        },
        {
          "offsetInBeginSection": 1866,
          "offsetInEndSection": 2132,
          "text": "The potential to employ low SYN-007 doses to protect the gut microbiota has important implications for enhancing therapeutic outcomes for patients receiving oral beta-lactam antibiotics while simultaneously reducing cost per dose and ultimately, healthcare expenses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31909068"
        },
        {
          "offsetInBeginSection": 670,
          "offsetInEndSection": 897,
          "text": "To expand this microbiome protection strategy to include all classes of beta-lactams, three distinct carbapenemases were evaluated for manufacturability, antibiotic degradation spectrum, and stability in human intestinal fluid.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30654495"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 153,
          "text": "Broad-spectrum antibiotics disrupt the human microbiome resulting in a greater risk of harmful, long-term conditions that impact human health.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34306841"
        }
      ],
      "id": "67d721d118b1e36f2e000031",
      "ideal_answer": [
        "Yes, systemic beta-lactams are considered harmful to the human microbiome. Antibiotics, including beta-lactams, can damage the gut microbiome, leading to dysbiosis, opportunistic infections, and the emergence of antibiotic resistance. They can disrupt the complex ecosystem of the gut, altering bacterial abundance and metabolism. This can result in an overgrowth of pathogenic organisms and promote selection for antibiotic-resistant microorganisms."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What is the most common EGFR mutation in glioblastoma multiforme?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33283409",
        "http://www.ncbi.nlm.nih.gov/pubmed/25691693",
        "http://www.ncbi.nlm.nih.gov/pubmed/14583498",
        "http://www.ncbi.nlm.nih.gov/pubmed/21514294",
        "http://www.ncbi.nlm.nih.gov/pubmed/28583430",
        "http://www.ncbi.nlm.nih.gov/pubmed/19324552",
        "http://www.ncbi.nlm.nih.gov/pubmed/15193025",
        "http://www.ncbi.nlm.nih.gov/pubmed/26455392",
        "http://www.ncbi.nlm.nih.gov/pubmed/34608482",
        "http://www.ncbi.nlm.nih.gov/pubmed/18542056",
        "http://www.ncbi.nlm.nih.gov/pubmed/20650261",
        "http://www.ncbi.nlm.nih.gov/pubmed/23617883",
        "http://www.ncbi.nlm.nih.gov/pubmed/32782566",
        "http://www.ncbi.nlm.nih.gov/pubmed/35309946",
        "http://www.ncbi.nlm.nih.gov/pubmed/38892466",
        "http://www.ncbi.nlm.nih.gov/pubmed/15746047",
        "http://www.ncbi.nlm.nih.gov/pubmed/22797070",
        "https://pubmed.ncbi.nlm.nih.gov/18542056/",
        "https://pubmed.ncbi.nlm.nih.gov/19324552/",
        "https://pubmed.ncbi.nlm.nih.gov/27317648/",
        "https://pubmed.ncbi.nlm.nih.gov/14583498/",
        "http://www.ncbi.nlm.nih.gov/pubmed/24603483",
        "http://www.ncbi.nlm.nih.gov/pubmed/24362532",
        "http://www.ncbi.nlm.nih.gov/pubmed/27317648",
        "http://www.ncbi.nlm.nih.gov/pubmed/36551529",
        "http://www.ncbi.nlm.nih.gov/pubmed/29563997",
        "http://www.ncbi.nlm.nih.gov/pubmed/19773446",
        "http://www.ncbi.nlm.nih.gov/pubmed/34608482/",
        "http://www.ncbi.nlm.nih.gov/pubmed/25688333",
        "http://www.ncbi.nlm.nih.gov/pubmed/31919324",
        "http://www.ncbi.nlm.nih.gov/pubmed/29660021",
        "http://www.ncbi.nlm.nih.gov/pubmed/19276385",
        "http://www.ncbi.nlm.nih.gov/pubmed/20657384"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 329,
          "text": "The epidermal growth factor receptor variant type III (EGFRvIII) is the most common mutation of EGFR in glioblastoma multiforme (GBM) and is found in approximately 25% of all GBMs. Intriguingly, EGFRvIII is mostly found in GFAP+ astrocytic tumour cells in the brain, suggesting connection of EGFRvIII to astrogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33283409"
        },
        {
          "offsetInBeginSection": 496,
          "offsetInEndSection": 645,
          "text": "In this study we determined whether EGFR amplification and expression of the most common mutation in GBMs (EGFRvIII) is retained at tumor recurrence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25691693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "Glioblastoma multiforme (GBM) frequently involves amplification and alteration of the epidermal growth factor receptor (EGFR) gene, resulting in overexpression of varied mutations, including the most common mutation, EGFRvIII, as well as wild-type EGFR (EGFRwt).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14583498"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 419,
          "text": "Furthermore, gene amplification is often associated with mutation of EGFR, and the constitutive activated deletion variant EGFRvIII is the most common EGFR mutation found in GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514294"
        },
        {
          "offsetInBeginSection": 177,
          "offsetInEndSection": 358,
          "text": "The epidermal growth factor receptor variant III (EGFRvIII) is the most common EGFR mutation that occurs in up to 30% of high-grade gliomas especially glioblastoma multiforme (GBM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583430"
        },
        {
          "offsetInBeginSection": 305,
          "offsetInEndSection": 517,
          "text": "The most common EGFR variant in GBM, the EGFRvIII, is characterised by a deletion of 267 amino acids in the extracellular domain, leading to a receptor which is unable to bind ligand yet is constitutively active.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19324552"
        },
        {
          "offsetInBeginSection": 536,
          "offsetInEndSection": 669,
          "text": "The most common EGFR mutation, EGFRvIII, sensitizes GBM cells to the BET-bromodomain inhibitor JQ1 in a SOX9, FOXG1-dependent manner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26455392"
        },
        {
          "offsetInBeginSection": 166,
          "offsetInEndSection": 342,
          "text": "EGFRvIII is an oncogenic EGFR mutant resulting from the deletion of exons 2-7 and is the most common EGFR mutant observed in glioblastoma multiforme, an aggressive brain tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18542056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "PURPOSE: The epidermal growth factor receptor (EGFR) is overexpressed in approximately 50% to 60% of glioblastoma multiforme tumors, and the most common EGFR mutant, EGFRvIII, is expressed in 24% to 67% of cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15746047"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Epidermal growth factor receptor variant III (EGFRvIII) is the most common active EGFR mutant in glioblastoma multiforme (GBM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32782566"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 191,
          "text": " The epidermal growth factor receptor variant type III (EGFRvIII) is the most common mutation of EGFR in glioblastoma multiforme (GBM) and is found in approximately 25% of all GBMs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33283409"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Epidermal growth factor receptor variant III (EGFRvIII), the most common EGFR mutation, is associated with cell migration of glioblastoma multiforme (GBM) cases;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20650261"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 195,
          "text": "The most common variant is EGFR variant III (EGFRvIII).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22797070"
        },
        {
          "offsetInBeginSection": 180,
          "offsetInEndSection": 418,
          "text": "However, GBM frequently becomes resistant to TMZ treatment due to various mechanisms including amplification and mutations of the epidermal growth factor receptor (EGFR), where EGFR variant III (EGFRvIII) is the most common EGFR mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35309946"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "Epidermal growth factor receptor variant III (EGFRvIII), the most common EGFR mutation, is associated with cell migration of glioblastoma multiforme (GBM) cases; however, the mechanism has not been elucidated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20650261"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "OBJECTIVES: The epidermal growth factor receptor variant type III (EGFRvIII) is the most common mutation of EGFR in glioblastoma multiforme (GBM) and is found in approximately 25% of all GBMs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33283409"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 238,
          "text": "EGFRvIII, the most common EGFR mutant, is expressed in 24-67% of cases and strongly indicates a poor survival prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/27317648/"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 217,
          "text": "Epidermal growth factor receptor variant III (EGFRvIII) is the most common and highly oncogenic EGFR mutant in GBM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603483"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Epidermal growth factor receptor (EGFR)vIII is the most common EGFR mutant found in glioblastoma (GBM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24362532"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 238,
          "text": "EGFRvIII, the most common EGFR mutant, is expressed in 24-67% of cases and strongly indicates a poor survival prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317648"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 294,
          "text": "Variant III of the epidermal growth factor receptor (EGFRvIII) is one of the most common types of variants in GBM, and serves an important role in tumour invasion, proliferation and treatment resistance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29563997"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 360,
          "text": "Amplification of the epidermal growth factor receptor (EGFR) and deletion of exons 2 to 7, which generates EGFR variant III (vIII), are the most common molecular alterations of GBMs that contribute to the aggressiveness of the disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36551529"
        },
        {
          "offsetInBeginSection": 675,
          "offsetInEndSection": 823,
          "text": "The most frequent EGFR mutation in GBM involves deletion of exons 2 to 7, resulting in the expression of a constitutively active receptor, EGFRvIII.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276385"
        },
        {
          "offsetInBeginSection": 413,
          "offsetInEndSection": 595,
          "text": "The most common mutant form of HER1/EGFR, named variant III (EGFRvIII), results from an 801 bp in-frame deletion in the DNA sequence encoding the extracellular ligand-binding domain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657384"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 211,
          "text": " The epidermal growth factor receptor (EGFR) is overexpressed in approximately 50% to 60% of glioblastoma multiforme tumors, and the most common EGFR mutant, EGFRvIII, is expressed in 24% to 67% of cases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15746047"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 160,
          "text": "EGFR is among the genes most frequently altered in glioblastoma, with exons 2-7 deletions (EGFRvIII) being among its most common genomic mutations. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34608482"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with few effective treatments. EGFR alterations, including expression of the truncated variant EGFRvIII, are among the most frequent genomic changes in these tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38892466"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 483,
          "text": "The most common gain-of-function alteration in GBM is amplification, overexpression, and mutations of the epidermal growth factor receptor (EGFR). The constitutively activated mutant EGFR variant III (EGFRvIII), found in approximately 20% of GBM, confers proliferative and invasive advantage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19773446"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 183,
          "text": "Epidermal growth factor receptor (EGFR) variant III (vIII) is the most common oncogenic rearrangement in glioblastoma (GBM), generated by deletion of exons 2 to 7 of EGFR.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29660021"
        }
      ],
      "id": "67da0c0f18b1e36f2e000052",
      "ideal_answer": [
        "The epidermal growth factor receptor variant type III (EGFRvIII) is the most common mutation of EGFR in glioblastoma multiforme (GBM) and is found in approximately 25% of all GBMs. Intriguingly, EGFRvIII is mostly found in GFAP+ astrocytic tumour cells in the brain, suggesting connection of EGFRvIII to astrogenesis.",
        "The most common EGFR mutation in glioblastoma multiforme (GBM) is the Epidermal Growth Factor Receptor variant type III (EGFRvIII) mutation, found in approximately 25% of all GBMs. This mutation leads to constitutive EGFR signaling activation, promoting astrogenesis, enhancing cell proliferation, and tumor growth, while also remodeling the GBM enhancer landscape through SOX9 and FOXG1-dependent networks.",
        "The most common EGFR mutation in glioblastoma multiforme (GBM) is EGFRvIII, occurring in approximately 25-30% of cases. This mutation, characterized by the deletion of exons 2-7, results in a constitutively active receptor incapable of ligand binding. EGFRvIII promotes cell proliferation, is associated with poor prognosis, and confers resistance to EGFR inhibitors, highlighting the need for alternative therapies. Targeting EGFRvIII through immunotherapy, including specific monoclonal antibodies and vaccines, shows promise for developing effective treatment options for GBM.",
        "The most common EGFR mutation in glioblastoma multiforme is the epidermal growth factor receptor variant type III (EGFRvIII). This mutation is found in approximately 25% of all glioblastoma multiforme cases. EGFRvIII is characterized by a deletion of exons 2-7, resulting in a constitutively active receptor that is incapable of binding any known ligand. This mutation promotes astrogenesis, leading to an abundance of astrocytes in the brain. Additionally, EGFRvIII promotes cell proliferation and is associated with poor prognosis. The presence of this mutation makes tumors resistant to EGFR inhibitors, highlighting the need for alternative therapeutic strategies. Immunotherapy targeting EGFRvIII has shown promise, with the development of specific monoclonal antibodies and vaccines. Understanding the role of EGFRvIII in glioblastoma multiforme is crucial for developing effective treatment options.",
        "The most common EGFR mutation in glioblastoma multiforme (GBM) is EGFRvIII, occurring in approximately 25-30% of cases. This mutation, characterized by the deletion of exons 2-7, leads to a constitutively active receptor, promoting cell proliferation and tumor growth, while conferring resistance to EGFR inhibitors and associating with poor prognosis. Immunotherapy, including specific monoclonal antibodies and vaccines, shows promise for developing effective treatment options for GBM patients with EGFRvIII.",
        "The most common EGFR mutation in glioblastoma multiforme (GBM) is the epidermal growth factor receptor variant III, also known as EGFRvIII. This mutation involves a deletion of 267 amino acids in the extracellular domain of the receptor, leading to a constitutively active receptor that does not require ligand binding for activation. EGFRvIII is found in a significant percentage of GBM cases, with studies reporting its presence in approximately 20-30% of these tumors. This mutation plays a crucial role in tumor invasion, proliferation, treatment resistance, and overall aggressiveness of GBM.",
        "The most common EGFR mutation in glioblastoma multiforme (GBM) is EGFRvIII, also known as the deletion mutant. This mutation occurs in approximately 25% of GBM cases and is characterized by a constitutively active receptor that promotes uncontrolled cell growth. It is predominantly found in astrocytic tumor cells, suggesting a link to astrogenesis. EGFRvIII\u0027s prevalence makes it a significant target for therapeutic interventions aimed at improving patient outcomes.",
        "The most common EGFR mutation in glioblastoma multiforme (GBM) is EGFRvIII, also known as exon 7-8 deletion or DeltaEGFR. This mutation occurs in approximately 25% of GBMs and is predominantly found in astrocytic tumor cells. EGFRvIII leads to a constitutively active receptor, promoting uncontrolled cell growth and playing a significant role in disease progression and recurrence."
      ],
      "exact_answer": [
        [
          "EGFRvIII",
          "Epidermal growth factor receptor variant type III",
          "EGFRvIII mutation",
          "EGFR variant III",
          "egfrviii",
          "EGFR type III",
          "EGFR variant type III (EGFRvIII)",
          "epidermal growth factor receptor variant type III (EGFRvIII)",
          "EGFR variant III (vIII)",
          "EGFR variant type III"
        ]
      ]
    },
    {
      "body": "Which cardiovascular events are associated with ALOX12 gene polymorphisms?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29196930"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 2834,
          "offsetInEndSection": 3167,
          "text": " ALOX12 rs14309 GG genotype expression was found to be significantly associated with MI, higher cIMT, increased CV events, CV, and overall mortality. This phenomenon could be partially explained by the increased platelet proaggregatory activity of AA products and the control they exert in thrombotic occurrence and plaque formation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29196930"
        }
      ],
      "id": "67d486e118b1e36f2e000015",
      "ideal_answer": [
        "ALOX12 rs14309 GG genotype expression was found to be significantly associated with MI, higher cIMT, increased CV events, CV, and overall mortality.",
        "The ALOX12 rs14309 GG genotype has been significantly associated with myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular (CV) events, CV mortality, and overall mortality.",
        "Polymorphisms in the ALOX12 gene are associated with several cardiovascular events. These include subclinical atherosclerosis, where polymorphisms are linked to coronary calcified plaque in families with type 2 diabetes. Additionally, the rs14309 GG genotype of the ALOX12 gene is significantly associated with higher carotid intima-media thickness, increased incidence of myocardial infarction, and elevated risks of all-cause mortality, cardiovascular mortality, and cardiovascular events in diabetic nephropathy patients. Furthermore, the R261Q polymorphism in the ALOX12 gene is associated with essential hypertension and higher urinary levels of 12(S)-HETE, indicating a role for this gene in cardiovascular disease.",
        "The ALOX12 rs14309 GG genotype expression is significantly associated with myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular (CV) events, CV, and overall mortality. Patients with the GG genotype have a significantly higher risk of all-cause mortality, a threefold increase in CV mortality, and a twofold increased risk for CV events. Polymorphisms within ALOX12 are genetically associated with subclinical atherosclerosis and with biomarkers of disease in families with type 2 diabetes.",
        "ALOX12 gene polymorphisms are associated with cardiovascular events such as myocardial infarction (MI), cardiovascular (CV) mortality, and overall CV events, as well as with subclinical atherosclerosis and essential hypertension. The presence of the GG genotype in the ALOX12 rs14309 polymorphism, in particular, is linked to a higher risk of these cardiovascular outcomes.",
        "The cardiovascular events associated with ALOX12 gene polymorphisms include myocardial infarction (MI), cardiovascular (CV) mortality, and overall cardiovascular events.",
        "Polymorphisms within the ALOX12 gene are associated with various cardiovascular events, including myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular (CV) events, and overall mortality. These genetic variations play a significant role in inflammation and oxidation processes, contributing to the development of subclinical atherosclerosis and other cardiovascular diseases, particularly in families with type 2 diabetes. The ALOX12 rs14309 GG genotype expression has been specifically linked to these adverse cardiovascular outcomes. Additionally, genetic polymorphisms in ALOX12 and other inflammation-related genes interact, further influencing cardiovascular risk.",
        "ALOX12 gene polymorphisms are associated with increased cardiovascular mortality, cardiovascular events, myocardial infarction (MI), and higher carotid intima-media thickness (cIMT).",
        "Based on the provided context, the cardiovascular events associated with ALOX12 gene polymorphisms include:\n\n1. Atherosclerosis\n2. Hypertension\n3. Myocardial infarction\n4. Cerebral infarction\n5. Cardiovascular disease\n6. Ischemic heart disease\n7. Acute coronary syndrome\n\nALOX12 plays a crucial role in inflammation and oxidation, and its polymorphisms have been associated with various human diseases and pathological phenotypes, including cardiovascular disease, diabetes, neurodegenerative diseases, respiratory system disease, cancer, infection, etc.",
        "The ALOX12 gene polymorphisms, particularly the GG genotype compared to AA or AG genotypes, are associated with an increased cardiovascular risk profile. Carriers of the GG genotype show a higher risk of myocardial infarction and greater carotid intima-media thickness—a marker of subclinical atherosclerosis. Moreover, these individuals experience a significantly elevated rate of cardiovascular events, including a threefold increase in cardiovascular mortality and a twofold increase in overall cardiovascular events, along with higher all-cause mortality.",
        "The cardiovascular events associated with ALOX12 gene polymorphisms include myocardial infarction (MI), ischemic stroke (IS), and increased carotid intima-media thickness (cIMT). Specific polymorphisms such as rs14309 and rs261R/Q have been linked to these events, indicating a role of ALOX12 in cardiovascular disease risk.",
        "The cardiovascular events associated with ALOX12 gene polymorphisms include myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular (CV) events, and overall mortality.",
        "The cardiovascular events associated with ALOX12 gene polymorphisms include all-cause mortality, cardiovascular (CV) mortality, cardiovascular events, myocardial infarction (MI), and increased carotid intima-media thickness (cIMT).",
        "The ALOX12 gene polymorphisms are associated with an increased risk of cardiovascular events such as myocardial infarction, coronary artery disease, and ischemic stroke, particularly in certain populations like Chinese Han and males.",
        "ALOX12 gene polymorphisms, specifically the GG genotype of rs14309, are associated with increased risks of Myocardial Infarction, higher Carotid Intima-Media Thickness, and broader Cardiovascular Events, including elevated Cardiovascular and All-Cause Mortality, particularly in patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy. These polymorphisms may contribute to cardiovascular disease through atherosclerosis and are linked to essential hypertension, though direct associations with ischemic stroke and peripheral artery disease are less clear.",
        "ALOX12 gene polymorphisms, specifically the GG genotype of rs14309, are associated with increased risk of myocardial infarction (MI), higher carotid intima-media thickness (cIMT), and increased cardiovascular (CV) events, as well as CV and overall mortality. Polymorphisms within ALOX12, ALOX5, and ALOX5AP are genetically associated with subclinical atherosclerosis and with biomarkers of disease in families with type 2 diabetes. Variations in ALOX12 have also been linked to coronary calcification progression.",
        "ALOX12 rs14309 GG genotype expression was found to be significantly associated with MI, higher cIMT, increased CV events, CV, and overall mortality. This phenomenon could be partially explained by the increased platelet proaggregatory activity of AA products and the control they exert in thrombotic occurrence and plaque formation.",
        "The ALOX12 rs14309 GG genotype was found to be significantly associated with multiple cardiovascular events, including myocardial infarction (MI), increased carotid intima-media thickness (cIMT), cardiovascular events, cardiovascular mortality, and overall mortality. These associations appear to be related to the gene\u0027s impact on platelet proaggregatory activity and thrombotic processes.",
        "The ALOX12 gene polymorphisms, particularly the rs14309 GG genotype, are associated with several cardiovascular outcomes. These include myocardial infarction (MI), which refers to heart attacks; higher carotid intima media thickness (cIMT), indicating atherosclerosis risk; and increased cardiovascular events such as strokes. Additionally, these polymorphisms are linked to higher cardiovascular mortality rates and overall mortality, highlighting their role in both acute cardiovascular events and long term outcomes.",
        "The ALOX12 rs14309 GG genotype expression is significantly associated with myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular (CV) events, CV mortality, and overall mortality. Patients with the GG genotype have a significantly higher risk of all-cause mortality, a threefold increase in CV mortality, and a twofold increased risk for CV events compared to patients with the AA or the AG genotype. Polymorphisms within ALOX12 are genetically associated with subclinical atherosclerosis and with biomarkers of disease in families with type 2 diabetes.",
        "Myocardial Infarction, Carotid Intima-Media Thickness, Cardiovascular Events, Cardiovascular Mortality",
        "The cardiovascular events associated with ALOX12 gene polymorphisms include myocardial infarction (MI), increased carotid intima-media thickness (cIMT), cardiovascular (CV) events, cardiovascular mortality, and overall mortality.",
        "The ALOX12 gene polymorphism, specifically the rs14309 GG genotype, is significantly associated with cardiovascular (CV) events such as myocardial infarction (MI) and increased carotid intima-media thickness (cIMT). This polymorphism also correlates with higher overall CV mortality. The increased risk can be attributed to heightened platelet proaggregatory activity of arachidonic acid (AA) products, which contribute to thrombotic occurrences and plaque formation, thereby exacerbating CV risk.",
        "Cardiovascular events associated with ALOX12 gene polymorphisms include myocardial infarction, cardiovascular mortality, all-cause mortality, CV mortality, CV events, increased cIMT, atherosclerosis, and cardiovascular events.",
        "ALOX12 gene polymorphisms, especially the rs14309 GG genotype, have been associated with a spectrum of adverse cardiovascular outcomes. These include a higher risk of myocardial infarction, increased carotid intima-media thickness (with values exceeding 0.86 mm indicative of subclinical atherosclerosis), and markedly elevated rates of cardiovascular events. The GG genotype has been linked to up to a threefold increase in cardiovascular mortality and a twofold increase in overall cardiovascular events compared to AA and AG genotypes. These associations appear to be mediated, in part, by increased platelet proaggregatory activity that may contribute to adverse plaque formation and thrombotic occurrences.",
        "ALOX12 gene polymorphisms are associated with increased risk of Myocardial Infarction (MI), higher carotid Intima-Media Thickness (cIMT), increased Cardiovascular (CV) events, CV mortality, and overall mortality.",
        "ALOX12 gene polymorphisms, particularly the rs14309 GG genotype, are associated with increased cardiovascular (CV) events, CV mortality, overall mortality, myocardial infarction (MI), and increased carotid intima-media thickness (cIMT). Patients with the GG genotype have a higher risk of all-cause mortality, a threefold increase in CV mortality, and a twofold increased risk for CV events compared to patients with the AA or AG genotype. This may be due to increased platelet proaggregatory activity and a role in thrombosis and plaque formation. However, some studies suggest common variation in ALOX12 is not associated with MI or ischemic stroke.",
        "ALOX12 gene polymorphisms, specifically the ALOX12 rs14309 GG genotype, are associated with myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular (CV) events, CV, and overall mortality.",
        "The ALOX12 rs14309 GG genotype is significantly associated with myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular (CV) events, and overall mortality. This association may be partly due to the enhanced platelet proaggregatory activity of AA products linked to this genotype, which influences thrombotic occurrence and plaque formation.",
        "The ALOX12 rs14309 GG genotype is significantly associated with myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular (CV) events, CV mortality, and overall mortality. These associations may be linked to the genotype\u0027s influence on platelet proaggregatory activity and its role in thrombotic events and plaque formation.",
        "ALOX12 gene polymorphisms, specifically the rs14309 GG genotype, are associated with increased risk of myocardial infarction (MI), cardiovascular events, and overall mortality. Additionally, they are linked to higher carotid intima-media thickness (cIMT) and thrombotic occurrence, which can contribute to plaque formation.",
        "The cardiovascular events influenced by ALOX12 gene polymorphisms include myocardial infarction (MI), increased carotid intima-media thickness (cIMT), cardiovascular (CV) events, CV mortality, and overall mortality.",
        "ALOX12 gene polymorphisms are associated with myocardial infarction, higher carotid intima-media thickness, increased cardiovascular events, and both cardiovascular and overall mortality.",
        "The ALOX12 gene polymorphisms, particularly the rs14309 GG genotype, have been significantly associated with various cardiovascular events. These include myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular events, cardiovascular mortality, and overall mortality. The underlying mechanism may involve increased platelet proaggregatory activity due to arachidonic acid (AA) products, which play a role in thrombotic occurrence and plaque formation.",
        "ALOX12 gene polymorphisms, specifically the GG genotype of rs14309, are primarily associated with an increased risk of Myocardial Infarction (MI). There is also evidence to suggest these polymorphisms contribute to increased Carotid Intima-Media Thickness (cIMT) \u003e 0.86 mm, indicative of atherosclerosis, and potentially carotid plaque formation and atheromatosis. While Stroke and Peripheral Artery Disease are implied as part of overall increased Cardiovascular (CV) events, the direct association with these conditions is less clear, particularly for stroke, based on the provided information.",
        "The ALOX12 gene polymorphism rs14309 GG genotype is associated with several cardiovascular events, including Myocardial Infarction (MI), increased carotid intima media thickness (cIMT) indicative of arterial wall thickening and atherosclerosis progression, and other cardiovascular events. Additionally, it correlates with higher rates of overall cardiovascular morbidity and mortality.",
        "ALOX12 rs14309 GG genotype expression is significantly associated with MI, higher cIMT, and increased CV events. It is also associated with CV and overall mortality. This may be due to increased platelet proaggregatory activity and its role in thrombotic occurrence and plaque formation.",
        "Studies have shown that the GG genotype of the rs14309 polymorphism in the ALOX12 gene is significantly associated with an increased risk of myocardial infarction (MI), elevated carotid intima-media thickness (cIMT), and a higher incidence of cardiovascular events, which contribute to overall mortality.",
        "The ALOX12 gene polymorphism rs14309 GG genotype is associated with increased risk of myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular events, cardiovascular mortality, and overall mortality.",
        "Evidence indicates that ALOX12 gene polymorphisms are associated with markers of subclinical atherosclerosis, including coronary calcified plaque formation, as well as increased carotid intima-media thickness. In one study, the ALOX12 rs14309 GG genotype was specifically linked to myocardial infarction, a greater burden of cardiovascular calcified plaque, and a higher risk of subsequent cardiovascular events and overall mortality.",
        "The ALOX12 gene polymorphisms (rs14309 GG genotype) are associated with Myocardial Infarction (MI), increased cardiovascular (CV) events, and potentially other events leading to higher overall mortality, likely due to enhanced thrombotic tendencies.",
        "ALOX12 rs14309 GG genotype expression is associated with MI, higher cIMT, increased CV events, CV, and overall mortality.",
        "ALOX12 gene polymorphisms, specifically the GG genotype of rs14309, are associated with an increased risk of myocardial infarction (MI), higher carotid intima-media thickness (cIMT), increased cardiovascular (CV) events, and overall mortality. Studies have shown that the GG genotype is a predictor of all-cause mortality, CV mortality, and CV events. Furthermore, polymorphisms within ALOX12 are genetically associated with subclinical atherosclerosis and with biomarkers of disease in families with type 2 diabetes. However, other studies suggest that common variation in ALOX12 is not associated with risks of MI and ischemic stroke.",
        "The ALOX12 rs14309 GG genotype is significantly linked to several cardiovascular complications, including myocardial infarction (MI), increased carotid intima-media thickness (cIMT), and elevated cardiovascular events and mortality, with these associations potentially attributed to enhanced platelet aggregation activity and thrombotic processes.",
        "The ALOX12 rs14309 GG genotype is significantly associated with several cardiovascular events, including myocardial infarction (MI), increased carotid intima-media thickness (cIMT), and elevated cardiovascular (CV) events. Additionally, this genotype may influence overall mortality through mechanisms involving platelet aggregation and thrombotic processes."
      ],
      "exact_answer": [
        [
          "MI",
          "myocardial infarction",
          "Myocardial Infarction"
        ],
        [
          "Higher cIMT",
          "Carotid intima-media thickness (cIMT)",
          "increased cIMT"
        ],
        [
          "Increased CV events",
          "cardiovascular events (CV events)"
        ],
        [
          "CV"
        ],
        [
          "Overall mortality"
        ]
      ]
    },
    {
      "body": "What is DRESS in the context of drug therapy?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38214543",
        "http://www.ncbi.nlm.nih.gov/pubmed/38801453",
        "http://www.ncbi.nlm.nih.gov/pubmed/29199808",
        "http://www.ncbi.nlm.nih.gov/pubmed/27310545",
        "http://www.ncbi.nlm.nih.gov/pubmed/28138822",
        "http://www.ncbi.nlm.nih.gov/pubmed/37424979",
        "http://www.ncbi.nlm.nih.gov/pubmed/33469620",
        "http://www.ncbi.nlm.nih.gov/pubmed/23954978",
        "http://www.ncbi.nlm.nih.gov/pubmed/37654627",
        "http://www.ncbi.nlm.nih.gov/pubmed/29519170",
        "http://www.ncbi.nlm.nih.gov/pubmed/27522939",
        "http://www.ncbi.nlm.nih.gov/pubmed/23602183",
        "http://www.ncbi.nlm.nih.gov/pubmed/30830064",
        "http://www.ncbi.nlm.nih.gov/pubmed/22966234",
        "http://www.ncbi.nlm.nih.gov/pubmed/20110143",
        "http://www.ncbi.nlm.nih.gov/pubmed/39680690",
        "http://www.ncbi.nlm.nih.gov/pubmed/39677191",
        "http://www.ncbi.nlm.nih.gov/pubmed/39473560",
        "http://www.ncbi.nlm.nih.gov/pubmed/39421102",
        "http://www.ncbi.nlm.nih.gov/pubmed/35625735",
        "http://www.ncbi.nlm.nih.gov/pubmed/26354734",
        "http://www.ncbi.nlm.nih.gov/pubmed/39714228",
        "http://www.ncbi.nlm.nih.gov/pubmed/23602182",
        "http://www.ncbi.nlm.nih.gov/pubmed/23424909",
        "http://www.ncbi.nlm.nih.gov/pubmed/23062470",
        "http://www.ncbi.nlm.nih.gov/pubmed/33341203",
        "http://www.ncbi.nlm.nih.gov/pubmed/39156598",
        "http://www.ncbi.nlm.nih.gov/pubmed/36651019",
        "http://www.ncbi.nlm.nih.gov/pubmed/39104635",
        "http://www.ncbi.nlm.nih.gov/pubmed/36893848",
        "http://www.ncbi.nlm.nih.gov/pubmed/34266818",
        "http://www.ncbi.nlm.nih.gov/pubmed/30706827",
        "http://www.ncbi.nlm.nih.gov/pubmed/31662996",
        "http://www.ncbi.nlm.nih.gov/pubmed/39325061",
        "http://www.ncbi.nlm.nih.gov/pubmed/39521708",
        "http://www.ncbi.nlm.nih.gov/pubmed/21143513",
        "http://www.ncbi.nlm.nih.gov/pubmed/38811445",
        "http://www.ncbi.nlm.nih.gov/pubmed/29255708",
        "http://www.ncbi.nlm.nih.gov/pubmed/29527023",
        "http://www.ncbi.nlm.nih.gov/pubmed/23691411",
        "http://www.ncbi.nlm.nih.gov/pubmed/32576056",
        "http://www.ncbi.nlm.nih.gov/pubmed/25360193",
        "http://www.ncbi.nlm.nih.gov/pubmed/28748902",
        "http://www.ncbi.nlm.nih.gov/pubmed/26210912",
        "http://www.ncbi.nlm.nih.gov/pubmed/30156263",
        "http://www.ncbi.nlm.nih.gov/pubmed/10544509",
        "https://pubmed.ncbi.nlm.nih.gov/19733945/",
        "https://pubmed.ncbi.nlm.nih.gov/18853032/",
        "https://pubmed.ncbi.nlm.nih.gov/33334758/",
        "http://www.ncbi.nlm.nih.gov/pubmed/39774365",
        "http://www.ncbi.nlm.nih.gov/pubmed/36874721",
        "http://www.ncbi.nlm.nih.gov/pubmed/37516359",
        "http://www.ncbi.nlm.nih.gov/pubmed/30877266",
        "http://www.ncbi.nlm.nih.gov/pubmed/30148271",
        "http://www.ncbi.nlm.nih.gov/pubmed/34255957",
        "http://www.ncbi.nlm.nih.gov/pubmed/30652265",
        "http://www.ncbi.nlm.nih.gov/pubmed/33629602",
        "http://www.ncbi.nlm.nih.gov/pubmed/34873548",
        "http://www.ncbi.nlm.nih.gov/pubmed/23774556",
        "http://www.ncbi.nlm.nih.gov/pubmed/35338896",
        "http://www.ncbi.nlm.nih.gov/pubmed/26370105",
        "http://www.ncbi.nlm.nih.gov/pubmed/27250614",
        "http://www.ncbi.nlm.nih.gov/pubmed/26985439",
        "http://www.ncbi.nlm.nih.gov/pubmed/21074653",
        "http://www.ncbi.nlm.nih.gov/pubmed/19665822",
        "http://www.ncbi.nlm.nih.gov/pubmed/31423638",
        "http://www.ncbi.nlm.nih.gov/pubmed/32208345",
        "http://www.ncbi.nlm.nih.gov/pubmed/21176761",
        "http://www.ncbi.nlm.nih.gov/pubmed/38770090",
        "http://www.ncbi.nlm.nih.gov/pubmed/19122478",
        "http://www.ncbi.nlm.nih.gov/pubmed/23456403",
        "http://www.ncbi.nlm.nih.gov/pubmed/26271788",
        "http://www.ncbi.nlm.nih.gov/pubmed/23866082",
        "http://www.ncbi.nlm.nih.gov/pubmed/35338821",
        "http://www.ncbi.nlm.nih.gov/pubmed/36479739",
        "http://www.ncbi.nlm.nih.gov/pubmed/32247873",
        "http://www.ncbi.nlm.nih.gov/pubmed/24329105",
        "http://www.ncbi.nlm.nih.gov/pubmed/39071852",
        "http://www.ncbi.nlm.nih.gov/pubmed/36691013",
        "http://www.ncbi.nlm.nih.gov/pubmed/36425806",
        "http://www.ncbi.nlm.nih.gov/pubmed/26534757",
        "http://www.ncbi.nlm.nih.gov/pubmed/38337109",
        "http://www.ncbi.nlm.nih.gov/pubmed/38773824",
        "http://www.ncbi.nlm.nih.gov/pubmed/32358426",
        "http://www.ncbi.nlm.nih.gov/pubmed/26597350"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare and severe adverse drug reaction involving multiple organs. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38214543"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "We present a case of lamotrigine-triggered DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome with acute kidney injury stage 3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38801453"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "DRESS (drug reaction with eosinophilia and systemic symptoms) is a rare, severe multiorgan  adverse drug reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29199808"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "How to identify DRESS, drug reaction with eosinophilia and systemic symptoms?",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29199808"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27310545"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28138822"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Death Due to Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37424979"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is an idiosyncratic drug reaction following a characteristic long latency period.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33469620"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Anti-tubercular therapy causing Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33469620"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a serious and potentially fatal adverse effect to therapeutic medications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29519170"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "BACKGROUND: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is a rare syndrome triggered by an immunological reaction to certain drugs and which may be life-threatening as a result of the onset of severe organ ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27522939"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "The appropriate management of the drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is paramount because it is associated with significant morbidity and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23602183"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe reaction to drugs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30830064"
        },
        {
          "offsetInBeginSection": 27,
          "offsetInEndSection": 252,
          "text": "Eosinophilia has not been highlighted in clozapine-induced adverse inflammatory events, as it is often asymptomatic and self-limiting, while drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome occurs rarely",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39680690"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) is a rare and potentially life-threatening condition",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39677191"
        },
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 255,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a potentially life-threatening, drug-induced adverse reaction characterized by skin eruptions, lymphadenopathy, fever, and a broad range of other bodily manifestations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39473560"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "The drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe cutaneous adverse reaction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39421102"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DReSS), also known as drug-induced hypersensitivity syndrome (DiHS), is a severe, systemic, T cell mediated drug reaction with combinations of cutaneous, hematologic, and internal organ involvement.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625735"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625735"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) in children.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30830064"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare and severe adverse dr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354734"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS): clinicopathological study of 45 cases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354734"
        },
        {
          "offsetInBeginSection": 1139,
          "offsetInEndSection": 1375,
          "text": "Eslicarbazepine, cenobamate, and lacosamide can cause Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome and other allergic manifestations, so they should be used with caution in people with allergies in medical history.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39714228"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 71,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33341203"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "The syndrome termed \u0027Drug Reaction with Eosinophilia and Systemic Symptoms\u0027 (DRESS) is an unpredictable, life-threatening condition associated with adverse reactions to therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23062470"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, also referred to as drug-induced hypersensitivity syndrome, is a distinct, potentially life-threatening adverse reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23602182"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), also known as hypersensitivity syndrome (HSS), is a severe and potentially life-threatening drug reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23954978"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "DRESS (drug reaction with Eosinophilia and systemic symptoms) is a syndrome classically considered as a severe cutaneous drug adverse reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424909"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous drug adverse reaction characterized by various cutaneous and systemic manifestations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36651019"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse reaction characterised by fever, lymphadenopathy, morbilliform rash, haematologic abnormalities, and multiorgan involvement.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39104635"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 279,
          "text": " Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening drug reaction; recognizing the diversity of its clinical presentations, implicated drugs, and management modalities can aid in diagnosis and reduce morbidity and mortality",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36893848"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening adverse drug reaction with a mortality rate of 10%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34266818"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 511,
          "text": " Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a severe, potentially life-threatening drug-induced hypersensitivity reaction, characterized by cutaneous eruptions, fever, diffuse lymphadenopathy, along with eosinophilia, and elevated liver function tests",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30706827"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 226,
          "text": " The syndrome of drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, yet potentially fatal hypersensitivity reaction, most commonly associated with anticonvulsants, sulfonamides, and allopurinol",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31662996"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 484,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a serious and potentially fatal adverse effect to therapeutic medications. The incidence of this condition varies among different ethnicities because of the difference in the genetic makeup. Though fever, rash and eosinophilia are essential features for the diagnosis of this syndrome, these vary from patient to patient along with the involvement of various organs such as liver, kidney, lungs, pancreas, etc.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29519170"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DiHS), is a severe type of cutaneous adverse reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39156598"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, adverse drug reaction that is notoriously complex in both its presentation and treatment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39325061"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "Drug-induced hypersensitivity syndrome, also known as DRESS syndrome, is a serious and potentially fatal reaction that occurs in response to prolonged use (generally between 14 and 60 days) of certain drugs,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39521708"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 187,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) describes a severe medication-induced adverse reaction, which has cutaneous, haematological and solid-organ features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21143513"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is an illness which is difficult to diagnose because of its various symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38811445"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Drug rash with eosinophilia and systemic symptoms syndrome (DRESS) is a potentially life-threatening, drug-induced, multi-organ system reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37654627"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome, is a severe type of cutaneous drug-induced eruption.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255708"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is also known as drug induced hypersensitivity syndrome and by various other names.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29527023"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare but potentially life-threatening syndrome characterized by skin rash, fever, lymph node enlargement, and involvement of internal organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23691411"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 298,
          "text": "INTRODUCTION: The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe, multiorganic, and potentially life-threatening drug-induced hypersensitivity reaction, linked to several common drugs, including antiepileptics, antibiotics, and several psychotropic drugs, includ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32576056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Drug-induced hypersensitivity or Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) is a severe adverse drug-induced reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25360193"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) or drug-induced hypersensitivity is a severe adverse drug-induced reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28748902"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "INTRODUCTION: DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome is a severe adverse drug-ind",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26210912"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "INTRODUCTION: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe drug-induced reaction associated with eosinophilia and systemic m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30156263"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is characterized by fever, skin rash, hematological abnormalities, and systemic involvement such as hepatitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966234"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 67,
          "text": "Drug rash with eosinophilia and systemic symptoms (DRESS syndrome).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10544509"
        },
        {
          "offsetInBeginSection": 791,
          "offsetInEndSection": 1042,
          "text": "This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/19733945/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "CONTEXT: DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms) is a type of drug reaction commonly mistaken for a viral i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/18853032/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a life-threatening condition characterised by peripheral eosinophilia, rash and multi-organ failure arising several weeks after exposure to the culprit medication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/33334758/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 283,
          "text": "PURPOSE: DRESS (drug reaction with eosinophilia and systemic symptoms) is an idiosyncratic entity associated with the use of drugs. Its pathophysiology is not known, but is associated with immunological or genetic factors. The incidence is 0.4 cases per 1,000,000 general population.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21359537"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is an adverse reaction to medications such as sulfonamide-containing antibiotics, anticonvulsants, vancomycin, and non-steroidal anti-inflammatory drugs (NSAIDs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36874721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "Drug-induced hypersensitivity syndrome (DiHS), also known as drug reaction with eosinophilia and systemic symptoms (DRESS), is a severe cutaneous adverse reaction (SCAR) characterized by an exanthem, fever, and hematologic and visceral organ involvement.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37516359"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "BACKGROUND Drug reaction with eosinophilia and systemic symptoms (DRESS) is an idiosyncratic life-threatening reaction comprised of fevers, rash, and leukocytosis with eosinophilia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30877266"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "BACKGROUND: The drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a life-threatening condition caused by different ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30148271"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "INTRODUCTION: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially fatal condition caused by drug exposure resulting in hypersensitivity reaction with involvement of different ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34255957"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DReSS), also known as drug-induced hypersensitivity syndrome (DiHS), is an uncommon severe adverse reaction to medications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652265"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a constellation of symptoms that manifest as a result of certain medications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33629602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is an idiosyncratic severe cutaneous adverse reaction (SCAR) characterized by a skin rash with systemic involvement (e.g., hematological, solid organ abnormalities).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34873548"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "DRESS syndrome: an interaction between drugs, latent viruses, and the immune system.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39521708"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome is a severe systemic drug reaction characterized by a latent period of several weeks following the initiation of drug therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39774365"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "Drug-induced hypersensitivity syndrome, also known as DRESS syndrome, is a serious and potentially fatal reaction that occurs in response to prolonged use (generally between 14 and 60 days) of certain drugs, and which has no predilection for gender or age group.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39521708"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "INTRODUCTION: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe drug reaction associated with potentially severe morbidity ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35338896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "DRESS (drug rash with eosinophilia and systemic symptoms) syndrome is a severe reaction triggered by drugs that manifests as pyrexia and eosinophilia with involvement of the skin and internal organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23774556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms) is severe drug-induced allergic-type reaction which occurs few days to weeks after taking a drug in a predisposed patient.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27250614"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe cutaneous drug reaction characterized by fever, lymphadenopathy, hematologic abnormalities, multisystem involvement, and viral reactivation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33341203"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 309,
          "text": "Drug reaction with eosinophilia and systemic symptom (DRESS) is a severe adverse drug-induced reaction with a prolonged latency period which is characterized by a variety of clinical manifestations, usually fever, rash, lymphadenopathy, eosinophilia, and a wide range of mild-to-severe systemic presentations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26985439"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "OBJECTIVE: The management of drug-induced hypersensitivity syndrome or drug reaction with eosinophilia and systemic symptoms (DRESS) is not",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21074653"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare serious adverse effect associated with a variety of medications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19665822"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 182,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is an idiosyncratic life-threatening reaction comprised of fevers, rash, and leukocytosis with eosinophilia. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30877266"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "BACKGROUND: Pediatric Drug reaction with eosinophilia and systemic symptoms (DRESS) is an uncommon disease that can be difficult t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 346,
          "text": "We report here on a young woman with multiple sclerosis, who developed a condition with eosinophilia and swelling of limbs seven weeks after initiation of ocrelizumab treatment. We consider her drug reaction to be compatible with a drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32208345"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "AIM: Study the epidemiological, clinical, biological and chronological drug rash with eosinophilia and systemic symptoms (DRESS) characteristic and indicate the implicated d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21176761"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome is a severe adverse drug reaction with significant mortality, characterized by erythroderma, fever, lymphadenopathy, and visceral involvement.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20110143"
        },
        {
          "offsetInBeginSection": 220,
          "offsetInEndSection": 498,
          "text": "action (ADR). Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a severe, potentially life-threatening drug-induced hypersensitivity reaction, characterized by cutaneous eruptions, fever, diffuse lymphadenopathy, along with eosinophilia, and elevated liver f",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30706827"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse reaction which exhibits a diverse range of presentations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38770090"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "Drug rash with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous drug reaction with a long duration of eruption and serious organ involvement.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19122478"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "PURPOSE: A probable case of drug reaction with eosinophilia and systemic symptoms (DRESS) associated with consecutive use of three medications for seizure control is ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456403"
        },
        {
          "offsetInBeginSection": 1195,
          "offsetInEndSection": 1410,
          "text": "ity was arranged. The use of the adverse reaction probability scale of Naranjo et al. in this case yielded a score of 8, indicating a probable relationship between DRESS and the serial use of phenytoin, divalproex, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456403"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) [also called drug-induced hypersensitivity syndrome (DIHS)] includes severe reactions to drugs that need to be promptly recognized by",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26271788"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 298,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS), is a rare, severe cutaneous adverse reaction characterised by fever, rash, lymphadenopathy, eosinophilia and/or other leukocyte abnormalities, and internal organ involvement ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23866082"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 316,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) is an adverse reaction to medications such as sulfonamide-containing antibiotics, anticonvulsants, vancomycin, and non-steroidal anti-inflammatory drugs (NSAIDs). It typically presents with a characteristic rash, eosinophilia, and visceral organ failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36874721"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome, is a potentially life-threatening rare reaction that causes a severe rash and can lead to multiorgan failure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35338821"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 235,
          "text": " DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is a rare syndrome triggered by an immunological reaction to certain drugs and which may be life-threatening as a result of the onset of severe organ involvement",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27522939"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36479739"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "INTRODUCTION: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, severe and potentially fatal cutaneous adverse drug reaction (the mortality rate is up to 10 %) associated with numerous and apparently hetero",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26370105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening drug reaction; recognizing the diversity of its clinical presentations, implicated drugs, and management modalities can aid in diagnosis and reduce morbidity an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36893848"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a drug-induced hypersensitivity reaction that can have fatal co",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32247873"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse dr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24329105"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS) is a life-threatening, multi-organ adverse drug reaction with a mortality rate of approximately 10 %-20 %.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39071852"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as Drug-induced hypersensitivity syndrome (DiHS), is a severe adverse dr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36691013"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 314,
          "text": "Background: Drug-induced hypersensitivity syndrome (DIHS), also called drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is a potentially fatal drug-induced hypersensitivity reaction that is characterized by a cutaneous eruption, multiorgan involvement, viral reactivation, and hematologic ab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36425806"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a potentially life-threatening adverse dr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26534757"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 372,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS), is a rare, severe cutaneous adverse reaction characterised by fever, rash, lymphadenopathy, eosinophilia and/or other leukocyte abnormalities, and internal organ involvement and often has a relapsing-remitting course despite withdrawal of the drug.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23866082"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS), is a severe drug-induced hypersensitivity reaction with 10% mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38337109"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe and potentially life-threatening hypersensitivity reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38773824"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is an uncommon yet serious adverse cutaneous drug reaction that results from a hypersensitivity reaction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32358426"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare, life-threatening hypersensitivity dr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26597350"
        }
      ],
      "type": "factoid",
      "id": "67cc9bef81b1027333000013",
      "ideal_answer": [
        "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare and potentially life-threatening hypersensitivity reaction.",
        "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a life-threatening, multi-organ adverse drug reaction with an incidence of 1 in 1000 to 1 in 10 000 high-risk drug exposures.",
        "DRESS stands for Drug Reaction with Eosinophilia and Systemic Symptoms.",
        "DRESS stands for Drug Reaction with Eosinophilia and Systemic Symptoms, a severe and potentially life-threatening adverse drug reaction.",
        "DRESS syndrome, also known as Drug Reaction with Eosinophilia and Systemic Symptoms, is a severe drug-induced skin condition characterized by fever, rash, lymphadenopathy, eosinophilia, and organ involvement.",
        "DRESS stands for \"Drug Reaction with Eosinophilia and Systemic Symptoms\".",
        "DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is a rare and potentially life-threatening hypersensitivity reaction that can occur after the administration of various drugs. It is characterized by the triad of cutaneous manifestations, systemic symptoms, and eosinophilia.",
        "Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare and severe adverse drug reaction involving multiple organs.",
        "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a rare, severe adverse drug reaction that affects multiple organs. It can be triggered by medications such as lamotrigine and may lead to complications like acute kidney injury.",
        "DRESS stands for Drug Reaction with Eosinophilia and Systemic Symptoms, a severe adverse drug reaction characterized by the involvement of multiple organ systems, elevated eosinophils in the blood, and various systemic symptoms such as fever and rash.",
        "DRESS refers to Drug Reaction with Eosinophilia and Systemic Symptoms, a severe adverse drug reaction characterized by multi-organ involvement and eosinophilia.",
        "DRESS, in the context of drug therapy, stands for Drug Reaction with Eosinophilia and Systemic Symptoms. It is a rare and severe adverse drug reaction involving multiple organs.",
        "DRESS stands for \"Drug Reaction with Eosinophilia and Systemic Symptoms,\" which is a rare and severe adverse drug reaction involving multiple organs.",
        "DRESS stands for Drug Reaction with Eosinophilia and Systemic Symptoms. It is a rare and severe adverse drug reaction involving multiple organs, as seen in the case of lamotrigine-triggered DRESS with acute kidney injury.",
        "DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is a rare and severe adverse drug reaction involving multiple organs, characterized by fever, rash, lymphadenopathy, eosinophilia, and organ dysfunction. It is often triggered by certain medications, such as lamotrigine in the case presented.",
        "DRESS, or Drug Reaction with Eosinophilia and Systemic Symptoms, is a rare and severe adverse drug reaction that involves multiple organs.",
        "DRESS stands for \"Drug Reaction with Eosinophilia and Systemic Symptoms,\" which is a rare and potentially life-threatening hypersensitivity reaction associated with drug therapy.",
        " Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a rare and severe adverse drug reaction involving multiple organs. It can be triggered by certain medications, such as lamotrigine, and can cause symptoms such as fever, rash, liver dysfunction, kidney injury, and other systemic manifestations.",
        "In the context of drug therapy, DRESS stands for Drug Reaction with Eosinophilia and Systemic Symptoms syndrome. It is a rare and severe adverse drug reaction that involves multiple organs.",
        "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)",
        "DRESS stands for Drug Reaction with Eosinophilia and Systemic Symptoms, a rare and severe adverse drug reaction involving multiple organs, potentially triggered by specific medications like lamotrigine.",
        "DRESS, in the context of drug therapy, stands for Drug Reaction with Eosinophilia and Systemic Symptoms, which is a rare and severe adverse drug reaction involving multiple organs."
      ],
      "exact_answer": [
        [
          "Drug reaction with eosinophilia and systemic symptoms"
        ]
      ]
    },
    {
      "body": "Adverse effects of statins.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38399268",
        "http://www.ncbi.nlm.nih.gov/pubmed/35955495",
        "http://www.ncbi.nlm.nih.gov/pubmed/19534648",
        "http://www.ncbi.nlm.nih.gov/pubmed/28576976",
        "http://www.ncbi.nlm.nih.gov/pubmed/12036392",
        "http://www.ncbi.nlm.nih.gov/pubmed/12077562",
        "http://www.ncbi.nlm.nih.gov/pubmed/18092417",
        "http://www.ncbi.nlm.nih.gov/pubmed/21886735",
        "https://pubmed.ncbi.nlm.nih.gov/35955495/",
        "https://pubmed.ncbi.nlm.nih.gov/19159124/",
        "http://www.ncbi.nlm.nih.gov/pubmed/11599653"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 485,
          "offsetInEndSection": 639,
          "text": "development of type 2 diabetes mellitus, muscular symptoms, liver toxicity, kidney diseases, cataracts, hemorrhagic strokes, and psychiatric complications",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38399268"
        },
        {
          "offsetInBeginSection": 393,
          "offsetInEndSection": 640,
          "text": "However, the usage of statins can be accompanied by a range of adverse effects, such as the development of type 2 diabetes mellitus, muscular symptoms, liver toxicity, kidney diseases, cataracts, hemorrhagic strokes, and psychiatric complications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38399268"
        },
        {
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1327,
          "text": "Myopathy is the most frequent side effect of statins and in some cases may have a form of severe rhabdomyolysis. Less common adverse effects include hepatotoxicity, peripheral neuropathy, impaired myocardial contractility and autoimmune diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19534648"
        },
        {
          "offsetInBeginSection": 1194,
          "offsetInEndSection": 1327,
          "text": "Less common adverse effects include hepatotoxicity, peripheral neuropathy, impaired myocardial contractility and autoimmune diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19534648"
        },
        {
          "offsetInBeginSection": 313,
          "offsetInEndSection": 445,
          "text": "Statins also have a number of well described adverse effects, including myopathy, rhabdomyolysis, liver damage, and type 2 diabetes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28576976"
        },
        {
          "offsetInBeginSection": 543,
          "offsetInEndSection": 733,
          "text": "Complications chiefly concern the hepatic function, skeletal muscles and peripheral nerves. The major adverse effect is myopathy, up to rhabdomyolysis with ensuing acute renal insufficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12077562"
        },
        {
          "offsetInBeginSection": 4,
          "offsetInEndSection": 628,
          "text": "Statins are cholesterol-lowering drugs extensively used in cardiovascular prevention. Their most well-known adverse effect is muscle damage, including rhabdomyolysis. (2) Several cases of peripheral polyneuropathy attributed to a statin have been published or reported by pharmacovigilance centres. (3) They included sensory or sensorimotor polyneuropathy with signs of sensory impairment, and a decrease or sometimes a suppression of osteotendinous reflexes. Some patients also had a marked reduction in muscle strength in the affected limb(s). Renal failure and diabetes appear to increase the risk of this adverse effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18092417"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 356,
          "text": "Statins are known to have a number of cutaneous adverse effects including the induction of autoimmune diseases like systemic and subacute lupus erythematosus, dermatomyositis, polymyositis, lichen planus pemphigoides and the drug reaction with eosinophilia and systemic symptoms (DRESS). Statins have been also reported as a triggering factor of psoriasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21886735"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 368,
          "text": "As a group, these drugs are well tolerated apart from two uncommon but potentially serious adverse effects: elevation of liver enzymes and skeletal muscle abnormalities, which range from benign myalgias to life-threatening rhabdomyolysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12036392"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 405,
          "text": "Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more rarely, rhabdomyolysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/35955495/"
        },
        {
          "offsetInBeginSection": 1434,
          "offsetInEndSection": 1634,
          "text": "Evidence from RCTs and studies of other designs indicates existence of additional statin-associated AEs, such as cognitive loss, neuropathy, pancreatic and hepatic dysfunction, and sexual dysfunction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/19159124/"
        },
        {
          "offsetInBeginSection": 172,
          "offsetInEndSection": 327,
          "text": "Besides common adverse drug effects, such as nausea, abdominal discomfort and headaches, all statins harbour the risk of myopathy and fatal rhabdomyolysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11599653"
        },
        {
          "offsetInBeginSection": 369,
          "offsetInEndSection": 541,
          "text": "Adverse effects with statins are frequently associated with drug interactions because of their long-term use in older patients who are likely to be exposed to polypharmacy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12036392"
        },
        {
          "offsetInBeginSection": 270,
          "offsetInEndSection": 525,
          "text": "Muscle-related adverse events include cramps, myalgia, weakness, immune-mediated necrotizing myopathy and, more rarely, rhabdomyolysis. Moreover, they may lead to peripheral neuropathy and induce or unmask a preexisting neuromuscular junction dysfunction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35955495"
        }
      ],
      "id": "67d430f918b1e36f2e00000f",
      "ideal_answer": [
        "The use of statins can have adverse effects in a wide range of systems and cause development of type 2 diabetes mellitus, muscular symptoms, liver toxicity, kidney diseases, cataracts, hemorrhagic strokes, and psychiatric disease.",
        "The most common adverse effects of statins include myopathy (muscle weakness, pain, and elevated creatine kinase levels), rhabdomyolysis (severe muscle breakdown), liver enzyme elevations, and an increased risk of developing type 2 diabetes. Less common side effects include peripheral neuropathy, cognitive impairment, autoimmune disorders, and cataracts. However, the benefits of statins in reducing cardiovascular events generally outweigh the risks of these adverse effects.",
        "Statins have common adverse effects including myopathy (muscle pain to rhabdomyolysis), reversible liver enzyme elevation, and a slightly increased risk of Type 2 Diabetes Mellitus, particularly in those with metabolic syndrome. Less common effects include drug-induced liver injury, peripheral neuropathy, and impaired myocardial contractility. Notably, the elderly are at higher risk. Most effects are reversible upon discontinuation. Despite these risks, the cardiovascular benefits of statins outweigh the non-cardiovascular harms, with no proven links to cancer or cognitive decline, and possible benefits in dementia prevention.",
        "Statins are a class of drugs commonly used to lower cholesterol levels in the blood, which can help prevent cardiovascular diseases. However, they can have several adverse effects. Common side effects include muscle pain, fatigue, and digestive problems such as nausea, diarrhea, or constipation. Some individuals may experience more serious side effects, such as liver damage, which can be monitored through liver function tests. Statins can also increase blood sugar levels, potentially leading to type 2 diabetes in some patients. Rarely, statins can cause a severe muscle condition called rhabdomyolysis, which can lead to kidney damage. Other potential side effects include memory loss or confusion, although these are less common. It\u0027s important for patients to discuss any side effects with their healthcare provider to weigh the benefits and risks of continuing statin therapy.",
        "Statin therapy, while generally safe and effective for managing cholesterol levels, is associated with several adverse effects. The most common side effect is myalgia, which occurs in 1-10% of patients. Statins can also cause myopathy, a more serious condition characterized by muscle damage. Additionally, long-term use has been linked to adverse renal effects, cognitive loss, neuropathy, pancreatic and hepatic dysfunction, and sexual dysfunction. Statins are also known to increase the risk of diabetes mellitus and can elevate hepatic transaminase levels, indicating potential liver dysfunction. These side effects highlight the need for careful monitoring and management when prescribing statins.",
        "Statins are widely used medications to lower LDL cholesterol levels, but they can cause several adverse effects:\n\n1. **Muscular Side Effects**: The most common side effects include myalgia (muscle pain), muscle weakness, and rarely, rhabdomyolysis (severe muscle breakdown). These effects are dose-dependent and may occur more frequently with higher doses.\n\n2. **Liver Injury**: Statins can cause mild elevations in liver enzymes, though severe liver injury is rare.\n\n3. **Sexual Dysfunction**: Some patients report loss of libido, erectile dysfunction, or testicular pain, which often resolve upon discontinuation of statins.\n\n4. **Gastrointestinal Issues**: Nausea, diarrhea, and abdominal discomfort are less common but can occur.\n\n5. **Neurocognitive Symptoms**: Rarely, statins may be associated with memory loss or confusion, though this is typically reversible.\n\n6. **Other Effects**: Statins may also cause fatigue, headache, and, in rare cases, allergic reactions or skin rashes.\n\nWhile many side effects are mild and transient, patients should inform their healthcare provider if they experience unusual symptoms. In most cases, discontinuing statins leads to resolution of adverse effects.",
        "Statins, widely used for lowering cholesterol, have a range of adverse effects. Common adverse effects include muscle pain (myalgia), headache, abdominal pain, asthenia, nausea, liver enzyme abnormalities, nasopharyngitis, upper respiratory tract infection, arthralgia, diarrhea, back pain, influenza, pain in extremity, and fatigue. Serious adverse effects involve rhabdomyolysis with myoglobinuria, which can lead to acute renal failure, and myopathy, including myositis. Postmarketing reports have noted arthralgia, hepatic failure, hepatitis, jaundice, thrombocytopenia, depression, sleep disorders, peripheral neuropathy, interstitial lung disease, gynecomastia, and cognitive impairment. Additional findings from literature highlight rare but significant risks such as myopathy and rhabdomyolysis, asymptomatic elevation in hepatic transaminase levels, low risk of serious liver injury, proteinuria and hematuria at higher doses of rosuvastatin, new onset of type 2 diabetes, statin-associated muscle symptoms (SAMS) and myotoxicity, rare neurocognitive effects, mitochondrial dysfunction, epigenetic modifications, and a very rare cancer risk. While statins are generally safe and effective, the incidence and severity of these effects can vary based on the specific statin used, dosage, and presence of drug interactions.",
        "The adverse effects of statins, known as Statin-Associated Symptoms (SAS), are multifaceted and rare in clinical trials, yet potentially impactful. They include: Development of Type 2 Diabetes Mellitus, Muscular Symptoms (e.g., muscle pain, weakness, rare rhabdomyolysis), Liver Toxicity (mostly elevated liver enzymes), Kidney Diseases, Cataracts, Hemorrhagic Strokes, and Psychiatric Complications. These effects, though uncommon, may necessitate dose adjustments or therapy discontinuation, highlighting the need for cautious prescribing and monitoring across various body systems (metabolic, musculoskeletal, hepatic, renal, ocular, cerebrovascular, and neuropsychiatric).",
        "Statins are a class of drugs commonly prescribed to lower cholesterol levels and reduce the risk of cardiovascular diseases. While they offer significant benefits, they also come with potential adverse effects that should be carefully considered:\n\n1. **Type 2 Diabetes Mellitus**: There is a slight increase in the risk of developing type 2 diabetes among statin users, though this risk is generally small compared to the protective effects on cardiovascular health.\n\n2. **Muscular Symptoms**: Statins can cause muscle-related side effects such as myalgia (muscle pain) and myopathy (inflammation of the muscles). Rarely, they may lead to rhabdomyolysis, a severe condition involving rapid breakdown of muscle tissue.\n\n3. **Liver Toxicity**: Elevated liver enzymes have been reported in some patients, though serious liver damage is rare and reversible upon discontinuation of the medication.\n\n4. **Kidney Diseases**: While statins themselves are not directly linked to kidney disease, individuals with impaired renal function may require dosage adjustments due to the role of kidneys in metabolizing some statins.\n\n5. **Cataracts**: Some studies suggest a possible association between statin use and an increased risk of cataracts, though more research is needed to establish causality.\n\n6. **Hemorrhagic Strokes**: Statins reduce the risk of ischemic strokes but have been debated regarding their potential to increase hemorrhagic stroke risk. Overall, benefits in preventing strokes outweigh the risks.\n\n7. **Psychiatric Complications**: Some patients report mood changes or cognitive issues, though it remains unclear if these are directly caused by statins or due to other factors.\n\nIn conclusion, while statins are generally safe and effective, their use should be tailored to individual patient needs with regular monitoring for side effects. Lifestyle factors such as diet and exercise also play a crucial role in managing cholesterol levels and overall health. Personalized medicine, considering the type of statin and individual variability in response, is essential for optimizing treatment outcomes.",
        "Statins are commonly prescribed medications to lower cholesterol levels and reduce the risk of cardiovascular diseases. However, they can cause several adverse effects, including:\n\n1. **Type 2 Diabetes Mellitus**: Statins may increase the risk of developing type 2 diabetes in some individuals.\n\n2. **Muscular Symptoms**: Muscle pain, weakness, or cramps (myopathy) are common side effects. In rare cases, statins can lead to severe muscle damage (rhabdomyolysis).\n\n3. **Liver Toxicity**: Statins may cause elevated liver enzymes, indicating potential liver damage in some patients.\n\n4. **Kidney Diseases**: There is a reported association between statin use and kidney dysfunction or disease.\n\n5. **Cataracts**: Some studies suggest an increased risk of cataract formation with long-term statin use.\n\n6. **Hemorrhagic Strokes**: While statins reduce the overall risk of strokes, they may slightly increase the risk of hemorrhagic strokes in certain populations.\n\n7. **Psychiatric Complications**: Rarely, statins have been linked to mood changes, memory loss, or other psychiatric issues.\n\nIt is important to weigh the benefits and risks of statin therapy with a healthcare provider, as these side effects are not universal and vary among individuals."
      ],
      "exact_answer": [
        [
          "development of type 2 diabetes mellitus"
        ],
        [
          "muscular symptoms"
        ],
        [
          "liver toxicity"
        ],
        [
          "kidney diseases"
        ],
        [
          "cataracts"
        ],
        [
          "hemorrhagic strokes"
        ],
        [
          "psychiatric complications"
        ]
      ]
    },
    {
      "body": "Describe oncoEnrichR",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37551617"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 442,
          "offsetInEndSection": 1718,
          "text": "As a means to simplify and strengthen the support for this endeavor, we have developed oncoEnrichR, a flexible bioinformatics tool that allows cancer researchers to comprehensively interrogate a given gene list along multiple facets of cancer relevance. oncoEnrichR differs from general gene set analysis frameworks through the integration of an extensive set of prior knowledge specifically relevant for cancer, including ranked gene-tumor type associations, literature-supported proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, as well as prognostic associations, gene aberrations and co-expression patterns across tumor types. The software produces a structured and user-friendly analysis report as its main output, where versions of all underlying data resources are explicitly logged, the latter being a critical component for reproducible science. We demonstrate the usefulness of oncoEnrichR through interrogation of two candidate lists from proteomic and CRISPR screens. oncoEnrichR is freely available as a web-based service hosted by the Galaxy platform (https://oncotools.elixir.no), and can also be accessed as a stand-alone R package (https://github.com/sigven/oncoEnrichR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37551617"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Comprehensive interrogation of gene lists from genome-scale cancer screens with oncoEnrichR.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37551617"
        }
      ],
      "type": "summary",
      "id": "67d3460218b1e36f2e000004",
      "ideal_answer": [
        "OncoEnrichR is a flexible bioinformatics tool that allows cancer researchers to comprehensively interrogate a given gene list along multiple facets of cancer relevance. The software produces a structured and user-friendly analysis report as its main output, where versions of all underlying data resources are explicitly logged, the latter being a critical component for reproducible science.",
        "OncoEnrichR is a tool designed to facilitate the analysis and interpretation of cancer-related genomic data. It provides functionalities for enrichment analysis, allowing researchers to identify and prioritize cancer-related genes and pathways from large datasets. The tool integrates various data sources and offers visualization options to help in understanding the biological significance of genomic alterations in cancer research.",
        "OncoEnrichR is a bioinformatics tool designed to facilitate the analysis and interpretation of cancer-related genomic data. It provides researchers with a comprehensive platform to prioritize and annotate genes of interest in the context of cancer. OncoEnrichR integrates various data sources, including genomic, transcriptomic, and proteomic information, to offer insights into the functional relevance of genes, their involvement in cancer pathways, and potential therapeutic targets. The tool is particularly useful for identifying oncogenes, tumor suppressor genes, and other cancer-associated genes, helping researchers to better understand the molecular mechanisms underlying cancer and to develop targeted treatment strategies.",
        "OncoEnrichR is a bioinformatics tool designed to facilitate the prioritization and functional annotation of cancer-related genes by integrating various genomic and proteomic data sources.",
        "OncoEnrichR is a web-based tool for analyzing and interpreting cancer genomics data. It integrates various biological information, such as gene annotations, pathways, protein-protein interactions, and cancer-related data, to provide insights into the molecular mechanisms of cancer. Researchers can upload gene lists from high-throughput experiments and perform enrichment analysis to identify significantly overrepresented biological processes, pathways, and networks. This helps in understanding the roles of genes in cancer and identifying potential therapeutic targets.",
        "OncoEnrichR is a flexible bioinformatics tool designed to help cancer researchers comprehensively analyze gene lists across multiple facets of cancer relevance. It integrates an extensive set of prior knowledge specific to cancer, including ranked gene-tumor type associations, proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across tumor types. It differs from general gene set analysis frameworks through this integration of cancer-specific information. OncoEnrichR is available as a web-based service hosted by the Galaxy platform and can also be accessed as a stand-alone R package.",
        "OncoEnrichR is a bioinformatics tool designed to investigate differentially expressed genes and gene sets in cancer research. It provides functional profiles and pathway enrichment analysis, aiding in the identification of significant biological processes and pathways that are altered in cancer. By leveraging this tool, researchers can gain deeper insights into the molecular mechanisms underlying various cancer types, facilitating the discovery of potential therapeutic targets and biomarkers.",
        "OncoEnrichR is a flexible bioinformatics tool designed for cancer research that enables comprehensive interrogation of gene lists across multiple facets of cancer relevance. It differentiates itself from general gene set analysis frameworks by integrating an extensive array of cancer-specific prior knowledge, including literature-supported annotations for proto-oncogenes and tumor suppressor genes, ranked gene-tumor type associations, druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns. The tool is freely available as a web-based service on the Galaxy platform as well as a standalone R package. Its main output is a structured and user-friendly analysis report that explicitly logs the versions of all underlying data resources, ensuring the reproducibility of analyses.",
        "OncoEnrichR is a bioinformatics tool designed to facilitate the analysis and interpretation of cancer-related genomic data. It provides researchers with a comprehensive platform to prioritize and annotate genes of interest in the context of cancer. OncoEnrichR integrates various data sources, including genomic, transcriptomic, and proteomic information, to offer insights into the functional relevance of genes, their involvement in cancer pathways, and potential therapeutic targets. The tool is particularly useful for identifying oncogenes, tumor suppressor genes, and other cancer-associated genes, helping researchers to better understand the molecular mechanisms driving cancer and to develop targeted treatment strategies.",
        "OncoEnrichR is a tool designed to facilitate the functional interpretation of cancer-related genomic data. It provides comprehensive annotations and enrichment analyses for genes of interest, helping researchers understand the biological significance and potential clinical implications of their findings in cancer research.",
        "OncoEnrichR is a flexible bioinformatics tool that allows cancer researchers to comprehensively analyze a given gene list for cancer relevance. It integrates prior knowledge specific to cancer, including gene-tumor associations, proto-oncogene and tumor suppressor annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across tumor types. This tool differs from general gene set analysis frameworks by providing a comprehensive and cancer-specific analysis.",
        "OncoEnrichR is a bioinformatics tool designed to help cancer researchers analyze gene lists from genome-scale cancer screens. It integrates extensive cancer-relevant knowledge, including gene-tumor type associations, proto-oncogene and tumor suppressor gene annotations, druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across different tumor types.\n\nOncoEnrichR is used in various applications, such as exploring functional and drug curation sources to investigate the clinical utility of colorectal cancer target genes identified at risk loci. It has also been used for localization studies in cancer research, revealing active migration regulated by self-generated gradients and adhesion sites.",
        "OncoEnrichR is a computational tool used to investigate differentially expressed genes and gene sets in cancer research. It helps describe functional profiles and pathway enrichment in cancer data.",
        "OncoEnrichR is a web-based tool and R package designed for gene set enrichment analysis in cancer research. It helps researchers identify cancer-related pathways, functions, and associations that are enriched within a given set of genes or proteins. OncoEnrichR integrates data from various sources, including cancer-specific databases, gene annotations, and pathway information, to provide comprehensive enrichment results. It allows users to input a list of genes and then performs statistical analysis to determine which cancer-related terms are significantly overrepresented in the input list compared to a background set. The tool offers interactive visualizations and detailed reports, making it easier to interpret the results and gain insights into the biological mechanisms underlying cancer development and progression.",
        "OncoEnrichR is a comprehensive bioinformatics tool designed to analyze gene lists from genome-scale cancer screens. It integrates extensive cancer-relevant knowledge, including associations between specific genes and various tumor types, annotations of proto-oncogenes and tumor suppressor genes, druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns. The tool\u0027s capabilities are demonstrated through analyses such as proteomic and CRISPR screens. It is also used for functional and drug curation, gene set analysis, and localization studies in cancer research.",
        "OncoEnrichR is a flexible bioinformatics tool designed for cancer researchers to comprehensively interrogate a given gene list along multiple facets of cancer relevance. It integrates prior knowledge specifically relevant for cancer, including ranked gene-tumor type associations, literature-supported proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations and co-expression patterns across tumor types. The software produces a structured and user-friendly analysis report as its main output, where versions of all underlying data resources are explicitly logged. It is available as a web-based service hosted by the Galaxy platform (https://oncotools.elixir.no), and can also be accessed as a stand-alone R package (https://github.com/sigven/oncoEnrichR).",
        "OncoEnrichR is a flexible bioinformatics tool designed to simplify and strengthen support for cancer research endeavors by allowing comprehensive interrogation of gene lists along multiple facets of cancer relevance. It integrates an extensive set of prior knowledge specifically relevant for cancer, including ranked gene-tumor type associations, literature-supported annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across tumor types. This tool produces a structured and user-friendly analysis report, logging versions of all underlying data resources to ensure reproducible science. OncoEnrichR can be accessed as a web-based service hosted by the Galaxy platform or as a stand-alone R package, making it a valuable resource for cancer studies, particularly in the interrogation of gene lists from genome-scale cancer screens, such as those derived from proteomic and CRISPR screens.",
        "OncoEnrichR is a specialized bioinformatics tool designed for cancer researchers to analyze gene lists, integrating extensive cancer-specific data such as gene-tumor associations, druggability information, and regulatory interactions. It provides a structured analysis report and is accessible via a web-based service on the Galaxy platform or as an R package, ensuring reproducibility and ease of use.",
        "OncoEnrichR is a flexible bioinformatics tool designed to help cancer researchers comprehensively analyze gene lists in the context of cancer relevance. It integrates a wide range of cancer-specific prior knowledge, including gene-tumor type associations, proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across tumor types. It simplifies and strengthens the support for cancer research endeavors. The tool is available as a web-based service hosted by the Galaxy platform and as a stand-alone R package. Its usefulness has been demonstrated through the interrogation of candidate lists from proteomic and CRISPR screens.",
        "oncoEnrichR is a bioinformatics tool for cancer researchers to comprehensively analyze gene lists along multiple facets of cancer relevance.",
        "OncoEnrichR is a bioinformatics tool designed to assist cancer researchers in analyzing gene lists with a focus on cancer relevance. It integrates extensive prior knowledge specific to cancer, such as gene-tumor associations, proto-oncogene and tumor suppressor annotations, druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across tumor types. Available both as a web-based service on the Galaxy platform and as an R package, it provides structured analysis reports that log underlying data resources for reproducibility.",
        "OncoEnrichR is a flexible bioinformatics tool designed for cancer researchers to comprehensively analyze gene lists, integrating cancer-specific prior knowledge. This includes ranked gene-tumor type associations, proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across tumor types. It produces a structured analysis report, logging versions of underlying data resources. OncoEnrichR is available as a web-based service via the Galaxy platform (https://oncotools.elixir.no) and as a stand-alone R package (https://github.com/sigven/oncoEnrichR).",
        "OncoEnrichR is a bioinformatics tool designed for cancer researchers to comprehensively analyze gene lists from genome-scale screens. It integrates an extensive set of prior knowledge specific to cancer, including ranked gene-tumor type associations, proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across tumor types. The tool produces a structured and user-friendly analysis report, logging versions of all underlying data resources for reproducible science. OncoEnrichR is available as a web-based service hosted by the Galaxy platform and can also be accessed as a stand-alone R package. It enables researchers to simplify and strengthen their analysis of gene lists from cancer screens, facilitating the identification of potential therapeutic targets and biomarkers.",
        "OncoEnrichR is a bioinformatics tool designed for cancer researchers. It allows comprehensive interrogation of a given gene list along multiple facets of cancer relevance. It is available as a web-based service and as a stand-alone R package.",
        "OncoEnrichR is a bioinformatics tool designed for cancer researchers to comprehensively analyze gene lists from genome-scale screens. It integrates an extensive set of prior knowledge specific to cancer, including gene-tumor type associations, proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across tumor types. The tool produces a structured and user-friendly analysis report, logging versions of all underlying data resources for reproducible science. OncoEnrichR is available as a web-based service hosted by the Galaxy platform and can also be accessed as a stand-alone R package.",
        "OncoEnrichR is a bioinformatics tool designed for cancer researchers to comprehensively interrogate a given gene list along multiple facets of cancer relevance. It differs from general gene set analysis frameworks through the integration of prior knowledge specifically relevant for cancer, including ranked gene-tumor type associations, proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations and co-expression patterns across tumor types. OncoEnrichR is available as a web-based service hosted by the Galaxy platform (https://oncotools.elixir.no), and can also be accessed as a stand-alone R package (https://github.com/sigven/oncoEnrichR).",
        "OncoEnrichR is a bioinformatics tool designed to comprehensively interrogate gene lists for cancer relevance. It simplifies the interpretation of gene lists from genome-scale cancer screens, which are often long and require extensive analysis. OncoEnrichR integrates cancer-specific prior knowledge, including gene-tumor type associations, proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, prognostic associations, gene aberrations, and co-expression patterns across tumor types. It produces a structured analysis report and is available as a web-based service via the Galaxy platform (https://oncotools.elixir.no) and as a stand-alone R package (https://github.com/sigven/oncoEnrichR)."
      ]
    },
    {
      "body": "What are the treatments for endometrioma/endometriosis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39579221",
        "http://www.ncbi.nlm.nih.gov/pubmed/38327007",
        "http://www.ncbi.nlm.nih.gov/pubmed/38160479",
        "http://www.ncbi.nlm.nih.gov/pubmed/38434126",
        "http://www.ncbi.nlm.nih.gov/pubmed/39098538",
        "http://www.ncbi.nlm.nih.gov/pubmed/2190793",
        "http://www.ncbi.nlm.nih.gov/pubmed/21654610",
        "http://www.ncbi.nlm.nih.gov/pubmed/27926971",
        "http://www.ncbi.nlm.nih.gov/pubmed/15157645",
        "http://www.ncbi.nlm.nih.gov/pubmed/27503693",
        "http://www.ncbi.nlm.nih.gov/pubmed/17641475",
        "http://www.ncbi.nlm.nih.gov/pubmed/14644830",
        "http://www.ncbi.nlm.nih.gov/pubmed/36279764",
        "http://www.ncbi.nlm.nih.gov/pubmed/11288628",
        "http://www.ncbi.nlm.nih.gov/pubmed/29946962",
        "http://www.ncbi.nlm.nih.gov/pubmed/21401632",
        "http://www.ncbi.nlm.nih.gov/pubmed/22400429",
        "http://www.ncbi.nlm.nih.gov/pubmed/10189796",
        "http://www.ncbi.nlm.nih.gov/pubmed/12917790",
        "http://www.ncbi.nlm.nih.gov/pubmed/20938427",
        "http://www.ncbi.nlm.nih.gov/pubmed/11949960",
        "http://www.ncbi.nlm.nih.gov/pubmed/2533447",
        "https://pubmed.ncbi.nlm.nih.gov/31486802/",
        "http://www.ncbi.nlm.nih.gov/pubmed/12699263",
        "http://www.ncbi.nlm.nih.gov/pubmed/39724876",
        "http://www.ncbi.nlm.nih.gov/pubmed/26089705",
        "http://www.ncbi.nlm.nih.gov/pubmed/27067871",
        "http://www.ncbi.nlm.nih.gov/pubmed/8886699",
        "http://www.ncbi.nlm.nih.gov/pubmed/27615386"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "text": "Endometrioma patients are under-treated with endocrine endometriosis therapy",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39579221"
        },
        {
          "offsetInBeginSection": 16,
          "offsetInEndSection": 115,
          "text": "What are the complications of transvaginal ethanol sclerotherapy for the treatment of endometriomas",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38327007"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 48,
          "text": "Treatment of endometriomas: Surgical approaches ",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38160479"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Efficacy of Ethanol Sclerotherapy Versus Laparoscopic Excision in the Treatment of Ovarian Endometrioma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38434126"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Recurrence after surgery for endometrioma: a systematic review and meta-analyses.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39098538"
        },
        {
          "offsetInBeginSection": 247,
          "offsetInEndSection": 328,
          "text": "These endometriomas can, in addition to medical treatment, be treated surgically.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39098538"
        },
        {
          "offsetInBeginSection": 329,
          "offsetInEndSection": 420,
          "text": "After surgery, hormonal therapy is still frequently used for the treatment of endometriosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39098538"
        },
        {
          "offsetInBeginSection": 291,
          "offsetInEndSection": 345,
          "text": "The primary treatment for an endometrioma is surgical.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2190793"
        },
        {
          "offsetInBeginSection": 699,
          "offsetInEndSection": 837,
          "text": "The most widely exerted medical therapy for endometriosis involves gonadotropin-releasing hormone (GnRH) agonists and oral contraceptives.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21654610"
        },
        {
          "offsetInBeginSection": 701,
          "offsetInEndSection": 993,
          "text": "Four basic hormonal regimens are currently available for the treatment of endometriosis: (a) danazol; (b) gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH); gonadorelin] agonists; (c) progesterones (progestins); and (d) combined estrogens and progesterones.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2190793"
        },
        {
          "offsetInBeginSection": 279,
          "offsetInEndSection": 794,
          "text": "Therapeutic strategies and innovations of hormonal drugs for endometriosis are increasing. Acting on estrogen receptors are hormonal drugs decreasing systemic and local estrogen synthesis (GnRH analogs, GnRH antagonists, Aromatase inhibitors) or estrogen activity (selective estrogen receptor modulators). The progesterone resistance is counteracted by progestins (Medroxyprogesterone acetate, Dienogest, Danazol, Levonorgestrel) or by Selective progesterone receptor modulators, a class of drugs under development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 52,
          "text": "[Surgical management of endometriosis--an overview].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17641475"
        },
        {
          "offsetInBeginSection": 787,
          "offsetInEndSection": 1412,
          "text": "Therapeutic options include no treatment, medical therapy, surgery, or combination therapy. Oral contraceptives, androgenic agents, progestins, and gonadotropin releasing hormone (GnRH) analogs have all been used successfully, although at the present time, the latter preparations are the most popular medical therapy for endometriosis. Leuprolide acetate, goserelin acetate, and nafarelin acetate are all effective agents. Surgical therapy is appropriate, especially for advanced stages of the disease. Laparoscopy is an effective surgical approach with the goal of excision of visible endometriosis in a hemostatic fashion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14644830"
        },
        {
          "offsetInBeginSection": 299,
          "offsetInEndSection": 904,
          "text": "Hormonal drugs, by blocking menstruation, are the most effective for the treatment of endometriosis-related pain, independently of phenotype (ovarian, deep, or superficial endometriosis). Gonadotropin-releasing hormone analogs and oral antagonists act on hypothalamus-pituitary-ovary axis inducing iatrogenic menopause, thus reducing dysmenorrhea and all pain symptoms. The side effects, such as hot flushes and bone loss, may be reduced by an add-back therapy. However, the cost in terms of women\u0027s health remains high in view of a long-term treatment. Progestins are considered the first-line treatment,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36279764"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 674,
          "text": "It is applied Danazol, Ru 486, GnRh agonists. Nafarelin diminishes the pain syndrome in 70% of the cases. The relapses are 53.4% for 5 years. However, the GnRH agonists provoke suppress on E2, which lead to transient bones demineralization. Therefore they are impracticable in adolescent age when the bone growth occurs. Therefore in adolescent age for treatment on the endometriosis is recommend low-dose oral contraceptive drugs and in a case of inadequate effect to make Laparoscopic vaporization on the endometriomas by trained operator.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11288628"
        },
        {
          "offsetInBeginSection": 245,
          "offsetInEndSection": 406,
          "text": "Currently, there are several medical options for the management of patients with endometriosis. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29946962"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 824,
          "text": "Surgical treatment of endometriosis starts with clinical recognition of the condition that may be enhanced by narrow band imaging. Surgery is effective in pain control and enhancing fertility. Tubal ligation or salpingectomy can be considered. Robotic surgery is unlikely to create a cure, but may assist surgery. Medical treatment including aromatase inhibitors may also be effective. Tubal flushing with lipiodol increases fecundity; other immunomodulators and neuromodulators may also be effective. Complementary therapies, however, have not been subjected to randomized clinical trials. Environmental factors, diet, and lifestyle modification may be effective.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21401632"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 894,
          "text": "The surgical removal of endometriosis is the primary therapeutic aim. Medical treatment plays a very important role in the therapy of this chronic disease. A symptomatic therapy by analgetics should be combined with a hormonal treatment. The use of oral contraceptives in extended cycle or long-term use is effective against endometriosis associated pain. Progestogens, especially dienogest, which is licensed for endometriosis treatment and good investigated, are very effective and also available for long-term use. GnRH-analogues are effective for a short-term treatment (duration of 3 months). The long-term treatment with GnRH-analogues should only be used in selected cases and in combination with an add back therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22400429"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 447,
          "text": "The treatment of first intention for endometriosis must be surgery. In cases of infertility the surgical treatment of choice is laparoscopic surgery, maybe in conjunction with the medical treatment and possibly followed-up by a second-look. When there is pelvic pain, the treatment relies on complete exeresis of the endometriotic lesions. In this context, laparoscopic surgery is as efficient as laparotomy for dealing with ovarian endometriomas,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10189796"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 769,
          "text": "Current research has focused upon medications designed to attack specific aspects of the development and maintenance of endometriosis. These include progesterone receptor modulators, gonadotropin releasing hormone (GnRH) antagonists, aromatase inhibitors, tumor necrosis factor alpha (TNF-alpha) inhibitors, angiogenesis inhibitors, matrix metalloproteinase inhibitors, pentoxifylline (and other general immune modulators), and estrogen receptor beta agonists.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15157645"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 383,
          "text": "Treatments such as danazol, progestogens, oral contraceptives, GnRH-agonists, and gestrinone achieve their effects upon endometriosis via this method.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12917790"
        },
        {
          "offsetInBeginSection": 584,
          "offsetInEndSection": 1040,
          "text": "Current management of endometriosis is based on pharmacologic treatment and surgical intervention. In particular, combined oral contraceptives, danazol, gonadotropin-releasing hormone (GnRH) analogues and progestins have been extensively used in clinical practice. Novel agents that will hopefully improve the therapeutic potential include aromatase inhibitors, immunomodulators, anti-inflammatory agents, steroids receptor modulators and GnRH antagonists.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20938427"
        },
        {
          "offsetInBeginSection": 291,
          "offsetInEndSection": 993,
          "text": "The primary treatment for an endometrioma is surgical. However, long term postoperative hormone therapy may be necessary to prevent new endometriomas from developing. There is no evidence that hormonal therapy of endometriosis will improve fecundability in women with endometriosis and infertility. Pelvic pain due to endometriosis can be successfully treated with hormonal agents in the majority of patients. Four basic hormonal regimens are currently available for the treatment of endometriosis: (a) danazol; (b) gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH); gonadorelin] agonists; (c) progesterones (progestins); and (d) combined estrogens and progesterones.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2190793"
        },
        {
          "offsetInBeginSection": 396,
          "offsetInEndSection": 607,
          "text": "Endometriosis is often treated surgically upon diagnosis; however, the rate of recurrence is high, suggesting that a combination of therapeutic approaches might provide better outcomes than any one option alone.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11949960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "STUDY QUESTION: What does this document on the surgical treatment of endometriosis jointly prepared by the European Society for Gynaecological Endoscopy (ESGE), ESHRE, and the World Endometriosis Societ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/31486802/"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 254,
          "text": "Laparoscopic coagulation can be used for many cases of superficial endometriosis. Resection seems to be associated with an increased resolution of endometriosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12699263"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "EFFECTIVENESS OF COMBINED SURGICAL AND HORMONAL THERAPY IN TREATMENT OF ENDOMETRIOMAS.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724876"
        },
        {
          "offsetInBeginSection": 946,
          "offsetInEndSection": 1050,
          "text": "Hormonal treatments currently available are effective in the relief of pain associated to endometriosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089705"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 491,
          "text": "The clinical management of women with deep peritoneal endometriosis remains controversial. The debate focuses mainly on the precise role of hormonal medical treatment and surgery and on the most suitable surgical technique to be used. In particular, considering the risks of second-line surgery, prevention of recurrences after first-line surgery is a priority in this context. Post-surgical medical therapy has been advocated to improve the effectiveness of surgery and prevent recurrences.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27067871"
        },
        {
          "offsetInBeginSection": 879,
          "offsetInEndSection": 1123,
          "text": "Oral contraceptives, androgenic agents, progestins, and gonadotropin releasing hormone (GnRH) analogs have all been used successfully, although at the present time, the latter preparations are the most popular medical therapy for endometriosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14644830"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 290,
          "text": "Surgical treatment of endometriosis starts with clinical recognition of the condition that may be enhanced by narrow band imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21401632"
        },
        {
          "offsetInBeginSection": 1185,
          "offsetInEndSection": 1389,
          "text": "Based on these results we conclude that a combination of GnRHa and low dose danazol is an effective alternative treatment modality in the treatment of severe endometriosis without any serious side effect.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8886699"
        },
        {
          "offsetInBeginSection": 542,
          "offsetInEndSection": 936,
          "text": "he review focuses on currently utilized pharmacologic therapies for endometrioma (oral contraceptives, the levonorgestrel-releasing IUS, the hormone-releasing subdermal implant, Implanon); experimental and future treatments are also mentioned (GnRH antagonists, progesterone receptor modulators, antioestrogens, newer subdermal implants and intracystic administration of pharmacologic agents). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27615386"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "INTRODUCTION: Treatment of ovarian endometriomas is commonly achieved through laparoscopic surgery and this can be effective in eliminating the disease, although a majority of recent trials documented an adverse effect of surgery on ovarian re",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27615386"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 614,
          "text": "Adequate management of endometriosis by laparoscopy included 3 steps: a laparoscopic diagnosis with peritoneal fluid sampling for cytologic examination and biopsies of implants and of peritoneum to assure a correct diagnosis, a laparoscopic evaluation of extension with the American Fertility Society (AFS) 85 scoring system in order to classify the severity of the disease, and a laparoscopic treatment with the following strategy: drainage of the ovarian endometrioma and careful peritoneal washing, treatment of peritoneal implants, ovariolysis, treatment of the ovarian cysts, hemostasis and peritoneal lavage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2533447"
        },
        {
          "offsetInBeginSection": 728,
          "offsetInEndSection": 855,
          "text": "Ovarian endometriomas are treated by laparoscopic cystectomy using a transparietal cystectomy or an intraperitoneal cystectomy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2533447"
        }
      ],
      "type": "list",
      "id": "67cc9ca681b1027333000014",
      "ideal_answer": [
        "Endometrioma/endometriosis patients are treated with endocrine endometriosis therapy, Ethanol endometrioma sclerotherapy, surgery, laparoscopic xxcision and hormonal therapy",
        "The main treatments for endometriosis/endometrioma include hormonal therapies like oral contraceptives, progestins (e.g. dienogest), danazol, GnRH agonists (with add-back therapy), and surgical removal of endometriotic lesions or cysts (endometriomas). Newer potential treatments under investigation include GnRH antagonists, aromatase inhibitors, selective progesterone receptor modulators, angiogenesis inhibitors, and COX-2 inhibitors.",
        "The treatments for endometrioma/endometriosis are:\n1) Combined oral contraceptives\n2) Danazol\n3) Dydrogesterone\n4) Gestrinone\n5) Gonadorelin analogues\n6) Hormonal treatment before surgery\n7) Hormonal treatment\n8) Laparoscopic cystectomy\n9) Laparoscopic removal of endometriotic deposits (alone or with uterine nerve ablation)\n10) Laparoscopic removal plus presacral neurectomy\n11) Laparoscopic uterine nerve ablation\n12) Non-steroidal anti-inflammatory drugs\n13) Presacral neurectomy alone\n14) Progestogens other than dydrogesterone\n15) Levonorgestrel-releasing intrauterine system (LNG-IUD)\n16) Gonadotropin-releasing hormone analogues (GnRHa)\n17) Laparoscopic ablation\n18) Excision\n19) Hysterectomy\n20) Myomectomy\n21) Uterine nerve ablation\n22) Progestin therapy\n23) GnRH agonists\n24) NSAIDs\n25) Pain management with opioids and NSAIDs",
        "The treatments for endometrioma/endometriosis include: hysterectomy and bilateral oophorectomy, which are considered effective but limited by patient age and fertility concerns.",
        "The treatments for endometrioma/endometriosis include danazol, GnRH agonists, laparoscopic cystectomy, combined estrogens and progesterones, combined oral contraceptives, dydrogesterone, gestrinone, and gonadorelin analogues.",
        "The main treatments for endometriosis and endometriomas include medical therapy (oral contraceptives, progestins, GnRH agonists/antagonists, aromatase inhibitors, etc.), surgical treatment (laparoscopic excision or ablation of endometriotic lesions and endometriomas), and assisted reproductive technologies (ovulation induction, intrauterine insemination, in vitro fertilization) for infertility cases. A combination of medical and surgical approaches is often used. However, none of these treatments offer a complete cure for endometriosis.",
        "The treatments for endometrioma/endometriosis include: \n1) Combined oral contraceptives\n2) Danazol\n3) Dydrogesterone\n4) Gestrinone\n5) Gonadorelin analogues\n6) Hormonal treatment before surgery\n7) Hormonal treatment\n8) Laparoscopic cystectomy\n9) Laparoscopic removal of endometriotic deposits (alone or with uterine nerve ablation)\n10) Laparoscopic removal plus presacral neurectomy\n11) Laparoscopic uterine nerve ablation\n12) Non-steroidal anti-inflammatory drugs\n13) Presacral neurectomy alone\n14) Progestogens other than dydrogesterone\n15) Aromatase inhibitors\n16) Hysterectomy\n17) Myomectomy\n18) Uterine nerve ablation\n19) Presacral neurectomy\n20) Progestins\n21) GnRH agonists\n22) GnRH antagonists\n23) In vitro fertilization\n24) Intrauterine insemination\n25) Laparoscopic ablation of endometrial deposits\n26) Laparoscopic ovarian drilling\n27)",
        "Treatments for endometrioma/endometriosis can be broadly categorized into hormonal therapies, surgical treatments, post-operative management, catheter-directed ethanol sclerotherapy, assisted reproductive technology (ART), and general management.\n\nHormonal therapies, such as progestin and GnRH therapies, are used post-surgery to improve menstrual bleeding profiles and reduce recurrence rates. These treatments can shrink the size of endometrioma but may carry a risk of ovarian cancer.\n\nSurgical treatments include laparoscopic cystectomy and laser vaporization, which have shown positive outcomes in terms of mature follicles, fertilization rates, implantation rates, and clinical pregnancy rates. Postoperative medication significantly reduces recurrence rates.\n\nPost-operative management with progesterone for 6 months is protective against recurrence, while clomiphene increases the risk.\n\nCatheter-directed ethanol sclerotherapy (CDS) has minimal adverse effects on ovarian reserve.\n\nAssisted reproductive technology (ART), including IVF and ICSI, is an option for infertility due to endometriosis. While women with endometriosis may have lower oocyte yields, their cumulative live-birth rates are similar to those of women without endometriosis.\n\nControlled ovarian stimulation protocols, such as GnRHa and GnRH antagonist protocols, are used for their suppression effect on ectopic endometrial tissue.\n\nGeneral management includes laparoscopy, expectant management, medical therapy, ovulation induction, and ART, but none offer a cure. There is a lack of data from randomized trials to determine the optimal management for pain relief, recurrence, and fertility.",
        "The primary treatment for an endometrioma is surgical. Hormone therapy, including danazol, GnRH agonists, progesterones, and combined estrogens and progesterones, may also be used to treat endometriosis.",
        "Treatments for endometrioma/endometriosis include hormonal options like combined oral contraceptives, danazol, and progestogens; non-hormonal options like NSAIDs; and surgical interventions such as laparoscopic cystectomy, ablation techniques, and presacral neurectomy. For endometrioma specifically, additional considerations are expectant management, medical therapy, laparoscopic treatment, and for those with infertility, ovulation induction and assisted reproductive technology. However, no treatment offers a cure for endometriosis.",
        "Endometrioma and endometriosis can be treated through multiple approaches, including medical and surgical interventions. The primary treatment modalities include hormonal therapy, laparoscopic surgical excision, ethanol sclerotherapy, and ongoing medical management to prevent recurrence.",
        "Treatments for endometrioma/endometriosis include: \n    1. Endocrine (Hormonal) Therapy for reduced recurrence risk, \n    2. Surgical Approaches like Cystectomy (low recurrence, higher ovarian reserve risk), Ablation (minimal ovarian impact, low recurrence), Sclerotherapy (variable outcomes), and Oophorectomy (last resort due to significant fertility impact),\n    3. Minimally Invasive Transvaginal Ethanol Sclerotherapy for quicker recovery, and \n    4. Postoperative Hormonal Therapy to manage endometriosis post-surgery. Treatment choice should be tailored to individual fertility and therapeutic goals.",
        "Endometriomas can be treated through both medical and surgical approaches. Surgical options include laparoscopic excision, while medical treatments involve hormonal therapy, which is often used post-surgery to manage endometriosis. Additionally, ethanol sclerotherapy is another treatment method for ovarian endometriomas.",
        "Hormonal therapy, ethanol sclerotherapy, laparoscopic excision, and surgical treatment can be used for the treatment of endometrioma/endometriosis.",
        "The treatment of endometriosis focuses upon amelioration of two symptoms: pain and infertility. Treatment options include medical therapy, surgical intervention, and assisted reproduction. Medical therapies include hormonal drugs (contraceptives, progestatives, GnRH analogues) and non-hormonal ones (anti-aromatase, anti-progestative, anti-tissular growth factors). Surgical approaches are also used. After surgery, hormonal therapy is still frequently used for the treatment of endometriosis.",
        "Endometriomas can be treated medically or surgically. After surgery, hormonal therapy is frequently used for the treatment of endometriosis.",
        "Endometrioma patients are under-treated with endocrine endometriosis therapy. These endometriomas can, in addition to medical treatment, be treated surgically. Efficacy of Ethanol Sclerotherapy Versus Laparoscopic Excision in the Treatment of Ovarian Endometrioma. After surgery, hormonal therapy is still frequently used for the treatment of endometriosis.",
        "Treatments for endometrioma/endometriosis include surgical approaches such as laparoscopic excision and medical treatments like hormonal therapy. Ethanol sclerotherapy is also an option for treating ovarian endometriomas.",
        "The treatments for endometrioma/endometriosis include: surgical approaches (such as laparoscopic excision), ethanol sclerotherapy, hormonal therapies (including aromatase inhibitors and gonadotropin-releasing hormone antagonists), in vitro fertilization for infertility, and plant-derived agents as natural treatment options.",
        "The treatments for endometrioma/endometriosis include: surgical approaches, hormonal therapy, ethanol sclerotherapy, physiotherapy, and individualized multimodal treatment strategies.",
        "Endometrioma and endometriosis can be treated with surgical options like laparoscopic excision and ethanol sclerotherapy, as well as hormonal and medical therapies.",
        "The treatments for endometrioma/endometriosis include: surgical approaches (such as laparoscopic excision or ablation), hormonal therapies (like combined oral contraceptive pills and progestogens), ethanol sclerotherapy, and non-pharmacologic conservative therapies (such as physical activity and exercise). Additionally, management may involve addressing infertility through surgery, superovulation with intrauterine insemination, and in vitro fertilization.",
        "Endometrioma patients are under-treated with endocrine endometriosis therapy. Endometriomas can, in addition to medical treatment, be treated surgically. After surgery, hormonal therapy is still frequently used for the treatment of endometriosis.",
        "Endometriomas can be treated medically or surgically. After surgery, hormonal therapy is frequently used for endometriosis. Ethanol sclerotherapy and laparoscopic excision are also treatment options.",
        "The main treatments for endometrioma/endometriosis include surgical approaches like laparoscopic excision or cystectomy, hormonal therapy or endocrine therapy, and other medical treatments like ethanol sclerotherapy. After surgery, hormonal therapy is often used to prevent recurrence.",
        "Treatments for endometrioma/endometriosis include endocrine (hormonal) therapy, surgical approaches (such as laparoscopic excision), and transvaginal ethanol sclerotherapy, with hormonal therapy often used post-surgery to manage endometriosis.",
        "Treatments for endometrioma/endometriosis are Laparoscopic Excision, Ethanol Sclerotherapy, Hormonal Therapy, Surgical Treatment and Medical treatment.",
        "Treatments for endometriomas/endometriosis include endocrine endometriosis therapy, transvaginal ethanol sclerotherapy, surgical approaches, laparoscopic excision, and hormonal therapy."
      ],
      "exact_answer": [
        [
          "Endocrine endometriosis therapy"
        ],
        [
          "Surgery"
        ],
        [
          "Ethanol endometrioma sclerotherapy"
        ],
        [
          "Laparoscopic Excision"
        ],
        [
          "hormonal therapy"
        ]
      ]
    },
    {
      "body": "Association between hypothyroidism and depression.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36961565",
        "http://www.ncbi.nlm.nih.gov/pubmed/38341154",
        "http://www.ncbi.nlm.nih.gov/pubmed/39100850",
        "http://www.ncbi.nlm.nih.gov/pubmed/38788859",
        "http://www.ncbi.nlm.nih.gov/pubmed/34147730",
        "http://www.ncbi.nlm.nih.gov/pubmed/24847450",
        "http://www.ncbi.nlm.nih.gov/pubmed/19168226",
        "http://www.ncbi.nlm.nih.gov/pubmed/36003348",
        "http://www.ncbi.nlm.nih.gov/pubmed/11054982",
        "http://www.ncbi.nlm.nih.gov/pubmed/29705022",
        "http://www.ncbi.nlm.nih.gov/pubmed/39184762"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 35,
          "offsetInEndSection": 116,
          "text": "subclinical hypothyroidism (SCH) are prevalent in major depressive disorder (MDD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36961565"
        },
        {
          "offsetInBeginSection": 16,
          "offsetInEndSection": 145,
          "text": "causal relationship between different hypothyroidism subtypes and the risk of major depression (MD) is yet to be fully elucidated",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38341154"
        },
        {
          "offsetInBeginSection": 1181,
          "offsetInEndSection": 1254,
          "text": "high rate of comorbidity between hypothyroidism and psychiatric disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39100850"
        },
        {
          "offsetInBeginSection": 47,
          "offsetInEndSection": 153,
          "text": "relationship between depression and thyroid diseases and function, its causal relationship remains unclear",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38788859"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "BACKGROUND: Subclinical hypothyroidism has been associated with increased risk for depression, yet the findings remain controversial. It is possible that subclinical hypothyroidism is associated with some, but not all symptoms of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34147730"
        },
        {
          "offsetInBeginSection": 1280,
          "offsetInEndSection": 1470,
          "text": "sulted in similar findings.CONCLUSIONS: In a nationally representative sample of US adults, we observed no association between subclinical hypothyroidism and overall depression risk or any o",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34147730"
        },
        {
          "offsetInBeginSection": 1090,
          "offsetInEndSection": 1304,
          "text": "This review strengthens the link between hypothyroidism and depression, and it also demonstrates how treating the underlying hypothyroidism in people who have been diagnosed with depression will be very beneficial.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36003348"
        },
        {
          "offsetInBeginSection": 1210,
          "offsetInEndSection": 1406,
          "text": "This is consistent with the observation that T3 is superior to T4 as adjuvant therapy in the treatment of unipolar depression.CONCLUSIONS: Depressed patients should be screened for hypothyroidism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11054982"
        },
        {
          "offsetInBeginSection": 748,
          "offsetInEndSection": 878,
          "text": "Treating underlying hypothyroidism with thyroid replacement therapy could significantly improve mood disorders such as depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36003348"
        },
        {
          "offsetInBeginSection": 233,
          "offsetInEndSection": 378,
          "text": "Multiple studies concluded that undiagnosed, untreated, undertreated patients with hypothyroidism are at increased risk of developing depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36003348"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 646,
          "text": "There has been an established relationship between hypothyroidism and depression. Studies have demonstrated that somatostatin and serotonin influence the hypothalamus-pituitary-thyroid axis, which links hypothyroidism to depression. Multiple studies concluded that undiagnosed, untreated, undertreated patients with hypothyroidism are at increased risk of developing depression. Autoimmune thyroiditis is also associated with an increased risk of depression. Elevated thyroid-stimulating hormone (TSH), antithyroglobulin (TgAb), and thyroid peroxidase antibodies (TPOAb) levels have all been linked to depression and an increased risk of suicide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36003348"
        },
        {
          "offsetInBeginSection": 474,
          "offsetInEndSection": 769,
          "text": "tiple logistic regression analysis adjusting for age, race, smoking and body mass index showed that women with TSH\u003e10 mUI/ml had a threefold chance of presenting depressive symptoms compared to those with normal levels of TSH. Among those with clinical hypothyroidism the adjusted OR was 8.7.CON",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19168226"
        },
        {
          "offsetInBeginSection": 1242,
          "offsetInEndSection": 1439,
          "text": "In conclusion, our analyses suggest that abnormal thyroid function, especially hypothyroidism, is linked to depression severity and associated with distinct psychopathologic features of depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29705022"
        },
        {
          "offsetInBeginSection": 131,
          "offsetInEndSection": 333,
          "text": "Deficiency or lack of thyroid hormone causes patients to have a slower metabolism, which may lead to secondary medical issues such as weight gain, fatigue, depression, and increased cardiovascular risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39184762"
        }
      ],
      "id": "67d7fee818b1e36f2e000048",
      "ideal_answer": [
        "While there is a clear epidemiological association between hypothyroidism and depression, the causal relationship remains unclear.",
        "The association between hypothyroidism and depression appears to be significant, with several potential mechanisms linking these conditions:\n\n1. **Hormonal Imbalance**: Hypothyroidism involves low levels of thyroid hormones (T3 and T4), which are crucial for metabolism and brain function. This hormonal imbalance can lead to symptoms such as fatigue and weight gain, which may contribute to depressive feelings.\n\n2. **Brain Function Impact**: Thyroid hormones play a role in regulating mood and cognitive functions. Reduced levels of these hormones might impair neurotransmitter production, including serotonin, affecting mood regulation and increasing the risk of depression.\n\n3. **Inflammation Connection**: Both hypothyroidism and depression are associated with chronic inflammation, suggesting that inflammation could serve as a bridge between these conditions.\n\n4. **Treatment Implications**: Addressing hypothyroidism through hormone replacement therapy may alleviate depressive symptoms, highlighting the importance of considering thyroid function in treating mood disorders.\n\n5. **Demographic Factors**: Women are more prone to both conditions, and the severity of hypothyroidism might influence the strength of the association with depression.\n\nIn conclusion, while there is evidence supporting an increased risk of depression in individuals with hypothyroidism, further research is needed to fully understand the mechanisms and extent of this connection."
      ]
    },
    {
      "body": "Which computational method exists for prediction of transcriptional condensate-associated genomic regions?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36394233"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "SEGCOND predicts putative transcriptional condensate-associated genomic regions by integrating multi-omics data.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36394233"
        },
        {
          "offsetInBeginSection": 615,
          "offsetInEndSection": 1026,
          "text": "In this work, we present SEGCOND, a computational framework aiming to highlight genomic regions involved in the formation of transcriptional condensates. SEGCOND is flexible in combining multiple genomic datasets related to enhancer activity and chromatin accessibility, to perform a genome segmentation. It then uses this segmentation for the detection of highly transcriptionally active regions of the genome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36394233"
        }
      ],
      "id": "67d48f6c18b1e36f2e000017",
      "ideal_answer": [
        "SEGCOND is a computational framework aiming to highlight genomic regions involved in the formation of transcriptional condensates. SEGCOND is flexible in combining multiple genomic datasets related to enhancer activity and chromatin accessibility, to perform a genome segmentation. It then uses this segmentation for the detection of highly transcriptionally active regions of the genome.",
        "SEGCOND is a computational method for prediction of transcriptional condensate-associated genomic regions by integrating multi-omics data.",
        "The SEGCOND method is a computational approach that predicts putative transcriptional condensate-associated genomic regions by integrating multi-omics data. It aims to identify the genomic regions responsible for the formation of transcriptional condensates based on genomic and conformational data.",
        "The SEGCOND framework is a computational method developed to predict transcriptional condensate-associated genomic regions. It integrates multiple types of multi-omics data, such as enhancer activity, chromatin accessibility, and Hi-C data, to identify potential regions associated with transcriptional condensates.",
        "SEGCOND is a computational framework that aims to highlight genomic regions involved in the formation of transcriptional condensates. It combines multiple genomic datasets related to enhancer activity and chromatin accessibility to perform a genome segmentation. It then uses this segmentation for the detection of highly transcriptionally active regions of the genome and identifies regions of putative transcriptional condensates (PTCs) as genomic domains where multiple enhancer elements coalesce in 3D space. CondSigDetector is another computational framework designed to detect condensate-like chromatin-associated protein co-occupancy signatures (CondSigs), to predict genomic loci and component proteins of distinct chromatin-associated biomolecular condensates.",
        "SEGCOND is a computational method that predicts putative transcriptional condensate-associated genomic regions by integrating multi-omics data, including enhancer activity and chromatin accessibility. This method is designed to identify genomic regions involved in the formation of transcriptional condensates, which are important for the regulation of gene expression.",
        "SEGCOND is a computational framework designed to predict transcriptional condensate-associated genomic regions.",
        "SEGCOND is a computational framework designed to identify genomic regions involved in the formation of transcriptional condensates. It combines multiple genomic datasets related to enhancer activity and chromatin accessibility to perform genome segmentation. This segmentation is then used to detect highly transcriptionally active regions. By integrating Hi-C data, SEGCOND identifies regions of putative transcriptional condensates (PTCs) as genomic domains where multiple enhancer elements coalesce in 3D space.",
        "SEGCOND and CondSigDetector are the computational methods that exist for the prediction of transcriptional condensate-associated genomic regions.",
        "SEGCOND is the computational method specifically designed for predicting transcriptional condensate-associated genomic regions. It integrates multi-omics data, including enhancer activity, chromatin accessibility, and Hi-C data, to perform genome segmentation and detect highly transcriptionally active regions. SEGCOND identifies putative transcriptional condensates (PTCs) where multiple enhancer elements coalesce in 3D space. Successfully applied to B-cell to macrophage transdifferentiation, it has identified novel genes involved in the process. The method is available for use, with its source code hosted at https://github.com/AntonisK95/SEGCOND.",
        "SEGCOND is a computational framework for the prediction of transcriptional condensate-associated genomic regions.",
        "SEGCOND is a computational framework that predicts putative transcriptional condensate-associated genomic regions. It integrates multi-omics data related to enhancer activity and chromatin accessibility to perform genome segmentation. This segmentation is then used to detect highly transcriptionally active regions of the genome. Finally, SEGCOND identifies regions of putative transcriptional condensates by integrating Hi-C data, which are genomic domains where multiple enhancer elements coalesce in 3D space. SEGCOND has been shown to identify a subset of enhancer segments with increased transcriptional activity and significantly overlap highly interconnected enhancer elements and super enhancers. It has also been applied to data from B-cell to macrophage transdifferentiation, leading to the identification of previously unreported genes involved in the process. The source code for SEGCOND is available at https://github.com/AntonisK95/SEGCOND.",
        "SEGCOND is a computational method that predicts putative transcriptional condensate-associated genomic regions by integrating multi-omics data. It identifies regions in the genome that are responsible for the formation of transcriptional condensates, which are membraneless bodies formed through liquid-liquid phase separation and play important roles in gene regulation.",
        "The computational method SEGCOND exists for predicting putative transcriptional condensate-associated genomic regions by integrating multi-omics data. It identifies genomic regions responsible for the formation of transcriptional condensates, which are membraneless bodies formed through liquid-liquid phase separation and play important roles in gene regulation.",
        "The computational method SEGCOND is designed to predict putative transcriptional condensate-associated genomic regions by integrating multi-omics data. It identifies regions in the genome that are likely involved in the formation of transcriptional condensates, which are membraneless bodies formed through liquid-liquid phase separation and play important roles in gene regulation.",
        "SEGCOND is the primary computational method for predicting transcriptional condensate-associated genomic regions. It uniquely integrates enhancer activity, chromatin accessibility, and Hi-C data to identify putative transcriptional condensates through genome segmentation. Successfully applied in studying B-cell to macrophage transdifferentiation, SEGCOND highlights its effectiveness in uncovering novel genes involved in transcriptional condensate formation. Its source code is publicly available at https://github.com/AntonisK95/SEGCOND, making it a readily accessible tool for researchers.",
        "The computational method known as SEGCOND is used for predicting transcriptional condensate-associated genomic regions. SEGCOND integrates multi-omics data, including enhancer activity, chromatin accessibility, and Hi-C data, to make its predictions. This method utilizes bioinformatic analysis to achieve its goals.",
        "SEGCOND",
        "The computational method for predicting transcriptional condensate-associated genomic regions is SEGCOND, which integrates multi-omics data to identify regions involved in condensate formation. SEGCOND is flexible and can combine various genomic datasets related to enhancer activity and chromatin accessibility for genome segmentation.",
        "SEGCOND is a computational framework designed to highlight genomic regions involved in the formation of transcriptional condensates. It combines multiple genomic datasets related to enhancer activity and chromatin accessibility to perform genome segmentation. This segmentation is then used to detect highly transcriptionally active regions. By integrating Hi-C data, SEGCOND identifies regions of putative transcriptional condensates (PTCs) as genomic domains where multiple enhancer elements coalesce in 3D space.",
        "The computational method known as SEGCOND exists for the prediction of transcriptional condensate-associated genomic regions. SEGCOND is a computational framework that integrates multi-omics data, including enhancer activity, chromatin accessibility, and Hi-C data, to predict putative transcriptional condensate-associated genomic regions.",
        "SEGCOND is a computational framework designed to predict transcriptional condensate-associated genomic regions by integrating multi-omics data. It uses genome segmentation and combines multiple genomic datasets related to enhancer activity and chromatin accessibility to detect highly transcriptionally active regions of the genome.",
        "SEGCOND is a computational method designed to predict putative transcriptional condensate associated genomic regions. It achieves this by integrating multi omics data, which allows for a comprehensive analysis of various molecular information. This integration enables SEGCOND to identify regions associated with transcriptional condensates, which are liquid droplets within the cell nucleus that play a significant role in gene regulation and cellular processes.",
        "SEGCOND is a computational framework that predicts putative transcriptional condensate-associated genomic regions. It integrates multi-omics data, including genomic, enhancer activity, chromatin accessibility, and Hi-C data, through a comprehensive approach involving genome segmentation and identification of highly transcriptionally active regions, thereby providing a robust method for such predictions.",
        "SEGCOND is a computational method designed for the prediction of transcriptional condensate associated genomic regions. Transcriptional condensates are specialized membraneless organelles that play a critical role in regulating gene expression by concentrating transcriptional machinery and regulatory factors. SEGCOND integrates multi omics data, such as genomics, transcriptomics, and proteomics, to identify putative genomic regions associated with these condensates. This approach enables researchers to better understand the spatial organization of the genome and its relationship to transcriptional activity.",
        "The computational framework SEGCOND is designed to predict transcriptional condensate-associated genomic regions. It achieves this by combining multiple genomic datasets related to enhancer activity and chromatin accessibility, then performing genome segmentation to identify highly transcriptionally active regions.",
        "SEGCOND is a computational method designed to predict putative transcriptional condensate associated genomic regions. It achieves this by integrating multi omics data, which allows researchers to identify regions involved in forming transcriptional condensates. These condensates are liquid droplets within cells that play a crucial role in gene regulation. By predicting these regions, SEGCOND aids in understanding the complex regulatory mechanisms at the cellular level and contributes to advancements in genomics research.",
        "SEGCOND is the computational method that exists for the prediction of transcriptional condensate-associated genomic regions.",
        "SEGCOND is a computational framework that predicts putative transcriptional condensate-associated genomic regions by integrating multi-omics data. It combines multiple genomic datasets related to enhancer activity and chromatin accessibility to perform a genome segmentation and detects highly transcriptionally active regions of the genome. It identifies regions of putative transcriptional condensates (PTCs) as genomic domains where multiple enhancer elements coalesce in 3D space through the integration of Hi-C data.",
        "SEGCOND is a computational framework that predicts putative transcriptional condensate-associated genomic regions by integrating multi-omics data.",
        "SEGCOND predicts putative transcriptional condensate-associated genomic regions by integrating multi-omics data.",
        "SEGCOND is a computational framework for predicting transcriptional condensate-associated genomic regions.",
        "SEGCOND is a computational framework designed to predict putative transcriptional condensate-associated genomic regions. It integrates multi-omics data to highlight genomic regions involved in the formation of transcriptional condensates. By combining various genomic datasets related to enhancer activity and chromatin accessibility, SEGCOND performs genome segmentation to identify highly transcriptionally active regions. This approach allows for a comprehensive analysis of genomic regions likely to be involved in transcriptional condensate formation.",
        "The computational methods for prediction of transcriptional condensate-associated genomic regions are SEGCOND and CondSigDetector.",
        "SEGCOND is a computational framework that predicts putative transcriptional condensate-associated genomic regions. It integrates multiple genomic datasets, including those related to enhancer activity and chromatin accessibility, to perform genome segmentation. This segmentation is then used to identify regions with high transcriptional activity that may be involved in the formation of transcriptional condensates.",
        "SEGCOND is a computational framework that predicts putative transcriptional condensate-associated genomic regions. It integrates multi-omics data and performs genome segmentation to detect highly transcriptionally active regions. SEGCOND is flexible in combining multiple genomic datasets related to enhancer activity and chromatin accessibility.",
        "SEGCOND is a computational method for predicting putative transcriptional condensate-associated genomic regions by integrating multi-omics data.",
        "SEGCOND is a computational framework designed to predict putative transcriptional condensate-associated genomic regions. It operates by integrating multi-omics data, specifically combining multiple genomic datasets related to enhancer activity and chromatin accessibility to perform genome segmentation. This segmentation is then used to detect highly transcriptionally active regions of the genome. Finally, by integrating Hi-C data, SEGCOND identifies regions of putative transcriptional condensates as genomic domains where multiple enhancer elements coalesce in 3D space.",
        "SEGCOND is a computational framework designed to predict transcriptional condensate-associated genomic regions by integrating multi-omics data.",
        "The SEGCOND computational framework is designed to predict transcriptional condensate-associated genomic regions. It integrates multiple genomic datasets, such as enhancer activity and chromatin accessibility data, to perform genome segmentation. This segmentation helps in identifying highly transcriptionally active regions of the genome.",
        "SEGCOND is the computational method for the prediction of transcriptional condensate-associated genomic regions.",
        "SEGCOND is a computational framework designed to predict transcriptional condensate-associated genomic regions by integrating multi-omics data, including enhancer activity and chromatin accessibility, to perform genome segmentation and identify highly transcriptionally active regions.",
        "SEGCOND is a computational method designed to predict transcriptional condensate-associated genomic regions.",
        "SEGCOND is the computational method that predicts transcriptional condensate-associated genomic regions by integrating multi-omics data, including enhancer activity, chromatin accessibility, and Hi-C data. It performs genome segmentation to identify highly transcriptionally active regions where multiple enhancer elements coalesce in 3D space. Proven flexible and useful, SEGCOND has been applied to study B-cell to macrophage transdifferentiation, uncovering new genes involved. The method\u0027s source code is available at https://github.com/AntonisK95/SEGCOND, ensuring accessibility for further research and applications.",
        "SEGCOND is a computational method for the prediction of transcriptional condensate-associated genomic regions.",
        "SEGCOND is a computational method designed to predict putative transcriptional condensate-associated genomic regions. It achieves this by integrating multi-omics data, which allows for a comprehensive analysis of the genomic landscape and identification of regions potentially involved in transcriptional condensate formation. This method is useful for researchers studying gene regulation and chromatin organization, as it provides insights into the spatial and functional aspects of genomic regions associated with transcriptional condensates.",
        "SEGCOND is a computational framework that predicts putative transcriptional condensate-associated genomic regions by integrating multi-omics data, including genomic, enhancer activity, chromatin accessibility, and Hi-C data, through approaches such as genome segmentation and identification of highly transcriptionally active regions.",
        "SEGCOND is a computational framework aiming to highlight genomic regions involved in the formation of transcriptional condensates. It is flexible in combining multiple genomic datasets related to enhancer activity and chromatin accessibility, to perform a genome segmentation. It then uses this segmentation for the detection of highly transcriptionally active regions of the genome.",
        "SEGCOND is a computational method designed to predict putative transcriptional condensate associated genomic regions. It achieves this by integrating multi omics data, enabling researchers to identify genomic loci linked with transcriptional condensates. These condensates are membraneless organelles that play a critical role in gene regulation and are implicated in various diseases, including cancer.",
        "SEGCOND is a computational framework that predicts transcriptional condensate-associated genomic regions. It integrates multi-omics data related to enhancer activity and chromatin accessibility. This segmentation is then used to detect highly transcriptionally active regions of the genome.",
        "SEGCOND is a computational framework designed to predict putative transcriptional condensate-associated genomic regions. It works by integrating multiple genomic datasets related to enhancer activity and chromatin accessibility to perform genome segmentation. This segmentation is then utilized to detect highly transcriptionally active regions of the genome that may be involved in the formation of transcriptional condensates. SEGCOND\u0027s flexible approach allows it to combine various multi-omics data sources to identify these important regulatory genomic regions.",
        "SEGCOND is a computational framework designed to predict transcriptional condensate-associated genomic regions. It integrates multi-omics data, such as enhancer activity and chromatin accessibility, to perform genome segmentation and detect highly transcriptionally active regions.",
        "SEGCOND is a computational framework that predicts putative transcriptional condensate-associated genomic regions by integrating multi-omics data related to enhancer activity and chromatin accessibility.",
        "SEGCOND is a computational method designed to predict transcriptional condensate-associated genomic regions by integrating multi-omics data",
        "SEGCOND is a computational framework developed to predict putative transcriptional condensate-associated genomic regions by integrating multiple genomic datasets related to enhancer activity and chromatin accessibility.",
        "SEGCOND is a computational framework that predicts genomic regions associated with transcriptional condensates by integrating multiple genomic datasets related to enhancer activity and chromatin accessibility. The framework performs genome segmentation to identify highly transcriptionally active regions, effectively highlighting genomic areas involved in condensate formation.",
        "The computational framework SEGCOND is designed to predict transcriptional condensate-associated genomic regions. It achieves this by integrating multiple types of genomic datasets related to enhancer activity and chromatin accessibility, and then performing genome segmentation to identify highly transcriptionally active regions.",
        "SEGCOND is a computational framework that predicts transcriptional condensate-associated genomic regions by integrating multi-omics data and performing genome segmentation to detect highly transcriptionally active regions."
      ],
      "exact_answer": [
        [
          "SEGCOND",
          "CondSigDetector",
          "condsigdetector"
        ]
      ]
    },
    {
      "body": "What tissue would be used to derive  Wharton\u0027s Jelly Mesenchymal Stem Cells?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35313748",
        "http://www.ncbi.nlm.nih.gov/pubmed/33975986",
        "http://www.ncbi.nlm.nih.gov/pubmed/25747736",
        "http://www.ncbi.nlm.nih.gov/pubmed/21733573",
        "http://www.ncbi.nlm.nih.gov/pubmed/16336835",
        "http://www.ncbi.nlm.nih.gov/pubmed/37140810",
        "http://www.ncbi.nlm.nih.gov/pubmed/33562192",
        "http://www.ncbi.nlm.nih.gov/pubmed/25517045",
        "http://www.ncbi.nlm.nih.gov/pubmed/32290584",
        "http://www.ncbi.nlm.nih.gov/pubmed/23727936",
        "http://www.ncbi.nlm.nih.gov/pubmed/30729769",
        "http://www.ncbi.nlm.nih.gov/pubmed/38618506",
        "http://www.ncbi.nlm.nih.gov/pubmed/32557631",
        "http://www.ncbi.nlm.nih.gov/pubmed/29267140",
        "http://www.ncbi.nlm.nih.gov/pubmed/37629090",
        "http://www.ncbi.nlm.nih.gov/pubmed/18442646",
        "http://www.ncbi.nlm.nih.gov/pubmed/28963712",
        "http://www.ncbi.nlm.nih.gov/pubmed/24736473",
        "http://www.ncbi.nlm.nih.gov/pubmed/22785368",
        "http://www.ncbi.nlm.nih.gov/pubmed/39740941",
        "http://www.ncbi.nlm.nih.gov/pubmed/39711971",
        "http://www.ncbi.nlm.nih.gov/pubmed/25622293",
        "http://www.ncbi.nlm.nih.gov/pubmed/22563663",
        "http://www.ncbi.nlm.nih.gov/pubmed/35088933",
        "http://www.ncbi.nlm.nih.gov/pubmed/29931444",
        "http://www.ncbi.nlm.nih.gov/pubmed/26482184",
        "http://www.ncbi.nlm.nih.gov/pubmed/37760347",
        "http://www.ncbi.nlm.nih.gov/pubmed/24704519",
        "https://pubmed.ncbi.nlm.nih.gov/23727936/",
        "http://www.ncbi.nlm.nih.gov/pubmed/15579650",
        "http://www.ncbi.nlm.nih.gov/pubmed/36094263",
        "http://www.ncbi.nlm.nih.gov/pubmed/39037235",
        "http://www.ncbi.nlm.nih.gov/pubmed/36526818",
        "http://www.ncbi.nlm.nih.gov/pubmed/38397024",
        "http://www.ncbi.nlm.nih.gov/pubmed/26148883",
        "http://www.ncbi.nlm.nih.gov/pubmed/19958166",
        "http://www.ncbi.nlm.nih.gov/pubmed/28261617",
        "http://www.ncbi.nlm.nih.gov/pubmed/29772841",
        "http://www.ncbi.nlm.nih.gov/pubmed/39408777",
        "http://www.ncbi.nlm.nih.gov/pubmed/25069491",
        "http://www.ncbi.nlm.nih.gov/pubmed/39560969",
        "http://www.ncbi.nlm.nih.gov/pubmed/33564725",
        "http://www.ncbi.nlm.nih.gov/pubmed/35252487",
        "http://www.ncbi.nlm.nih.gov/pubmed/20880767",
        "http://www.ncbi.nlm.nih.gov/pubmed/23176558",
        "http://www.ncbi.nlm.nih.gov/pubmed/23595555",
        "http://www.ncbi.nlm.nih.gov/pubmed/23279098",
        "http://www.ncbi.nlm.nih.gov/pubmed/29552470",
        "http://www.ncbi.nlm.nih.gov/pubmed/25206475",
        "http://www.ncbi.nlm.nih.gov/pubmed/32777963",
        "http://www.ncbi.nlm.nih.gov/pubmed/33176838",
        "http://www.ncbi.nlm.nih.gov/pubmed/32085697",
        "http://www.ncbi.nlm.nih.gov/pubmed/26279972",
        "http://www.ncbi.nlm.nih.gov/pubmed/29714147",
        "http://www.ncbi.nlm.nih.gov/pubmed/23176305",
        "http://www.ncbi.nlm.nih.gov/pubmed/18022578",
        "http://www.ncbi.nlm.nih.gov/pubmed/25388392"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Mesenchymal stem cells derived from umbilical cord Wharton\u0027s Jelly (WJ-MSCs) are emerging as promising therapeutics for a variety of diseases due to their ability of regeneration and immunomodulation,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35313748"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Human umbilical cord Wharton\u0027s jelly-derived mesenchymal stem cell transplantation could improve diabetic intracavernosal pressure.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33975986"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 275,
          "text": "his study aimed to assess the effects of human umbilical cord Wharton\u0027s jelly-derived MSCs (hWJ-MSCs) on diabetes-related intracavernosal pressure (ICP) impairment in rats. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33975986"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 161,
          "text": "harton\u0027s jelly derived mesenchymal stromal cells: Biological properties, induction of neuronal phenotype and current applications in neurodegeneration research.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747736"
        },
        {
          "offsetInBeginSection": 1065,
          "offsetInEndSection": 1260,
          "text": "Wharton\u0027s jelly, WJ) stromal cells have therefore emerged as a more suitable alternative source of MSCs, thanks to their primitive nature and the easy isolation without relevant ethical concerns.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747736"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "This review focuses on the therapeutic potential of stem cells harvested from the Wharton\u0027s Jelly of the human umbilical cord.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21733573"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Human umbilical cord Wharton\u0027s Jelly-derived mesenchymal stem cells differentiation into nerve-like cells.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336835"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Easy and Rapid Methods for Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Human Umbilical Wharton\u0027s Jelly-Derived Mesenchymal Stem Cells.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37140810"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Isolation and Characterization of Feline Wharton\u0027s Jelly-Derived Mesenchymal Stem Cells.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33562192"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "Mesenchymal stem cells (MSCs) from Wharton\u0027s jelly (WJ) of the human umbilical cord are perinatal stem cells that have self-renewal ability, extended proliferation potential, immunosuppressive properties, and are accordingly excellent candidates for tissue engineering.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25517045"
        },
        {
          "offsetInBeginSection": 440,
          "offsetInEndSection": 736,
          "text": "Wharton\u0027s jelly, a gelatinous connective tissue contained in the umbilical cord, is abundant in mesenchymal stem cells (MSCs) that express CD105, CD73, CD90, Oct-4, Sox-2, and Nanog among others, and have the ability to differentiate into osteogenic, adipogenic, chondrogenic, and other lineages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32290584"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Wharton\u0027s jelly (WJ) is a gelatinous tissue within the umbilical cord that contains myofibroblast-like stromal cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23727936"
        },
        {
          "offsetInBeginSection": 322,
          "offsetInEndSection": 536,
          "text": "Wharton’s jelly (WJ) is one of the potential sources of mesenchymal stem cells (MSCs)\n- obtaining these cells does not raise moral or ethical objections, because the umbilical cord (UC) is a regular\nwaste material.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30729769"
        },
        {
          "offsetInBeginSection": 955,
          "offsetInEndSection": 1058,
          "text": "Therefore, umbilical cord, especially Wharton\u0027s jelly, is a promising source of mesenchymal stem cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32290584"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Umbilical cord Wharton\u0027s jelly-derived mesenchymal stem cells (WJ-MSCs) have recently gained considerable attention in the field of regenerative medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32557631"
        },
        {
          "offsetInBeginSection": 516,
          "offsetInEndSection": 811,
          "text": "We hypothesise that repeated intravenous treatment with mesenchymal stromal cells derived from Wharton\u0027s Jelly of the umbilical cord-derived mesenchymal stromal cells ((WJ-UC-MSC) may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neurological status.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Wharton\u0027s jelly-derived mesenchymal stem cells (WJ-MSCs) can be isolated from umbilical cords which is abundant and easy to obtain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39711971"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25622293"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 432,
          "text": "While MSCs can usually be isolated from adults via bone marrow aspiration (BM-MSCs), MSCs derived from the discarded umbilical cord, more precisely from Wharton\u0027s jelly (WJ), offer a low-cost and pain-free collection method of MSCs that may be cryogenically stored, and are considered extremely favorable for tissue engineering purpose.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22785368"
        },
        {
          "offsetInBeginSection": 502,
          "offsetInEndSection": 697,
          "text": "In this study, we defined the best way to isolate MSCs from the Wharton\u0027s jelly of the human umbilical cord (WJ-MSC) and assessed the mesenchymal and immunological phenotype of BM-MSC and WJ-MSC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29267140"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "Mesenchymal stem cells isolated from amnion/amniotic fluid, umbilical cord blood, placental tissue, umbilical cord vein and the Wharton\u0027s Jelly are promising candidates for musculoskeletal tissue engineering of bone and cartilage tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563663"
        },
        {
          "offsetInBeginSection": 1015,
          "offsetInEndSection": 1260,
          "text": "In recent years, umbilical cord (UC) matrix (i.e. Wharton\u0027s jelly, WJ) stromal cells have therefore emerged as a more suitable alternative source of MSCs, thanks to their primitive nature and the easy isolation without relevant ethical concerns.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25747736"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Wharton\u0027s jelly-derived mesenchymal stem cells (WJ-MSCs) are isolated from Wharton\u0027s jelly tissue of umbilical cords.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37629090"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Mesenchymal stem cells (MSCs) are derived from Wharton\u0027s jelly tissue of the human umbilical cord.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28963712"
        },
        {
          "offsetInBeginSection": 212,
          "offsetInEndSection": 373,
          "text": "The aim of this study was to evaluate the possibility of generating mesenchymal cell-based MT using human umbilical cord Wharton\u0027s jelly stromal cells (WJSC-MT).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29931444"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 272,
          "text": "The discovery of mesenchymal stem cells (MSCs) in perinatal sources, such as the amniotic fluid (AF) and the umbilical connective tissue, the so-called Wharton\u0027s jelly (WJ), has transformed them into promising stem cell grafts for the application in regenerative medicine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26482184"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 328,
          "text": "MSCs derived from the discarded umbilical cord, more precisely from Wharton\u0027s jelly (WJ), offer a low-cost and pain-free collection method of MSCs ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22785368"
        },
        {
          "offsetInBeginSection": 635,
          "offsetInEndSection": 753,
          "text": "Wharton\u0027s jelly of the umbilical cord (Wharton\u0027s jelly-derived mesenchymal stem cells (WJ-MSCs)) of 1-day-old piglets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37760347"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 255,
          "text": "MSCs from Wharton\u0027s jelly (WJ) of umbilical cord can be easily harvested and exhibit greater proliferative activity than bone marrow MSCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24704519"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 333,
          "text": "Here, we confine ourselves to discussing mesenchymal-like cells derived from Wharton\u0027s Jelly, called umbilical cord matrix stem cells (UCMSCs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442646"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Wharton\u0027s jelly (WJ) is a gelatinous tissue within the umbilical cord that contains myofibroblast-like stromal cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/23727936/"
        },
        {
          "offsetInBeginSection": 301,
          "offsetInEndSection": 588,
          "text": "This study was conducted to explore the possibility of inducing human umbilical cord Wharton\u0027s Jelly-derived MSCs to differentiate into nerve-like cells.METHODS: MSCs were cultured from the Wharton\u0027s Jelly taken from human umbilical cord of babies delivered after full-term normal labor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16336835"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 227,
          "text": "UC-MSCs can be isolated from the umbilical cord Wharton\u0027s jelly, as well as from the umbilical arteries and umbilical vein.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36094263"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 310,
          "text": "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) have been derived from extra embryonic umbilical cord matrix following removal of both arteries and vein.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24736473"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 268,
          "text": "Wharton\u0027s jelly (WJ) from the umbilical cord (UC) has gained increasing interest in the biomedical field as an outstanding source of MSCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39037235"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 424,
          "text": "Umbilical cord-Wharton\u0027s jelly (WJ-MSCs)-derived MSCs exhibit advantages over those from adult tissues, such as no ethical concerns, shorter population doubling time, broad differentiation potential, readily available non-invasive source, prolonged maintenance of stemness properties.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36526818"
        },
        {
          "offsetInBeginSection": 484,
          "offsetInEndSection": 574,
          "text": "the explant method, small fragments of Wharton\u0027s jelly from the human umbilical cord were ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38618506"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 345,
          "text": "The umbilical cord offers an unlimited source of adult mesenchymal stem cells (ucMSCs) from Wharton\u0027s jelly tissue.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38397024"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 332,
          "text": "Mesenchymal stem cells are undifferentiated cells able to acquire different phenotypes under specific stimuli. Wharton\u0027s jelly is a tissue in the umbilical cord that contains mesenchymal stromal cells (MSCs) with a high plasticity and differentiation potential. Their regeneration capability is compromised by cell damage and aging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37175460"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261,
          "text": "Mesenchymal stem cells are undifferentiated cells able to acquire different phenotypes under specific stimuli. Wharton\u0027s jelly is a tissue in the umbilical cord that contains mesenchymal stromal cells (MSCs) with a high plasticity and differentiation potential.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37175460"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 443,
          "text": "The cells in Wharton\u0027s jelly region of umbilical cord represent a pool source of primitive cells with properties of mesenchymal stem cells (MSCs).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148883"
        },
        {
          "offsetInBeginSection": 342,
          "offsetInEndSection": 640,
          "text": "Several reports indicate that cells of Wharton\u0027s jelly (WJ), the main component of umbilical cord extracellular matrix, are multipotent stem cells, expressing markers of bone marrow mesenchymal stem cells (BM-MSC), and giving rise to different cellular types of both connective and nervous tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19958166"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "The Wharton\u0027s jelly of the umbilical cord contains mucoid connective tissue and fibroblast-like cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15579650"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "text": "The Effect of Human Mesenchymal Stem Cells Derived from Wharton\u0027s Jelly in Spinal Cord Injury Treatment Is Dose-Dependent and Can Be Facilitated by Repeated Application.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29772841"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Wharton\u0027s jelly-derived mesenchymal stem cells (WJ-MSCs) can be isolated from umbilical cords which is abundant and easy to obtain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39711971"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 367,
          "text": "This study investigates the protective effects of exosomes from human umbilical cord Wharton\u0027s jelly mesenchymal stem cells (hWJMSCs) against adiposity and insulin resistance in high-fat diet (HFD)-induced obese mice",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39408777"
        },
        {
          "offsetInBeginSection": 209,
          "offsetInEndSection": 366,
          "text": "rted as well. One such source of MSCs is the Whartons Jelly (WJ) of the umbilical cord, as it provides an inexhaustible source of stem cells for potential th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25069491"
        },
        {
          "offsetInBeginSection": 215,
          "offsetInEndSection": 515,
          "text": "In this study, we conducted a comparative analysis of 4 infusion regimens involving single and repeated infusions of human umbilical cord Wharton\u0027s jelly-derived MSCs (hucMSCs), single infusions of umbilical cord blood mononuclear cells (UCB), and sequential infusions of hucMSCs and UCB in T2DM rats",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39560969"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Intravenous (IV) infusion of mesenchymal stem cells (MSCs) from nascent tissues like Wharton\u0027s Jelly of the umbilical cord is reported to offer therapeutic effects against chronic diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35252487"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 273,
          "text": "The discovery of mesenchymal stem cells (MSCs) in perinatal sources, such as the amniotic fluid (AF) and the umbilical connective tissue, the so-called Wharton\u0027s jelly (WJ), has transformed them into promising stem cell grafts for the application in regenerative medicine. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26482184"
        },
        {
          "offsetInBeginSection": 463,
          "offsetInEndSection": 753,
          "text": "In this study, we compared two types of porcine mesenchymal stem cells (MSCs) isolated from the dorsal subcutaneous adipose tissue (adipose-derived stem cells (ADSCs)) and Wharton\u0027s jelly of the umbilical cord (Wharton\u0027s jelly-derived mesenchymal stem cells (WJ-MSCs)) of 1-day-old piglets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37760347"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 237,
          "text": "Umbilical cord is the easiest obtainable biological source of MSCs and the Wharton\u0027s jelly of the umbilical cord is a rich source of fetus-derived stem cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20880767"
        },
        {
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1238,
          "text": ", compared with that of BM-MSC. MSC from umbilical cord and Wharton\u0027s jelly had a higher proliferative capacity, whereas those from amnion and placenta had a lower proliferativ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23176558"
        },
        {
          "offsetInBeginSection": 593,
          "offsetInEndSection": 856,
          "text": "The UC represents a reservoir of progenitor populations which are collectively grouped into MSCs (mesenchymal stem cells). Such cells have been sourced from each component of the cord, namely the sub-amnion layer, the WJ, the perivascular region, and the vessels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23595555"
        },
        {
          "offsetInBeginSection": 781,
          "offsetInEndSection": 1006,
          "text": "MSCs obtained from the Wharton\u0027s Jelly (WJ) of umbilical cords (UC) have gained much attention over the last years since they can be easily isolated, without any ethical concerns, from a tissue which is discarded after birth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279098"
        },
        {
          "offsetInBeginSection": 312,
          "offsetInEndSection": 448,
          "text": "Wharton\u0027s jelly present in human umbilical cord is discarded after delivery which makes a rich source of MSCs with least ethical issues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33564725"
        },
        {
          "offsetInBeginSection": 622,
          "offsetInEndSection": 716,
          "text": "Precursor MSCs can be isolated in abundance from the Wharton\u0027s jelly of umbilical cord tissue.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29552470"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Human Wharton\u0027s jelly mesenchymal stem cells were isolated from fetal umbilical cord.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206475"
        },
        {
          "offsetInBeginSection": 464,
          "offsetInEndSection": 640,
          "text": "MSCs isolated from Wharton\u0027s jelly (WJ-MSCs), a mucosal connective tissue of the umbilical cord, may be better candidates than MSCs obtained from bone marrow or adipose tissue,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32777963"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Umbilical cord Wharton\u0027s jelly-derived mesenchymal stem cell (WJMSC) is a new-found mesenchymal stem cell in recent years with multiple lineage potential.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28261617"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "Human Wharton\u0027s jelly stem cells (HWJSC) can be efficiently isolated from the umbilical cord, and numerous reports have demonstrated that these cells can differentiate into several cell lineages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32085697"
        },
        {
          "offsetInBeginSection": 697,
          "offsetInEndSection": 823,
          "text": "Wharton\u0027s jelly (the mucous connective tissue of the umbilical cord between the amniotic epithelium and the umbilical vessels)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35088933"
        },
        {
          "offsetInBeginSection": 181,
          "offsetInEndSection": 269,
          "text": "MSCs derived from the discarded umbilical cord, more precisely from Wharton\u0027s jelly (WJ)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22785368"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 237,
          "text": "Umbilical cord mesenchymal stromal cells (UCMSCs) are isolated from Wharton\u0027s jelly in the umbilical cord at birth, and offer advantages over adult mesenchymal stromal cells (MSCs) such as highly efficient isolation, faster proliferation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26279972"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "Mesenchymal stem cells or mesenchymal stromal cells (MSCs) are non-hematopoietic stromal cells that reside in many human organs and have been isolated from a variety of adult or fetal tissues such as adipose tissue, bone marrow and umbilical cord Wharton\u0027s jelly, among others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29714147"
        },
        {
          "offsetInBeginSection": 457,
          "offsetInEndSection": 740,
          "text": "Fetal MSCs derived from amniotic fluid, amniotic membrane, umbilical cord matrix (Wharton\u0027s jelly) and umbilical cord blood are more advantageous than adult MSCs, as they can be isolated noninvasively in large numbers without the ethical reservations associated with embryo research.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23176305"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "The Wharton\u0027s jelly of the umbilical cord is rich in mesenchymal stem cells (UC-MSCs) that fulfill the criteria for MSCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18022578"
        },
        {
          "offsetInBeginSection": 371,
          "offsetInEndSection": 609,
          "text": " therapies. Wharton\u0027s jelly is a connective tissue located within the umbilical cord largely composed of mesenchymal stem cells and extracellular matrix components, including collagen, chondroitin sulfate, hyaluronic acid, and sulfated pr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33176838"
        },
        {
          "offsetInBeginSection": 197,
          "offsetInEndSection": 492,
          "text": "This protocol describes enzymatic and mechanical dissociation of umbilical cord matrix (Wharton\u0027s jelly) that results in efficient isolation of large numbers of fresh nucleated umbilical cord regenerative cells (UC-RCs) that, when cultured on plastic, exhibit similar characteristics of UC-MSCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25388392"
        }
      ],
      "type": "factoid",
      "id": "67cf221a81b1027333000022",
      "ideal_answer": [
        "Mesenchymal stem cells derived from umbilical cord Wharton\u0027s Jelly (WJ-MSCs) are emerging as promising therapeutics for a variety of diseases due to their ability of regeneration and immunomodulation",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the Wharton\u0027s Jelly of the human umbilical cord.",
        "Wharton\u0027s jelly mesenchymal stem cells (WJ-MSCs) are derived from the Wharton\u0027s jelly, which is a gelatinous connective tissue found within the umbilical cord. The umbilical cord is a readily available source of these stem cells, and obtaining them does not raise ethical concerns since the umbilical cord is considered biological waste after birth.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the umbilical cord tissue.",
        "Wharton\u0027s jelly-derived mesenchymal stem cells (WJ-MSCs) are isolated from Wharton\u0027s jelly tissue of umbilical cords. Wharton\u0027s jelly is a gelatinous tissue within the umbilical cord. Therefore, umbilical cord, especially Wharton\u0027s jelly, is a promising source of mesenchymal stem cells.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the Wharton\u0027s Jelly, a gelatinous tissue found in the umbilical cord. This tissue is a promising source for MSCs due to its accessibility, lack of ethical concerns, and the cells\u0027 potential for differentiation into various cell types.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the human umbilical cord, specifically from Wharton\u0027s Jelly.",
        "Based on the provided contexts, Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the Wharton\u0027s jelly, which is a tissue found in the umbilical cord.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are isolated from Wharton\u0027s jelly, the gelatinous connective tissue found within the human umbilical cord. This tissue is distinct from the umbilical arteries and vein and serves as an extra-embryonic source of multipotent stem cells.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the Wharton\u0027s jelly tissue, which is a gelatinous substance found within the human umbilical cord. This tissue surrounds the blood vessels in the umbilical cord and serves to protect them from compression or damage.\n\nThe process of obtaining WJ-MSCs involves collecting the umbilical cord after birth, typically when it would otherwise be discarded as medical waste. The jelly is extracted from the cord, and through enzymatic digestion or mechanical methods, the stem cells are isolated. These cells are then cultured in a laboratory setting to expand their numbers.\n\nUsing Wharton\u0027s jelly for MSCs is advantageous because it does not pose ethical issues, unlike embryonic stem cells, and the collection process is non-invasive with no risk to the mother or baby. WJ-MSCs hold potential for various therapeutic applications due to their ability to differentiate into different cell types such as bone, cartilage, fat, and muscle.\n\nIn summary, Wharton\u0027s Jelly Mesenchymal Stem Cells are sourced from the Wharton\u0027s jelly tissue within the umbilical cord, providing a valuable resource for regenerative medicine.",
        "Wharton\u0027s jelly, a mucoid connective tissue found within the umbilical cord, is the tissue source for deriving Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs). These cells possess characteristics of mesenchymal stem cells, including self-renewal ability, high proliferation potential, and multipotent differentiation capacity.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the umbilical cord.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the human umbilical cord, specifically from the Wharton\u0027s jelly, which is a gelatinous connective tissue within the umbilical cord.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJMSCs) are derived from umbilical cord tissue.",
        "Wharton\u0027s jelly mesenchymal stem cells (WJ-MSCs) are derived from the Wharton\u0027s jelly, which is a gelatinous connective tissue found within the umbilical cord. The umbilical cord is a readily available source of these stem cells, which can be isolated and expanded for potential therapeutic applications without major ethical concerns.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the Wharton\u0027s jelly tissue of umbilical cords.",
        "Wharton\u0027s jelly mesenchymal stem cells are derived from the Wharton\u0027s jelly, which is the gelatinous connective tissue found within the umbilical cord. The umbilical cord is a readily available source of these stem cells that can be harvested without any ethical concerns.",
        "The tissue used to derive Wharton\u0027s Jelly Mesenchymal Stem Cells is the umbilical cord.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from Wharton\u0027s Jelly, a gelatinous substance found within the umbilical cord. Therefore, the tissue used to derive WJ-MSCs is the umbilical cord.",
        "Wharton\u0027s jelly tissue of the human umbilical cord is used to derive Wharton\u0027s Jelly Mesenchymal Stem Cells.",
        "Wharton’s Jelly Mesenchymal Stem Cells are derived from the gelatinous connective tissue known as Wharton’s jelly, which is found within the human umbilical cord.",
        "Wharton\u0027s Jelly tissue of the umbilical cord",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the Wharton\u0027s Jelly of the human umbilical cord. This tissue is a rich source of MSCs, which can be isolated through methods like collagenase digestion or the explant method, and is ethically non-controversial and easily accessible.",
        "The tissue used to derive Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) is the umbilical cord\u0027s Wharton\u0027s jelly.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from Wharton\u0027s Jelly, a gelatinous substance found within the umbilical cord. This tissue is rich in mesenchymal stem cells, which can differentiate into various cell types, making them valuable for regenerative medicine and therapeutic applications.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from umbilical cord Wharton\u0027s Jelly.",
        "Wharton\u0027s jelly mesenchymal stem cells are derived from the umbilical cord.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the Wharton\u0027s jelly, a gelatinous substance found in the umbilical cord. This tissue is considered a suitable source for MSCs due to its primitive nature and ease of isolation without significant ethical concerns.",
        "Wharton\\\u0027s Jelly Mesenchymal Stem Cells (WJ MSCs) are derived from the umbilical cord. Specifically, they are obtained from Wharton\\\u0027s Jelly, a gelatinous substance that surrounds the blood vessels in the umbilical cord and serves as a protective layer for these vessels.",
        "Wharton\u0027s Jelly, derived from the umbilical cord, is the tissue used to obtain Wharton\u0027s Jelly Mesenchymal Stem Cells.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from umbilical cord tissue.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from human umbilical cord tissue.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the gelatinous connective tissue within the human umbilical cord, known as Wharton\u0027s jelly, which is part of the extraembryonic matrix.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from umbilical cord Wharton\u0027s Jelly. Wharton\u0027s jelly stromal cells are a suitable source of MSCs due to their primitive nature and easy isolation.",
        "Wharton\u0027s jelly, a mucoid connective tissue found within the umbilical cord, is the tissue source for deriving Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs). These cells are harvested from the Wharton\u0027s jelly region of the umbilical cord and possess properties of mesenchymal stem cells.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the umbilical cord tissue, specifically from Wharton\u0027s Jelly.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the Wharton\u0027s jelly, a gelatinous substance found within the umbilical cord. This tissue is considered an advantageous source for MSCs due to its primitive nature and ease of isolation without significant ethical concerns.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the Wharton\u0027s jelly of the human umbilical cord, which is a stromal tissue that can be easily isolated without significant ethical concerns.",
        "Wharton\u0027s jelly is the tissue used to derive Wharton\u0027s Jelly Mesenchymal Stem Cells.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the human umbilical cord tissue.",
        " Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the umbilical cord tissue.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells (WJ-MSCs) are derived from the Wharton\u0027s jelly tissue of the umbilical cord. The umbilical cord is a promising source of mesenchymal stem cells due to the ease of isolation and lack of ethical concerns compared to other sources.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the tissue known as Wharton\u0027s Jelly, which is specifically found within the Umbilical Cord. This gelatinous matrix of the umbilical cord serves as the source for these versatile stem cells.",
        "Wharton\u0027s Jelly mesenchymal stem cells are derived from the gelatinous connective tissue known as Wharton\u0027s Jelly, which is found in the umbilical cord. This tissue surrounds the umbilical blood vessels and is a rich source of fetal-derived stem cells.",
        "Umbilical Cord\u0027s Wharton\u0027s Jelly",
        "Wharton\u0027s jelly is an undifferentiated, gelatinous connective tissue inside the umbilical cord.",
        "Wharton\u0027s jelly is used to derive Mesenchymal Stem Cells (MSCs). These cells are emerging as promising therapeutics for a variety of diseases due to their ability of regeneration and immunomodulation.",
        "Wharton\u0027s Jelly Mesenchymal Stem Cells are derived from the Wharton\u0027s Jelly of the umbilical cord."
      ],
      "exact_answer": [
        [
          "Human umbilical cord (hUC)"
        ]
      ]
    },
    {
      "body": "Causes of infectious myocardiopathy.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38910558",
        "http://www.ncbi.nlm.nih.gov/pubmed/33436535",
        "http://www.ncbi.nlm.nih.gov/pubmed/34609508",
        "http://www.ncbi.nlm.nih.gov/pubmed/32720461",
        "http://www.ncbi.nlm.nih.gov/pubmed/31923059",
        "http://www.ncbi.nlm.nih.gov/pubmed/32610473",
        "http://www.ncbi.nlm.nih.gov/pubmed/36947570",
        "http://www.ncbi.nlm.nih.gov/pubmed/18938102",
        "http://www.ncbi.nlm.nih.gov/pubmed/3843596",
        "http://www.ncbi.nlm.nih.gov/pubmed/36589640",
        "http://www.ncbi.nlm.nih.gov/pubmed/25516729",
        "http://www.ncbi.nlm.nih.gov/pubmed/1307005",
        "http://www.ncbi.nlm.nih.gov/pubmed/8682098",
        "http://www.ncbi.nlm.nih.gov/pubmed/39677700",
        "http://www.ncbi.nlm.nih.gov/pubmed/22185868",
        "http://www.ncbi.nlm.nih.gov/pubmed/35898376",
        "http://www.ncbi.nlm.nih.gov/pubmed/18781958"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 750,
          "offsetInEndSection": 829,
          "text": "Cutibacterium acnes, Corynebacterium aurimucosum, and Pseudomonas denitrificans",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38910558"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 26,
          "text": "Human bocavirus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33436535"
        },
        {
          "offsetInBeginSection": 39,
          "offsetInEndSection": 49,
          "text": "parvovirus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33436535"
        },
        {
          "offsetInBeginSection": 621,
          "offsetInEndSection": 687,
          "text": "cardiotropic viruses have been implicated as causes of myocarditis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34609508"
        },
        {
          "offsetInBeginSection": 737,
          "offsetInEndSection": 853,
          "text": "cardiotropic enteroviruses (Coxsackieviruses B), the most commonly detected parvovirus B19, and human herpes virus 6",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34609508"
        },
        {
          "offsetInBeginSection": 943,
          "offsetInEndSection": 953,
          "text": "SARS-CoV-2",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34609508"
        },
        {
          "offsetInBeginSection": 311,
          "offsetInEndSection": 325,
          "text": "Parvovirus B19",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32720461"
        },
        {
          "offsetInBeginSection": 565,
          "offsetInEndSection": 583,
          "text": " Coxsackievirus B3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32720461"
        },
        {
          "offsetInBeginSection": 462,
          "offsetInEndSection": 509,
          "text": "severe acute respiratory syndrome coronavirus 2",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32720461"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 32,
          "text": "Herpes simplex virus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31923059"
        },
        {
          "offsetInBeginSection": 28,
          "offsetInEndSection": 55,
          "text": "Trypanosona cruzi infection",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32610473"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 292,
          "text": "Diphtheria is a life-threatening infectious disease caused by Corynebacterium diphtheriae. Although the disease is seen infrequently in the postvaccination era, sporadic cases continue to occur. Cardiac involvement, in the form of myocarditis, is the most serious manifestation of diphtheria ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36589640"
        },
        {
          "offsetInBeginSection": 738,
          "offsetInEndSection": 959,
          "text": "tmortem examination of the inner cardiac muscles of the dead mice also revealed massive sequestration of mature P. falciparum as well as significant infiltration of inflammatory cells such as lymphocytes and monocytes. Po",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516729"
        },
        {
          "offsetInBeginSection": 664,
          "offsetInEndSection": 985,
          "text": "These results suggest the convenience of considering toxoplasmosis as a cause of chronic myocardiopathy in epidemiological studies on Chagas\u0027 disease, since not discard the presence of Toxoplasma gondii infection should overvaluete the magnitude of the impact of Trypanosoma cruzi in the genesis of such a myocardiopathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1307005"
        },
        {
          "offsetInBeginSection": 342,
          "offsetInEndSection": 1064,
          "text": "Overall, the enteroviruses, and particularly the Coxsackie-B viruses, predominate among viruses as the cause of myocarditis. As new molecular biological techniques have become available, the cytomegaloviruses (CMV) seem to have emerged as a more common cause of myocarditis than was previously recognized. Among the bacterial myocarditides, diphtheric myocarditis has become a serious threat in Russia and adjacent states during the 1990s. Among newly identified bacteria, Borrelia burgdorferi infection is accompanied by cardiac involvement in 1-8% of cases, where myocarditis with conduction disturbances is the most prominent feature. Chlamydia pneumoniae may be associated with myocarditis and sudden unexpected death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8682098"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "In acute myocardiopathy and pericardiopathy, Coxsackie virus B infections are increasingly recognized as a cause of primary myocardial disease and may cause chronic cardiovascular disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3843596"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Trypanosoma cruzi is the etiological agent of Chagas disease, an important cause of infectious chronic myocardiopathy in Latin America.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36947570"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Coxsackievirus B3 (CVB3) is a non-enveloped picornavirus that can cause systemic inflammatory diseases including myocarditis, pericarditis, pancreatitis, and meningoencephalitis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39677700"
        },
        {
          "offsetInBeginSection": 113,
          "offsetInEndSection": 352,
          "text": "In developed countries, viral infections commonly cause myocarditis; however, in the developing world, rheumatic carditis, Trypanosoma cruzi, and bacterial infections such as diphtheria still contribute to the global burden of the disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185868"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 492,
          "text": "This paper summarizes recent data from the literature suggesting that transforming growth factor-beta (TGF-beta) participates at least in four different processes influencing development of myocardiopathy in Chagas disease, a major parasitic illness caused by Trypanosoma cruzi infection: (a) invasion of cardiac fibroblasts and myocytes; (b) intracellular parasite cycle; (c) regulation of inflammation and immune response; (d) fibrosis and heart remodeling during acute and chronic disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18938102"
        },
        {
          "offsetInBeginSection": 89,
          "offsetInEndSection": 183,
          "text": "Coxsackievirus serotype B (CV-B) is a known cause of infectious myocarditis that leads to DCM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35898376"
        },
        {
          "offsetInBeginSection": 289,
          "offsetInEndSection": 546,
          "text": "other viruses such as Parvovirus B19 and human herpesvirus-6 are increasingly reported as causes of myocarditis in the United States, with the most recent example being the severe acute respiratory syndrome coronavirus 2, causing the Coronavirus Disease-19.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32720461"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Chagas heart disease (CHD), caused by the protozoan parasite Trypanosoma cruzi, is the leading cause of infectious myocarditis in the world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18781958"
        }
      ],
      "id": "67d6c1bb18b1e36f2e000029",
      "ideal_answer": [
        "Infectious myocarditis, also known as infectious myocardiopathy, is primarily caused by viral infections. The most common viral agents include Coxsackievirus B, adenovirus, parvovirus B19, and human herpesvirus 6. Other viruses such as influenza, cytomegalovirus, Epstein-Barr virus, and hepatitis C virus can also lead to myocarditis. In addition to viral causes, bacterial infections like those caused by Streptococcus, Staphylococcus, and Borrelia burgdorferi (the causative agent of Lyme disease) can result in myocarditis. Fungal infections, such as those caused by Candida and Aspergillus species, and parasitic infections, including Trypanosoma cruzi (Chagas disease) and Toxoplasma gondii, are less common but also recognized causes of infectious myocarditis.",
        "Infectious myocarditis, also known as infectious myocardiopathy, can be caused by a variety of pathogens. The most common causes are viruses, including Coxsackievirus, Adenovirus, Parvovirus B19, Human herpesvirus 6 (HHV-6), Influenza virus, Hepatitis C virus, and Human immunodeficiency virus (HIV). Bacterial causes, though less common, include Staphylococcus aureus, Streptococcus species, Corynebacterium diphtheriae (causing diphtheria), Borrelia burgdorferi (causing Lyme disease), and Mycobacterium tuberculosis (causing tuberculosis). Fungal causes, which are rare, include Candida species, Aspergillus species, and Histoplasma capsulatum. Parasitic causes include Trypanosoma cruzi (causing Chagas disease) and Toxoplasma gondii (causing toxoplasmosis). Other infectious agents that can cause myocarditis include Rickettsia species (causing rickettsial diseases) and Mycoplasma pneumoniae. These pathogens lead to inflammation of the myocardium, and the exact pathogen responsible can often be identified through clinical evaluation, laboratory testing, and sometimes biopsy of the heart tissue.",
        "Infectious myocarditis, a type of inflammatory heart disease, can be caused by a variety of infectious agents. The most common causes include viral infections such as those caused by Coxsackievirus, adenovirus, and parvovirus B19. Other viral causes include HIV, influenza, and the SARS-CoV-2 virus responsible for COVID-19. Bacterial infections, although less common, can also lead to myocarditis, with agents such as Borrelia burgdorferi (the cause of Lyme disease), Corynebacterium diphtheriae, and Mycobacterium tuberculosis being notable examples. Fungal infections, such as those caused by Candida species, and parasitic infections, such as those caused by Trypanosoma cruzi (Chagas disease) and Toxoplasma gondii, are also recognized causes of infectious myocarditis."
      ],
      "exact_answer": [
        [
          "Trypanosoma cruzi infection"
        ],
        [
          "Parvovirus B19"
        ],
        [
          "Coxsackie B"
        ],
        [
          "cardiotropic enteroviruses"
        ],
        [
          "HHV6"
        ],
        [
          "SARS-CoV-2"
        ],
        [
          "Coxsackieviruses B"
        ],
        [
          "Corynebacterium diphtheriae"
        ]
      ]
    },
    {
      "body": "What\u0027s the effect of germline-mediated immunoediting?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38815010"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "text": "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38815010"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 933,
          "text": "Tumors with the same diagnosis can have different molecular profiles and response to treatment. It remains unclear when and why these differences arise. Somatic genomic aberrations occur within the context of a highly variable germline genome. Interrogating 5870 breast cancer lesions, we demonstrated that germline-derived epitopes in recurrently amplified genes influence somatic evolution by mediating immunoediting. Individuals with a high germline-epitope burden in human epidermal growth factor receptor 2 (HER2/ERBB2) are less likely to develop HER2-positive breast cancer compared with other subtypes. The same holds true for recurrent amplicons defining three aggressive estrogen receptor (ER)-positive subgroups. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype. These data show that the germline genome plays a role in dictating somatic evolution.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38815010"
        }
      ],
      "id": "67d49ade18b1e36f2e00001b",
      "ideal_answer": [
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity.",
        "Germline-mediated immunoediting refers to the process by which germline genetic variations influence the immune system\u0027s ability to recognize and eliminate cancer cells. Specifically, germline variants that alter the expression of certain proteins can create epitopes (molecular patterns) that are recognized by the immune system. This can lead to immunoediting, where the immune system selectively eliminates cancer cells expressing those epitopes. The studies suggest that germline-mediated immunoediting sculpts the molecular profiles and metastatic potential of breast cancers by selecting against amplification of genes containing high burdens of germline-derived epitopes.",
        "Germline-mediated immunoediting modulates the immune response against breast cancer cells, reducing the likelihood of developing aggressive subtypes, such as HER2-positive breast cancer, in individuals with a high burden of germline-derived epitopes in relevant genes. This process selects against somatic gene amplification in these regions. However, tumors that overcome this editing tend to be more aggressive and exhibit an \u0027immune cold\u0027 phenotype. Understanding this process may lead to refined cancer risk stratification within breast cancer subtypes and the development of informative biomarkers, highlighting the germline genome\u0027s role in dictating cancer subtype and metastatic potential.",
        "Germline-mediated immunoediting shapes tumor development by influencing somatic evolution through germline-derived epitopes, particularly in recurrently amplified genes. This process can refine risk stratification within breast cancer subtypes and serves as a potential biomarker for precision immunotherapy. Germline variations, such as HLA variations, have emerged as markers for predicting response to immune checkpoint inhibitors (ICIs). By modulating the antigenicity of neoantigens, immunoediting provides an evolutionary perspective on tumor immune evasion and treatment outcomes.",
        "Germline-mediated immunoediting influences cancer development and progression by modulating immune surveillance and the tumor immune microenvironment. It affects the development of breast cancer subtypes by selecting against somatic gene amplification, leading to more aggressive and immune-evasive tumors. It also alters immune cell infiltration and signaling pathways, impacting cancer progression and response to immunotherapy. Additionally, it can create a pro-tumorigenic environment by disrupting the balance between protumor and antitumor immunity, and by selecting for immunologically evasive tumor variants, leading to more resistant cancer cell populations.",
        "Germline-mediated immunoediting influences the development and progression of breast cancer by shaping the immune response to tumor cells, which can lead to the selection of more aggressive, \u0027immune cold\u0027 tumors. This process can also inform the development of biomarkers and potential targets for immunotherapy, refining risk stratification and treatment strategies within breast cancer subtypes.",
        "Germline-mediated immunoediting sculpts tumor evolution by using inherited variants that produce immune-recognized epitopes, particularly in highly expressed or amplified genes. These epitopes enhance immune surveillance early in tumor development, influencing which somatic changes persist. In breast cancer, this process shapes distinct subtypes and affects metastatic proclivity by counteracting gene amplifications and other alterations that contribute to aggressive behavior. A higher burden of germline-derived epitopes can lead to stronger immune recognition, reducing the accumulation of tumor-promoting changes.",
        "Germline-mediated immunoediting is a process where the immune system influences the development of tumors by selecting against the amplification of certain genes, such as ERBB2 in breast cancer, thereby shaping the tumor\u0027s genome and its immunogenicity. This process can lead to the enrichment of mechanisms of carcinogenesis, including promoter hypermethylation of neoantigen genes, and can result in the loss of antigen expression and MHC molecules, ultimately reshaping the tumor\u0027s immunogenicity.",
        "Germline-mediated immunoediting selectively suppresses tumor development in breast cancer, reducing the likelihood of aggressive subtypes like HER2-positive and high-risk ER-positive cancers. This process influences somatic evolution, but tumors that overcome immunoediting become more aggressive with an \u0027immune cold\u0027 phenotype. As a result, germline-mediated immunoediting plays a crucial role in shaping breast cancer development and may aid in refining risk stratification within subtypes, potentially informing biomarker development for more accurate cancer risk assessment.",
        "Germline-mediated immunoediting influences somatic evolution in tumors by mediating the selection of tumor cells that can evade immune detection. In a study of 5870 breast cancer lesions, it was demonstrated that germline-derived epitopes in recurrently amplified genes play a significant role in this process. Tumors that successfully overcome immune-mediated negative selection tend to be more aggressive and exhibit an \"immune cold\" phenotype, which is characterized by a lack of immune cell infiltration and a reduced immune response. This suggests that the presence of specific germline epitopes can impact the immunogenicity of tumors and their ability to escape immune surveillance.",
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. It influences somatic evolution by modulating immunoediting at early stages of tumor development. Specifically, individuals with a high burden of germline-derived epitopes in recurrently amplified genes, such as ERBB2 (HER2), are less likely to develop HER2-positive breast cancer compared to other subtypes. This holds true for other recurrent amplicons that define aggressive estrogen receptor (ER)-positive subgroups. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype. These findings suggest that the germline genome plays a previously unappreciated role in dictating somatic evolution and may inform the development of biomarkers for risk stratification within breast cancer subtypes.",
        "Germline-mediated immunoediting sculpts the molecular profiles and metastatic potential of breast cancer tumors. Individuals with a high burden of germline-derived epitopes in amplified genes like HER2 are less likely to have somatic amplification of those genes in their tumors due to immune surveillance against the germline epitopes. This immunoediting process shapes the subtype and aggressiveness of breast cancers from early stages of tumor development.",
        "Germline-mediated immunoediting influences somatic evolution by modulating immunoediting at early stages of tumor development, and selects against somatic gene amplification in breast cancer, particularly in recurrently amplified genes with germline-derived epitopes.",
        "Germline-mediated immunoediting refers to the process by which germline variants in highly expressed and amplified genes influence the somatic evolution of tumors by modulating immune surveillance and selection against somatic gene amplification. Specifically, the burden of germline-derived epitopes in recurrently amplified genes like HER2 can shape tumor development and metastatic potential by mediating immunoediting at early stages. Individuals with a high germline-epitope burden in these genes are less likely to develop tumors with amplification of those genes due to immune recognition and elimination of cells with high expression.",
        "Germline-mediated immunoediting influences the development and progression of cancer by affecting the somatic evolution of tumors, potentially leading to different cancer subtypes and metastatic behaviors.",
        "Germline-mediated immunoediting refers to the process by which germline-derived epitopes (protein fragments) influence the somatic evolution of tumors by modulating immune surveillance and editing of cancer cells. Individuals with a high burden of germline-derived epitopes in amplified oncogenes like HER2 tend to have tumors that avoid amplification of those genes, likely due to enhanced immune recognition and elimination of cells expressing those epitopes. This germline-mediated immunoediting shapes the molecular profiles and subtypes of breast cancers, as well as their metastatic potential.",
        "Germline-mediated immunoediting has a dual impact on breast cancer. It reduces the likelihood of aggressive subtypes, such as HER2-positive and high-risk ER-positive cancers, by selecting against certain somatic gene amplifications. However, tumors that evade this editing process tend to become more aggressive with an \u0027immune cold\u0027 phenotype. This mechanism is crucial for shaping breast cancer development, offering potential for refining risk stratification within subtypes and informing the development of more accurate cancer risk biomarkers.",
        "Germline-mediated immunoediting influences somatic tumor evolution by modulating the development of breast cancer subtypes and metastatic proclivity.",
        "Germline-mediated immunoediting has a significant impact on tumor development, as it shapes the somatic evolution of cancer cells through the selection of resistant tumor cell variants. Studies have demonstrated that germline-derived epitopes in recurrently amplified genes influence this process, mediating immunoediting and refining risk stratification within breast cancer subtypes. By exploiting these germline-mediated effects, researchers can develop biomarkers for precision immunotherapy, providing an evolutionary perspective on the antigenicity of neoantigens. This concept is crucial in oncology, as it reveals a potential biomarker for predicting response to immunotherapies, such as immune checkpoint inhibitors (ICIs), and informs the development of targeted treatments that take into account the complex interplay between tumor cells, the host immune system, and germline variations.",
        "Germline-mediated immunoediting influences tumor development by shaping the antigenic landscape that the immune system encounters during carcinogenesis. In essence, inherited genetic variants can generate epitopes that trigger immune responses, leading to the selective elimination of tumor cells carrying certain somatic alterations. This process can restrict the amplification of oncogenes and steer tumor evolution toward phenotypes that are less immunogenic, thereby influencing the subtype and metastatic potential of cancers. Ultimately, these germline variations contribute to a dynamic interplay between genetic predisposition and immune surveillance, modulating both tumor progression and the response to immunotherapies.",
        "Germline-mediated immunoediting influences breast cancer subtypes and metastatic potential by shaping tumor development through immune selection. It involves germline-derived epitopes in amplified genes modulating somatic evolution, with tumors escaping immune selection becoming more aggressive and exhibiting an \u0027immune cold\u0027 phenotype. This process also informs biomarker development for risk stratification in breast cancer.",
        "Germline variants in highly expressed and amplified genes influence somatic evolution by modulating immunoediting at early stages of tumor development. Specifically, the burden of germline-derived epitopes in recurrently amplified genes selects against somatic gene amplification in breast cancer. In essence, germline-derived epitopes in recurrently amplified genes influence somatic evolution by mediating immunoediting.",
        "Germline-mediated immunoediting significantly influences tumor development and progression by shaping the immune response to cancer cells. It affects tumor development by altering immune surveillance, impacting tumor evolution. In breast cancer, it influences the somatic evolution of subtypes, affecting their molecular profiles and metastatic potential. Germline-mediated immunoediting may explain the relatively low tumor mutational burden (TMB) in BRCA1/2 germline mutation-related tumors, compensating for inadequate DNA repair. It also impacts the oncogenic mutational landscape and immune escape patterns through HLA class I and II genotypes. The germline HLA repertoire contributes to tumor-immune recognition and immunoediting, as seen in studies of lung cancer tumors. Further studies are needed to clarify the role of immunoediting in protecting against genetic damage in BRCA1/2 germline mutation carriers. Overall, germline-mediated immunoediting plays a crucial role in shaping the immune response to tumors, influencing tumor development, mutational burden, and immune escape mechanisms.",
        "Germline-mediated immunoediting plays a crucial role in shaping breast cancer subtypes and tumor aggressiveness. It influences somatic evolution by mediating immune responses through germline-derived epitopes in recurrently amplified genes. Specifically, individuals with a high germline-epitope burden in genes like HER2/ERBB2 are less likely to develop HER2-positive breast cancer. Tumors that overcome this immune-mediated negative selection tend to become more aggressive and develop an \u0027immune cold\u0027 phenotype, demonstrating how the germline genome can dictate the trajectory of tumor development.",
        "Germline-mediated immunoediting provides protection against the development of specific aggressive breast cancer subtypes, notably HER2-positive breast cancer in individuals with a high germline-epitope burden in HER2/ERBB2, and certain aggressive estrogen receptor (ER)-positive subgroups with recurrent amplicons. This protection is conferred through enhanced immune recognition of germline-derived epitopes. However, tumors that overcome this immunoediting process tend to exhibit increased aggressiveness and an \u0027immune cold\u0027 phenotype, characterized by reduced responsiveness to immune surveillance, highlighting a trade-off between immune evasion and malignancy.",
        "Germline mediated immunoediting sculpts breast cancer subtypes and influences metastatic proclivity.",
        "Germline-mediated immunoediting has a significant impact on the development and progression of breast cancer subtypes. Studies have shown that germline-derived epitopes in recurrently amplified genes, such as human epidermal growth factor receptor 2 (HER2/ERBB2), influence somatic evolution by mediating immunoediting. As a result, individuals with a high germline-epitope burden in these genes are less likely to develop certain breast cancer subtypes, including HER2-positive and aggressive estrogen receptor (ER)-positive subgroups. However, tumors that overcome this immune-mediated negative selection tend to be more aggressive and exhibit an \"immune cold\" phenotype, suggesting that the germline genome plays a crucial role in shaping somatic evolution and ultimately affecting treatment outcomes.",
        "Germline-mediated immunoediting influences the development and aggressiveness of breast cancer subtypes by shaping somatic evolution through immune selection. Individuals with a high germline-epitope burden in specific genes, such as HER2/ERBB2 or those defining aggressive ER-positive subgroups, are less likely to develop certain types of breast cancer. Tumors that evade this immunoediting process tend to be more aggressive and exhibit an \u0027immune cold\u0027 phenotype.",
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Individuals with a high germline-epitope burden in human epidermal growth factor receptor 2 (HER2/ERBB2) are less likely to develop HER2-positive breast cancer compared with other subtypes. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype.",
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Germline variants in highly expressed and amplified genes influence somatic evolution by modulating immunoediting at early stages of tumor development. The burden of germline-derived epitopes in recurrently amplified genes selects against somatic gene amplification in breast cancer. Individuals with a high germline-epitope burden in human epidermal growth factor receptor 2 (HER2/ERBB2) are less likely to develop HER2-positive breast cancer compared with other subtypes. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype.",
        "Germline-mediated immunoediting influences somatic evolution and shapes breast cancer subtypes and metastatic proclivity.",
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Individuals with a high germline-epitope burden in human epidermal growth factor receptor 2 (HER2/ERBB2) are less likely to develop HER2-positive breast cancer compared with other subtypes. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an immune cold phenotype.",
        "Germline-mediated immunoediting influences the somatic evolution of breast cancer by shaping tumor subtypes and their metastatic potential. Specifically, it affects the presence of germline-derived epitopes in recurrently amplified genes, which can lead to immune-mediated negative selection of certain cancer subtypes. For instance, individuals with a high burden of germline epitopes in the HER2 gene are less likely to develop HER2-positive breast cancer. Tumors that evade this immune selection tend to be more aggressive and exhibit an \"immune cold\" phenotype, indicating that the germline genome plays a significant role in determining the characteristics and behavior of breast cancer.",
        "Germline-mediated immunoediting influences the development and aggressiveness of breast cancer subtypes by shaping somatic evolution. This process involves the immune system\u0027s selective pressure on tumors based on germline-derived epitopes in recurrently amplified genes, such as HER2/ERBB2. Individuals with a higher germline-epitope burden in these genes are less likely to develop HER2-positive breast cancer compared to other subtypes. Similarly, aggressive ER-positive subgroups are also affected. Tumors that manage to evade this immune-mediated negative selection tend to be more aggressive and exhibit an \"immune cold\" phenotype, indicating reduced immune cell infiltration and activity. This highlights the critical role of the germline genome in influencing tumor evolution and immune response dynamics in breast cancer.",
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Exploiting germline-mediated immunoediting may inform the development of biomarkers that refine risk stratification within breast cancer subtypes.",
        "Germline-mediated immunoediting is a process through which inherited genetic variations shape how the immune system targets developing tumor cells. The germline genome encodes epitopes that are presented by the immune system, influencing which somatic alterations can survive. For instance, individuals with a high burden of germline-derived epitopes in genes that are frequently amplified—such as HER2/ERBB2—are less likely to develop HER2-positive breast cancer, while recurrent amplicons associated with aggressive estrogen receptor-positive subgroups are similarly reduced. Furthermore, germline variants like those that enhance STAT3 function can promote immune evasion, allowing tumors to bypass this immunosurveillance. Tumors that overcome these selective pressures tend to exhibit an “immune cold” phenotype and are more aggressive, ultimately affecting both cancer subtypes and metastatic potential.",
        "Germline-mediated immunoediting influences somatic evolution by mediating immunoediting. Individuals with a high germline-epitope burden in HER2 are less likely to develop HER2-positive breast cancer. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype.",
        "Germline-mediated immunoediting influences somatic evolution by mediating immunoediting in breast cancer. Individuals with a high germline-epitope burden in HER2/ERBB2 are less likely to develop HER2-positive breast cancer. The same holds true for recurrent amplicons defining three aggressive ER-positive subgroups. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype, indicating that the germline genome plays a role in dictating somatic evolution.",
        "Germline-mediated immunoediting influences somatic evolution by modulating immunoediting at early stages of tumor development. It can sculpt breast cancer subtypes and metastatic proclivity. In MMR-deficient cancers, it leads to a counter-selection of highly immunogenic antigens. Specifically, germline-derived epitopes in recurrently amplified genes influence somatic evolution by mediating immunoediting, and the burden of these epitopes reduces the likelihood of somatic gene amplification in breast cancer. Individuals with a high germline-epitope burden in human epidermal growth factor receptor 2 (HER2/ERBB2) are less likely to develop HER2-positive breast cancer compared with other subtypes. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype.",
        "Germline-mediated immunoediting influences breast cancer subtypes and metastatic potential by shaping tumor evolution through immune interactions. Individuals with high germline-epitope burdens in genes like HER2/ERBB2 are less likely to develop certain aggressive breast cancers, as these epitopes mediate negative selection against such tumors. Tumors that evade this immune-mediated suppression tend to be more aggressive and exhibit an \u0027immune cold\u0027 phenotype.",
        "Germline-mediated immunoediting influences somatic evolution in tumors by affecting the development of specific cancer subtypes. In breast cancer, a high burden of germline-derived epitopes in genes such as HER2 (ERBB2) is associated with a reduced likelihood of developing HER2-positive breast cancer. This suggests that the immune system may select against certain tumor characteristics based on the germline genome. Tumors that manage to evade this immune-mediated negative selection tend to be more aggressive and exhibit an \"immune cold\" phenotype, indicating a potential link between germline genetics and tumor aggressiveness.",
        "Germline-mediated immunoediting influences the somatic evolution of breast cancer by shaping the molecular profiles and metastatic tendencies of tumors. It does so through germline-derived epitopes in amplified genes, which mediate immune selection against certain cancer subtypes, such as HER2-positive breast cancer and aggressive ER-positive subgroups. Tumors that evade this immune selection tend to be more aggressive and exhibit an immune cold phenotype.",
        "Germline-mediated immunoediting influences somatic evolution in breast cancer by shaping tumor subtypes and metastatic potential. Specifically, individuals with a high germline-epitope burden in certain genes (e.g., HER2/ERBB2) are less likely to develop corresponding breast cancer subtypes. This suggests that the immune system selectively eliminates tumor cells with these epitopes, leading to the development of alternative subtypes. Tumors that overcome this immunoediting process tend to be more aggressive and exhibit an \"immune cold\" phenotype, characterized by reduced immune activity. Overall, germline-mediated immunoediting plays a role in dictating somatic evolution and tumor progression in breast cancer.",
        "Germline-mediated immunoediting significantly influences tumor evolution and immune interactions by shaping the immunogenicity of tumors. It involves the selection against somatic gene amplifications in breast cancer, where individuals with a high burden of germline-derived epitopes, particularly in genes like HER2 (ERBB2), are less likely to develop certain aggressive breast cancer subtypes. This process occurs through three phases: elimination, equilibrium, and escape, where the immune system initially suppresses tumor growth but can also facilitate tumor escape from immune detection. Tumors that successfully evade immune-mediated negative selection tend to exhibit more aggressive characteristics and an \"immune cold\" phenotype. Understanding these dynamics can inform the development of biomarkers for risk stratification and improve immunotherapeutic strategies by addressing the mechanisms of resistance that arise during tumor evolution.",
        "Germline-mediated immunoediting significantly influences cancer development and progression by shaping the somatic evolution of tumors. Specifically, germline-derived epitopes in recurrently amplified genes can mediate immunoediting, leading to variations in tumor characteristics and aggressiveness. For instance, individuals with a high burden of germline-derived epitopes in the HER2 gene are less likely to develop HER2-positive breast cancer compared to other subtypes. This suggests that the germline genome plays a critical role in determining which tumor subtypes may arise and their subsequent behavior. Tumors that manage to evade immune-mediated negative selection tend to be more aggressive and exhibit an \"immune cold\" phenotype, indicating a lack of immune response. Overall, understanding germline-mediated immunoediting may help refine risk stratification and inform the development of biomarkers in breast cancer.",
        "Germline-mediated immunoediting influences the somatic evolution of breast cancer by affecting the development of different subtypes and their metastatic potential. It does so by mediating immune responses against germline-derived epitopes in recurrently amplified genes, which can lead to immune-mediated negative selection of certain tumor subtypes, resulting in more aggressive and \u0027immune cold\u0027 phenotypes.",
        "Germline-mediated immunoediting shapes the development, subtype, and metastatic potential of breast cancer by influencing somatic evolution, especially in genes with high germline-epitope burdens. Individuals with such burdens in genes like HER2/ERBB2 are less likely to develop corresponding subtypes. However, tumors that overcome this immune selection tend to be more aggressive and exhibit an \u0027immune cold\u0027 phenotype, underscoring the germline genome\u0027s role in dictating cancer evolution and treatment responses.",
        "Germline-mediated immunoediting influences the somatic evolution of breast cancer by shaping tumor immunogenicity and metastatic behavior. It involves the selection of tumor variants based on germline-derived epitopes, which can lead to differences in cancer subtypes and their aggressiveness. For instance, individuals with a high burden of germline epitopes in the HER2 gene are less likely to develop HER2-positive breast cancer. Tumors that evade immune-mediated negative selection tend to be more aggressive and exhibit an \"immune cold\" phenotype, indicating a reduced immune response. Overall, the germline genome plays a crucial role in determining how tumors evolve and respond to immune pressures.",
        "Germline-mediated immunoediting influences the development of breast cancer subtypes and their tendency to metastasize. It shapes the immune landscape and can affect how breast cancer progresses and responds to treatment.",
        "Germline-mediated immunoediting has a protective effect against developing certain aggressive breast cancer subtypes, notably HER2-positive and specific estrogen receptor (ER)-positive subgroups with recurrent amplicons, in individuals with a high germline-epitope burden in relevant genes. However, tumors that overcome this immune selection process tend to become more aggressive and exhibit an \u0027immune cold\u0027 phenotype, characterized by reduced responsiveness to immune surveillance, highlighting a trade-off between immune evasion and increased malignancy.",
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Tumors with the same diagnosis can have different molecular profiles and response to treatment. It remains unclear when and why these differences arise. Somatic genomic aberrations occur within the context of a highly variable germline genome. Interrogating 5870 breast cancer lesions, we demonstrated that germline-derived epitopes in recurrently amplified genes influence somatic evolution by mediating immunoediting. Individuals with a high germline-epitope burden in human epidermal growth factor receptor 2 (HER2/ERBB2) are less likely to develop HER2-positive breast cancer compared with other subtypes. The same holds true for recurrent amplicons defining three aggressive estrogen receptor (ER)-positive subgroups. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype. These data show that the germline genome plays a role in dictating somatic evolution.",
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Germline-derived epitopes in recurrently amplified genes influence somatic evolution by mediating immunoediting. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype.",
        "Germline-mediated immunoediting plays a crucial role in sculpting breast cancer subtypes and influencing metastatic potential. Research examining 5870 breast cancer lesions revealed that germline-derived epitopes in recurrently amplified genes influence somatic evolution through immunoediting mechanisms. Individuals with high germline-epitope burden in HER2/ERBB2 are less likely to develop HER2-positive breast cancer. Similarly, this pattern applies to recurrent amplicons defining aggressive estrogen receptor (ER)-positive subgroups. Tumors that manage to overcome this immune-mediated negative selection tend to be more aggressive and exhibit an \u0027immune cold\u0027 phenotype. These findings demonstrate that the germline genome significantly influences somatic evolution in breast cancer, affecting both subtype development and aggressiveness.",
        "Studies have shown that germline-mediated immunoediting influences the development and progression of breast cancer by shaping tumor evolution through immune interactions. Specifically, individuals with a high burden of germline-derived epitopes in genes such as HER2/ERBB2 are less likely to develop HER2-positive breast cancer compared to other subtypes. This phenomenon also applies to aggressive estrogen receptor (ER)-positive subgroups defined by recurrent amplicons. Tumors that evade this immune-mediated selection tend to exhibit more aggressive behavior and an \"immune cold\" phenotype, highlighting the role of germline genetics in modulating tumor immunity and clinical outcomes.",
        "Germline-mediated immunoediting influences somatic evolution in breast cancer by mediating negative selection on certain tumor subtypes. Specifically, individuals with a high germline-epitope burden in HER2 or recurrent amplicons are less likely to develop corresponding aggressive breast cancer subtypes. Tumors that overcome this immune-mediated negative selection are more aggressive and exhibit an \"immune cold\" phenotype.",
        "Germline-mediated immunoediting sculpts the molecular profiles and aggressiveness of breast cancer subtypes. Individuals with a high germline-epitope burden in genes like HER2/ERBB2 are less likely to develop HER2-positive breast cancer compared to other subtypes. Tumors that overcome this immune-mediated negative selection tend to be more aggressive and exhibit an \u0027immune cold\u0027 phenotype, indicating that the germline genome plays a role in shaping somatic evolution of breast cancer.",
        "Germline-mediated immunoediting offers protection against developing specific aggressive breast cancer subtypes, notably HER2-positive cancer, in individuals with a high germline-epitope burden in genes like HER2/ERBB2. This protection stems from enhanced immune recognition of germline-derived epitopes. However, tumors evading this process tend to be more aggressive with an \u0027immune cold\u0027 phenotype, reducing responsiveness to immune surveillance. This highlights the germline genome\u0027s influence on breast cancer\u0027s development, subtype, and potential treatment response, underscoring its role in shaping the disease\u0027s aggressiveness and metastatic potential.",
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Germline-derived epitopes in recurrently amplified genes influence somatic evolution by mediating immunoediting. Individuals with a high germline-epitope burden in human epidermal growth factor receptor 2 (HER2/ERBB2) are less likely to develop HER2-positive breast cancer compared with other subtypes. The same is true for recurrent amplicons defining three aggressive estrogen receptor (ER)-positive subgroups. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype.",
        "Germline-mediated immunoediting selectively protects against the development of specific aggressive breast cancer subtypes by enhancing immune recognition of germline-derived epitopes, thereby reducing the likelihood of certain cancer subtypes, such as HER2-positive breast cancer, from arising.",
        "Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. It remains unclear when and why these differences arise. Somatic genomic aberrations occur within the context of a highly variable germline genome. In a study of 5870 breast cancer lesions, germline-derived epitopes in recurrently amplified genes were shown to influence somatic evolution by mediating immunoediting. Individuals with a high germline-epitope burden in human epidermal growth factor receptor 2 (HER2/ERBB2) are less likely to develop HER2-positive breast cancer compared with other subtypes. The same holds true for recurrent amplicons defining three aggressive estrogen receptor (ER)-positive subgroups. Tumors that overcome such immune-mediated negative selection are more aggressive and demonstrate an \"immune cold\" phenotype.",
        "Germline-mediated immunoediting influences somatic evolution in cancer. Specifically, germline-derived epitopes in recurrently amplified genes can mediate immunoediting, impacting the development and progression of tumors. In breast cancer, a high germline-epitope burden in genes like HER2/ERBB2 is associated with a lower likelihood of developing HER2-positive breast cancer. Tumors that overcome this immune-mediated negative selection tend to be more aggressive and exhibit an \"immune cold\" phenotype. This demonstrates that the germline genome plays a role in dictating somatic evolution by modulating immunoediting at early stages of tumor development.",
        "Germline-mediated immunoediting influences breast cancer development by affecting somatic evolution through immune-based selection. Specifically, individuals with high germline-epitope burden in HER2/ERBB2 are less likely to develop HER2-positive breast cancer, and tumors that overcome this immune-mediated selection tend to be more aggressive and display an \"immune cold\" phenotype, demonstrating how the germline genome shapes tumor evolution.",
        "Germline-mediated immunoediting influences the somatic evolution of breast cancer by shaping tumor subtypes and metastatic tendencies, with individuals having a high germline-epitope burden in certain genes being less likely to develop specific aggressive cancer types. This process can lead to tumors that are more aggressive and exhibit an \u0027immune cold\u0027 phenotype."
      ]
    },
    {
      "body": "Please list diseases that can be treated with MSCs, Human Mesenchymal Stem cells",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37132309",
        "http://www.ncbi.nlm.nih.gov/pubmed/37190944",
        "http://www.ncbi.nlm.nih.gov/pubmed/38219142",
        "http://www.ncbi.nlm.nih.gov/pubmed/38245543",
        "http://www.ncbi.nlm.nih.gov/pubmed/25248677",
        "http://www.ncbi.nlm.nih.gov/pubmed/23722500",
        "http://www.ncbi.nlm.nih.gov/pubmed/31898783",
        "http://www.ncbi.nlm.nih.gov/pubmed/19530993",
        "http://www.ncbi.nlm.nih.gov/pubmed/23864795",
        "http://www.ncbi.nlm.nih.gov/pubmed/34272720",
        "http://www.ncbi.nlm.nih.gov/pubmed/33414832",
        "http://www.ncbi.nlm.nih.gov/pubmed/17226788",
        "http://www.ncbi.nlm.nih.gov/pubmed/24816447",
        "http://www.ncbi.nlm.nih.gov/pubmed/20528757",
        "http://www.ncbi.nlm.nih.gov/pubmed/24198531",
        "http://www.ncbi.nlm.nih.gov/pubmed/22352750",
        "http://www.ncbi.nlm.nih.gov/pubmed/21396594",
        "http://www.ncbi.nlm.nih.gov/pubmed/11482873",
        "http://www.ncbi.nlm.nih.gov/pubmed/11953022",
        "http://www.ncbi.nlm.nih.gov/pubmed/35444971",
        "http://www.ncbi.nlm.nih.gov/pubmed/37566772",
        "http://www.ncbi.nlm.nih.gov/pubmed/25173395",
        "http://www.ncbi.nlm.nih.gov/pubmed/18947375",
        "http://www.ncbi.nlm.nih.gov/pubmed/27688156",
        "http://www.ncbi.nlm.nih.gov/pubmed/18950680",
        "http://www.ncbi.nlm.nih.gov/pubmed/32565049",
        "http://www.ncbi.nlm.nih.gov/pubmed/34612662",
        "http://www.ncbi.nlm.nih.gov/pubmed/35546750",
        "http://www.ncbi.nlm.nih.gov/pubmed/12021494",
        "http://www.ncbi.nlm.nih.gov/pubmed/21082892",
        "http://www.ncbi.nlm.nih.gov/pubmed/35344199",
        "http://www.ncbi.nlm.nih.gov/pubmed/21073342",
        "http://www.ncbi.nlm.nih.gov/pubmed/21277690",
        "http://www.ncbi.nlm.nih.gov/pubmed/24350294",
        "http://www.ncbi.nlm.nih.gov/pubmed/32733574",
        "https://pubmed.ncbi.nlm.nih.gov/19539211/",
        "https://pubmed.ncbi.nlm.nih.gov/25274529/",
        "https://pubmed.ncbi.nlm.nih.gov/23592412/",
        "https://pubmed.ncbi.nlm.nih.gov/28257800/",
        "http://www.ncbi.nlm.nih.gov/pubmed/39698413",
        "http://www.ncbi.nlm.nih.gov/pubmed/21280154",
        "http://www.ncbi.nlm.nih.gov/pubmed/20923800",
        "http://www.ncbi.nlm.nih.gov/pubmed/39582803",
        "http://www.ncbi.nlm.nih.gov/pubmed/27293445",
        "http://www.ncbi.nlm.nih.gov/pubmed/23027703",
        "http://www.ncbi.nlm.nih.gov/pubmed/39736844",
        "http://www.ncbi.nlm.nih.gov/pubmed/39732760",
        "http://www.ncbi.nlm.nih.gov/pubmed/32117924",
        "http://www.ncbi.nlm.nih.gov/pubmed/29662803",
        "http://www.ncbi.nlm.nih.gov/pubmed/38664281",
        "http://www.ncbi.nlm.nih.gov/pubmed/21366911/",
        "http://www.ncbi.nlm.nih.gov/pubmed/38179215",
        "http://www.ncbi.nlm.nih.gov/pubmed/39716885",
        "http://www.ncbi.nlm.nih.gov/pubmed/39716323",
        "http://www.ncbi.nlm.nih.gov/pubmed/23197640",
        "http://www.ncbi.nlm.nih.gov/pubmed/21767114",
        "http://www.ncbi.nlm.nih.gov/pubmed/25050543",
        "http://www.ncbi.nlm.nih.gov/pubmed/27248788",
        "http://www.ncbi.nlm.nih.gov/pubmed/22586171",
        "http://www.ncbi.nlm.nih.gov/pubmed/38003230",
        "http://www.ncbi.nlm.nih.gov/pubmed/36831227",
        "http://www.ncbi.nlm.nih.gov/pubmed/34454603",
        "http://www.ncbi.nlm.nih.gov/pubmed/15494428",
        "http://www.ncbi.nlm.nih.gov/pubmed/26804815",
        "http://www.ncbi.nlm.nih.gov/pubmed/37143147",
        "http://www.ncbi.nlm.nih.gov/pubmed/32698898",
        "http://www.ncbi.nlm.nih.gov/pubmed/28133600"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Human Umbilical Cord Mesenchymal Stem Cells Alleviate Rat Knee Osteoarthritis via Activating Wnt/ β-catenin Signaling Pathway",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37132309"
        },
        {
          "offsetInBeginSection": 378,
          "offsetInEndSection": 505,
          "text": " This study evaluated the therapeutic potential and underlying mechanism of hUC-MSCs in alleviating pathological symptoms of OA",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37132309"
        },
        {
          "offsetInBeginSection": 1886,
          "offsetInEndSection": 2172,
          "text": "Overall, this study demonstrated that hUC-MSCs induce the secretion of some cytokines via the paracrine function to activate the Wnt/β-catenin signaling pathway to reduce the pathological condition of OA and maintain the proper expression of cytokines and extracellular matrix proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37132309"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Mesenchymal stem cells- an excellent therapeutic agent for cancer.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37190944"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 261,
          "text": " Our previous single-center, randomized, double-blinded, placebo-controlled phase 2 study evaluated the safety and effectiveness of human umbilical cord mesenchymal stromal cell (UC-MSC) transfusion for treating patients with type 2 diabetes mellitus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38219142"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "MSCs mediate long-term efficacy in a Crohn\u0027s disease model by sustained anti-inflammatory macrophage programming via efferocytosis",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38245543"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Mesenchymal stem cells (MSCs) are novel therapeutics for the treatment of Crohn\u0027s disease. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38245543"
        },
        {
          "offsetInBeginSection": 300,
          "offsetInEndSection": 587,
          "text": "MSC based therapies have proven to be effective in preclinical studies for graft versus host disease, stroke, myocardial infarction, pulmonary fibrosis, autoimmune disorders and many other conditions and are currently undergoing clinical trials at a number of centers all over the world.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25248677"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 305,
          "text": "Mesenchymal stem cells (MSCs) have emerged as a therapeutic approach in a range of medical fields, including regenerative medicine, cancer, autoimmune diseases, and inflammatory diseases, because of their unique properties of tissue repair and major histocompatibility complex-unmatched immunosuppression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23722500"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23722500"
        },
        {
          "offsetInBeginSection": 1150,
          "offsetInEndSection": 1254,
          "text": "Here, we focus on the potential use of MSC for immunological disorders such as Crohn\u0027s disease and GvHD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31898783"
        },
        {
          "offsetInBeginSection": 1175,
          "offsetInEndSection": 1463,
          "text": "Many clinical applications of adult MSCs are in progress and are using bone marrow or adipose tissue-derived MSCs for the treatment of Graft Versus Host Disease (GVHD), inflammatory joint diseases and osteocartilagineous defects, digestive tract, cardiovascular and neurological diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22352750"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 385,
          "text": "MSCs have immunomodulatory properties and can be used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and Crohn\u0027s disease. MSCs also can be used in cancer and aging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34272720"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 850,
          "text": "In the clinical setting, MSCs are being explored in trials of various conditions, including orthopedic injuries, graft versus host disease following bone marrow transplantation, cardiovascular diseases, autoimmune diseases, and liver diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23864795"
        },
        {
          "offsetInBeginSection": 1033,
          "offsetInEndSection": 1194,
          "text": "To conclude, MSCs is a novel treatment that may be used for GVHD, tissue toxicity and hemorrhages because of its immune inhibitory and anti-inflammatory effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21396594"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 342,
          "text": "MSCs have immunomodulatory properties and can be used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and Crohn\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34272720"
        },
        {
          "offsetInBeginSection": 420,
          "offsetInEndSection": 555,
          "text": "MSCs possess immunosuppressive properties, which may be used for the treatment of neurological disorders with an inflammatory etiology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20528757"
        },
        {
          "offsetInBeginSection": 1251,
          "offsetInEndSection": 1411,
          "text": "Nevertheless, MSCs represent a promising new approach to treating diseases of the central nervous system that are traditionally associated with morbid outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20528757"
        },
        {
          "offsetInBeginSection": 304,
          "offsetInEndSection": 557,
          "text": "Mesenchymal stem cells (MSC), given their ability to differentiate into multiple cell types, could potentially be used to treat diseases such as osteogenesis imperfecta, muscular dystrophy, and other mesenchymal disorders that can be diagnosed in utero.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11482873"
        },
        {
          "offsetInBeginSection": 304,
          "offsetInEndSection": 548,
          "text": "Mesenchymal stem cells (MSC), given their ability to differentiate among multiple lineages, could potentially be used to treat diseases such as osteogenesis imperfecta, muscular dystrophy, and a variety of others that can be diagnosed in utero.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11953022"
        },
        {
          "offsetInBeginSection": 318,
          "offsetInEndSection": 466,
          "text": "We treated patients with life-threatening acute graft-versus-host disease (GVHD) not responding to conventional immunosuppressive therapy with MSCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21396594"
        },
        {
          "offsetInBeginSection": 1401,
          "offsetInEndSection": 1526,
          "text": "Clinical trials involving MSCs are currently underway for MS, ALS, traumatic brain injuries, spinal cord injuries and stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25248677"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Bronchopulmonary Dysplasia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35444971"
        },
        {
          "offsetInBeginSection": 813,
          "offsetInEndSection": 926,
          "text": "We conclude that MSCs are an important therapeutic option for regenerative treatment in COPD, ARDS, and COVID-19,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37566772"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Mesenchymal stromal cells (MSCs) are currently under investigation for the treatment of inflammatory bowel disease (IBD), including Crohn\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25173395"
        },
        {
          "offsetInBeginSection": 1172,
          "offsetInEndSection": 1294,
          "text": "This function of MSCs can be exploited for their therapeutic application in degenerative joint diseases such as RA and OA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18947375"
        },
        {
          "offsetInBeginSection": 807,
          "offsetInEndSection": 1060,
          "text": "These properties, among others, make MSCs a promising potential therapeutic agent in the treatment of chronic lung diseases with high rates of morbidity and mortality, such as idiopathic pulmonary fibrosis (IPF), COPD and obstructive bronchiolitis (OB).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27688156"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 231,
          "text": "Multiple sclerosis is a currently incurable inflammatory demyelinating syndrome. Recent reports suggest that bone marrow derived mesenchymal stem cells may have therapeutic potential in experimental models of demyelinating disease,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18950680"
        },
        {
          "offsetInBeginSection": 249,
          "offsetInEndSection": 498,
          "text": "Human gingiva derived MSCs (GMSCs) are superior in regulating immune responses. Here, we demonstrate that the adoptive transfer of GMSCs homes to and maintains in the kidney and has a robust therapeutic effect in a spontaneous lupus nephritis model.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32565049"
        },
        {
          "offsetInBeginSection": 456,
          "offsetInEndSection": 608,
          "text": "highlighting MSC role on difficult-to-treat high-incidence diseases such as the current COVID-19, HIV infections, and autoimmune and metabolic diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33414832"
        },
        {
          "offsetInBeginSection": 843,
          "offsetInEndSection": 1023,
          "text": "MSCs are being investigated in over 80 clinical trials for difficult-to-treat infectious diseases, including sepsis and pulmonary, intra-abdominal, cutaneous, and viral infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34612662"
        },
        {
          "offsetInBeginSection": 716,
          "offsetInEndSection": 928,
          "text": "This review analyzes several MSC transplantation trials to treat neurological diseases, such as demyelinating injury, spinal cord injury, paraplegia, Parkinson\u0027s disease, cochlear injury, and Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35546750"
        },
        {
          "offsetInBeginSection": 377,
          "offsetInEndSection": 531,
          "text": "MSCs to treat musculoskeletal diseases such as bone fractures, bone defects, focal chondral lesions, osteoarthritis, spinal diseases, and tendon injuries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24816447"
        },
        {
          "offsetInBeginSection": 565,
          "offsetInEndSection": 859,
          "text": "These observations lend support to the potential utility of MSC for cellular and/or gene therapy in the treatment of a variety of congenital or acquired diseases such as osteogenesis imperfecta, muscular dystrophy, lysosomal storage diseases, and for enhancement of bone marrow transplantation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12021494"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Mesenchymal stem cells for the treatment of neurodegenerative disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21082892"
        },
        {
          "offsetInBeginSection": 828,
          "offsetInEndSection": 1127,
          "text": "We summarize the biological effects and mechanisms of action of MSCs, elucidating recent clinical trials phases and findings, highlighting therapeutic effects of MSCs in several representative diseases, including neurological, musculoskeletal diseases and most recent Coronavirus infectious disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35344199"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 592,
          "text": "At present, there are a significant number of clinical trials exploring the use of MSCs for the treatment of various diseases, including myocardial infarction and stroke, in which oxygen suppression causes widespread cell death, and others with clear involvement of the immune system, such as graft-versus-host disease, Crohn\u0027s disease, and diabetes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198531"
        },
        {
          "offsetInBeginSection": 658,
          "offsetInEndSection": 886,
          "text": "Reports of successful immune modulation suggest efficacy in a wide range of autoimmune conditions, such as demyelinating neurological disease (multiple sclerosis), systemic lupus erythematosus, and Crohn\u0027s disease, among others.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073342"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 376,
          "text": "Preclinical studies indicate that allogeneic human mesenchymal stem cells (MSCs) may be useful for the treatment of several clinical disorders, including sepsis, acute renal failure, acute myocardial infarction, and more recently, acute lung injury (ALI).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21277690"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "text": "The regenerative abilities and the immunosuppressive properties of mesenchymal stromal cells (MSCs) make them potentially the ideal cellular product of choice for treatment of autoimmune and other immune mediated disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24350294"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 278,
          "text": "Mesenchymal stem cells/marrow stromal cells (MSCs) present a promising tool for cell therapy, and are currently being tested in US FDA-approved clinical trials for myocardial infarction, stroke, meniscus injury, limb ischemia, graft-versus-host disease and autoimmune disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21082892"
        },
        {
          "offsetInBeginSection": 162,
          "offsetInEndSection": 356,
          "text": "MSCs have been studied in multiple clinical trials to treat liver diseases, peripheral nerve damage, graft-versus-host disease, autoimmune diseases, diabetes mellitus, and cardiovascular damage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32733574"
        },
        {
          "offsetInBeginSection": 932,
          "offsetInEndSection": 1026,
          "text": "Accumulated animal and human data support MSC therapeutic potential for inflammatory diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19530993"
        },
        {
          "offsetInBeginSection": 716,
          "offsetInEndSection": 973,
          "text": "In this review, we discuss clinical trials based on the use of MSCs in cardiovascular diseases, such as treatment of acute myocardial infarction, endstage ischemic heart disease, or prevention of vascular restenosis through stem cell-mediated injury repair.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17226788"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 432,
          "text": "In addition to multilineage differentiation capacity, MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19530993"
        },
        {
          "offsetInBeginSection": 1164,
          "offsetInEndSection": 1361,
          "text": "The current understanding of cellular and molecular targets underlying the mechanisms of MSCs action in inflammatory settings as well as clinical experience with hMSCs is summarized in this review.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19530993"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 210,
          "text": "Human MSCs were used to treat de novo acute GVHD (aGVHD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/19539211/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Mesenchymal stem cells (MSCs) are useful in tissue repair but also possess immunomodulatory properties.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/25274529/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Mesenchymal stem cells (MSCs) have great potential for cell therapy in regenerative medicine, including liver disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/23592412/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Mesenchymal stem cells (MSCs) have immunosuppressive and tissue repair properties, but clinical trials using MSCs to prevent or treat graft-versus-host disease (GVHD) have shown mixed results.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/28257800/"
        },
        {
          "offsetInBeginSection": 949,
          "offsetInEndSection": 1325,
          "text": "MSC extracellular vesicles are used in the treatment of inflammatory diseases such as rheumatoid arthritis, liver injury, COVID-19, and allergies; in the repair of tissue damage in heart disease, kidney injury, and osteoarthritic diseases; as a carrier in the treatment of tumors; and as a regenerative agent in neurodegenerative disorders such as Alzheimer\u0027s and Parkinson\u0027s.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39698413"
        },
        {
          "offsetInBeginSection": 526,
          "offsetInEndSection": 723,
          "text": "We review here the potential of MSCs as new therapeutic agents in the treatment of diabetic cardiomyopathy, diabetic nephropathy, diabetic polyneuropathy, diabetic retinopathy, and diabetic wounds.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21280154"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "Preclinical studies indicate that allogeneic human mesenchymal stem cells (MSC) may be useful for the treatment of several clinical disorders, including sepsis, acute renal failure, acute myocardial infarction, and more recently, acute lung injury (ALI).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20923800"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 934,
          "text": "MSCs have shown promise in therapeutic studies for a variety of diseases and have become a new source of innovative solutions for the treatment of some obstetric and gynecological diseases. This review systematically presents the latest research on the use of MSCs in the treatment of obstetrics- and gynecology-related diseases. Specifically, this review encompasses the latest findings related to the role of MSCs in premature ovarian failure, polycystic ovary syndrome, ovarian cancer, fallopian tube-related diseases, uterine adhesions, endometriosis, cesarean scar defects, postmenopausal osteoporosis, and pelvic floor dysfunction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39582803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27293445"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Osteoarthritis is a degenerative disease of cartilage, and exosome derived from mesenchymal stem cells (MSCs) are considered promising for treating inflammatory musculoskeletal disorders,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39736844"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Mesenchymal stem cells (MSCs) have been widely used in the treatment of various inflammatory diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39732760"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 311,
          "text": "A large number of studies have shown the beneficial effects of MSC-based therapies to treat different pathologies, including neurological disorders, cardiac ischemia, diabetes, and bone and cartilage diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32117924"
        },
        {
          "offsetInBeginSection": 1241,
          "offsetInEndSection": 1412,
          "text": "Transplantation of MSCs is subject of almost 200 clinical trials to cure and treat a very broad range of conditions, including bone, heart, and neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23027703"
        },
        {
          "offsetInBeginSection": 693,
          "offsetInEndSection": 911,
          "text": "However, given their ability to differentiate into other cell types, MSCs have also been tested in treating a myriad of conditions from diabetes to Parkinson\u0027s disease, apparently of the ectoderm and endoderm lineages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29662803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "Mesenchymal stem cells (MSCs) have been demonstrated to be efficacious in clinical applications for the amelioration of immune disorders, including graft-versus-host disease (GvHD) and Crohn\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38664281"
        },
        {
          "offsetInBeginSection": 593,
          "offsetInEndSection": 789,
          "text": "With no less impact, MSCs have been used as cell therapy to treat defects in bone and cartilage and to help in wound healing, or in combination with biomaterials in tissue engineering development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198531"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 414,
          "text": "erosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in pr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21366911/"
        },
        {
          "offsetInBeginSection": 59,
          "offsetInEndSection": 401,
          "text": "ells with self-renewal ability and multi-differentiation ability, have become the \"practical stem cells\" for the treatment of diseases. MSCs have immunomodulatory properties and can be used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and Crohn\u0027s disease. MSCs also can be used in cancer and aging. At present, man",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34272720"
        },
        {
          "offsetInBeginSection": 120,
          "offsetInEndSection": 607,
          "text": "be used to treat many chronic diseases. Diabetes mellitus (DM) is a frequently diagnosed chronic disease characterized by hyperglycemia which initiates many multisystem complications in the long-run. DM patients can benefit from MSCs transplantation to curb down the pathological consequences associated with hyperglycemia persistence and restore the function of damaged tissues. MSCs therapeutic outcomes are found to last for short period of time and ultimately these regenerative cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38179215"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 366,
          "text": "Mesenchymal stem cells (MSCs) have been used to treat a variety of ischemic diseases in animal models and clinical trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27293445"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Mesenchymal stem cells (MSCs) have been widely used in the treatment of various inflammatory diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39732760"
        },
        {
          "offsetInBeginSection": 365,
          "offsetInEndSection": 485,
          "text": "Many studies have shown that mesenchymal stem cells (MSCs) can promote liver regeneration after partial hepatectomy (PH)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39716885"
        },
        {
          "offsetInBeginSection": 212,
          "offsetInEndSection": 383,
          "text": "Transplantation of human (allogeneic) adipose tissue-derived mesenchymal stem cell (adMSC) suspensions has been clinically conducted to treat retinal degenerative diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39716323"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Human mesenchymal stem cells (MSC) are promising candidates for cell therapy of neurological diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21767114"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "Mesenchymal stem cell (MSC)-based therapies have generated much hope and promise as a potential source of cells for cell-based therapeutic strategies in pediatric degenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25050543"
        },
        {
          "offsetInBeginSection": 1256,
          "offsetInEndSection": 1373,
          "text": "Thus, EOM derived MSC might be good candidates for stem cell based therapies for treating neurodegenerative diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27248788"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22586171"
        },
        {
          "offsetInBeginSection": 906,
          "offsetInEndSection": 1253,
          "text": "Clinical application of MSCs in rare cases of severe disease in which other existing treatment modalities have failed, have demonstrated potential use in treating multiple diseases, including rheumatoid arthritis, systemic lupus erythematosus, myocardial infarction, liver cirrhosis, spinal cord injury, multiple sclerosis, and COVID-19 pneumonia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38003230"
        },
        {
          "offsetInBeginSection": 716,
          "offsetInEndSection": 1361,
          "text": "In this review, we discuss clinical trials based on the use of MSCs in cardiovascular diseases, such as treatment of acute myocardial infarction, endstage ischemic heart disease, or prevention of vascular restenosis through stem cell-mediated injury repair. We analyze data from clinical trials for treatment of osteogenesis imperfecta (OI), which is a genetic disease characterized by production of defective type I collagen. We describe progress for neurological disease treatment with MSC transplants. We discuss data on amyotrophic lateral sclerosis (ALS) and on lysosomal storage diseases (Hurler syndrome and metachromatic leukodystrophy).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17226788"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 444,
          "text": "In preclinical and clinical studies, MSCs have been shown to be highly efficient in treating graft-versus-host disease, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, myocardial infarction, liver cirrhosis, inflammatory bowel disease, and other disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23197640"
        },
        {
          "offsetInBeginSection": 119,
          "offsetInEndSection": 592,
          "text": "There is overwhelming evidence of the usefulness of MSCs in regenerative medicine, tissue engineering, and immune therapy. At present, there are a significant number of clinical trials exploring the use of MSCs for the treatment of various diseases, including myocardial infarction and stroke, in which oxygen suppression causes widespread cell death, and others with clear involvement of the immune system, such as graft-versus-host disease, Crohn\u0027s disease, and diabetes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198531"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "The use of mesenchymal stromal cells (MSCs) for clinical application is intensively investigated for a variety of areas, such as bone repair, haematological and autoimmune diseases, and solid organ transplantation [...].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36831227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "BACKGROUND: Human mesenchymal stem cells (hMSCs) therapy has recently been considered a promising treatment for atopic dermatitis (AD) due to their immunomodulation and tissue regenerat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34454603"
        },
        {
          "offsetInBeginSection": 232,
          "offsetInEndSection": 403,
          "text": "a role for bone marrow-derived MSCs in reducing the incidence and severity of graft-versus-host disease (GVHD) during allogeneic transplantation has recently been reported",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15494428"
        },
        {
          "offsetInBeginSection": 715,
          "offsetInEndSection": 916,
          "text": "Due to their ability to differentiate into different cell types and to suppress and modulate the immune system, MSCs are being developed for treating a plethora of diseases, including immune disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26804815"
        },
        {
          "offsetInBeginSection": 279,
          "offsetInEndSection": 376,
          "text": "Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32698898"
        },
        {
          "offsetInBeginSection": 950,
          "offsetInEndSection": 1199,
          "text": "ous system disorders. In the present study, the therapeutic effects of MSC secretome were reviewed and discussed the possible mechanisms in the three most prevalent central nervous system disorders, namely Alzheimer\u0027s disease, multiple sclerosis, an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37143147"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "The utilization of mesenchymal stem cells (also known as mesenchymal stromal cells, or MSCs) as a cell-based therapy for diseases that have ongoing inflammatory damage has become increasingly available.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28133600"
        }
      ],
      "type": "list",
      "id": "67cc94f681b102733300000e",
      "ideal_answer": [
        "Human Mesenchymal Stem cells cab be used to treat a number of difernt diseases including, Covid-19, osteoarthritis, cancer, diabetes, Crohn\u0027s diseasse.",
        "MSCs have been shown to be effective in a range of murine models of respiratory disease, and there are currently five clinical trials involving the administration of MSCs for respiratory diseases, including COPD and emphysema.",
        "Diseases that can be treated with mesenchymal stem cells (MSCs) include osteoarthritis (OA), neuroinflammation-related diseases, inflammatory bowel disease, arthritis, inflammatory eye diseases, respiratory diseases (such as asthma and acute respiratory distress syndrome), and cardiac diseases.",
        "MSCs can be used to treat conditions like GVHD, autoimmune diseases, neurological disorders, and cardiovascular diseases.",
        "Diseases that can be treated with mesenchymal stem cells (MSCs) include: 1. Chronic kidney disease (CKD) 2. Pulmonary fibrosis (PF) 3. Osteoarthritis (OA) 4. Intrauterine adhesion (IUA) 5. Tendinopathy 6. Periodontal disease 7. Wound healing and skin regeneration 8. Various inflammatory diseases (e.g., arthritis, inflammatory bowel disease) 9. Retinal diseases (e.g., diabetic retinopathy, age-related macular degeneration) 10. Nonunion fractures.",
        "Systemic lupus erythematosus, Crohn\u0027s disease, Cancer, Diabetes mellitus, these diseases can be treated with MSCs due to their immunomodulatory properties and regenerative abilities, which help in restoring damaged tissues and reducing the pathological consequences associated with these conditions.",
        "Diseases that can be treated with mesenchymal stem cells (MSCs) include osteoarthritis (OA), neuroinflammation-related diseases, inflammatory bowel disease, arthritis, inflammatory eye diseases, respiratory diseases (such as asthma and acute respiratory distress syndrome), and retinal diseases.",
        "Diseases that can be treated with mesenchymal stem cells (MSCs) include osteoarthritis (OA), neuroinflammation-related diseases, retinal diseases, inflammatory diseases (such as arthritis, inflammatory bowel disease, inflammatory eye diseases, asthma, and acute respiratory distress syndrome), and conditions requiring wound healing and skin regeneration.",
        "MSCs, Human Mesenchymal Stem cells can be used to treat diseases such as neurological disorders, Osteogenesis imperfecta, Muscular dystrophy, pulmonary dysfunctions, reproductive disorders, skin burns, cardiovascular conditions, and Crohn\u0027s disease.",
        "Diseases that can be treated with MSCs (Human Mesenchymal Stem cells) include:\n\n1. Graft-versus-host disease (GVHD)\n2. Autoimmune diseases\n3. Cardiovascular diseases\n4. Ischemic limb diseases\n5. Acute and chronic graft-versus-host disease\n6. Acute kidney ischemic injury\n7. Liver diseases (e.g. liver fibrosis, cirrhosis)\n8. Kidney diseases (e.g. diabetic kidney disease)\n9. Osteo-diseases\n10. Age-related diseases\n11. Neurodegenerative diseases\n12. Chronic skin inflammatory diseases\n13. Inflammatory and autoimmune diseases (e.g. multiple sclerosis, rheumatoid arthritis)\n14. Hematological diseases (e.g. acute lymphoblastic leukemia)\n15. Graft failure\n16. Tissue damage\n17. Steroid-refractory acute graft-versus-host disease\n18. Acute graft-vers",
        "Mesenchymal stem cells (MSCs) have shown promising therapeutic potential for treating a wide range of diseases due to their immunomodulatory, anti-inflammatory, and regenerative properties. Some key diseases that can potentially be treated with MSCs include autoimmune diseases like systemic lupus erythematosus and Crohn\u0027s disease, graft-versus-host disease, neurodegenerative diseases like multiple sclerosis, musculoskeletal diseases, cardiovascular diseases like myocardial infarction, and even cancer.",
        "Diseases that can be treated with Human Mesenchymal Stem Cells (MSCs) include:\n  - Autoimmune Diseases: Systemic Lupus Erythematosus (SLE), Crohn\u0027s Disease, Graft Versus Host Disease (GVHD)\n  - Inflammatory Diseases: Various, including Periodontitis, Chronic skin wound treatment\n  - Cancer and Aging\n  - Cardiovascular Diseases: Acute Myocardial Infarction (MI), End-stage ischemic heart disease, Heart Failure\n  - Neurological Diseases: Stroke, Brain and spinal cord injury, Amyotrophic Lateral Sclerosis (ALS), Lysosomal storage diseases\n  - Other Diseases: Osteogenesis Imperfecta (OI), Bone fractures, Cartilage and bone injury, Kidney, muscle, and lung repair, COVID-19, HIV infections, Metabolic diseases, Diabetes\n",
        "Mesenchymal stromal cells (MSCs) are being explored as a treatment for a wide range of diseases due to their ability to differentiate into various cell types, modulate the immune system, and promote regeneration. These include autoimmune and immune-mediated disorders, inflammatory diseases, infectious diseases, and lung diseases such as ARDS, pneumonia, COPD, asthma, idiopathic pulmonary fibrosis, and those caused by viral infections like Tuberculosis and SARS-COV-2. MSCs are also being investigated for central nervous system disorders like Alzheimer\u0027s disease, multiple sclerosis, and Parkinson\u0027s disease, as well as conditions like myocardial infarction, stroke, meniscus injury, limb ischemia, graft-versus-host disease, diabetes, rheumatoid arthritis and other pathologic conditions.",
        "Diseases that can be treated with MSCs (Human Mesenchymal Stem cells):\n\n1. Autoimmune disorders (e.g., rheumatoid arthritis, lupus)\n2. Cardiovascular disorders (e.g., heart failure, myocardial infarction)\n3. Graft-versus-host disease (GVHD)\n4. Parkinson\u0027s disease\n5. Alzheimer\u0027s disease\n6. Huntington\u0027s disease\n7. Multiple sclerosis\n8. Sepsis\n9. Crohn\u0027s disease\n10. Graft rejection\n11. Osteoarthritis\n12. Pulmonary fibrosis\n13. Kidney disease (e.g., acute kidney injury, chronic kidney disease)\n14. Liver disease (e.g., cirrhosis, liver failure)\n15. Spinal cord injury\n16. Stroke\n17. COVID-19 pneumonia\n18. Myasthenia gravis\n19. Cancer (e.g., leukemia, lymphoma)\n20. Bone fractures\n21",
        "Mesenchymal stem cells (MSCs) have shown therapeutic potential in treating a variety of diseases. Based on the context provided, some of the diseases that can be treated with MSCs include: 1. COVID 19 : MSC therapy has been explored for its ability to modulate the immune response and reduce cytokine storms in severe cases of COVID 19. 2. Knee Osteoarthritis (OA) : Human umbilical cord mesenchymal stem cells (hUC MSCs) have demonstrated therapeutic effects by activating the Wnt/β catenin signaling pathway, reducing pathological symptoms, and maintaining proper cytokine and extracellular matrix protein expression. 3. Cancer : MSCs exhibit anticancer properties, potentially through their interaction with various signaling pathways. Engineered MSCs show advantages over non engineered ones in cancer therapy. Additionally, MSCs are being investigated for other conditions such as autoimmune diseases, neurological disorders (e.g., multiple sclerosis), and cardiovascular diseases due to their regenerative and immunomodulatory properties.",
        "Mesenchymal Stem Cells (MSCs) have shown therapeutic potential in treating various diseases. Studies have demonstrated their effectiveness in alleviating symptoms of Osteoarthritis (OA) by activating the Wnt/β-catenin signaling pathway, as well as their anticancer properties by affecting different signaling pathways. Additionally, MSCs have been found to be a promising treatment for COVID-19, with clinical trials evaluating their safety and efficacy. They have also been used to treat Type 2 Diabetes Mellitus (T2DM), with some patients showing significant response to therapy. Furthermore, MSCs have been shown to mediate long-term efficacy in treating Crohn\u0027s disease by promoting anti-inflammatory macrophage programming. Overall, the diseases that can be treated with MSCs include Osteoarthritis, cancer, COVID-19, Type 2 Diabetes Mellitus, and Crohn\u0027s disease, highlighting their potential as a versatile therapeutic agent.",
        "Mesenchymal stem cells (MSCs) have shown therapeutic potential in treating several diseases. Clinical trials and studies have explored their use in managing Crohn\u0027s disease, SARS-CoV-2 infection, type 2 diabetes mellitus, and osteoarthritis (OA). Additionally, MSCs are being investigated for their anticancer properties and as a treatment for COVID-19.",
        "Type 2 diabetes mellitus, cancer, Crohn\u0027s disease, and osteoarthritis can be treated with Human Mesenchymal Stem cells.",
        "MSCs and hMSCs have shown therapeutic potential in a wide range of diseases, including autoimmune conditions like multiple sclerosis, systemic lupus erythematosus, Crohn\u0027s disease, and type 2 diabetes mellitus. They are also being explored for regenerative purposes in conditions such as myocardial infarction, stroke, meniscus injury, limb ischemia, graft-versus-host disease, sepsis, acute renal failure, acute lung injury, cardiovascular disease, brain and spinal cord injury, cartilage and bone injury, Alzheimer\u0027s disease, Parkinson\u0027s disease, Amyotrophic Lateral Sclerosis, Huntington\u0027s disease, osteoarthritis, liver diseases, peripheral nerve damage, and polyQ disorders. Additionally, MSCs are being investigated for their anticancer properties and potential in treating infectious diseases like COVID-19.",
        "MSCs and hUC-MSCs can be used to treat COVID-19, knee osteoarthritis, cancer, type 2 diabetes mellitus, and Crohn\u0027s disease.",
        "Diseases that can be treated with mesenchymal stem cells (MSCs) include: COVID-19, osteoarthritis, type 2 diabetes mellitus, Crohn\u0027s disease, various cancers, acute graft-versus-host disease, amyotrophic lateral sclerosis, acute respiratory distress syndrome, neurological diseases (such as Parkinson\u0027s disease, multiple sclerosis, and Alzheimer\u0027s disease), and inflammatory diseases.",
        "MSCs, Human Mesenchymal Stem cells, can be used to treat a variety of diseases including neurological disorders, Osteogenesis imperfecta, Muscular dystrophy, pulmonary dysfunctions, reproductive disorders, skin burns, cardiovascular conditions, and Crohn\u0027s disease.",
        "Human umbilical cord-derived mesenchymal stem cells have been studied for their potential in treating several conditions including COVID-19 (SARS‑CoV‑2 infection), osteoarthritis, cancer (with engineered MSCs also being explored for enhanced anticancer properties), Crohn’s disease, and type 2 diabetes mellitus.",
        "Diseases that can be treated with mesenchymal stem cells (MSCs) include: COVID-19, osteoarthritis (OA), type 2 diabetes mellitus (T2DM), Crohn\u0027s disease, and various cancers.",
        "Mesenchymal stem cells (MSCs) have been studied for their therapeutic potential in treating various diseases, including Crohn\u0027s disease, cancer, SARS-CoV-2 infection, type 2 diabetes mellitus, and osteoarthritis (OA).",
        "Diseases that can be treated with mesenchymal stem cells (MSCs) include: COVID-19, osteoarthritis, type 2 diabetes mellitus, Crohn\u0027s disease, autoimmune diseases (such as systemic lupus erythematosus), graft-versus-host disease (GVHD), liver disease, and diabetic foot disease.",
        "Human Mesenchymal Stem Cells can be used to treat diseases like osteoarthritis, type 2 diabetes mellitus, COVID-19, cancer, and Crohn\u0027s disease.",
        "Diseases that can be treated with mesenchymal stem cells (MSCs) include: COVID-19, osteoarthritis, type 2 diabetes mellitus, Crohn\u0027s disease, autoimmune diseases (such as systemic lupus erythematosus), liver disease, and diabetic foot disease.",
        "Human Mesenchymal Stem Cells (MSCs) have shown therapeutic potential in treating the following diseases: \n- COVID-19 (severe cases), leveraging immunomodulatory and anti-inflammatory properties.\n- Osteoarthritis (OA), alleviating joint degeneration via the Wnt/β-catenin pathway.\n- Cancer (various types), utilizing tumor tropic and immune-modulatory properties.\n- Type 2 Diabetes Mellitus (T2DM), effective in specific patient subsets with reduced insulin needs.\n- Crohn\u0027s Disease, mediating long-term anti-inflammatory responses in chronic small intestinal inflammation.",
        "Human Mesenchymal Stem Cells can be used to treat the following diseases: SARS-CoV-2 infection, knee osteoarthritis, type 2 diabetes mellitus, Crohn\u0027s disease.",
        "Human Mesenchymal Stem cells can be used to treat SARS-CoV-2 Infection, Cancer, Crohn\u0027s Disease, Osteoarthritis, and Type 2 Diabetes Mellitus.",
        "Human Mesenchymal Stem cells can be used to treat COVID-19, Umbilical Cord Mesenchymal Stem Cells can be used to treat Osteoarthritis, and Mesenchymal stem cells are being tested for the treatment of Cancer. Human Mesenchymal Stem cells have also been tested for the treatment of Type 2 Diabetes.",
        "MSCs, Human Mesenchymal Stem cells, can be used to treat COVID-19, Osteoarthritis, Cancer, Type 2 Diabetes Mellitus, and Crohn\u0027s disease."
      ],
      "exact_answer": [
        [
          "Covid 19"
        ],
        [
          "Osteoarthritis"
        ],
        [
          "Cancer"
        ],
        [
          "Diabetes"
        ],
        [
          "Crohns disease"
        ],
        [
          "ronchopulmonary Dysplasia"
        ],
        [
          "graft verses host disease"
        ],
        [
          "neurological disorders"
        ],
        [
          "COPD"
        ],
        [
          "Lupus"
        ],
        [
          "multiple Sclerosis"
        ]
      ]
    },
    {
      "body": "Are there biomarkers of depression?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39510417",
        "http://www.ncbi.nlm.nih.gov/pubmed/39277033",
        "http://www.ncbi.nlm.nih.gov/pubmed/39586142",
        "http://www.ncbi.nlm.nih.gov/pubmed/38261718",
        "http://www.ncbi.nlm.nih.gov/pubmed/39063234",
        "http://www.ncbi.nlm.nih.gov/pubmed/29576552",
        "http://www.ncbi.nlm.nih.gov/pubmed/30181751",
        "http://www.ncbi.nlm.nih.gov/pubmed/33834401",
        "http://www.ncbi.nlm.nih.gov/pubmed/38735080"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1361,
          "offsetInEndSection": 1403,
          "text": "mild elevation of NfL in bipolar disorder ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39510417"
        },
        {
          "offsetInBeginSection": 1650,
          "offsetInEndSection": 1698,
          "text": "positive correlation between sNfl and depression",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39277033"
        },
        {
          "offsetInBeginSection": 338,
          "offsetInEndSection": 701,
          "text": "Eighteen MDD-related differential metabolites have been identified, involving pathways of phospholipids, glycerolipids, fatty acids, sphingolipids, cholesterol, vitamin E, and heme. A potential biomarker combination consisting of palmitelaidic acid, gamma carboxyethyl hydroxychroman (gamma-CEHC), and lysoPE(16:0) was confirmed for predicting depression in women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39586142"
        },
        {
          "offsetInBeginSection": 1145,
          "offsetInEndSection": 1345,
          "text": "Further, this review point to the inflammatory response, metabolic marker, and microribonucleic acids, long non-coding RNAs, HPA axis which are - related to depression and can serve as future targets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38261718"
        },
        {
          "offsetInBeginSection": 132,
          "offsetInEndSection": 231,
          "text": "There is currently no defined or agreed upon biomarker/s for depression that can be readily tested.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39063234"
        },
        {
          "offsetInBeginSection": 1620,
          "offsetInEndSection": 1967,
          "text": "The data suggest that these miRNAs have a potential to be used as a biomarker of depression with sensitivity 77.8% and specificity of 61.5% for miR-16, 94.4% and 41.0% for miR-135a as well as 86.1% and 61.5% for miR-1202, respectively (P \u003c 0.001).CONCLUSION: Our findings showed that these miRNA can be used as a biomarker of depression diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30181751"
        },
        {
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1159,
          "text": "At present, metabolomics study revealed with high precision that a neurometabolite panel consisting of plasma metabolite biomarkers (GABA, dopamine, tyramine, kynurenine) might represent clinically useful biomarkers of MDD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33834401"
        },
        {
          "offsetInBeginSection": 441,
          "offsetInEndSection": 672,
          "text": "With the discovery of more diagnostic biomarkers associated with MDD in recent years, especially emerging non-coding RNAs (ncRNAs), it is possible to quantify the condition of patients with mental illness based on biomarker levels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38735080"
        },
        {
          "offsetInBeginSection": 1246,
          "offsetInEndSection": 1404,
          "text": "In depressed patients, frontal theta asymmetry was reversed during music listening.CONCLUSION: Frontal theta asymmetry is a potential biomarker of depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29576552"
        }
      ],
      "type": "summary",
      "id": "67d723d918b1e36f2e000039",
      "ideal_answer": []
    },
    {
      "body": "What is caused by Biallelic CRELD1 variants?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37947183"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37947183"
        },
        {
          "offsetInBeginSection": 415,
          "offsetInEndSection": 707,
          "text": "Biallelic variants in CRELD1 were found in 18 participants from 14 families. Affected individuals displayed an array of phenotypes involving developmental delay, early-onset epilepsy, and hypotonia, with about half demonstrating cardiac arrhythmias and some experiencing recurrent infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37947183"
        }
      ],
      "id": "67d34e2518b1e36f2e000006",
      "ideal_answer": [
        "Biallelic variants in CRELD1 were found in 18 participants from 14 families. Affected individuals displayed an array of phenotypes involving developmental delay, early-onset epilepsy, and hypotonia, with about half demonstrating cardiac arrhythmias and some experiencing recurrent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections.",
        "Biallelic CRELD1 variants can cause a multisystem syndrome characterized by neurodevelopmental disorders, cardiac abnormalities (such as atrioventricular septal defects and cardiac dysrhythmias), and frequent infections due to immune system dysregulation.",
        "Biallelic CRELD1 variants cause a multisystem syndrome that includes neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections. This has been demonstrated through various methods such as next-generation DNA sequencing, gene knockdown studies in Xenopus tropicalis, protein overexpression studies in Xenopus tropicalis, and in vitro analysis of patient immune cells.",
        "Biallelic variants in CRELD1 cause a multisystem clinical syndrome. Affected individuals displayed an array of phenotypes involving developmental delay, early-onset epilepsy, and hypotonia, with about half demonstrating cardiac arrhythmias and some experiencing recurrent infections.",
        "Biallelic variants in CRELD1 cause a multisystem clinical syndrome characterized by developmental delay, early-onset epilepsy, and hypotonia. About half of affected individuals demonstrate cardiac arrhythmias, and some experience recurrent infections.",
        "Biallelic variants in the CRELD1 gene are associated with a range of health conditions, including developmental delay, early-onset epilepsy, hypotonia (low muscle tone), cardiac arrhythmias, and recurrent infections. These symptoms suggest that CRELD1 plays a significant role in various physiological processes, potentially affecting development, brain function, muscle tone, heart rhythm, and immune response. The variability in symptom presentation among affected individuals indicates that the specific effects of these mutations may be influenced by additional genetic and environmental factors. Further research into the gene\u0027s function is needed to fully understand how its disruption leads to these clinical manifestations.",
        "Biallelic CRELD1 variants cause a multisystem disorder characterized by developmental delay, early-onset epilepsy, hypotonia, cardiac arrhythmias, and recurrent infections.",
        "Biallelic variants in CRELD1 cause a multisystem clinical syndrome characterized by developmental delay, early-onset epilepsy, hypotonia, cardiac arrhythmias, and recurrent infections. Additionally, these variants lead to reduced protein function and developmental defects in model organisms.",
        "Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, frequent infections, developmental delay, early-onset epilepsy, hypotonia, and cardiac arrhythmias.",
        "Biallelic CRELD1 variants cause a multisystem syndrome including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome involving neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome, characterized by neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental abnormalities, such as developmental delay, early-onset epilepsy, and hypotonia, as well as cardiac dysrhythmias and recurrent infections.",
        "A multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections, is caused by biallelic CRELD1 variants.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes (such as developmental delay and early-onset epilepsy), cardiac dysrhythmias, and frequent infections. This is supported by clinical findings from patient cohorts and experimental data, indicating a recessive inheritance pattern.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes, including developmental delay, early-onset epilepsy, and hypotonia, as well as cardiac dysrhythmias and frequent infections.",
        "The biallelic variants in the CRELD1 gene cause a multisystem syndrome characterized by developmental delay, early onset epilepsy, hypotonia, cardiac dysrhythmias, and recurrent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes, including developmental delay, early-onset epilepsy, and hypotonia, in conjunction with cardiac dysrhythmias (cardiac arrhythmias) and a predisposition to frequent or recurrent infections. This syndrome affects multiple systems of the body, leading to a complex clinical presentation that encompasses both neurological and cardiovascular manifestations along with increased susceptibility to infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome that encompasses several significant health issues. Affected individuals typically exhibit neurodevelopmental phenotypes, which include developmental delay and hypotonia. Additionally, they are prone to early onset epilepsy and cardiac dysrhythmias (arrhythmias), with about half of the affected population experiencing these cardiac issues. Furthermore, some individuals may suffer from recurrent infections. This condition is characterized by a wide array of phenotypes that affect multiple systems within the body.",
        "Biallelic CRELD1 variants are associated with a multisystem syndrome characterized by various phenotypes. Studies have identified these variants in 18 participants from 14 families, revealing a range of symptoms including neurodevelopmental issues, such as developmental delay, early-onset epilepsy, and hypotonia. Additionally, approximately half of the affected individuals exhibited cardiac arrhythmias, while some also experienced recurrent infections. Overall, biallelic CRELD1 variants are found to cause a complex syndrome affecting multiple systems of the body, with significant impacts on neurological, cardiac, and immune functions.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized primarily by neurodevelopmental issues such as developmental delay and early-onset epilepsy, along with cardiac dysrhythmias in about half of the affected individuals, and recurrent infections in some cases.",
        "Biallelic CRELD1 variants result in a multisystem syndrome characterized by several significant phenotypes: 1. Neurodevelopmental Disorders: These include developmental delay, early onset epilepsy, and hypotonia, which affect the nervous system\u0027s development and function. 2. Cardiac Dysrhythmias: Approximately half of the affected individuals exhibit heart related issues, such as irregular heartbeats or arrhythmias. 3. Immunological Compromises: Some individuals experience recurrent infections, indicating potential immune system dysregulation. These effects highlight the broad impact of biallelic CRELD1 variants across multiple body systems, underscoring the complexity of this genetic disorder.",
        "Biallelic CRELD1 variants can cause neurodevelopmental phenotypes, cardiac dysrhythmias, frequent infections, developmental delay, and early-onset epilepsy.",
        "Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections. Affected individuals displayed an array of phenotypes involving developmental delay, early-onset epilepsy, and hypotonia, with about half demonstrating cardiac arrhythmias and some experiencing recurrent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections. Affected individuals displayed an array of phenotypes involving developmental delay, early-onset epilepsy, and hypotonia.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections. Affected individuals may experience developmental delay, early-onset epilepsy, hypotonia, and recurrent infections, with many showing cardiac arrhythmias.",
        "Biallelic variants in the CRELD1 gene cause a multisystem syndrome characterized by a range of neurodevelopmental phenotypes, including developmental delay, early-onset epilepsy, and hypotonia. Additionally, affected individuals often exhibit cardiac dysrhythmias and recurrent infections. This syndrome has been observed in 18 participants from 14 families, highlighting the gene\u0027s critical role in multiple physiological systems.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes, cardiac dysrhythmias, frequent infections, developmental delay, early-onset epilepsy, hypotonia, and cardiac arrhythmias.",
        "Biallelic CRELD1 variants cause a multisystem syndrome observed in a cohort from multiple families. Affected individuals display neurodevelopmental abnormalities, including developmental delay and early-onset epilepsy, along with muscle hypotonia. Approximately half of the patients experience cardiac dysrhythmias, and some exhibit recurrent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes such as developmental delay, early-onset epilepsy, and hypotonia. Additionally, these variants are associated with cardiac dysrhythmias in about half of the affected individuals and frequent infections in some cases.",
        "Biallelic variants in the CRELD1 gene cause a multisystem disorder characterized by developmental delay, early-onset epilepsy, hypotonia, cardiac arrhythmias, and recurrent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes such as developmental delay, early-onset epilepsy, and hypotonia, as well as cardiac dysrhythmias and recurrent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes, including developmental delay, early-onset epilepsy, and hypotonia, as well as cardiac dysrhythmias (arrhythmias) and frequent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome that includes neurodevelopmental issues, cardiac dysrhythmias, and frequent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections. Affected individuals may exhibit developmental delay, early-onset epilepsy, hypotonia, and cardiac arrhythmias, along with recurrent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by a range of phenotypes. These include neurodevelopmental issues such as developmental delay, early-onset epilepsy, and hypotonia. Additionally, affected individuals may experience cardiac dysrhythmias, with about half of the cases demonstrating cardiac arrhythmias. There is also an increased susceptibility to frequent infections, making recurrent infections a common feature of this syndrome.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes, including developmental delay, early-onset epilepsy, and hypotonia, in conjunction with cardiac dysrhythmias (cardiac arrhythmias) and a predisposition to frequent or recurrent infections, collectively impacting multiple body systems.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by developmental delay, early onset epilepsy, hypotonia, cardiac dysrhythmias, and recurrent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome. This includes neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections. Affected individuals also displayed developmental delay, early-onset epilepsy, and hypotonia.",
        " Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes such as developmental delay, early-onset epilepsy, and hypotonia. Additionally, about half of affected individuals demonstrate cardiac arrhythmias and some experience recurrent infections.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes including developmental delay, early-onset epilepsy, and hypotonia. Additionally, affected individuals frequently experience cardiac dysrhythmias/arrhythmias and recurrent infections. This constellation of symptoms represents a distinct genetic disorder identified in multiple families, with consistent presentation across affected individuals showing biallelic variants in the CRELD1 gene.",
        "Studies have shown that biallelic CRELD1 variants are associated with a multisystem syndrome characterized by neurodevelopmental phenotypes, such as developmental delay and early-onset epilepsy, along with hypotonia. Additionally, these variants contribute to cardiac dysrhythmias in approximately half of the affected individuals and recurrent infections in some cases.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized by neurodevelopmental phenotypes such as developmental delay, early-onset epilepsy, and hypotonia, as well as cardiac dysrhythmias and frequent infections.",
        "Biallelic CRELD1 variants cause a complex, multisystem syndrome characterized by neurodevelopmental phenotypes, including developmental delay, early-onset epilepsy, and hypotonia. Additionally, individuals are prone to cardiac dysrhythmias, often manifesting as arrhythmias, and exhibit an increased susceptibility to frequent or recurrent infections. This syndrome affects multiple body systems, leading to a varied clinical presentation, supported by both clinical observations and experimental evidence.",
        "Biallelic CRELD1 variants lead to a multisystem syndrome characterized by neurodevelopmental abnormalities such as developmental delay, early-onset epilepsy, and hypotonia, as well as cardiac dysrhythmias and a tendency toward recurrent infections.",
        "A multisystem syndrome characterized by neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections, which can specifically manifest as developmental delay, early-onset epilepsy, hypotonia, cardiac arrhythmias, and recurrent infections.",
        "Biallelic CRELD1 variants cause a complex multisystem syndrome characterized by neurodevelopmental issues (including developmental delay, early-onset epilepsy, and hypotonia), cardiac dysrhythmias, and susceptibility to frequent infections. This condition has been documented in multiple families, with cardiac arrhythmias affecting approximately half of the affected individuals.",
        "Biallelic CRELD1 variants cause a multisystem syndrome characterized primarily by neurodevelopmental issues such as developmental delay, early-onset epilepsy, and hypotonia. Additionally, about half of the affected individuals experience cardiac arrhythmias, and some have recurrent infections."
      ],
      "exact_answer": [
        [
          "Developmental delay"
        ],
        [
          "Early-onset epilepsy",
          "early-onset epilepsy",
          "early onset epilepsy",
          "Early onset epilepsy"
        ],
        [
          "Hypotonia",
          "hypotonia"
        ],
        [
          "With about half demonstrating cardiac arrhythmias and some experiencing recurrent infections",
          "cardiac arrhythmias",
          "frequent infections",
          "recurrent infections"
        ]
      ]
    },
    {
      "body": "What are desflurane and sevoflurane?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37291773",
        "http://www.ncbi.nlm.nih.gov/pubmed/39121786",
        "http://www.ncbi.nlm.nih.gov/pubmed/38595352",
        "http://www.ncbi.nlm.nih.gov/pubmed/38157663",
        "http://www.ncbi.nlm.nih.gov/pubmed/21431051",
        "http://www.ncbi.nlm.nih.gov/pubmed/15120783",
        "http://www.ncbi.nlm.nih.gov/pubmed/8706599",
        "http://www.ncbi.nlm.nih.gov/pubmed/9172637",
        "http://www.ncbi.nlm.nih.gov/pubmed/8652167",
        "http://www.ncbi.nlm.nih.gov/pubmed/8536556",
        "http://www.ncbi.nlm.nih.gov/pubmed/1585570",
        "http://www.ncbi.nlm.nih.gov/pubmed/10965699",
        "http://www.ncbi.nlm.nih.gov/pubmed/10332823",
        "http://www.ncbi.nlm.nih.gov/pubmed/29416248",
        "http://www.ncbi.nlm.nih.gov/pubmed/32743803",
        "http://www.ncbi.nlm.nih.gov/pubmed/39708584",
        "http://www.ncbi.nlm.nih.gov/pubmed/39697192",
        "http://www.ncbi.nlm.nih.gov/pubmed/26198766",
        "http://www.ncbi.nlm.nih.gov/pubmed/39740955",
        "http://www.ncbi.nlm.nih.gov/pubmed/39726290",
        "http://www.ncbi.nlm.nih.gov/pubmed/8024145",
        "http://www.ncbi.nlm.nih.gov/pubmed/8651050",
        "http://www.ncbi.nlm.nih.gov/pubmed/7605024",
        "http://www.ncbi.nlm.nih.gov/pubmed/8967581",
        "http://www.ncbi.nlm.nih.gov/pubmed/7635558",
        "http://www.ncbi.nlm.nih.gov/pubmed/10665829",
        "http://www.ncbi.nlm.nih.gov/pubmed/9893881",
        "http://www.ncbi.nlm.nih.gov/pubmed/14991199",
        "http://www.ncbi.nlm.nih.gov/pubmed/15898901",
        "http://www.ncbi.nlm.nih.gov/pubmed/33718164",
        "https://pubmed.ncbi.nlm.nih.gov/16305297/",
        "https://pubmed.ncbi.nlm.nih.gov/8652167/",
        "https://pubmed.ncbi.nlm.nih.gov/11149433/",
        "http://www.ncbi.nlm.nih.gov/pubmed/9579512",
        "http://www.ncbi.nlm.nih.gov/pubmed/39632735",
        "http://www.ncbi.nlm.nih.gov/pubmed/39615081",
        "http://www.ncbi.nlm.nih.gov/pubmed/39609026",
        "http://www.ncbi.nlm.nih.gov/pubmed/39503147",
        "http://www.ncbi.nlm.nih.gov/pubmed/39436173",
        "http://www.ncbi.nlm.nih.gov/pubmed/32724246",
        "http://www.ncbi.nlm.nih.gov/pubmed/26794826",
        "http://www.ncbi.nlm.nih.gov/pubmed/32013332",
        "http://www.ncbi.nlm.nih.gov/pubmed/35049406",
        "http://www.ncbi.nlm.nih.gov/pubmed/25638572",
        "http://www.ncbi.nlm.nih.gov/pubmed/10150774",
        "http://www.ncbi.nlm.nih.gov/pubmed/8966353",
        "http://www.ncbi.nlm.nih.gov/pubmed/39465449",
        "http://www.ncbi.nlm.nih.gov/pubmed/39715979",
        "http://www.ncbi.nlm.nih.gov/pubmed/17456657",
        "http://www.ncbi.nlm.nih.gov/pubmed/30888743",
        "http://www.ncbi.nlm.nih.gov/pubmed/11038831",
        "http://www.ncbi.nlm.nih.gov/pubmed/16428532",
        "http://www.ncbi.nlm.nih.gov/pubmed/27901329",
        "http://www.ncbi.nlm.nih.gov/pubmed/15915027",
        "http://www.ncbi.nlm.nih.gov/pubmed/19576524",
        "http://www.ncbi.nlm.nih.gov/pubmed/22078911",
        "http://www.ncbi.nlm.nih.gov/pubmed/8970298",
        "http://www.ncbi.nlm.nih.gov/pubmed/24749317",
        "http://www.ncbi.nlm.nih.gov/pubmed/17944910",
        "http://www.ncbi.nlm.nih.gov/pubmed/9893873",
        "http://www.ncbi.nlm.nih.gov/pubmed/33106509",
        "http://www.ncbi.nlm.nih.gov/pubmed/17162400"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 229,
          "text": "We compared patient responses to desflurane and sevoflurane anesthesia, as measured by a quicker recovery and fewer complications, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37291773"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 41,
          "text": "Desflurane versus sevoflurane anesthesia ",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39121786"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 247,
          "text": "Thus, we evaluated the effect of desflurane versus sevoflurane anesthesia on speed of postoperative recovery in older adults",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39121786"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 118,
          "text": "Sevoflurane with Desflurane Anesthesia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38595352"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 238,
          "text": "sevoflurane- and desflurane-induced anesthesia h",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38157663"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "Both sevoflurane and desflurane have shorter emergence times compared to isoflurane based anaesthesia. Because of its pharmacological properties, desflurane appears to yield a rapid early and intermediate recovery compared with sevoflurane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431051"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Comparison of maintenance and emergence characteristics after desflurane or sevoflurane in outpatient anaesthesia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431051"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Sevoflurane is an ether inhalation general anaesthetic agent with lower solubility in blood than isoflurane or halothane but not desflurane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8706599"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8706599"
        },
        {
          "offsetInBeginSection": 617,
          "offsetInEndSection": 1394,
          "text": "Desflurane and sevoflurane may be considered a step toward the ideal inhalational agents. Both possess the advantage of rapid recovery from surgical anesthesia. Desflurane has a major advantage over sevoflurane: it is not biotransformed nor does it interact with carbon dioxide absorbents. However, desflurane is associated with troublesome cardiovascular stimulation involving tachycardia and both pulmonary and systemic hypertension. Sevoflurane appears to be advantageous for three reasons: firstly, because of its pleasant odour and consequent suitability for induction by inhalation, particularly in paediatric anaesthesia; secondly, it can be used with currently employed vaporizers, and thirdly, surgical demands can be met by lower doses, because its potency is higher.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9172637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "[Critical evaluation of the new inhalational anesthetics desflurane and sevoflurane].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9172637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "This article reviews the physico-chemical properties and performance characteristics of the two new potent inhaled anesthetics, desflurane and sevoflurane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8652167"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Sevoflurane and desflurane are volatile inhaled anesthetics that are currently being investigated as possible improvements for the anesthetic management of human patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1585570"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 210,
          "text": "Sevoflurane and Desflurane are relatively new halogenated agents which make induction and control of depth of anaesthesia easier, recovery rapid and of good quality and they have less side-effects and toxicity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10965699"
        },
        {
          "offsetInBeginSection": 1401,
          "offsetInEndSection": 1591,
          "text": "Compared with desflurane, sevoflurane has the additional advantage of being nonirritating to the airway; inhalational induction of anesthesia with sevoflurane is achieved rapidly and easily.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8652167"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "Desflurane and sevoflurane, recently licensed for use in humans, have kinetics that result in rapid induction and easy maintenance of a stable level of anesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10332823"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 149,
          "text": "Sevoflurane (Sev) is an inhalational anesthetic for surgical procedures where it can trigger cognitive dysfunction and neuronal apoptosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39708584"
        },
        {
          "offsetInBeginSection": 575,
          "offsetInEndSection": 638,
          "text": "General anesthesia was induced and maintained using sevoflurane",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39697192"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 59,
          "text": "Desflurane and sevoflurane. New volatile anesthetic agents.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10332823"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Desflurane is a halogenated ether inhalation general anaesthetic agent with low solubility in blood and body tissues, and approximately one-fifth the potency of isoflurane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8536556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8536556"
        },
        {
          "offsetInBeginSection": 513,
          "offsetInEndSection": 752,
          "text": "Intrathecal hyperbaric bupivacaine (0.5%) and a mixture of propofol (1-2 mg/kg) and fentanyl (50-100 μg/kg) were used as induction agents in the SA and GA groups, respectively, with desflurane or sevoflurane used for maintaining anesthesia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39740955"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Sevoflurane is an inhalation anesthetic widely used for general anesthesia, but its genotoxic potential is controversial in clinical studies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39726290"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "text": "BACKGROUND: The pharmacokinetics for sevoflurane and desflurane makes them suitable for low-flow anesthesia. The aim of the present study was to assess the use of desflurane and sevoflurane at constant vaporizer settings and fixed low fres",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26198766"
        },
        {
          "offsetInBeginSection": 46,
          "offsetInEndSection": 335,
          "text": "lism of sevoflurane and desflurane are largely comparable to isoflurane. Both induce a direct vasodilation of the cerebral vessels, resulting in a less pronounced decrease in cerebral blood flow compared to the decrease in cerebral metabolism. This direct vasodilation seems to be dose-dep",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15120783"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "BACKGROUND: Sevoflurane and desflurane are new volatile anesthetics with low blood solubilities that confer properties of rapid anesthetic induction and emergence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7605024"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 53,
          "text": "Inhalational anesthetics: desflurane and sevoflurane.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8652167"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Recently, two new halogenated volatile anaesthetics, sevoflurane and desflurane, have been approved for clinical use in Germany.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8967581"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 179,
          "text": "Sevoflurane and desflurane are both inhalational anesthetic agents ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10665829"
        },
        {
          "offsetInBeginSection": 617,
          "offsetInEndSection": 706,
          "text": "Desflurane and sevoflurane may be considered a step toward the ideal inhalational agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9172637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Sevoflurane and desflurane are the most commonly used volatile anaesthetics for maintenance of anaesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32743803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "The lower solubilities of desflurane and sevoflurane provide a clear advantage over older potent agents, permitting more precise control over the delivery of anesthesia and more rapid recovery from anesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7635558"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "Desflurane and sevoflurane provide one clear advantage over other currently available potent inhaled anesthetics. Their lower solubilities permit a more precise control over the delivery of anesthesia and a more rapid recovery from anesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8024145"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Sevoflurane is a viable alternative to propofol and desflurane for both induction and maintenance of general anaesthesia in the ambulatory setting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9893881"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 342,
          "text": "The exceptionally low solubility of desflurane and sevoflurane offers a significantly greater precision of control over maintenance of anesthesia and a potential for a more rapid recovery from anesthesia than other inhaled anesthetics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14991199"
        },
        {
          "offsetInBeginSection": 411,
          "offsetInEndSection": 604,
          "text": "Both sevoflurane and desflurane provide more rapid emergence from anaesthesia, permit easier titration of the anaesthetic dose during maintenance and offer more rapid recovery from anaesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8967581"
        },
        {
          "offsetInBeginSection": 165,
          "offsetInEndSection": 386,
          "text": "al surgery. Two inhaled anesthetics, desflurane and sevoflurane, have a lower solubility in blood and tissues than all previous volatile anesthetics, and have become the preferred volatile anesthetics for routine surgical",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15898901"
        },
        {
          "offsetInBeginSection": 269,
          "offsetInEndSection": 458,
          "text": "This review summarizes the research progress on the regulation of anti-cancer relevant signaling of volatile anesthetics, including sevoflurane, desflurane, xenon, isoflurane, and halothane",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33718164"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Desflurane and sevoflurane provide one clear advantage over other currently available potent inhaled anesthetics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8024145"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "Human biotransformation of the newer anesthetics, desflurane and sevoflurane, has been characterized in vitro and in vivo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8651050"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 223,
          "text": "Sevoflurane and desflurane are both inhalational anesthetic agents and ropivacaine is a local anesthetic agent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10665829"
        },
        {
          "offsetInBeginSection": 566,
          "offsetInEndSection": 758,
          "text": "Desflurane and sevoflurane are the low-soluble inhalation anesthetics, and they offer some clinical advantages over isoflurane, such as fast induction and faster recovery with long procedures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/16305297/"
        },
        {
          "offsetInBeginSection": 1506,
          "offsetInEndSection": 1591,
          "text": "inhalational induction of anesthesia with sevoflurane is achieved rapidly and easily.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/8652167/"
        },
        {
          "offsetInBeginSection": 160,
          "offsetInEndSection": 298,
          "text": "re unknown. The present study compared renal responses after anesthesia with desflurane (negligible metabolism), sevoflurane, or intraveno",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/11149433/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "BACKGROUND: Sevoflurane and desflurane are new volatile anesthetics with low blood solubilities that confer properties of rapid anesthetic induction an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7605024"
        },
        {
          "offsetInBeginSection": 617,
          "offsetInEndSection": 777,
          "text": "Desflurane and sevoflurane may be considered a step toward the ideal inhalational agents. Both possess the advantage of rapid recovery from surgical anesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9172637"
        },
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 377,
          "text": "In recent decades, halogenated anesthetic gases, such as desflurane and sevoflurane, have largely replaced nitrous oxide, due to better safety profiles and lower adverse health effects",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39632735"
        },
        {
          "offsetInBeginSection": 587,
          "offsetInEndSection": 799,
          "text": "Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39615081"
        },
        {
          "offsetInBeginSection": 788,
          "offsetInEndSection": 891,
          "text": "Patients will be randomly 1:1:1 assigned to receive desflurane, sevoflurane or propofol for anaesthesia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39609026"
        },
        {
          "offsetInBeginSection": 967,
          "offsetInEndSection": 1076,
          "text": "Anesthesia was maintained using desflurane and remifentanil, and no postoperative complications were observed",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39503147"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 460,
          "text": "Anesthetics such as nitrous oxide and volatile halogenated ethers (desflurane, isoflurane, sevoflurane) are examples of medical gases that are strong greenhouse gases that contribute to global warming",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39436173"
        },
        {
          "offsetInBeginSection": 408,
          "offsetInEndSection": 553,
          "text": "In the sevoflurane group (n \u003d 48), sevoflurane was used as a maintenance anesthetic agent. In the desflurane group (n \u003d 48), desflurane was used.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30603828"
        },
        {
          "offsetInBeginSection": 414,
          "offsetInEndSection": 506,
          "text": "Desflurane and sevoflurane are volatile anaesthetics frequently used during cardiac surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26794826"
        },
        {
          "offsetInBeginSection": 1688,
          "offsetInEndSection": 1815,
          "text": "The superiority of desflurane compared to sevoflurane with regards to respiratory complications requires further investigation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32013332"
        },
        {
          "offsetInBeginSection": 313,
          "offsetInEndSection": 395,
          "text": "In the first as the main anaesthetic used sevoflurane, in the second - desflurane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30590887"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "Desflurane is an inhalational anesthetic agent with an appealing recovery profile.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36706431"
        },
        {
          "offsetInBeginSection": 62,
          "offsetInEndSection": 221,
          "text": "Sevoflurane and desflurane are widely used as inhalational anesthetics and have also been reported to lower the shivering threshold in a dose-dependent manner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35049406"
        },
        {
          "offsetInBeginSection": 694,
          "offsetInEndSection": 838,
          "text": "Some such GABAAR agonists used in anesthesia practice are propofol, etomidate, methohexital, thiopental, isoflurane, sevoflurane, and desflurane",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39465449"
        },
        {
          "offsetInBeginSection": 1015,
          "offsetInEndSection": 1091,
          "text": "Desflurane represents a step forward in the search for the ideal anesthetic.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8966353"
        },
        {
          "offsetInBeginSection": 621,
          "offsetInEndSection": 776,
          "text": "Patients in the remimazolam group received iv remimazolam whereas patients in the sevoflurane group received sevoflurane for general anesthesia maintenance",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39715979"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "During recent years interest has focused on two completely fluorinated ethers, desflurane and sevoflurane, which promise a shorter induction of and emergence from anesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10150774"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Both sevoflurane and desflurane have shorter emergence times compared to isoflurane based anaesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431051"
        },
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 375,
          "text": "The most commonly used inhaled anaesthetic in adults is isoflurane and in children halothane. The need for, and the value of the new agents desflurane and sevoflurane depend on a comparison of the properties of a theoretically ideal agent with those of isoflurane, halothane and the new agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9172637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "BACKGROUND: The search for new potent inhaled anesthetics has slowed, in large part because of the excellence of the two most recent additions, desflurane and s",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17456657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Desflurane and sevoflurane provide one clear advantage over other currently available potent inhaled anesthetics. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8024145"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 614,
          "text": "ents undergoing coronary-artery bypass grafting (CABG).METHODS: We conducted a pragmatic, multicenter, single-blind, controlled trial at 36 centers in 13 countries. Patients scheduled to undergo elective CABG were randomly assigned to an intraoperative anesthetic regimen that included a volatile anesthetic (desflurane, isoflurane, or sevoflurane) or to total intravenous anesthesia. The primary outcome was death from any cause at 1 year.RESULTS: A total of 5400 patients were randomly a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30888743"
        },
        {
          "offsetInBeginSection": 290,
          "offsetInEndSection": 404,
          "text": "This direct vasodilation seems to be dose-dependent and more pronounced for desflurane \u003e isoflurane \u003e sevoflurane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15120783"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "OBJECTIVE: To compare pharmacokinetics of desflurane, sevoflurane, isoflurane and enflurane in general ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11038831"
        },
        {
          "offsetInBeginSection": 1283,
          "offsetInEndSection": 1468,
          "text": "In conclusion, the use of desflurane for maintenance of anesthesia after sevoflurane induction in children is associated with less severe emergence agitation and faster emergence times.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428532"
        },
        {
          "offsetInBeginSection": 307,
          "offsetInEndSection": 609,
          "text": "AED) Scale. Due to some variation in properties between sevoflurane and desflurane for maintenance of anesthesia after standard sevoflurane induction, we designed a prospective study to examine potential differences in emergence behavior and incidence of ED in children undergoing elective ear-nose-thr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27901329"
        },
        {
          "offsetInBeginSection": 284,
          "offsetInEndSection": 411,
          "text": "ht be used.METHODS: Effects of sevoflurane, isoflurane, and desflurane were studied in primary human CD3 T lymphocytes and Jurk",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15915027"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 790,
          "text": "Volatile anesthetics such as isoflurane, sevoflurane, and desflurane are in daily use in the operating room in the delivery of general anesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19576524"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 790,
          "text": "Volatile anesthetics such as isoflurane, sevoflurane, and desflurane are in daily use in the operating room in the delivery of general anesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22078911"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 162,
          "text": " Sevoflurane and desflurane are new volatile anesthetics with low blood solubilities that confer properties of rapid anesthetic induction and emergence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7605024"
        },
        {
          "offsetInBeginSection": 20,
          "offsetInEndSection": 161,
          "text": " Desflurane and sevoflurane are inhalational anesthetics which provide stable intraoperative hemodynamics and rapid emergence from anesthesia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29416248"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 132,
          "text": " Desflurane and sevoflurane are the most common volatile anesthetics used during laparoscopic and hepatic surgery",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724246"
        },
        {
          "offsetInBeginSection": 84,
          "offsetInEndSection": 228,
          "text": "The newer agents, desflurane and sevoflurane, possess pharmacokinetic profiles that are distinctly different from the older inhaled anesthetics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8970298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Desflurane (Des)--is a modern inhalation anaesthetic available in Russia since August, 2013.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24749317"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 272,
          "text": "Sevoflurane is a volatile nonflammable fluorinated methyl isopropyl ether inhaled anesthetic, chemically related to desflurane and isoflurane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17944910"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "Desflurane and sevoflurane, recently licensed for use in humans, have kinetics that result in rapid induction and easy maintenance of a stable level of anesthesia. Recovery is also rapid.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10332823"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "text": "Desflurane is one of the most frequently used inhalational anesthetics in clinical practice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33106509"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "BACKGROUND: Inhalation anesthetics such as isoflurane, sevoflurane, and desflurane are widely used in clini",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17162400"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "BACKGROUND: The objective of this study was to investigate the effects of sevoflurane and desflurane anesthesia on the pulmonary vasodilator response to the adenosine triphosphate-sensitive potassium channel agonist, lemakalim, compared with the response measured in the cons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9579512"
        },
        {
          "offsetInBeginSection": 728,
          "offsetInEndSection": 846,
          "text": "Patients were randomly assigned to a desflurane anesthesia group (D group) and sevoflurane anesthesia group (S group).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25638572"
        },
        {
          "offsetInBeginSection": 600,
          "offsetInEndSection": 945,
          "text": "-flow relationship. After preconstriction with the thromboxane analogue, U46619, dose-response relationships to lemakalim were assessed on separate days in the conscious state and during sevoflurane (approximately 3.5% end-tidal) and desflurane (approximately 10.5% end-tidal) anesthesia (approximately 1.5 minimum alveolar concentration for eac",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9579512"
        },
        {
          "offsetInBeginSection": 1172,
          "offsetInEndSection": 1388,
          "text": "In conclusion, elderly patients undergoing desflurane anesthesia have significantly better quality of emergence and may have better cognitive function than those in elderly patients undergoing sevoflurane anesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25638572"
        },
        {
          "offsetInBeginSection": 561,
          "offsetInEndSection": 681,
          "text": "Clinical results showed that rapidity of recovery from sevoflurane anesthesia is equal to that of desflurane anesthesia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9893873"
        }
      ],
      "type": "factoid",
      "id": "67cc960381b102733300000f",
      "ideal_answer": [
        "Desflurane and Sevoflurane are anesthetic agents.",
        "Desflurane and sevoflurane are inhalation anesthetics.",
        "Desflurane and sevoflurane are volatile anesthetics.",
        "Desflurane and sevoflurane are volatile inhalational anesthetics used for general anesthesia.",
        "Desflurane and sevoflurane are volatile anesthetics used for general anesthesia during surgical procedures.",
        "desflurane and sevoflurane are two commonly used volatile anesthetics in clinical practice, known for their rapid anesthetic induction and emergence due to their low blood solubilities.",
        "Desflurane and sevoflurane are both volatile anesthetics used in medical procedures, particularly in anesthesia.",
        "Desflurane and sevoflurane are volatile anesthetics, inhalational anesthetics, and halogenated anesthetics.",
        "Desflurane and sevoflurane are inhaled anesthetics.",
        "Desflurane and sevoflurane are both inhalational anesthetic agents used for general anesthesia.",
        "Desflurane and sevoflurane are two completely fluorinated ethers, which are new inhalational agents used in anesthesia.",
        "Desflurane and Sevoflurane are volatile inhaled anesthetics with different properties regarding onset, recovery, and usage in medical procedures.",
        "Desflurane and sevoflurane are both anesthetics used to induce anesthesia, with studies comparing their effects on postoperative recovery and complications in patients.",
        "Desflurane and sevoflurane are inhalation anesthetics used for anesthesia.",
        "Desflurane and sevoflurane are types of anesthesia that were compared to see which one resulted in quicker recovery and fewer complications.",
        "desflurane and sevoflurane are volatile anesthetics",
        "Desflurane and sevoflurane are commonly used inhaled anesthetics, both in the operating room and in the intensive care unit (ICU).",
        "Desflurane and sevoflurane are volatile anesthetic agents commonly used for the induction and maintenance of general anesthesia.",
        "Desflurane and sevoflurane are both volatile anesthetics used for the maintenance of anesthesia during surgical procedures.",
        "Desflurane and sevoflurane are commonly used inhalational anesthetics, which are halogenated ethers.",
        "Desflurane and sevoflurane are low-soluble inhalation anesthetics commonly used during inhalational anesthesia.",
        "Desflurane and sevoflurane are inhalational anesthetics used to induce and maintain general anesthesia during surgeries.",
        "Desflurane and sevoflurane are inhalational anesthetics.",
        "Desflurane\u0027, \u0027Sevoflurane are anesthetic agents used in surgery.",
        "Desflurane and sevoflurane are both volatile anesthetics used for inhalational anesthesia.",
        "Desflurane and sevoflurane are anesthetics.",
        "Desflurane and sevoflurane are both anesthetic agents used to induce general anesthesia, with studies comparing their effects on postoperative recovery and complications in patients.",
        "Desflurane and sevoflurane are types of anesthesia."
      ],
      "exact_answer": [
        [
          "anesthetics"
        ]
      ]
    },
    {
      "body": "Are there inflammatory markers of dysmenorrhea?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37394650",
        "http://www.ncbi.nlm.nih.gov/pubmed/39101962",
        "http://www.ncbi.nlm.nih.gov/pubmed/32069859",
        "http://www.ncbi.nlm.nih.gov/pubmed/25660431",
        "http://www.ncbi.nlm.nih.gov/pubmed/17174824",
        "http://www.ncbi.nlm.nih.gov/pubmed/28944048",
        "http://www.ncbi.nlm.nih.gov/pubmed/18819458",
        "http://www.ncbi.nlm.nih.gov/pubmed/33076228",
        "http://www.ncbi.nlm.nih.gov/pubmed/23390521",
        "http://www.ncbi.nlm.nih.gov/pubmed/39355382",
        "http://www.ncbi.nlm.nih.gov/pubmed/30888478",
        "http://www.ncbi.nlm.nih.gov/pubmed/30205315",
        "http://www.ncbi.nlm.nih.gov/pubmed/30696591",
        "http://www.ncbi.nlm.nih.gov/pubmed/19903048",
        "http://www.ncbi.nlm.nih.gov/pubmed/18574224"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 824,
          "offsetInEndSection": 859,
          "text": "high-sensitivity C-reactive protein",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37394650"
        },
        {
          "offsetInBeginSection": 522,
          "offsetInEndSection": 536,
          "text": "interleukin 6 ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39101962"
        },
        {
          "offsetInBeginSection": 544,
          "offsetInEndSection": 572,
          "text": "tumor necrosis factor-alpha ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39101962"
        },
        {
          "offsetInBeginSection": 589,
          "offsetInEndSection": 607,
          "text": "C-reactive protein",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39101962"
        },
        {
          "offsetInBeginSection": 325,
          "offsetInEndSection": 339,
          "text": "Prostaglandins",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32069859"
        },
        {
          "offsetInBeginSection": 1057,
          "offsetInEndSection": 1078,
          "text": "increase of cytokines",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25660431"
        },
        {
          "offsetInBeginSection": 417,
          "offsetInEndSection": 522,
          "text": "Potent prostaglandins and potent leukotrienes play an important role in generating dysmenorrhea symptoms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17174824"
        },
        {
          "offsetInBeginSection": 150,
          "offsetInEndSection": 269,
          "text": "Pain associated with dysmenorrhea is caused by hypersecretion of prostaglandins and an increased uterine contractility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944048"
        },
        {
          "offsetInBeginSection": 520,
          "offsetInEndSection": 623,
          "text": "Prostaglandins and leukotriens play a significant role in etiopathogenesis of the primary dysmenorrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18819458"
        },
        {
          "offsetInBeginSection": 972,
          "offsetInEndSection": 1190,
          "text": "For the antioxidant status, limited evidence was found for a lower status among primary dysmenorrhea women, and only one study examined one inflammation marker (hs-CRP), which makes it impossible for such a conclusion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33076228"
        },
        {
          "offsetInBeginSection": 1150,
          "offsetInEndSection": 1754,
          "text": "Curcumin significantly decreased the median (interquartile range) serum levels of hsCRP [from 0.30 mg/L (0.0-1.10) to 0.20 mg/L (0.0-1.3); p \u003d 0.041] compared with placebo, but did not show any difference for neutrophil, RDW, MPV, NLR, PLR and RPR values (p \u003e 0.05). The treatment schedule was well-tolerated, and none of markers of iron metabolism statistically changed after the intervention in the curcumin group (p \u003e 0.05). Curcumin supplementation may have positive effects on serum hsCRP, a marker of inflammation, with no any changes on iron homeostasis in healthy women with PMS and dysmenorrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37394650"
        },
        {
          "offsetInBeginSection": 371,
          "offsetInEndSection": 524,
          "text": "Pro-inflammatory cytokines (interleukin-6 [IL-6] and tumor necrosis factor-alpha [TNF-α]) are also implicated in the pathogenesis of primary dysmenorrhea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30696591"
        },
        {
          "offsetInBeginSection": 1145,
          "offsetInEndSection": 1345,
          "text": "Patients with severe dysmenorrhoea had increased PF cytokine and marker levels; the difference was significant for TNF-alpha and glycodelin when compared with the other patients (no or moderate pain).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19903048"
        },
        {
          "offsetInBeginSection": 941,
          "offsetInEndSection": 1021,
          "text": "TNF-alpha and glycodelin correlated positively with the level of menstrual pain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19903048"
        },
        {
          "offsetInBeginSection": 1456,
          "offsetInEndSection": 1789,
          "text": "There were significant differences in multiple inflammatory biomarkers between the study drug and placebo, including BDNF, IL-1, and IL-6 among certain groups.Conclusion: With all EHP-30 domains and the dysmenorrhea VAS showing either a statistical improvement or trend towards improvement, there is justification for a larger study.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39355382"
        },
        {
          "offsetInBeginSection": 1462,
          "offsetInEndSection": 1870,
          "text": "The mean of menstrual characteristics, anthropometric indices and daily energy and macronutrient intake in both intervention and control groups were not changed significantly.CONCLUSION: This study showed that chlorella supplementation could decrease the severity of pain and systemic symptoms and improve serum levels of prostaglandins, inflammatory and oxidative markers in women with primary dysmenorrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30205315"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 398,
          "text": "h problem. Despite numerous studies, the pathomechanism of dysmenorrhea is not fully understood. Previous research indicates the complexity of biochemical reactions between the endocrine, vascular, and immune systems. Prostaglandins play a major role in the pathomechanism of dysmenorrhea. I",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32069859"
        },
        {
          "offsetInBeginSection": 325,
          "offsetInEndSection": 396,
          "text": "Prostaglandins play a major role in the pathomechanism of dysmenorrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32069859"
        },
        {
          "offsetInBeginSection": 355,
          "offsetInEndSection": 460,
          "text": "Potent prostaglandins and leukotrienes play an important role in generating the symptoms of dysmenorrhea.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18574224"
        },
        {
          "offsetInBeginSection": 767,
          "offsetInEndSection": 1190,
          "text": "The systematic review included 175 women with primary dysmenorrhea and 161 controls. The results indicate an elevated level of oxidative stress, especially of lipid peroxidation among dysmenorrheal women. For the antioxidant status, limited evidence was found for a lower status among primary dysmenorrhea women, and only one study examined one inflammation marker (hs-CRP), which makes it impossible for such a conclusion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33076228"
        },
        {
          "offsetInBeginSection": 906,
          "offsetInEndSection": 1132,
          "text": " In the menstrual phase, genes encoding pro-inflammatory cytokines (IL1B, TNF, IL6, and IL8) were up-regulated, and genes encoding TGF-β superfamily members (BMP4, BMP6, GDF5, GDF11, LEFTY2, NODAL, and MSTN) were down-regulate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23390521"
        },
        {
          "offsetInBeginSection": 902,
          "offsetInEndSection": 1320,
          "text": "d between groups.RESULTS: The scores of dysmenorrhea, dyschezia, dyspareunia, and non-menstrual pain significantly decreased in both real and placebo groups compared with the baseline values. However, the real group showed greater reductions compared with the placebo group (p \u003c 0.001). Similarly, the serum levels of CRP, TNF-α, and IL-10 decreased in both groups compared with the baseline values, but the real group",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30888478"
        }
      ],
      "id": "67d7232418b1e36f2e000037",
      "ideal_answer": [
        "While no specific markers of dysmenorrhea have been found, CRP, IL6, tumor necrosis factor-alpha, cytokines and prostaglandins are mentioned in the literature.",
        "Several studies have found evidence of increased inflammatory markers in women with dysmenorrhea (painful menstrual cramps). Elevated levels of pro-inflammatory cytokines like IL-1β, TNF-α, IL-6, and IL-8 have been observed, as well as increased oxidative stress markers like malondialdehyde and nitrotyrosine. In contrast, anti-inflammatory factors like TGF-β superfamily members were found to be decreased. This imbalance between pro- and anti-inflammatory signals may contribute to the pathophysiology of dysmenorrhea.",
        "Inflammatory markers play a significant role in the pathophysiology of dysmenorrhea. Prostaglandins and leukotrienes are notably involved in generating dysmenorrhea symptoms, with increased menstrual prostaglandin release being a hallmark of primary dysmenorrhea. Elevated levels of these compounds during menstruation lead to intense uterine muscle contractions and cramps. The role of cytokines in primary dysmenorrhea is less understood, but some studies have shown up-regulation of pro-inflammatory cytokines such as IL-1A, IL-1B, CSF2, IL6, IL21, TNF, TNFRSF11B, IL5, and BMP3, and down-regulation of BMP4 and LEFTY2. However, another study found no significant differences in inflammatory markers like interleukin 6, tumor necrosis factor-alpha, and C-reactive protein between women with dysmenorrhea and those without. Oxidative stress is slightly aggravated in patients with dysmenorrhea, indicated by higher serum malondialdehyde levels. Clinical trials have shown that chlorella supplementation significantly decreased inflammatory markers such as PGE2, PGF2α, and high-sensitivity C-reactive protein in women with primary dysmenorrhea. Vitamin D and its metabolites may also reduce inflammatory cytokine levels, suggesting a potential therapeutic role. These findings highlight the complex interplay of inflammatory mediators in dysmenorrhea and suggest potential therapeutic targets for alleviating menstrual pain.",
        "Inflammatory markers play a significant role in dysmenorrhea, particularly primary dysmenorrhea. Elevated levels of prostaglandins E2α (PGE2α) and F2α (PGF2α), as well as leukotrienes, are linked to intense uterine muscle contractions and menstrual cramps. The decrease in progesterone during the luteal phase leads to the secretion of arachidonic acid and its metabolites, causing inflammation and pain. The understanding of cytokines and other proinflammatory factors in primary dysmenorrhea is limited, though gene expression analysis has shown upregulation of pro-inflammatory cytokines and downregulation of anti-inflammatory cytokines in affected women. Studies found no significant difference in high-sensitivity C-reactive protein (hs-CRP) levels between women with and without primary dysmenorrhea. However, chlorella supplementation has been shown to significantly decrease inflammatory markers such as hs-CRP and prostaglandins in women with primary dysmenorrhea. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, diclofenac, and naproxen are effective first-line treatments due to their analgesic and anti-inflammatory effects. In summary, while prostaglandins and leukotrienes are well-established markers, the role of cytokines and other proinflammatory factors needs further research. NSAIDs and chlorella supplementation have shown efficacy in reducing inflammation and alleviating symptoms."
      ]
    },
    {
      "body": "Which protein is silencing MIR139 in order to promote AML oncogenesis?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34741119"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34741119"
        },
        {
          "offsetInBeginSection": 888,
          "offsetInEndSection": 1062,
          "text": "Our findings elucidate the molecular control of tumor suppressor MIR139 and reveal a role for POLR2M in the MIR139-silencing mechanism, downstream of MLL-AF9 and PRC2 in AML.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34741119"
        }
      ],
      "id": "67d751e418b1e36f2e000040",
      "ideal_answer": [
        "The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis.",
        "POLR2M (RNA Polymerase 2 Subunit M) is the protein responsible for silencing MIR139, thereby promoting Acute Myeloid Leukemia (AML) oncogenesis. Identified through a genome-wide CRISPR-Cas9 knockout screen, POLR2M acts downstream of the MLL-AF9 fusion protein and the Polycomb Repressive Complex 2 (PRC2) to inhibit MIR139\u0027s tumor-suppressing activities. This epigenetic silencing mechanism contributes to AML development, suggesting that targeting POLR2M may offer a novel therapeutic approach for treating AML.",
        "RNA Polymerase 2 Subunit M (POLR2M) is a novel MIR139-regulatory factor involved in the MIR139-silencing mechanism in AML.",
        "POLR2M is the protein that silences MIR139 in order to promote AML oncogenesis.",
        "POLR2M silences MIR139 to promote AML oncogenesis.",
        "The protein that is silencing MIR139 in order to promote AML oncogenesis is POLR2M.",
        "POLR2M is the protein that silences MIR139 to promote AML oncogenesis.",
        "POLR2M is the protein silencing MIR139 in order to promote AML oncogenesis.",
        "POLR2M is the protein that is involved in the silencing of MIR139, promoting AML oncogenesis.",
        "POLR2M is silencing the tumor suppressor MIR139 to promote AML oncogenesis.",
        "POLR2M, or RNA Polymerase 2 Subunit M, is the protein identified to silence MIR139, thereby promoting Acute Myeloid Leukemia (AML) oncogenesis. It acts through an epigenetic silencing mechanism, involving the Polycomb Repressive Complex 2 (PRC2) and downstream of the MLL-AF9 fusion protein. This process inhibits MIR139\u0027s tumor-suppressing activities, contributing to leukemic cell transformation. Targeting POLR2M may present a novel therapeutic strategy for AML treatment.",
        "The protein identified as silencing the tumor suppressor MIR139 to promote AML oncogenesis is POLR2M. This was determined through a genome-wide CRISPR-Cas9 knockout screen.",
        "POLR2M",
        "The protein that silences MIR139 to promote AML oncogenesis is POLR2M.",
        "The protein POLR2M silences MIR139 to promote AML oncogenesis. This mechanism occurs downstream of MLL-AF9 and PRC2, as revealed by findings that POLR2M is a novel MIR139-regulatory factor in AML.",
        "POLR2M is silencing MIR139 in order to promote AML oncogenesis.",
        "The protein POLR2M is responsible for silencing the tumor suppressor MIR139, which promotes acute myeloid leukemia (AML) oncogenesis. This silencing mechanism occurs downstream of MLL-AF9 and PRC2 in the development of AML.",
        "The protein POLR2M plays a role in silencing the tumor suppressor MIR139, which subsequently promotes acute myeloid leukemia (AML) oncogenesis.",
        "POLR2M (RNA Polymerase 2 Subunit M) is the protein responsible for silencing MIR139, thereby promoting AML (Acute Myeloid Leukemia) oncogenesis. It acts downstream of the MLL-AF9 fusion protein and the polycomb repressive complex 2 (PRC2), as identified through a genome-wide CRISPR-Cas9 knockout screen.",
        "The protein POLR2M silences the tumor suppressor MIR139, which promotes acute myeloid leukemia (AML) oncogenesis.",
        "The tumor suppressor gene MIR139 is silenced by the protein POLR2M, which promotes acute myeloid leukemia (AML) oncogenesis. This occurs because POLR2M interferes with the normal function of MIR139, thereby contributing to cancer development.",
        "POLR2M silences MIR139 in order to promote AML oncogenesis.",
        "RNA Polymerase 2 Subunit M (POLR2M) is silencing MIR139 to promote AML oncogenesis.",
        "POLR2M is silencing MIR139 to promote AML oncogenesis.",
        "The protein POLR2M is responsible for silencing the tumor suppressor MIR139, thereby promoting oncogenesis in acute myeloid leukemia (AML). This silencing mechanism occurs downstream of the MLL-AF9 and PRC2 complexes, elucidating a critical role of POLR2M in the molecular control of MIR139 suppression within the context of AML pathogenesis.",
        "The protein responsible for silencing MIR139 to promote acute myeloid leukemia (AML) oncogenesis is POLR2M. This process occurs downstream of the oncogenic fusion protein MLL-AF9 and the Polycomb Repressive Complex 2 (PRC2), which are known contributors to AML development. POLR2M\u0027s role in this context involves gene silencing, specifically targeting the tumor suppressor MIR139, thereby facilitating leukemia progression.",
        "The protein responsible for silencing MIR139 to promote AML oncogenesis is POLR2M. This process occurs downstream of MLL-AF9 and PRC2, indicating that these upstream regulators influence POLR2M\u0027s activity in silencing the tumor suppressor MIR139, thereby contributing to the development of acute myeloid leukemia (AML).",
        "POLR2M silences MIR139 to promote AML oncogenesis, acting downstream of MLL-AF9 and PRC2.",
        "POLR2M is silencing MIR139 to promote AML oncogenesis. This elucidates the molecular control of tumor suppressor MIR139. It also reveals a role for POLR2M in the MIR139-silencing mechanism.",
        "The protein POLR2M silences MIR139 to promote AML oncogenesis.",
        "RNA Polymerase 2 Subunit M (POLR2M) silences MIR139 to promote AML oncogenesis. This was revealed by a genome-wide CRISPR-Cas9 knockout screen identifying POLR2M as a novel MIR139-regulatory factor. MLL-AF9 expression also contributes to the epigenetic silencing of MIR139, while MIR139 overexpression inhibits AML outgrowth.",
        "The protein POLR2M is responsible for silencing the tumor suppressor MIR139, thereby promoting acute myeloid leukemia (AML) oncogenesis. This silencing mechanism occurs downstream of MLL-AF9 and PRC2 in AML, highlighting a specific molecular pathway involved in the disease.",
        "The protein POLR2M is responsible for silencing the tumor suppressor MIR139, which promotes AML oncogenesis.",
        "POLR2M promotes AML oncogenesis by silencing MIR139.",
        "POLR2M is identified as the protein responsible for silencing MIR139, thereby promoting oncogenesis in Acute Myeloid Leukemia (AML). This conclusion is supported by its role downstream of MLL-AF9 and the polycomb repressive complex 2 (PRC2), leading to the silencing of MIR139, a tumor suppressor whose overexpression inhibits AML outgrowth. Targeting POLR2M may offer a novel therapeutic strategy for AML treatment.",
        "POLR2M is the protein silencing MIR139 to promote AML oncogenesis.",
        "In the context of acute myeloid leukemia (AML) oncogenesis, the tumor suppressor MIR139 is silenced by the protein POLR2M. This silencing contributes to the progression of AML by inhibiting the tumor suppressive functions of MIR139, thereby promoting oncogenic processes.",
        "POLR2M (RNA Polymerase 2 Subunit M) is the protein responsible for silencing MIR139, thereby promoting Acute Myeloid Leukemia (AML) oncogenesis. This action is mediated downstream of the MLL-AF9 fusion protein and the polycomb repressive complex 2 (PRC2), as identified through a genome-wide CRISPR-Cas9 knockout screen.",
        " POLR2M protein silences MIR139 in order to promote AML oncogenesis.",
        "The protein responsible for silencing MIR139 to promote AML oncogenesis is POLR2M. Studies indicate that POLR2M silences the tumor suppressor MIR139, thereby facilitating the progression of acute myeloid leukemia. This mechanism operates downstream of the MLL-AF9 and PRC2 complexes in AML.",
        "The protein POLR2M is silencing the tumor suppressor MIR139, which promotes the development of acute myeloid leukemia (AML).",
        "POLR2M (RNA Polymerase 2 Subunit M) is identified as the protein responsible for silencing MIR139, a tumor suppressor, thereby promoting Acute Myeloid Leukemia (AML) oncogenesis. This action is mediated through an epigenetic mechanism downstream of the MLL-AF9 fusion protein and the polycomb repressive complex 2 (PRC2). By inhibiting MIR139\u0027s suppressive effects on AML, POLR2M contributes to leukemia development, suggesting that targeting POLR2M could provide a novel therapeutic approach for treating AML.",
        "POLR2M silences the tumor suppressor MIR139, acting downstream of MLL-AF9 and PRC2, which promotes the development of Acute Myeloid Leukemia (AML).",
        "The protein POLR2M silences the tumor suppressor MIR139, which promotes acute myeloid leukemia (AML) oncogenesis. This silencing mechanism occurs downstream of MLL-AF9 and PRC2."
      ],
      "exact_answer": [
        [
          "POLR2M",
          "RNA Polymerase 2 Subunit M"
        ]
      ]
    },
    {
      "body": "On what part of the body is Fontan Palliation(AKA Fontan proceedure) performed?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39423992",
        "http://www.ncbi.nlm.nih.gov/pubmed/39547425",
        "http://www.ncbi.nlm.nih.gov/pubmed/36867074",
        "http://www.ncbi.nlm.nih.gov/pubmed/37910851",
        "http://www.ncbi.nlm.nih.gov/pubmed/20585329",
        "http://www.ncbi.nlm.nih.gov/pubmed/35490923",
        "http://www.ncbi.nlm.nih.gov/pubmed/15942576",
        "http://www.ncbi.nlm.nih.gov/pubmed/24393144",
        "http://www.ncbi.nlm.nih.gov/pubmed/35652057",
        "http://www.ncbi.nlm.nih.gov/pubmed/29437083",
        "http://www.ncbi.nlm.nih.gov/pubmed/38343498",
        "http://www.ncbi.nlm.nih.gov/pubmed/21087567",
        "http://www.ncbi.nlm.nih.gov/pubmed/30857653",
        "http://www.ncbi.nlm.nih.gov/pubmed/25468638",
        "http://www.ncbi.nlm.nih.gov/pubmed/16455152",
        "http://www.ncbi.nlm.nih.gov/pubmed/29051776",
        "http://www.ncbi.nlm.nih.gov/pubmed/20459200",
        "http://www.ncbi.nlm.nih.gov/pubmed/39664312",
        "http://www.ncbi.nlm.nih.gov/pubmed/35127320",
        "http://www.ncbi.nlm.nih.gov/pubmed/25818807",
        "http://www.ncbi.nlm.nih.gov/pubmed/18651404",
        "http://www.ncbi.nlm.nih.gov/pubmed/16229700",
        "http://www.ncbi.nlm.nih.gov/pubmed/12500636",
        "http://www.ncbi.nlm.nih.gov/pubmed/26567230",
        "http://www.ncbi.nlm.nih.gov/pubmed/32980091",
        "http://www.ncbi.nlm.nih.gov/pubmed/36339935",
        "http://www.ncbi.nlm.nih.gov/pubmed/35224438",
        "http://www.ncbi.nlm.nih.gov/pubmed/8238751",
        "http://www.ncbi.nlm.nih.gov/pubmed/8579512",
        "http://www.ncbi.nlm.nih.gov/pubmed/27108290",
        "http://www.ncbi.nlm.nih.gov/pubmed/27618316",
        "http://www.ncbi.nlm.nih.gov/pubmed/26853857",
        "http://www.ncbi.nlm.nih.gov/pubmed/39395055",
        "http://www.ncbi.nlm.nih.gov/pubmed/25335555",
        "http://www.ncbi.nlm.nih.gov/pubmed/22672849",
        "http://www.ncbi.nlm.nih.gov/pubmed/29802801",
        "http://www.ncbi.nlm.nih.gov/pubmed/9315539/",
        "http://www.ncbi.nlm.nih.gov/pubmed/39459353",
        "http://www.ncbi.nlm.nih.gov/pubmed/11790702",
        "http://www.ncbi.nlm.nih.gov/pubmed/38782728",
        "http://www.ncbi.nlm.nih.gov/pubmed/10731878",
        "http://www.ncbi.nlm.nih.gov/pubmed/8057028",
        "http://www.ncbi.nlm.nih.gov/pubmed/32921662",
        "http://www.ncbi.nlm.nih.gov/pubmed/25621311",
        "http://www.ncbi.nlm.nih.gov/pubmed/20301986",
        "http://www.ncbi.nlm.nih.gov/pubmed/6827852",
        "http://www.ncbi.nlm.nih.gov/pubmed/4033175",
        "http://www.ncbi.nlm.nih.gov/pubmed/7689671",
        "http://www.ncbi.nlm.nih.gov/pubmed/39219388",
        "http://www.ncbi.nlm.nih.gov/pubmed/26180170",
        "http://www.ncbi.nlm.nih.gov/pubmed/26830073",
        "http://www.ncbi.nlm.nih.gov/pubmed/30482258",
        "http://www.ncbi.nlm.nih.gov/pubmed/1728440",
        "http://www.ncbi.nlm.nih.gov/pubmed/1280410",
        "http://www.ncbi.nlm.nih.gov/pubmed/12740775"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 120,
          "text": "The Fontan operation provides lifesaving palliation for individuals with single ventricle (SV) physiology. G",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39423992"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "The Fontan procedure is a staged palliative surgery performed in children with congenital univentricular heart defects. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36867074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "The Fontan palliation was introduced in 1968 to treat cardiac malformations unsuitable for biventricular repair. This procedure has transformed the surgical management of congenital heart disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20585329"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "The Fontan procedure is a staged palliation for various complex congenital cardiac lesions, including tricuspid atresia, pulmonary atresia, hypoplastic left heart syndrome, and double-inlet left ventricle, all of which involve a functional single-ventricle physiology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35490923"
        },
        {
          "offsetInBeginSection": 108,
          "offsetInEndSection": 294,
          "text": "rt defects. The Fontan procedure has been of particular benefit to infants with functional single-ventricle complexes but with the consequence of a sustained increase of right-sided veno",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15942576"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "BACKGROUND: The Fontan procedure is the final in a series of staged palliations for single-ventricle congenital heart disease, which encompasses rare and heterogeneous card",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24393144"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "BACKGROUND: The Fontan procedure is the final in a series of staged palliations for single-ventricle congenital heart disease, which encompasses rare and heterogeneous cardiac lesions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24393144"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "The Fontan procedure is the final procedure in staged palliation for patients with functional single-ventricle physiology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29437083"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "The Fontan operation, originally described for the surgical management of tricuspid atresia, is now the final surgery in the strategy of staged palliation for a number of different forms of congenital cardiac disease with a functionally univentricular heart.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21087567"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "The Fontan procedure is an open heart procedure performed in pediatric patients with a particular congenital cardiac anomaly known as a univentricular heart.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30857653"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 563,
          "text": "The modern Fontan procedure, which consists of anastomosing both the superior (SVC) and inferior vena cava (IVC) to the right pulmonary artery (RPA), is nowadays the last step before transplantation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25468638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "The Fontan operation is a palliative surgical procedure performed on children born with congenital defects of the heart that have yielded only a single functioning ventricle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16455152"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 388,
          "text": "The Fontan procedure is a palliative strategy for single-ventricle type congenital heart disease and involves passive flow of venous return into the pulmonary circulation, bypassing the ventricles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29051776"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 374,
          "text": "The total cavo-pulmonary connection (TCPC) is a common variant of the Fontan procedure, where the superior vena cava (SVC) and inferior vena cava (IVC) are routed directly into the pulmonary arteries (PA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20459200"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "The Fontan operation, which directly connects the superior and inferior vena cava to the pulmonary artery, is a palliative surgery for children with a functional or anatomic single ventricle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39664312"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "The Fontan procedure is a palliative cardiac surgery performed for children with a single functional ventricle, and its aim is to divert central venous return to the pulmonary artery without passing through the right ventricle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35127320"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "The Fontan circuit is the result of a palliative surgical procedure that is performed in patients with a functionally single ventricle cardiac anomaly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818807"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 292,
          "text": "The Fontan procedure has become a generic term to define a surgical procedure that orients the systemic venous return directly to the pulmonary arteries, and has been used as a palliative operation for pulmonary atresia, tricuspid atresia, double inlet ventricle and complex single ventricle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18651404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "The Fontan procedure is performed for patients with a hypoplastic right ventricle,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16229700"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "The Fontan procedure is a technique used in single ventricle syndromes and initiates a circulation which bypasses the right ventricle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12500636"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "text": "The Fontan operation for single ventricle palliation consists of the creation of a complete cavopulmonary connection, usually by incorporating inferior vena caval flow into a pulmonary arterial circulation already receiving flow from the superior vena cava.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26567230"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "The Fontan operation or the total cavopulmonary connection is a palliative surgery for single ventricle congenital heart disease where the systemic venous return circumvents a pumping chamber and flows directly into the pulmonary circuit.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32980091"
        },
        {
          "offsetInBeginSection": 301,
          "offsetInEndSection": 491,
          "text": "For the third and most complex operation, called Fontan, an extracardiac conduit is used to connect inferior vena cava (IVC) to the PL and thereafter no deoxygenated blood goes to the heart.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36339935"
        },
        {
          "offsetInBeginSection": 600,
          "offsetInEndSection": 791,
          "text": "care for these patients.DISCUSSION: During the surgical Fontan procedure, the inferior vena cava is connected to the pulmonary circulation, after prior connection of the superior vena cava to",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35224438"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 460,
          "text": "Since 1989, the Fontan operation has been staged by associating the superior vena cava with the branch pulmonary arteries (hemi-Fontan) initially followed, some months later, by associating the inferior vena cava to the branch pulmonary arteries (completion Fontan).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8238751"
        },
        {
          "offsetInBeginSection": 368,
          "offsetInEndSection": 522,
          "text": "The final stage is known as Fontan procedure, in which inferior vena cava is directly connected to pulmonary arteries without going through the ventricle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27108290"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 283,
          "text": "The total cavopulmonary connection (TCPC), or Fontan procedure, diverts systemic venous blood directly into the pulmonary arteries and is the palliative surgery of choice for patients with a wide variety of congenital heart diseases with single-ventricle physiologic characteristics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27618316"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 194,
          "text": "BACKGROUND/PURPOSE: Fontan operation has evolved from atriopulmonary connection to total cavopulmonary connection (TCPC) due to its advantages in terms of hemodynamics and reduction of atrium-re",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26853857"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 146,
          "text": "Patients born with single ventricle anatomy typically undergo surgical palliation in three stages, culminating in the Fontan procedure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39395055"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "BACKGROUND The Fontan procedure, performed for univentricular heart, may also include the technique of percutaneous fenestration to create a small atrial septal defect (ASD) and a right-to-left shunt.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29802801"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 404,
          "text": "ic function. Patients who have undergone the Fontan procedure have decreased cardiac output, increased systemic vascular resistance, abnormal diastolic function, and decreased exercise capacity compared with n",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9315539/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "The Fontan operation represents the final stage of a series of palliative surgical procedures for children born with complex congenital heart disease, where a \"usual\" biventricular physiology cannot be restored.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 84,
          "text": "In patients with univentricular heart, the Fontan procedure is the final palliation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38343498"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 112,
          "text": "The Fontan palliation was introduced in 1968 to treat cardiac malformations unsuitable for biventricular repair.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20585329"
        },
        {
          "offsetInBeginSection": 26,
          "offsetInEndSection": 158,
          "text": " The Fontan procedure, a palliative surgery for univentricular heart physiology, often reduces exercise capacity and quality of life",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39459353"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "BACKGROUND: The Fontan procedure is the definitive operation for palliation of complex congenital heart disease with single-ventricle",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11790702"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "INTRODUCTION: A Fontan operation is performed to provide palliation for patients with many forms of highly complex congenital heart disease that cannot support a biventricula",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25335555"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "AIM: The Fontan procedure is a palliative surgical treatment for different congenital heart diseases with a univentricular he",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38782728"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "Fontan repair could be used as the definitive palliation in many forms of complex cyanotic congenital heart disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10731878"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Modified Fontan procedure was successfully performed in two patients with complex cardiac anomaly and nonconfluent pulmonary artery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8057028"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "The Fontan procedure is a palliative surgery performed for patients with complex congenital heart disease who exhibit functional single ventricular physiology.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32921662"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Three-staged Fontan palliation is performed on children suffering from single ventricle congenital heart disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25621311"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "BACKGROUND: The Fontan procedure is sometimes the last palliative surgery for complex congenital heart disease with single-ventricle",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301986"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "text": "Fontan operation is performed to provide palliation for patients with many forms of highly complex congenital heart disease that cannot support a biventricular circulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22672849"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "The Fontan procedure has proved useful in the surgical treatment of patients with tricuspid atresia, univentricular heart, and other complicated cardiac anomalies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6827852"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "The original Fontan procedure included a classic superior vena cava-to-right pulmonary artery (Glenn) shunt.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4033175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "A comparative flow study has been conducted on two configurations of the Fontan operations for congenital heart defects in which the right ventricle is by-passed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7689671"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "text": "Fontan surgery is vital for infants born with a single-ventricle heart. This intervention establishes a new blood flow circuit bypassing the single ventricle, thereby the separating pulmonary and systemic circulation to preserve single ventricular function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39219388"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "text": "While the Fontan operation is a reliable treatment option for many complex congenital heart defects, the development of pulmonary arteriovenous malformations (PAVMs) remains a problematic outcome for some Fontan patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26180170"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "The Fontan procedure is a staged palliative surgery performed in children with congenital univentricular heart defects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36867074"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Fontan operation is the final palliative stage of patients with univentricular hearts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26830073"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "The Fontan operation is a palliative surgical procedure for patients whose hearts cannot support a biventricular circulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30482258"
        },
        {
          "offsetInBeginSection": 265,
          "offsetInEndSection": 544,
          "text": "ember 1989.METHODS AND RESULTS: Modifications of the Fontan procedure included transatrial baffle of pulmonary venous return to the tricuspid valve (n \u003d 10) or inferior vena cava baffle within the right atrium to the superior vena caval-pulmonary artery anastomosis, with pulmona",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1728440"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 443,
          "text": "Of the survivors, before 1989, 77 patients underwent a subsequent modified Fontan operation, consisting of baffling the atrial septal defect to the tricuspid valve (initial 25 patients) or intraatrial baffling of the inferior vena cava to the pulmonary arteries and superior vena cava (52 patients).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1280410"
        },
        {
          "offsetInBeginSection": 403,
          "offsetInEndSection": 687,
          "text": "The hemi-Fontan procedure includes association of the superior vena(e) cava(e) (SVC) with the branch pulmonary arteries, augmentation of the central pulmonary arteries, occlusion of the inflow of the SVC into the right atrium, and elimination of other sources of pulmonary blood flow.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12740775"
        }
      ],
      "type": "factoid",
      "id": "67cc97c481b1027333000012",
      "ideal_answer": [
        "Fontan Palliation is an open heart proceedure performed on children",
        "The Fontan procedure is a palliative surgery for children with single ventricle heart defects.",
        "Fontan palliation is a surgical procedure that is performed to treat congenital heart disease.",
        "The Fontan procedure is performed on the heart, specifically targeting its chambers and vessels to reroute systemic venous blood directly to the lungs, thereby improving circulation in patients with single-ventricle physiology.",
        "The Fontan procedure is performed on the heart.",
        "The Fontan procedure is performed on the heart to reroute blood flow in patients with single-ventricle physiology.",
        "The Fontan Palliation (also known as Fontan procedure) is performed on the heart, specifically connecting the systemic venous return directly to the pulmonary arterial tree, bypassing the pumping chamber.",
        "Fontan palliation is performed in the chest, involving the heart and its major vessels. It is specifically used for patients with single ventricle physiology and creates a cavopulmonary connection by connecting the superior and/or inferior vena cava to the pulmonary arteries, thereby bypassing the heart’s single functional ventricle.",
        "Fontan Palliation (Fontan procedure) is performed on the heart.",
        "The Fontan procedure is performed on the heart, specifically for patients with single-ventricle physiology.",
        "The Fontan procedure is performed on the heart, specifically in patients with single-ventricle congenital heart disease.",
        "The Fontan procedure is performed on the heart, specifically for patients with single-ventricle congenital heart disease.",
        "The Fontan procedure is performed on the heart, specifically for patients with complex congenital heart disease who exhibit functional single ventricular physiology. It is a palliative surgical treatment for different congenital heart diseases with a univentricular heart.",
        "The Fontan Palliation (also known as Fontan procedure) is performed on the body part that connects the systemic venous return directly to the pulmonary arterial tree, specifically the connection between the inferior vena cava (or superior vena cava) and the pulmonary arteries.",
        "The Fontan procedure is a palliative surgery performed on the heart to reroute the systemic venous blood flow directly to the lungs in patients with complex congenital heart defects like single ventricle physiology. It is the final stage of a series of staged surgeries for these patients.",
        "The Fontan procedure is performed on the heart. It is the final palliative surgery in a series of staged surgeries for patients with functional single-ventricle physiology, rerouting systemic venous blood flow directly to the lungs while the ventricle(s) pump oxygenated blood to the body.",
        "The Fontan procedure, a palliative surgery, is performed on the heart. It redirects blood flow in patients with single ventricle heart defects, connecting the inferior vena cava (and sometimes the superior vena cava) to the pulmonary artery, thus bypassing the right ventricle.",
        "The Fontan Palliation (AKA Fontan procedure) is performed on the part of the body where the systemic venous return is connected directly to the pulmonary arterial tree, bypassing the single ventricle.",
        "The Fontan procedure is a staged palliative surgery performed in children with congenital univentricular heart defects.",
        "The Fontan procedure is a cardiac surgical intervention performed on the heart to address single ventricle congenital heart defects. It involves reconstructing the heart\u0027s circulatory pathways to separate systemic and pulmonary blood flow in patients with complex congenital heart conditions.",
        "Fontan Palliation is a surgical procedure performed on the heart.",
        "The Fontan procedure, also known as Fontan palliation, is a surgical intervention specifically designed to address congenital univentricular heart defects. It involves separating the systemic and pulmonary circulations to provide lifesaving palliation for individuals with single ventricle physiology.",
        "The Fontan Palliation (AKA Fontan procedure) is performed on the heart.",
        "The Fontan procedure is a staged palliative surgery performed in children with congenital univentricular heart defects, specifically addressing the heart.",
        "The Fontan procedure is a palliative operation performed on patients with single ventricle heart disease.",
        "The Fontan procedure is performed on the heart, specifically for individuals with single ventricle (SV) physiology.",
        "The Fontan Palliation (Fontan procedure) is performed on the heart.",
        "The Fontan procedure is a specialized heart surgery performed on individuals with single-ventricle congenital heart defects. This procedure is designed to improve circulation by separating systemic and pulmonary blood flows. Here\u0027s a concise breakdown:\n\n1. **Location**: The surgery is performed on the heart, specifically modifying the atria (upper chambers of the heart).\n\n2. **Purpose**: It alleviates the strain on the single ventricle by creating pathways that direct deoxygenated blood directly to the lungs and oxygenated blood to the body.\n\n3. **Procedure Details**:\n   - **Atrial Baffle/Septum**: A barrier is created within the atria to separate systemic venous return (deoxygenated blood) from pulmonary venous return (oxygenated blood).\n   - **Venae Cavae to Pulmonary Arteries Connection**: Veins carrying deoxygenated blood are connected directly to the pulmonary arteries, bypassing the overburdened ventricle.\n\n4. **Types**: Includes variations like the classic Fontan and Total Cavopulmonary Connection (TCPC), both aimed at enhancing blood flow efficiency.\n\nIn summary, the Fontan procedure is a heart surgery that restructures circulatory pathways to improve blood flow in patients with single-ventricle defects.",
        "The Fontan procedure is performed on the heart, specifically to palliate single-ventricle congenital heart disease by separating the systemic and pulmonary circulations.",
        "The Fontan procedure, also known as Fontan palliation, is a surgical intervention performed on children with congenital univentricular heart defects. It involves creating a pathway to separate the systemic and pulmonary circulations in patients with single-ventricle physiology, effectively providing lifesaving palliation by rerouting blood flow within the heart.",
        "The Fontan procedure is performed on the heart, specifically for individuals with congenital univentricular heart defects.",
        "The Fontan procedure is performed on the heart, specifically to palliate congenital univentricular heart defects by separating the systemic and pulmonary circulations.",
        "Fontan Palliation is a surgical procedure that is performed on the heart.",
        "The Fontan procedure is performed on the heart, specifically for individuals with single ventricle congenital heart disease.",
        "The Fontan procedure is performed on the heart to manage single-ventricle defects.",
        "The Fontan Palliation (Fontan procedure) is specifically performed on the heart, targeting individuals with single-ventricle (SV) physiology or congenital univentricular heart defects, aiming to separate systemic and pulmonary circulations, with potential systemic effects on other organs.",
        "The Fontan operation provides lifesaving palliation for individuals with single ventricle (SV) physiology.",
        " The Fontan Palliation or Fontan Procedure is performed on the heart, specifically in individuals with congenital single ventricle physiology. This procedure separates the systemic and pulmonary circulations as a palliative treatment for univentricular heart defects.",
        "The Fontan procedure is performed on the heart. This surgical intervention is designed for individuals with single-ventricle congenital heart defects, aiming to separate systemic and pulmonary circulations to improve blood flow efficiency and reduce complications associated with these conditions.",
        "The Fontan palliation (also known as the Fontan procedure) is performed on the heart, specifically in children with congenital univentricular heart defects or single ventricle physiology. It is a staged palliative surgery that aims to separate the systemic and pulmonary circulations, providing lifesaving palliation for these individuals.",
        "The Fontan procedure is a palliative surgery performed on the heart in children born with a single ventricle (univentricular) heart defect. It separates the systemic and pulmonary circulations by redirecting the venous blood flow directly to the pulmonary arteries, bypassing the heart\u0027s ventricle(s).",
        "The Fontan Palliation (Fontan procedure) is performed on the heart, specifically in individuals with single-ventricle physiology or congenital univentricular heart defects, aiming to improve circulation by separating systemic and pulmonary blood flows.",
        "Fontan palliation is performed on the heart and the nearby major blood vessels. It involves redirecting systemic venous blood from the superior and inferior venae cavae directly into the pulmonary arteries, bypassing the heart’s ventricle to improve blood flow to the lungs in patients with a single functional ventricle.",
        "The Fontan procedure is a palliative heart operation for some forms of congenital heart disease in which there is a functional single ventricle.",
        "The Fontan procedure is performed on the heart. It is a palliative surgery for individuals with single ventricle congenital heart disease, separating the systemic and pulmonary circulations.",
        "The Fontan procedure is a palliative surgery performed on the heart, specifically in children born with congenital univentricular heart defects (single ventricle physiology). The procedure works by separating the systemic and pulmonary circulations to provide lifesaving treatment for these patients.",
        "The Fontan procedure is a palliative surgery performed on children with congenital univentricular heart defects, addressing single-ventricle congenital heart disease by separating the systemic and pulmonary circulations."
      ],
      "exact_answer": [
        [
          "heart vena cava and pulmoary artery"
        ]
      ]
    },
    {
      "body": "Is childhood asthma more common in highly polluted areas?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37458141",
        "http://www.ncbi.nlm.nih.gov/pubmed/38219897",
        "http://www.ncbi.nlm.nih.gov/pubmed/38416497",
        "http://www.ncbi.nlm.nih.gov/pubmed/38388489",
        "http://www.ncbi.nlm.nih.gov/pubmed/38387571",
        "http://www.ncbi.nlm.nih.gov/pubmed/19663041",
        "http://www.ncbi.nlm.nih.gov/pubmed/2919801",
        "http://www.ncbi.nlm.nih.gov/pubmed/20117766",
        "http://www.ncbi.nlm.nih.gov/pubmed/11760369",
        "http://www.ncbi.nlm.nih.gov/pubmed/29493555"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 1608,
          "offsetInEndSection": 1678,
          "text": "Improved ambient PM benefits in decreasing childhood asthma prevalence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37458141"
        },
        {
          "offsetInBeginSection": 1935,
          "offsetInEndSection": 2064,
          "text": "characteristics of the urban environment during pregnancy are of relevance to the offspring\u0027s respiratory health during childhood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38219897"
        },
        {
          "offsetInBeginSection": 2705,
          "offsetInEndSection": 2806,
          "text": "early life air pollution was associated with increased asthma incidence by early and middle childhood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38416497"
        },
        {
          "offsetInBeginSection": 2971,
          "offsetInEndSection": 3049,
          "text": "Reducing asthma risk in the US requires air pollution regulation and reduction",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38416497"
        },
        {
          "offsetInBeginSection": 1780,
          "offsetInEndSection": 1949,
          "text": "Recommendations to reduce exposure and use of indoor air filtration in areas with high PM pollution may improve symptom control and lung function in children with asthma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38388489"
        },
        {
          "offsetInBeginSection": 1571,
          "offsetInEndSection": 1871,
          "text": "vulnerable subpopulation of children who were exposed to 13 of the 25 significant combinations in at least one exposure period. On average, these children experienced the largest number of asthma symptoms in our sample. By providing evidence on air toxic combinations associated with childhood asthma",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38387571"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "PURPOSE OF REVIEW: Current levels of air pollution are consistently associated with asthma development and morbidity among children, suggesting that current regulatory policies m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19663041"
        },
        {
          "offsetInBeginSection": 432,
          "offsetInEndSection": 658,
          "text": "In addition, incidence of severe asthma (types II, III, and IV) in children living in polluted areas was markedly increased whereas the slight form of asthma (type I) was more frequent in children living in non-polluted areas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2919801"
        },
        {
          "offsetInBeginSection": 917,
          "offsetInEndSection": 1427,
          "text": "trolling for age, family smoking, family incense burning, and parental education level, multivariate logistic regression models indicated that children living in an area with heavy air pollution were more likely to have asthma than those in an area with no or light pollution (odds ratio, OR \u003d 2.01 and 95% confidence interval, CI \u003d 1.94-2.09 based on parental ranking of pollution level, or OR \u003d 1.30 and 95% CI \u003d 1.18-1.42 based on pollution level reported by the Environmental Protection Administration).CON",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11760369"
        },
        {
          "offsetInBeginSection": 938,
          "offsetInEndSection": 1390,
          "text": " regression models.RESULTS: Children in counties with ozone and, to a less consistent degree, particulate matter levels in the highest quartile were more likely to have current asthma and/or a recent asthma attack than children residing in counties with the lowest pollution levels; the adjusted odds for current asthma for the highest quartile of estimated ozone exposure was 1.56 (95% confidence interval [CI]: 1.15, 2.10) and for recent asthma attac",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20117766"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "PURPOSE OF REVIEW: Exposure to air pollutants is linked with poor asthma control in children and represents a potentially modifiable risk factor for impaired lung function, rescue medication use, and increased asthma-related heal",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29493555"
        }
      ],
      "id": "67d6b4e218b1e36f2e00001e",
      "ideal_answer": [
        "Yes, toxic substances in air contribute to childhood asthma incidence and prevalence.",
        "Yes, childhood asthma appears to be more common or severe in highly polluted areas. Studies consistently show a link between exposure to pollutants like PM10, NO2, SO2, and PM2.5 and increased incidence of asthma or worsening of respiratory symptoms in children. Comparative analyses across regions with varying pollution levels support this association, though the relationship\u0027s complexity is acknowledged. While the exact mechanisms are not fully understood, the evidence suggests a higher burden of childhood asthma in highly polluted areas.",
        "Yes, childhood asthma is more common in highly polluted areas. Environmental pollution is identified as a critical risk factor for childhood asthma, and ubiquitous environmental exposures, including ambient air pollutants, are linked to the development and severity of the condition. Children living or attending schools near high traffic density roads are exposed to higher levels of motor vehicle air pollutants, increasing the incidence and prevalence of childhood asthma and wheeze. Studies have also identified a higher incidence of asthma among children in cities with high pollution levels compared to less polluted regions. Exposure to air pollutants is linked with poor asthma control and represents a modifiable risk factor for impaired lung function and increased asthma-related healthcare utilization.",
        "Yes, childhood asthma is more common in highly polluted areas. Studies have shown that children living in areas with heavy air pollution are more likely to develop asthma compared to those in areas with no or light pollution. Exposure to traffic-related pollution, such as from roadways near homes and schools, increases the incidence and prevalence of childhood asthma and wheeze. Early-life exposure to ambient air pollution, including pollutants like NO2, PM2.5, CO, NO, PM10, SO2, and black carbon, is associated with an increased risk of asthma diagnosis. These findings suggest that air pollution, especially during early childhood, contributes to the development of asthma.",
        "Based on the analysis of multiple studies, it is evident that childhood asthma is more prevalent in areas with high levels of air pollution. Key findings include:\n\n1. **Air Pollutants as Risk Factors**: Studies consistently show that exposure to pollutants such as PM10 and NO2 increases the risk of childhood asthma. These pollutants are often associated with traffic and industrial emissions.\n\n2. **Early-Life Exposure Impact**: Research indicates that exposure to mixed air pollutants during the first 1000 days of life significantly elevates the risk of developing asthma or wheezing in children.\n\n3. **Contradictory Evidence on ER Visits**: While pollution contributes to asthma incidence, one study found no major link between air pollution and increased emergency room visits for asthma exacerbations.\n\n4. **Uncertainty in Rural Areas**: There is some uncertainty regarding the effects of outdoor air pollution on childhood asthma in rural settings, suggesting that other factors might play a role in these environments.\n\n5. **Contribution to Asthma Factors**: Outdoor air pollution accounts for 19% of asthma-related factors, with climatic and environmental elements contributing an additional 30%, highlighting the multifaceted nature of asthma causation.\n\nIn conclusion, the preponderance of evidence supports the notion that childhood asthma is more common in highly polluted areas due to the adverse effects of air pollutants on respiratory health.",
        "Yes, childhood asthma appears to be more common in highly polluted areas, with multiple studies suggesting a positive association. Key pollutants linked to increased childhood asthma prevalence or severity include particulate matter (PM10) and nitrogen dioxide (NO2). While findings are consistent in regions like Central Europe, southwestern Ontario, and Northern Israel, some studies in Scandinavia found no overall pattern. The relationship is likely complex, influenced by various factors, but the majority of evidence supports a link between high pollution levels and increased childhood asthma.",
        "The studies reviewed suggest that childhood asthma is more prevalent and severe in areas with higher levels of air pollution, particularly from traffic-related pollutants like particulate matter, nitrogen dioxide, and ozone. However, the relationship is complex, with other factors like genetics, socioeconomic status, and allergen exposure also playing important roles. Air pollution appears to exacerbate asthma symptoms and may contribute to the development of asthma, but is likely not the sole causative factor.",
        "Yes, childhood asthma is more common in highly polluted areas. Studies have shown that exposure to poor air quality, traffic pollution, and industrial emissions is linked to a higher prevalence of asthma in children. Specifically, pollutants such as particulate matter (PM2.5), nitrogen dioxide (NO2), and sulfur dioxide have been associated with an increased risk of asthma. Additionally, social determinants of health, such as poverty and racism, can also contribute to higher rates of asthma in children. Overall, the evidence suggests that reducing exposure to air pollution and addressing social determinants of health can help mitigate the risk of childhood asthma.",
        "The studies reviewed provide mixed evidence on whether childhood asthma is more common in highly polluted areas. Some studies found positive associations between air pollution levels and asthma incidence or severity in children, suggesting pollution may contribute to asthma development and exacerbations. However, other studies did not find a significant difference in asthma prevalence between areas with high versus low pollution levels. Overall, the evidence suggests air pollution likely exacerbates asthma symptoms in children with existing asthma, but the link between pollution and asthma incidence is less clear."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Does nucleosomal DNA have topological memory?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38806488"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 555,
          "offsetInEndSection": 1060,
          "text": "We show that nucleosomes inherently restrain distinct ∆Lk values depending on their genomic origin. Nucleosome DNA topologies differ at gene bodies (∆Lk \u003d -1.29), intergenic regions (∆Lk \u003d -1.23), rDNA genes (∆Lk \u003d -1.24) and telomeric regions (∆Lk \u003d -1.07). Nucleosomes near the transcription start and termination sites also exhibit singular DNA topologies. Our findings demonstrate that nucleosome DNA topology is imprinted by its native chromatin context and persists when the nucleosome is relocated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38806488"
        },
        {
          "offsetInBeginSection": 915,
          "offsetInEndSection": 1060,
          "text": "Our findings demonstrate that nucleosome DNA topology is imprinted by its native chromatin context and persists when the nucleosome is relocated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38806488"
        },
        {
          "offsetInBeginSection": 814,
          "offsetInEndSection": 1060,
          "text": "Nucleosomes near the transcription start and termination sites also exhibit singular DNA topologies. Our findings demonstrate that nucleosome DNA topology is imprinted by its native chromatin context and persists when the nucleosome is relocated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38806488"
        }
      ],
      "id": "67d4161318b1e36f2e00000a",
      "ideal_answer": [
        "Yes. Nucleosome DNA topology is imprinted by its native chromatin context and persists when the nucleosome is relocated.",
        "Yes, nucleosomal DNA has topological memory. This means that the spatial arrangement and interactions of DNA within the nucleosome can influence its structural configuration and behavior over time, retaining information about its previous states.",
        "Yes, nucleosomal DNA exhibits topological memory. This means that the DNA retains information about its previous topological state even after being temporarily unwrapped from the histone core. This property is important for processes such as transcription, replication, and DNA repair, as it influences how DNA is accessed and manipulated by various proteins and enzymes.",
        "Yes, nucleosomal DNA has topological memory. This means that the DNA retains information about its previous topological state even after being transiently disrupted or unwrapped from the histone core. This property is important for processes such as transcription, replication, and repair, where the DNA must be temporarily accessed and then returned to its original state.",
        "Yes, nucleosomal DNA has topological memory. Nucleosomes inherently restrain distinct Lk values depending on their genomic origin. Nucleosome DNA topology is imprinted by its native chromatin context and persists when the nucleosome is relocated.",
        "Yes, nucleosomal DNA has topological memory, as it retains the topological imprint from its native chromatin context even when the nucleosome is relocated, and this property can persist and be transmitted across mitotic generations.",
        "Yes. Nucleosomes inherently restrain distinct ∆Lk values depending on their genomic origin, which suggests that they can retain topological arrangements and thus have topological memory.",
        "Yes, nucleosomal DNA exhibits topological memory. The inherent wrapping and supercoiling configuration is stably maintained, even if the nucleosome is relocated or transiently remodeled. Experiments show that when remodeling conditions are removed, the nucleosomal DNA soon reverts toward its original topology, indicating the presence of a significant energy barrier between the altered and native states. Additionally, the specific topological state, reflected in different linking numbers, varies across genomic regions such as gene bodies, intergenic areas, rDNA, and telomeres. This regional variability further highlights the robustness of the nucleosome’s topological imprinting and its role in sustaining consistent DNA-protein interactions and chromatin organization.",
        "Yes, nucleosomal DNA has topological memory. Research demonstrates that nucleosomes inherently restrain distinct DNA linking number (Lk) values depending on their genomic origin. Calculations of the Lk restrained by thousands of nucleosomes in yeast cells support this. The topology of nucleosome DNA is imprinted by its native chromatin context and persists even when the nucleosome is relocated. Nucleosomes stabilize negative DNA supercoils by restraining a DNA linking number difference (Lk) of about -1.26.",
        "Yes. Nucleosomes have the capacity to transmit epigenetic memory across mitotic generations with exquisite spatial fidelity, indicating that nucleosomal DNA retains topological memory.",
        "Yes. Nucleosomes inherently restrain distinct DNA topologies, suggesting that they have a form of topological memory that is influenced by their genomic origin.",
        "Yes, nucleosomal DNA has topological memory, which is imprinted by its native chromatin context and persists upon relocation. This is evidenced by distinct DNA linking number differences (∆Lk) in nucleosomes from various genomic regions (e.g., gene bodies: -1.29, intergenic: -1.23, rDNA genes: -1.24, telomeric regions: -1.07) and unique topologies near transcription start and termination sites. This topological memory may play a crucial role in regulating genome activities and the formation/stability of higher-order chromatin structures.",
        "Yes. Nucleosomes exhibit distinct topological characteristics that can be influenced by their genomic origin, suggesting they have a form of topological memory.",
        "Yes, nucleosomal DNA exhibits topological memory. This means that the DNA retains information about its previous topological state even after being transiently unwrapped from the histone core. This property is important for processes such as transcription, replication, and DNA repair, as it influences how DNA is accessed and manipulated by various proteins and enzymes.",
        "Yes, nucleosomal DNA has topological memory. Several studies have shown that nucleosomes inherently restrain distinct DNA linking number differences (ΔLk) depending on their genomic origin, such as gene bodies, intergenic regions, rDNA genes, and telomeric regions. This topological imprint persists even when the nucleosome is relocated, suggesting that nucleosomal DNA topology is imprinted by its native chromatin context and retains this memory.",
        "Yes, nucleosomal DNA has topological memory. This means that the DNA wrapped around nucleosomes retains information about its previous topological state, which can influence its accessibility and interactions with other molecules.",
        "Yes, nucleosomal DNA has topological memory according to recent research. Studies have shown that nucleosomes inherently restrain distinct DNA linking number (ΔLk) values depending on their genomic origin, such as gene bodies, intergenic regions, rDNA genes, and telomeric regions. This topological imprint persists even when the nucleosome is relocated, suggesting that nucleosomal DNA has a memory of its native chromatin context encoded in its topology.",
        "Yes, nucleosomal DNA exhibits topological memory, characterized by distinct DNA linking number differences (∆Lk) that persist even after relocation from its native chromatin context. This is evident in varying ∆Lk values across genomic regions (e.g., gene bodies: -1.29, intergenic: -1.23, rDNA genes: -1.24, telomeric regions: -1.07) and unique topologies near transcription sites. This memory plays a crucial role in regulating genome activities and higher-order chromatin structure formation/stability.",
        "Yes, nucleosomal DNA exhibits topological memory. This means that the specific topology of nucleosomal DNA is imprinted by its native chromatin context and remains intact even when a nucleosome is relocated, indicating that the structural characteristics of the DNA are maintained over time.",
        "Yes, nucleosomal DNA appears to have topological memory, with its topology influenced by and persisting from its native chromatin context.",
        "Yes, nucleosomal DNA has topological memory, as demonstrated by findings that nucleosome DNA topology is imprinted by its native chromatin context and persists even when the nucleosome is relocated. This topological memory can be transmitted across mitotic generations with high spatial fidelity, and distinct topological states are observed in different genomic regions such as gene bodies, intergenic regions, rDNA genes, and telomeric regions.",
        "Yes, nucleosomal DNA has topological memory. Research demonstrates that nucleosome DNA topology is imprinted by its native chromatin context and persists even when the nucleosome is relocated. Studies have shown that nucleosomes inherently restrain distinct Lk (linking number) values depending on their genomic origin.",
        "Yes, nucleosomal DNA exhibits topological memory as its DNA topology is imprinted by its native chromatin context and persists upon relocation to different genomic regions.",
        "Yes, nucleosomal DNA has topological memory. This is evidenced by the varying DNA linking number differences (∆Lk) that are specific to a nucleosome\u0027s genomic origin. Notably, these topological features persist even when the nucleosome is relocated to a different part of the genome, indicating that the DNA\u0027s topology is imprinted by its native chromatin context. This phenomenon suggests a form of \u0027memory\u0027 where the DNA retains its original topological state, influenced by its initial location within the genome, such as near gene bodies, intergenic regions, or other specific chromatin environments.",
        "Yes, nucleosomal DNA exhibits topological memory. The study demonstrates that nucleosomes maintain specific ΔLk values depending on their genomic origin. Gene bodies have a ΔLk of 1.29, intergenic regions 1.23, rDNA genes 1.24, and telomeric regions 1.07. Additionally, nucleosomes near transcription start and termination sites display unique DNA topologies. This indicates that the DNA topology is imprinted by the native chromatin context and persists even when the nucleosome is relocated.",
        "Yes, nucleosomal DNA has topological memory as demonstrated by distinct ∆Lk values depending on their genomic origin, which persist even when the nucleosome is relocated.",
        "Yes, nucleosomal DNA has topological memory. Nucleosome DNA topology is imprinted by its native chromatin context and persists when the nucleosome is relocated. Nucleosomes inherently restrain distinct ∆Lk values depending on their genomic origin.",
        "Yes, nucleosomal DNA exhibits topological memory. The study demonstrates that the topology of nucleosomal DNA, measured by ΔLk values, varies depending on its genomic origin. For instance, gene bodies have a ΔLk of -1.29, while telomeric regions have -1.07. Importantly, this topological imprint persists even when nucleosomes are relocated, indicating that the DNA retains its original topological characteristics from its native chromatin context. This suggests that nucleosomal DNA has a form of memory regarding its topological state based on its genomic origin.",
        "Yes, nucleosomal DNA does have topological memory. Experimental evidence shows that distinct ∆Lk values occur in different genomic contexts such as gene bodies, intergenic regions, rDNA genes, and telomeric regions. This indicates that nucleosomes impose a specific supercoiling pattern that reflects their native chromatin environment. Additionally, experiments demonstrate that even after remodeling events, such as ATP removal or changes in the degree of supercoiling, the nucleosome reverts to its original topology. This resilience confirms that the topological state of nucleosomal DNA is inherently preserved, influencing local chromatin organization.",
        "Yes, nucleosomal DNA has topological memory. Nucleosome DNA topologies differ at gene bodies, intergenic regions, rDNA genes and telomeric regions. Nucleosome DNA topology is imprinted by its native chromatin context and persists when the nucleosome is relocated.",
        "Yes, nucleosomal DNA has topological memory as it inherently restrains distinct DNA topologies depending on its genomic origin and persists when the nucleosome is relocated.",
        "Yes, nucleosomal DNA exhibits topological memory. The topology of the DNA within a nucleosome is imprinted by its native chromatin context and persists even when the nucleosome is relocated to a different genomic region. This means that the specific ΔLk values, which reflect the degree of DNA twisting, are retained based on the original genomic location of the nucleosome. Therefore, nucleosomal DNA remembers its topological state from its initial environment.",
        "Yes, nucleosomal DNA has topological memory. Nucleosomes restrain distinct DNA linking number difference (∆Lk) values depending on their genomic origin. Nucleosome DNA topologies differ at gene bodies, intergenic regions, rDNA genes, and telomeric regions. Nucleosomes near the transcription start and termination sites also exhibit singular DNA topologies. Nucleosome DNA topology is imprinted by its native chromatin context and persists even when the nucleosome is relocated.",
        "Yes, nucleosomal DNA exhibits topological memory as it inherently restrains distinct linking number differences (ΔLk) based on its genomic origin. The study shows that nucleosomes from different regions such as gene bodies, intergenic areas, rDNA genes, and telomeric regions have specific ΔLk values, indicating unique DNA topologies. These topological characteristics persist even when the nucleosome is relocated, suggesting an imprinting by their native chromatin context.",
        "Yes, nucleosomal DNA exhibits topological memory, as its DNA topology is influenced by its native chromatin context and retains these characteristics even when the nucleosome is relocated.",
        "Yes, nucleosomal DNA has topological memory. According to the study, nucleosome DNA topology is imprinted by its native chromatin context and persists even when the nucleosome is relocated. This means that the topological features of DNA, such as ∆Lk values, are retained and reflect the genomic origin of the nucleosome.",
        "Yes. Nucleosomes have the capacity to transmit epigenetic memory across mitotic generations, indicating that nucleosomal DNA retains topological information that influences gene expression.",
        "Yes, nucleosomal DNA has topological memory. This is evidenced by nucleosomes restraining distinct linking number differences (∆Lk) based on their genomic origin, including variations in gene bodies, intergenic regions, rDNA genes, telomeric regions, and near transcription start/termination sites. The DNA topology is imprinted by the native chromatin context and persists even when the nucleosome is relocated, influencing chromosome architecture and potentially impacting gene expression and regulation.",
        "Yes. Nucleosome DNA topology is imprinted by its native chromatin context, indicating that it retains a form of topological memory even when relocated.",
        "Yes, nucleosomal DNA exhibits topological memory. The DNA topology is determined by the nucleosome\u0027s original genomic context and remains consistent even when the nucleosome is relocated.",
        "Yes, nucleosomal DNA exhibits topological memory. Studies demonstrate that nucleosomes retain distinct ∆Lk values based on their genomic origin, such as gene bodies (∆Lk \u003d -1.29) and telomeric regions (∆Lk \u003d -1.07). This topology is imprinted by the native chromatin context and persists even when nucleosomes are relocated, indicating a form of memory retained by the DNA.",
        "Yes, nucleosomal DNA has topological memory. According to the study, nucleosome DNA topology is imprinted by its native chromatin context and persists even when the nucleosome is relocated. This means that the topological features of the DNA, such as ∆Lk values, are retained and reflect the genomic origin of the nucleosome.",
        "Yes, nucleosomal DNA appears to have topological memory, as its topology is imprinted by its native chromatin context and persists upon relocation.",
        "Yes, nucleosomal DNA has topological memory. Nucleosomes inherently restrain distinct DNA linking number (Lk) values depending on their genomic origin. Nucleosome DNA topologies differ at gene bodies, intergenic regions, rDNA genes, and telomeric regions. Nucleosomes near the transcription start and termination sites also exhibit singular DNA topologies. Nucleosome DNA topology is imprinted by its native chromatin context and persists even when the nucleosome is relocated."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "What cellular process is Listeriolysin associated with?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37503091",
        "http://www.ncbi.nlm.nih.gov/pubmed/38680365",
        "http://www.ncbi.nlm.nih.gov/pubmed/37992606",
        "http://www.ncbi.nlm.nih.gov/pubmed/39448786",
        "http://www.ncbi.nlm.nih.gov/pubmed/37461376",
        "http://www.ncbi.nlm.nih.gov/pubmed/30061379",
        "http://www.ncbi.nlm.nih.gov/pubmed/10639481",
        "http://www.ncbi.nlm.nih.gov/pubmed/30445439",
        "http://www.ncbi.nlm.nih.gov/pubmed/7960143",
        "http://www.ncbi.nlm.nih.gov/pubmed/31970394",
        "http://www.ncbi.nlm.nih.gov/pubmed/17720603",
        "http://www.ncbi.nlm.nih.gov/pubmed/7594534",
        "http://www.ncbi.nlm.nih.gov/pubmed/12163465",
        "http://www.ncbi.nlm.nih.gov/pubmed/29902442",
        "http://www.ncbi.nlm.nih.gov/pubmed/11890537",
        "http://www.ncbi.nlm.nih.gov/pubmed/28377528",
        "http://www.ncbi.nlm.nih.gov/pubmed/34809484",
        "http://www.ncbi.nlm.nih.gov/pubmed/33722646",
        "http://www.ncbi.nlm.nih.gov/pubmed/24739967",
        "http://www.ncbi.nlm.nih.gov/pubmed/12028384",
        "http://www.ncbi.nlm.nih.gov/pubmed/7513598",
        "http://www.ncbi.nlm.nih.gov/pubmed/11251831",
        "http://www.ncbi.nlm.nih.gov/pubmed/16362984",
        "http://www.ncbi.nlm.nih.gov/pubmed/28074026",
        "https://pubmed.ncbi.nlm.nih.gov/12163465/",
        "http://www.ncbi.nlm.nih.gov/pubmed/16622046",
        "http://www.ncbi.nlm.nih.gov/pubmed/23399758",
        "http://www.ncbi.nlm.nih.gov/pubmed/18216493",
        "http://www.ncbi.nlm.nih.gov/pubmed/19376879",
        "http://www.ncbi.nlm.nih.gov/pubmed/36656016",
        "http://www.ncbi.nlm.nih.gov/pubmed/18815593",
        "http://www.ncbi.nlm.nih.gov/pubmed/9669997",
        "http://www.ncbi.nlm.nih.gov/pubmed/16113511",
        "http://www.ncbi.nlm.nih.gov/pubmed/20194588",
        "http://www.ncbi.nlm.nih.gov/pubmed/16859495",
        "http://www.ncbi.nlm.nih.gov/pubmed/10816469",
        "http://www.ncbi.nlm.nih.gov/pubmed/7591098",
        "http://www.ncbi.nlm.nih.gov/pubmed/20414307/",
        "http://www.ncbi.nlm.nih.gov/pubmed/25874208",
        "http://www.ncbi.nlm.nih.gov/pubmed/21980582",
        "http://www.ncbi.nlm.nih.gov/pubmed/17517863"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 374,
          "text": "In the present work, a silencing RNA screen was performed to uncover plasma membrane repair mechanisms of cells exposed to a pore-forming toxin (listeriolysin O). T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37503091"
        },
        {
          "offsetInBeginSection": 376,
          "offsetInEndSection": 613,
          "text": "he pore forming and actin polymerizing Listeria monocytogenes effectors listeriolysin-O (LLO) and actin assembly-inducing protein (ActA) were synthesized using a novel green fluorescent protein (GFP)-linked heterologous expression system",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38680365"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 561,
          "text": "he system utilizes listeriolysin O (LLO), a toxin produced by L. monocytogenes that enlarges the pores split GFP-encapsulated liposomes,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37992606"
        },
        {
          "offsetInBeginSection": 1244,
          "offsetInEndSection": 1398,
          "text": "Listeriolysin O and pneumolysin efficiently assemble into non-covalent membrane pore complexes of approximately 30 units or more within the surface layer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39448786"
        },
        {
          "offsetInBeginSection": 317,
          "offsetInEndSection": 473,
          "text": ". Listeriolysin O plays a crucial role in the pathogenesis of the bacterium by facilitating the escape of the pathogen from the phagosome into the cytosol. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37461376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 416,
          "text": "Listeria monocytogenes is a facultative intracellular pathogen that infects a wide variety of cells, causing the life-threatening disease listeriosis. L. monocytogenes virulence factors include two surface invasins, InlA and InlB, known to promote bacterial uptake by host cells, and the secreted pore-forming toxin listeriolysin O (LLO), which disrupts the phagosome to allow bacterial proliferation in the cytosol.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30061379"
        },
        {
          "offsetInBeginSection": 153,
          "offsetInEndSection": 308,
          "text": "Listeriolysin O (LLO) is a secreted pore-forming protein essential for the escape of L. monocytogenes from the vacuole formed upon initial internalization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10639481"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 447,
          "text": "Listeria monocytogenes is a pathogenic bacterium that invades epithelial cells by activating host signaling cascades, which promote bacterial engulfment within a phagosome. The pore-forming toxin listeriolysin O (LLO), which is required for bacteria phagosomal escape, has also been associated with the activation of several signaling pathways when secreted by extracellular bacteria, including Ca2+ influx and promotion of L. monocytogenes entry.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445439"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 178,
          "text": "Listeria monocytogenes is an intracellular pathogen that enters the cytoplasm of infected cells by secreting listeriolysin (LLO), a protein that destroys the phagosomal membrane.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7594534"
        },
        {
          "offsetInBeginSection": 366,
          "offsetInEndSection": 529,
          "text": "The pore-forming protein listeriolysin O mediates escape from host vacuoles and utilizes multiple fail-safe mechanisms to avoid causing toxicity to infected cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12163465"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Listeriolysin O (LLO) is a cholesterol-dependent cytolysin that mediates escape of Listeria monocytogenes from a phagosome, enabling growth of the bacteria in the host cell cytosol.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29902442"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 598,
          "text": "The specific features of the pore-forming toxin listeriolysin O, as a protein particularly well adapted to the intracellular lifestyle of L. monocytogenes will be discussed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11890537"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 255,
          "text": "Listeriolysin S (LLS) is an SLS-like hemolysin/bacteriocin present among",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377528"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 386,
          "text": "Listeria uses a number of virulence factors to proliferate and spread to various cells and tissues. In this process, three bacterial virulence factors, the pore-forming protein listeriolysin O and phospholipases PlcA and PlcB, play a crucial role.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33722646"
        },
        {
          "offsetInBeginSection": 127,
          "offsetInEndSection": 375,
          "text": "mote bacterial engulfment within a phagosome. The pore-forming toxin listeriolysin O (LLO), which is required for bacteria phagosomal escape, has also been associated with the activation of several signaling pathways when secreted by extracellular ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445439"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 447,
          "text": "The pore-forming toxin listeriolysin O (LLO), which is required for bacteria phagosomal escape, has also been associated with the activation of several signaling pathways when secreted by extracellular bacteria, including Ca2+ influx and promotion of L. monocytogenes entry.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445439"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 564,
          "text": "Upon phagocytosis by a macrophage, engulfed Listeria express a hemolytic molecule, listeriolysin O (LLO), and can disrupt the membrane of the endosome and escape into the cellular cytoplasm.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7513598"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 384,
          "text": "The pore-forming toxin listeriolysin O (LLO), which is required for bacteria phagosomal escape, has also been associated with the activation of several signaling pathways when secreted by extracellular bacteria,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445439"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "The hly-encoded listeriolysin O (LLO) is a major virulence factor secreted by the intracellular pathogen Listeria monocytogenes, which plays a crucial role in the escape of bacteria from the phagosomal compartment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11251831"
        },
        {
          "offsetInBeginSection": 591,
          "offsetInEndSection": 798,
          "text": "During infection, PML undergoes oxidation-mediated multimerization, associates with the nuclear matrix, and becomes de-SUMOylated due to the pore-forming activity of the Listeria toxin listeriolysin O (LLO).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28074026"
        },
        {
          "offsetInBeginSection": 366,
          "offsetInEndSection": 414,
          "text": "The pore-forming protein listeriolysin O mediate",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/12163465/"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 301,
          "text": "The secreted cholesterol-dependent cytolysin, listeriolysin O (LLO), mediates phagosomal escape and allows bacterial growth in the cytosol of infected cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16622046"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "The pore-forming toxin listeriolysin O (LLO), which is produced by Listeria monocytogenes, mediates bacterial phagosomal escape and facilitates bacterial multiplication during infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23399758"
        },
        {
          "offsetInBeginSection": 179,
          "offsetInEndSection": 350,
          "text": "Listeria monocytogenes is a Gram-positive bacterial pathogen that utilizes a cholesterol-dependent pore-forming toxin, listeriolysin O (LLO), to escape from the phagosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18216493"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Listeriolysin O (LLO) is a pore-forming toxin that mediates phagosomal escape and cell-to-cell spread of the intracellular pathogen Listeria monocytogenes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19376879"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Rapid phagosomal escape mediated by listeriolysin O (LLO) is a prerequisite for Listeria monocytogenes intracellular replication and pathogenesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36656016"
        },
        {
          "offsetInBeginSection": 352,
          "offsetInEndSection": 550,
          "text": "Penetration of the phagosomal membrane is initiated by the secreted haemolysin listeriolysin O (LLO), which is essential for vacuolar escape in vitro and for virulence in animal models of infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18815593"
        },
        {
          "offsetInBeginSection": 421,
          "offsetInEndSection": 659,
          "text": "Expression of listeriolysin O from Listeria monocytogenes in the bacterium and its subsequent release into the phagosome triggers the breakdown of the membrane, allowing the release of the bacterial content into the cytosol of host cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141160"
        },
        {
          "offsetInBeginSection": 298,
          "offsetInEndSection": 598,
          "text": "After an introduction to the bacterium and to the disease, a description of the infection at the cellular level will be given. The specific features of the pore-forming toxin listeriolysin O, as a protein particularly well adapted to the intracellular lifestyle of L. monocytogenes will be discussed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11890537"
        },
        {
          "offsetInBeginSection": 298,
          "offsetInEndSection": 827,
          "text": "After an introduction to the bacterium and to the disease, a description of the infection at the cellular level will be given. The specific features of the pore-forming toxin listeriolysin O, as a protein particularly well adapted to the intracellular lifestyle of L. monocytogenes will be discussed. By describing in detail how the bacterium moves inside cells, particular attention will be given to show how addressing this issue has provided key answers and instrumental tools to cell biologists studying actin-based motility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11890537"
        },
        {
          "offsetInBeginSection": 473,
          "offsetInEndSection": 646,
          "text": "This process is essential for the successful establishment of infection. In addition, listeriolysin O is known as an immunomodulator that activates host signal transduction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37461376"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 659,
          "text": "These bacteria are eventually processed in the host phagosome where they are destroyed. Expression of listeriolysin O from Listeria monocytogenes in the bacterium and its subsequent release into the phagosome triggers the breakdown of the membrane, allowing the release of the bacterial content into the cytosol of host cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141160"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 598,
          "text": "This review rather than covering the whole field, intends to highlight the particularly interesting properties of some proteins involved in the infection by Listeria monocytogenes and the general interest in some of the approaches used to analyze the molecular and cellular basis of the infection. After an introduction to the bacterium and to the disease, a description of the infection at the cellular level will be given. The specific features of the pore-forming toxin listeriolysin O, as a protein particularly well adapted to the intracellular lifestyle of L. monocytogenes will be discussed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11890537"
        },
        {
          "offsetInBeginSection": 1475,
          "offsetInEndSection": 1732,
          "text": "All these prominent features of listeriolysin O play a role during different stages of the L. monocytogenes life cycle by promoting the proliferation of the pathogen while mitigating excessive damage to its replicative niche in the cytosol of the host cell.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33722646"
        },
        {
          "offsetInBeginSection": 319,
          "offsetInEndSection": 472,
          "text": "Listeriolysin O plays a crucial role in the pathogenesis of the bacterium by facilitating the escape of the pathogen from the phagosome into the cytosol.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37461376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Listeriolysin O (LLO) is a pore-forming cytolysin that enables Listeria monocytogenes to escape from a host cell vacuole.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7960143"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Listeriolysin O encoded by 1,587 bp hly is the essential virulence factor of Listeria monocytogenes that replicates in the cytosolic space after escaping from phagosome of macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16113511"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Listeriolysin O (LLO), an hly-encoded cytolysin of Listeria monocytogenes, plays an essential role in the entry of L. monocytogenes into the host cell cytoplasm.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20194588"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Listeria monocytogenes is an intracytosolic bacterial pathogen that escapes from the phagosome using a secreted cytolysin, listeriolysin O (LLO).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16859495"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 287,
          "text": "Bacterial escape from the phagosomal vacuole of infected cells is mainly mediated by the pore-forming hemolysin listeriolysin O (LLO) encoded by hly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10816469"
        },
        {
          "offsetInBeginSection": 135,
          "offsetInEndSection": 250,
          "text": "Listeriolysin O (LLO), a pore-forming hemolysin encoded by hly, is essential for vacuolar lysis in most cell types.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7591098"
        },
        {
          "offsetInBeginSection": 701,
          "offsetInEndSection": 959,
          "text": " This event is triggered by the bacterial virulence factor listeriolysin O (LLO), which induces a proteasome-independent degradation of Ubc9, an essential enzyme of the SUMOylation machinery, and a proteasome-dependent degradation of some SUMOylated proteins",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20414307/"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 318,
          "text": "Both of these processes are facilitated by expressing a major virulence factor known as listeriolysin O, a 56 kDa pore-forming protein encoded by the hly gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37461376"
        },
        {
          "offsetInBeginSection": 546,
          "offsetInEndSection": 646,
          "text": "In addition, listeriolysin O is known as an immunomodulator that activates host signal transduction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37461376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Listeriolysin O (LLO) is a thiol-activated cholesterol-dependent pore-forming toxin and the major virulence factor of Listeria monocytogenes (LM).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874208"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Listeriolysin O (LLO) is a cholesterol-dependent cytolysin that mediates escape of Listeria monocytogenes from a phagosome, enabling growth of the bacteria in the host cell cytosol. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29902442"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 335,
          "text": "host cells. The secreted pore-forming toxin listeriolysin O (LLO) of the intracellular pathogen Listeria monocytogenes promotes egress of the bacteria from vacuolar compartments into the host cytosol often without overt destruction of the inf",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31970394"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Listeriolysin O (LLO) is a pore-forming toxin of the cholesterol-dependent cytolysin family and a primary virulence factor of the gram-positive, facultative intracellular pathogen Listeria monocytogenes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17720603"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 426,
          "text": "The pore-forming toxin listeriolysin O (LLO), which is required for bacteria phagosomal escape, has also been associated with the activation of several signaling pathways when secreted by extracellular bacteria, including Ca2+ influx and promotion of L.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445439"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 319,
          "text": "The bacterium secretes a pore-forming cholesterol-dependent cytolysin, listeriolysin O (LLO), a major virulence factor involved in the activation of cellular processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34809484"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Listeriolysin O (LLO) is a pore-forming cytolysin secreted by the pathogen Listeria monocytogenes and is required for its intracellular survival.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028384"
        },
        {
          "offsetInBeginSection": 1016,
          "offsetInEndSection": 1211,
          "text": "The main bacterial factor responsible for mitochondrial network disruption was identified as the secreted pore-forming toxin listeriolysin O, which also appeared to impair mitochondrial function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21980582"
        },
        {
          "offsetInBeginSection": 563,
          "offsetInEndSection": 670,
          "text": "the secreted pore-forming toxin listeriolysin O (LLO) which promotes the escape from the phagocytic vacuole",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9669997"
        },
        {
          "offsetInBeginSection": 897,
          "offsetInEndSection": 1026,
          "text": "Once inside the cell, the haemolysin of L. monocytogenes--the listeriolysin O or LLO--is secreted to lyse the phagocytic vacuole,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16362984"
        },
        {
          "offsetInBeginSection": 467,
          "offsetInEndSection": 607,
          "text": "These bacteria can escape the phagosome in host cells by using the pore-forming toxin listeriolysin O (LLO) and two phospholipase C enzymes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24739967"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Listeria monocytogenes evades the antimicrobial mechanisms of macrophages by escaping from the phagosome into the cytosolic space via a unique cytolysin that targets the phagosomal membrane, listeriolysin O (LLO), encoded by hly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17517863"
        }
      ],
      "type": "factoid",
      "id": "67c9e84181b1027333000008",
      "ideal_answer": [
        "Listeriolysin O is a pore forming toxin produce by Listeria monocytogenes.",
        "Listeriolysin O (LLO) is a secreted pore-forming protein essential for the escape of L. monocytogenes from the vacuole formed upon initial internalization.",
        "Listeriolysin O (LLO) is a virulence factor present in Lm that plays a central role in the cell-to-cell spread process.",
        "Listeriolysin is associated with the cellular process of phagosomal escape, where it facilitates the destruction of the phagosomal membrane, allowing Listeria monocytogenes to enter the cytoplasm of infected cells.",
        "Listeriolysin O (LLO) is associated with membrane damage and pore formation in host cells, facilitating phagosomal escape, intracellular replication, and cell-to-cell spread of Listeria monocytogenes.",
        "Listeriolysin O (LLO) is primarily associated with phagosomal escape in infected cells.",
        "Listeriolysin O (LLO) is associated with the cellular process of phagocytosis and membrane damage.",
        "Listeriolysin O (LLO) is associated with the cellular process of membrane damage and pore formation in host cells, facilitating phagosomal escape, intracellular replication, and cell-to-cell spread of Listeria monocytogenes.",
        "The cellular process associated with Listeriolysin (LLO) is autophagy and membrane repair, but most notably it is associated with pore-forming and membrane disruption, allowing Listeria monocytogenes to escape from a host cell vacuole and grow in the cytosol.",
        "Listeriolysin O (LLO) is a pore-forming protein produced by Listeria monocytogenes that facilitates the escape of the pathogen from the phagosome into the cytosol.",
        "Listeriolysin O is a pore-forming toxin produced by Listeria monocytogenes that plays a critical role in bacterial pathogenesis by facilitating the escape of the bacterium from the phagosome into the cytosol. It forms membrane pore complexes and is involved in membrane disruption and cellular invasion.",
        "Listeriolysin O is a pore forming toxin that creates holes in cell membranes. The study focuses on identifying how cells repair their plasma membrane after exposure to this toxin, highlighting the cellular process of membrane repair as a response to pore formation.",
        "Listeriolysin O (LLO) is a pore forming toxin produced by the bacterium Listeria monocytogenes. Its primary function is to disrupt the host cell membrane integrity by creating pores, leading to cell lysis. This process allows the bacteria to escape from the host cells after replication, facilitating their spread and infection of nearby cells.",
        "Listeriolysin O (LLO) is a pore-forming toxin produced by Listeria monocytogenes that plays a crucial role in the pathogenesis of the bacterium by facilitating the escape of the pathogen from the phagosome into the cytosol.",
        "Listeriolysin O, a toxin produced by the bacterium L. monocytogenes, is primarily associated with facilitating the escape of the pathogen from phagosomes into the cytosol by forming membrane pores.",
        "Listeriolysin is associated with pore formation.",
        "Listeriolysin O is associated with plasma membrane repair mechanisms, pore formation, and facilitating the escape of pathogens from the phagosome into the cytosol.",
        "Listeriolysin O (LLO) is a pore-forming toxin produced by the bacterial pathogen Listeria monocytogenes. It plays a crucial role in the pathogenesis of the bacterium by facilitating the escape of the pathogen from the phagosome into the cytosol.",
        "Listeriolysin O is associated with the cellular process of membrane pore formation, facilitating the escape of Listeria monocytogenes from the phagosome into the cytosol.",
        "Listeriolysin O is a cholesterol-dependent cytolysin that facilitates the escape of Listeria monocytogenes from the phagosome by forming pores in its membrane. This process allows the bacterium to access the host cell cytosol, where it can replicate and spread from cell to cell.",
        "Listeriolysin O is associated with the process of cellular membrane disruption, specifically facilitating the escape of Listeria monocytogenes from the phagosome into the cytosol by forming pores in the membrane.",
        "Listeriolysin O (LLO) is a pore-forming toxin produced by Listeria monocytogenes.",
        "Listeriolysin O (LLO) is associated with plasma membrane repair mechanisms and facilitates the escape of pathogens from the phagosome into the cytosol. It is a toxin produced by L. monocytogenes that enlarges pores. LLO also assembles into non-covalent membrane pore complexes.",
        "Listeriolysin is primarily associated with the cellular process of plasma membrane repair, driven by its pore-forming activity, which triggers repair mechanisms in response to membrane injury, and also plays roles in endosomal/phagosomal escape, actin polymerization, inflammasome activation, and immunomodulation.",
        "Listeriolysin O plays a crucial role in the pathogenesis of the bacterium by facilitating the escape of the pathogen from the phagosome into the cytosol.",
        "Listeriolysin O, a toxin produced by the bacterium L. monocytogenes, is primarily associated with facilitating the escape of the pathogen from the phagosome into the cytosol by forming pores in membranes."
      ],
      "exact_answer": [
        [
          "membrane pore forming"
        ]
      ]
    },
    {
      "body": "Estimated prevalence of postpartum psychosis.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35061103",
        "http://www.ncbi.nlm.nih.gov/pubmed/35900686",
        "http://www.ncbi.nlm.nih.gov/pubmed/36775196",
        "http://www.ncbi.nlm.nih.gov/pubmed/28754094",
        "http://www.ncbi.nlm.nih.gov/pubmed/37546727",
        "http://www.ncbi.nlm.nih.gov/pubmed/33406713",
        "http://www.ncbi.nlm.nih.gov/pubmed/17199053",
        "http://www.ncbi.nlm.nih.gov/pubmed/38160890",
        "http://www.ncbi.nlm.nih.gov/pubmed/25939231",
        "http://www.ncbi.nlm.nih.gov/pubmed/30092921",
        "http://www.ncbi.nlm.nih.gov/pubmed/38398277",
        "http://www.ncbi.nlm.nih.gov/pubmed/39564219",
        "http://www.ncbi.nlm.nih.gov/pubmed/17503476",
        "http://www.ncbi.nlm.nih.gov/pubmed/8796764",
        "http://www.ncbi.nlm.nih.gov/pubmed/20604641",
        "http://www.ncbi.nlm.nih.gov/pubmed/26089908"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 944,
          "offsetInEndSection": 1053,
          "text": "Five studies reported cumulative incidence of postpartum psychosis (ranging from 1.1 to 16.7 per 1000 births)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35061103"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Postpartum psychosis has been found to affect 0.89-2.6 per 1000 women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35900686"
        },
        {
          "offsetInBeginSection": 1276,
          "offsetInEndSection": 1460,
          "text": "13,894 (1.1 per 1000) had a diagnosis of postpartum psychosis during the delivery hospitalization, and 7128 (0.6 per 1000) had a 60-day postpartum readmission with postpartum psychosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36775196"
        },
        {
          "offsetInBeginSection": 882,
          "offsetInEndSection": 1031,
          "text": "x studies met the criteria. Five studies reported incidence of puerperal psychosis (ranging from 0.89 to 2.6 in 1000 women) and one reported prevalen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28754094"
        },
        {
          "offsetInBeginSection": 952,
          "offsetInEndSection": 1150,
          "text": " (1.78, 95% CI\u003d0.70-3.62). Despite the higher familial risk of postpartum psychosis among full siblings, the absolute risk for women with an affected sibling is relatively low, estimated at 1.55% wi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37546727"
        },
        {
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1418,
          "text": "nge with 95% confidence intervals.RESULTS: Of 12,334,506 deliveries in the analysis, 13,894 (1.1 per 1000) had a diagnosis of postpartum psychosis during the delivery hospitalization, and 7128 (0.6 per 1000) had a 60-day postpa",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36775196"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Postpartum psychoses are a severe form of postnatal mood disorders, affecting 1-2 in every 1000 deliveries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33406713"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Postpartum psychosis (PP) is a severe psychiatric illness that occurs in about 1 to 2 per 1000 people in the perinatal period.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38160890"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 310,
          "text": "The prevalence of postpartum blues ranges from 300 to 750 per 1,000 mothers, while postpartum psychosis has a prevalence of 0.89-2.6 cases per 1,000 births",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39564219"
        },
        {
          "offsetInBeginSection": 154,
          "offsetInEndSection": 310,
          "text": " The prevalence of postpartum blues ranges from 300 to 750 per 1,000 mothers, while postpartum psychosis has a prevalence of 0.89-2.6 cases per 1,000 births",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39564219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Postpartum psychosis has been found to affect 0.89-2.6 per 1000 women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35900686"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 59,
          "text": "Postpartum psychosis occurs in 1-2/1000 childbearing women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25939231"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 73,
          "text": " Postpartum psychosis occurs in 1 to 2 cases per 1000 live births",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17199053"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Postpartum psychosis is a psychiatric emergency that affects 1 to 2 per 1000 women.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30092921"
        },
        {
          "offsetInBeginSection": 204,
          "offsetInEndSection": 304,
          "text": "Puerperal psychosis is the most extreme form of postnatal psychosis, occurring in 1 in 1,000 births.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17503476"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 62,
          "text": "Puerperal psychosis occurs after delivery in 1-2/1,000 births.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8796764"
        },
        {
          "offsetInBeginSection": 81,
          "offsetInEndSection": 135,
          "text": "Incidence is one to two women every 1,000 live births.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20604641"
        },
        {
          "offsetInBeginSection": 724,
          "offsetInEndSection": 815,
          "text": "There were 29 cases of postpartum psychosis giving an incidence of 1.1 per 1000 deliveries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089908"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 225,
          "text": "Around 1 in 1000 women are affected by postpartum psychosis, and the symptoms usually appear within 2 weeks after birth.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38398277"
        }
      ],
      "type": "factoid",
      "id": "67d7203018b1e36f2e00002d",
      "ideal_answer": [],
      "exact_answer": [
        [
          "0.89-2.6 per 1,000 births"
        ]
      ]
    },
    {
      "body": "What\u0027s the effect of liver RBFOX2?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36536133"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36536133"
        },
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 370,
          "text": "Here, we identify a key role for the splicing factor RNA-binding Fox protein 2 (RBFOX2) in maintaining cholesterol homeostasis in a lipogenic environment in the liver.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36536133"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 458,
          "text": "ction are poorly understood. Here, we identify a key role for the splicing factor RNA-binding Fox protein 2 (RBFOX2) in maintaining cholesterol homeostasis in a lipogenic environment in the liver. Using enhanced individual-nucleotide-resolution ultra-violet cross-linking and immunopr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36536133"
        }
      ],
      "id": "67d497c418b1e36f2e00001a",
      "ideal_answer": [
        "Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice.",
        "The RNA-binding protein RBFOX2 plays a key role in regulating cholesterol homeostasis in the liver by modulating alternative splicing of the Scarb1 gene, which encodes the scavenger receptor class B type I. RBFOX2 levels are decreased in diet-induced obesity, leading to dysregulation of Scarb1 splicing and altered lipid homeostasis in hepatocytes. Targeting this RBFOX2-mediated splicing network can alleviate obesity-induced inflammation and promote an anti-atherogenic lipoprotein profile.",
        "Liver RBFOX2 plays a crucial role in maintaining cholesterol homeostasis through Scarb1 alternative splicing, which is disrupted in diet-induced obesity. It is essential for liver physiology, and its dysregulation contributes to lipotoxic effects. Notably, lower RBFOX2 expression is associated with hepatocellular carcinoma progression, suggesting a tumor-suppressive function. Additionally, RBFOX2 regulates insulin receptor splicing in hepatoma cells, influencing insulin signaling. Overall, RBFOX2\u0027s multifaceted effects are vital for liver function, cancer prevention, and metabolic regulation.",
        "Liver RBFOX2 regulates cholesterol homeostasis by controlling Scarb1 alternative splicing and affecting lipid metabolism.",
        "Liver RBFOX2, a splicing factor, is essential for maintaining cholesterol homeostasis in a lipogenic environment. When its function decreases, as seen in diet-induced obesity, it triggers an isoform switch in the Scarb1 gene, which in turn disrupts hepatocyte lipid metabolism.",
        "In the liver, RBFOX2 plays a key role in maintaining cholesterol homeostasis in a lipogenic environment. Its function is decreased in diet-induced obesity, leading to a Scarb1 isoform switch and altered hepatocyte lipid homeostasis. Additionally, RBFOX2 expression is lower in hepatocellular carcinoma (HCC) tumor tissues compared to adjacent tissues, potentially inhibiting liver cancer metastasis. Downregulation of RBFOX2 also promotes pancreatic cancer progression and liver metastasis by regulating exon splicing events in transcripts encoding proteins involved in cytoskeletal remodeling programs.",
        "RBFOX2 plays a key role in maintaining cholesterol homeostasis in the liver and regulates alternative splicing profiles that are crucial for liver physiology. Its function is decreased in diet-induced obesity, leading to alterations in hepatocyte lipid homeostasis.",
        "The effect of liver RBFOX2 is to maintain cholesterol homeostasis, regulate Scarb1, and prevent obesity-induced inflammation in the liver.",
        "RBFOX2 plays a key role in maintaining cholesterol homeostasis in a lipogenic environment in the liver, and its function is decreased in diet-induced obesity, causing a Scarb1 isoform switch and alteration of hepatocyte lipid homeostasis.",
        "Liver RBFOX2 plays a crucial role in maintaining cholesterol homeostasis by regulating Scarb1 alternative splicing. Its dysregulation is linked to diet-induced obesity, altering lipid metabolism. In cancer, decreased RBFOX2 expression promotes progression and metastasis in hepatocellular carcinoma and pancreatic cancer, affecting cytoskeletal remodeling. Overall, RBFOX2 is vital for liver physiology, and its dysfunction can lead to metabolic diseases and cancer progression, highlighting its potential as a therapeutic target.",
        "RBFOX2 promotes the growth and metastasis of liver cancer cells, and its downregulation is associated with altered lipid homeostasis and poor prognosis in liver cancer.",
        "Liver RBFOX2 plays a crucial role in maintaining cholesterol homeostasis in the liver. It regulates the alternative splicing of Scarb1, which is involved in lipid metabolism. In diet-induced obesity, the function of RBFOX2 is decreased, leading to a switch in Scarb1 isoforms and alterations in hepatocyte lipid homeostasis. This dysregulation contributes to lipotoxic effects and inflammation in the liver. Furthermore, RBFOX2 has been implicated in cancer progression and metastasis, including pancreatic cancer and hepatocellular carcinoma. It mediates exon splicing events in transcripts encoding proteins involved in cytoskeletal remodeling programs, which are linked to cancer cell migration and invasion. Overall, RBFOX2 is an important regulator of liver physiology and its dysregulation can lead to metabolic diseases and cancer progression.",
        "RBFOX2 in the liver regulates cholesterol homeostasis by modulating alternative splicing of the Scarb1 gene, which encodes a scavenger receptor involved in cholesterol uptake. Dysregulation of RBFOX2 in obesity leads to an isoform switch of Scarb1, disrupting cholesterol homeostasis and contributing to lipotoxicity. RBFOX2 also plays a role in regulating alternative polyadenylation of genes involved in mitochondrial function and muscle contraction in myoblasts, which may be relevant to heart diseases.",
        "Liver RBFOX2 plays a crucial role in maintaining cholesterol homeostasis through alternative splicing of Scarb1 and influencing insulin signaling. Its dysregulation is linked to diet-induced obesity, lipotoxic effects, and the progression of certain cancers, notably hepatocellular carcinoma and pancreatic cancer. Given its importance in liver physiology, RBFOX2 is vital for preventing metabolic diseases and cancer, positioning it as a potential therapeutic target.",
        "Liver RBFOX2 plays a key role in maintaining cholesterol homeostasis in the liver, particularly in a lipogenic environment. It regulates the alternative splicing of Scarb1, which is essential for hepatocyte lipid homeostasis.",
        "Liver RBFOX2 is crucial for maintaining cholesterol balance and proper lipid metabolism. In a lipogenic environment, RBFOX2 regulates alternative splicing events that are key for lipid homeostasis. When RBFOX2 function is reduced, as seen in diet-induced obesity, there is an isoform switch in genes such as Scarb1, leading to disturbed lipid regulation in hepatocytes. Additionally, lower levels of RBFOX2 in hepatocellular carcinoma suggest that its normal function may help inhibit tumor progression and metastasis in the liver.",
        "Liver RBFOX2 inhibits the metastasis of liver cancer, as evidenced by studies showing that knockdown of RBFOX2 promotes cancer cell growth and metastasis. Additionally, RBFOX2 plays a role in maintaining cholesterol homeostasis in the liver by regulating alternative splicing of Scarb1, which is crucial for lipid metabolism.",
        "RBFOX2 is a protein involved in alternative splicing, a process where different exons of a gene are combined to produce multiple protein variants from a single mRNA precursor. In the context of the liver, which is crucial for metabolism and detoxification, RBFOX2 plays a significant role in regulating gene expression.\n\nResearch indicates that RBFOX2 influences various aspects of liver function and disease. It may regulate genes involved in lipid metabolism, glucose regulation, and detoxification pathways, which are essential for maintaining liver health. Additionally, RBFOX2 has been implicated in both protective roles, such as aiding liver regeneration and repair, and pathological conditions, including hepatocellular carcinoma.\n\nIn terms of specific effects, RBFOX2 might act as an oncogene or tumor suppressor depending on the context. It could promote cell proliferation or inhibit apoptosis, contributing to cancer development, or it might help regulate inflammation and tissue repair, offering protective benefits. Furthermore, interactions with signaling pathways like Wnt/β-catenin suggest a role in liver regeneration and cancer progression.\n\nTo fully understand RBFOX2\u0027s effects in the liver, further investigation into its specific interactions and regulatory functions within hepatocytes is necessary. This would provide insights into its impact on metabolic pathways, fibrosis, and the liver\u0027s response to injury or disease.",
        "In the liver, RBFOX2 plays a key role in maintaining cholesterol homeostasis in a lipogenic environment. Its function is decreased in diet-induced obesity, leading to a Scarb1 isoform switch and altered hepatocyte lipid homeostasis. Additionally, RBFOX2 expression is lower in hepatocellular carcinoma (HCC) tumor tissues compared to adjacent tissues, suggesting a potential role in inhibiting liver cancer metastasis. Downregulation of RBFOX2 also promotes pancreatic cancer progression and liver metastasis by regulating exon splicing events in transcripts encoding proteins involved in cytoskeletal remodeling programs.",
        "RBFOX2 is a splicing factor in the liver that plays a crucial role in regulating cholesterol homeostasis, specifically by controlling alternative splicing of the Scarb1 gene in mice. This suggests that RBFOX2 is important for maintaining cholesterol balance in a lipogenic (fat-producing) liver environment.",
        "Liver RBFOX2 regulates cholesterol homeostasis in mice by controlling the alternative splicing of the Scarb1 gene. This process allows Scarb1 to produce different protein variants, which are crucial for maintaining proper cholesterol levels.",
        "Liver RBFOX2 plays a crucial role in maintaining cholesterol homeostasis by regulating the alternative splicing of Scarb1, a key gene in lipid metabolism. Impaired RBFOX2 function, as seen in diet-induced obesity, disrupts hepatocyte lipid balance, leading to lipotoxic effects and liver inflammation. Conversely, preserving RBFOX2\u0027s activity helps maintain liver physiology, alleviates obesity-induced liver inflammation, and promotes a favorable lipoprotein profile, underscoring its importance in lipid homeostasis, particularly in a lipogenic liver environment.",
        "Liver RBFOX2 plays a crucial role in maintaining cholesterol homeostasis by regulating the alternative splicing of Scarb1 (Scavenger Receptor Class B Type 1). This process occurs in mice and ensures proper lipid metabolism and transport, thereby contributing to overall cholesterol balance within the organism.",
        "Studies have identified a crucial role for the splicing factor RNA-binding Fox protein 2 (RBFOX2) in the liver, where it regulates cholesterol homeostasis. Specifically, liver RBFOX2 maintains balance in a lipogenic environment through its effects on Scarb1 alternative splicing. This highlights the importance of RBFOX2 in managing cholesterol levels, suggesting that its activity is vital for preventing disruptions in cholesterol homeostasis in the liver. By regulating Scarb1 splicing, RBFOX2 plays a key part in ensuring proper lipid metabolism, underscoring its significance in maintaining overall liver function and health.",
        "Liver RBFOX2 plays a crucial role in regulating cholesterol balance, particularly in conditions that promote fat production. It achieves this by influencing the alternative splicing of Scarb1, a gene involved in cholesterol transport.",
        "Liver RBFOX2 plays a crucial role in maintaining cholesterol levels by influencing the alternative splicing of Scarb1 mRNA. This process generates different protein isoforms that affect cholesterol transport and metabolism, ensuring proper regulation within cellular environments. Specifically, Scarb1 is involved in reverse cholesterol transport, and its splicing variants likely modulate how cholesterol is processed and eliminated from the liver, thereby contributing to overall cholesterol homeostasis in mice.",
        "Liver RBFOX2 regulates cholesterol homeostasis.",
        "Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice. RBFOX2 function is decreased in the liver in diet-induced obesity, causing a Scarb1 isoform switch and alteration of hepatocyte lipid homeostasis. RBFOX2 expression was found to be lower in hepatocellular carcinoma (HCC) patients\u0027 tumor tissues compared to their paired adjacent tissues. Downregulation of RBFOX2 promotes pancreatic cancer progression and liver metastasis.",
        "RBFOX2, an RNA-binding protein, plays a crucial role in regulating cholesterol homeostasis in the liver. Specifically, it influences cholesterol metabolism by modulating the alternative splicing of Scarb1, a gene involved in cholesterol transport. This regulatory function is particularly significant in a lipogenic environment, where the liver is actively involved in lipid synthesis and metabolism. By controlling the splicing of Scarb1, RBFOX2 helps maintain proper cholesterol levels, highlighting its importance in the intricate balance of lipid homeostasis within the liver.",
        "RBFOX2 in the liver plays a crucial role in maintaining cholesterol homeostasis, particularly in environments with high lipid activity. It achieves this by regulating the alternative splicing of Scarb1 (Scavenger Receptor Class B Type 1), which is involved in the uptake and processing of cholesterol-rich particles from the bloodstream into liver cells. Through this mechanism, RBFOX2 ensures that cholesterol levels are appropriately managed, preventing potential disruptions such as high cholesterol or lipid-related issues.",
        "Liver RBFOX2 is essential for maintaining cholesterol balance by controlling the alternative splicing of Scarb1, a gene critical for lipid metabolism in hepatocytes. Its activity ensures the production of the specific Scarb1 isoforms required for proper cholesterol uptake and processing, particularly in a lipogenic environment. In diet-induced obesity, decreased RBFOX2 function leads to an isoform switch in Scarb1, which disrupts normal hepatocyte lipid homeostasis and contributes to metabolic imbalances.",
        "The effect of liver RBFOX2 is crucial in regulating cholesterol homeostasis. Specifically, RBFOX2 influences the alternative splicing of Scarb1, a gene involved in cholesterol transport. This process helps maintain balanced cholesterol levels, particularly in environments where lipid synthesis is active. By modulating Scarb1 splicing, RBFOX2 plays a key role in ensuring proper cholesterol metabolism and preventing potential issues related to imbalanced cholesterol levels.",
        "The effect of liver RBFOX2 is to maintain cholesterol homeostasis in a lipogenic environment by regulating the alternative splicing of Scarb1.",
        "RBFOX2, a splicing factor located in the liver, plays a crucial role in maintaining cholesterol homeostasis. It achieves this by regulating the Scarb1 gene through alternative splicing, a process where different combinations of exons are used to produce various protein variants. This regulation ensures that cholesterol levels remain balanced, particularly in environments with high lipid production. The proper functioning of RBFOX2 is essential for preventing cholesterol-related health issues, such as heart disease. Further research into the specific mechanisms and downstream effects of RBFOX2 could provide deeper insights into its role in liver function and overall health.",
        "Liver RBFOX2 plays a key role in maintaining cholesterol homeostasis by regulating Scarb1 alternative splicing, causing a Scarb1 isoform switch, and influencing hepatocyte lipid homeostasis. Its function is decreased in the liver in diet-induced obesity. RBFOX2 regulates exon splicing events in transcripts encoding proteins involved in cytoskeletal remodeling programs. Downregulation of RBFOX2 promotes pancreatic cancer progression and liver metastasis, and its expression is lower in hepatocellular carcinoma patients\u0027 tumor tissues compared to adjacent tissues.",
        "Liver RBFOX2 plays a crucial role in maintaining cholesterol homeostasis, particularly in lipogenic environments within the liver. It achieves this by regulating the alternative splicing of Scarb1 (Scavenger Receptor Class B Type 1), which is involved in cholesterol transport and metabolism. Through this mechanism, RBFOX2 ensures that cholesterol levels are balanced, especially under conditions where lipid production is heightened. This regulation underscores the importance of RBFOX2 in modulating cholesterol dynamics within the liver.",
        "Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice, playing a key role in maintaining cholesterol homeostasis in a lipogenic environment in the liver.",
        "The liver-specific expression of the splicing factor RBFOX2 plays a crucial role in regulating cholesterol homeostasis by influencing the alternative splicing of Scarb1, particularly in environments that promote lipid synthesis. This regulation is essential for maintaining balanced cholesterol levels within the liver.",
        "Liver RBFOX2 plays a crucial role in regulating cholesterol homeostasis by influencing the alternative splicing of Scarb1 in mice, particularly in a lipogenic environment.",
        "The liver RBFOX2 maintains cholesterol homeostasis in a lipogenic environment.",
        "Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice, and its function is decreased in the liver in diet-induced obesity, causing a Scarb1 isoform switch and alteration of hepatocyte lipid homeostasis.",
        "Liver RBFOX2 helps regulate cholesterol homeostasis by affecting Scarb1 alternative splicing.",
        "Liver RBFOX2 plays a crucial role in maintaining cholesterol homeostasis through the regulation of Scarb1 alternative splicing in mice, particularly in lipogenic environments. In diet-induced obesity, decreased RBFOX2 function disrupts hepatocyte lipid homeostasis, leading to lipotoxic effects and inflammation. However, this pathway can be therapeutically targeted with splice-switching oligonucleotides to alleviate liver inflammation and promote a more favorable lipoprotein profile, highlighting the potential of isoform-specific RNA therapeutics in treating metabolic diseases.",
        "Liver RBFOX2 plays a crucial role in regulating cholesterol homeostasis in mice by influencing the alternative splicing of Scarb1. This regulation is important for maintaining proper cholesterol levels and ensuring normal physiological functions related to cholesterol metabolism.",
        "Liver RBFOX2 plays a crucial role in regulating cholesterol homeostasis through the alternative splicing of Scarb1, a key gene in lipid metabolism. Proper functioning of RBFOX2 is essential for maintaining hepatocyte lipid balance. Conversely, decreased RBFOX2 function, as observed in diet-induced obesity, disrupts lipid homeostasis, leading to lipotoxic effects and liver inflammation. Maintaining or restoring RBFOX2\u0027s regulatory activity helps preserve liver physiology, alleviates obesity-induced liver inflammation, and promotes a beneficial blood lipoprotein profile, underscoring its importance in liver health and metabolic regulation.",
        "Liver RBFOX2 plays a key role in maintaining cholesterol homeostasis. This is achieved through Scarb1 alternative splicing in mice. It is especially important in a lipogenic environment.",
        "Liver RBFOX2 is critical for maintaining cholesterol and lipid homeostasis. It modulates alternative splicing of the Scarb1 gene, producing isoforms that are essential for proper lipid uptake and metabolism in hepatocytes. In conditions such as diet-induced obesity, reduced RBFOX2 activity leads to a switch in Scarb1 isoforms, which disrupts cholesterol regulation and liver lipid balance.",
        "The effect of liver RBFOX2 is to regulate and maintain cholesterol homeostasis, specifically in a lipogenic environment, through the alternative splicing of Scarb1, thereby influencing cholesterol levels in the liver.",
        "Liver RBFOX2 plays a role in regulating cholesterol homeostasis via Scarb1 alternative splicing in mice. Its function is decreased in the liver in diet-induced obesity, causing a Scarb1 isoform switch and alteration of hepatocyte lipid homeostasis. RBFOX2 downregulation promotes pancreatic cancer progression and liver metastasis, regulating exon splicing events in transcripts encoding proteins involved in cytoskeletal remodeling programs. RBFOX2 expression is lower in hepatocellular carcinoma (HCC) patients\u0027 tumor tissues compared to adjacent tissues, suggesting a potential role in inhibiting metastasis of liver cancer.",
        "RBFOX2, a splicing factor protein in the liver, plays a crucial role in maintaining cholesterol homeostasis through regulation of Scarb1 alternative splicing in mice, particularly in lipogenic environments.",
        "Liver RBFOX2 plays a crucial role in regulating cholesterol balance, particularly in conditions that promote fat production. It achieves this by influencing the alternative splicing of Scarb1, a gene involved in cholesterol metabolism.",
        "Liver RBFOX2 plays a key role in maintaining cholesterol homeostasis in a lipogenic environment, specifically by regulating Scarb1 alternative splicing in mice."
      ],
      "exact_answer": [
        [
          "Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice."
        ]
      ]
    },
    {
      "body": "Is Geographic Atrophy(GA) found in the hand or foot?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39025435",
        "http://www.ncbi.nlm.nih.gov/pubmed/38809658",
        "http://www.ncbi.nlm.nih.gov/pubmed/39121994",
        "http://www.ncbi.nlm.nih.gov/pubmed/39745839",
        "http://www.ncbi.nlm.nih.gov/pubmed/23706948",
        "http://www.ncbi.nlm.nih.gov/pubmed/17290203",
        "http://www.ncbi.nlm.nih.gov/pubmed/31589762",
        "http://www.ncbi.nlm.nih.gov/pubmed/27552292",
        "http://www.ncbi.nlm.nih.gov/pubmed/24626824",
        "http://www.ncbi.nlm.nih.gov/pubmed/37125931",
        "http://www.ncbi.nlm.nih.gov/pubmed/39691308",
        "http://www.ncbi.nlm.nih.gov/pubmed/26469230",
        "http://www.ncbi.nlm.nih.gov/pubmed/38983017",
        "http://www.ncbi.nlm.nih.gov/pubmed/39578546",
        "http://www.ncbi.nlm.nih.gov/pubmed/37986170",
        "http://www.ncbi.nlm.nih.gov/pubmed/37933607",
        "http://www.ncbi.nlm.nih.gov/pubmed/29110945",
        "http://www.ncbi.nlm.nih.gov/pubmed/10393046",
        "http://www.ncbi.nlm.nih.gov/pubmed/2476333",
        "http://www.ncbi.nlm.nih.gov/pubmed/34308667",
        "http://www.ncbi.nlm.nih.gov/pubmed/21088948",
        "http://www.ncbi.nlm.nih.gov/pubmed/26158084",
        "http://www.ncbi.nlm.nih.gov/pubmed/35814763",
        "http://www.ncbi.nlm.nih.gov/pubmed/32084285",
        "http://www.ncbi.nlm.nih.gov/pubmed/38999523",
        "http://www.ncbi.nlm.nih.gov/pubmed/18003121",
        "http://www.ncbi.nlm.nih.gov/pubmed/39241860",
        "http://www.ncbi.nlm.nih.gov/pubmed/37933608",
        "http://www.ncbi.nlm.nih.gov/pubmed/38290804",
        "http://www.ncbi.nlm.nih.gov/pubmed/26638551",
        "http://www.ncbi.nlm.nih.gov/pubmed/37933609",
        "http://www.ncbi.nlm.nih.gov/pubmed/36520185",
        "http://www.ncbi.nlm.nih.gov/pubmed/29443034",
        "http://www.ncbi.nlm.nih.gov/pubmed/27864062",
        "http://www.ncbi.nlm.nih.gov/pubmed/27043351",
        "http://www.ncbi.nlm.nih.gov/pubmed/32868879",
        "http://www.ncbi.nlm.nih.gov/pubmed/28391446",
        "http://www.ncbi.nlm.nih.gov/pubmed/30208410",
        "http://www.ncbi.nlm.nih.gov/pubmed/33893984",
        "http://www.ncbi.nlm.nih.gov/pubmed/21035861",
        "http://www.ncbi.nlm.nih.gov/pubmed/33075546",
        "http://www.ncbi.nlm.nih.gov/pubmed/39445352",
        "http://www.ncbi.nlm.nih.gov/pubmed/38386187",
        "http://www.ncbi.nlm.nih.gov/pubmed/37847167",
        "http://www.ncbi.nlm.nih.gov/pubmed/30047199",
        "http://www.ncbi.nlm.nih.gov/pubmed/19752426"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 224,
          "text": "Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39745839"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "The Discrepancy Between Visual Acuity Decline and Foveal Involvement in Geographic Atrophy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39121994"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 125,
          "text": "To investigate the discrepancy between visual acuity (VA) decline and foveal involvement in geographic atrophy (GA) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39121994"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Ophthalmologists\u0027 awareness of geographic atrophy: An Italian survey including 365 participants.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38809658"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 141,
          "text": "Geographic atrophy (GA) is a severe complication of age-related macular degeneration (AMD) and leads to irreversible visual decline.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38809658"
        },
        {
          "offsetInBeginSection": 1384,
          "offsetInEndSection": 1554,
          "text": "This survey provided an overview of how GA patients are managed in Italy. The Italian ophthalmology community appears to be ready to adopt the upcoming treatments for GA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38809658"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39025435"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 149,
          "text": "o determine whether oral micronutrient supplementation slows geographic atrophy (GA) progression in age-related macular degeneration (AMD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39025435"
        },
        {
          "offsetInBeginSection": 2276,
          "offsetInEndSection": 2422,
          "text": "Oral micronutrient supplementation slowed GA progression toward the central macula, likely by augmenting the natural phenomenon of foveal sparing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39025435"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Designing clinical trials for age-related geographic atrophy of the macula: enrollment data from the geographic atrophy natural history study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17290203"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "BACKGROUND AND OBJECTIVE: Geographic atrophy (GA) involves the progressive loss of retinal pigment epithelium (RPE), photoreceptors, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31589762"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "IMPORTANCE: Geographic atrophy (GA) is the major cause of blind registration in Western communities, although, with few exceptions, it is less common than choroidal neovascu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24626824"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 293,
          "text": "Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that first start in the outer retina and progressively expand to cover the macula and the fovea, the center of the macula, leading to irreversible loss of vision over time.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37125931"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "Background: Geographic atrophy (GA) is an advanced form of age-related macular degeneration leading to irreversible vision loss and negative impacts on qual",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39691308"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "BACKGROUND AND OBJECTIVE: To compare the anatomy of different retinal layers adjacent to areas of geographic atrophy (GA) to those of eyes with",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26469230"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "text": "PURPOSE: To present a method developed for measuring areas of geographic atrophy (GA) in advanced age-related macular degeneration,METHODS: A microfilm reader projected the 30 degrees fundus photogra",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10393046"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 66,
          "text": "Evolution of geographic atrophy of the retinal pigment epithelium.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2476333"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 60,
          "text": "Long-term retinal changes in progressive geographic atrophy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34308667"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "text": "BACKGROUND: Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that can lead to visual impairment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39745845"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "Geographic Atrophy (GA) of the retinal pigment epithelium (RPE) is an advanced form of atrophic age-related macular degeneration (AMD) and is responsible for about 20% of AMD-related legal blindness in the United States.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22255206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Geographic atrophy (GA) is an advanced stage of age-related macular degeneration (AMD) that leads to gradual and permanent vision loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38983017"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Geographic atrophy (GA) as the late stage manifestation of age-related macular degeneration (AMD) is a progressive disease process afflicting the retinal pigment epithelium, choriocapillaris and the outer neurosensory retina.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21088948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Geographic atrophy (GA) is a manifestation of the advanced or late stage of age-related macular degeneration (AMD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26158084"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Geographic Atrophy (GA) of the retinal pigment epithelium (RPE) is an advanced form of atrophic age-related macular degeneration (AMD) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22255206"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Geographic atrophy (GA) is the advanced stage of non-neovascular (dry) age-related macular degeneration, defined by the presence of sharply demarcated atrophic lesions of the outer retina.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39578546"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible loss of visual function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29110945"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Geographic atrophy (GA), the late stage of age-related macular degeneration, is a major cause of visual disability whose pathophysiology remains largely unknown.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35814763"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "The authors present the case of a 73-year-old woman affected by geographic atrophy (GA) in her left eye.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32084285"
        },
        {
          "offsetInBeginSection": 23,
          "offsetInEndSection": 177,
          "text": "Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) leading to the progressive and irreversible loss of visual function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38999523"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Fundus auto-fluorescence (FAF) images with hypo-fluorescence indicate geographic atrophy (GA) of the retinal pigment epithelium (RPE) in age-related macular degeneration (AMD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18003121"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Geographic atrophy (GA), the atrophic late stage of age-related macular degeneration (AMD), is one of the leading causes of vision loss in developed countries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39241860"
        },
        {
          "offsetInBeginSection": 126,
          "offsetInEndSection": 305,
          "text": "Geographic atrophy (GA) is the atrophic late form of AMD and its prevalence increases markedly with age with around 1 in 5 persons aged 85 and above having GA in at least one eye.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37933608"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "text": "Geographic atrophy (GA) is an advanced and irreversible form of age-related macular degeneration (AMD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38290804"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "Geographic atrophy is a manifestation of the advanced age-related macular degeneration and form of irreversible atrophy of retinal pigment epithelium and photoreceptor layer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26638551"
        },
        {
          "offsetInBeginSection": 1540,
          "offsetInEndSection": 1655,
          "text": " term \"geographic atrophy\" prevailed for the nonexudative late-stage of age-related macular degeneration itself. Al",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552292"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Geographic atrophy (GA) is a prevalent cause of vision loss among elderly and is associated with a significant loss of function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37933609"
        },
        {
          "offsetInBeginSection": 8,
          "offsetInEndSection": 166,
          "text": " Geographic atrophy (GA) is a late-stage form of age-related macular degeneration (AMD) characterized by the expansion of atrophic lesions in the outer retina",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36520185"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Geographic atrophy (GA) is a progressive degenerative disease that significantly contributes to visual impairment in individuals aged 50 years and older.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37986170"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Geographic atrophy (GA) is characterized by atrophy of the retina, retinal pigment epithelium and choriocapillaris, causing a gradual loss of vision over time.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37933607"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "Geographic atrophy (GA), the late stage of dry age-related macular degeneration is characterized by loss of the retinal pigment epithelial (RPE) layer, which leads to subsequent degeneration of vital retinal structures (e.g., photoreceptors) causing severe vision impairment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29443034"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "PURPOSE: To determine if en face optical coherence tomography (OCT) imaging can identify nascent geographic atrophy (nGA) in eyes with intermediate age-related macular degeneratio",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27864062"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "text": "PURPOSE: The aim of this study was to clarify the characteristic findings in patients with geographic atrophy with or without hyperautofluorescent choroidal vessels within macular atrophic areas on short-wavelength fundus autofluorescence",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27043351"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "PURPOSE: Geographic atrophy (GA) is a late-stage form of age-related macular degeneration (AMD) characterized by the expansion of atrophic lesions in the oute",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36520185"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 272,
          "text": "Geographic atrophy (GA), the late stage of dry AMD, is typically defined as a round or oval area of atrophy of 175 µm or more.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28391446"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Purpose: Geographic atrophy (GA) is the late stage of non-neovascular age-related macular dege",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30208410"
        },
        {
          "offsetInBeginSection": 154,
          "offsetInEndSection": 365,
          "text": "Geographic atrophy is defined by the presence of sharply demarcated atrophic lesions of the outer retina, resulting from loss of photoreceptors, retinal pigment epithelium (RPE), and underlying choriocapillaris.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29110945"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Geographic atrophy (GA) is an advanced form of age-related macular degeneration, a late-onset, complex, genetic degenerative disease of the retina.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33893984"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "Geographic atrophy (GA), the late stage of dry age-related macular degeneration is characterized by loss of the retinal pigment epithelial (RPE) layer, which leads to subsequent degeneration of vital retinal structures (e.g., photoreceptors) causing severe vision impairment",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29443034"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 247,
          "text": "The aim of this study was to clarify the characteristic findings in patients with geographic atrophy with or without hyperautofluorescent choroidal vessels within macular atrophic areas on short-wavelength fundus autofluorescence imaging.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27043351"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "PURPOSE: To determine the area and enlargement rate (ER) of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) using the spectral domain optical coherence tomography (SD-OCT) fund",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21035861"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "PURPOSE: To examine whether the rate of geographic atrophy (GA) enlargement is influenced by subsequent exudative neovascular age-related macular degeneration (nAMD) and hence, to explore indirectly whether nonexudative nAMD may slow GA enl",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33075546"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "PURPOSE: To examine early age-related macular degeneration (AMD) lesion characteristics and risk factors associated with the long-term development and progression of geographic atro",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23706948"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "PURPOSE: To study the progression of geographic atrophy (GA) secondary to age-related macular degeneration over a five-year f",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39445352"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Geographic atrophy is an eye disease that greatly interferes with the daily lives of patients and their families,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38386187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Geographic atrophy (GA) is a progressive and irreversible retinal disease ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37847167"
        },
        {
          "offsetInBeginSection": 22,
          "offsetInEndSection": 79,
          "text": " Geographic atrophy (GA) is a common cause of visual loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32868879"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 184,
          "text": " Geographic atrophy (GA) is the major cause of blind registration in Western communities, although, with few exceptions, it is less common than choroidal neovascular disease",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24626824"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "BACKGROUND: Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that can lead to visual",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39745845"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "IMPORTANCE: Geographic atrophy (GA) is a progressing atrophy of the neuroretina with no treat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30047199"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "OBJECTIVE: To characterize progression of geographic atrophy (GA) associated with age-related macular degeneration in AREDS as measured by digitized fundus p",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19752426"
        }
      ],
      "type": "yesno",
      "id": "67cc826c81b102733300000b",
      "ideal_answer": [
        "Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States",
        "No, Geographic Atrophy (GA) is found in the macula.",
        "No, Geographic Atrophy (GA) is found in the eye.",
        "Geographic Atrophy (GA) is not found in the hand or foot. It is an advanced form of age-related macular degeneration (AMD) that affects the retina, specifically the macula, leading to irreversible vision loss.",
        "Geographic Atrophy (GA) affects the eye, not the hand or foot.",
        "Geographic Atrophy (GA) is related to age-related macular degeneration (AMD), a condition affecting the eyes, specifically the retina. It is characterized by the loss of the retinal pigment epithelium (RPE) layer, leading to vision impairment. The provided documents do not mention GA being found in the hand or foot.",
        "Geographic Atrophy (GA) is a form of late-stage age-related macular degeneration (AMD) that affects the eye, specifically the macula, and is not typically found in the hand or foot. It is a common cause of visual loss and is associated with changes in the retina, not the skin or extremities.",
        "No, Geographic Atrophy(GA) is found in the eye.",
        "No. Geographic Atrophy (GA) is not mentioned in relation to the hand or foot in the provided documents; it primarily pertains to conditions affecting the retina.",
        "Geographic Atrophy (GA) is not found in the hand or foot. It is an advanced stage of age-related macular degeneration (AMD) that affects the eyes, leading to progressive and irreversible vision loss.",
        "Geographic atrophy (GA) is a form of age-related macular degeneration that affects the retina in the eye, leading to progressive and irreversible vision loss. It does not occur in the hand or foot.",
        "Geographic atrophy (GA) is a condition affecting the retina in the eye, specifically the macula region, and is not found in the hand or foot. GA is an advanced form of age-related macular degeneration characterized by atrophic lesions that progressively expand and lead to irreversible vision loss over time.",
        "Geographic atrophy (GA) is a condition affecting the retina in the eye, specifically the macula region responsible for central vision. It involves progressive loss of retinal pigment epithelium, photoreceptors, and the underlying choriocapillaris in the macula. GA does not occur in the hand or foot.",
        "No, geographic atrophy (GA) is found in the macula, not in the hand or foot.",
        "No, Geographic Atrophy (GA) is not found in the hand or foot. GA is associated with age-related macular degeneration and affects the eyes, specifically the retinal pigment epithelium.",
        "Geographic Atrophy (GA) is a form of age-related macular degeneration that affects the retina in the eye, specifically the macula. It is not found in the hand or foot.",
        "Geographic atrophy is not found in the hand or foot. In the context of age-related macular degeneration, geographic atrophy refers to the degeneration of retinal tissue in the eye, particularly in the macular region, leading to vision loss.",
        "No, Geographic Atrophy (GA) is not found in the hand or foot; it is specifically associated with the eye, affecting the macula and fovea, leading to vision loss.",
        "No, Geographic Atrophy (GA) is not found in the hand or foot. It is an advanced form of age-related macular degeneration (AMD) that affects the retina, specifically the macula and fovea, leading to irreversible vision loss.",
        "Based on the provided contexts, it appears that Geographic Atrophy (GA) is a condition affecting the retina, specifically the macula, and is related to age-related macular degeneration (AMD). The contexts do not mention the hand or foot as being affected by GA.\n\nThe question \"Is Geographic Atrophy(GA) found in the hand or foot?\" can be answered as:\n\nNo, the contexts do not indicate that Geographic Atrophy (GA) is found in the hand or foot. The condition is associated with the retina and macula, not the extremities.",
        "No, Geographic Atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States.",
        "Geographic Atrophy (GA) is a form of advanced age related macular degeneration that affects the macula, located at the center of the retina. It primarily causes vision loss in the central visual field and does not affect other parts of the body such as the hands or feet.",
        "Geographic Atrophy (GA) is not found in the hand or foot. It is an eye condition, specifically associated with Age-Related Macular Degeneration (AMD), primarily affecting the macula and, in some cases, the fovea and retina, leading to potential irreversible visual decline or impairment.",
        "Geographic Atrophy (GA) is a form of advanced age related macular degeneration (AMD) that affects the eyes, specifically the macula region of the retina. It does not occur in the hand or foot but is associated with irreversible vision impairment and contributes to legal blindness.",
        "Geographic atrophy (GA) is not found in the hand or foot; it is a severe form of age-related macular degeneration (AMD) that affects the eyes, leading to irreversible vision impairment and visual decline.",
        "No, Geographic Atrophy (GA) is not found in the hand or foot. It primarily affects the macula of the eye and does not extend to other body parts like the extremities.",
        "No, Geographic Atrophy (GA) is not found in the hand or foot, as it is a condition that affects the retina in the eye.",
        "No. Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment.",
        "No, Geographic Atrophy (GA) is not found in the hand or foot. It is a severe complication of age-related macular degeneration (AMD) and leads to irreversible visual decline.",
        "Geographic atrophy (GA) is a severe complication of age-related macular degeneration (AMD). It leads to irreversible visual decline. GA affects the macula and can cause irreversible vision impairment.",
        "No, Geographic Atrophy (GA) is not found in the hand or foot. It is a form of advanced age-related macular degeneration (AMD) that affects the central part of the retina, specifically the macula, which is located in the eye.",
        "Geographic Atrophy (GA) is a form of age-related macular degeneration (AMD) that affects the macula, a part of the retina responsible for central vision. It does not occur in the hand or foot; GA is exclusively related to the eyes and causes visual impairments such as blind spots or loss of sharpness in central vision.",
        "No. Geographic Atrophy (GA) is a condition associated with age-related macular degeneration (AMD) that affects the retina in the eye, not the hand or foot.",
        "Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that affects the retina in the eye, leading to irreversible vision impairment. It is not a condition found in the hand or foot, as it specifically pertains to the degeneration of retinal tissue in the macula of the eye.",
        "No. Geographic Atrophy (GA) is a form of advanced age-related macular degeneration that affects the retina and is not found in the hand or foot.",
        "No. Geographic Atrophy (GA) is a form of advanced age-related macular degeneration primarily affecting the retina and is not found in the hand or foot.",
        "Geographic Atrophy affects the eyes, not the hand or foot.",
        "Geographic Atrophy (GA) is not found in the hand or foot. It is a form of advanced age-related macular degeneration (AMD) that affects the eyes, leading to vision impairment. GA is specifically related to the degeneration of the macula, which is a part of the retina in the eye, and is not associated with conditions affecting the hand or foot.",
        "Geographic Atrophy (GA) is exclusively an eye condition, not found in the hand or foot. It specifically affects the macula, with the fovea also being impacted, as part of the broader context of Age-Related Macular Degeneration (AMD), potentially leading to irreversible visual decline, impairment, or blindness.",
        "No, geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States.",
        "Geographic Atrophy (GA) is not found in the hand or foot. It is a form of advanced age related macular degeneration (AMD), which affects the macula, a part of the eye responsible for central vision. GA primarily causes vision impairment and does not occur in other body parts such as hands or feet.",
        "Geographic atrophy (GA) is a severe complication of age-related macular degeneration (AMD). It leads to irreversible visual decline. Oral micronutrient supplementation slowed GA progression toward the central macula.",
        " Geographic Atrophy (GA) is not found in the hand or foot. GA is a form of advanced age-related macular degeneration (AMD) that affects the central part of the retina, which is responsible for sharp, straight-ahead vision. It does not occur in the hands or feet.",
        "Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that affects the eyes and can lead to irreversible vision impairment and blindness. It does not involve the hand or foot.",
        "Geographic Atrophy (GA) is not located in the hand or foot; instead, it affects the eye, specifically the macula, and is a complication of Age-Related Macular Degeneration (AMD). This condition leads to irreversible visual decline due to progressive loss of retinal cells, ultimately impairing vision.",
        "No, Geographic Atrophy (GA) refers to the deterioration of retinal tissue in the eye, particularly associated with age-related macular degeneration, and is not a condition of the hand or foot.",
        "Geographic Atrophy (GA) is not found in the hand or foot, but rather is a severe form of age-related macular degeneration (AMD) that affects the eye, specifically the macula. It is a serious condition that causes irreversible vision loss and is responsible for approximately 20% of legal blindness in the United States.",
        "Geographic atrophy (GA) is not found in the hand or foot; it is a severe form of advanced age-related macular degeneration (AMD) that affects the eyes, leading to irreversible vision impairment and visual decline."
      ],
      "exact_answer": "no"
    },
    {
      "body": "Manifestations of herpes genital infection.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38331482",
        "http://www.ncbi.nlm.nih.gov/pubmed/37105647",
        "http://www.ncbi.nlm.nih.gov/pubmed/36812284",
        "http://www.ncbi.nlm.nih.gov/pubmed/36751550",
        "http://www.ncbi.nlm.nih.gov/pubmed/9891681",
        "http://www.ncbi.nlm.nih.gov/pubmed/21515747"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 130,
          "text": "recurrent, self-limited genital ulcers",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38331482"
        },
        {
          "offsetInBeginSection": 64,
          "offsetInEndSection": 127,
          "text": "recurrent, self-limited genital, buttock, and thigh ulcerations",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37105647"
        },
        {
          "offsetInBeginSection": 480,
          "offsetInEndSection": 567,
          "text": "painful necrotic ulcers of both labia minora, urinary retention, and extreme discomfort",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36812284"
        },
        {
          "offsetInBeginSection": 656,
          "offsetInEndSection": 708,
          "text": "pain and burning sensation and swelling of the vulva",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36812284"
        },
        {
          "offsetInBeginSection": 807,
          "offsetInEndSection": 872,
          "text": "vagina and cervix were covered with ulcerated and crustal lesions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36812284"
        },
        {
          "offsetInBeginSection": 1397,
          "offsetInEndSection": 1581,
          "text": "primary genital herpes, after a short incubation period, multiple bilaterally located papules, vesicles, painful ulcers, and crusts appear, which resolve over a period of 15 to 21 days",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36812284"
        },
        {
          "offsetInBeginSection": 1587,
          "offsetInEndSection": 1766,
          "text": "Clinically atypical presentations include either unusual sites or atypical morphological forms of genital disease, exophytic (verrucoid or nodular) superficially ulcerated lesions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36812284"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 344,
          "text": "formation of ulcers and erosions within the mucous membranes. It is characterized by a wide range of clinical symptoms from serous-filled blisters located on the erythematous and oedematous substrate to asymptomatic infection. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36751550"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Genital herpes (GH) is a sexually transmitted infection causing recurrent, self-limited genital, buttock, and thigh ulcerations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37105647"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 300,
          "text": "Atypical genital herpes is often described in immunocompromised patients and can present as large, chronic, hyperkeratotic ulcers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9891681"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 401,
          "text": "While it is well known that the characteristic presentation of HSV is a vesicular rash or crops of erosions, the clinical presentation of genital HSV infection in HIV is varied and can assume vegetative, hypertrophic, condyloma-like, nodular, ulcerative and tumour-like nodules or plaques.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21515747"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Genital herpes is a chronic, lifelong sexually transmitted viral infection, which can cause recurrent, self-limited genital ulcers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38331482"
        }
      ],
      "id": "67d7fe6a18b1e36f2e000046",
      "ideal_answer": [
        "Genital herpes usually produces recurrent, self-limited genital (formation of ulcers and erosions within the mucous membranes), buttock, and thigh ulcerations which resolve over a period of 15 to 21 days",
        "Genital herpes is a sexually transmitted infection caused by herpes simplex virus (HSV) types 1 and 2. Primary infections often present with severe symptoms like fever, malaise, painful genital ulcers, and tender lymph nodes that last 2-3 weeks. Recurrent infections tend to be milder with fewer lesions that heal faster. Atypical manifestations like chronic ulcers can occur in immunocompromised patients. Complications include aseptic meningitis, autonomic dysfunction, and secondary infections. Diagnosis is typically clinical but can be confirmed by viral culture or antigen detection. While antiviral drugs can reduce symptoms and viral shedding, there is no cure, and the psychological impact of a lifelong infection can be significant.",
        "Manifestations of herpes genital infection include:\n\n* Lesions and inflammation around the genital area\n* Enlarged inguinal nodes\n* Recurrent infections resulting in lesions\n* Inflammation and pain in the genital area\n* Potential for asymptomatic infection and transmission\n* Recurrent nature of the infection\n* Potential for complications such as eczema herpeticum, genital and gluteal recurrent herpes, and herpes zoster.\n\nThe infection can also manifest in other areas, such as the lumbar area or gluteus, and can be differentiated from varicella-zoster virus infection.\n\nAdditionally, the infection can cause:\n\n* Psychological morbidity\n* Physical consequences such as pain and discomfort\n* Potential for neonatal infection if the mother is infected during pregnancy\n* Potential for transmission to sexual partners\n* Potential for complications such as encephalitis and genital forms of the disease."
      ]
    },
    {
      "body": "What is caused by heterozygous loss of function SPTAN1?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39371122",
        "http://www.ncbi.nlm.nih.gov/pubmed/31515523"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Heterozygous loss-of-function variants in SPTAN1 cause a novel early childhood onset distal myopathy with chronic neurogenic features.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39371122"
        },
        {
          "offsetInBeginSection": 1219,
          "offsetInEndSection": 1391,
          "text": "This study expands the phenotype of SPTAN1 mutations, which at the heterozygous state, when occurred de novo, may cause early infantile epileptic encephalopathy-5 (EIEE5). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31515523"
        }
      ],
      "id": "67d352e918b1e36f2e000009",
      "ideal_answer": [
        "Heterozygous loss-of-function variants in SPTAN1 cause a novel early childhood onset distal myopathy with chronic neurogenic features. \nFurther, SPTAN1 mutations, at the heterozygous state, when occurred de novo, may cause early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in the SPTAN1 gene are associated with a novel early childhood onset distal myopathy characterized by chronic neurogenic features. Additionally, deletions involving SPTAN1 have been linked to early infantile epileptic encephalopathy, infantile spasms, intellectual disability, and hypomyelination. However, the exact contribution of SPTAN1 haploinsufficiency to the severe phenotype remains uncertain.",
        "Heterozygous loss of function in the SPTAN1 gene is associated with several conditions, including early childhood onset distal myopathy with chronic neurogenic features, hypoplastic brain structures, intellectual disability, and both fine and gross motor impairments. It also presents a broad phenotypical spectrum ranging from axonal neuropathy phenotypes to neurodevelopmental phenotypes with or without epilepsy. Additionally, it can cause early-onset epileptic encephalopathy, exerting a dominant-negative effect, and early infantile epileptic encephalopathy-5 (EIEE5), particularly when the variants occur de novo. These conditions highlight the critical role of SPTAN1 in neurological development and function.",
        "Heterozygous loss-of-function variants in SPTAN1 cause childhood onset distal weakness syndrome, early infantile epileptic encephalopathy-5 (EIEE5), intellectual disability, and distal myopathy with chronic neurogenic features.",
        "Heterozygous loss-of-function variants in SPTAN1 are associated with a diverse spectrum of neurogenetic disorders, including childhood-onset distal myopathy, early infantile epileptic encephalopathy, ataxia, intellectual disability, and hereditary spastic paraplegia. These variants can lead to symptoms such as distal weakness, foot abnormalities, seizures, and developmental delays.",
        "Heterozygous loss of function SPTAN1 is associated with a range of conditions including Hereditary Spastic Paraplegia (HSP), intellectual disability, autism, distal myopathy, and early infantile epileptic encephalopathy-5, among other neurodevelopmental phenotypes.",
        "Heterozygous loss of function SPTAN1 causes a variety of conditions including intellectual disability, infantile spasms, hypomyelination, brain atrophy, early childhood onset distal myopathy, infantile epilepsy, early infantile epileptic encephalopathy-5, and chronic neurogenic features.",
        "Heterozygous loss-of-function SPTAN1 variants are associated with two primary conditions. Firstly, a novel early childhood onset distal myopathy characterized by distal weakness, foot abnormalities, mixed electrophysiology findings, and distinct muscle imaging/biopsy changes. Secondly, de novo variants are linked to Early Infantile Epileptic Encephalopathy-5 (EIEE5). These associations highlight the varied phenotypic spectrum of SPTAN1 mutations, ranging from predominantly muscular to neurological manifestations. The conditions present with early childhood onset, emphasizing the importance of early diagnosis and intervention.",
        "Heterozygous loss-of-function variants in the SPTAN1 gene can cause a range of neurological disorders, including early childhood onset distal myopathy with chronic neurogenic features, hereditary spastic paraplegia (both pure and complicated forms), cerebellar ataxia, and a broad spectrum of neurodevelopmental disorders like epileptic encephalopathy, intellectual disability, and axonal neuropathy phenotypes.",
        "Heterozygous loss-of-function SPTAN1 variants are associated with two primary conditions: (1) A novel early childhood onset distal myopathy, characterized by distal weakness, foot abnormalities, and mixed electrophysiology findings; and (2) Early Infantile Epileptic Encephalopathy-5 (EIEE5), predominantly linked to de novo variants. Both conditions present with early childhood onset, highlighting the need for prompt diagnosis and intervention to address either the muscular or neurological manifestations.",
        "Heterozygous loss of function in the SPTAN1 gene is associated with a range of neurodevelopmental disorders and intellectual and motor impairments. These conditions include early-onset epileptic encephalopathy, early infantile epileptic encephalopathy-5 (EIEE5), developmental epileptic encephalopathy, developmental delay with or without seizures, hereditary spastic paraplegia or hereditary ataxia, early onset intractable seizures, severe developmental delay, diffuse hypomyelination, and widespread brain atrophy. Other associated conditions are abnormal neurodevelopment, drug-resistant epilepsy, left hippocampal sclerosis, cognitive and developmental challenges, hypoplastic brain structures, intellectual disability, fine and gross motor impairments, infantile spasms, mild generalized epilepsy, and pontocerebellar atrophy. Additionally, a novel early childhood onset distal myopathy with chronic neurogenic features has been linked to this genetic mutation. These findings are supported by various studies, including patient case studies, genetic analyses, gene enrichment analyses, and functional studies on patient-derived fibroblasts.",
        "Heterozygous loss of function in the SPTAN1 gene is associated with a variety of conditions, including early childhood onset distal myopathy with chronic neurogenic features, hypoplastic brain structures, intellectual disability, and both fine and gross motor impairments. It also includes a broad phenotypical spectrum ranging from axonal neuropathy phenotypes to neurodevelopmental phenotypes with or without epilepsy, early-onset epileptic encephalopathy exerting a dominant-negative effect, and early infantile epileptic encephalopathy-5 (EIEE5) when occurring de novo. These conditions reflect a wide range of neurological and developmental disorders, highlighting the critical role of the SPTAN1 gene in neurodevelopment and function.",
        "Heterozygous loss-of-function variants in the SPTAN1 gene can cause two distinct clinical conditions: a novel early childhood onset distal myopathy with chronic neurogenic features, and early infantile epileptic encephalopathy-5 (EIEE5), particularly when the mutations occur de novo.",
        "Heterozygous loss of function variants in SPTAN1 can result in two distinct conditions: 1. Early Childhood Onset Distal Myopathy with Chronic Neurogenic Features : This condition begins early in childhood and is characterized by muscle weakness, particularly affecting distal muscles. It is accompanied by chronic neurological symptoms, indicating a complex interaction between muscle and nervous system functions. 2. Early Infantile Epileptic Encephalopathy 5 (EIEE5) : When these mutations occur de novo, they can lead to EIEE5, a severe form of epilepsy that manifests in early infancy. This condition is associated with significant developmental challenges and neurological issues, underscoring the diverse impact of SPTAN1 mutations on both muscle and brain functions.",
        "Heterozygous loss of function SPTAN1 primarily causes a novel early childhood onset distal myopathy characterized by distal weakness, foot abnormalities, and mixed myogenic/neurogenic muscle changes. This condition often presents with early childhood onset and includes myopathic changes with mild dystrophic and chronic neurogenic changes on muscle biopsy. Notably, in cases of de novo mutations, heterozygous loss-of-function SPTAN1 variants can also lead to Early Infantile Epileptic Encephalopathy-5 (EIEE5), highlighting the gene\u0027s role in distinct neurological and muscular disorders depending on the mutation context.",
        "Heterozygous loss of function variants in SPTAN1 are associated with several neurological conditions. Specifically, these mutations can cause early childhood onset distal myopathy with chronic neurogenic features. Additionally, when SPTAN1 mutations occur de novo and are heterozygous, they may lead to early infantile epileptic encephalopathy 5 (EIEE5), a severe epilepsy syndrome characterized by early onset seizures and developmental impairment.",
        "Heterozygous loss-of-function variants in SPTAN1 have been found to cause a novel early childhood onset distal myopathy with chronic neurogenic features. This condition presents with distinct characteristics, expanding the known phenotype of SPTAN1 mutations. Notably, when these mutations occur de novo at the heterozygous state, they may also lead to early infantile epileptic encephalopathy-5 (EIEE5), highlighting the significant impact of SPTAN1 variants on neurological and muscular development in early childhood. Studies have shed light on the role of SPTAN1 in these conditions, underscoring the importance of considering SPTAN1 mutations in the diagnosis of early onset myopathies and epileptic encephalopathies.",
        "Heterozygous loss-of-function variants in the SPTAN1 gene can lead to either a novel early childhood onset distal myopathy with chronic neurogenic features or, when occurring de novo, early infantile epileptic encephalopathy-5 (EIEE5).",
        "A heterozygous loss of function mutation in SPTAN1 leads to two primary conditions. First, it causes a novel early childhood onset distal myopathy, which affects the muscles furthest from the trunk and is accompanied by chronic neurogenic features impacting the nervous system. Second, when these mutations occur de novo (for the first time in the individual), they result in early infantile epileptic encephalopathy 5 (EIEE5), a severe disorder characterized by early onset seizures and significant developmental challenges.",
        "Heterozygous loss-of-function variants in SPTAN1 can cause early infantile epileptic encephalopathy-5 and a novel early childhood onset distal myopathy with chronic neurogenic features.",
        "Heterozygous loss-of-function variants in SPTAN1 cause a novel early childhood onset distal myopathy with chronic neurogenic features. Common features include global developmental delays, intellectual disability, and behavioral disturbances. Identification of loss-of-function variants suggests a haploinsufficiency mechanism, but additional functional studies are required to fully elucidate disease pathogenesis. At the heterozygous state, when occurred de novo, may cause early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in SPTAN1 cause a novel early childhood onset distal myopathy with chronic neurogenic features and may cause early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in SPTAN1 are associated with several conditions, including early childhood onset distal myopathy, early infantile epileptic encephalopathy type 5 (EIEE5), and a broad phenotypical spectrum ranging from intellectual disability to distal weakness with a predominant myogenic cause.",
        "Heterozygous loss-of-function variants in the SPTAN1 gene can cause a novel early childhood onset distal myopathy with chronic neurogenic features. Additionally, de novo heterozygous mutations in SPTAN1 have been associated with early infantile epileptic encephalopathy-5 (EIEE5). These findings expand the known phenotypic spectrum of SPTAN1 mutations, highlighting the gene\u0027s critical role in both neuromuscular and neurological development.",
        "Heterozygous loss of function SPTAN1 causes intellectual disability, infantile spasms, hypomyelination, brain atrophy, early childhood onset distal myopathy, infantile epilepsy, early infantile epileptic encephalopathy-5, and chronic neurogenic features.",
        "Heterozygous loss-of-function variants in SPTAN1 cause a novel early childhood onset distal myopathy with chronic neurogenic features. SPTAN1 mutations, when occurred de novo, may also cause early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss of function SPTAN1 can cause a novel early childhood onset distal myopathy with chronic neurogenic features, as well as early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in SPTAN1 cause a novel early childhood onset distal myopathy with chronic neurogenic features. Additionally, these mutations may cause early infantile epileptic encephalopathy-5 (EIEE5) when they occur de novo.",
        "Heterozygous loss-of-function variants in the SPTAN1 gene are associated with a novel early childhood onset distal myopathy characterized by chronic neurogenic features. Additionally, these mutations can lead to early infantile epileptic encephalopathy-5 (EIEE5) when they occur de novo.",
        "Heterozygous loss-of-function variants in SPTAN1 cause a novel childhood onset distal weakness syndrome with primarily skeletal muscle involvement, which includes phenotypes such as distal myopathy, intellectual disability, and various foot abnormalities. Additionally, these variants may lead to early infantile epileptic encephalopathy-5 (EIEE5) when occurring de novo.",
        "Heterozygous loss-of-function variants in the SPTAN1 gene are associated with a novel early childhood onset distal myopathy characterized by chronic neurogenic features, and when occurring de novo, they may also lead to early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in SPTAN1 cause a novel early childhood onset distal myopathy with chronic neurogenic features. Additionally, de novo heterozygous SPTAN1 mutations can also cause early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in SPTAN1 are associated with a diverse spectrum of neurogenetic disorders, including early childhood onset distal myopathy with chronic neurogenic features, intellectual disability, and early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in SPTAN1 cause a spectrum of disorders including early childhood onset distal myopathy with chronic neurogenic features, early infantile epileptic encephalopathy-5 (EIEE5), and other neurogenetic disorders. These variants can lead to conditions ranging from intellectual disability to distal weakness, primarily affecting skeletal muscle.",
        "Heterozygous loss-of-function variants in SPTAN1 can cause early childhood onset distal myopathy with chronic neurogenic features and may also lead to early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss of function SPTAN1 primarily causes a novel early childhood onset distal myopathy with chronic neurogenic features, characterized by distal weakness, foot abnormalities, and specific electrophysiological and imaging findings. Additionally, SPTAN1 variants are associated with autosomal recessive Hereditary Spastic Paraplegia (HSP), particularly in cases with biallelic variants. Furthermore, de novo heterozygous mutations in SPTAN1 have been linked to Early Infantile Epileptic Encephalopathy-5 (EIEE5), highlighting the gene\u0027s role in diverse neurological and muscular conditions.",
        "Heterozygous loss-of-function variants in SPTAN1 cause a novel early childhood onset distal myopathy with chronic neurogenic features and may also lead to early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in the SPTAN1 gene can lead to a novel early childhood onset distal myopathy characterized by chronic neurogenic features. Additionally, when these mutations occur de novo in a heterozygous state, they may cause early infantile epileptic encephalopathy-5 (EIEE5), a severe neurological disorder that begins in infancy.",
        "Heterozygous loss-of-function variants in SPTAN1 can cause a novel early childhood onset distal myopathy with chronic neurogenic features. These mutations, when occurring de novo, may also cause early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in SPTAN1 cause a novel early childhood onset distal myopathy with chronic neurogenic features, as well as early infantile epileptic encephalopathy-5 (EIEE5) when occurred de novo.",
        "Heterozygous loss-of-function variants in the SPTAN1 gene can cause two distinct disorders: a novel early childhood onset distal myopathy with chronic neurogenic features, and early infantile epileptic encephalopathy-5 (EIEE5) when the variants occur de novo.",
        "Heterozygous loss of function SPTAN1 is primarily associated with two distinct conditions. The first is a novel early childhood onset distal myopathy, characterized by distal weakness, foot abnormalities, and mixed muscle changes. The second condition is Early Infantile Epileptic Encephalopathy-5 (EIEE5), particularly in cases involving de novo mutations. These associations highlight the gene\u0027s critical role in both muscular and neurological disorders, leading to varied clinical presentations depending on the mutation context.",
        "Heterozygous loss of function SPTAN1 can cause either a novel early childhood onset distal myopathy with chronic neurogenic features or early infantile epileptic encephalopathy-5 (EIEE5), with the latter specifically noted in de novo occurrences.",
        "Heterozygous loss-of-function variants in SPTAN1 are responsible for causing a newly identified early childhood onset distal myopathy with chronic neurogenic features, and when occurring de novo, they may also cause early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in the SPTAN1 gene can lead to either a novel form of early childhood onset distal myopathy with chronic neurogenic features or, when occurring de novo, early infantile epileptic encephalopathy-5 (EIEE5).",
        "Heterozygous loss-of-function variants in SPTAN1 can cause a novel early childhood onset distal myopathy with chronic neurogenic features, and early infantile epileptic encephalopathy-5 (EIEE5)."
      ],
      "exact_answer": [
        [
          "A novel early childhood onset distal myopathy with chronic neurogenic features."
        ],
        [
          "An early infantile epileptic encephalopathy-5 (EIEE5)"
        ]
      ]
    },
    {
      "body": "Whats is the effect of berberine in ischemic stroke?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38328828",
        "http://www.ncbi.nlm.nih.gov/pubmed/36996739",
        "http://www.ncbi.nlm.nih.gov/pubmed/35093536",
        "http://www.ncbi.nlm.nih.gov/pubmed/33995012",
        "http://www.ncbi.nlm.nih.gov/pubmed/22119079",
        "http://www.ncbi.nlm.nih.gov/pubmed/30266998",
        "http://www.ncbi.nlm.nih.gov/pubmed/28495517",
        "http://www.ncbi.nlm.nih.gov/pubmed/19457765",
        "http://www.ncbi.nlm.nih.gov/pubmed/22052603",
        "http://www.ncbi.nlm.nih.gov/pubmed/31400402",
        "http://www.ncbi.nlm.nih.gov/pubmed/25279238",
        "http://www.ncbi.nlm.nih.gov/pubmed/38201839",
        "http://www.ncbi.nlm.nih.gov/pubmed/18838103",
        "http://www.ncbi.nlm.nih.gov/pubmed/38180752",
        "http://www.ncbi.nlm.nih.gov/pubmed/36453191",
        "http://www.ncbi.nlm.nih.gov/pubmed/39672277",
        "http://www.ncbi.nlm.nih.gov/pubmed/25192195",
        "https://pubmed.ncbi.nlm.nih.gov/37421347/",
        "https://pubmed.ncbi.nlm.nih.gov/18838103/",
        "https://pubmed.ncbi.nlm.nih.gov/22119079/",
        "http://www.ncbi.nlm.nih.gov/pubmed/35142272",
        "http://www.ncbi.nlm.nih.gov/pubmed/24603897",
        "http://www.ncbi.nlm.nih.gov/pubmed/22316297"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Berberine Alleviates Ischemic Brain Injury by Enhancing Autophagic Flux via Facilitation of TFEB Nuclear Translocation.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38328828"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Berberine has been demonstrated to alleviate cerebral ischemia/reperfusion injury, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38328828"
        },
        {
          "offsetInBeginSection": 48,
          "offsetInEndSection": 147,
          "text": " berberine can improve the nerve function deficits in ischemic stroke by inhibiting inflammation. T",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36996739"
        },
        {
          "offsetInBeginSection": 1333,
          "offsetInEndSection": 1504,
          "text": "our results indicate that BBR confers neuroprotective effects by activating PPARδ to scavenge ROS, providing a novel mechanistic insight for the antioxidant action of BBR.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35093536"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Berberine Attenuates Cerebral Ischemia-Reperfusion Injury Induced Neuronal Apoptosis by Down-Regulating the CNPY2 Signaling Pathwa",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33995012"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Berberine (BBR) has a neuroprotective effect against ischemic stroke, but its specific protective mechanism has not been clearly elaborated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33995012"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Berberine is a candidate clinical neuroprotective agent against ischemic stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22119079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "PI3K p55γ promoter activity enhancement is involved in the anti-apoptotic effect of berberine against cerebral ischemia-reperfusion.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22119079"
        },
        {
          "offsetInBeginSection": 739,
          "offsetInEndSection": 1820,
          "text": "We showed that pretreatment with berberine dose-dependently decreased the infarct size, neurological deficits, hispathological changes, brain edema, and inflammatory mediators in serum and ischemic cortical tissue. We revealed that pretreatment with berberine significantly enhanced uptake of 18F-fluorodeoxyglucose of ischemic hemisphere comparing with the vehicle group at 24 h after stroke. Furthermore, pretreatment with berberine dose-dependently suppressed the nuclear-to cytosolic translocation of high-mobility group box1 (HMGB1) protein, the cytosolic-to nuclear translocation of nuclear factor kappa B (NF-κB) and decreased the expression of TLR4 in ischemic cortical tissue. Moreover, co-administration of glycyrrhizin and berberine exerted more potent suppression on the HMGB1/TLR4/NF-κB pathway than berberine or glycyrrhizin administered alone. These results demonstrate that berberine protects the brain from ischemia-reperfusion injury and the mechanism may rely on its anti-inflammatory effects mediated by suppressing the activation of HMGB1/TLR4/NF-κB signaling.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30266998"
        },
        {
          "offsetInBeginSection": 1108,
          "offsetInEndSection": 1225,
          "text": "ti-inflammatory cytokines.CONCLUSIONS: These findings confirm the validity of berberine as a potent anti-inflammatory",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28495517"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Berberine confers neuroprotection in coping with focal cerebral ischemia by targeting inflammatory cytokines.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28495517"
        },
        {
          "offsetInBeginSection": 613,
          "offsetInEndSection": 1042,
          "text": "Pathologic review of the samples obtained from rats treated with different doses of berberine in comparison with samples from pups treated by normal saline showed that there was a significant reduction of brain injury and edema in the rats treated with berberine. Our study also demonstrates that berberine reduces brain ischemic-hypoxic injury dose-dependently. Therefore, beberine may be considered as useful anti-stroke agent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19457765"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 63,
          "text": "Berberine reduces the hypoxic-ischemic insult in rat pup brain.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19457765"
        },
        {
          "offsetInBeginSection": 877,
          "offsetInEndSection": 975,
          "text": "Our study also demonstrates that berberine reduces brain ischemic-hypoxic injury dose-dependently.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19457765"
        },
        {
          "offsetInBeginSection": 91,
          "offsetInEndSection": 343,
          "text": "iseases. A neuroprotective effect of berberine against cerebral ischemia has been reported; however, the effects of berberine on apoptosis in relation to reactive astrogliosis and microglia activation under ischemic conditions have not yet been fully e",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25279238"
        },
        {
          "offsetInBeginSection": 739,
          "offsetInEndSection": 953,
          "text": "We showed that pretreatment with berberine dose-dependently decreased the infarct size, neurological deficits, hispathological changes, brain edema, and inflammatory mediators in serum and ischemic cortical tissue.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30266998"
        },
        {
          "offsetInBeginSection": 69,
          "offsetInEndSection": 224,
          "text": "Although there are increasing evidences that berberine exhibits neuroprotective effects against ischemic brain damage, little is known about the mechanism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18838103"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 302,
          "text": "SCOPE: Existing research indicates that anti-inflammatory and antioxidant properties of berberine play major roles in coping with oxidative stress in neurodegenerative diseases, but it is not known if this isoquinoline alkaloid affects inflammatory cytokines such as interleukin 10 in focal cerebral is",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28495517"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Berberine has been demonstrated to alleviate cerebral ischemia/reperfusion injury, but its neuroprotective mechanism has yet to be understood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38328828"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 144,
          "text": "Our previous studies have shown that berberine can improve the nerve function deficits in ischemic stroke by inhibiting inflammation",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36996739"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 208,
          "text": "Berberine (BBR) presents anti-inflammatory and immunosuppressive properties in many diseases",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36453191"
        },
        {
          "offsetInBeginSection": 373,
          "offsetInEndSection": 518,
          "text": "Although recent research has shown antioxidant effect of berberine (BBR), little is known regarding its effect upon ROS-PPARs signaling in stroke",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35093536"
        },
        {
          "offsetInBeginSection": 843,
          "offsetInEndSection": 1030,
          "text": "Findings of this study suggest that berberine protects against ischemic brain injury by decreasing the intracellular ROS level and subsequently inhibiting mitochondrial apoptotic pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18838103"
        },
        {
          "offsetInBeginSection": 1058,
          "offsetInEndSection": 1771,
          "text": "nd cytochrome c.RESULTS: Our results revealed that berberine treatment alleviated ischemia-induced short-term memory impairment. Treatment with berbeine also attenuated ischemia-induced apoptosis and inhibited reactive astrogliosis and microglia activation. Furthermore, berberine enhanced phospho-PI3K and phospho-Akt expression in the hippocampus of ischemic gerbils.CONCLUSIONS: Berberine exerted a neuroprotective effect against ischemic insult by inhibiting neuronal apoptosis via activation of the PI3K/Akt signaling pathway. The antiapoptotic effect of berberine was achieved through inhibition of reactive astrogliosis and microglia activation. Berberine may therefore serve as a therapeutic agent for str",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25279238"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Our previous study demonstrated that Berberine (BBR) significantly enhances autophagic flux, alleviating ischemic neuronal injury by restoring autolysosomal function, but how BBR augmented autolysosomal functions remained elusive",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39672277"
        },
        {
          "offsetInBeginSection": 87,
          "offsetInEndSection": 324,
          "text": "Berberine (BBR), derived from the traditional Chinese herbal medicine Huang Lian, has been reported to inhibit the progression of stroke, but the specific mechanism whereby BBR modulates the progression of ischemic stroke remains unclear",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38180752"
        },
        {
          "offsetInBeginSection": 644,
          "offsetInEndSection": 842,
          "text": "The results showed that berberine inhibited reactive oxygen species (ROS) generation, and subsequent release of pro-apoptotic factor cytochrome c and apoptosis-inducing factors (AIFs) evoked by OGD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18838103"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 842,
          "text": "We found that berberine improved neurological outcome and reduced ischemia/reperfusion (I/R)-induced cerebral infarction 48h after MCAO. The protective effect of berberine was confirmed in in vitro study. Berberine protected PC12 cells against oxygen-glucose deprivation (OGD)-induced injury. The results showed that berberine inhibited reactive oxygen species (ROS) generation, and subsequent release of pro-apoptotic factor cytochrome c and apoptosis-inducing factors (AIFs) evoked by OGD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18838103"
        },
        {
          "offsetInBeginSection": 1892,
          "offsetInEndSection": 2073,
          "text": "Our study suggests that berberine-induced neuroprotection against ischemic stroke is elicited by enhancing autophagic flux via facilitation of TFEB nuclear translocation in neurons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38328828"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 559,
          "text": "Berberine, a nutraceutical traditionally used as an antibiotic, has recently been proposed to act as a multi-target protective agent against type 2 diabetes, dyslipidemias, ischemic brain injury and neurodegenerative diseases, such as Parkinson\u0027s and Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25192195"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "We conducted a meta-analysis to evaluate the clinical efficacy of berberine (BBR) in treating acute ischemic stroke (AIS), explore i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/37421347/"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 487,
          "text": "We found that berberine improved neurological outcome and reduced ischemia/reperfusion (I/R)-induced cerebral infarction 48h after MCAO.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/18838103/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 80,
          "text": "Berberine is a candidate clinical neuroprotective agent against ischemic stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/22119079/"
        },
        {
          "offsetInBeginSection": 1403,
          "offsetInEndSection": 1551,
          "text": "pus of ischemic gerbils.CONCLUSIONS: Berberine exerted a neuroprotective effect against ischemic insult by inhibiting neuronal apoptosis via activat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25279238"
        },
        {
          "offsetInBeginSection": 1794,
          "offsetInEndSection": 2002,
          "text": " Therefore, our study indicates that BBR-conferred neuroprotection against ischemic stroke is induced through facilitating autophagosome-lysosome fusion, by which enhancing autophagic flux in ischemic neurons",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39672277"
        },
        {
          "offsetInBeginSection": 768,
          "offsetInEndSection": 1264,
          "text": "The infarct volume decreased in treatment group compared to ischemia group. Berberine administration significantly decreased brain edema and contributed to the restoration of motor function. Moreover, berberine potently contributed to neuroprotection in motor area through downregulation of pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines.CONCLUSIONS: These findings confirm the validity of berberine as a potent anti-inflammatory agent in treatment of ischemic stroke.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28495517"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "BACKGROUND: Our previous studies have shown that berberine can improve the nerve function deficits in ischemic stroke by inhibiting inflammation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36996739"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "text": "BACKGROUND: Our previous studies have shown that berberine can improve the nerve function deficits in ischemic stroke by",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36996739"
        },
        {
          "offsetInBeginSection": 688,
          "offsetInEndSection": 782,
          "text": "Our findings suggest that berberine improves stroke outcomes by modulating the gut microbiota.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38201839"
        },
        {
          "offsetInBeginSection": 1381,
          "offsetInEndSection": 1514,
          "text": "Our results suggest that berberine may improve stroke outcomes by modulating the gut flora to increase the abundance of butyric acid.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38201839"
        },
        {
          "offsetInBeginSection": 226,
          "offsetInEndSection": 371,
          "text": "However, there are few reports regarding the protective effect of berberine against neuronal damage following transient global cerebral ischemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22052603"
        },
        {
          "offsetInBeginSection": 318,
          "offsetInEndSection": 466,
          "text": "Emerging evidence indicates that berberine has potential protective effects against I/R injury in brain, heart, kidney, liver, intestine and testis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31400402"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Berberine is a candidate clinical neuroprotective agent against ischemic stroke. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22119079"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Berberine has been demonstrated to alleviate cerebral ischemia/reperfusion injury, but its neuroprotective mechanism has yet to be understood. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38328828"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "BACKGROUND: Our previous studies have shown that berberine can improve the nerve function deficits in ischemic stroke by inhibiting in",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36996739"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 375,
          "text": "l practice. Berberine has demonstrated good neuroprotective effects in models of acute cerebral ischemia; however, whether it can alleviate cognitive impairment caused by chronic cerebral hypoperfusion has rarely been i",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35142272"
        },
        {
          "offsetInBeginSection": 225,
          "offsetInEndSection": 350,
          "text": "In this study, we investigated the effect of berberine on ischemic injury in a middle cerebral artery occlusion (MCAO) model.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18838103"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Berberine Attenuates Cerebral Ischemia-Reperfusion Injury Induced Neuronal Apoptosis by Down-Regulating the CNPY2 Signaling Pathway.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33995012"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "text": "Berberine, an isoquinoline alkaloid component of Coptidis Rhizoma (goldenthread) extract, has been reported to have therapeutic potential for central nervous system disorders such as Alzheimer\u0027s disease, cerebral ischemia, and schizophrenia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22316297"
        }
      ],
      "type": "summary",
      "id": "67cc969581b1027333000010",
      "ideal_answer": [
        "Berberine can improve the nerve function deficits in ischemic stroke by inhibiting inflammation.",
        "Berberine is a candidate clinical neuroprotective agent against ischemic stroke.",
        "Berberine has been shown to have neuroprotective effects in ischemic stroke by reducing inflammation, oxidative stress, and neuronal apoptosis, thereby improving neurological outcomes.",
        "Berberine has been shown to confer neuroprotective effects in ischemic stroke models by activating PPARδ to scavenge ROS.",
        "Berberine has neuroprotective effects, reduces brain injury and edema, decreases infarct size, improves neurological outcomes, and reduces inflammatory markers in ischemic stroke models.",
        "Berberine has been demonstrated to exert neuroprotective effects against ischemic stroke by reducing brain ischemic-hypoxic injury dose-dependently, alleviating cerebral ischemia/reperfusion injury, and promoting angiogenesis after cerebral ischemia.",
        "Berberine has been shown to have a neuroprotective effect against ischemic stroke by down-regulating the CNPY2 signaling pathway, thereby inhibiting neuronal apoptosis.",
        "The effect of berberine in ischemic stroke is to alleviate the injury by enhancing autophagy through promoting the nuclear translocation of TFEB. This process helps clear cellular debris and reduces damage, leading to a beneficial outcome in managing ischemic stroke.",
        "Berberine has been demonstrated to alleviate cerebral ischemia/reperfusion injury,",
        "Berberine has a neuroprotective effect against ischemic stroke by alleviating cerebral ischemia/reperfusion injury, improving nerve function deficits, and attenuating neuronal apoptosis.",
        "Berberine potently contributed to neuroprotection in the motor area through downregulation of pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines. These findings confirm the validity of berberine as a potent anti-inflammatory agent in the treatment of ischemic stroke.",
        "Berberine (BBR) has a neuroprotective effect against ischemic stroke. It can improve nerve function deficits by inhibiting inflammation. Berberine also confers neuroprotective effects by activating PPARδ to scavenge ROS.",
        "Berberine has a neuroprotective effect against ischemic stroke. It can alleviate cerebral ischemia/reperfusion injury and improve nerve function deficits by inhibiting inflammation. Berberine also confers neuroprotective effects by activating PPARδ to scavenge ROS.",
        "Berberine has a neuroprotective effect in ischemic stroke, alleviating brain injury and improving nerve function deficits through multiple mechanisms including enhanced autophagy, reduced inflammation, antioxidant action, and prevention of neuronal apoptosis.",
        "Berberine (BBR) has a neuroprotective effect against ischemic stroke, but its specific protective mechanism has not been clearly elaborated."
      ]
    },
    {
      "body": "Association between eating disorders and ADHD.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38246426",
        "http://www.ncbi.nlm.nih.gov/pubmed/39070652",
        "http://www.ncbi.nlm.nih.gov/pubmed/39096466",
        "http://www.ncbi.nlm.nih.gov/pubmed/39074349",
        "http://www.ncbi.nlm.nih.gov/pubmed/38925001",
        "http://www.ncbi.nlm.nih.gov/pubmed/38890597",
        "http://www.ncbi.nlm.nih.gov/pubmed/27693587",
        "http://www.ncbi.nlm.nih.gov/pubmed/17700082",
        "http://www.ncbi.nlm.nih.gov/pubmed/29172099",
        "http://www.ncbi.nlm.nih.gov/pubmed/36356347",
        "http://www.ncbi.nlm.nih.gov/pubmed/27480884",
        "http://www.ncbi.nlm.nih.gov/pubmed/39543370",
        "http://www.ncbi.nlm.nih.gov/pubmed/39568093",
        "http://www.ncbi.nlm.nih.gov/pubmed/33480309",
        "http://www.ncbi.nlm.nih.gov/pubmed/25007864"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Attention deficit hyperactivity disorder (ADHD) symptoms are associated with disordered eating",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38246426"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Eating disorders (EDs) commonly co-occur with other psychiatric and neurodevelopmental disorders including attention-deficit/hyperactivity disorder (ADHD) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39070652"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 158,
          "text": "Binge eating disorder (BED) is the most common specific eating disorder (ED). It is frequently associated with attention deficit hyperactivity disorder (ADHD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39096466"
        },
        {
          "offsetInBeginSection": 50,
          "offsetInEndSection": 155,
          "text": "symptoms of attention deficit hyperactivity disorder (ADHD) with binge eating spectrum conditions - BESC ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39074349"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 193,
          "text": "Difficulties with inhibitory control have been identified in eating disorders (EDs) and neurodevelopmental disorders (NDs; including attention deficit hyperactivity disorder (ADHD) ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38890597"
        },
        {
          "offsetInBeginSection": 120,
          "offsetInEndSection": 242,
          "text": "There is both empirical and theoretical support for an association between ADHD and eating disorders or disordered eating.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27693587"
        },
        {
          "offsetInBeginSection": 591,
          "offsetInEndSection": 706,
          "text": "Twenty-six studies supported a strong empirical association between ADHD and eating disorders or disordered eating.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27693587"
        },
        {
          "offsetInBeginSection": 998,
          "offsetInEndSection": 1170,
          "text": "without eating disorders.CONCLUSIONS: ADHD significantly increases the risk of eating disorders. The presence of an eating disorder in girls with ADHD heightens the risk of",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17700082"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Autistic people and those with attention deficit hyperactivity disorder are at a high risk of developing an eating disorder",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39568093"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 283,
          "text": "Eating disorders (EDs) commonly co-occur with other psychiatric and neurodevelopmental disorders including attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD); however, the pattern of family history and genetic overlap among them requires clarification",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39543370"
        },
        {
          "offsetInBeginSection": 564,
          "offsetInEndSection": 1126,
          "text": "In both sexes, those with lifetime and past 12-month BE and binge eating disorder had significantly higher prevalence of ADHD than those without BE and binge eating disorder, respectively. Women with lifetime and past 12-month bulimia nervosa and lifetime anorexia nervosa also had significantly higher prevalence of ADHD compared with women without these diagnoses. Given that ADHD invariably began earlier than the ED, ADHD may be an important risk factor for subsequent BE and related ED, and there may be opportunities for intervention among youth with ADHD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480884"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 338,
          "text": "INTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders with overactivity, inattention, and impulsivity as core characteristics. Recent studies suggest that 20 % of children with ADHD also develop eating disorders (EDs), including anorexia nervosa, bulimia nervosa and binge ea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36356347"
        },
        {
          "offsetInBeginSection": 708,
          "offsetInEndSection": 1136,
          "text": "Lifetime ADHD was strongly and significantly associated with lifetime bulimia nervosa (BN), binge eating disorder (BED), and any ED in unadjusted models, but not with anorexia nervosa or subthreshold BED. After adjusting for demographic variables and psychiatric comorbidities, all associations of lifetime ADHD with EDs were substantially attenuated, and only the association of ADHD with BN remained statistically significant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29172099"
        },
        {
          "offsetInBeginSection": 545,
          "offsetInEndSection": 815,
          "text": "findings indicated that higher ADHD symptoms significantly predicted higher ED symptoms. When symptoms of both disorders were further delineated, inattentive ADHD symptoms consistently predicted higher ED symptoms (bulimia, body dissatisfaction, and drive for thinness).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33480309"
        },
        {
          "offsetInBeginSection": 817,
          "offsetInEndSection": 1315,
          "text": "Significantly increased risk for any ED was observed following an ADHD or ASD diagnosis. Mediation analysis suggested that intermediate mood or anxiety disorders could account for 44%-100% of the association between ADHD or ASD and ED. Individuals with a full sibling or maternal half sibling with ASD had increased risk of AN compared to those with siblings without ASD. A positive association was found between ASD-PGS and AN risk whereas a negative association was found between AN-PGS and ADHD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39543370"
        },
        {
          "offsetInBeginSection": 614,
          "offsetInEndSection": 1009,
          "text": "Results reveal that those with clinical ADHD are more likely to experience (a) clinical eating disorder, (b) clinical-level binging and/or purging behaviors, and (c) clinical-level restrictive behaviors. Those with subclinical ADHD (both inattentive and hyperactive/impulsive) were more likely to experience subclinical binging and/or purging behaviors but not subclinical restrictive behaviors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007864"
        },
        {
          "offsetInBeginSection": 753,
          "offsetInEndSection": 930,
          "text": "Women with lifetime and past 12-month bulimia nervosa and lifetime anorexia nervosa also had significantly higher prevalence of ADHD compared with women without these diagnoses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27480884"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Autistic people and those with attention deficit hyperactivity disorder are at a high risk of developing an eating disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39568093"
        },
        {
          "offsetInBeginSection": 708,
          "offsetInEndSection": 912,
          "text": "Lifetime ADHD was strongly and significantly associated with lifetime bulimia nervosa (BN), binge eating disorder (BED), and any ED in unadjusted models, but not with anorexia nervosa or subthreshold BED.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29172099"
        }
      ],
      "id": "67d7fe9318b1e36f2e000047",
      "ideal_answer": [
        "ADHD symptoms are associated with disordered eating, difficulties with inhibitory control have been identified in eating disorders and neurodevelopmental disorders, including ADHD.",
        "Several studies have found a strong association between attention-deficit/hyperactivity disorder (ADHD) and eating disorders, particularly bulimia nervosa and binge eating disorder. The association appears to be partially explained by the impulsivity and other psychiatric comorbidities common in ADHD. However, even after adjusting for demographic factors and comorbid disorders, ADHD remains significantly associated with bulimia nervosa. The shared neural substrates involving dopaminergic signaling may contribute to the co-occurrence of these disorders. Children with ADHD are at increased risk for disordered eating behaviors, while adolescents and adults with ADHD have elevated rates of full-blown eating disorders.",
        "The association between eating disorders (ED) and ADHD has been extensively studied, revealing a significant empirical link between the two conditions. Key findings from various studies indicate a strong association between ADHD and eating disorders or disordered eating across the lifespan. Impulsivity symptoms of ADHD are consistently linked to overeating and bulimia nervosa. Girls with ADHD are significantly more likely to develop eating disorders such as anorexia or bulimia nervosa. Individuals with binge eating and binge eating disorder have a higher prevalence of ADHD, and there is a notable overlap between ADHD and bulimia nervosa/binge eating disorder, with high ADHD symptoms negatively impacting recovery. Preliminary evidence suggests that impulse control deficits may play a role in these disorders, and there is an association between ADHD, obesity, and binge-eating behavior. Both clinical and subclinical levels of ADHD are associated with eating disorders, binging/purging behaviors, and restrictive behaviors. In the context of bariatric surgery, both ADHD and eating disorders are common, with an observed association between adult ADHD and binge eating disorder. These findings highlight the need for integrated treatment approaches addressing both ADHD and eating disorders.",
        "There is a notable association between eating disorders and ADHD. Individuals with ADHD are at a higher risk of developing eating disorders such as binge eating disorder, bulimia nervosa, and anorexia nervosa. This association may be due to shared underlying neurobiological factors, impulsivity, and difficulties with self-regulation that are common in both conditions. Additionally, ADHD symptoms such as impulsivity and inattention can contribute to disordered eating behaviors. Treatment for individuals with both ADHD and eating disorders often requires a comprehensive approach that addresses both conditions simultaneously.",
        "Yes, there is a strong association between eating disorders (ED) and Attention-Deficit/Hyperactivity Disorder (ADHD). Studies suggest a significant comorbidity between the two conditions, with ADHD potentially contributing to the severity of eating disorders. Individuals with ADHD are more likely to exhibit disordered eating behaviors, including binge eating and bulimia. The co-occurrence of ADHD and ED is observed across various eating disorder subtypes, including anorexia nervosa (particularly the binge-purge subtype), bulimia nervosa, and binge eating disorder. Research indicates that ADHD may precede the development of eating disorders, suggesting it could be a risk factor. Difficulties with inhibitory control are seen in both EDs and ADHD, further supporting the link between these conditions."
      ]
    },
    {
      "body": "What is the association of ORM1 and cell-free DNA?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35272364"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35272364"
        },
        {
          "offsetInBeginSection": 1084,
          "offsetInEndSection": 1396,
          "text": "Finally, genetic correlation analysis between cfDNA and thrombosis identified a suggestive association (ρ g \u003d 0.43, p \u003d 0.089).All in all, we show evidence of the role of ORM1 in regulating cfDNA levels in plasma, which might contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35272364"
        },
        {
          "offsetInBeginSection": 1211,
          "offsetInEndSection": 1396,
          "text": "All in all, we show evidence of the role of ORM1 in regulating cfDNA levels in plasma, which might contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35272364"
        }
      ],
      "id": "67d418f418b1e36f2e00000c",
      "ideal_answer": [
        "There is evidence suggesting a role of ORM1 in regulating cfDNA levels in plasma, which might contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis.",
        "ORM1 is genetically and expressively associated with cell-free DNA (cfDNA) levels. Variants in the ORM1 gene, such as rs1687391, and increased multiallelic copy number variation (mCNV) correlate with elevated cfDNA levels. This association suggests ORM1\u0027s role in regulating cfDNA, potentially contributing to thrombosis risk through immunothrombosis and NET formation. While primarily linked to thrombotic conditions, ORM1 also serves as a biomarker in hepatitis B-associated hepatocellular carcinoma, underscoring its broader disease relevance.",
        "The Genetic Analysis of Idiopathic Thrombophilia 2 (GAIT-2) Project identified a significant association between plasma cell-free DNA (cfDNA) levels and a locus near ORM1. Plasma cfDNA serves as a surrogate marker for neutrophil extracellular traps (NETs), which are implicated in immunothrombosis. This suggests that ORM1 may play a role in regulating or influencing NET formation, potentially impacting thrombotic processes.",
        "ORM1, or orosomucoid 1, is associated with the regulation of plasma cell-free DNA (cfDNA) levels, which may contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis. This association was identified in a genome-wide association study, suggesting that ORM1 could be a potential regulator of cfDNA and a marker for venous thromboembolism risk.",
        "The expression of ORM1 is significantly correlated with levels of cell-free DNA (cfDNA), indicating that ORM1 may play a role in regulating cfDNA levels in plasma. Increased dosages of multiallelic copy number variation (mCNV) in ORM1 are associated with decreased gene expression and upregulated cfDNA levels. This relationship suggests that ORM1 could be a novel marker for cfDNA levels, which may contribute to the risk of venous thromboembolism (VTE) through mechanisms related to immunothrombosis. Additionally, genetic correlation analysis has identified a suggestive association between cfDNA and thrombosis, further highlighting the potential importance of ORM1 in this context.",
        "The expression of ORM1 is significantly correlated with levels of cell-free DNA (cfDNA), indicating that ORM1 may serve as a novel marker for cfDNA levels, which could influence the risk of venous thromboembolism (VTE). Increased dosages of multiallelic copy number variation (mCNV) in ORM1 are associated with decreased gene expression and elevated cfDNA levels. Furthermore, genetic correlation analysis suggests a potential link between cfDNA and thrombosis, highlighting ORM1\u0027s role in regulating cfDNA in plasma and its contribution to susceptibility to thrombosis through immunothrombosis mechanisms.",
        "ORM1 is positively associated with cell-free DNA (cfDNA) levels, playing a regulatory role in controlling cfDNA, a surrogate marker for neutrophil extracellular traps (NETs) contributing to immunothrombosis. Genetic associations (e.g., rs1687391) and correlations between ORM1 expression and cfDNA levels (p \u003d 4.38 × 10^-4) support this link. Increased multiallelic copy number variation in ORM1 may lead to decreased ORM1 expression, upregulating cfDNA levels and potentially contributing to thrombosis risk. This association highlights ORM1\u0027s importance in regulating cfDNA levels and its implications in thrombotic disorders.",
        "ORM1 is positively associated with regulating cell-free DNA (cfDNA) levels, influencing thrombosis risk through immunothrombosis and NET formation. Genetic variants like rs1687391 and increased multiallelic copy number variation in ORM1, leading to decreased ORM1 expression, correlate with elevated cfDNA levels. This association underscores ORM1\u0027s importance in thrombotic disorders, with broader disease relevance, including as a biomarker in hepatitis B-associated hepatocellular carcinoma.",
        "The ORM1 gene is associated with the regulation of plasma cell-free DNA levels, which may contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis.",
        "A recent genome-wide association study in the Genetic Analysis of Idiopathic Thrombophilia 2 (GAIT-2) Project found a significant associated locus near ORM1 with plasma cell-free DNA (cfDNA) levels. Plasma cfDNA is considered a surrogate marker of neutrophil extracellular traps (NETs) that contribute to immunothrombosis. This association suggests a potential link between ORM1 and the formation or regulation of NETs, which could have implications for understanding the role of ORM1 in thrombotic disorders. The study of ORM1 phenotypes in healthy volunteers and its correlation with cfDNA levels may provide further insights into the relationship between ORM1 and cell-free DNA, potentially shedding light on the underlying mechanisms of immunothrombosis and its associated conditions.",
        "ORM1 is associated with plasma cell-free DNA (cfDNA) levels, as evidenced by genome-wide association studies and gene expression analyses. This association suggests that ORM1 may regulate cfDNA levels, which are linked to immunothrombosis and venous thromboembolism risk. Additionally, ORM1 has been identified as a potential biomarker in other conditions, such as tuberculosis and lung cancer.",
        "The association of ORM1 (Orosomucoid 1) and cell-free DNA (cfDNA) has been investigated in several studies, particularly regarding plasma cfDNA levels and their implications for thrombosis susceptibility. A genome-wide association study (GWAS) and expression quantitative trait loci (eQTL) analysis identified a significant association between the ORM1 gene and plasma cfDNA levels, suggesting that ORM1 may regulate cfDNA levels and contribute to thrombosis susceptibility through mechanisms of immunothrombosis. Additionally, multiallelic copy number variation (mCNV) in ORM1 is associated with plasma cfDNA levels. This was demonstrated through a GWAS and further validated by next-generation sequencing, CNV quantification, and expression analysis in the GAIT-2 Project, with replication in the RETROVE study. These findings indicate that ORM1 may have a regulatory role in cfDNA levels, which could have implications for understanding and managing thrombosis risk.",
        "ORM1 appears to be a potential regulator of plasma cell-free DNA (cfDNA) levels, with genetic evidence suggesting it may contribute to thrombosis risk. Research indicates that ORM1 plays a role in modulating cfDNA concentrations in plasma, potentially through mechanisms related to immunothrombosis. A genetic correlation analysis showed a suggestive association between cfDNA levels and thrombosis, with a correlation coefficient of 0.43 (p \u003d 0.089).",
        "ORM1 is positively associated with cell-free DNA (cfDNA) levels in plasma, supported by a significant genetic association (rs1687391, p \u003d 3.55 × 10^-10) and positive correlation with ORM1 expression (p \u003d 4.38 × 10^-4). This association suggests ORM1 may regulate cfDNA levels, potentially contributing to an increased susceptibility to thrombosis through immunothrombosis mechanisms. The findings are consistent across analyses, with the association being statistically significant, thereby reinforcing the potential regulatory role of ORM1 in cfDNA levels and its implications for thrombosis risk.",
        "Studies suggest that ORM1 may play a role in regulating plasma levels of cell-free DNA (cfDNA), which could contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis. The genetic correlation analysis between cfDNA and thrombosis revealed a suggestive association, indicating a potential link between ORM1, cfDNA, and thrombosis risk. Specifically, the analysis found a correlation coefficient (ρg) of 0.43, with a p-value of 0.089, providing evidence for the involvement of ORM1 in modulating cfDNA levels in plasma, which may have implications for thrombosis susceptibility.",
        "The genetic analysis suggests that ORM1 plays a role in regulating the levels of cell-free DNA (cfDNA) in plasma, with evidence indicating a potential link between cfDNA levels and thrombosis risk through mechanisms like immunothrombosis.",
        "ORM1 is a potential regulator of plasma levels of cell-free DNA (cfDNA) and thrombosis risk. ORM1 plays a role in regulating cfDNA levels in plasma, which might contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis.",
        "ORM1 is implicated in the regulation of plasma levels of cell-free DNA (cfDNA), with evidence showing that increased mCNV dosages in ORM1 lead to decreased gene expression and upregulated cfDNA levels. A significant genetic association was identified between ORM1 and cfDNA levels, with a heritability estimate of 0.26. Additionally, ORM1 expression correlated with cfDNA levels (p \u003d 4.38 × 10^-4), suggesting that ORM1 may influence thrombosis risk through mechanisms related to immunothrombosis. Genetic correlation analysis indicated a suggestive association between cfDNA and thrombosis (ρg \u003d -0.43, p \u003d 0.089), highlighting ORM1\u0027s potential role in susceptibility to thrombosis via its regulation of cfDNA.",
        "The gene ORM1 has been identified as a potential regulator of plasma levels of cell-free DNA (cfDNA), which may influence thrombosis risk. Genetic correlation analysis suggests a possible association between cfDNA levels and thrombosis, with ORM1 playing a role in this relationship. The evidence indicates that ORM1 might modulate cfDNA levels in plasma, potentially contributing to an increased susceptibility to thrombosis through mechanisms involving immunothrombosis. Although the genetic correlation is suggestive (ρg \u003d 0.43, p \u003d 0.089), it points towards a potential link between ORM1 and the regulation of cfDNA, which could have implications for understanding thrombotic disorders.",
        "Genome-wide association and gene expression studies indicate that multiallelic copy number variation in ORM1 is linked to plasma cell-free DNA levels. This suggests that genetic variations in ORM1 may regulate cfDNA circulation, with the modulation of cfDNA serving as an intermediate phenotype for venous thromboembolism. Such regulation could contribute to thrombosis risk, potentially through mechanisms involving immunothrombosis.",
        "ORM1 is a potential regulator of plasma levels of cell-free DNA. It might contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis. Genetic correlation analysis between cfDNA and thrombosis identified a suggestive association.",
        "The association between ORM1 (Osteoclastogenesis Regulatory Transmembrane Protein 1) and cell-free DNA (cfDNA) is that ORM1 regulates the levels of cfDNA in the plasma. This regulatory role may contribute to the susceptibility of thrombosis through mechanisms involving immunothrombosis, as evidenced by genetic correlation analysis linking cfDNA levels with thrombosis risk.",
        "ORM1 has been identified as a potential regulator of plasma levels of cell-free DNA (cfDNA), and this regulation may contribute to thrombosis susceptibility through mechanisms of immunothrombosis.",
        "The association between ORM1 and cell-free DNA (cfDNA) has significant implications for thrombotic disorders and immunothrombosis. ORM1 appears to regulate plasma levels of cfDNA, which is a marker of neutrophil extracellular traps (NETs) that contribute to immunothrombosis. Increased levels of cfDNA are linked to a higher susceptibility to thrombosis, as evidenced by genetic correlation analyses showing a suggestive association between cfDNA and thrombosis risk. The study indicates that variations in ORM1 expression, influenced by common genetic variants and copy number variations (mCNV), correlate with cfDNA levels. This suggests that ORM1 could serve as a novel biomarker for assessing the risk of venous thromboembolism (VTE) and highlights the potential for targeting ORM1 in therapeutic strategies aimed at mitigating thrombosis associated with elevated cfDNA levels.",
        "ORM1 is suggested to be a potential regulator of plasma levels of cell-free DNA, which may influence thrombosis risk through mechanisms of immunothrombosis.",
        "ORM1 is implicated in the regulation of plasma levels of cell-free DNA (cfDNA), with studies showing a significant correlation between ORM1 expression and cfDNA levels (p \u003d 4.38 × 10^-4). Genetic analyses indicate that variations near the ORM1 gene are associated with cfDNA levels and thrombosis risk, suggesting that ORM1 may contribute to susceptibility to thrombosis through mechanisms related to immunothrombosis. Additionally, increased mCNV dosages in ORM1 were found to decrease gene expression while upregulating cfDNA levels, highlighting ORM1 as a potential novel marker for cfDNA levels and venous thromboembolism (VTE) risk.",
        "ORM1 is positively associated with cell-free DNA (cfDNA) levels, supported by a significant genetic variant (rs1687391, p \u003d 3.55 × 10^-10) and a positive correlation with ORM1 expression in whole blood (p \u003d 4.38 × 10^-4). This association suggests ORM1 may regulate plasma cfDNA levels, potentially influencing thrombosis susceptibility through immunothrombosis mechanisms, as indicated by consistent findings across analyses.",
        "ORM1 is a potential regulator of plasma levels of cell-free DNA. Evidence suggests ORM1 plays a role in regulating cfDNA levels in plasma. This regulation might contribute to thrombosis susceptibility through immunothrombosis mechanisms.",
        "ORM1 is suggested to be a potential regulator of plasma levels of cell-free DNA (cfDNA) based on integrated GWAS and gene expression analysis. The evidence indicates that ORM1 plays a role in regulating cfDNA levels in plasma, which might contribute to thrombosis susceptibility through mechanisms of immunothrombosis. Genetic correlation analysis between cfDNA and thrombosis identified a suggestive association with a genetic correlation coefficient (ρg) of 0.43 (p \u003d 0.089), further supporting the potential link between ORM1, cfDNA regulation, and thrombosis risk.",
        "Studies suggest that ORM1 may play a role in regulating the levels of cell-free DNA (cfDNA) in plasma, potentially influencing susceptibility to thrombosis through mechanisms related to immunothrombosis.",
        "ORM1 exhibits a positive association with cell-free DNA (cfDNA) levels in plasma, supported by significant statistical correlations (p-values as low as 4.38 × 10^-4) and genetic findings (e.g., variant rs1687391, p \u003d 3.55 × 10^-10). This association suggests ORM1 plays a regulatory role in cfDNA levels, potentially influencing thrombosis risk through immunothrombosis mechanisms, with consistent support across studies despite variable correlation strengths.",
        "Research indicates that variations in the ORM1 gene, including multiallelic copy number variation, are associated with altered plasma cell-free DNA levels. This association suggests that ORM1 may play a role in regulating cfDNA concentrations, with changes in these levels potentially acting as an intermediate phenotype for thrombosis risk. In essence, modifications in ORM1 might influence processes such as immunothrombosis, thereby contributing to an individual’s susceptibility to venous thromboembolism.",
        "ORM1 is positively associated with cell-free DNA (cfDNA) levels in plasma, acting as a potential regulator, and this association may contribute to an increased susceptibility to thrombosis through mechanisms of immunothrombosis.",
        "ORM1 is identified as a potential regulator of plasma levels of cell-free DNA (cfDNA). A genome-wide association study showed a significant associated locus near ORM1 related to cfDNA levels. Genetic correlation analysis between cfDNA and thrombosis identified a suggestive association, indicating that ORM1\u0027s role in regulating cfDNA levels in plasma might contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis.",
        "ORM1 is a potential regulator of plasma levels of cell-free DNA, which might contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis."
      ]
    },
    {
      "body": "Are ameleographics (AKA tooth prints) useful for forensic identification?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28584483",
        "http://www.ncbi.nlm.nih.gov/pubmed/39724130",
        "http://www.ncbi.nlm.nih.gov/pubmed/32337126",
        "http://www.ncbi.nlm.nih.gov/pubmed/32566521",
        "http://www.ncbi.nlm.nih.gov/pubmed/31110448",
        "http://www.ncbi.nlm.nih.gov/pubmed/34720517",
        "http://www.ncbi.nlm.nih.gov/pubmed/29284931",
        "http://www.ncbi.nlm.nih.gov/pubmed/21731343",
        "http://www.ncbi.nlm.nih.gov/pubmed/27051220",
        "http://www.ncbi.nlm.nih.gov/pubmed/37654278",
        "http://www.ncbi.nlm.nih.gov/pubmed/10709556",
        "http://www.ncbi.nlm.nih.gov/pubmed/28123281"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 244,
          "text": " We know that teeth trouble us a lot when we are alive, but they last longer for thousands of years even after we are dead. Teeth being the strongest and resistant structure are the most significant tool in forensic investigations. P",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28584483"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 74,
          "text": "Can dead man tooth do tell tales? Tooth prints in forensic identification.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28584483"
        },
        {
          "offsetInBeginSection": 322,
          "offsetInEndSection": 454,
          "text": "This study is aimed to know whether these tooth prints can become a forensic tool in personal identification such as finger prints. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28584483"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 77,
          "text": "Reliability of ameloglyphics in forensic identification: a systematic review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724130"
        },
        {
          "offsetInBeginSection": 721,
          "offsetInEndSection": 827,
          "text": " To assess if ameloglyphics is an accurate and reliable method for forensic identification of individuals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724130"
        },
        {
          "offsetInBeginSection": 2235,
          "offsetInEndSection": 2370,
          "text": "he results of the eighteen studies included in this review suggest that Ameloglyphicsis an useful adjunct for forensic identification.P",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724130"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 56,
          "text": "Ameloglyphics: A Forensic Tool for Human Identification.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37654278"
        },
        {
          "offsetInBeginSection": 663,
          "offsetInEndSection": 818,
          "text": " Thus, ameloglyphics was created to serve as a key tool in forensic odontology, particularly in the case of huge fatalities caused by natural catastrophes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37654278"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Forensic Odontology, a Boon and a Humanitarian Tool: A Literature Review.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32337126"
        },
        {
          "offsetInBeginSection": 688,
          "offsetInEndSection": 853,
          "text": "The techniques involved in forensic odontology include: bite mark analysis, tooth prints, rugroscopy, cheiloscopy, dental DNA analysis, radiographs, and photographs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32337126"
        },
        {
          "offsetInBeginSection": 1343,
          "offsetInEndSection": 1674,
          "text": ", the SEM analysis established the viability and reliability.CONCLUSION: Ameloglyphics is a sensitive and reproducible scientific tool that can be utilized for the management, examination, and evaluation of dental evidence for identification at crime scene and disaster sites. Its importance vis-a-vis fingerprints cannot be unders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32566521"
        },
        {
          "offsetInBeginSection": 676,
          "offsetInEndSection": 1026,
          "text": "There are various important aspects in forensic odontology which are associated with the study of tooth prints, i.e., ameloglyphics, radiographs, the study of palatal rugae patterns, i.e., rugoscopy, cheiloscopy, i.e., the study of lip patterns, tongue prints which can serve as an important biometric tool to aid in the human identification process.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34720517"
        },
        {
          "offsetInBeginSection": 664,
          "offsetInEndSection": 818,
          "text": "Thus, ameloglyphics was created to serve as a key tool in forensic odontology, particularly in the case of huge fatalities caused by natural catastrophes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37654278"
        },
        {
          "offsetInBeginSection": 588,
          "offsetInEndSection": 710,
          "text": "This characteristic of uniqueness of the tooth print can serve as a significant biometric tool in forensic identification.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724130"
        },
        {
          "offsetInBeginSection": 676,
          "offsetInEndSection": 1025,
          "text": "There are various important aspects in forensic odontology which are associated with the study of tooth prints, i.e., ameloglyphics, radiographs, the study of palatal rugae patterns, i.e., rugoscopy, cheiloscopy, i.e., the study of lip patterns, tongue prints which can serve as an important biometric tool to aid in the human identification process",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34720517"
        },
        {
          "offsetInBeginSection": 1670,
          "offsetInEndSection": 1805,
          "text": "Tooth prints may be used as an effective aid in person identification even in adverse conditions such as burn and acid attack injuries.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27051220"
        },
        {
          "offsetInBeginSection": 281,
          "offsetInEndSection": 783,
          "text": "Teeth have the highest resistance to most environmental effects like fire, desiccation, and decomposition, and may be used as a forensic evidence.AIMS AND OBJECTIVES: The aim of the study was to evaluate if the tooth prints could be used for an individual\u0027s identification and reproducibility and permanency of these tooth prints after exposing the teeth to acid and various degrees of temperature.MATERIALS AND METHODS: 90 tooth prints from 20 freshly extracted maxillary premolar teeth were obtained.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27051220"
        },
        {
          "offsetInBeginSection": 243,
          "offsetInEndSection": 453,
          "text": "Patterns of enamel rod end on the tooth surface are known as tooth prints.AIM: This study is aimed to know whether these tooth prints can become a forensic tool in personal identification such as finger prints.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28584483"
        },
        {
          "offsetInBeginSection": 1926,
          "offsetInEndSection": 2233,
          "text": "The data obtained from the eighteen included studies were systematically reviewed but a meta-analysis could not be performed due to heterogeneity of the data.CONCLUSION: Ameloglyphics is a relatively newer technique and a fair number of research are done on its application in identification of individuals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724130"
        },
        {
          "offsetInBeginSection": 206,
          "offsetInEndSection": 633,
          "text": "These are called as tooth prints and they help in personal identification in forensic odontology.AIMS AND OBJECTIVES: The aim of the present study is to analyze the enamel rod end pattern on the tooth surface for personal identification and to analyze the familial inheritance of enamel rod end pattern.MATERIALS AND METHODS: In the present study, 100 different families were considered for the analysis of tooth print pattern.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31110448"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Ameloglyphics: A possible forensic tool for person identification following high temperature and acid exposure.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27051220"
        },
        {
          "offsetInBeginSection": 588,
          "offsetInEndSection": 876,
          "text": "This characteristic of uniqueness of the tooth print can serve as a significant biometric tool in forensic identification.OBJECTIVES: To assess if ameloglyphics is an accurate and reliable method for forensic identification of individuals.METHODOLOGY: Registration number- CRD42022338138.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39724130"
        },
        {
          "offsetInBeginSection": 639,
          "offsetInEndSection": 862,
          "text": "This review encompasses about the basis of using enamel rod end patterns, methods of obtaining the patterns and further suggests these tooth prints as an analogy to finger print in personal identification in mass disasters.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29284931"
        },
        {
          "offsetInBeginSection": 540,
          "offsetInEndSection": 692,
          "text": "The various methods employed in forensic odontology include tooth prints, radiographs, photographic study, rugoscopy, cheiloscopy and molecular methods.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21731343"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Teeth are one of the most important factors in the identification of unknown cadavers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10709556"
        },
        {
          "offsetInBeginSection": 306,
          "offsetInEndSection": 437,
          "text": "oth prints.AIM: This study is aimed to know whether these tooth prints can become a forensic tool in personal identification such a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28584483"
        },
        {
          "offsetInBeginSection": 1290,
          "offsetInEndSection": 1380,
          "text": "Lip prints and fingerprints can be used for personal identification in a forensic scenario",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28123281"
        },
        {
          "offsetInBeginSection": 225,
          "offsetInEndSection": 738,
          "text": "l, oral, and paraoral structures-Forensic Odontology, is a boon in itself. It has been seen that the role of forensic odontology has increased as most of the times teeth and other orally associated structures remain the only means of identification in the worst of scenarios where the conventional biometrics such as fingerprint, iris scan, palm print, etc., may be lost and are therefore not reliable enough to resolve the purpose of identification. There are various important aspects in forensic odontology whi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34720517"
        }
      ],
      "type": "yesno",
      "id": "67cc9d4c81b1027333000015",
      "ideal_answer": [
        "Ameloglyphics is an accurate and reliable method for forensic identification of individuals.",
        "Yes. Tooth prints are unique to an individual and can be used as a valuable inexpensive tool in forensic odontology for personal identification.",
        "Yes, ameleographics, also known as tooth prints, are useful for forensic identification. The uniqueness of each individual\u0027s tooth print makes it a significant biometric tool that can aid in identifying persons in forensic investigations.",
        "Yes, amelographics (AKA tooth prints) are useful for forensic identification.",
        "Yes, ameloglyphics (tooth prints) can be useful for forensic identification. They involve the unique patterns and characteristics of the enamel on the surface of teeth, which can be used to identify individuals similarly to fingerprints.",
        "Yes, ameloglyphics, or tooth prints, are useful for forensic identification. The unique patterns of enamel rod ends on the tooth surface, which are distinct for each individual, make them a valuable biometric tool. Additionally, teeth are highly resistant to environmental effects, further supporting their use in forensic odontology for personal identification.",
        "Yes. Ameloglyphics, also known as tooth prints, are considered a useful adjunct for forensic identification based on various studies.",
        "Yes, tooth prints are unique and can be a valuable tool in forensic identification.",
        "Yes. Ameloglyphics, or tooth prints, are considered a useful adjunct for forensic identification due to the uniqueness of the patterns formed on the surface of enamel, which can serve as significant biometric tools.",
        "Yes. Ameloglyphics, or tooth prints, are considered a useful adjunct for forensic identification based on various studies and their unique characteristics.",
        "Yes. Ameloglyphics, or tooth prints, are considered a useful adjunct for forensic identification, enhancing the precision and reliability of forensic analyses.",
        "Yes, ameloglyphics (tooth prints) are useful for forensic identification.",
        "Yes. Ameloglyphics, or tooth prints, are considered a useful adjunct for forensic identification, as they provide unique characteristics that can aid in identifying individuals.",
        "Yes, amelographics (tooth prints) can be useful for forensic identification, as they are unique patterns on the tooth surface.",
        "Ameleglyphics, also known as tooth prints, are considered unique to an individual and can serve as a significant biometric tool in forensic identification due to their unique enamel rod patterns.",
        "Yes, ameloglyphics (tooth prints) are useful for forensic identification, especially in adverse conditions or mass disasters, due to their uniqueness, resistance to environmental degradation, and validated methodologies for analysis and reproduction.",
        "Yes, ameloglyphics (tooth prints) are useful for forensic identification as they are unique to each individual and can serve as a reliable biometric tool. Studies have shown that tooth prints remain distinct even after exposure to high temperatures and acids, making them valuable in forensic odontology for personal identification.",
        "Ameloglyphics, or tooth prints, are indeed useful for forensic identification. They involve analyzing unique patterns on the enamel of teeth, which can survive harsh conditions that destroy other tissues. These patterns are influenced by genetics and environment, making them potentially unique identifiers.\n\nWhile ameloglyphics is still being explored and may not be as widely used as traditional methods like dental records or DNA analysis, it holds promise, especially in mass fatality scenarios where conventional methods might be less effective. The method\u0027s reliability depends on the availability of specialized equipment and expertise, and factors like dental work could affect results.\n\nIn summary, ameloglyphics can serve as a valuable tool in forensic identification, particularly when combined with other methods, offering a unique approach to identifying individuals in challenging circumstances.",
        "Based on the provided contexts, ameleographics (AKA tooth prints) do not appear to be explicitly discussed or evaluated as a useful tool for forensic identification. However, lip prints, tongue prints, and other dental biometrics are discussed as potential tools for forensic identification.\n\nBut since there is no information about ameleographics in the given contexts, it is difficult to give a definitive answer to the question.",
        "Yes. Ameleographics (AKA tooth prints) are useful for forensic identification.",
        "Yes, amelographics (also known as tooth prints) are indeed useful for forensic identification. Teeth are strong and resistant structures that can last for thousands of years, making them significant tools in forensic investigations due to their durability and distinctiveness.",
        "Yes. Tooth prints are unique and can be used for forensic identification.",
        "Ameloglyphics, also known as tooth prints, have been studied extensively to determine their usefulness in forensic identification. Eighteen studies reviewed suggest that ameloglyphics can serve as a useful adjunct for identifying individuals, particularly in cases of mass fatalities where traditional methods may be challenging.",
        "Yes, ameloglyphics (tooth prints) are useful for forensic identification, serving as a key tool in forensic odontology.",
        "The studies included in the review suggest that ameloglyphics is an useful adjunct for forensic identification.",
        "Yes. The results of the eighteen studies included in this review suggest that Ameloglyphicsis an useful adjunct for forensic identification.",
        "Yes. Ameloglyphics is an accurate and reliable method for forensic identification of individuals.",
        "Yes. Ameloglyphics, also known as tooth prints, are considered a useful adjunct for forensic identification of individuals.",
        "Yes, ameloglyphics, or tooth prints, can be a useful adjunct for forensic identification. They can serve as a key tool in forensic odontology, especially in cases of mass fatalities. This is because teeth are the strongest and most resistant structures, lasting for thousands of years.",
        "Yes. Ameloglyphics, or tooth prints, are considered a useful adjunct for forensic identification due to their uniqueness and reliability in personal identification.",
        "Yes. Tooth prints are useful for forensic identification.",
        "Yes. Ameloglyphics, also known as tooth prints, are considered a useful adjunct for forensic identification, as they can aid in personal identification similar to fingerprints.",
        "Yes, tooth prints can be useful for forensic identification.",
        "Yes, ameloglyphics is an useful adjunct for forensic identification.",
        "Yes, amelographics (tooth prints) are highly useful for forensic identification because teeth remain strong and resistant over thousands of years, preserving unique characteristics that aid in identifying individuals.",
        "Yes, ameloglyphics, also known as tooth prints, can be a useful adjunct for forensic identification. They can serve as a key tool in forensic odontology, especially in cases of mass fatalities. Teeth are the strongest and most resistant structures, making them significant in forensic investigations.",
        " Yes, ameloglyphics (tooth prints) have been found to be useful for forensic identification based on a systematic review of eighteen studies. The results suggest that tooth prints can serve as an adjunct for personal identification in forensic investigations.",
        "Yes, ameloglyphics (tooth prints) are useful for forensic identification, especially in specific scenarios like massive fatalities.",
        "Yes, ameloglyphics is an accurate and reliable method for forensic identification of individuals.",
        "Yes, ameloglyphics (AKA tooth prints) are useful for forensic identification.",
        "Yes. Ameloglyphics (tooth prints) can be a useful adjunct for forensic identification, particularly in cases of mass fatalities. They are considered a key tool in forensic odontology."
      ],
      "exact_answer": "yes"
    },
    {
      "body": "Characteristics of prion diseases.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32315552",
        "http://www.ncbi.nlm.nih.gov/pubmed/28674988",
        "http://www.ncbi.nlm.nih.gov/pubmed/29887138",
        "http://www.ncbi.nlm.nih.gov/pubmed/20216075",
        "http://www.ncbi.nlm.nih.gov/pubmed/7598484",
        "http://www.ncbi.nlm.nih.gov/pubmed/34334283"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 263,
          "offsetInEndSection": 384,
          "text": "evolving dementia in conjunction with neurological symptoms such as ataxia, myoclonus, pyramidal and extrapyramidal signs",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315552"
        },
        {
          "offsetInBeginSection": 677,
          "offsetInEndSection": 701,
          "text": "isolated visual symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315552"
        },
        {
          "offsetInBeginSection": 747,
          "offsetInEndSection": 770,
          "text": "isolated anomic aphasia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315552"
        },
        {
          "offsetInBeginSection": 789,
          "offsetInEndSection": 822,
          "text": "non-convulsive status epilepticus",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315552"
        },
        {
          "offsetInBeginSection": 989,
          "offsetInEndSection": 1140,
          "text": "psychiatric and visual symptoms, which are relatively common, epileptic seizures, otologic symptoms and presentation of sCJD as an acute vascular event",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315552"
        },
        {
          "offsetInBeginSection": 1152,
          "offsetInEndSection": 1303,
          "text": "language, communication and writing impairments, movement disorders, symptoms from the peripheral nervous system and bulbar signs were reported as well",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315552"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 258,
          "text": "encephalopathies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29887138"
        },
        {
          "offsetInBeginSection": 531,
          "offsetInEndSection": 578,
          "text": "neuronal loss, astrogliosis, and cognitive loss",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29887138"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 92,
          "text": "neurodegenerative disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28674988"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 417,
          "text": "Prion diseases are a rare group of fatal neurodegenerative disorders of humans and animals that manifest primarily as progressive dementia and ataxia. Unique to these diseases is the prion, a misfolded isoform of the prion protein that can transmit disease from cell to cell or host to host by associating with, and transforming, normal prion protein into the misfolded isoform (the pathogenic scrapie-inducing form).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20216075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 367,
          "text": "The human transmissible spongiform encephalopathies (TSEs), or prion diseases, are a group of rapidly progressive disorders characterized by a spectrum of clinical abnormalities that include cognitive impairment, ataxia, myoclonus, and visual, pyramidal, and extrapyramidal signs. They share a spongiform (vacuolar) degeneration and variable amyloid plaque formation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7598484"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 500,
          "text": "Being considered among the most fatal neurological conditions, Creutzfeldt-Jakob disease is a transmissible spongiform encephalopathy characterized by its unknown etiology and rapidly progressive neurodegenerative symptoms that often lead to a mean survival of 6 to 12 months. The accumulation of the prionic protein causes brain matter degeneration, which leads to a set of clinical findings that include rapidly progressive dementia, myoclonus, tremors, cerebellar ataxia, and extrapyramidal signs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34334283"
        }
      ],
      "id": "67d81c7218b1e36f2e00004d",
      "ideal_answer": [
        "Prion diseases manifest primarily with CNS symptoms such as progressive dementia, pyramidal and extrapyramidal signs, language and writing impairments, ataxia, myoclonus, epilepsia, movement disorders, bulbar signs, communication impairment, symptoms from the peripheral nervous system, and psychiatric and visual symptoms.",
        "Prion diseases are a group of rare, progressive neurodegenerative disorders characterized by distinctive clinical features and neuropathological findings. Key characteristics include: 1. Neurological Symptoms : Evolving dementia with symptoms such as ataxia (loss of coordination), myoclonus (involuntary muscle jerks), pyramidal signs (e.g., increased reflexes, spasticity), and extrapyramidal signs (e.g., rigidity, bradykinesia). 2. Cognitive and Psychiatric Symptoms : Isolated anomic aphasia (difficulty finding words) and other language impairments; psychiatric symptoms such as anxiety or depression may also occur. 3. Visual and Otologic Symptoms : Isolated visual disturbances and otologic symptoms (e.g., hearing loss, vertigo). 4. Seizures and Epileptic Events : Non convulsive status epilepticus and epileptic seizures are common presentations. 5. Movement Disorders : Peripheral nervous system involvement, bulbar signs (e.g., difficulty swallowing, speaking), and other movement disorders may be observed. 6. Encephalopathies : Widespread brain dysfunction leading to cognitive decline and neuropsychiatric symptoms. 7. Pathological Features : Neuronal loss, astrogliosis (reactive astrocytes), and spongiform changes in the brain tissue. These diseases often present as acute or subacute neurological conditions and are associated with a rapid progression of symptoms leading to severe disability and death."
      ],
      "exact_answer": [
        [
          "evolving dementia"
        ],
        [
          "pyramidal signs"
        ],
        [
          "extrapyramidal signs"
        ],
        [
          "psychiatric symptoms"
        ],
        [
          "visual symptoms"
        ],
        [
          "language and writing impairments"
        ],
        [
          "ataxia"
        ],
        [
          "myoclonus"
        ],
        [
          "epilepsia"
        ],
        [
          "movement disorders"
        ],
        [
          "symptoms from the peripheral nervous system"
        ],
        [
          "bulbar signs"
        ],
        [
          "communication impairment"
        ]
      ]
    },
    {
      "body": "Which gene shapes the 3D enhancer network of the developing T cell genome?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36376298"
      ],
      "type": "factoid",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "The 3D enhancer network of the developing T cell genome is shaped by SATB1.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 757,
          "text": "Mechanisms of tissue-specific gene expression regulation via 3D genome organization are poorly understood. Here we uncover the regulatory chromatin network of developing T cells and identify SATB1, a tissue-specific genome organizer, enriched at the anchors of promoter-enhancer loops. We have generated a T-cell specific Satb1 conditional knockout mouse which allows us to infer the molecular mechanisms responsible for the deregulation of its immune system. H3K27ac HiChIP and Hi-C experiments indicate that SATB1-dependent promoter-enhancer loops regulate expression of master regulator genes (such as Bcl6), the T cell receptor locus and adhesion molecule genes, collectively being critical for cell lineage specification and immune system homeostasis. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376298"
        }
      ],
      "id": "67d4903418b1e36f2e000018",
      "ideal_answer": [
        "The 3D enhancer network of the developing T cell genome is shaped by SATB1.",
        "SATB1 is the gene that shapes the 3D enhancer network of the developing T cell genome. It acts as a tissue-specific genome organizer, enriched at promoter-enhancer loop anchors, regulating key genes for T cell lineage and immune system homeostasis. This role is supported by H3K27ac HiChIP, Hi-C experiments, and studies using T-cell specific Satb1 conditional knockout mice, which highlight SATB1\u0027s crucial function in controlling transcription programs through spatial chromatin arrangements.",
        "The gene that shapes the 3D enhancer network of the developing T cell genome is SATB1 (Special AT-rich sequence-binding protein 1).",
        "The 3D enhancer network of the developing T cell genome is shaped by SATB1, as indicated by H3K27ac HiChIP and Hi-C experiments which show that SATB1-dependent promoter-enhancer loops regulate the expression of key genes for T cell development and immune system homeostasis.",
        "SATB1, a genome organizer, plays a pivotal role in shaping the 3D enhancer network of the developing T cell genome, while TCF-1 promotes chromatin interactions across topologically associating domains (TADs) in T cell progenitors, and the interplay between lineage-specific transcription factors and chromatin architecture, such as enhancer-promoter interactions, also drives cell type-specific gene expression.",
        "SATB1 is a T-cell specific genome organizer, enriched at the anchors of promoter-enhancer loops.",
        "SATB1 shapes the 3D enhancer network of the T cell genome.",
        "SATB1 shapes the 3D enhancer network of the developing T cell genome, acting as a tissue-specific genome organizer. It regulates key genes for T cell development, including master regulators, the T cell receptor locus, and adhesion molecules, as validated through knockout mice models and chromatin structure experiments. This function is crucial for cell lineage specification and maintaining immune system balance, operating within a higher-order chromatin scaffold provided by CTCF and other factors.",
        "SATB1",
        "The gene SATB1 (special AT-rich binding protein 1) shapes the 3D enhancer network of the developing T cell genome. SATB1 is a tissue-specific genome organizer that is enriched at the anchors of promoter-enhancer loops in T cells. It regulates the expression of key genes involved in T cell lineage specification and immune system homeostasis by controlling the spatial chromatin arrangements and 3D enhancer-promoter interactions.",
        "The gene SATB1 shapes the 3D enhancer network of the developing T cell genome. SATB1 is a tissue-specific genome organizer that is enriched at the anchors of promoter-enhancer loops in T cells. It regulates the expression of master regulator genes, the T cell receptor locus, and adhesion molecule genes by controlling the spatial chromatin arrangements and promoter-enhancer loops.",
        "SATB1 is the gene that shapes the 3D enhancer network of the developing T cell genome, acting as a tissue-specific genome organizer to regulate key T cell development genes, as validated by knockout mouse models and chromatin structure experiments.",
        "The gene that shapes the 3D enhancer network of the developing T cell genome is SATB1. This was identified through H3K27ac HiChIP and Hi-C experiments. Additionally, ARID1A has been shown to shape the 3D enhancer network by establishing de novo open chromatin regions at enhancers, particularly in antiviral CD8+ T cells during infection. Furthermore, transcription factors such as T lineage-defining Tcf1 and TCR-induced Batf may also have intrinsic abilities and/or engage CTCF to shape the 3D enhancer network.",
        "The gene SATB1 shapes the 3D enhancer network of the developing T cell genome, as it regulates promoter-enhancer loops critical for lineage specification and immune homeostasis, complementing ubiquitously expressed genome organizers.",
        "The gene SATB1 plays a crucial role in shaping the 3D enhancer network of the developing T cell genome. This has been demonstrated through various experiments such as H3K27ac HiChIP and Hi-C analyses. Additionally, CTCF-binding sites in the Mdm1-Il22-Ifng locus and transcription factors like Tcf1 also contribute to this 3D enhancer network.",
        "SATB1 is a tissue-specific genome organizer, enriched at the anchors of promoter-enhancer loops. SATB1-dependent promoter-enhancer loops regulate expression of master regulator genes (such as Bcl6), the T cell receptor locus and adhesion molecule genes, collectively being critical for cell lineage specification and immune system homeostasis.",
        "SATB1 is a tissue-specific genome organizer that plays a critical role in shaping the 3D enhancer network of the developing T cell genome. Through its enrichment at promoter-enhancer loop anchors, SATB1 regulates the expression of key genes involved in T cell lineage specification and immune system homeostasis.",
        "The 3D enhancer network of the developing T cell genome is shaped by SATB1, a transcription factor that plays a critical role in organizing chromatin structure and regulating gene expression during T cell development. This organization ensures proper cellular identity and function.",
        "SATB1 is the gene that shapes the 3D enhancer network of the developing T cell genome, playing a crucial role in chromatin organization and gene regulation during T cell development, as uniformly identified across all provided answers and supported by its known biomedical functions.",
        "The gene that shapes the 3D enhancer network of the developing T cell genome is SATB1. It plays a critical role in organizing the 3D genome architecture, which is essential for regulating gene expression during T cell development.",
        "Studies have identified SATB1 as the gene that shapes the 3D enhancer network of the developing T cell genome. This tissue-specific genome organizer is enriched at the anchors of promoter-enhancer loops, playing a crucial role in regulating tissue-specific gene expression. The regulatory chromatin network of developing T cells, including master regulator genes such as Bcl6, the T cell receptor locus, and adhesion molecule genes, is controlled by SATB1-dependent promoter-enhancer loops. These loops are essential for cell lineage specification and immune system homeostasis, highlighting the importance of SATB1 in the development and function of T cells.",
        "The gene SATB1 shapes the 3D enhancer network of the developing T cell genome by acting as a tissue-specific genome organizer enriched at the anchors of promoter-enhancer loops, which is crucial for regulating key genes involved in T cell lineage specification and immune system homeostasis.",
        "The gene responsible for shaping the 3D enhancer network of the developing T cell genome is SATB1. This transcription factor plays a crucial role in organizing chromatin structure and regulating gene expression during T cell development, ensuring proper enhancer function.",
        "SATB1 shapes the 3D enhancer network of the developing T cell genome. It is a tissue-specific genome organizer, enriched at the anchors of promoter-enhancer loops. SATB1-dependent regulatory chromatin loops regulate expression of master regulator genes (such as Bcl6), the T cell receptor locus and adhesion molecule genes, collectively being critical for cell lineage specification and immune system homeostasis.",
        "The gene that shapes the 3D enhancer network of the developing T cell genome is SATB1.",
        "The 3D enhancer network of the developing T cell genome is shaped by the gene SATB1, which acts as a tissue-specific genome organizer. SATB1 is enriched at the anchors of promoter-enhancer loops and plays a crucial role in regulating the expression of master regulator genes, such as Bcl6, the T cell receptor locus, and adhesion molecule genes. This regulation is essential for cell lineage specification and maintaining immune system homeostasis. The importance of SATB1 in this context is further supported by T-cell specific Satb1 conditional knockout mice, which exhibit deregulation of their immune system, highlighting SATB1\u0027s critical role in the 3D chromatin network of developing T cells.",
        "The gene SATB1 shapes the 3D enhancer network of the developing T cell genome by organizing promoter-enhancer loops that regulate key immune genes critical for T cell development and immune system homeostasis.",
        "SATB1 shapes the 3D enhancer network of the developing T cell genome. It is a tissue-specific genome organizer enriched at the anchors of promoter-enhancer loops. SATB1-dependent promoter-enhancer loops regulate expression of master regulator genes.",
        "The gene SATB1 shapes the 3D enhancer network of the developing T cell genome.",
        "SATB1 shapes the 3D enhancer network of the developing T cell genome. SATB1 is a tissue-specific genome organizer enriched at the anchors of promoter-enhancer loops. It regulates the expression of master regulator genes, the T cell receptor locus, and adhesion molecule genes, which are critical for cell lineage specification and immune system homeostasis.",
        "The gene SATB1 shapes the 3D enhancer network of the developing T cell genome by organizing tissue-specific chromatin networks and forming promoter-enhancer loops. It is enriched at these loop anchors, regulating key genes involved in T cell lineage specification and immune system homeostasis, such as Bcl6, the T cell receptor locus, and adhesion molecule genes.",
        "The gene SATB1 shapes the 3D enhancer network of the developing T cell genome by organizing promoter-enhancer loops critical for gene regulation and immune system homeostasis.",
        "The SATB1 gene shapes the 3D enhancer network of the developing T cell genome.",
        "SATB1 is the gene that shapes the 3D enhancer network of the developing T cell genome. It acts as a tissue-specific genome organizer, enriched at promoter-enhancer loop anchors, regulating master regulator genes, the T cell receptor locus, and adhesion molecule genes. This role is supported by studies using T-cell specific Satb1 conditional knockout mice and advanced chromatin analysis techniques like H3K27ac HiChIP and Hi-C experiments, highlighting SATB1\u0027s crucial function in cell lineage specification and immune system homeostasis.",
        "The 3D enhancer network of the developing T cell genome is shaped by the SATB1 gene. SATB1 is a genome organizer that plays a crucial role in the regulation of gene expression by influencing the spatial organization of chromatin, thereby impacting the development and function of T cells.",
        "SATB1 is the gene that shapes the 3D enhancer network of the developing T cell genome, due to its role in chromatin organization and gene regulation, as unanimously indicated by all provided responses.",
        "The gene that shapes the 3D enhancer network of the developing T cell genome is SATB1. This protein plays a critical role in organizing chromatin structure by forming specific loops and domains, which facilitate interactions between enhancers and promoters. These interactions are essential for regulating gene expression during T cell differentiation and development.",
        "SATB1 shapes the 3D enhancer network of the developing T cell genome. It is enriched at the anchors of promoter-enhancer loops. These loops regulate expression of master regulator genes.",
        " SATB1 gene shapes the 3D enhancer network of the developing T cell genome.",
        "The 3D enhancer network of the developing T cell genome is shaped by SATB1, a tissue-specific genome organizer enriched at promoter-enhancer loop anchors. Studies using a T-cell specific Satb1 conditional knockout mouse and techniques like H3K27ac HiChIP and Hi-C reveal that SATB1-dependent loops regulate genes critical for T cell development, including master regulators like Bcl6, the T cell receptor locus, and adhesion molecule genes.",
        "The gene SATB1 shapes the 3D enhancer network of the developing T cell genome. SATB1 is a tissue-specific genome organizer that is enriched at the anchors of promoter-enhancer loops in T cells. Knockout of SATB1 in a mouse model disrupts the 3D chromatin organization and deregulates the expression of key genes involved in T cell development and function.",
        "SATB1 is the gene that shapes the 3D enhancer network of the developing T cell genome, playing a crucial role in chromatin organization and gene regulation. Specifically, SATB1 is enriched at promoter-enhancer loop anchors, influencing key genes for T cell lineage specification and immune system homeostasis, as supported by Satb1 knockout studies and HiChIP/Hi-C experiments.",
        "The gene is SATB1. It plays a key role by acting as a tissue-specific genome organizer that shapes the 3D enhancer network during T cell development.",
        "SATB1 shapes the 3D enhancer network of the developing T cell genome. It is a tissue-specific genome organizer enriched at the anchors of promoter-enhancer loops. SATB1-dependent promoter-enhancer loops regulate the expression of master regulator genes, the T cell receptor locus, and adhesion molecule genes, which are critical for cell lineage specification and immune system homeostasis.",
        "SATB1, a tissue-specific genome organizer, plays a crucial role in shaping the 3D enhancer network of developing T cells by mediating promoter-enhancer loops that regulate key genes involved in T cell development and immune system function.",
        "The gene SATB1 shapes the 3D enhancer network of the developing T cell genome by acting as a tissue-specific genome organizer enriched at the anchors of promoter-enhancer loops, regulating critical genes for T cell lineage specification and immune system homeostasis."
      ],
      "exact_answer": [
        [
          "SATB1"
        ]
      ]
    },
    {
      "body": "How is a  neoantigen created?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38090649",
        "http://www.ncbi.nlm.nih.gov/pubmed/37038186",
        "http://www.ncbi.nlm.nih.gov/pubmed/35339647",
        "http://www.ncbi.nlm.nih.gov/pubmed/31578439",
        "http://www.ncbi.nlm.nih.gov/pubmed/31610619",
        "http://www.ncbi.nlm.nih.gov/pubmed/31462330",
        "http://www.ncbi.nlm.nih.gov/pubmed/31293573",
        "http://www.ncbi.nlm.nih.gov/pubmed/38548414",
        "http://www.ncbi.nlm.nih.gov/pubmed/36604431",
        "http://www.ncbi.nlm.nih.gov/pubmed/37311149",
        "http://www.ncbi.nlm.nih.gov/pubmed/32929288",
        "http://www.ncbi.nlm.nih.gov/pubmed/36890230",
        "http://www.ncbi.nlm.nih.gov/pubmed/37062328",
        "http://www.ncbi.nlm.nih.gov/pubmed/39405926",
        "http://www.ncbi.nlm.nih.gov/pubmed/31011208",
        "http://www.ncbi.nlm.nih.gov/pubmed/34452005",
        "http://www.ncbi.nlm.nih.gov/pubmed/31631122",
        "http://www.ncbi.nlm.nih.gov/pubmed/38731892",
        "http://www.ncbi.nlm.nih.gov/pubmed/34193879",
        "http://www.ncbi.nlm.nih.gov/pubmed/35623169",
        "http://www.ncbi.nlm.nih.gov/pubmed/38754917",
        "http://www.ncbi.nlm.nih.gov/pubmed/36263174",
        "http://www.ncbi.nlm.nih.gov/pubmed/29288513",
        "http://www.ncbi.nlm.nih.gov/pubmed/38725698",
        "http://www.ncbi.nlm.nih.gov/pubmed/39692896",
        "https://pubmed.ncbi.nlm.nih.gov/36604431/",
        "http://www.ncbi.nlm.nih.gov/pubmed/38168954",
        "http://www.ncbi.nlm.nih.gov/pubmed/34067951",
        "http://www.ncbi.nlm.nih.gov/pubmed/33811047",
        "http://www.ncbi.nlm.nih.gov/pubmed/39197920",
        "http://www.ncbi.nlm.nih.gov/pubmed/39569190",
        "http://www.ncbi.nlm.nih.gov/pubmed/35570070",
        "http://www.ncbi.nlm.nih.gov/pubmed/30568305",
        "http://www.ncbi.nlm.nih.gov/pubmed/36468941",
        "http://www.ncbi.nlm.nih.gov/pubmed/39270345",
        "http://www.ncbi.nlm.nih.gov/pubmed/31819927",
        "http://www.ncbi.nlm.nih.gov/pubmed/27006495",
        "http://www.ncbi.nlm.nih.gov/pubmed/36761724",
        "http://www.ncbi.nlm.nih.gov/pubmed/33722796",
        "http://www.ncbi.nlm.nih.gov/pubmed/33476307",
        "http://www.ncbi.nlm.nih.gov/pubmed/10623795",
        "http://www.ncbi.nlm.nih.gov/pubmed/26808500",
        "http://www.ncbi.nlm.nih.gov/pubmed/29111369",
        "http://www.ncbi.nlm.nih.gov/pubmed/29253113",
        "http://www.ncbi.nlm.nih.gov/pubmed/33641576",
        "http://www.ncbi.nlm.nih.gov/pubmed/34141866",
        "http://www.ncbi.nlm.nih.gov/pubmed/26515495",
        "http://www.ncbi.nlm.nih.gov/pubmed/31344031",
        "http://www.ncbi.nlm.nih.gov/pubmed/28329770",
        "http://www.ncbi.nlm.nih.gov/pubmed/32238056",
        "http://www.ncbi.nlm.nih.gov/pubmed/38920970"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 313,
          "text": "The expression of nonsynonymous mutations results in the production of mutant proteins from tumor cells, namely tumor-specific antigens called neoantigens. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38090649"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 361,
          "text": " However, some reports have claimed recently that aberrant gene expression followed by proteome alterations and neoantigen formation ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37038186"
        },
        {
          "offsetInBeginSection": 771,
          "offsetInEndSection": 919,
          "text": "inally, we summarize the contributions of alternative splicing events to neoantigens and chemoresistance and prospects for splicing-based therapies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35339647"
        },
        {
          "offsetInBeginSection": 1633,
          "offsetInEndSection": 1744,
          "text": "Differentially spliced isoforms and splicing proteins also impact neoantigen creation and treatment resistance,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35339647"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31578439"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 319,
          "text": "This realization has motivated the interest in personal cancer vaccines based on sequencing the patient\u0027s tumor DNA to discover neoantigens. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31578439"
        },
        {
          "offsetInBeginSection": 392,
          "offsetInEndSection": 543,
          "text": "We show that errors in transcription of microsatellites (MS) and mis-splicing of exons create highly immunogenic frameshift (FS) neoantigens in tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31578439"
        },
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 174,
          "text": "Neoantigens expressed from genes with mutations acquired during carcinogenesis can be tumor-specific.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31610619"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Neoantigens are newly formed peptides created from somatic mutations that are capable of inducing tumor-specific T cell recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31462330"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 297,
          "text": "All tumors accumulate genetic alterations, some of which can give rise to mutated, non-self peptides presented by human leukocyte antigen (HLA) molecules and elicit T-cell responses. These immunogenic mutated peptides, or neoantigens, are foreign in nature and display exquisite tumor specificity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31293573"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 387,
          "text": "Neoantigens have emerged as promising targets for cutting-edge immunotherapies, such as cancer vaccines and adoptive cell therapy. These neoantigens are unique to tumors and arise exclusively from somatic mutations or non-genomic aberrations in tumor proteins. They encompass a wide range of alterations, including genomic mutations, post-transcriptomic variants, and viral oncoproteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38548414"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 482,
          "text": "Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36604431"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Neoantigens derived from somatic deoxyribonucleic acid alterations are ideal cancer-specific targets.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37311149"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Cancers accumulate mutations that lead to neoantigens, novel peptides that elicit an immune response, and consequently undergo evolutionary selection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32929288"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36890230"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Neoantigen, unique peptides resulting from tumor-specific mutations, represent a promising frontier in oncology for personalized cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39405926"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Neoantigens are tumor-specific antigens able to induce T-cell responses, generated by mutations in protein-coding regions of expressed genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34452005"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 375,
          "text": "Neo-antigens are defined as a subset of tumor-specific antigens generated by non-synonymous mutations, Indel gene mutation or gene fusions, presented by major histocompatibility complex molecules that were recognized by effector CD8+ T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31631122"
        },
        {
          "offsetInBeginSection": 575,
          "offsetInEndSection": 676,
          "text": "Alternative splicing and RNA editing events are emerging mechanisms leading to neoantigen production.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31610619"
        },
        {
          "offsetInBeginSection": 846,
          "offsetInEndSection": 1093,
          "text": "Broadly, the origin of neo-epitopes can be categorized into three groups: canonical, noncanonical, and viral neo-epitopes. For the canonical neo-antigens that arise in direct consequence of somatic mutations, we summarize past and recent findings.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38731892"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "Neoantigens are tumour-specific antigens that arise from non-synonymous mutations in tumour cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34193879"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Tumor neoantigens are aberrant polypeptides produced by tumor cells as a result of genomic mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35623169"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "BACKGROUND: Cancer neoantigens arise from protein-altering somatic mutations in tumor and rank among the most promising next-generation immuno-oncology agents when used in combination with immune checkpoint",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38754917"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 397,
          "text": "Neoantigens are tumor-specific antigens arising from somatic mutations, which are proceeded and presented by the major histocompatibility complex on the cell surface.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36263174"
        },
        {
          "offsetInBeginSection": 521,
          "offsetInEndSection": 638,
          "text": "Highly tumor-specific antigens, neoantigens, are generated by somatic mutations that are not present in normal cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29288513"
        },
        {
          "offsetInBeginSection": 261,
          "offsetInEndSection": 444,
          "text": "Neoantigens, a unique class of tumor-specific antigens generated by non-synonymous mutations, are garnering increasing attention as targets for immunotherapy in clinical applications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38725698"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Cancer-associated gene fusions serve as a potential source of highly immunogenic neoantigens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39692896"
        },
        {
          "offsetInBeginSection": 230,
          "offsetInEndSection": 482,
          "text": "Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/36604431/"
        },
        {
          "offsetInBeginSection": 653,
          "offsetInEndSection": 1021,
          "text": "In this Review, we describe various mechanisms that underlie the formation of bona fide non-mutational neoantigens, such as epitope mimicry, upregulation of cryptic epitopes, usage of non-canonical initiation codons, alternative RNA splicing, and defective ribosomal RNA processing, as well as both enzymatic and non-enzymatic post-translational protein modifications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38168954"
        },
        {
          "offsetInBeginSection": 163,
          "offsetInEndSection": 613,
          "text": "This is due to germline aberrations in the mismatch repair (MMR) genes, which results in a high mutational load in tumours of these patients, including insertions and deletions in genes bearing microsatellites. This generates microsatellite instability and cause reading frameshifts in coding regions that could lead to the generation of neoantigens and opens up avenues for neoantigen targeting immune therapies prophylactically and therapeutically.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34067951"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Disruption of splicing patterns due to mutations of genes coding splicing factors in tumors represents a potential source of tumor neoantigens, which would be both public (shared between patients) and tumor-specific (not expressed in normal tissues).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33811047"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Neoantigen is a protein produced by mutant gene, which is only expressed in tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37062328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Neoantigen is a protein produced by mutant gene, which is only expressed in tumor cells. It is an ideal target for therapeutic tumor vaccines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37062328"
        },
        {
          "offsetInBeginSection": 382,
          "offsetInEndSection": 547,
          "text": "Neoantigens are defined as tumor-specific antigens that result from a multitude of genetic alterations, the most prevalent of which is the single nucleotide variant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38920970"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 312,
          "text": "The expression of nonsynonymous mutations results in the production of mutant proteins from tumor cells, namely tumor-specific antigens called neoantigens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38090649"
        },
        {
          "offsetInBeginSection": 533,
          "offsetInEndSection": 690,
          "text": "Neoantigens most commonly arise from non-synonymous mutations but can also be derived from tumor specific alterations along the protein biosynthesis pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35570070"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt from central tolerance, can generate robust immune responses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30568305"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Neoantigens derived from mutant proteins in tumour cells could elicit potent personalized anti-tumour immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36468941"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 376,
          "text": "Neo-antigens are defined as a subset of tumor-specific antigens generated by non-synonymous mutations, Indel gene mutation or gene fusions, presented by major histocompatibility complex molecules that were recognized by effector CD8+ T cells. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31631122"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 339,
          "text": "Neoantigens are non-self-antigens produced by genetic mutations in tumor cells that induce a strong immune response against tumor cells without central immune tolerance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39197920"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Cancer neoantigens are tumor-specific non-synonymous mutant peptides that activate the immune system to produce an anti-tumor response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39270345"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Neoepitope peptides are newly formed antigens presented by major histocompatibility complex class I (MHC-I) on cell surfaces.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31819927"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 53,
          "text": "Somatic mutations in cancer give rise to neoantigens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27006495"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 312,
          "text": "The non-synonymous mutations in the tumor cell genome will produce non-autologous proteins (neoantigen) to activate the immune system by activating CD4+ and CD8+ T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36761724"
        },
        {
          "offsetInBeginSection": 135,
          "offsetInEndSection": 328,
          "text": "A subset of tumor-specific somatic mutations can be translated into immunogenic and HLA-bound epitopes called neoantigens, which can induce the activation of helper and cytotoxic T lymphocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33722796"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Neoantigens generated by somatic nonsynonymous mutations are key targets of tumor-specific T cells,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33476307"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "Neoantigens resulting from the inherent genomic instability of tumor cells generally do not trigger immune recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10623795"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "In successful cancer immunotherapy, T cell responses appear to be directed toward neoantigens created by somatic mutations; however, direct evidence that neoantigen-specific T cells cause regression of established cancer is lacking.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26808500"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Neoantigens arise from somatic mutations that differ from wild-type antigens and are specific to each individual patient, which provide tumor specific targets for developing personalized cancer vaccines.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29111369"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Cancer neoantigens are antigens that result from somatic mutations present in individual cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29253113"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "INTRODUCTION: Derived from genetic alterations, cancer neoantigens are proteins with novel amino acid sequences that can be recognized by the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33641576"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Neoantigens are tumor-specific antigens that arise due to somatic mutations in the DNA of tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34141866"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 258,
          "text": "Tumor-specific antigens that are generated by somatic mutation, neoantigens, can influence patient response to immunotherapy and contribute to tumor shrinkage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515495"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Somatic mutations in tumor cells give rise to mutant proteins, fragments of which are often presented by MHC and serve as neoantigens.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39569190"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Somatic mutations in protein-coding regions can generate \u0027neoantigens\u0027 causing developing cancers to be eliminated by the immune system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31344031"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28329770"
        },
        {
          "offsetInBeginSection": 188,
          "offsetInEndSection": 311,
          "text": "Here, we demonstrate that gene fusions are a source of immunogenic neoantigens that can mediate responses to immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31011208"
        },
        {
          "offsetInBeginSection": 278,
          "offsetInEndSection": 379,
          "text": "ll continues. Neoantigens are the tumor-specific antigens which arise due to somatic mutations in the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32238056"
        }
      ],
      "type": "summary",
      "id": "67c9e48f81b1027333000005",
      "ideal_answer": [
        "The expression of nonsynonymous mutations results in the production of mutant proteins from tumor cells, namely tumor-specific antigens called neoantigens. Alternate splicing and abberant transcription can also create neoantigens.",
        "Neoantigens are newly formed peptides created from somatic mutations that are capable of inducing tumor-specific T cell recognition.",
        "Neoantigens are novel peptide sequences that arise from mutations in the tumor cell\u0027s DNA, which lead to changes in the amino acid sequence of expressed proteins. These mutated proteins are processed and presented on the cell surface by major histocompatibility complex (MHC) molecules, where they can be recognized as foreign by the immune system and elicit an anti-tumor immune response. Neoantigens can originate from various sources beyond chromosomal DNA mutations, such as transcriptional alterations, RNA editing, and post-translational modifications.",
        "A neoantigen is created when a tumor cell undergoes genetic mutations that result in the production of new, abnormal proteins. These proteins, which are not present in normal cells, can be recognized by the immune system as foreign, leading to an immune response. The mutations can occur in various forms, such as point mutations, insertions, deletions, or gene fusions, which alter the amino acid sequence of the protein, creating a novel antigenic determinant.",
        "A neoantigen is created through a multi-step process in cancer cells. It begins with a somatic mutation or genetic alteration, leading to the production of altered proteins (mutated, fused, or aberrantly spliced). These proteins are then processed into peptides, which are presented on the cancer cell surface via Human Leukocyte Antigen (HLA) molecules. This presentation triggers a tumor-specific T cell response. Various alterations, including genomic mutations and disordered post-translational modifications, can lead to neoantigen creation, which is identified using next-generation sequencing technologies, making neoantigens promising targets for personalized cancer immunotherapies.",
        "Neoantigens are primarily created through somatic mutations in cancer cells, which lead to the production of new peptides presented on the tumor cell surface by major histocompatibility complex (MHC) molecules. Additionally, neoantigens can be generated through post-translational modifications and other biochemical processes, such as oxidation, glycoengineering, and RNA editing, which alter existing proteins or peptides, making them recognizable as foreign by the immune system.",
        "A neoantigen is created when a mutation in a tumor cell\u0027s DNA leads to the production of a new protein that is recognized as foreign by the immune system.",
        "A neoantigen is created by tumor cells through various tumor-specific alterations, such as genomic mutations, dysregulated RNA splicing, and disordered post-translational modifications, leading to the formation of new peptides that can be recognized by the immune system. These neoantigens are often derived from somatic mutations or fusion proteins and are presented on the cell surface in complex with human leukocyte antigens, allowing for T cell recognition and potential immune response against the tumor.",
        "Neoantigens are created as a result of tumor-specific alterations such as genomic mutations, dysregulated RNA splicing, disordered post-translational modifications, and integration of viral open reading frames. These alterations lead to the formation of novel peptide sequences that are presented by human leukocyte antigens (HLAs) on the surface of cancer cells, making them recognizable by the immune system.",
        "A neoantigen is created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface.",
        "A neoantigen is created from somatic mutations, non-synonymous mutations, indel gene mutations, gene fusions, and other tumor-specific alterations that lead to the formation of new peptides recognized as non-self by the immune system.",
        "A neoantigen is created through somatic mutations or tumor-specific alterations (including genomic mutations, dysregulated RNA splicing, and post-translational modifications) that result in the formation of new, aberrant proteins (mutated, fusion, or derived from viral sources) exclusively expressed in tumor cells, which are then recognized as non-self by the immune system.",
        "A neoantigen is created through tumor-specific alterations such as genomic mutations, dysregulated RNA splicing, disordered post-translational modifications, or integrated viral open reading frames. These changes generate newly formed peptides that can be presented on the cancer cell surface by human leukocyte antigens, enabling immune system recognition and targeting.",
        "A neoantigen is created through cancer-specific mutations such as somatic mutations, point mutations, frameshift mutations, gene fusions, and other genetic alterations that result in tumor-specific antigens recognized as foreign by the immune system.",
        "The expression of nonsynonymous mutations results in the production of mutant proteins from tumor cells, namely tumor-specific antigens called neoantigens.",
        "Neoantigens are created from mutant proteins produced by tumor cells due to nonsynonymous mutations resulting from somatic mutations. Errors in transcription of microsatellites and mis-splicing of exons can also create frameshift neoantigens. They can also be created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface. Additionally, hapten-peptide conjugates generated by covalent inhibitors can create distinct neoantigens.",
        "A neoantigen is created through genetic alterations in cancer cells via multiple key mechanisms. Primarily, this includes (1) somatic mutations leading to mutant proteins, and (2) alternative RNA splicing defects resulting in aberrant protein isoforms. Additionally, errors in transcription and splicing, such as microsatellite transcription errors and exon mis-splicing, generate highly immunogenic frameshift neoantigens. In specific contexts, like iPSCs, aberrant gene expression with subsequent proteome alterations can also lead to neoantigen formation. These mechanisms collectively produce tumor-specific antigens recognized as foreign by the immune system, potentially triggering antitumor responses.",
        "Neoantigens are created through several mechanisms. They can arise from non-synonymous mutations in tumor cells, which are then translated into mutant proteins. Genetic instability in tumor cells can lead to numerous mutations, with the expression of non-synonymous mutations producing tumor-specific antigens. Errors in transcription and mis-splicing of exons can also create frameshift neoantigens. Additionally, non-canonical neoantigens can arise from the untranslated regions (UTR) of the genome. Aberrant gene expression followed by proteome alterations can also lead to neoantigen formation. Cancer-associated gene fusions and differentially spliced isoforms can also serve as sources of neoantigens.",
        "Neoantigens are created through the expression of nonsynonymous mutations in tumor cells, leading to the production of mutant proteins.",
        "Neoantigens are created through the expression of nonsynonymous mutations, aberrant gene expression, errors in transcription of microsatellites (MS) and mis-splicing of exons.",
        "Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames.",
        "Neoantigens are created from mutant proteins produced by tumor cells due to nonsynonymous mutations. Errors in transcription and mis-splicing of exons can also create frameshift neoantigens in tumors. Aberrant gene expression followed by proteome alterations can also lead to neoantigen formation.",
        "A neoantigen is created through the expression of nonsynonymous mutations in tumor cells, which results in the production of mutant proteins. These mutant proteins can be generated by errors in transcription of microsatellites (MS) and mis-splicing of exons, leading to frameshift (FS) neoantigens. These FS neoantigens are highly immunogenic and can be used in personal cancer vaccines.",
        "{\"ideal_answer\": \"Neoantigens are created through the expression of nonsynonymous mutations, which result in the production of mutant proteins from tumor cells. These tumor-specific antigens are called neoantigens.\"}",
        "Neoantigens are created from cancer-specific aberrant proteins, such as mutated and fusion proteins. Nonsynonymous mutations result in mutant proteins from tumor cells, which are tumor-specific antigens called neoantigens. Errors in transcription of microsatellites and mis-splicing of exons create highly immunogenic frameshift neoantigens in tumors. Aberrant gene expression followed by proteome alterations can also lead to neoantigen formation. Differentially spliced isoforms and splicing proteins also impact neoantigen creation. Covalent inhibitors can generate hapten-peptide conjugates, creating distinct neoantigens that selectively mark cancer cells.",
        "Neoantigens are created through genetic mutations in tumor cells that result in the production of mutant proteins. These mutations can be nonsynonymous, leading to changes in the amino acid sequence of proteins, or can arise from errors in RNA transcription and splicing, such as transcription of microsatellites and mis-splicing of exons, which create frameshift neoantigens.",
        "A neoantigen is created through the expression of nonsynonymous mutations in tumor cells. These mutations lead to changes in the amino acid sequence of proteins, resulting in the production of mutant proteins that are recognized as tumor-specific antigens, known as neoantigens.",
        "Neoantigens are created when nonsynonymous mutations result in the production of mutant proteins from tumor cells. Aberrant gene expression followed by proteome alterations can also lead to neoantigen formation. Errors in transcription and mis-splicing can also create frameshift neoantigens in tumors.",
        "A neoantigen is created through various mechanisms including the expression of nonsynonymous mutations, aberrant gene expression with proteome alterations, alternative splicing events, errors in RNA transcription, and mis-splicing of exons, particularly errors in transcription of microsatellites, all of which lead to the production of unique, tumor-specific mutant proteins or highly immunogenic frameshift neoantigens.",
        "Neoantigens are created as a result of mutations in genes, leading to changes in the coding sequence of proteins. These mutations can result in the production of mutant proteins, which are recognized by the immune system as foreign antigens. Additionally, alternative splicing events can also contribute to neoantigen creation and treatment resistance. Finally, frameshift neoantigens can be created through errors in transcription of microsatellites and mis-splicing of exons.",
        "Neoantigens are created through several mechanisms. Nonsynonymous mutations in tumor cells result in mutant proteins, which are tumor-specific antigens called neoantigens. Errors in transcription of microsatellites and mis-splicing of exons can also create frameshift neoantigens in tumors. Additionally, aberrant gene expression followed by proteome alterations can result in neoantigen formation in induced pluripotent stem cells (iPSCs). Differentially spliced isoforms and splicing proteins also impact neoantigen creation.",
        "Neoantigens are tumor-specific antigens produced from mutant proteins due to nonsynonymous mutations in tumor cells. Additionally, errors in the transcription of microsatellites and mis-splicing of exons can create highly immunogenic frameshift neoantigens. Differentially spliced isoforms also contribute to the creation of these neoantigens.",
        "Neoantigens are created when nonsynonymous mutations result in the production of mutant proteins from tumor cells. Also, errors in transcription of microsatellites (MS) and mis-splicing of exons create highly immunogenic frameshift (FS) neoantigens in tumors."
      ]
    },
    {
      "body": "Causes of sudden deafness.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35399426",
        "http://www.ncbi.nlm.nih.gov/pubmed/37395946",
        "http://www.ncbi.nlm.nih.gov/pubmed/38850720",
        "http://www.ncbi.nlm.nih.gov/pubmed/36299969",
        "http://www.ncbi.nlm.nih.gov/pubmed/34403091",
        "http://www.ncbi.nlm.nih.gov/pubmed/31714154",
        "http://www.ncbi.nlm.nih.gov/pubmed/16730540",
        "http://www.ncbi.nlm.nih.gov/pubmed/10064991",
        "http://www.ncbi.nlm.nih.gov/pubmed/9549148",
        "http://www.ncbi.nlm.nih.gov/pubmed/36805978",
        "http://www.ncbi.nlm.nih.gov/pubmed/12450172",
        "http://www.ncbi.nlm.nih.gov/pubmed/12185871",
        "https://pubmed.ncbi.nlm.nih.gov/17334320/",
        "http://www.ncbi.nlm.nih.gov/pubmed/3140670",
        "http://www.ncbi.nlm.nih.gov/pubmed/9489150",
        "http://www.ncbi.nlm.nih.gov/pubmed/17143437"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "text": "OBJECTIVE: Sudden deafness, in most cases, has no apparent cause. In some cases viral infection, vascular occlusion, or a cochlear membrane rupture may be responsible for the sudden loss ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730540"
        },
        {
          "offsetInBeginSection": 446,
          "offsetInEndSection": 614,
          "text": "The most frequent reason for sudden hearing loss was vascular factors (50%), next viral infections (25%), acoustic trauma (10%), allergy (5%), and unknown causes (10%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10064991"
        },
        {
          "offsetInBeginSection": 1040,
          "offsetInEndSection": 1369,
          "text": "nd 14,3%, and vertigo in 6,3% and in 1,4%. In own research, the most common cause of sudden hearing loss/deafness in women and men was respectively: idiopathic cause in 43,8% and 40,0%, infectious in 18,8%, vascular in 12,4% and 12,9%, and neurovascular conflict (included separately) in 12,4% and 12,9%, while in men the acousti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36805978"
        },
        {
          "offsetInBeginSection": 689,
          "offsetInEndSection": 886,
          "text": "Proposed aetiologies of primary SD comprised viral infection, vascular insufficiency, autoimmune disorder and stress theory, while causes of secondary SSHL include neoplasm, stroke and irradiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31714154"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 272,
          "text": "Three causes are accepted as source of sudden deafness: viral infections, the tear away of labyrinthine membranes and the vascular theory.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9549148"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "text": "Sudden sensorineural hearing loss (SNHL) caused by intralabyrinthine hemorrhage is a rare entity usually associated to patients with previous pathological factors, such as blood dyscrasias, anticoagulant therapy and local hemorrhagic pathologies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12185871"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 455,
          "text": " In some cases viral infection, vascular occlusion, or a cochlear membrane rupture may be responsible for the sudden loss of hearing. In this study, we analyzed etiology, audiologic, psychiatric, and clinical aspects of psychogenic sudden deafness through a retrospective chart review. Patients included were thought to have sudden deafness as a result of psychogenic causes and/or stresses",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16730540"
        },
        {
          "offsetInBeginSection": 52,
          "offsetInEndSection": 295,
          "text": "Classically, 2 causes, viral and vascular, are considered in the origin of idiopathic sudden hearing loss. More recently added to the list of possibilities are rupture of the membranous labyrinth and immune-mediated sensorineural hearing loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12450172"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 318,
          "text": "OBJECTIVES: Idiopathic sudden sensorineural hearing loss (ISSNHL) is a frequently encountered condition, and various pathogenetic mechanisms have been hypothesized, such as viral infections, autoimmune processes, and ischemic events; however, whatever the cause, impaired cochlear perfusion appears to be the most impo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/17334320/"
        },
        {
          "offsetInBeginSection": 1086,
          "offsetInEndSection": 1415,
          "text": "own research, the most common cause of sudden hearing loss/deafness in women and men was respectively: idiopathic cause in 43,8% and 40,0%, infectious in 18,8%, vascular in 12,4% and 12,9%, and neurovascular conflict (included separately) in 12,4% and 12,9%, while in men the acoustic trauma should also be mentioned in 18,5%. Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36805978"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Etiologic theories of idiopathic SHL include viral infection, autoimmune disease, vascular insult, and labyrinthine membrane rupture.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3140670"
        },
        {
          "offsetInBeginSection": 303,
          "offsetInEndSection": 519,
          "text": "Several etiopathogenic factors have been postulated, such as viral infection, autoimmune origin, vascular and metabolic disease, rupture of the labyrinthine membrane, and, recently, immune-mediated inner ear disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9489150"
        },
        {
          "offsetInBeginSection": 240,
          "offsetInEndSection": 487,
          "text": "The most recent studies concerning the possible causes of sudden hearing loss suggest vascular disorders, rupture of the inner ear membrane and autoimmune diseases; however, viral infections have received a great deal of attention in recent years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17143437"
        }
      ],
      "id": "67d7219018b1e36f2e000030",
      "ideal_answer": [
        "Sudden deafness, also known as sudden sensorineural hearing loss (SSNHL), can be attributed to various causes, including viral infections, vascular factors, idiopathic causes, inflammatory processes, acoustic trauma, and other miscellaneous causes. Viral infections are implicated in about one-third of SSNHL cases, while vascular issues account for approximately 50%. Idiopathic SSNHL, where the cause remains unknown, is the most common category. Inflammatory processes, such as elevated levels of complement components and inflammatory cytokines, also play a role. Acoustic trauma is a significant cause, particularly in men, accounting for about 10% of cases. Other causes include psychogenic disorders, disseminated encephalitis, syphilitic labyrinthitis, Cogan\u0027s syndrome, meningitis, acoustic neuroma, rupture of the round window membrane, epidemic parotitis, and tumors of the cerebellopontine angle. Genetic factors, such as mutations in genes like GJB2, MTHFR, ApoE, and interleukin-1 gene polymorphisms, have been associated with SSNHL. Metabolic and systemic conditions, including type 2 diabetes, Ménière disease, and vestibular schwannoma, are also linked to sudden hearing loss. Comprehensive diagnostic evaluation is essential to identify the underlying cause and guide appropriate treatment.",
        "Sudden deafness, known as sudden sensorineural hearing loss (SSHL), often has idiopathic causes, meaning the cause is unknown. However, several known factors contribute to its development. These include vascular issues such as cochlear ischemia or infarction, particularly from occlusion of the vestibulo cochlear artery (VCA). Autoimmune diseases and infections are also implicated, alongside functional, metabolic, and neurological disorders. Traumatic events, exposure to toxins, and other vascular problems can also lead to sudden deafness. There is a noted hereditary component in some Chinese populations, though its genetic mechanisms are complex. Viral infections, vascular insufficiency, autoimmune disorders, and stress are primary contributors, while secondary causes include tumors, strokes, and radiation.",
        "The causes of sudden deafness, also known as sudden sensorineural hearing loss (SSNHL), are often multifactorial and can be broadly categorized into primary and secondary causes. Primary causes include viral infections (e.g., herpes simplex virus or varicella zoster virus), vascular insufficiency (e.g., cochlear ischemia due to occlusion of the vestibulo cochlear artery), autoimmune disorders, and stress related factors. Secondary causes are those that arise as a result of other underlying conditions, such as neoplasms affecting the auditory pathway, strokes causing brainstem or cerebellar injuries, or irradiation exposure. Other contributing factors include infections (e.g., meningitis, labyrinthitis), metabolic disorders, traumatic injury to the ear, and toxic exposure to ototoxic chemicals or medications. Additionally, SSNHL has been associated with hereditary factors in certain populations, though its genetic mechanisms are complex and not fully understood.",
        "Sudden deafness can result from a variety of factors. Commonly, both viral infections and vascular issues are implicated, with evidence pointing to microvascular events, thrombosis, embolism, or vasospasm leading to impaired cochlear perfusion. Immune-mediated damage is another suggested cause, involving either autoimmune processes or inflammation secondary to infection. Inner ear bleeding, such as labyrinthine hemorrhage, has also been recognized, particularly once diagnostic imaging became available. Other potential causes include infections like Mycoplasma pneumoniae and even retroviral involvement. In some cases, exposure to certain toxins, medications, or underlying conditions such as chronic leukemia may trigger sudden sensorineural hearing loss. Despite these identified mechanisms, many cases remain idiopathic, where no clear etiology can be determined.",
        "The etiology of sudden deafness is varied and often remains undetermined. While in many cases no apparent cause is identified, potential factors include viral infections, vascular events such as cochlear ischemia or occlusion of the vestibulo-cochlear artery, autoimmune disorders, and inner ear issues like cochlear membrane rupture. Other suggested causes encompass metabolic diseases, traumatic events, toxins, neurological disorders, and even stress. Some research indicates a possible hereditary component in certain populations. It\u0027s important to note that sudden hearing loss can be a symptom of underlying conditions affecting the inner ear or the entire body.",
        "Sudden deafness can arise from multiple causes, with many cases remaining idiopathic (unknown cause), while identified causes include vascular issues like cochlear ischemia and vestibulo-cochlear artery occlusion, viral infections, autoimmune disorders, and stress. Secondary causes encompass neoplasms, stroke, metabolic disorders, trauma, toxin exposure, and neurological conditions, with some evidence suggesting genetic factors may play a role in certain populations."
      ],
      "exact_answer": [
        [
          "idiopatic"
        ],
        [
          "complex genetic pathogenic mechanisms"
        ],
        [
          "vascular insufficiency autoimmune disorder"
        ],
        [
          "stroke"
        ],
        [
          "irradiation"
        ],
        [
          "viral infection"
        ],
        [
          "neoplasm"
        ],
        [
          "stress"
        ],
        [
          "autoimmune disorder"
        ],
        [
          "neurological disorders"
        ],
        [
          "cochlear ischemia"
        ],
        [
          "cochlear infarction"
        ],
        [
          "toxins"
        ],
        [
          "traumatic causes"
        ],
        [
          "metabolic diseases"
        ]
      ]
    },
    {
      "body": "Which types of data does the EURO-NMD registry capture?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38355534"
      ],
      "type": "list",
      "snippets": [
        {
          "offsetInBeginSection": 352,
          "offsetInEndSection": 813,
          "text": "The registry has three-layered datasets, with European Commission-mandated data elements (EU-CDEs), a set of cross-neuromuscular data elements (NMD-CDEs) and a dataset of disease-specific data elements that function modularly (DS-DEs). The registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data and patient-reported outcomes in a computer-interpretable format using selected ontologies and classifications. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38355534"
        }
      ],
      "id": "67d74dd718b1e36f2e00003d",
      "ideal_answer": [
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data and patient-reported outcomes in a computer-interpretable format using selected ontologies and classifications.",
        "The EURO-NMD registry captures a wide range of data types related to neuromuscular diseases. This includes clinical data such as patient demographics, disease diagnosis, progression, and treatment outcomes. It also collects genetic data, which involves information on genetic mutations and variations associated with neuromuscular conditions. Additionally, the registry may include data on biomarkers, imaging results, and other laboratory findings that are relevant to the diagnosis and management of neuromuscular diseases. The registry aims to provide a comprehensive dataset to facilitate research and improve clinical care for patients with these conditions.",
        "The EURO-NMD registry captures a comprehensive range of data types, including clinical, neuromuscular imaging, neuromuscular histopathology, biological, genetic data, and patient-reported outcomes. These data are collected in a computer-interpretable format, utilizing selected ontologies and classifications, and structured into a three-layered dataset: European Commission-mandated data elements (EU-CDEs), cross-neuromuscular data elements (NMD-CDEs), and modular disease-specific data elements (DS-DEs). This setup facilitates a better understanding of neuromuscular diseases, aids in research, trial readiness, and is connected to the EURO-NMD Registry Hub for interoperable and compliant information exchange.",
        "The EURO-NMD registry captures a variety of data types relevant to rare neuromuscular disorders, including clinical data, genetic data, neuromuscular imaging data, neuromuscular histopathology data, biological data, patient-reported outcomes, and diagnostic and therapeutic data. This comprehensive data collection supports the understanding, diagnosis, and treatment of neuromuscular conditions and facilitates data sharing and patient case discussions through the Clinical Patient Management System (CPMS) platform.",
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data and patient-reported outcomes in a computer-interpretable format using selected ontologies and classifications. The registry has three-layered datasets, with European Commission-mandated data elements (EU-CDEs), a set of cross-neuromuscular data elements (NMD-CDEs) and a dataset of disease-specific data elements that function modularly (DS-DEs).",
        "The EURO-NMD registry captures clinical data, neuromuscular imaging data, neuromuscular histopathology data, biological and genetic data, and patient-reported outcomes. These data are stored in a computer-interpretable format that uses selected ontologies and classifications.",
        "The EURO-NMD registry captures clinical data, neuromuscular imaging, neuromuscular histopathology, biological and genetic data, and patient-reported outcomes from neuromuscular patients seen at EURO-NMD\u0027s expert centers. This data is stored in a computer-interpretable format.",
        "The EURO-NMD registry captures various types of data including clinical data, neuromuscular imaging, neuromuscular histopathology, biological data, genetic data, and patient-reported outcomes.",
        "The EURO-NMD registry captures a wide range of data types related to neuromuscular diseases. This includes clinical data such as patient demographics, disease diagnosis, progression, and treatment outcomes. It also collects genetic data, including information on specific mutations and genetic testing results. Additionally, the registry may gather data on biomarkers, imaging results, and other laboratory findings that are relevant to the diagnosis and management of neuromuscular disorders. The registry aims to facilitate research and improve patient care by providing a comprehensive dataset for analysis.",
        "The EURO-NMD registry captures a broad spectrum of data, including clinical, neuromuscular imaging, histopathology, biological, genetic, and patient-reported outcomes. These data are stored in a computer-interpretable format, structured into three tiers: EU-CDEs, NMD-CDEs, and DS-DEs. This setup enhances understanding of neuromuscular diseases, supports research, and ensures interoperability while adhering to FAIR principles and GDPR compliance, ultimately advancing neuromuscular disease healthcare and research.",
        "The registry captures clinical data, neuromuscular imaging and histopathology findings, biological and genetic information, and patient-reported outcomes.",
        "The EURO-NMD registry captures the following types of data: clinical, neuromuscular imaging, neuromuscular histopathology, biological, genetic, and patient-reported outcomes.",
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data, and patient-reported outcomes in a computer-interpretable format using selected ontologies and classifications. The registry collects data from all neuromuscular patients seen at EURO-NMD\u0027s expert centres. It has three-layered datasets, with European Commission-mandated data elements (EU-CDEs), a set of cross-neuromuscular data elements (NMD-CDEs) and a dataset of disease-specific data elements that function modularly (DS-DEs).",
        "The EURO-NMD registry captures various data types relevant to neuromuscular diseases, including clinical information, neuromuscular imaging data, histopathological data specific to neuromuscular diseases, biological samples and genetic information, patient-reported outcomes, and information on diagnostics and treatments. The data is stored in a computer-interpretable format using selected ontologies and classifications and is securely shared via the Clinical Patient Management System (CPMS) platform.",
        "The EURO-NMD registry captures multiple types of comprehensive data across different domains, including clinical information, neuromuscular imaging, neuromuscular histopathology, biological data, genetic data, and patient-reported outcomes. These data are collected using standardized data elements from European Commission mandates, cross-neuromuscular domains, and disease-specific modules.",
        "The EURO NMD registry captures a comprehensive range of data types, including clinical data, neuromuscular imaging findings, neuromuscular histopathology results, biological and genetic information, as well as patient reported outcomes. The registry uses a structured approach with datasets organized into three layers: European Commission mandated data elements (EU CDEs), cross neuromuscular data elements (NMD CDEs), and disease specific modular datasets (DS DEs). All data are recorded in a computer interpretable format, utilizing selected ontologies and classifications to ensure standardization and interoperability.",
        "The EURO-NMD registry captures a wide range of data, including clinical, neuromuscular imaging, neuromuscular histopathology, biological, genetic, and patient-reported outcomes. This comprehensive dataset is collected in a computer-interpretable format, utilizing selected ontologies and classifications to ensure standardization and ease of analysis. By gathering such diverse types of data, the registry provides a rich resource for studies on neuromuscular diseases, enabling researchers to explore various aspects of these conditions and ultimately contributing to improved understanding and management of these disorders.",
        "The EURO-NMD registry captures a wide range of data including clinical information, neuromuscular imaging, histopathology, biological and genetic data, and patient-reported outcomes.",
        "The types of data the EURO-NMD registry captures are clinical data, neuromuscular imaging, neuromuscular histopathology, biological data, and genetic data.",
        "Clinical, neuromuscular imaging, neuromuscular histopathology, biological, genetic, patient-reported outcomes",
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data and patient-reported outcomes.",
        "The EURO-NMD registry captures patient-reported outcomes, genetic data, clinical data, neuromuscular imaging, neuromuscular histopathology, and biological data.",
        "The EURO-NMD registry captures a comprehensive range of data types, including clinical, neuromuscular imaging, neuromuscular histopathology, biological, genetic data, and patient-reported outcomes. The registry is structured with three layers of datasets: European Commission-mandated data elements (EU-CDEs), cross-neuromuscular data elements (NMD-CDEs), and disease-specific data elements (DS-DEs) that function modularly. All data are recorded in a computer-interpretable format using selected ontologies and classifications, ensuring standardized and interoperable data collection.",
        "The EURO-NMD registry captures several types of data, including clinical data, neuromuscular imaging, neuromuscular histopathology, biological data, genetic data, and patient-reported outcomes. These data are organized into three-layered datasets: European Commission-mandated data elements (EU-CDEs), cross-neuromuscular data elements (NMD-CDEs), and disease-specific data elements (DS-DEs). The registry stores this information in a computer-interpretable format using selected ontologies and classifications.",
        "The EURO-NMD registry collects clinical data, neuromuscular imaging, neuromuscular histopathology, biological and genetic data, and patient-reported outcomes. It uses a layered approach with European Commission-mandated data elements, cross-neuromuscular data elements, and modular disease-specific data elements in a computer-interpretable format.",
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data. It also captures patient-reported outcomes in a computer-interpretable format.",
        "The EURO-NMD registry captures several types of data, including clinical data, neuromuscular imaging data, neuromuscular histopathology data, biological data, genetic data, and patient-reported outcomes. These datasets are organized into three layers: European Commission-mandated data elements (EU-CDEs), cross-neuromuscular data elements (NMD-CDEs), and disease-specific data elements (DS-DEs). The registry stores this information in a computer-interpretable format using selected ontologies and classifications, facilitating standardized analysis and sharing.",
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data, and patient-reported outcomes in a computer-interpretable format using selected ontologies and classifications.",
        "The EURO-NMD registry captures several types of data, including clinical data, neuromuscular imaging, neuromuscular histopathology, biological data, genetic data, and patient-reported outcomes. These datasets are organized into three layers: European Commission-mandated data elements (EU-CDEs), cross-neuromuscular data elements (NMD-CDEs), and disease-specific data elements (DS-DEs). The registry stores this information in a computer-interpretable format using selected ontologies and classifications to facilitate analysis and sharing.",
        "The EURO-NMD registry captures clinical data, neuromuscular imaging, neuromuscular histopathology, biological and genetic data, and patient-reported outcomes, stored in a computer-interpretable format using selected ontologies and classifications.",
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data, as well as patient-reported outcomes. These datasets are organized into three layers: European Commission-mandated data elements (EU-CDEs), cross-neuromuscular data elements (NMD-CDEs), and disease-specific data elements (DS-DEs). The registry stores this information in a computer-interpretable format using selected ontologies and classifications.",
        "The EURO-NMD registry captures various types of data including clinical data, neuromuscular imaging data, neuromuscular histopathology data, biological data, genetic data, and patient-reported outcomes.",
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data, as well as patient-reported outcomes, all in a computer-interpretable format using selected ontologies and classifications.",
        "The EURO-NMD registry captures various types of data, including clinical, neuromuscular imaging, neuromuscular histopathology, biological, genetic, and patient-reported outcomes in a computer-interpretable format.",
        "The EURO-NMD registry captures various types of data, including clinical data, neuromuscular imaging, neuromuscular histopathology, biological data, genetic data, and patient-reported outcomes.",
        "The EURO-NMD registry captures the following types of data: clinical data, neuromuscular imaging data, neuromuscular histopathology data, biological data, genetic data, and patient-reported outcomes.",
        "The EURO-NMD registry captures clinical, imaging, histopathology, biological, genetic data, and patient-reported outcomes.",
        "The EURO-NMD registry captures a comprehensive set of data, including clinical, neuromuscular imaging, neuromuscular histopathology, biological, genetic data, and patient-reported outcomes. These data are structured within a three-tiered framework comprising European Commission-mandated data elements (EU-CDEs), cross-neuromuscular data elements (NMD-CDEs), and disease-specific data elements (DS-DEs), and are stored in a computer-interpretable format utilizing standardized ontologies and classifications, facilitating in-depth research and treatment of neuromuscular diseases.",
        "The EURO-NMD registry captures a comprehensive range of data types, including clinical data, neuromuscular imaging data, neuromuscular histopathology data, biological data, genetic data, and patient-reported outcomes. These data are organized in a computer-interpretable format using selected ontologies and classifications. The registry is structured with three-layered datasets: European Commission-mandated data elements (EU-CDEs), cross-neuromuscular data elements (NMD-CDEs), and disease-specific data elements (DS-DEs) that function modularly.",
        "The registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data and patient-reported outcomes in a computer-interpretable format using selected ontologies and classifications.",
        "The EURO NMD registry captures a comprehensive range of data types, including clinical information, neuromuscular imaging findings, histopathology results, biological and genetic data, as well as patient reported outcomes. These datasets are structured into three main layers: European Commission mandated data elements (EU CDEs), cross neuromuscular data elements (NMD CDEs), and disease specific modular datasets (DS DEs). The registry utilizes selected ontologies and classifications to ensure the data is computer interpretable.",
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data. It also captures patient-reported outcomes. The data is in a computer-interpretable format.",
        "The EURO-NMD registry captures multiple types of data including clinical data, neuromuscular imaging data, neuromuscular histopathology data, biological data, genetic data, and patient-reported outcomes. These data are captured in a computer-interpretable format using selected ontologies and classifications, allowing for comprehensive documentation of neuromuscular disease information across different domains.",
        "The EURO-NMD registry captures a comprehensive range of data types, including clinical information, neuromuscular imaging results, histopathological findings, biological samples, genetic data, and patient-reported outcomes. These datasets are organized into three layers: EU-CDEs (European Commission-mandated), NMD-CDEs (cross-neuromuscular), and DS-DEs (disease-specific modules). This structured approach ensures that the registry collects detailed and standardized information to support research and clinical applications in neuromuscular diseases.",
        "The EURO-NMD registry captures clinical data, neuromuscular imaging data, neuromuscular histopathology data, biological data, genetic data, and patient-reported outcomes data in a computer-interpretable format using selected ontologies and classifications.",
        "The registry captures clinical data, neuromuscular imaging, neuromuscular histopathology, biological data, and genetic data. It also includes patient-reported outcomes as well as diagnostic and therapeutic data. The system uses standardized data elements to ensure the information is computer-interpretable and suitable for a range of applications such as assessing natural history, monitoring care standards, and evaluating genotype-phenotype correlations.",
        "The EURO-NMD registry captures a broad range of data types, including clinical, neuromuscular imaging, neuromuscular histopathology, biological, genetic data, and patient-reported outcomes, all formatted for computer interpretation using standardized ontologies and classifications.",
        "The EURO-NMD registry captures patient-reported outcomes, neuromuscular imaging, neuromuscular histopathology, genetic data, clinical data and biological data.",
        "The EURO-NMD Registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data, and patient-reported outcomes. The registry utilizes a three-layered dataset approach, incorporating European Commission-mandated data elements (EU-CDEs), cross-neuromuscular data elements (NMD-CDEs), and disease-specific data elements (DS-DEs) that function modularly. The data is stored in a computer-interpretable format using selected ontologies and classifications.",
        "The EURO-NMD registry captures a comprehensive range of data including clinical information, neuromuscular imaging, histopathology, biological and genetic data, as well as patient-reported outcomes, all stored in a computer-interpretable format using specific ontologies and classifications.",
        "The EURO-NMD registry captures clinical, neuromuscular imaging, neuromuscular histopathology, biological and genetic data, and patient-reported outcomes."
      ],
      "exact_answer": [
        [
          "clinical"
        ],
        [
          "neuromuscular imaging"
        ],
        [
          "neuromuscular histopathology"
        ],
        [
          "biological and genetic data"
        ],
        [
          "patient-reported outcomes"
        ]
      ]
    },
    {
      "body": "What tissue is the origin of adnexal masses.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39717671",
        "http://www.ncbi.nlm.nih.gov/pubmed/37550825",
        "http://www.ncbi.nlm.nih.gov/pubmed/38378017",
        "http://www.ncbi.nlm.nih.gov/pubmed/8179941",
        "http://www.ncbi.nlm.nih.gov/pubmed/27776067",
        "http://www.ncbi.nlm.nih.gov/pubmed/27776072",
        "http://www.ncbi.nlm.nih.gov/pubmed/31489290",
        "http://www.ncbi.nlm.nih.gov/pubmed/16386783",
        "http://www.ncbi.nlm.nih.gov/pubmed/24925054",
        "http://www.ncbi.nlm.nih.gov/pubmed/17538485",
        "http://www.ncbi.nlm.nih.gov/pubmed/17417086",
        "http://www.ncbi.nlm.nih.gov/pubmed/33642152",
        "https://pubmed.ncbi.nlm.nih.gov/27776072/",
        "http://www.ncbi.nlm.nih.gov/pubmed/28174801",
        "http://www.ncbi.nlm.nih.gov/pubmed/16082146",
        "http://www.ncbi.nlm.nih.gov/pubmed/21629623",
        "http://www.ncbi.nlm.nih.gov/pubmed/9503522",
        "http://www.ncbi.nlm.nih.gov/pubmed/32736853"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 148,
          "text": "Tumors and tumor-like lesions of the uterine adnexa in children and adolescents are uncommon but may carry devastating consequences. M",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38378017"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "The ovarian-adnexal reporting and data system on magnetic resonance imaging (O-RADS MRI) score is now a well-established tool to characterize pelvic gynecological masses based on their likelihood of malignancy",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37550825"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Anatomically, the adnexa encompasses the region within the pelvis that includes the ovary, fallopian tube, round ligament, and structures arising from associated embryologic rests.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8179941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Adnexal masses (ie, masses of the ovary, fallopian tube, or surrounding tissues) commonly are encountered by obstetrician-gynecologists and often present diagnostic and management dilemmas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27776067"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Adnexal masses (ie, masses of the ovary, fallopian tube, or surrounding tissues) commonly are encountered by obstetrician-gynecologists and often present diagnostic and management dilemmas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27776072"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 222,
          "text": "CONTEXT: Adnexal masses of ovarian origin are of growing concern due to high fatality associated with ovarian malignancy because they are diagnosed at advanced stage due to vague symptoms and absence of recommended screeni",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489290"
        },
        {
          "offsetInBeginSection": 1393,
          "offsetInEndSection": 1603,
          "text": "Serous endometrial intraepithelial carcinoma is frequently associated with serous cancers of adnexal or tubal origin, indicating that endometrial and adnexal or tubal serous cancers may share similar etiologies",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24925054"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 303,
          "text": "Determining whether an adnexal mass is of ovarian or extraovarian origin is key in arriving at the most likely diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17538485"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Adnexal masses are common in women of all ages. A range of physiological and benign ovarian conditions that develop in women, especially in the reproductive age, and adnexal malignancies can be evaluated with magnetic resonance imaging (MRI).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17417086"
        },
        {
          "offsetInBeginSection": 285,
          "offsetInEndSection": 392,
          "text": "Pathological examination revealed an adnexal carcinoma of follicular origin, thus a trichilemmal carcinoma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33642152"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 527,
          "text": "OBJECTIVE: To describe ultrasound characteristics of adnexal malignancies, i.e., borderline ovarian tumors, primary invasive ovarian epithelial cancer stage 1, primary invasive ovarian epithelial cancer stages 2-4, rare types of malignancy, and metastatic tumors.METHODS: In a prospective international study involving nine European ultrasound centers, 1,066 women with a pelvic mass judged to be of adnexal origin underwent transvaginal gray scale and color Doppler ultrasound examination by a skilled examiner before surgery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16386783"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "Adnexal masses (ie, masses of the ovary, fallopian tube, or surrounding tissues) commonly are encountered by obstetrician-gynecologists and often present diagnostic and management dilemmas.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/27776072/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "INTRODUCTION: An adnexal mass (mass of the ovary, Fallopian tube, or surrounding connective tissues) is a common gynecolo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28174801"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 68,
          "text": "Adnexal masses caused by pelvic inflammatory disease: MR appearance.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16082146"
        },
        {
          "offsetInBeginSection": 402,
          "offsetInEndSection": 822,
          "text": "Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21629623"
        },
        {
          "offsetInBeginSection": 510,
          "offsetInEndSection": 643,
          "text": "Adnexal pathology reviewed includes endometriosis, polycystic ovaries, teratomas, and benign and malignant ovarian epithelial tumors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9503522"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Adnexal masses (ie, masses of the ovary, fallopian tube, or surrounding tissues) commonly are encountered by obstetrician-gynecologists ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27776067"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 134,
          "text": " An adnexal mass (mass of the ovary, Fallopian tube, or surrounding connective tissues) is a common gynecological problem",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28174801"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 260,
          "text": " adnexal masses, defined as lumps that appear near the uterus or in or around ovaries, fallopian tubes, or surrounding connective tissu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32736853"
        }
      ],
      "type": "factoid",
      "id": "67cdbdb981b1027333000018",
      "ideal_answer": [
        "An adnexal mass forms on your ovaries, fallopian tubes or nearby tissue.",
        "Adnexal masses are masses that arise from the adnexa, which includes the ovary, fallopian tube, and round ligament.",
        "Adnexal masses originate from tissues within the uterine adnexa, including the ovaries, fallopian tubes, and supporting ligaments. These structures can give rise to both benign and malignant masses, with MRI being a useful tool for determining their origin and tissue content.",
        "Adnexal masses originate from the tissues of the adnexa of the uterus, which include the ovaries, fallopian tubes, and the surrounding connective tissues.",
        "The origin of serous female adnexal tumors is still debated. Possible tissues of origin are the ovarian surface epithelium, the Fallopian tube epithelium, and the secondary Mullerian system. It can be concluded that the Fallopian tubes play a major role in the development of female serous cancer.",
        "Adnexal masses can originate from the ovary, fallopian tube, peritoneum, or mesonephric remnants.",
        "The origin of adnexal masses is typically the ovaries, but can also be from other sources such as the fallopian tubes, peritoneal inclusion cysts, paraovarian cysts, and rare causes including masses that arise from the gastrointestinal tract or the sacrum.",
        "Adnexal masses originate from the tissues of the ovaries and fallopian tubes, which are part of the female reproductive system and referred to as the adnexae of the uterus. These masses can be benign or malignant and include examples such as dysgerminomas, a type of ovarian tumor.",
        "The origin of adnexal masses can be from the ovary, fallopian tube, surrounding tissues, corpus, or luteum.",
        "Adnexal masses can originate from various tissues, including soft tissue, skin appendages, and ectodermal structures.",
        "Adnexal masses predominantly originate from the para-adnexal soft tissues, including structures such as the fallopian tube and ovary.",
        "Adnexal masses originate from tissues such as the ovary, fallopian tube, peritoneum, mesonephric remnants, and embryologic rests.",
        "Adnexal masses can originate from various tissues, including the broad ligament, fallopian tube, and ovarian hilum, as well as from ectodermal adnexal structures such as sebaceous glands, hair follicles, and sweat glands.",
        "The adnexal masses originate from the ovary.",
        "Adnexal masses are masses of the ovary, fallopian tube, or surrounding tissues.",
        "Adnexal masses originate from the ovary, fallopian tube, or surrounding tissues.",
        "The most common origin of adnexal masses is the ovary, but they can also arise from the fallopian tube, paraovarian cysts, peritoneal inclusion cysts, and rarely from the gastrointestinal tract or sacrum.",
        "Adnexal masses primarily originate from the ovarian or fallopian tube tissues. These can include various types of growths ranging from benign cysts to malignant tumors, such as ovarian cancer.",
        "Adnexal masses originate from the uterine adnexa, which includes the ovaries and related structures.",
        "Adnexal masses in children and adolescents primarily originate from the ovaries, which are part of the uterine adnexa. These masses can arise from various tissues within the ovary or surrounding structures, such as the fallopian tubes, but the most common origin is ovarian tissue.",
        "Adnexal masses originate from ovarian tissue.",
        "Controversy still exists on the origin of serous female adnexal tumors. Three possible tissues of origin are proposed: the ovarian surface epithelium, the Fallopian tube epithelium, and the secondary Mullerian system.",
        "Adnexal masses originate from the uterine adnexa.",
        "the origin of adnexal masses is ovarian tissue",
        "Adnexal masses can originate from multiple types of tissues, including follicular or sebaceous differentiation, and may also involve skin adnexal tissues, as well as other tissues in the pelvic region.",
        "Adnexal masses originate from the tissues of the ovaries and fallopian tubes, which are part of the uterine adnexa. These structures are attached to the uterus and can develop growths or abnormalities that may be benign or malignant.",
        "Adnexal masses can originate from various tissues including the ovary, fallopian tube, peritoneum, mesonephric remnants, and embryologic rests.",
        "Adnexal masses originate from the tissues of the uterine adnexa, which include the ovaries, fallopian tubes, and the surrounding connective tissues.",
        "Adnexal masses originate from the ovarian tissue.",
        "Adnexal masses originate from the tissues of the uterine adnexa, which include the ovaries, fallopian tubes, and surrounding connective tissues.",
        "The origin of adnexal masses is the uterine adnexa, which refers to the tissues surrounding the uterus, including the ovaries, fallopian tubes, and supporting ligaments.",
        "Adnexal masses can originate from the Müllerian epithelium, which is distributed throughout the subperitoneal mesenchyme.",
        "Adnexal masses may originate from the Müllerian epithelium, which is distributed throughout the subperitoneal mesenchyme.",
        "Adnexal masses typically originate from ovarian, fallopian tube, or connective tissues.",
        "Adnexal masses originate from cutaneous adnexal structures, which include lesions with apocrine, eccrine, follicular, sebaceous, and mixed differentiation.",
        "Adnexal masses originate from the tissues of the uterine adnexa, which include the ovaries, fallopian tubes, and the surrounding connective tissues. These masses can be either benign or malignant and may arise from any of these structures, leading to a variety of clinical presentations and potential complications.",
        "Adnexal masses are tumors and tumor-like lesions of the uterine adnexa in children and adolescents.",
        "Adnexal masses originate from tumors and tumor-like lesions of the uterine adnexa. These masses can be characterized using the O-RADS MRI score to determine the likelihood of malignancy.",
        " Adnexal masses originate from the ovaries or the fallopian tubes (adnexa) in the female reproductive system.",
        "Adnexal masses originate from tissues of the uterine adnexa, including structures like the ovaries and fallopian tubes.",
        "The origin of adnexal masses is the uterine adnexa, which refers to the tissues surrounding the uterus, including the ovaries, fallopian tubes, and ligaments.",
        "Adnexal masses originate from the ovaries, fallopian tubes, or surrounding connective tissues in the female reproductive system.",
        "Adnexal masses primarily originate from the ovaries, with the involved tissues including germ cell, epithelial, connective, and supportive tissues. Additionally, the fallopian tubes can also be a source. Notably, in certain cases, especially among children and adolescents, other surrounding structures within the uterine adnexa may also give rise to these masses.",
        "The origin of adnexal masses is most commonly associated with tissues of the uterine adnexa, specifically the ovaries, and potentially the fallopian tubes and supporting ligaments.",
        "Adnexal masses originate from the uterine adnexa, which includes the ovaries and related structures in children and adolescents.",
        "Adnexal masses originate from the uterine adnexa, which includes the ovaries and surrounding structures."
      ],
      "exact_answer": [
        [
          "ovaries, fallopian tubes or nearby tissue."
        ]
      ]
    },
    {
      "body": "Mean survival after a diagnosis of multiple sclerosis.",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/39258870",
        "http://www.ncbi.nlm.nih.gov/pubmed/36882223",
        "http://www.ncbi.nlm.nih.gov/pubmed/18632781",
        "http://www.ncbi.nlm.nih.gov/pubmed/7936244",
        "http://www.ncbi.nlm.nih.gov/pubmed/10408717",
        "http://www.ncbi.nlm.nih.gov/pubmed/17368674",
        "http://www.ncbi.nlm.nih.gov/pubmed/3495637",
        "http://www.ncbi.nlm.nih.gov/pubmed/10908197",
        "http://www.ncbi.nlm.nih.gov/pubmed/26148099"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1061,
          "offsetInEndSection": 1253,
          "text": "Compared to matched controls, median life expectancy was 8-9 years shorter in pwMS with survival diverging from controls during the first decade after diagnosis, more clearly in men than women",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39258870"
        },
        {
          "offsetInBeginSection": 1269,
          "offsetInEndSection": 1393,
          "text": "New Zealanders with MS have a median survival age 7.2 years lower than the general population and twice the mortality risk. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36882223"
        },
        {
          "offsetInBeginSection": 462,
          "offsetInEndSection": 1281,
          "text": " in MS and expected mortality.RESULTS: Median survival from onset was 41 years versus 49 years in the corresponding population, and mortality (SMR) was 2.7-fold increased in MS. The median survival was 43 years among women and 36 years among men, but women had higher relative mortality, when compared with the corresponding population, than men (RMR \u003d 1.40). The median survival time was 45 years among young-onset patients (21-30 years) and 23 years among older-onset patients (51-60 years), but young-onset patients had higher relative mortality than older-onset patients, as shown by a significant reduction by 10-year interval of age at onset (RMR \u003d 0.65). Median survival from onset was longer (43 years) among relapsing-remitting MS than primary progressive MS ([PPMS]; 49 years), and the relative mortality was ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18632781"
        },
        {
          "offsetInBeginSection": 630,
          "offsetInEndSection": 748,
          "text": "The median survival time from diagnosis was 22 years in men (versus 37 years) and 28 years in women (versus 42 years).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7936244"
        },
        {
          "offsetInBeginSection": 192,
          "offsetInEndSection": 691,
          "text": "Over a mean follow-up of 21.7 years, the following factors negatively influenced the prognosis by the univariate analysis: male sex, age at onset over 25, pyramidal involvement or spasticity at onset, \u003e or \u003d3 functional systems affected at onset or after 5 years, incomplete first remission, length of the first remission \u003c or \u003d1 year, \u003e5 attacks in the first 10 years, secondary or primary-progressive disease, time to reach secondary progression over 5 years and time to reach EDSS 6 over 7 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10408717"
        },
        {
          "offsetInBeginSection": 1018,
          "offsetInEndSection": 1127,
          "text": "Eighty five per cent of those with onset of multiple sclerosis over the age of 50 years died within 20 years.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3495637"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "BACKGROUND: Recent studies in multiple sclerosis (MS) showed longer survival times from clinical onset than older hospital-based series.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148099"
        },
        {
          "offsetInBeginSection": 281,
          "offsetInEndSection": 395,
          "text": "Median survival times from onset were 43 years (white females), 30 years (black males) and 34 years (white males).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10908197"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 201,
          "text": " Recent studies in multiple sclerosis (MS) showed longer survival times from clinical onset than older hospital-based series. However estimated median time ranges widely, from 24 to 45 years",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148099"
        },
        {
          "offsetInBeginSection": 308,
          "offsetInEndSection": 521,
          "text": "the Australian population, there is approximately a 10% reduction in survival time in multiple sclerosis patients, after 20 years or more from disease onset. The expected time to reach DSS 3 and DSS 6 was 7 years ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17368674"
        }
      ],
      "type": "factoid",
      "id": "67d7228818b1e36f2e000034",
      "ideal_answer": [],
      "exact_answer": [
        [
          "Survival shorter than the general population by 7-9 years"
        ]
      ]
    },
    {
      "body": "Describe the SEQUOIA tool for predicting cancer transcriptomics profiles from histology images",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/37808782"
      ],
      "type": "summary",
      "snippets": [
        {
          "offsetInBeginSection": 489,
          "offsetInEndSection": 956,
          "text": "Here, we develop SEQUOIA, a transformer model to predict cancer transcriptomes from whole-slide histology images. To enable the full potential of transformers, we first pre-train the model using data from 1,802 normal tissues. Then, we fine-tune and evaluate the model in 4,331 tumor samples across nine cancer types. The prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37808782"
        }
      ],
      "id": "67d49cf318b1e36f2e00001c",
      "ideal_answer": [
        "SEQUOIA is a transformer model to predict cancer transcriptomes from whole-slide histology images. It\u0027s pre-trained the using data from 1,802 normal tissues. Then, it\u0027s fine-tuned and evaluated in 4,331 tumor samples across nine cancer types. The prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from WSIs. SEQUOIA is developed using 7584 tumor samples across 16 cancer types, with its generalization capacity validated on two independent cohorts comprising 1368 tumors. Accurately predicted genes are associated with key cancer processes, including inflammatory response, cell cycles and metabolism. Further, SEQUOIA is demonstrated in stratifying the risk of breast cancer recurrence and in resolving spatial gene expression at loco-regional levels. SEQUOIA hence deciphers clinically relevant information from WSIs, opening avenues for personalized cancer management.",
        "SEQUOIA is a deep learning model that can predict cancer transcriptomic profiles from whole slide histology images. It uses a linearized transformer architecture to overcome the limitations of small dataset sizes and high model complexity faced by standard transformers. SEQUOIA was developed using 7584 tumor samples across 16 cancer types and validated on independent cohorts totaling 1368 tumors, demonstrating its generalization capability. The genes accurately predicted by SEQUOIA are associated with key cancer processes like inflammatory response, cell cycles, and metabolism. SEQUOIA can stratify breast cancer recurrence risk and resolve spatial gene expression patterns, deciphering clinically relevant information from histology images and enabling personalized cancer management.",
        "SEQUOIA is a computational tool designed to predict cancer transcriptomics profiles from histology images. It utilizes advanced machine learning algorithms to analyze histological data and generate insights into the gene expression patterns associated with various cancer types. By integrating image analysis with transcriptomic data, SEQUOIA aims to enhance the understanding of cancer biology and improve diagnostic and therapeutic strategies.",
        "SEQUOIA is a linearized transformer model predicting cancer transcriptomic profiles from whole slide images (WSIs). Developed with 7,584 tumor samples across 16 cancer types and validated on 1,368 independent tumors, it accurately predicts genes tied to key cancer processes. SEQUOIA enables stratification of breast cancer recurrence risk and resolves spatial gene expression at loco-regional levels, offering insights for personalized cancer management through analysis of WSIs.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from WSIs. SEQUOIA is developed using 7584 tumor samples across 16 cancer types, with its generalization capacity validated on two independent cohorts comprising 1368 tumors. Accurately predicted genes are associated with key cancer processes, including inflammatory response, cell cycles and metabolism. Further, SEQUOIA is demonstrated to be useful in stratifying the risk of breast cancer recurrence and in resolving spatial gene expression at loco-regional levels. SEQUOIA hence deciphers clinically relevant information from WSIs, opening avenues for personalized cancer management.",
        "SEQUOIA is a computational tool designed to predict cancer transcriptomics profiles from histology images. It leverages deep learning techniques to analyze histological images and infer gene expression patterns, providing insights into the molecular characteristics of tumors. This tool aims to bridge the gap between histopathological examination and genomic analysis, enabling researchers and clinicians to gain a deeper understanding of cancer biology and potentially guide personalized treatment strategies. By using SEQUOIA, it is possible to predict transcriptomic data without the need for direct RNA sequencing, which can be resource-intensive and time-consuming.",
        "SEQUOIA is a linearized transformer model designed to predict cancer transcriptomic profiles from whole slide images (WSIs). It was developed using 7584 tumor samples across 16 cancer types and validated on two independent cohorts with 1368 tumors. SEQUOIA accurately predicts genes associated with key cancer processes such as inflammatory response, cell cycles, and metabolism. It also aids in stratifying the risk of breast cancer recurrence and resolving spatial gene expression at loco-regional levels, thus providing clinically relevant information for personalized cancer management.",
        "SEQUOIA is a computational tool that predicts cancer transcriptomics profiles from histology images using deep learning techniques. It analyzes digitized histopathology slides to infer gene expression patterns, integrating image analysis with transcriptomic data. This tool provides insights into the molecular characteristics of tumors, aiding in diagnosis, prognosis, and treatment planning. SEQUOIA is particularly useful when obtaining high-quality RNA samples is difficult, offering a non-invasive alternative to traditional transcriptomic profiling methods.\n\nThe tool involves training a convolutional neural network (CNN) on paired histology images and corresponding transcriptomic data. Once trained, the model can predict gene expression levels directly from new histology images. This approach enhances understanding of the tumor microenvironment and supports personalized medicine by providing detailed molecular information from routine histopathological examinations.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from whole slide images (WSIs). It was developed using 7584 tumor samples across 16 cancer types, and its generalization capacity was validated on two independent cohorts comprising 1368 tumors.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomic profiles from whole-slide histology images, enabling the deciphering of clinically relevant gene expression patterns. It shows high performance in predicting gene expression levels, particularly in cancers of the breast, kidney, and lung, and has the potential to predict spatial gene expression patterns, opening new possibilities for personalized cancer management and therapy.",
        "SEQUOIA is a linearized transformer model designed to predict cancer transcriptomic profiles from whole-slide histology images (WSIs). It accurately predicts gene expression levels across various cancers, including breast, kidney, and lung, with high performance. The model extracts clinically relevant gene expression patterns, aiding in personalized cancer management and improved treatment strategies. SEQUOIA is trained at the tissue level but also demonstrates potential in predicting spatial gene expression patterns using spatial transcriptomics datasets.",
        "SEQUOIA is a deep learning-based tool that uses convolutional neural networks to predict cancer transcriptomic profiles directly from histology images. It learns the complex correlations between tissue morphology captured in digital slides and the expression levels of specific gene signatures associated with cancer by training on paired image-expression data. Once the model is trained, SEQUOIA can efficiently infer molecular profiles from new histology images, offering a rapid and cost-effective alternative to traditional RNA sequencing. This integration of digital pathology with advanced computational analysis has the potential to enhance diagnostic precision and inform treatment decisions, thereby streamlining clinical workflows and supporting personalized medicine strategies.",
        "The SEQUOIA tool predicts cancer transcriptomics profiles from histology images using a deep learning model. It leverages a multi-scale convolutional neural network (CNN) architecture to extract features from histology images at different resolutions. These features are then used to predict gene expression levels. The model is trained on paired histology images and transcriptomics data from cancer patients. SEQUOIA can predict the expression of thousands of genes directly from a histology image, providing a way to infer molecular information from readily available pathology slides. This enables researchers to study the relationship between tissue morphology and gene expression, identify potential biomarkers, and potentially predict patient outcomes based on image analysis.",
        "SEQUOIA is a linearized transformer model designed to predict cancer transcriptomic profiles from whole slide images (WSIs). It leverages a dataset of 7,584 tumor samples across 16 different cancer types and has been validated for its generalization capacity on two independent cohorts totaling 1,368 tumors. The model accurately predicts genes linked to critical cancer processes such as inflammatory response, cell cycles, and metabolism. SEQUOIA also demonstrates its utility in stratifying the risk of breast cancer recurrence and in analyzing spatial gene expression at loco-regional levels. This tool thus provides clinically relevant insights from WSIs, facilitating personalized cancer management.",
        "SEQUOIA is a computational tool that utilizes histology images to predict cancer transcriptomics profiles, providing insights into the molecular characteristics of tumors.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomic profiles from whole-slide histology images (WSIs). It was developed using a substantial dataset of 7,584 tumor samples across 16 different cancer types, with its generalization capabilities validated on two independent cohorts totaling 1,368 tumors. SEQUOIA excels in predicting the expression levels of 25,749 genes, showing the highest accuracy in breast, kidney, and lung cancers, where it successfully predicts over 10,000 genes in each type. The model identifies clinically relevant gene expression patterns linked to critical cancer processes such as inflammatory responses, cell cycles, and metabolism. Additionally, SEQUOIA aids in stratifying breast cancer recurrence risk and can resolve spatial gene expression at loco-regional levels. By leveraging deep learning techniques, SEQUOIA represents a significant advancement in personalized cancer management and molecular profiling, addressing the challenges posed by cancer heterogeneity.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from whole-slide histology images.",
        "SEQUOIA is a linearized transformer model predicting cancer transcriptomic profiles from whole-slide histology images. Developed with a large dataset (7584 tumor samples across 16 cancer types), it accurately predicts genes linked to key cancer processes (inflammatory response, cell cycles, metabolism). SEQUOIA stratifies breast cancer recurrence risk, resolves spatial gene expression at loco-regional levels, and facilitates personalized cancer management by extracting clinically relevant information from histology images, offering improved treatment outcomes.",
        "SEQUOIA is a computational tool designed to predict cancer transcriptomics profiles from histology images. It leverages deep learning techniques to analyze histological images and infer gene expression patterns, providing insights into the molecular characteristics of tumors. By integrating image-based data with transcriptomic information, SEQUOIA aims to enhance the understanding of cancer biology and improve diagnostic and prognostic capabilities. This tool can potentially facilitate personalized medicine approaches by linking visual histological features with underlying genetic and molecular profiles.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from whole slide images (WSIs). It was developed using 7584 tumor samples across 16 cancer types and validated on two independent cohorts comprising 1368 tumors. SEQUOIA accurately predicts genes associated with key cancer processes, including inflammatory response, cell cycles, and metabolism. It also stratifies the risk of breast cancer recurrence and resolves spatial gene expression at loco-regional levels, opening avenues for personalized cancer management.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from whole slide histology images (WSIs). It was developed using 7584 tumor samples across 16 cancer types, and its generalization capacity was validated on two independent cohorts comprising 1368 tumors. SEQUOIA accurately predicted genes associated with key cancer processes like inflammatory response, cell cycles, and metabolism. It demonstrated value in stratifying breast cancer recurrence risk and resolving spatial gene expression at loco-regional levels, enabling personalized cancer management by deciphering clinically relevant information from WSIs.",
        "SEQUOIA is a tool designed to predict cancer transcriptomics profiles from histology images. It utilizes advanced machine learning algorithms to analyze histological data and generate predictions about the gene expression profiles of cancerous tissues. This tool aims to bridge the gap between histological examination and molecular profiling, providing insights that can aid in the diagnosis and treatment planning for cancer patients.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from Whole Slide Images (WSIs). It is a tool designed to analyze histology images and generate predictions about the underlying gene expression profiles of cancer tissues.",
        "SEQUOIA is a deep learning model that can predict cancer transcriptomic profiles from whole slide histology images. It is a linearized transformer model developed using 7584 tumor samples across 16 cancer types. SEQUOIA\u0027s generalization ability was validated on two independent cohorts comprising 1368 tumors. The genes accurately predicted by SEQUOIA are associated with key cancer processes like inflammatory response, cell cycles, and metabolism. SEQUOIA can stratify the risk of breast cancer recurrence and resolve spatial gene expression at loco-regional levels, deciphering clinically relevant information from histology images and opening avenues for personalized cancer management.",
        "SEQUOIA is a deep learning model that can predict cancer transcriptomic profiles from whole slide histology images. It uses a linearized transformer architecture to overcome the limitations of small dataset sizes and high model complexity faced by standard transformers. SEQUOIA was developed using 7584 tumor samples across 16 cancer types and validated on independent cohorts totaling 1368 tumors, demonstrating its generalization capability. The genes accurately predicted by SEQUOIA are associated with key cancer processes like inflammatory response, cell cycles, and metabolism. SEQUOIA can stratify breast cancer recurrence risk and resolve spatial gene expression patterns, enabling personalized cancer management from histology images alone.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from whole slide images, developed using 7584 tumor samples across 16 cancer types, and validated on two independent cohorts, accurately predicting genes associated with key cancer processes and aiding in risk stratification and spatial gene expression analysis.",
        "SEQUOIA is a linearized transformer model that can predict cancer transcriptomic profiles from whole slide histology images (WSIs). It was developed using 7584 tumor samples across 16 cancer types, and its generalization ability was validated on two independent cohorts comprising 1368 tumors. SEQUOIA accurately predicted genes associated with key cancer processes like inflammatory response, cell cycles, and metabolism. It demonstrated value in stratifying breast cancer recurrence risk and resolving spatial gene expression patterns at local tumor regions. SEQUOIA thus deciphers clinically relevant information from WSIs, opening up possibilities for personalized cancer management.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from whole-slide histology images. Developed with 7,584 tumor samples across 16 cancer types and validated on 1,368 independent tumors, it accurately predicts genes tied to key cancer processes like inflammatory response, cell cycles, and metabolism. SEQUOIA enables breast cancer recurrence risk stratification and resolves spatial gene expression, facilitating personalized cancer management and potentially improving treatment outcomes through analysis of histology images.",
        "The SEQUOIA tool is a transformer model developed to predict cancer transcriptomics profiles from whole-slide histology images. It has been validated on 7584 tumor samples across 16 cancer types and tested on two independent cohorts comprising 1368 tumors. SEQUOIA accurately predicts gene expression levels and associated pathways, showing potential in predicting spatial gene expression patterns and recurrence risk in breast cancer. The model is useful in stratifying breast cancer recurrence risk and resolving spatial gene expression.",
        "SEQUOIA is a deep learning model that predicts cancer transcriptomes from whole-slide histology images. It is pre-trained on normal tissues and fine-tuned on tumor samples across nine cancer types, achieving high performance in predicting gene expression levels and identifying clinically relevant gene expression patterns.",
        "SEQUOIA is a linearized transformer model that predicts cancer transcriptomic profiles from whole slide images. Developed using 7,584 tumor samples across 16 cancer types, the model has demonstrated robust performance and generalization on independent cohorts. It not only infers transcriptomics profiles from histology images but also extracts clinically relevant information, such as stratifying the risk of breast cancer recurrence and delineating spatial gene expression patterns within tumor regions. By linking histopathology with molecular data, SEQUOIA opens new avenues for personalized cancer management.",
        "SEQUOIA is a linearized transformer model (or transformer with grouped vision attention) that predicts cancer transcriptomic profiles from whole-slide histology images, trained on large datasets (up to 7584 tumor samples across 16 cancer types) and validated on independent cohorts, accurately predicting genes linked to key cancer processes and applicable to stratifying breast cancer recurrence risk and spatial gene expression analysis.",
        "SEQUOIA is a transformer-based deep learning model designed to predict cancer transcriptomic profiles from whole-slide histology images (WSIs). It accurately predicts gene expression levels across multiple cancer types, with high performance in breast, kidney, and lung cancers, and can also infer spatial gene expression patterns. This tool enables clinically relevant insights from routine histopathology, aiding personalized cancer management and therapy.",
        "The SEQUOIA tool predicts cancer transcriptomics profiles from histology images using a deep learning model. It leverages a multi-scale convolutional neural network (CNN) architecture to extract features from histology images at different resolutions. These features are then used to predict gene expression levels. The model is trained on paired histology images and transcriptomics data from cancer patients. SEQUOIA can predict the expression of thousands of genes directly from a histology image, providing a way to infer molecular characteristics of tumors from readily available pathology slides. This enables researchers to investigate the relationship between tissue morphology and gene expression, identify potential biomarkers, and potentially guide treatment decisions.",
        "The SEQUOIA tool is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. It is a linearized transformer model pre-trained on data from 1,802 normal tissues and fine-tuned on 4,331 tumor samples across nine cancer types. The model was validated using 7,584 tumor samples across 16 cancer types and two independent cohorts comprising 1,368 tumors. SEQUOIA\u0027s performance was assessed using Pearson correlation analysis and root mean square error, showing high accuracy in predicting gene expression levels, particularly in breast, kidney, and lung cancers. The predictions were associated with key cancer processes. SEQUOIA demonstrated generalization capacity across two independent cohorts and has potential in predicting spatial gene expression patterns using spatial transcriptomics datasets.",
        "SEQUOIA is a linearized transformer model designed to predict cancer transcriptomic profiles from whole slide images, trained on 7584 tumor samples across 16 cancer types, and validated on independent cohorts, aiding in predicting genes related to key cancer processes and cancer management.",
        "SEQUOIA is a transformer model to predict cancer transcriptomes from whole-slide histology images. To enable the full potential of transformers, the model is first pre-trained using data from 1,802 normal tissues. Then, the model is fine-tuned and evaluated in 4,331 tumor samples across nine cancer types. The prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error. The generalization capacity is validated across two independent cohorts comprising 1,111 and 1,111 tumor samples, respectively.",
        "SEQUOIA is a transformer-based machine learning model designed to predict cancer transcriptomes directly from whole-slide histology images. The model employs a two-stage approach: first, pre-training on 1,802 normal tissue samples to establish a foundational understanding, and then fine-tuning on 4,331 tumor samples across nine different cancer types. Performance evaluation is conducted using Pearson correlation analysis and root mean square error, assessing prediction accuracy at both individual gene and pathway levels.",
        "SEQUOIA is a transformer model developed to predict cancer transcriptomes from whole-slide histology images. It is pre-trained using data from 1,802 normal tissues and fine-tuned and evaluated in 4,331 tumor samples across nine cancer types. The prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error. Generalization capacity is validated across two independent cohorts comprising 1,305 tumors. In predicting the expression levels of 25,749 genes, the highest performance is observed in cancers from breast, kidney and lung, where SEQUOIA accurately predicts the expression of 11,069, 10,086 and 8,759 genes, respectively.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes using whole slide histology images. The model undergoes two stages of training: initial pre training on 1,802 normal tissue samples, followed by fine tuning and evaluation across 4,331 tumor samples from nine cancer types. Performance assessment was conducted at both gene and pathway levels using Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a transformer-based deep learning tool that predicts cancer transcriptomics profiles from whole-slide histology images. It leverages a two-stage training process: pre-training on 1,802 normal tissue samples, followed by fine-tuning on 4,331 tumor samples across nine cancer types. SEQUOIA demonstrates high accuracy in predicting gene expression levels, particularly for breast, kidney, and lung cancers. Its predictive capabilities extend to spatial gene expression and recurrence risk assessment, utilizing evaluation metrics such as Pearson correlation and root mean square error. This enables the identification of clinically relevant gene expression patterns, ultimately supporting personalized cancer management and therapies.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole slide histology images. The tool was developed by first pre training on data from 1,802 normal tissues to enable the full potential of transformers. Subsequently, it was fine tuned and evaluated using 4,331 tumor samples across nine different cancer types. Performance assessment included Pearson correlation analysis and root mean square error at both individual gene levels and pathway levels, demonstrating its effectiveness in predicting transcriptomics profiles from histology images.",
        "SEQUOIA is a transformer model to predict cancer transcriptomes from whole-slide histology images. To enable the full potential of transformers, the model is first pre-trained using data from 1,802 normal tissues. Then, the model is fine-tuned and evaluated in 4,331 tumor samples across nine cancer types. The prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error. The generalization capacity is validated across two independent cohorts comprising 1,111 tumor samples from the Cancer Genome Atlas (TCGA) and 1,111 tumor samples from the Cancer Proteomic Atlas (TCAP).",
        "The SEQUOIA tool is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. To unlock its full potential, the model is first pre-trained on a large dataset of 1,802 normal tissues. It is then fine-tuned and evaluated on a diverse set of 4,331 tumor samples spanning nine different cancer types. The performance of SEQUOIA is assessed through rigorous analysis, including Pearson correlation and root mean square error calculations, to determine its accuracy in predicting individual gene levels and pathway levels. This approach enables SEQUOIA to effectively predict cancer transcriptomics profiles from histology images, making it a valuable tool in cancer research studies.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes using whole-slide histology images, pre-trained on normal tissue data and fine-tuned on tumor samples across nine cancer types. Its performance in predicting gene expression levels is evaluated through Pearson correlation analysis and root mean square error at both individual gene and pathway levels.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole slide histology images. The development process involves two main phases: pre training on data from 1,802 normal tissues to establish a baseline understanding of typical gene expression patterns, followed by fine tuning using 4,331 tumor samples across nine different cancer types. This approach allows SEQUOIA to generalize and adapt to various cancers effectively. The performance evaluation of SEQUOIA is conducted at both individual gene and pathway levels. Pearson correlation analysis measures the strength of linear relationships between predicted and actual transcriptome data, indicating how well the model aligns with real world gene expression profiles. Additionally, root mean square error (RMSE) assesses the accuracy of predictions by quantifying the differences between predicted and actual values, with lower RMSE indicating higher precision. By leveraging transformer architecture, SEQUOIA excels in capturing complex patterns within histology images, enabling it to predict transcriptomic profiles accurately across diverse cancer types. This tool represents a significant advancement in integrating image data with gene expression analysis, offering insights into cancer biology and potential therapeutic targets.",
        "SEQUOIA is a transformer model developed to predict cancer transcriptomes from whole-slide histology images (WSIs). It is pre-trained using data from normal tissues and then fine-tuned and evaluated in tumor samples across multiple cancer types. The prediction performance is assessed at individual gene and pathway levels through Pearson correlation analysis and root mean square error. SEQUOIA is developed using a large number of tumor samples across various cancer types, and its generalization capacity is validated on independent cohorts. It is also described as a linearized transformer model for predicting cancer transcriptomic profiles from WSIs.",
        "SEQUOIA is a transformer model that predicts cancer transcriptomes from whole-slide histology images, pre-trained on normal tissues and fine-tuned on tumor samples across nine cancer types.",
        "SEQUOIA is a transformer model developed to predict cancer transcriptomes from whole-slide histology images. It is pre-trained using data from normal tissues and then fine-tuned and evaluated in tumor samples across multiple cancer types.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. It is pre-trained using data from 1,802 normal tissues and then fine-tuned and evaluated in 4,331 tumor samples across nine cancer types. The prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a linearized transformer model designed to predict cancer transcriptomic profiles from whole-slide histology images (WSIs). It is initially pre-trained on data from 1,802 normal tissues and subsequently fine-tuned using 7,584 tumor samples across 16 cancer types, with its generalization validated on two independent cohorts of 1,368 tumors. The model\u0027s prediction performance is evaluated at both individual gene and pathway levels through Pearson correlation analysis and root mean square error metrics. SEQUOIA accurately predicts genes linked to critical cancer processes such as inflammatory response, cell cycles, and metabolism. Additionally, it aids in stratifying breast cancer recurrence risk and resolving spatial gene expression at loco-regional levels, thereby providing clinically relevant insights for personalized cancer management. This tool leverages recent advancements in deep learning to offer cost-effective predictions of genetic alterations from histology images, addressing the challenges posed by cancer\u0027s heterogeneity and the high costs of genetic profiling.",
        "SEQUOIA is a transformer-based model designed to predict cancer transcriptomes from whole-slide histology images. The model undergoes pre-training on data from 1,802 normal tissue samples to enhance its foundational understanding. Following pre-training, SEQUOIA is fine-tuned and evaluated using 4,331 tumor samples across nine different cancer types. The performance of the model in predicting transcriptomic profiles is rigorously assessed at both individual gene and pathway levels using Pearson correlation analysis and root mean square error metrics. This approach leverages the capabilities of transformer models to accurately predict complex transcriptomic data directly from histological images, providing a powerful tool for cancer research and diagnostics.",
        "SEQUOIA is an innovative tool designed to predict cancer transcriptomics profiles using whole-slide histology images. It leverages transformer models, which are highly effective at processing sequential data, to analyze the structural details of tissue samples and infer gene expression levels.\n\nThe development process involves two key phases: pre-training and fine-tuning. During pre-training, SEQUOIA is exposed to a dataset of 1,802 normal tissues, allowing it to learn general patterns and features that are foundational for understanding histological structures. This phase sets the stage for the model to grasp essential characteristics from normal samples.\n\nSubsequently, the model undergoes fine-tuning on a dataset comprising 4,331 tumor samples across nine distinct cancer types. This step refines SEQUOIA\u0027s ability to predict transcriptomes specifically in the context of cancerous tissues. The evaluation phase employs Pearson correlation analysis and root mean square error (RMSE) to assess the accuracy of these predictions. Pearson correlation measures the linear relationship between predicted and actual gene expressions, while RMSE quantifies the magnitude of prediction errors.\n\nIn essence, SEQUOIA serves as a bridge between histological imaging and transcriptomic data, offering insights into gene expression without the need for RNA sequencing. This tool holds significant potential for enhancing our understanding of cancer biology and could facilitate more efficient diagnostic and research processes.",
        "SEQUOIA is a transformer model developed to predict cancer transcriptomes from whole-slide histology images. It accurately predicts the expression levels of thousands of genes, with the highest performance observed in breast, kidney, and lung cancers. The model deciphers clinically relevant information from WSIs, opening avenues for personalized cancer management.",
        "SEQUOIA is a transformer model designed to predict detailed cancer transcriptomic profiles directly from whole-slide histology images. It is first pre-trained on data from 1,802 normal tissue samples to fully leverage the potential of transformers and generate comprehensive gene expression profiles from histological data. After this initial phase, the model is fine-tuned using 4,331 tumor samples covering nine distinct cancer types. The performance of SEQUOIA is evaluated at both individual gene and pathway levels through Pearson correlation analysis and root mean square error. This approach not only integrates imaging and transcriptomic data but also highlights the potential of transformer-based methodologies in deciphering the molecular underpinnings of cancer directly from histological slides.",
        "SEQUOIA is a transformer model developed to predict cancer transcriptomes from whole-slide histology images. The model is pre-trained using normal tissue data and then fine-tuned and evaluated on tumor samples across multiple cancer types. Its prediction performance is assessed at individual gene and pathway levels.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomics profiles from whole-slide histology images. It is pre-trained using data from 1,802 normal tissues and fine-tuned using 4,331 tumor samples across nine cancer types. The prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. The model is pre-trained using data from 1,802 normal tissues and then fine-tuned and evaluated using 4,331 tumor samples across nine cancer types. The performance of the model is assessed at both individual gene and pathway levels using Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. It leverages pre-training on data from 1,802 normal tissues and fine-tuning with 4,331 tumor samples across nine cancer types. The tool\u0027s prediction performance is evaluated at both individual gene levels and pathway levels using Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a transformer-based deep learning model designed to predict cancer transcriptomes from whole-slide histology images. To maximize its effectiveness, SEQUOIA is first pre-trained on data from 1,802 normal tissues before being fine-tuned and evaluated on 4,331 tumor samples across nine different cancer types. The model\u0027s performance is assessed at both individual gene and pathway levels using Pearson correlation analysis and root mean square error metrics. It demonstrates the highest predictive accuracy for breast, kidney, and lung cancers, successfully predicting the expression levels of over 11,000 genes associated with key biological processes such as inflammatory response, cell cycles, and metabolism. Additionally, SEQUOIA shows potential in predicting spatial gene expression patterns using spatial transcriptomics datasets. The tool also facilitates the development of a digital gene expression signature that can predict the risk of recurrence in breast cancer, thereby enhancing cancer management and enabling personalized therapies.",
        "SEQUOIA is a transformer model developed to predict cancer transcriptomes from whole-slide histology images (WSIs). It is pre-trained using data from 1,802 normal tissues and then fine-tuned and evaluated in 4,331 tumor samples across nine cancer types, or 7584 tumor samples across 16 cancer types. Prediction performance is assessed at individual gene and pathway levels using Pearson correlation analysis and root mean square error. SEQUOIA\u0027s generalization capacity is validated on two independent cohorts comprising 1,305 or 1,368 tumors. In predicting the expression levels of 25,749 genes, the highest performance is observed in cancers from breast, kidney and lung, where SEQUOIA accurately predicts the expression of 11,069, 10,086 and 8,759 genes, respectively.",
        "SEQUOIA is a transformer-based model designed to predict cancer transcriptomes from whole-slide histology images. It is pre-trained on data from 1,802 normal tissues and fine-tuned using 4,331 tumor samples across nine cancer types. The model\u0027s performance is evaluated at both individual gene and pathway levels using metrics such as Pearson correlation and root mean square error.",
        "SEQUOIA is a transformer-based tool that predicts cancer transcriptomes from whole-slide histology images. It involves two stages: pre-training and fine-tuning. Initially, the model is pre-trained on 1,802 normal tissue samples to enable its full potential. Then, it\u0027s fine-tuned and evaluated on 4,331 tumor samples across nine cancer types. The tool\u0027s performance is assessed at individual gene levels and pathway levels using Pearson correlation analysis and root mean square error. SEQUOIA has the potential to predict cancer transcriptomics profiles from histology images, which can aid in cancer diagnosis and research.",
        "SEQUOIA is a transformer-based model designed to predict cancer transcriptomic profiles from whole-slide histology images (WSIs). It is initially pre-trained on data from 1,802 normal tissues to harness the full potential of transformer architectures. The model is then fine-tuned and evaluated using 4,331 tumor samples across nine different cancer types. SEQUOIA demonstrates high prediction performance, particularly in breast, kidney, and lung cancers, accurately predicting the expression levels of over 11,000 genes in these cancers. The model not only identifies clinically relevant gene expression patterns but also aids in stratifying breast cancer recurrence risk and resolving spatial gene expression at loco-regional levels. Its development highlights the potential of deep learning in enhancing cancer management and personalized therapies by providing cost-effective molecular profiling from histology images.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. The model is initially pre-trained using data from 1,802 normal tissues, which allows it to leverage the full potential of transformer architecture. Following this pre-training, SEQUOIA is fine-tuned and evaluated on 4,331 tumor samples across nine different cancer types. The performance of the model is assessed at both individual gene levels and pathway levels using Pearson correlation analysis and root mean square error metrics. Additionally, SEQUOIA identifies a small cluster of genes whose expression is highly predictive of patient survival, as well as subsets of genes exhibiting coherent expression patterns with significant variation across different conditions.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. It is pre-trained using data from 1,802 normal tissues to harness the full potential of transformers. The model is then fine-tuned and evaluated on 4,331 tumor samples across nine cancer types. Its prediction performance is measured at both individual gene levels and pathway levels using Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. The model is initially pre-trained using data from 1,802 normal tissue samples to harness the full potential of transformers. It is then fine-tuned and evaluated on 4,331 tumor samples across nine different cancer types. The prediction performance of SEQUOIA is assessed at both individual gene levels and pathway levels using Pearson correlation analysis and root mean square error metrics.",
        "SEQUOIA is a transformer-based deep learning tool that predicts cancer transcriptomics profiles from whole-slide histology images. It leverages a two-stage approach: pre-trained on 1,802 normal tissue samples and fine-tuned on 4,331 tumor samples across nine cancer types. SEQUOIA demonstrates high accuracy in predicting gene expression levels, particularly for breast, kidney, and lung cancers. Its applications include deciphering clinically relevant gene expression patterns, predicting spatial gene expression, assessing recurrence risk, and informing personalized cancer therapies, with performance evaluated through metrics like Pearson correlation and root mean square error at gene and pathway levels.",
        "The SEQUOIA tool is a transformer model designed to predict cancer transcriptomics profiles from histology images. It was developed by first pre training the model using data from 1,802 normal tissue samples to enable it to learn general features of histology images. Subsequently, the model was fine tuned and evaluated on a dataset consisting of 4,331 tumor samples across nine different cancer types. The performance of SEQUOIA in predicting transcriptomic profiles was assessed at both individual gene levels and pathway levels using Pearson correlation analysis to measure the correlation between predicted and actual gene expressions, as well as root mean square error (RMSE) to quantify prediction accuracy.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. The model follows a two-step approach: first pre-training using data from 1,802 normal tissues, followed by fine-tuning and evaluation on 4,331 tumor samples across nine cancer types. This approach leverages the full potential of transformer architecture for transcriptome prediction. SEQUOIA\u0027s performance is rigorously evaluated at both individual gene and pathway levels using Pearson correlation analysis and root mean square error metrics to assess prediction accuracy.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomics profiles from whole-slide histology images. It was developed through a two-step process: pre-training on data from 1,802 normal tissues and fine-tuning using 4,331 tumor samples across nine cancer types. The model\u0027s performance was evaluated using Pearson correlation analysis and root mean square error at both individual gene and pathway levels to assess its predictive accuracy.",
        "SEQUOIA is a transformer model that predicts cancer transcriptomes from whole-slide histology images. It involves two stages: pre-training on normal tissue data (1,802 samples) and fine-tuning on tumor samples (4,331 samples across 9 cancer types). The model\u0027s performance is evaluated at individual gene levels and pathway levels using Pearson correlation analysis and root mean square error. SEQUOIA enables the prediction of cancer transcriptomics profiles from histology images, which can potentially aid in cancer diagnosis and research.",
        "SEQUOIA is a transformer model that can predict cancer transcriptomes (gene expression profiles) from whole-slide histology images of tumor tissue. The model is first pre-trained on data from 1,802 normal tissues to learn general patterns. It is then fine-tuned and evaluated on 4,331 tumor samples across nine different cancer types. The prediction performance is assessed by comparing the predicted and actual gene expression levels using metrics like Pearson correlation and root mean square error, both at the individual gene level and for entire biological pathways.",
        "SEQUOIA is a transformer-based deep learning tool that predicts cancer transcriptomics profiles from whole-slide histology images. Trained in a two-stage process (1,802 normal tissues for pre-training and 4,331 tumor samples across nine cancer types for fine-tuning), it achieves high accuracy, notably in breast, kidney, and lung cancers. SEQUOIA\u0027s applications include deciphering clinically relevant gene expression patterns, predicting spatial gene expression, assessing cancer recurrence risk (with a developed digital signature for breast cancer), and guiding personalized therapies, as evaluated through Pearson correlation and root mean square error analyses at gene and pathway levels.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes from whole-slide histology images. It was pre-trained using data from 1,802 normal tissues and fine-tuned on 4,331 tumor samples across nine cancer types, with performance evaluated via Pearson correlation and root mean square error at individual gene and pathway levels.",
        "SEQUOIA is a transformer model developed to predict cancer transcriptomes from whole-slide histology images. The model is first pre-trained using data from 1,802 normal tissues. It is then fine-tuned and evaluated in 4,331 tumor samples across nine cancer types. Prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a transformer-based tool that predicts cancer transcriptomics profiles from whole-slide histology images, developed through a two-stage process of pre-training on 1,802 normal tissues and fine-tuning on 4,331 tumor samples across nine cancer types, with performance evaluated at both individual gene and pathway levels using Pearson correlation and root mean square error, respectively.",
        "SEQUOIA is a transformer model developed to predict cancer transcriptomes from whole-slide histology images. It is pre-trained using data from 1,802 normal tissues and then fine-tuned and evaluated in 4,331 tumor samples across nine cancer types. The prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a transformer model to predict cancer transcriptomes from whole-slide histology images. The prediction performance is assessed at individual gene levels and pathway levels through Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a transformer-based model designed to predict cancer transcriptomes from whole-slide histology images, initially pre-trained on 1,802 normal tissue samples and then fine-tuned on 4,331 tumor samples across nine cancer types. The model\u0027s performance in predicting gene expression and pathway activities is evaluated through correlation analysis and error measurements, making it a powerful tool for connecting histological features with genomic information.",
        "SEQUOIA is a transformer model designed to predict cancer transcriptomes using whole-slide histology images, first pre-trained on normal tissues and then fine-tuned and evaluated across multiple cancer types. Its performance in predicting gene and pathway activity is measured through Pearson correlation analysis and root mean square error.",
        "SEQUOIA is a transformer model that predicts cancer transcriptomes from whole-slide histology images. It is pre-trained using data from 1,802 normal tissues and then fine-tuned and evaluated in 4,331 tumor samples across nine cancer types."
      ]
    },
    {
      "body": "What is the function of CD47",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38414061",
        "http://www.ncbi.nlm.nih.gov/pubmed/16776778",
        "http://www.ncbi.nlm.nih.gov/pubmed/12962580",
        "http://www.ncbi.nlm.nih.gov/pubmed/22774848",
        "http://www.ncbi.nlm.nih.gov/pubmed/25708195",
        "http://www.ncbi.nlm.nih.gov/pubmed/15880429",
        "http://www.ncbi.nlm.nih.gov/pubmed/15359629",
        "http://www.ncbi.nlm.nih.gov/pubmed/23401787",
        "http://www.ncbi.nlm.nih.gov/pubmed/24370062",
        "http://www.ncbi.nlm.nih.gov/pubmed/34707698",
        "http://www.ncbi.nlm.nih.gov/pubmed/23101472",
        "http://www.ncbi.nlm.nih.gov/pubmed/36105746",
        "http://www.ncbi.nlm.nih.gov/pubmed/38125492",
        "http://www.ncbi.nlm.nih.gov/pubmed/33015199",
        "http://www.ncbi.nlm.nih.gov/pubmed/31806995",
        "http://www.ncbi.nlm.nih.gov/pubmed/28077173",
        "http://www.ncbi.nlm.nih.gov/pubmed/36081498",
        "http://www.ncbi.nlm.nih.gov/pubmed/37248568",
        "http://www.ncbi.nlm.nih.gov/pubmed/39675550",
        "http://www.ncbi.nlm.nih.gov/pubmed/39415597",
        "http://www.ncbi.nlm.nih.gov/pubmed/22427202",
        "http://www.ncbi.nlm.nih.gov/pubmed/23801922",
        "http://www.ncbi.nlm.nih.gov/pubmed/22451913",
        "http://www.ncbi.nlm.nih.gov/pubmed/24215318",
        "http://www.ncbi.nlm.nih.gov/pubmed/29308321",
        "http://www.ncbi.nlm.nih.gov/pubmed/30938231",
        "http://www.ncbi.nlm.nih.gov/pubmed/28086180",
        "http://www.ncbi.nlm.nih.gov/pubmed/35754851",
        "http://www.ncbi.nlm.nih.gov/pubmed/32038992",
        "http://www.ncbi.nlm.nih.gov/pubmed/27569584",
        "http://www.ncbi.nlm.nih.gov/pubmed/31359339",
        "http://www.ncbi.nlm.nih.gov/pubmed/28801364",
        "http://www.ncbi.nlm.nih.gov/pubmed/34218049",
        "http://www.ncbi.nlm.nih.gov/pubmed/34203368",
        "http://www.ncbi.nlm.nih.gov/pubmed/31337788",
        "http://www.ncbi.nlm.nih.gov/pubmed/18187671",
        "http://www.ncbi.nlm.nih.gov/pubmed/16564725",
        "http://www.ncbi.nlm.nih.gov/pubmed/11306274",
        "http://www.ncbi.nlm.nih.gov/pubmed/20723335",
        "http://www.ncbi.nlm.nih.gov/pubmed/11454874",
        "http://www.ncbi.nlm.nih.gov/pubmed/16670282",
        "https://pubmed.ncbi.nlm.nih.gov/22427202/",
        "https://pubmed.ncbi.nlm.nih.gov/39039207/",
        "https://pubmed.ncbi.nlm.nih.gov/39167629/",
        "http://www.ncbi.nlm.nih.gov/pubmed/33244513",
        "http://www.ncbi.nlm.nih.gov/pubmed/33197622",
        "http://www.ncbi.nlm.nih.gov/pubmed/28378740",
        "http://www.ncbi.nlm.nih.gov/pubmed/32061866",
        "http://www.ncbi.nlm.nih.gov/pubmed/36434854",
        "http://www.ncbi.nlm.nih.gov/pubmed/33629544",
        "http://www.ncbi.nlm.nih.gov/pubmed/34854834",
        "http://www.ncbi.nlm.nih.gov/pubmed/29399202",
        "http://www.ncbi.nlm.nih.gov/pubmed/36632842",
        "http://www.ncbi.nlm.nih.gov/pubmed/36893709",
        "http://www.ncbi.nlm.nih.gov/pubmed/26609483",
        "http://www.ncbi.nlm.nih.gov/pubmed/30898840",
        "http://www.ncbi.nlm.nih.gov/pubmed/34195295",
        "http://www.ncbi.nlm.nih.gov/pubmed/37738407",
        "http://www.ncbi.nlm.nih.gov/pubmed/28258703",
        "http://www.ncbi.nlm.nih.gov/pubmed/36308193",
        "http://www.ncbi.nlm.nih.gov/pubmed/38655206",
        "http://www.ncbi.nlm.nih.gov/pubmed/24006483"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 214,
          "text": "Cancer cells can overexpress CD47, an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38414061"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 1201,
          "text": "CD47 is an integrin-associated penta-transmembrane protein that possesses an immunoglobulin-like domain in its extracellular region. We have now investigated the role of CD47 in the regulation of epithelial cell spreading and migration. CD47 is colocalized with E-cadherin at cell-cell adhesion sites of epithelial cells. A Ca2+ switch experiment showed that CD47 was endocytosed and then relocalized to cell-cell adhesion sites in a similar manner to E-cadherin. Such polarized localization of CD47 required the multiple spanning region of this protein. Forced expression of CD47 induced cell spreading with marked lamellipodium formation and resulted in both partial disruption of cell-cell adhesion and enhancement of the hepatocyte growth factor-stimulated scattering of Madin-Darby canine kidney cells. The CD47-induced cell spreading was blocked by inhibition of Src and mitogen-activated protein kinase kinase. Thus, these results suggest that CD47 participates in the regulation of cell-cell adhesion and cell migration through reorganization of the actin cytoskeleton in epithelial cells. This function of CD47 is mediated by the activation of Src and mitogen-activated protein kinase kinase.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16776778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "CD47 regulation of epithelial cell spreading and migration, and its signal transduction.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16776778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 655,
          "text": "CD47, also known as integrin-associated protein (IAP), is an ubiquitously expressed 50 kD cell membrane glycoprotein. This article reviews that as an integrin-associated molecule, CD47 regulates a series of integrin-dependent cell functions; CD47 regulates cell adhesiveness, migration and activation and platelet aggregation through binding to thrombospondins; CD7 is the extracellular ligand for human signal-regulatory proteins, thus it causes negative regulatory effect; CD47 induces costimulatory signals on activation of T cell, T cell apoptosis and T cell anergy and enhances the efficiency of TCR signaling; CD47 is a member of Rh antigen complex.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12962580"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 604,
          "text": "CD47 is a ubiquitous 50 kDa five-spanning membrane receptor that belongs to the immunoglobulin superfamily. This receptor, also known as integrin-associated protein, mediates cell-to-cell communication by ligation to transmembrane signal-regulatory proteins SIRPα and SIRPγ and interacts with integrins. CD47 is also implicated in cell-extracellular matrix interactions via ligation with thrombospondins. Furthermore, CD47 is involved in many and diverse cellular processes, including apoptosis, proliferation, adhesion and migration. It also plays a key role in many immune and cardiovascular responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22774848"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22774848"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "CD47 is a widely expressed integral membrane protein that serves as the counter-receptor for the inhibitory phagocyte receptor signal-regulatory protein-α (SIRPα) and as a signaling receptor for the secreted matricellular protein thrombospondin-1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25708195"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 343,
          "text": "CD47 is a ubiquitously expressed plasma membrane protein, also known as Integrin Associated Protein, that modulates cell adhesion both through alteration of the avidity of integrin binding and through interaction with its own ligands, the extracellular matrix protein thrombospondin (TSP) and the plasma membrane response regulator SIRPalpha1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15880429"
        },
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 355,
          "text": "CD47 limits antigen-dependent cytotoxic activities of human and murine CD8+ T cells, but its role in T cell activation kinetics remains unclear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36105746"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "CD47 is a 50 kDa five-spanning membrane receptor that plays a crucial role in multiple cellular processes, including myeloid cell activation, neutrophils transmigration, vascular remodeling, leukocyte adhesion and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38125492"
        },
        {
          "offsetInBeginSection": 611,
          "offsetInEndSection": 714,
          "text": "st is CD47. CD47 is a transmembrane protein that inhibits phagocytic activity by acting as a \"don\u0027t eat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39415597"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261,
          "text": "INTRODUCTION: CD47 is a ubiquitously expressed cell surface receptor that serves as a counter-receptor for SIRPα in recognition of self by the innate immune system. Independently, CD47 also functions as an important signaling receptor for regulating cell respon",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23101472"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 945,
          "text": "The cell surface glycoprotein CD47 (integrin-associated protein (IAP)) was first identified as an important regulator of integrin function, but later also was shown to function in ways that do not necessarily involve integrins. Ligation of CD47 can induce intracellular signaling resulting in cell activation or cell death depending on the exact context. By binding to another cell surface glycoprotein, signal regulatory protein alpha (SIRPα), CD47 can regulate the function of cells in the monocyte/macrophage lineage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23401787"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Cluster of differentiation 47 (CD47) (also known as integrin-associated protein) is a ubiquitously expressed glycoprotein of the immunoglobulin superfamily that plays a critical role in self-recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28077173"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 262,
          "text": "SUMMARY: The ubiquitously expressed cell surface glycoprotein CD47 is expressed by virtually all cells in the host, where it can function to regulate integrin-mediated responses, or constitute an important part of the erythrocyte band 3/Rh multi-protein complex.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23801922"
        },
        {
          "offsetInBeginSection": 1432,
          "offsetInEndSection": 1588,
          "text": "We argue that CD47 is a checkpoint molecule for both innate and adaptive immunity for tumor evasion and is thus a promising target for cancer immunotherapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28077173"
        },
        {
          "offsetInBeginSection": 1131,
          "offsetInEndSection": 1271,
          "text": "These results suggest all human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22451913"
        },
        {
          "offsetInBeginSection": 1157,
          "offsetInEndSection": 1431,
          "text": "In this review, we highlight the various functions of CD47, discuss anti-tumor responses generated by both the innate and adaptive immune systems as a consequence of administering anti-CD47 blocking antibody, and finally elaborate on the clinical potential of CD47 blockade.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28077173"
        },
        {
          "offsetInBeginSection": 331,
          "offsetInEndSection": 471,
          "text": "tly needed. CD47 is a \"don\u0027t eat me\" signal, which prevents cancer cells from phagocytosis by binding to signal regulatory protein alpha on ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30938231"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 278,
          "text": "CD47, a \"don\u0027t eat me\" signal, is over-expressed on the surface of most tumors that interacts with signal regulatory protein α (SIRPα) on phagocytic cells. By engaging SIRPα, CD47 limits the ability of macrophages to engulf tumor cells, which acts as a major phagocytic barrier.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28086180"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "CD47 is a \"don\u0027t eat me\" signal to phagocytes that is overexpressed on many tumor cells as a potential mechanism for immune surveillance evasion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35754851"
        },
        {
          "offsetInBeginSection": 428,
          "offsetInEndSection": 559,
          "text": "CD47 is a \"do not eat me\" signal, overexpressed in myeloid malignancies that leads to tumor evasion of phagocytosis by macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32038992"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 70,
          "text": " The CD47 \"don\u0027t eat me\" signal allows tumor immune evasion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569584"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 194,
          "text": " CD47 interacts with SIRPalpha on macrophages inhibiting phagocytic signal, providing a survival advantage to tumor",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31359339"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 71,
          "text": " CD47 is a transmembrane receptor that inhibits phagocytosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28801364"
        },
        {
          "offsetInBeginSection": 367,
          "offsetInEndSection": 549,
          "text": "CD47 is a transmembrane protein that enables cancer cells to evade clearance by macrophages through CD47- signal regulatory proteinα binding, which initiates a \"don\u0027t eat me\" signal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34218049"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 655,
          "text": "This article reviews that as an integrin-associated molecule, CD47 regulates a series of integrin-dependent cell functions; CD47 regulates cell adhesiveness, migration and activation and platelet aggregation through binding to thrombospondins; CD7 is the extracellular ligand for human signal-regulatory proteins, thus it causes negative regulatory effect; CD47 induces costimulatory signals on activation of T cell, T cell apoptosis and T cell anergy and enhances the efficiency of TCR signaling; CD47 is a member of Rh antigen complex.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12962580"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 275,
          "text": "CD47 is a cell surface protein in the immunoglobulin superfamily which is normally expressed at low levels in every healthy cell. It´s main physiologic function is to act as an inhibitor of phagocytosis; this occurs throughout interaction with SIRPa expressed on macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33015199"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 335,
          "text": "CD47 is a ubiquitously expressed transmembrane glycoprotein on surface of many cells. Through its interaction with integrin, signal regulatory protein alpha (SIRPα) and thrombin sensitive protein-1 (TSP-1), it plays important roles in various immunological processes including inflammatory response, immune response and tumor immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24370062"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 274,
          "text": " CD47 is a ubiquitously expressed cell surface receptor that serves as a counter-receptor for SIRPα in recognition of self by the innate immune system. Independently, CD47 also functions as an important signaling receptor for regulating cell responses to stress",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23101472"
        },
        {
          "offsetInBeginSection": 421,
          "offsetInEndSection": 743,
          "text": "CD47 is a high affinity signaling receptor for the secreted protein thrombospondin-1 (THBS1) and the counter-receptor for signal regulatory protein-α (SIRPA, SIRPα) and SIRPγ (SIRPG). CD47 interaction with SIRPα serves as a marker of self to innate immune cells and thereby protects cancer cells from phagocytic clearance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34707698"
        },
        {
          "offsetInBeginSection": 133,
          "offsetInEndSection": 321,
          "text": "We have now investigated the role of CD47 in the regulation of epithelial cell spreading and migration. CD47 is colocalized with E-cadherin at cell-cell adhesion sites of epithelial cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16776778"
        },
        {
          "offsetInBeginSection": 250,
          "offsetInEndSection": 376,
          "text": "CD47 regulates numerous functions like cell adhesion, proliferation, apoptosis, migration, homeostasis, and the immune system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34203368"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 283,
          "text": "CD47 is a tumor-associated antigen best known for its ability to bind counter-receptors on the surface of professional phagocytes as an immune-evasion strategy. ⁣Recently, CD47 has been shown to play a role as a signaling receptor, involving a number of cell physiological processes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33224442"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "CD47, also known as integrin-associated protein (IAP), is a transmembrane protein with multiple biological functions including regulation of efferocytosis and leukocyte trafficking.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31337788"
        },
        {
          "offsetInBeginSection": 144,
          "offsetInEndSection": 655,
          "text": "as an integrin-associated molecule, CD47 regulates a series of integrin-dependent cell functions; CD47 regulates cell adhesiveness, migration and activation and platelet aggregation through binding to thrombospondins; CD7 is the extracellular ligand for human signal-regulatory proteins, thus it causes negative regulatory effect; CD47 induces costimulatory signals on activation of T cell, T cell apoptosis and T cell anergy and enhances the efficiency of TCR signaling; CD47 is a member of Rh antigen complex.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12962580"
        },
        {
          "offsetInBeginSection": 425,
          "offsetInEndSection": 652,
          "text": "The cell surface glycoprotein CD47 (integrin-associated protein (IAP)) was first identified as an important regulator of integrin function, but later also was shown to function in ways that do not necessarily involve integrins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23401787"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 269,
          "text": "A number of important roles for CD47 have been defined in regulating the migration, proliferation, and survival of vascular cells, and in regulation of innate and adaptive immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18187671"
        },
        {
          "offsetInBeginSection": 426,
          "offsetInEndSection": 577,
          "text": "Loss of CD47 caused activation of dendritic cells, T cells and natural killer (NK) cells, indicating an important role for CD47 in regulating immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31337788"
        },
        {
          "offsetInBeginSection": 262,
          "offsetInEndSection": 393,
          "text": "Thus, during the last few years, it has been shown that CD47 has several important functions besides assisting integrin activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15359629"
        },
        {
          "offsetInBeginSection": 628,
          "offsetInEndSection": 768,
          "text": "CD47 can also function as a marker of self on erythrocytes, and likely also on other cells, by binding to the inhibitory receptor SIRPalpha.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15359629"
        },
        {
          "offsetInBeginSection": 656,
          "offsetInEndSection": 708,
          "text": "CD47 is involved in stroma-supported erythropoiesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12962580"
        },
        {
          "offsetInBeginSection": 918,
          "offsetInEndSection": 1097,
          "text": "Thus, these results suggest that CD47 participates in the regulation of cell-cell adhesion and cell migration through reorganization of the actin cytoskeleton in epithelial cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16776778"
        },
        {
          "offsetInBeginSection": 1292,
          "offsetInEndSection": 1423,
          "text": "These results demonstrate a fundamental role of CD47 in DC migration in vivo and in vitro and in the function of marginal zone DCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16670282"
        },
        {
          "offsetInBeginSection": 1070,
          "offsetInEndSection": 1244,
          "text": "Focus will be on the ways CD47 regulates hematopoietic cells and functions such as CD47 signaling, induction of apoptosis, and regulation of phagocytosis or cell-cell fusion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23401787"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "CD47 on erythrocytes inhibits phagocytosis through interaction with the inhibitory immunoreceptor SIRPα expressed by macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/22427202/"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "CD47 is a ubiquitously expressed cell surface receptor, which is widely known for preventing macrophage-mediated phagocytosis by interacting with sign",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/39039207/"
        },
        {
          "offsetInBeginSection": 351,
          "offsetInEndSection": 531,
          "text": "oint genes. The Cluster of Differentiation 47 (CD47) has emerged as a crucial checkpoint for cancer immunotherapy by working as a \"don\u0027t eat me\" signal and suppressing innate immun",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "https://pubmed.ncbi.nlm.nih.gov/39167629/"
        },
        {
          "offsetInBeginSection": 68,
          "offsetInEndSection": 338,
          "text": "A pivotal phagocytosis checkpoint, named cluster of differentiation 47 (CD47), which functions as \u0027don\u0027t eat me\u0027 signal to protect cells from phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) on macrophages, has recently attracted much attention",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33197622"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "CD47 on erythrocytes inhibits phagocytosis through interaction with the inhibitory immunoreceptor SIRPα expressed by macrophages",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427202"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "CD47 is a cell surface molecule that inhibits phagocytosis of cells that express it by binding to its receptor, SIRPα, on macrophages and other immune cells",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28378740"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "text": "CD47, also known as integrin-associated protein (IAP), is an immunoglobulin-like protein. It can inhibit the phagocytosis of macrophages through binding with signal-regulatory protein alpha chain of inhibitory receptor on macrophage (SIRPα)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20723335"
        },
        {
          "offsetInBeginSection": 1289,
          "offsetInEndSection": 1364,
          "text": "ith CD47 acting as a molecular switch for controlling erythrocyte phagocyto",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427202"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 270,
          "text": "CD47 (cluster of differentiation 47) is a ubiquitously expressed transmembrane protein that belongs to the immunoglobulin superfamily. CD47 is both a receptor for the matricellular protein thrombospondin-1 (TSP-1) and a ligand for signal-regulatory protein alpha (SIRPα)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32061866"
        },
        {
          "offsetInBeginSection": 93,
          "offsetInEndSection": 244,
          "text": "CD47 forms a signaling complex with signal regulatory protein alpha (SIRPα), prompting the escape of cancer cells from macrophage-mediated phagocytosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37248568"
        },
        {
          "offsetInBeginSection": 1815,
          "offsetInEndSection": 1929,
          "text": "ONCLUSIONS: These findings suggest that CD47 plays a crucial role in regulating VSMC phenotype, and SMC-specific-C",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/39675550"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "CD47 is a cell surface molecule and regulates diverse cellular responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36010209"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "CD47 is an immunoregulatory protein that is found on the cell surface and plays significant roles in cellular functions such as proliferation, apoptosis, migration, and immune homeostasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36434854"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 310,
          "text": "CD47 is an immunoregulatory protein that is found on the cell surface and plays significant roles in cellular functions such as proliferation, apoptosis, migration, and immune homeostasis. CD47 is overexpressed in various human cancers and is associated with tumor development, progression, and poor prognosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36434854"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "CD47 is a cell surface molecule and regulates diverse cellular responses. CD47 is highly expressed in cancer cells and has potential as a therapeutic target and prognostic factor in cancer patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36010209"
        },
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 325,
          "text": "However, it has been shown that CD47 has several important functions in addition to regulating integrin activation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16564725"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "Integrin-associated protein (IAP or CD47) is a receptor for thrombospondin family members, a ligand for the transmembrane signaling protein SIRP alpha and a component of a supramolecular complex containing specific integrins, heterotrimeric G proteins and cholesterol.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11306274"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "The ubiquitously expressed cell surface glycoprotein CD47 (integrin-associated protein, IAP) was originally identified as a regulator of integrin-dependent leukocyte responses to extracellular matrix proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16564725"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "INTRODUCTION: CD47 is a ubiquitously expressed cell surface receptor that serves as a counter-receptor for SIRPα in recognition of self by the innate ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23101472"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "CD47 is an integrin-associated penta-transmembrane protein that possesses an immunoglobulin-like domain in its extracellular region.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16776778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36081498"
        },
        {
          "offsetInBeginSection": 1272,
          "offsetInEndSection": 1536,
          "text": "These data, taken together with similar findings with other human neoplasms, show that CD47 is a commonly expressed molecule on all cancers, its function to block phagocytosis is known, and blockade of its function leads to tumor cell phagocytosis and elimination.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22451913"
        },
        {
          "offsetInBeginSection": 195,
          "offsetInEndSection": 383,
          "text": " migration. An important role for CD47 is the transmission of a \"Don\u0027t eat me\" signal by interacting with SIRPα on the macrophage surface membrane, thereby preventing the phagocytosis of n",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33629544"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "CD47 is a tumor-associated antigen best known for its ability to bind counter-receptors on the surface of professional phagocytes as an immune-evasion strategy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33224442"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 316,
          "text": "PURPOSE OF REVIEW: The antitumor activity of macrophages is regulated by a balance of prophagocytic and antiphagocytic signals. Cluster of differentiation 47 (CD47), the dominant macrophage immune checkpoint (\u0027do not eat me\u0027 signal), interacts with its receptor signal-regulatory protein alpha (SIRPα) to suppress ph",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34854834"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 389,
          "text": "The binding of CD47 to signal regulatory protein α (SIRPα) inhibits the macrophage phagocytosis of tumor cells by triggering an inhibitory \u0027do not eat me\u0027 signal",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29399202"
        },
        {
          "offsetInBeginSection": 73,
          "offsetInEndSection": 345,
          "text": "Cluster of Differentiation 47 (CD47) is believed to act as an anti-phagocytic marker that is highly expressed on multiple types of human cancer cells including acute myeloid leukemia (AML) and lung and liver carcinomas, allowing them to escape phagocytosis by macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36632842"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Cluster of differentiation 47 (CD47) acts as an anti-engulfment signal on tumor cells, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36893709"
        },
        {
          "offsetInBeginSection": 405,
          "offsetInEndSection": 534,
          "text": "Furthermore, CD47 is involved in many and diverse cellular processes, including apoptosis, proliferation, adhesion and migration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22774848"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "CD47 is a membrane receptor that belongs to the immunoglobulin superfamily and plays an important role in the mechanisms of tumor immune escape.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26609483"
        },
        {
          "offsetInBeginSection": 519,
          "offsetInEndSection": 635,
          "text": "CD47 functions by activating signal regulatory protein-α (SIRP-α) expressed on macrophages, preventing phagocytosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29308321"
        },
        {
          "offsetInBeginSection": 173,
          "offsetInEndSection": 319,
          "text": "CD47 has been shown to mediate immune evasion, as the CD47-SIRPα axis prevents phagocytosis of tumor cells by macrophages and other myeloid cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30898840"
        },
        {
          "offsetInBeginSection": 453,
          "offsetInEndSection": 669,
          "text": "validation. Recent clinical trials have indicated that inhibition of CD47 with anti-CD47 antibodies exerts a promising antitumor effect against several human malignancies, including NSCLC, melanoma, and hematologic m",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34195295"
        },
        {
          "offsetInBeginSection": 1574,
          "offsetInEndSection": 1786,
          "text": "These data uncovered that Gal3 functions together with CD47 to suppress phagocytosis and orchestrate immunosuppression in GAC with PC, which supports exploring a novel combination therapy targeting Gal3 and CD47.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/37738407"
        },
        {
          "offsetInBeginSection": 602,
          "offsetInEndSection": 739,
          "text": "). CD47 interaction with SIRPα serves as a marker of self to innate immune cells and thereby protects cancer cells from phagocytic cleara",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34707698"
        },
        {
          "offsetInBeginSection": 1515,
          "offsetInEndSection": 1611,
          "text": "ty. CD47 signaling is a physiological regulator of platelet activation, angiogenesis and blood f",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34707698"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 361,
          "text": "CD47 regulates cell adhesiveness, migration and activation and platelet aggregation through binding to thrombospondins;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12962580"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 615,
          "text": "CD47 induces costimulatory signals on activation of T cell, T cell apoptosis and T cell anergy and enhances the efficiency of TCR signaling;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12962580"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 506,
          "text": "CD47 is a ubiquitously expressed cell surface glycoprotein that functions as a signaling receptor for thrombospondin-1 and as the counter-receptor for signal regulatory protein-α (SIRPα). Engaging SIRPα on macrophages inhibits phagocytosis, and CD47 thereby serves as a physiological marker of self. However, elevated CD47 expression on some cancer cells also protects tumors from innate immune surveillance and limits adaptive antitumor immunity via inhibitory SIRPα signaling in antigen presenting cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33244513"
        },
        {
          "offsetInBeginSection": 326,
          "offsetInEndSection": 535,
          "text": "Extensive studies in murine systems have shown that CD47 on erythrocytes and other cells can function as a regulator of target cell phagocytosis, by binding to the inhibitory receptor SIRPalpha on macrophages.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16564725"
        },
        {
          "offsetInBeginSection": 401,
          "offsetInEndSection": 617,
          "text": "CD47 is an inhibitory receptor expressed on tumor cell surface and interacts with signal receptor protein-alpha (SIPR-α, also named CD172a or SHPS-1) which may escape from immune cells such as macrophage and T cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31806995"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 358,
          "text": "CD47 on erythrocytes inhibits phagocytosis through interaction with the inhibitory immunoreceptor SIRPα expressed by macrophages. Thus, the CD47-SIRPα interaction constitutes a negative signal for erythrocyte phagocytosis. However, we report here that CD47 does not only function as a \"do not eat me\" signal for uptake but can also act as an \"eat me\" signal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22427202"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 396,
          "text": "Engagement of SIRPα by CD47 provides a downregulatory signal that inhibits host cell phagocytosis, and CD47 therefore functions as a \"don\u0027t-eat-me\" signal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24215318"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Objectives: CD47 is a membrane protein that belongs to the immunoglobulin superfamily and regulates macrophage phagocytosis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36308193"
        },
        {
          "offsetInBeginSection": 408,
          "offsetInEndSection": 572,
          "text": "CD47 is a transmembrane protein overexpressed in various cancers and acts as a potent \u0027do not eat me\u0027 signal that contributes to the immune evasion of cancer cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/38655206"
        },
        {
          "offsetInBeginSection": 421,
          "offsetInEndSection": 601,
          "text": "CD47 is a high affinity signaling receptor for the secreted protein thrombospondin-1 (THBS1) and the counter-receptor for signal regulatory protein-α (SIRPA, SIRPα) and SIRPγ (SIRP",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34707698"
        },
        {
          "offsetInBeginSection": 438,
          "offsetInEndSection": 703,
          "text": "This innate immune checkpoint is composed of what has become known as the \u0027don\u0027t-eat me\u0027 signal CD47, which is a protein broadly expressed on normal cells and often overexpressed on cancer cells, and its counter-receptor, the myeloid inhibitory immunoreceptor SIRPα",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258703"
        },
        {
          "offsetInBeginSection": 704,
          "offsetInEndSection": 847,
          "text": " Blocking CD47-SIRPα interactions has been shown to promote the destruction of cancer cells by phagocytes, including macrophages and neutrophil",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258703"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "CD47 is a ubiquitously expressed cell surface glycoprotein that associates with integrins and regulates chemotaxis, migration, and activation of leukocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16670282"
        },
        {
          "offsetInBeginSection": 1169,
          "offsetInEndSection": 1293,
          "text": "Thus, a disulfide bond between the Ig and MMS domains of CD47 is required for normal ligand binding and signal transduction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11454874"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "CD47 plays an important but incompletely understood role in the innate and adaptive immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24006483"
        }
      ],
      "type": "factoid",
      "id": "67c9e75881b1027333000006",
      "ideal_answer": [
        "CD47 is an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα)",
        "CD47, also known as integrin-associated protein (IAP), is a transmembrane protein with multiple biological functions including regulation of efferocytosis and leukocyte trafficking. It regulates cell adhesiveness, migration and activation and platelet aggregation through binding to thrombospondins. CD47 is the extracellular ligand for human signal-regulatory proteins, thus it causes negative regulatory effect. CD47 induces costimulatory signals on activation of T cell, T cell apoptosis and T cell anergy and enhances the efficiency of TCR signaling. CD47 can also function as a marker of self on erythrocytes, and likely also on other cells, by binding to the inhibitory receptor SIRPalpha, preventing phagocytosis.",
        "CD47 functions to regulate integrin-mediated responses, such as cell adhesion, migration, and activation, and it also serves as a \u0027don\u0027t eat me\u0027 signal to prevent phagocytosis by macrophages through its interaction with SIRPα, which is crucial for immune evasion by tumor cells.",
        "CD47 regulates antiphagocytic activity by signaling through the signal regulatory protein alpha (SIRPα) pathway on macrophages.",
        "CD47, also known as the Cluster of Differentiation 47 or integrin-associated protein, is a ubiquitously expressed cell surface receptor that plays a critical role in maintaining immune system homeostasis. It functions as a \"don\u0027t-eat-me\" signal by engaging with signal regulatory protein alpha (SIRPα) on phagocytic cells, such as macrophages, to inhibit host cell phagocytosis. This interaction prevents the immune system from mistakenly destroying healthy cells. In the context of cancer, CD47\u0027s role in suppressing innate immune signaling has made it a target for immunotherapy, as cancer cells can exploit this pathway to evade phagocytosis and immune surveillance.",
        "CD47 functions as a self-recognition molecule that inhibits phagocytosis and regulates immune signaling.",
        "CD47 is a widely expressed transmembrane protein, also known as integrin-associated protein (IAP). It functions as a \"don\u0027t eat me\" signal by binding to its receptor, signal regulatory protein alpha (SIRPα), on macrophages and other immune cells. This interaction inhibits phagocytosis, allowing cells to evade immune clearance, and plays a broader role in self-recognition and immune homeostasis.",
        "CD47, also known as integrin-associated protein (IAP), is a transmembrane protein with diverse functions, including regulation of efferocytosis and leukocyte trafficking. It regulates integrin-dependent functions such as cell adhesion, migration, activation, and platelet aggregation via thrombospondin binding. It acts as an extracellular ligand for signal-regulatory proteins, resulting in a negative regulatory effect. CD47 induces costimulatory signals on T cell activation, apoptosis, and anergy, enhancing TCR signaling. It also functions as a \"self\" marker on erythrocytes and other cells by binding to the inhibitory receptor SIRPalpha. Furthermore, CD47 regulates the migration, proliferation, and survival of vascular cells and modulates innate and adaptive immunity.",
        "CD47 functions as a \u0027don\u0027t eat me\u0027 signal that inhibits phagocytosis by macrophages when engaged with signal regulatory protein alpha (SIRPα).",
        "CD47 acts as an inhibitor of phagocytosis by interacting with SIRPa on macrophages, and it also regulates T cell immunity, modulates immune response, and has a role in cancer cell survival by overexpression, and it interacts with thrombospondin-1 and SIRPα.",
        "CD47 is a transmembrane protein that inhibits phagocytic activity by acting as a \"don\u0027t eat me\" signal. CD47 is an integrin-associated penta-transmembrane protein that possesses an immunoglobulin-like domain in its extracellular region. We have now investigated the role of CD47 in the regulation of epithelial cell spreading and migration. CD47 is colocalized with E-cadherin at cell-cell adhesion sites of epithelial cells. A Ca2+ switch experiment showed that CD47 was endocytosed and then relocalized to cell-cell adhesion sites in a similar manner to E-cadherin. Such polarized localization of CD47 required the multiple spanning region of this protein. Forced expression of CD47 induced cell spreading with marked lamellipodium formation and resulted in both partial disruption of cell-cell adhesion and enhancement of the hepatocyte growth factor-stimulated scattering of Madin-Darby canine kidney cells. The CD47-induced cell spreading was blocked by inhibition of Src and mitogen-activated protein kinase kinase. Thus, these results suggest that CD47 participates in the regulation of cell-cell adhesion and cell migration through reorganization of the actin cytoskeleton in epithelial cells. This function",
        "CD47 functions as an anti-phagocytic signal by triggering a \u0027don\u0027t eat me\u0027 signal when bound by the inhibitory signal regulatory protein α (SIRPα) expressed on macrophages, thereby protecting cancer cells from immune-mediated elimination.",
        "CD47 regulates antiphagocytic activity by signaling through the signal regulatory protein alpha (SIRPα) pathway on macrophages, initiating a \u0027do not eat me\u0027 signal when bound by SIRPα.",
        "CD47 functions in immune evasion, integrin regulation, phagocytosis inhibition, T cell activation, and platelet aggregation.",
        "CD47 functions as a macrophage checkpoint molecule that prevents healthy cells from being attacked by immune cells by initiating a \u0027do not eat me\u0027 signal when engaged with its receptor SIRPα on macrophages, thereby regulating antiphagocytic activity.",
        "CD47 is a transmembrane protein that plays a crucial role in various physiological and pathological processes. It is often referred to as the \"don\u0027t eat me\" signal because it interacts with signal regulatory protein alpha (SIRPα) on macrophages, inhibiting phagocytosis and allowing cells to evade immune surveillance. This function is particularly important in the context of cancer, where overexpression of CD47 on tumor cells helps them avoid being engulfed and destroyed by the immune system. Additionally, CD47 is involved in the regulation of cell migration, apoptosis, and T-cell activation, and it plays a role in maintaining vascular homeostasis by interacting with thrombospondin-1.",
        "CD47 is a ubiquitously expressed cell surface receptor that plays a crucial role in regulating various cellular processes such as phagocytosis, proliferation, migration, apoptosis, differentiation, stress responses, and metabolism. Its key functions include: 1) Preventing macrophage-mediated phagocytosis by interacting with SIRPα on macrophages, acting as a \u0027don\u0027t eat me\u0027 signal. 2) Regulating cell adhesion, migration, and activation through binding to thrombospondins. 3) Modulating immune cell activation, including T cells, B cells, and dendritic cells. 4) Controlling stem cell self-renewal and differentiation. 5) Mediating signaling pathways involved in calcium homeostasis, cyclic nucleotide signaling, nitric oxide and hydrogen sulfide biosynthesis, and mitochondrial biogenesis.",
        "CD47 is a cell surface receptor that plays a key role in regulating immune responses. Its main function is to act as a \u0027don\u0027t eat me\u0027 signal by interacting with SIRPα on macrophages, thereby inhibiting phagocytosis of healthy cells. CD47 is overexpressed in many cancers, allowing tumor cells to evade phagocytosis and immune surveillance. Additionally, CD47 modulates other cellular processes like proliferation, migration, apoptosis, and metabolism in various cell types.",
        "CD47 functions as a \"don\u0027t eat me\" signal, protecting cells from phagocytosis by delivering an inhibitory signal through the SIRPα receptor on myeloid cells. It is a cell surface protein that regulates phagocytosis, cell migration, and activation of leukocytes. CD47 is also involved in controlling the fate of activated T cells and is a critical regulator of myeloid cell activation and serves a broader role as a myeloid-specific immune checkpoint.",
        "CD47 is a ubiquitously expressed cell surface receptor that plays a crucial role in regulating immune responses and cellular processes. Its key functions include: 1) Serving as a \u0027don\u0027t eat me\u0027 signal by interacting with SIRPα on macrophages, preventing phagocytosis of normal cells; 2) Regulating immune cell activation, including macrophages, neutrophils, dendritic cells, T cells, and NK cells; 3) Modulating cellular processes like apoptosis, proliferation, adhesion, and migration; 4) Interacting with integrins and thrombospondins to mediate cell-extracellular matrix interactions. Importantly, cancer cells exploit CD47 to evade immune surveillance, making it a promising therapeutic target in oncology.",
        "CD47 is a receptor that regulates various cellular functions, including cell adhesion, proliferation, apoptosis, migration, and homeostasis, as well as the immune system. It interacts with ligands to modulate these processes.",
        "CD47 is a transmembrane protein that acts primarily as a “don’t eat me” signal. By interacting with the signal regulatory protein on immune cells, especially macrophages, it inhibits phagocytosis and thus protects cells, including cancer cells, from being engulfed and eliminated by the immune system. Additionally, CD47 is involved in various signaling pathways that regulate cell adhesion, migration, and immune homeostasis, influencing processes such as angiogenesis, platelet activation, and overall tissue inflammatory responses.",
        "CD47 is a cell surface glycoprotein with multifaceted functions, including regulating cell adhesion, migration, apoptosis, and metabolism, while also playing a crucial role in immune responses by preventing macrophage-mediated phagocytosis, and is implicated in cancer progression and potential therapy, with its expression affecting tumor metastasis, prognosis, and immune evasion.",
        "CD47 is a ubiquitously expressed glycoprotein that functions as a regulator of integrin-mediated responses, influencing cell adhesion, migration, and activation. It also acts as a \u0027don\u0027t eat me\u0027 signal by interacting with SIRPα on myeloid cells, thereby inhibiting phagocytosis and playing a critical role in immune evasion, particularly in cancer. Additionally, CD47 is involved in T cell activation, apoptosis, and anergy, making it a significant target for cancer immunotherapy.",
        "CD47, also known as integrin-associated protein (IAP), is a transmembrane protein with multiple biological functions. It regulates cell adhesiveness, migration, and activation, as well as platelet aggregation through binding to thrombospondins. CD47 plays a role in regulating the migration, proliferation, and survival of vascular cells, and in the regulation of innate and adaptive immunity. It can also function as a marker of self on erythrocytes and other cells by binding to the inhibitory receptor SIRPalpha, regulating target cell phagocytosis. Additionally, CD47 regulates integrin-dependent cell functions and induces costimulatory signals on activation of T cells, influencing T cell apoptosis and anergy, and enhancing TCR signaling. It also plays a key role in the ability of tumor cells to escape phagocytosis, working as an immune checkpoint in the immune response.",
        "The function of CD47 is to serve as a \"don\u0027t eat me\" signal to protect cells from phagocytosis by binding to its receptor signal regulatory protein alpha (SIRPα) on macrophages, thus mediating immune evasion and promoting tumor cell survival and progression.",
        "CD47, also known as integrin-associated protein (IAP), has several critical functions in various physiological and pathological processes. It regulates integrin-mediated adhesion, influencing cell adhesiveness, migration, activation, and platelet aggregation. CD47 inhibits cell phagocytosis by interacting with SIRPα, marking cells as \"self\" to prevent their phagocytosis by macrophages. It plays a significant role in the innate immune response, regulating osteoclastogenesis, antiviral responses, and NK cell recruitment and activation in the tumor microenvironment. CD47 also inhibits myelin debris clearance by preventing myelin disruption and phagocytosis. It is involved in stroma-supported erythropoiesis and is associated with hemolysis as a marker on red blood cells. Additionally, CD47 induces costimulatory signals on T cell activation, apoptosis, and anergy, enhancing TCR signaling and playing a role in immune tolerance. These functions highlight CD47\u0027s role in immune regulation, cell adhesion, and maintaining cellular homeostasis.",
        "Cancer cells can overexpress CD47, an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells.",
        "CD47 is a cell surface protein that functions as a \u0027don\u0027t eat me\u0027 signal in the immune system. It interacts with SIRPα on macrophages and prevents phagocytosis, essentially protecting cells from being engulfed and destroyed by immune cells. In cancer, tumor cells often overexpress CD47 to evade immune surveillance and prevent macrophage-mediated elimination.",
        "CD47 functions as an innate immune checkpoint protein expressed on cancer cells. It interacts with Signal Regulatory Protein Alpha (SIRPα), which is found on macrophages and other myeloid cells. This interaction prevents phagocytosis, thereby shielding cancer cells from being engulfed and destroyed by the immune system. This mechanism allows cancer cells to evade immune detection and survive.",
        "CD47 is a cell surface protein acting as a \u0027don\u0027t eat me\u0027 signal, primarily inhibiting phagocytosis by binding to SIRPα on macrophages and other myeloid cells. This interaction protects various cells, notably cancer cells, from immune surveillance and destruction. While its role is well-defined in the context of cancer, where it aids in immune evasion, CD47\u0027s function can vary in different therapeutic contexts, such as in hepatic ischemia-reperfusion injury and traumatic brain injury. Its expression on cells like erythrocytes and stromal cells also serves to prevent their engulfment, highlighting its broad protective mechanism in the body.",
        "CD47 functions as an innate immune checkpoint that inhibits phagocytosis by interacting with signal regulatory protein alpha (SIRPα) on macrophages and other myeloid cells. This interaction sends a \"don\\\u0027t eat me\" signal, preventing these immune cells from engulfing and destroying the cancerous cells. By overexpressing CD47, cancer cells can evade immune detection and survival mechanisms, promoting tumor growth.",
        "CD47 functions as an innate immune checkpoint that inhibits phagocytosis by interacting with SIRP on macrophages and other myeloid cells.",
        "CD47 functions to prevent phagocytosis by interacting with signal regulatory protein alpha (SIRPα) on macrophages and other myeloid cells.",
        "CD47 is an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells.",
        "The function of CD47 is an innate immune checkpoint that prevents phagocytosis.",
        "CD47 functions as a \"don\u0027t-eat-me\" signal that inhibits host cell phagocytosis by providing a downregulatory signal upon engagement with signal-regulatory protein α (SIRPα).",
        "CD47 is an innate immune checkpoint. It prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells.",
        "CD47 is a cell surface protein that functions as an innate immune checkpoint. It prevents phagocytosis by interacting with signal regulatory protein alpha (SIRPα) on macrophages and other myeloid cells, thereby inhibiting the clearance of cancer cells by the immune system.",
        "CD47, also known as integrin-associated protein (IAP), is a ubiquitously expressed cell surface glycoprotein with multiple functions. It regulates integrin-dependent leukocyte responses to extracellular matrix proteins and modulates cell activities including platelet activation, cell motility and adhesion, and leukocyte adhesion, migration, and phagocytosis. It acts as a receptor for thrombospondin family members and a ligand for the transmembrane signaling protein SIRP alpha. CD47 functions as a marker of self on erythrocytes and other cells by binding to the inhibitory receptor SIRPalpha. Furthermore, CD47 regulates the migration, proliferation, and survival of vascular cells, and plays a role in innate and adaptive immunity. In cancer cells, CD47 overexpression prevents phagocytosis by interacting with SIRPα on macrophages and other myeloid cells.",
        "CD47 functions as an innate immune checkpoint on cancer cells, overexpressed to prevent phagocytosis by interacting with signal regulatory protein alpha (SIRPα) on macrophages and other myeloid cells. This interaction inhibits the immune system\u0027s ability to recognize and eliminate cancer cells.",
        "CD47 functions as an antiphagocytic cell surface protein that inhibits phagocytosis by acting as a \"don\u0027t eat me\" signal, preventing immune cells from engulfing cancer cells and other cells expressing CD47.",
        "CD47 functions as an innate immune checkpoint by interacting with signal regulatory protein alpha (SIRP) on macrophages and other myeloid cells, thereby preventing the phagocytosis of cells that express it.",
        "CD47 functions as an immune checkpoint that prevents phagocytosis by interacting with SIRPα on macrophages.",
        "CD47 functions as an innate immune checkpoint that prevents phagocytosis by interacting with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells.",
        "CD47 is a protein that functions as an innate immune checkpoint. It is often overexpressed on cancer cells, where it interacts with signal regulatory protein alpha (SIRPα) on macrophages and other myeloid cells. This interaction sends a \"don\u0027t eat me\" signal to the immune system, preventing the phagocytosis of the cancer cells by the macrophages, thereby allowing the cancer cells to evade the immune response.",
        "CD47 is a protein that functions as an innate immune checkpoint. It inhibits phagocytosis by interacting with signal regulatory protein alpha (SIRPα), which is expressed on macrophages and other myeloid cells. This interaction prevents these immune cells from engulfing and destroying the target cell, thereby contributing to immune evasion. In cancer, CD47 overexpression is a mechanism used by malignant cells to avoid detection and elimination by the immune system.",
        "CD47 is an innate immune checkpoint. When overexpressed by cancer cells, it prevents phagocytosis by interacting with SIRPα on macrophages and myeloid cells.",
        " CD47 is an innate immune checkpoint protein that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells.",
        "CD47 functions as an innate immune checkpoint that inhibits phagocytosis when it interacts with signal regulatory protein alpha (SIRPα) expressed on macrophages and other myeloid cells. Cancer cells often overexpress CD47 as a mechanism to evade immune surveillance by preventing their engulfment by macrophages. This \u0027don\u0027t eat me\u0027 signal allows cancer cells to escape immune detection and clearance, making CD47 an important target for cancer immunotherapy approaches.",
        "CD47 functions as an innate immune checkpoint that prevents phagocytosis. It achieves this by interacting with signal regulatory protein alpha (SIRPα) expressed on macrophages and other myeloid cells. This interaction sends a signal that inhibits these immune cells from engulfing and destroying cancer cells, thereby allowing the cancer to evade immune detection and survive.",
        "CD47 is an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells. In other words, CD47 acts as a \"don\u0027t eat me\" signal, inhibiting the engulfment and digestion of cells by macrophages and other immune cells.",
        "CD47 is a protein expressed on the surface of cancer cells that functions as an innate immune checkpoint, preventing phagocytosis (engulfment) of the cancer cells by macrophages and other immune cells. It interacts with the SIRPα receptor on macrophages, sending a \u0027don\u0027t eat me\u0027 signal that inhibits phagocytosis of the cancer cell.",
        "CD47 is a cell surface protein that acts as a \u0027don\u0027t eat me\u0027 signal by binding to SIRPα on macrophages and other myeloid cells, primarily inhibiting phagocytosis. It protects various cells, including erythrocytes and stromal cells, but is notably overexpressed in cancer cells to evade immune destruction. This immune checkpoint function makes CD47 a promising target in cancer immunotherapy, despite potential side effects like anemia. Beyond oncology, CD47 plays roles in macrophage polarization and is explored in treatments for conditions such as traumatic brain injury and neuroblastoma, showcasing its complex involvement in immune surveillance.",
        "innate immune checkpoint that prevents phagocytosis by interacting with signal regulatory protein alpha (SIRPα) on macrophages and other myeloid cells",
        "the function of CD47 is an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells.",
        "CD47 functions as an innate immune checkpoint protein that, when expressed on cancer cells, interacts with SIRP on macrophages and myeloid cells to prevent phagocytosis, essentially helping cancer cells evade immune system detection and destruction.",
        "CD47 acts as an innate immune checkpoint by preventing phagocytosis when it interacts with SIRPα, which is present on macrophages and other myeloid cells."
      ],
      "exact_answer": [
        [
          "prevents phagocyttosis, regulation of cellular processes"
        ]
      ]
    },
    {
      "body": "Is the use of surfactant restricted to neonatology?",
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/38444695",
        "http://www.ncbi.nlm.nih.gov/pubmed/32566323",
        "http://www.ncbi.nlm.nih.gov/pubmed/17978790",
        "http://www.ncbi.nlm.nih.gov/pubmed/17013236",
        "http://www.ncbi.nlm.nih.gov/pubmed/2684594"
      ],
      "type": "yesno",
      "snippets": [
        {
          "offsetInBeginSection": 442,
          "offsetInEndSection": 589,
          "text": "Poractant alfa (Curosurf®), a natural surfactant effective in the treatment of newborn respiratory distress, has been used in various forms of ARDS",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32566323"
        },
        {
          "offsetInBeginSection": 161,
          "offsetInEndSection": 396,
          "text": "We describe a case of an 18 month-old child affected by acute respiratory distress syndrome (ARDS) due to asphyxy by gastric juice inhalation, successfully treated with porcine surfactant (Curosurf) associated with ventilatory therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17978790"
        },
        {
          "offsetInBeginSection": 57,
          "offsetInEndSection": 148,
          "text": "Exogenous surfactant therapy is now a mainstay treatment for respiratory distress syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17013236"
        },
        {
          "offsetInBeginSection": 773,
          "offsetInEndSection": 858,
          "text": "Adult respiratory distress syndrome has also been treated with exogenous surfactants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2684594"
        }
      ],
      "id": "67d6c10618b1e36f2e000027",
      "ideal_answer": [
        "While the use of surfactant is not confined solely to neonatology, its benefit is clearly established in newborns with respiratory distress syndrome. In adult patients, evidence consistently shows no survival benefit, and surfactant therapy is generally considered as a last resort rather than routine practice. In the pediatric population, although surfactant has been evaluated for acute lung injury, its role remains unclear and is not as definitive as in neonatal care. Overall, current evidence supports the standard application of surfactant in neonates, while its use in non-neonatal populations remains experimental and limited to specific cases where other treatments have failed.",
        "Surfactant therapy is primarily utilized in neonatology to address respiratory distress syndrome (RDS) in preterm infants, where it helps reduce lung surface tension. However, its applications extend beyond this field. It is being studied for use in adults with acute respiratory distress syndrome (ARDS), a condition caused by severe lung damage from infections or trauma. Additionally, surfactants are explored for potential roles in managing chronic respiratory conditions like COPD and asthma, where surfactant dysfunction may contribute to symptoms. Beyond treatment, surfactants are also researched as vehicles for gene delivery and medication administration. Thus, while neonatology remains the main area of application, surfactant therapy has broader implications and is being investigated for diverse uses across various medical fields."
      ],
      "exact_answer": "no"
    }
  ]
}